<SEC-DOCUMENT>0001193125-13-453184.txt : 20131125
<SEC-HEADER>0001193125-13-453184.hdr.sgml : 20131125
<ACCEPTANCE-DATETIME>20131125172557
ACCESSION NUMBER:		0001193125-13-453184
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20130930
FILED AS OF DATE:		20131125
DATE AS OF CHANGE:		20131125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CymaBay Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001042074
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943103561
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55021
		FILM NUMBER:		131241875

	BUSINESS ADDRESS:	
		STREET 1:		3876 BAY CENTER PLACE
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		510-293-8800

	MAIL ADDRESS:	
		STREET 1:		3876 BAY CENTER PLACE
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METABOLEX, INC.
		DATE OF NAME CHANGE:	20090721

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METABOLEX INC
		DATE OF NAME CHANGE:	19970710
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d608283d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML><HEAD>
<TITLE>10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;10-Q </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2013 </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE TRANSITION PERIOD FROM
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> TO
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 000-55021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CymaBay
Therapeutics,&nbsp;Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94-3103561</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>3876 Bay Center Place<BR>Hayward, CA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>94545</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(650) 624-1100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the
Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past
90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&#167;232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the
Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2013, there were 9,455,064 shares of the registrant&#146;s Common Stock outstanding. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CYMABAY THERAPEUTICS,&nbsp;INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUARTERLY REPORT ON FORM&nbsp;10-Q </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2013 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART&nbsp;I</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B><A HREF="#tx608283_1">FINANCIAL INFORMATION</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item 1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx608283_2">Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx608283_3">Condensed Balance Sheets &#151; September&nbsp;30, 2013 (unaudited) and December&nbsp;31, 2012</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx608283_4">Condensed Statements of Comprehensive Income (Loss) for the three and nine months ended September&nbsp;
30, 2013 and 2012 (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx608283_5">Condensed Statements of Cash Flows for the nine months ended September&nbsp;30, 2013 and 2012
(Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx608283_6">Notes to Condensed Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item 2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx608283_7">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item 3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx608283_8">Quantitative and Qualitative Disclosures About Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item 4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx608283_9">Controls and Procedures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PART&nbsp;II</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B><A HREF="#tx608283_10">OTHER INFORMATION</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item 1A.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx608283_11">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item 2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx608283_12">Unregistered Sales of Equity Securities and Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item 6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx608283_13">Exhibits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx608283_15">Signatures</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx608283_1"></A>PART&nbsp;I. FINANCIAL INFORMATION </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx608283_2"></A>Item&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx608283_3"></A>CYMABAY THERAPEUTICS,&nbsp;INC.
</B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED BALANCE SHEETS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>unaudited</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and redeemable convertible preferred stock and stockholders&#146; equity (deficit</B>)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long term warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies <I>(Note&nbsp;8)</I></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.0001 par value: 55,258,608 shares authorized; 0 and 624,426 shares issued and outstanding as
of September&nbsp;30, 2013 and December&nbsp;31, 2012, respectively; aggregate liquidation preference of $256,750 as of December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value: 100,000,000 shares authorized; 8,790,764 and 5,792 shares issued and outstanding as of
September&nbsp;30, 2013 and&nbsp;December&nbsp;31, 2012, respectively</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(344,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(329,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(328,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and redeemable convertible preferred stock and stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See Accompanying Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx608283_4"></A>CYMABAY THERAPEUTICS,&nbsp;INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,866</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion to redemption value of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to stockholders</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss/income:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized losses on marketable securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net loss per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">422.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(637.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(433.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,098.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding used to calculate basic net loss per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net loss per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(637.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,098.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding used to calculate diluted net loss per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">731,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">688,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See Accompanying Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx608283_5"></A>CYMABAY THERAPEUTICS,&nbsp;INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF CASH FLOWS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of notes payable conversion option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-employee stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee and director stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash interest associated with discount accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,882</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from maturities of marketable securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from facility loan</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of commons stock and warrants, net of issuance costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchase of preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments on equipment loans</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of year</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of year</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock warrants-lenders</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock warrants-common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of preferred shares into common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">323,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock for debt extinguishment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See Accompanying Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx608283_6"></A>CymaBay Therapeutics,&nbsp;Inc. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Description of Business </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CymaBay Therapeutics Inc., formerly Metabolex, Inc., is focused on developing therapies to treat metabolic diseases.
Arhalofenate, our lead product candidate, is being developed for the treatment of gout. Arhalofenate has demonstrated two therapeutic actions: the prevention of painful attacks of gout in joints (flares) and the lowering of serum uric acid (sUA) by
promoting excretion of uric acid by the kidney. In addition, arhalofenate provides physicians with what they identified in a recent survey (TreatmentTrends<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>: Gout U.S. August 2011) as the most
important attributes when selecting a gout therapy: no serious safety issues, well tolerated, minimize frequency of flares and use in patients with a broad range of comorbidities, (other diseases that individual patients have in addition to gout).
The Company was incorporated in Delaware in October 1988 as Transtech.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CymaBay has completed three Phase 2 studies of arhalofenate in gout
patients in which it demonstrated a consistent pattern of reduction of flare incidence and duration and lowering of serum uric acid (sUA). Arhalofenate has established a safety profile in toxicology studies in animals and in clinical studies
involving nearly 1,000 patients exposed to arhalofenate. One additional Phase 2b clinical study of 12 weeks duration is planned to confirm the safety and efficacy of a higher dose prior to initiating Phase 3 studies. Due to its safety profile and
ability to both reduce flares and lower sUA, we believe that arhalofenate has a differentiated profile that is attractive for use in a large population, with significant advantages over marketed and emerging agents which have limitations in their
efficacy, tolerability, and use in patients with common comorbidities. CymaBay is poised to follow arhalofenate with two additional clinical stage product candidates, one in diabetes and one that has potential utility in high unmet need (no existing
or limited therapies) and/or orphan diseases (rare diseases).</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred net losses from operations since its inception and
has an accumulated deficit of $344.9 million and $329.5 million at September&nbsp;30, 2013, and December&nbsp;31, 2012, respectively. The Company recorded net loss of $6.2 million for the nine months ended September&nbsp;30, 2013. The Company also
recorded negative cash flows from operating activities during the nine months ended September&nbsp;30, 2013 of $4.9 million. To date, none of the Company&#146;s product candidates have been approved for marketing and sale, and the Company has not
recorded any product sales. Management expects operating losses to continue for the next several years. The Company&#146;s ability to achieve profitability is dependent primarily on its ability to successfully develop, acquire or in-license
additional product candidates, continue clinical trials for product candidates currently in clinical development, obtain regulatory approvals, and support commercialization activities for partnered product candidates. Products developed by the
Company will require approval of the U.S. Food and Drug Administration (FDA) or a foreign regulatory authority prior to commercial sale. The regulatory approval process is expensive, time-consuming, and uncertain, and any denial or delay of approval
could have a material adverse effect on the Company. Even if approved, the Company&#146;s products may not achieve market acceptance and will face competition from both generic and branded pharmaceutical products. As of September&nbsp;30, 2013, and
December&nbsp;31, 2012, the Company had cash and cash equivalents of $32.1 million and $7.7 million and a working capital surplus (deficit) of $29.9 million and ($9.9) million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, the Company sold shares of its common stock and warrants to purchase shares of its common stock in a private placement for
aggregate gross proceeds of $26.8 million, and raised an additional $5.0 million in venture debt financing pursuant to a $10.0 million loan agreement which the Company entered into simultaneously with the private placement on September&nbsp;30,
2013, resulting in aggregate net proceeds to the Company of $28.9 million after deducting placement agent fees and estimated offering expenses. At the same time the Company issued shares of its common stock in cancellation of approximately $16.9
million of debt owed to the holder of that debt. On October&nbsp;31, 2013, the Company sold additional shares of its common stock and warrants to purchase shares of its common stock, which sales are also part of the private placement, for aggregate
net proceeds of $2.9 million after deducting placement agent fees and estimated offering expenses. The private </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
placement, the venture debt financing and the issuance of common stock in cancellation of the $16.9 million of debt is referred to as the 2013 financing. After giving effect to the 2013
financing, the Company believes that its existing cash will allow the Company to continue operation through the third quarter of 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, on November&nbsp;22, 2013, Company entered into an agreement with investors to purchase shares of its common stock and warrants to
purchase shares of its common stock as part of the 2013 financing for aggregate gross proceeds of $3.0 million, which sales will occur shortly after the listing of the Company&#146;s common stock on the over-the-counter market. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been
prepared in accordance U.S. GAAP (&#147;GAAP&#148;) and following the requirements of the United States Securities and Exchange Commission (&#147;SEC&#148;) for interim reporting. As permitted under those rules, certain footnotes or other financial
information that are normally required by GAAP can be condensed or omitted. In management&#146;s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all
adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#146;s financial position and its results of operations and comprehensive income (loss) and its cash flows for periods presented. These
statements do not include all disclosures required by GAAP and should be read in conjunction with the Company&#146;s financial statements and accompanying notes for the fiscal year ended December&nbsp;31, 2012, which is contained in the
Company&#146;s filing on Form 10 Amendment No.&nbsp;4 on November&nbsp;22, 2013. The results for the three and nine months ended September&nbsp;30, 2013, are not necessarily indicative of results to be expected for the year ending December&nbsp;31,
2013, or for any other interim period or for any future year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation and Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements have been prepared in accordance with GAAP, which requires management to make estimates and assumptions that affect
the amounts and disclosures reported in the financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may
yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from those estimates. The Company
believes significant judgment is involved in determining revenue recognition and in estimating stock-based compensation, accrued liabilities, and equity and liability instrument valuations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reverse Stock Split </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;30, 2013, the Company filed an amended and restated certificates of incorporation under which the Company&#146;s preferred stock and common stock was reverse split on a 1-for-79.5 basis. The accompanying financial statements and notes
to the financial statements, give retroactive effect to the reverse split for all periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentration of Credit Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of
credit risk to the extent of the fair value recorded in the balance sheet. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established
guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value of Financial Instruments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial instruments consist of cash and cash equivalents, short-term marketable securities, accounts payable, accrued
expenses, warrant liabilities and convertible notes. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and
matters of significant judgment and therefore cannot be determined with precision. The carrying amounts of cash and cash equivalents, and accrued liabilities are generally considered to be representative of their respective fair values because of
the short-term nature of those instruments. The carrying amount of the warrant liabilities represents their fair values. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is
defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the
measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and
maximizes the use of unobservable inputs and is as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Quoted prices in active markets for identical assets or
liabilities that the Company has the ability to access at the measurement date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Inputs other than quoted prices in active
markets that are observable for the asset or liability, either directly or indirectly. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Inputs that are unobservable for the
asset or liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of financial instruments such as cash and cash equivalents, short-term marketable securities,
accounts payable, convertible notes, and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Marketable securities consist of available-for-sale securities that are reported at fair value, with
the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders&#146; equity (deficit). The Company values cash equivalents and marketable securities using quoted market prices or
alternative pricing sources and models utilizing observable market inputs and, as such, classifies cash equivalents and marketable securities within Level 1 or Level 2. As of September&nbsp;30, 2013, the Company also held a Level 3 liability
associated with warrants, issued in connection with the Company&#146;s equity offering, completed in September 2013. The warrants are considered a liability and are valued using an option-pricing model, the inputs for which include exercise price of
the warrants, market price of the underlying common shares, expected term, volatility based on a group of the Company&#146;s peers and the risk-free rate corresponding to the expected term of the warrants. Changes to any of the inputs can have a
significant impact to the estimated fair value of the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash, Cash Equivalents, and Marketable Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with a remaining maturity of 90 days or less at the time of purchase to be cash
equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking, interest-bearing, and demand money market accounts. The Company invests excess cash in marketable securities with high credit ratings. These securities
consist primarily of U.S. Treasury or agency obligations and corporate debt and are classified as &#147;available-for-sale.&#148; Management may liquidate any of these investments in order to meet the Company&#146;s liquidity needs in the next year.
Accordingly, any investments with contractual maturities greater than one year from the balance sheet date are classified as short-term in the balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Realized gains and losses from the sale of marketable securities, if any, are calculated using the specific identification method. Realized
gains and losses and declines in value judged to be other-than-temporary are included in interest income or expense in the statements of operations. Unrealized holding gains and losses are reported in accumulated other comprehensive income (loss),
in the balance sheet. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. In determining whether a decline in market value is other-than-temporary,
various factors are considered, including the cause, duration of time and severity of the impairment, any adverse changes in the investees&#146; financial condition, and the Company&#146;s intent and ability to hold the security for a period of time
sufficient to allow for an anticipated recovery in market value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property and Equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment is stated at cost, less accumulated depreciation and amortization. Depreciation and amortization is calculated using the
straight-line method, and the cost is amortized over the estimated useful lives of the respective assets, generally three to seven years. Leasehold improvements are amortized over the shorter of the useful lives or the non-cancelable term of the
related lease. Maintenance and repair costs are charged as expense in the statements of operations and comprehensive income (loss) as incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impairment of Long-Lived Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reviews long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of
the assets may not be fully recoverable. An impairment loss is recognized if the estimated undiscounted future cash flow expected to result from the use and eventual disposition of an asset is less than the carrying amount. While the Company&#146;s
current and historical operating losses and cash flows are indicators of impairment, the Company believes the future cash flows to be received support the carrying value of its long-lived assets. Accordingly, the Company has not recognized any
impairment losses as of September&nbsp;30, 2013, and December&nbsp;31, 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deferred Rent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records its costs under facility operating lease agreements as rent expense. Rent expense is recognized on a straight-line basis
over the non-cancelable term of the operating lease. The difference between the actual amounts paid and amounts recorded as rent expense is recorded to deferred rent in the balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
recognizes revenue when (i)&nbsp;persuasive evidence of an arrangement exists, (ii)&nbsp;delivery has occurred or services have been rendered, (iii)&nbsp;the price is fixed and determinable, and (iv)&nbsp;collectability is reasonably assured.
Payments received in advance of work performed are recorded as deferred revenue and recognized when earned. All revenue recognized to date under the collaboration agreements has been nonrefundable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All contract revenue was from one strategic partner for the nine months ended September&nbsp;30, 2012. There was no contract revenue for the
nine months ended September&nbsp;30, 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Multiple Element Arrangements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates revenue from agreements that have multiple elements to determine whether the components of the arrangement represent
separate units of accounting. Management considers whether components of an arrangement represent separate units of accounting based upon whether certain criteria are met, including whether the delivered element has stand-alone value to the
customer. To date, all of the Company&#146;s collaboration agreements have been assessed to have one unit of accounting. Up-front and license fees received for a combined unit of accounting have been deferred and recognized ratably over the
projected performance period. Non-refundable fees where the Company has no continuing performance obligations have been recognized as revenue when collection is reasonably assured and all other revenue recognition criteria have been met. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Milestones and Contingent Payments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contingent consideration received from the achievement of a substantive milestone will be recognized in its entirety in the period in which the
milestone is achieved. A milestone is defined as an event having all of the following characteristics: (i)&nbsp;there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, (ii)&nbsp;the event can
only be achieved based in whole or in part on either the Company&#146;s performance or a specific outcome resulting from the Company&#146;s performance and (iii)&nbsp;if achieved, the event would result in additional payments being due to the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s future research and development and license agreements may provide for success fees or payments to be paid to
the Company upon the achievement of certain development milestones. Given the challenges inherent in developing biologic products, there may be substantial uncertainty as to whether any such milestones would be achieved at the time the agreements
are executed. In addition, the Company will evaluate whether the development milestones meet all of the conditions to be considered substantive. The conditions include: (1)&nbsp;the consideration is commensurate with either of the following:
(a)&nbsp;the Company&#146;s performance to achieve the milestone or (b)&nbsp;the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the Company&#146;s performance to achieve the milestone;
(2)&nbsp;the consideration relates solely to past performance; and (3)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. If the Company considers the development milestones to be
substantive, revenue related to such future milestone payments will be recognized as the Company achieves each milestone. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Funding </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal and external research and development costs reimbursed in connection with research and development funding or collaboration agreements are recognized
as revenue in the same period as the costs are incurred, and are presented on a gross basis because the Company acts as a principal, has the discretion to choose suppliers, bears credit risk, and performs part of the services. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of costs incurred in identifying, developing, and testing product candidates. These expenses consist
primarily of costs for research and development personnel, including: related stock-based compensation; contract research organizations and other third parties that assist in managing, monitoring, and analyzing clinical trials; investigator and site
fees; laboratory services; consultants; contract manufacturing services; non-clinical studies, including materials; and allocated expenses, such as depreciation of assets, and facilities and information technology that support research and
development activities. Research and development costs are expensed as incurred, including expenses that may or may not be reimbursed under research and development funding arrangements. Research and development expenses under collaboration
agreements approximate the revenue recognized under such agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expenses related to clinical trials are based upon estimates of
the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations that conduct and manage clinical trials on behalf of the Company. Expenses related to clinical trials are
accrued based upon the level of activity incurred under each contract as indicated by such factors as progress made against specified milestones or targets in each period, patient enrollment levels, and other trial activities. Payments made to third
parties under these clinical trial arrangements in advance of the receipt of the related services are recorded as prepaid assets, depending on the terms of the agreement, until the services are rendered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employee and
director stock-based compensation is measured at the grant date, based on the fair-value based measurements of the stock awards, and the portion that is ultimately expected to vest is recognized as an expense over the related vesting periods, net of
estimated forfeitures. The Company calculates the fair-value based measurements of options using the Black-Scholes valuation model and the single-option approach and recognizes expense using the straight-line attribution method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity awards granted to non-employees have been accounted for using the Black-Scholes valuation model to determine the fair value-based
measurements of such instruments. The fair value-based measurements of options and warrants granted to non-employees are re-measured over the related vesting period and amortized to expense as earned. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrant Liabilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrants issued to
common stock holders and lenders by the Company in conjunction with the 2013 financing were classified as liabilities in the accompanying balance sheets, as the terms for redemption of the underlying security were outside the Company&#146;s control.
The warrants were recorded at fair value using either the Black-Scholes option pricing model, probability weighted expected return model or a binomial model, depending on the characteristics of the warrants. The fair value of these warrants is
re-measured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense) in the accompanying condensed statements of operations and comprehensive income (loss). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company utilizes the
liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and the tax bases of assets and liabilities and are measured using enacted
tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that all or part of a deferred tax asset will not be realized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company follows the accounting guidance for uncertainty in income taxes. The guidance
prescribes a recognition threshold and measurement attribute criteria for the financial recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more
likely than not to be sustained upon examination based on the technical merits of the position. Due to the Company&#146;s ongoing operating losses since inception, the Company has not recorded reserves for uncertain tax positions as of
September&nbsp;30, 2013, and December&nbsp;31, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the financial statement effects of a tax position when it is
more likely than not, based on the technical merits, that the position will be sustained upon examination. The Company records interest related to income taxes, if any, as interest, and any penalties would be recorded as other expense in the
statements of comprehensive income (loss). There was no interest or penalties related to income taxes recorded during the three and the nine months period ended September&nbsp;30, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comprehensive Income (Loss) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss) includes net income (loss) and net unrealized gains and losses on marketable securities, which are presented in a
single continuous statement. Comprehensive income (loss) is disclosed in the statements of redeemable convertible preferred stock and stockholders&#146; deficit, and is stated net of related tax effects, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Income (Loss) Per Common Share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic
net income (loss) per share of common stock is based on the weighted average number of shares of common stock outstanding equivalents during the period. Prior to the 2013 financing, in addition to common stock, the Company had preferred stock
outstanding that contractually entitled the holder to participate in dividends and earnings of the Company. Accordingly, the Company applied the two-class method for calculating net income (loss) per share. Under this method, all undistributed
earnings are allocated first to the preferred stockholders based on their contractual right to dividends. This right is calculated on a pro rated basis for the portion of the period the preferred shares were outstanding. In addition, in connection
with the 2013 financing, during the three and nine months ended September 30, 2013, the Company extinguished all outstanding preferred stock. The excess of the carrying amount of such preferred stock over the fair value of the consideration paid to
the holders was treated as an adjustment that reduced preferred stockholders&#146; dividend or distribution entitlement. The amount of earnings that resulted from adjusting net loss for the period as described above was allocated between weighted
average number of participating preferred and common stock shares based on their entitlement to such distributions as if all of the earnings of the period had been distributed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted net loss per share of common stock is calculated using the more dilutive of the two approaches: one, &#147;as-converted&#148; method,
under which the weighted average number of common stock shares outstanding during the period is adjusted to include the assumed conversion of redeemable convertible preferred stock at the beginning of the period, and the other, the
&#147;two-class&#148; method as described above. Under either approach, the weighted average number of shares outstanding is also adjusted to include the assumed exercises of stock options and warrants, if dilutive. For periods in which the Company
has basic net loss per share of common stock, such as for the three and nine months ended September 30, 2012, diluted net loss per share is the same as basic, as any adjustments would have been anti-dilutive. For three and nine months ended
September 30, 2013, the Company&#146;s diluted net loss per common share was calculated using the &#147;as-converted&#148; method, as it resulted in a net loss per share of common stock and accordingly, was more dilutive than the
&#147;two-class&#148; method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In all periods presented, the Company&#146;s outstanding stock options and warrants were excluded from the
calculation of earnings (loss) per share because the effect would be antidilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of
basic and diluted net income (loss) per share (in thousands, except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months&nbsp;Ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion to redemption value of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reduction in redeemable convertible preferred stock distribution entitlement upon extinguishment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts allocated to participating redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(266,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(282,006</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) allocated to common stock&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common stock shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share&#151;basic:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(637.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">422.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,098.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">433.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) allocated to common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments from assumed conversion of redeemable convertible preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,637</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss allocated to common stock&#151;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common stock shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of preferred stock shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">630,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total common stock shares equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">731,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">688,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;diluted:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(637.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,098.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the total outstanding securities considered anti-dilutive and therefore excluded
from the computation of diluted net income (loss) per share (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three and Nine Months<BR>Ended September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants for common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,543,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>In February 2013, Accounting Standards Codification Topic 220, <I>Comprehensive Income </I>was amended to require companies to report,
in one place, information about reclassifications out of accumulated other comprehensive income. Accordingly, a company can present this information on the face of the financial statements, if certain requirements are met, or the information must be
presented in the notes to the financial statements. The Company adopted this guidance as of January&nbsp;1, 2013, on a retrospective basis and the items reclassified out of accumulated other comprehensive income are not material for all periods
presented.<I> </I></P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Certain Balance Sheet Items </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consists of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment includes assets financed through equipment loans, which were fully paid in January
2012. In the third quarter of 2013, CymaBay sold or disposed of all of its machinery and equipment and a portion of its computers and furniture and fixtures which resulted in a gain on sale of assets of $0.4 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following (in thousands </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued pre-clinical and clinical trial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Warrants </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2013, in connection with a private placement of common stock and warrants, the Company issued five-year
warrants to purchase 1,421,698 shares of CymaBay&#146;s common stock at an exercise price of $5.75 per share. The Company also issued five-year warrants to purchase 121,739 shares of CymaBay&#146;s common stock at an exercise price of $5.00 per
share. These warrants contain provisions that are contingent on the occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes
Option Pricing Model (the &#147;Black-Scholes Model&#148;) on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in September 2013 as a liability at fair value. In addition, the
estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders&#146; equity, or expiration of the
warrants. At issuance date, the fair value of the total warrant liability was estimated to be $5.3 million using the Black-Scholes Model. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Collaboration Agreements </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sanofi-Aventis Deutschland GMBH </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, there were no contract revenues, and in September 2012 the Company recognized a final payment from Sanofi-Aventis of $2.9 million as
contract revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Takeda San Francisco, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, the Company entered into a research collaboration agreement with Takeda San Francisco, Inc. (TSF), a wholly owned subsidiary of
Takeda Pharmaceutical Company Limited. The Company collaborated with TSF on the evaluation and validation of protein targets for the development of biological products. Approximately $0.1 million was recognized as specific research and development
funding under this agreement in nine months ended September&nbsp;30, 2012. Takeda terminated this agreement on March&nbsp;16, 2013, with no further payments being made after its termination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pfizer, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 1998, the
Company entered into a collaboration agreement in the area of insulin secretion target discovery with the Parke-Davis division of Warner-Lambert Company, since acquired by Pfizer Inc., to identify genes involved in diabetes and to develop
therapeutic compounds from the research. The collaboration agreement provided for an initial five-year funded research term, which was subsequently extended an additional year until December 2004. The Company received payments for research and
development costs for the funded research term and is entitled to receive payments for specified drug development achievements. If products resulting from the collaboration are eventually marketed and sold, the Company will also receive royalties on
sales of such products. No amounts were received under this agreement in the three and nine months ended September&nbsp;30, 2012 and 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was also eligible to receive contingent payments if certain development and commercial events were achieved as well as royalties
on worldwide product sales, if any. No amounts were received under this agreement in the three and nine months ended September&nbsp;30, 2012 and 2013. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. License Agreements </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 1998, the Company entered into a license agreement with DiaTex, Inc. (DiaTex) relating to products containing
halofenate, its enantiomers, derivatives, and analogs (the licensed products). The license agreement provides that DiaTex and the Company are joint owners of all of the patents and patent applications covering the licensed products and methods of
producing or using such compounds, as well as certain other know-how (the covered IP). As part of the license agreement, the Company received an exclusive worldwide license, including as to DiaTex, to use the covered IP to develop and commercialize
the licensed products. The Company also retained the right to sub-license the covered IP. The license agreement contains a $2,000 per month license fee as well as a requirement to make additional payments for development achievements and royalty
payments on any sales of licensed products. Pursuant to the license agreement, all of the Company&#146;s patents and patent applications related to MBX-102, its use, and production are jointly owned with DiaTex. DiaTex is entitled to up to $0.8
million for the future development of MBX-102, as well as royalty payments on any sales of products containing MBX-102. No development payments were made in the three and nine months ended September&nbsp;30, 2012 and 2013, and no royalties have been
paid to date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Debt </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;20, 2006 the Company entered into a equity and loan facility with the Johnson and Johnson Development
Corporation (&#147;JJDC&#148;) pursuant to which the Company could drawn down up to an aggregate of $30 million in loans in the form of convertible preferred stock promissory notes. In March and September 2008, the Company issued notes in the
aggregate amount of $3.5 million and $10.5 million, respectively. The notes were due on March&nbsp;17 and September&nbsp;17, 2011, including interest that accrued at 7.57%&nbsp;per annum. In December 2010, the aggregate principal amount and all
accrued interest under the notes issued in March and September 2008 were converted into the Company&#146;s Series E-3 convertible preferred stock (Series E-3 Preferred) at 232.93&nbsp;per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February and July 2009, the Company issued notes in the aggregate amount of $7.0 million and $6.7 million, respectively, which represented
the remaining amount available to the Company, in accordance with the terms of the equity and loan facility with JJDC. The notes were due in February 2012 and July 2012, including interest that accrued at 4.42%&nbsp;per annum and 4.960%&nbsp;per
annum, respectively. In January 2012, the Company amended the maturity dates of the outstanding $7.0 million and $6.7 million convertible promissory notes to extend the maturity date to March&nbsp;1, 2013, and interest rates were increased to 4.919%
and 5.46%&nbsp;per annum, respectively. In addition, the conversion price of the notes to convert into shares of the Company&#146;s Series C-1 Preferred Stock was decreased from $438.84 per share to $292.56 per share. All of these notes were further
amended in March 2013, to extend the maturity date on the notes to August&nbsp;1, 2013, and to make the notes subordinate to repayment of the Company&#146;s severance obligations to all employees until January&nbsp;1, 2014. On July&nbsp;31, 2013,
the maturity date was extended to December&nbsp;31, 2013. There are no financial covenants associated with the notes. For the three and nine months ended September&nbsp;31, 2012 and 2013, the Company recognized $0.2 million and $0.6 million
respectively, of interest expense related to the convertible promissory notes. On September&nbsp;30, 2013, the outstanding principal and accrued interest of $16.9 million under the equity and loan facility with JJDC was extinguished in exchange for
624,944 shares of common stock as an integral part of the 2013 finance restructuring. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facility Loan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, the Company entered into a facility loan agreement with Silicon Valley Bank and Oxford Finance for a total loan
amount of $10.0 million of which the first tranche of $5.0 million was drawn as part of&nbsp;the 2013 financing.&nbsp;The loan is at a fixed interest rate of 8.75% payable twelve months interest only and thirty-six months amortization thereafter,
with a final interest payment of&nbsp;$0.3 million at the end of the loan period.&nbsp;Until positive Phase 2b data is achieved, the Company must be in compliance with one of two financial covenants at all times: (1)&nbsp;maintain 1.3 times cash to
outstanding debt or (2)&nbsp;maintain sufficient cash on hand to support eight months of operations based on a trailing average monthly cash burn. The first tranche loans under the term loan facility bear interest at a rate equal 8.75% per annum.
Loans under the second tranche will bear interest at a rate fixed at the time of borrowing equal to the greater of (i) 8.75% per annum and (ii) the sum of the Wall Street Journal prime rate plus 4.25% per annum. We were also required to pay a
facility fee of 1.00% on the term loan facility commitment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the time of the facility loan drawdown, the Company&nbsp;issued&nbsp;warrants exercisable
for a total of 121,739 shares of the Company&#146;s common stock to the lenders at an exercise price of $5.00 per share.&nbsp;As a result of this a long term warrant liability of $0.5 million was recorded in the accompanying condensed balance sheet
as of September&nbsp;30, 2013.</P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Commitments and Contingencies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases office and laboratory space in a single building in Hayward, California. The facility lease, as amended
on July&nbsp;15, 2010, has a term of four years, unless terminated earlier by the Company, and expires on April&nbsp;30, 2014. Rent expense was $0.4 million and $0.1 million for each of the nine and three months ended September&nbsp;30, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under this amended agreement are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lease&nbsp;Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ending December 31:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future minimum payments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and
provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. The Company&#146;s exposure under these agreements is unknown because it involves future claims that
may be made against the Company that may be, but have not yet been, made. To date, the Company has not paid any claims or been required to defend any action related to these indemnification obligations, and no amounts have been accrued in the
accompanying balance sheets related to these indemnification obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has agreed to indemnify its executive officers and
directors for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments the Company could be required
to make under this indemnification is unlimited; however, the Company maintains insurance policies that may limit its exposure and may enable it to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness
of the insurer to assume coverage, and subject to certain retention, loss limits, and other policy provisions, the Company believes the fair value of these indemnification obligations is not material. Accordingly, the Company has not recognized any
liabilities relating to these obligations as of September&nbsp;30, 2013, and December&nbsp;31, 2012. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without
expensive litigation against these insurers, in which case the Company may incur substantial liabilities as a result of these indemnification obligations. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Preferred Stock </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the private placement in September 2013, 46,626,294 outstanding shares of redeemable convertible
preferred stock were converted into 2,793,281 shares of common stock, and the related carrying value of $324.0 million was reclassified to additional paid-in capital. At September&nbsp;30, 2013, no shares of redeemable convertible preferred stock
were issued or outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, the Company had authorized 10,000,000 shares of preferred stock with a par value of $.0001 per share. No shares of
preferred stock were issued or outstanding as of September&nbsp;30, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the September&nbsp;30, 2013 conversion, the Company
had the following series of outstanding convertible preferred stock (collectively, the Preferred Stock): Series A-1 Preferred, Series B-1 Preferred, Series C-1 Preferred, Series D-1 Preferred, Series E-1 Preferred and Series E-3 Preferred. Series
E-1 Preferred and Series E-3 Preferred are collectively referred to as the Series E Preferred. The Preferred Stock was initially recorded at its original purchase price, which represented fair value on the date of issuance, net of issuance costs, if
any. The original purchase price per share of Series A-1 Preferred, Series B-1 Preferred, Series C-1 Preferred, Series D-1 Preferred, and Series E Preferred is equal to $232.93, $232.93, $365.70, $232.94, and $232.93 per share, respectively. The
preferred stock balances are recorded at the original fair value and the accreted dividends based on the per share terms at issuance of Series A-1 Preferred, Series B-1 Preferred, Series C-1 Preferred, Series D-1 Preferred, and Series E Preferred,
which are equal to $18.64, $18.64, $29.26, $18.64, and $18.64 per share per annum, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Series B-1 Preferred,
Series D-1 Preferred, and Series E Preferred were redeemable upon the request of the holders of at least 66 2/3% of outstanding shares of Series B-1 Preferred, voting as a separate class, and 51% of outstanding shares of Series D-1 Preferred and
Series E Preferred, voting together as a separate class. In this event, the Company would be required to redeem the shares in three equal annual installments, beginning in September 2021, at the applicable original purchase price per share. All
shares of Preferred Stock were redeemable in the event of a change of control at their liquidation preferences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As all Preferred Stock
was redeemable either at the option of the holder or upon an event outside the control of the Company (i.e., a change in control), the related amounts were presented outside of stockholders&#146; equity (deficit). In August and December 2003, the
Company completed two closings of a private placement of Series B-1 Preferred, in which the Company issued a total of 136,520 shares at a price of $232.93 per share for gross proceeds of $31.8 million. In November and December 2004, the Company
completed two further closings of Series B-1 Preferred, in which the Company issued a total of 188,894 shares at a price of $232.93 per share for gross proceeds of $44.0 million. The Series B-1 Preferred investors in these two final closings also
purchased warrants for 29,245 shares of common stock at an exercise price of $30.21 per </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share, with an exercise period of five years from the date of purchase, for $1.51 cents per share of common stock covered by the warrants. In November 2009, the exercise period of these warrants
was extended to December&nbsp;31, 2011. In December 2012, the Company&#146;s Board of Directors reduced the number of shares exercisable under these warrant by 45% of the original shares and approved the extension of the exercise period until
April&nbsp;1, 2013. In April 2013 these warrants expired in accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2006, the Company issued 27,345 shares
of Series C-1 Preferred to JJDC at a price of $365.70 per share, for gross proceeds of $10.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2007, the Company issued
137,592 shares of Series D-1 Preferred at a price of $232.94 per share, for gross proceeds of $32.0 million. In connection with the issuance, the Series D-1 Preferred investors also purchased warrants for an aggregate of 20,639 shares of common
stock at an exercise price of $22.13 per share, with an exercise period of five years from the date of purchase, for $0.79 cents per share of common stock covered by the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2008, the Company repurchased 646, 1,610 and 472 shares of Series A-1 Preferred, Series B-1 Preferred and Series D-1 Preferred,
respectively, and a warrant for 71 shares of common stock, for an aggregate purchase price of $82,000. The Company allocated the purchase price among the preferred shares and warrant based upon their respective fair values. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2009, the Company issued 1,288 shares of Series E-1 Preferred upon the conversion of debt issued under a loan agreement. In June
and December 2010, the Company issued 859 and 37,119 shares of Series E-1 Preferred, respectively, upon conversion of debt issued under a loan agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2010, the Company issued 71,543 shares of Series E-3 Preferred upon conversion of the JJDC convertible notes that were due in 2011
(Note 7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2012, convertible preferred stock balances were as follows (in thousands, except share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Issued</B><br><B>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">731,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">256,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">318,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant rights, privileges and preferences of the Preferred Stock were as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of
Series B-1 Preferred were entitled to elect five members of the Company&#146;s Board of Directors, the holders of Series D-1 Preferred were entitled to elect one member of the Company&#146;s Board of Directors, and the holders of common stock were
entitled to elect one member of the Company&#146;s Board of Directors, subject to certain restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preferred Stock carried voting rights equal to the number of shares of common stock into which it could be converted. Additionally, certain
corporate actions could only be exercised upon the approval of holders of 66 2/3% of the outstanding shares of Series B-1 Preferred and Series C-1 Preferred, voting together as a single class, and 51% of the outstanding shares of Series D-1
Preferred and Series E Preferred, voting together as a single class. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All dividends on the Preferred Stock were payable when and if declared by the Company&#146;s Board of Directors. The holders of Series E
Preferred were entitled to cumulative dividends in preference to the holders of Series A-1 Preferred, Series B-1 Preferred, Series C-1 Preferred, Series D-1 Preferred, and common stock. The holders of Series D-1 Preferred were entitled to cumulative
dividends in preference to the holders of Series A-1 Preferred, Series B-1 Preferred, Series C-1 Preferred, and common stock. The holders of Series B-1 Preferred and Series C-1 Preferred were entitled to cumulative dividends in preference to the
holders of Series A-1 Preferred and common stock. The holders of Series A-1 Preferred were entitled to cumulative dividends in preference to the holders of common stock. The dividend rate were $18.64, $18.64, $29.26, $18.64, and $18.64 per annum for
each outstanding share of Series E Preferred, Series D-1 Preferred, Series C-1 Preferred, Series B-1 Preferred, and Series A-1 Preferred, respectively. Additionally, if dividends were paid to any holder of common stock, the holders of Preferred
Stock would receive a dividend of a per share amount (on an as-if-converted to common stock basis) equal to the amount paid to the holders of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No dividends were declared as of December&nbsp;31, 2012. Prior to the conversion of the Preferred Stock, the aggregate cumulative dividends as
of September&nbsp;30, 2013, were $3.4 million ($47.28 per share), $1.9 million ($48.14 per share), $15.9 million ($116.00 per share), $5.6 million ($201.83 per share), $63.1 million ($168.96 per share), and $2.3 million ($183.64 per share) for
Series E-3 Preferred, Series E-1 Preferred, Series D-1 Preferred, Series C-1 Preferred, Series B-1 Preferred, and Series A-1 Preferred, respectively. The aggregate cumulative dividends as of December&nbsp;31, 2012, were $2.7 million ($38.04 per
share), 1.5&nbsp;million ($38.90 per share), $14.6 million ($106.75 per share), $5.1 million ($187.32 per share), $59.6 million ($159.72 per share), and $2.2 million ($174.40 per share) for Series E-3 Preferred, Series E-1 Preferred, Series D-1
Preferred, Series C-1 Preferred, Series B-1 Preferred, and Series A-1 Preferred, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Preference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Preferred Stock was outstanding, in the event of a liquidation, dissolution, winding up, or change in control of the Company, the
liquidation preference of each stockholder class was to be paid in the following order, from available funds: first to the holders of Series E-1 Preferred and Series E-3 Preferred, second to the holders of Series D-1 Preferred, third to the holders
of Series B-1 Preferred and Series C-1 Preferred, and fourth to the holders of Series A-1 Preferred. After payment of the Preferred Stock liquidation preferences, the remaining assets of the Company were to be distributed ratably to all holders of
common stock and Preferred Stock on an as-if-converted basis. The liquidation preference of Series E-1 Preferred, Series E-3 Preferred, Series D-1 Preferred, Series C-1 Preferred, Series B-1 Preferred, and Series A-1 Preferred was equal to $465.87,
$290.97, $232.94, $365.70, $232.93, and $232.93 per share, respectively, plus any cumulative unpaid dividends. If there were insufficient funds available to satisfy each liquidation preference in its entirety, the holders of Preferred Stock were to
be paid a pro rata amount based on their liquidation preference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock was convertible at any time, at the option of the holder, into shares of the Company&#146;s common stock at the
applicable conversion rate. The conversion rate for each of the series of Preferred Stock was 1:1, except for the Series D-1 Preferred, which had a conversion rate of 1.365:1. With respect to the Series E Preferred, Series D-1 Preferred, Series B-1
Preferred, and Series A-1 Preferred, if the Company issued common stock or securities convertible into or exercisable for shares of common stock at a price less than the respective original purchase price per share, the conversion rate of such stock
would be adjusted to the lowest price per share paid in such issuance. The conversion rate for Preferred Stock would not be adjusted for common stock issuances on the exercise of options or warrants issued to employees, directors, or consultants of
the Company and in certain other circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>Each share of Preferred Stock automatically converted on September&nbsp;30, 2013
into common stock upon the approval of holders of 66 2/3% of the outstanding shares of Series B-1 Preferred, voting as a separate class, and 51% of the outstanding shares of Series D-1 Preferred and Series E Preferred, voting together as a separate
class, or upon the closing of an underwritten public offering of the Company&#146;s common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended, at a per share price of at least $8.00, and raising
aggregate gross proceeds of at least $30.0 million. In connection with the Company&#146;s 2013 financing, each holder of the Company&#146;s preferred stock that participated in such financing for between 1% and up to 99% of such holders &#147;<I>Pro
Rata Share</I>&#148; (as defined in the Company&#146;s <I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
</I>then effective certificate of incorporation) had each shares of preferred stock represented by such participation amount convertible into four shares of common stock and the balance of any
shares of preferred stock converted into common stock at the applicable conversion rate as defined in the certificate of incorporation. Any holder that participated in the 2013 financing for between 100% and 300% of such holder&#146;s Pro Rata Share
(the &#147;<I>Participation Multiple</I>&#148;) had each shares of preferred stock convert into shares of common stock by multiplying the product of (y)&nbsp;the aggregate number of shares of preferred stock held by such holder multiplied by the
applicable Participation Multiple and (z)&nbsp;four (4).<I> </I></P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Common Stock </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, the Company authorized 100,000,000 shares of common stock with a par value of $.0001 per share.
On September&nbsp;30, 2013, 8,790,764 shares of common stock were issued at $5.00 per share in the 2013 financing which included a reverse split on a 1-for-79.5 basis of the Company&#146;s existing preferred and common stock . In addition, 1,421,698
warrants were issued at $5.75 per share and 121,739 warrants were issued at $5.00 per share. As a result of this a long term warrant liability of $4.8 million was recorded in the accompanying balance sheet as of September&nbsp;30, 2013.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2013 and December&nbsp;31, 2012, the Company had reserved shares of authorized but unissued common stock as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Reserved<BR>September&nbsp;30,&nbsp;2013<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Reserved<BR>December&nbsp;31,&nbsp;2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,543,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity incentive plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">577,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total reserved shares of common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,120,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">829,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the above reserved shares, the Company has reserved stock for issuance upon conversion of the
outstanding convertible notes (Note 7). </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Stock Plans and Stock-Based Compensation </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;30, 2013, the Company&#146;s stockholders approved the 2013 Equity Incentive Plan, or 2013 Plan, under which shares of the Company&#146;s common stock are reserved for issuance pursuant to stock awards, including, but not limited to,
incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, and performance cash awards. In addition, the share reserve will automatically increase
on January&nbsp;1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year, for a period of not more than ten years, commencing on January&nbsp;1, 2014, in an amount equal to 5% of the total number of shares of capital stock outstanding
on December&nbsp;31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of the preceding calendar year, unless the Board determines otherwise prior to December&nbsp;31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of such calendar year.
As of November&nbsp;1, 2013, we had issued options exercisable for an aggregate of 321,574&nbsp;shares of the Company&#146;s common stock under the 2013 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation Expense </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee and
Director Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employee and director stock-based compensation expense recorded was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Income Taxes </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No provision for U.S. income taxes exists due to tax losses incurred in all periods presented. Deferred income taxes reflect
the tax effects of net operating loss and tax credit carryforwards and the net temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Realization of the net deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which is uncertain. Based
on available objective evidence, management believes it more likely than not that the Company&#146;s deferred tax assets are not realizable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The net valuation
allowance increased by $0 and $4.5 million during the nine months ended September&nbsp;30, 2013 and the year ended December&nbsp;31, 2012, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2012, the Company had federal and state net operating loss carryforwards of approximately $156.0 million to offset
future federal income taxes which will expire beginning in 2024 through 2032 and the state income taxes which will expire beginning in 2014 through 2032. Current federal and state tax laws include substantial restrictions on the utilization of net
operating losses and tax credits in the event of an ownership change. Even if the carryforwards are available, they may be subject to annual limitations, lack of future taxable income, or future ownership changes that could result in the expiration
of the carryforwards before they are utilized. If the Company determines in the future that it will be able to realize all or a portion of its net operating loss carryforwards, an adjustment to the Company&#146;s net operating loss carryforwards
would increase net income in the period in which the Company makes such a determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Utilization of the net operating loss and tax
credits carryforwards may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the
expiration of net operating loss and tax credit carryforwards before utilization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes activity related to the
Company&#146;s gross unrecognized tax benefits (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases related to 2012 tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of September&nbsp;30, 2013 and December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unrecognized tax benefits, if recognized, would not have an impact on the Company&#146;s effective tax
rate. The Company does not expect a significant change to its unrecognized tax benefits over the next twelve months. The unrecognized tax benefits may increase or change during the next year for items that arise in the ordinary course of business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the U.S. federal and California jurisdiction and is not currently under examination by federal,
state, or local taxing authorities for any open tax years. The tax years 1998 through 2012 remain open to examination by the major taxing authorities. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Related-Party Transactions </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company paid a former member of its Board of Directors, who is also a member of its Scientific and Clinical Advisory
Boards, a total of $60,000 in the year ended December&nbsp;31, 2012 and $35,000 for the nine months ended September&nbsp;30, 2013, in monthly cash retainers. The Company also issued options to purchase shares of common stock to this individual in
his capacity as a member of its Scientific Advisory Board (Note 11). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Subsequent Events </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;31, 2013, the Company sold additional shares of common stock and warrants to purchase shares of the Company&#146;s common stock
in a second closing of the 2013 financing for gross proceeds of $3.3 million, resulting in net proceeds of $2.9 million after deducting placement agent fees and offering expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, on November&nbsp;22, 2013, the Company entered into an agreement with investors to purchase shares of its common stock and warrants
to purchase shares of its common stock as part of the 2013 financing for aggregate gross proceeds of $3.0 million, which sales will occur shortly after listing of the Company&#146;s common stock on the over-the-counter market </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Option Grants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">207,724 and 62,430
shares of common stock options were granted to the CEO and CSO, respectively, exercisable at $5.00 per share and vesting over a four-year period, with one-third (1/3)&nbsp;of the shares vested on October&nbsp;31, 2013, and the remaining 2/3 of the
shares vesting ratably, on a monthly basis, over the following forty-eight (48)&nbsp;months. In addition, 51,420 shares of common stock options exercisable at $5.00 per share with an early exercise date were granted to members of the Board of
Directors as compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lease Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;8, 2013, CymaBay entered into a new lease starting January&nbsp;1, 2014, and expiring in December&nbsp;31, 2018, for 8,894
square feet of office space in Newark, CA. The Company&#146;s lease obligations under this new lease are approximately $1.7 million. </P>
 <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx608283_7"></A>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Operating results for the three and nine months ended September&nbsp;30, 2013, are not necessarily indicative of results that may occur in
future interim periods or for the full fiscal year. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This Quarterly Report on Form&nbsp;10-Q contains statements indicating
expectations about future performance and other forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Exchange Act, that involve risks and uncertainties. We usually use words such as
&#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;intend,&#148; or the negative of these
terms or similar expressions to identify these forward-looking statements. These statements appear throughout this Quarterly Report on Form&nbsp;10-Q and are statements regarding our current expectation, belief or intent, primarily with respect to
our operations and related industry developments. Examples of these statements include, but are not limited to, statements regarding the following: our business and scientific strategies; the progress of our and our collaborators&#146; product
development programs, including clinical testing, and the timing of results thereof; our corporate collaborations and revenues that may be received from our collaborations and the timing of those potential payments; our expectations with respect to
regulatory submissions and approvals;&nbsp;our drug discovery technologies; our research and development expenses; protection of our intellectual property; sufficiency of our cash and capital resources and the need for additional capital; and our
operations and legal risks. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including as a result of the
risks and uncertainties discussed under the heading &#147;Risk Factors&#148; in Item&nbsp;1A of Part&nbsp;II of this Quarterly Report on Form&nbsp;10-Q. Any forward-looking statement speaks only as of the date on which it is made, and we undertake
no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible
for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in
any forward-looking statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CymaBay Therapeutics Inc., formerly Metabolex, Inc., is focused on developing therapies to treat metabolic diseases. Arhalofenate, our lead
product candidate, is being developed for the treatment of gout. Arhalofenate has demonstrated two therapeutic actions: the prevention of painful attacks of gout in joints (flares) and the lowering of serum uric acid (sUA) by promoting excretion of
uric acid by the kidney. In addition, arhalofenate provides physicians with what they identified in a recent survey (TreatmentTrends<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>: Gout U.S. August 2011) as the most important attributes
when selecting a gout therapy: no serious safety issues, well tolerated, minimize frequency of flares and use in patients with a broad range of comorbidities, (other diseases that individual patients have in addition to gout).</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CymaBay has completed three Phase 2 studies of arhalofenate in gout patients in which it demonstrated a consistent pattern of reduction of
flare incidence and duration and lowering of serum uric acid (sUA). Arhalofenate has established a safety profile in toxicology studies in animals and in clinical studies involving nearly 1,000 patients exposed to arhalofenate. One additional Phase
2b clinical study of 12 weeks duration is planned to confirm the safety and efficacy of a higher dose prior to initiating Phase 3 studies. Due to its safety profile and ability to both reduce flares and lower sUA, we believe that arhalofenate has a
differentiated profile that is attractive for use in a large population, with significant advantages over marketed and emerging agents which have limitations in their efficacy, tolerability, and use in patients with common comorbidities. CymaBay is
poised to follow arhalofenate with two additional clinical stage product candidates, one in diabetes and one that has potential utility in high unmet need (no existing or limited therapies) and/or orphan diseases (rare diseases).</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company. Under the JOBS Act emerging growth companies can delay adopting new or revised accounting standards until
such time of those standards apply to private companies. We plan to avail ourselves of this exemption from new or revised accounting standards, and therefore, we may not be subject to the same new or revised accounting standards as other public
companies that are not &#147;emerging growth companies&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reverse Stock Split and Conversion of Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, we effected a 1-for-79.5 reverse split of our preferred stock and common stock, which we refer to as the reverse
stock split, all of the shares of our outstanding preferred stock converted to common stock, we sold shares of our common stock and warrants to purchase shares of our common stock in a private placement for aggregate gross proceeds of $26.8 million,
and raised an additional $5.0 million in venture debt financing pursuant to a $10.0 million loan agreement which we entered into simultaneously with the private placement, resulting in aggregate net proceeds to CymaBay of $28.9 million after
deducting placement agent fees and estimated offering expenses. At the same time we issued shares of our common stock in cancellation of approximately $16.9 million of debt owed to the holder of that debt. On October&nbsp;31, 2013, we sold
additional shares of our common stock and warrants to purchase shares of our common stock, which sales are also part of the private placement, for aggregate net proceeds to CymaBay of $2.9 million after deducting placement agent fees and estimated
offering expenses. Further, on November&nbsp;22, 2013, the Company entered into an agreement with investors to purchase shares of its common stock and warrants to purchase shares of its common stock as part of the 2013 financing for aggregate gross
proceeds of $3.0 million, which sales will occur shortly after listing the Company&#146;s stock on the over the counter. We refer to the private placement, the venture debt financing and the issuance of our common stock in cancellation of the $16.9
million of debt as the 2013 financing. The discussion in this &#147;Management&#146;s Discussion and Analysis of Financial Conditions and Results of Operations&#148; gives retroactive effect to the reverse stock split that occurred on
September&nbsp;30, 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which
have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. We base our estimates on historical experience and on various other factors that
we believe to be materially reasonable under the circumstances and review our estimates on an ongoing basis. Actual results may materially differ from these estimates under different assumptions or conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We discussed accounting policies and assumptions that involve a higher degree of judgment and
complexity within Note 1 to our audited consolidated financial statements in our filing on Form 10, originally filed with the SEC on August&nbsp;12, 2013. There were no material changes to our critical accounting policies and estimates during the
quarter ended September&nbsp;30, 2013, except as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Warrant Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have issued freestanding warrants to purchase shares of our common stock. Our outstanding common stock warrants issued in connection with
our 2013 financing are classified as liabilities in the condensed balance sheet as they contain terms for redemption of the underlying security are outside our control. The fair value of all warrants is re-measured at each financial reporting date
with any changes in fair value being recognized in change in fair value of warrant liabilities, a component of other income (expense), in the condensed statements of operations and comprehensive income (loss). We will continue to re-measure the fair
value of the warrant liabilities until: (i)&nbsp;exercise, or (ii)&nbsp;expiration of the related warrant. We do not re-measure the fair value of warrants unless they are required to be accounted for as liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>JOBS Act </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April
2012, the JumpStart Our Business Startups Act of 2012, or the JOBS Act, was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an &#147;emerging growth company.&#148; As an
&#147;emerging growth company,&#148; we are electing to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards, and as a result, we will not comply with new or revised
accounting standards until such standards are required for non-emerging growth companies. Section&nbsp;107 of the JOBS Act provides that our decision to take advantage of the extended transition period is irrevocable. In addition, we are in the
process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if as an &#147;emerging growth company&#148; we choose to
rely on such exemptions, we may not be required to, among other things, (i)&nbsp;provide an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section&nbsp;404, (ii)&nbsp;provide all of the
compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii)&nbsp;comply with any requirement that may be adopted by the Public Company Accounting
Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (auditor discussion and analysis), and (iv)&nbsp;disclose certain
executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive Officer&#146;s compensation to median employee compensation. These exemptions will apply for a period
of five years following the completion of our initial public offering or until we no longer meet the requirements of being an &#147;emerging growth company,&#148; whichever is earlier. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not generated any income from operations. Since our date of incorporation through September&nbsp;30, 2013, we have an
accumulated deficit of $344.9 million, primarily as a result of expenditures for research and development and general and administrative expenses. While we may in the future generate revenue from a variety of sources, including license fees and
milestone payments in connection with strategic partnerships, our product candidates are at a mid-level stage of development and may never be successfully developed or commercialized. Accordingly, we expect to continue to incur substantial losses
from operations for the foreseeable future and there can be no assurance that we will ever generate significant revenue to achieve and sustain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three Months</B><br><B>Ended September&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months</B><br><B>Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B></B>(unaudited)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>($ in thousands)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(242</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,866</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (expense), net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contract Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our recent revenue comprises primarily collaboration agreement-related revenue. Collaboration agreement-related revenue has included license
fees, payments for research and development services and milestone and other contingent payments. All contract revenue was from one strategic partner, Sanofi-Aventis, for the nine months ended September&nbsp;30, 2012. We recognized a final payment
from Sanofi-Aventis of $2.9 million as contract revenue in 2012. For the three and nine months ended September&nbsp;30, 2013, there were no collaboration revenues. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research&nbsp;&amp; Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting research and development is central to our business model. For the three months ended September&nbsp;30, 2013 and 2012, research and
development expenses were, $0.7 million and $2.3 million, respectively, and for the nine months ended September&nbsp;30, 2013 and 2012, research and development expenses were $3.1 million and $7.6 million, respectively. Research and development
expenses are detailed in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;months&nbsp;ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MBX-102 Clinical and Non-Clinical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MBX-102 Gout &#150; Three Phase 2 Randomized Studies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MBX-8025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MBX-2982</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Projects</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Project Costs</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Internal Research and Development Costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Research and Development</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our external research and development costs consist primarily of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct our clinical trials and a substantial portion of our preclinical activities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of acquiring and manufacturing clinical trial and other materials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other costs associated with development activities, including additional studies </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal
research and development costs consist primarily of salaries and related fringe benefits costs for our employees (such as workers compensation and health insurance premiums), stock-based compensation charges, travel costs, lab supplies and overhead
expenses. Internal costs generally benefit multiple projects and are not separately tracked per project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total project costs decreased by
$0.8 million and $2.8 million for the three and nine months ended September&nbsp;30, 2013 as compared to September&nbsp;30, 2012, respectively, due to a hold placed on all projects until financing could be obtained. Internal research and development
cost decreased by $0.7 million and $1.7 million for the three and nine months ended September&nbsp;30, 2013 versus September&nbsp;30, 2012 due to cost cutting measures in 2013. There was an involuntary reduction in workforce at the end of May 2013
and the subsequent shutdown of the labs from June to September 2013 since we decided to place our primary focus on the clinical area. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
expect to continue to incur substantial expenses related to our development activities for the foreseeable future as we continue product development and initiate our next clinical study for arhalofenate. Since product candidates in later stages of
clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials, we expect that our research and development expenses
will increase in the future. In addition, if our product development efforts are successful, we expect to incur substantial costs to prepare for potential Phase 3 clinical trials and activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist principally of personnel-related costs, professional fees for legal, consulting, audit services,
rent and other general operating expenses not otherwise included in research and development. For the three months ended September&nbsp;30, 2013 and 2012, general and administrative expenses were $0.6 million, and $0.7 million, respectively, and for
the nine months ended September&nbsp;30, 2013 and 2012, general and administrative expenses were $2.8 million and $3.3 million, respectively. The $0.2 million decrease between the three months ended September&nbsp;30, 2013 and 2012 was due to a
reduction in labor costs of $0.1 million due to attrition of personnel and $0.1 million due to a reduction in spending on patent legal costs. The $0.5 million decrease in spending for nine months ending September&nbsp;30, 2013 as compared to
September&nbsp;30, 2012 was due to $0.4 million savings in labor costs due to attrition and $0.2 reduction in travel costs in keeping with cost reduction measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate general and administrative expenses will increase in future periods, reflecting an expanding infrastructure and increased
professional fees associated with being a public reporting company under the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have funded our operations through the sale of equity securities and collaborations with third parties. At September&nbsp;30, 2013,
we had cash and cash equivalents of $32.1 million, compared to $7.7 million at December&nbsp;31, 2012, primarily as a result of the aggregate net proceeds of $28.9 million we raised on September&nbsp;30, 2013, as described in &#147;Reverse Stock
Split and Conversion of Preferred Stock&#148; above. On October&nbsp;31, 2013, we raised additional aggregate net proceeds of $2.9 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, on November&nbsp;22, 2013, Company entered into an agreement with investors to purchase shares of its common stock and warrants to
purchase shares of its common stock as part of the 2013 financing for aggregate gross proceeds of $3.0 million, which sales will occur shortly after the listing of the Company&#146;s common stock on the over-the-counter market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on September&nbsp;30, 2013, we entered into a term loan facility with Silicon Valley Bank and Oxford Finance LLC, collectively
referred to as the lenders, for an aggregate amount of $10 million, $5 million of which was made available to us as of September&nbsp;30, 2013, and the remaining $5 million, which we refer to as the second tranche, of which shall be made available
to us upon the achievement of positive data and successful completion of all primary endpoints for either the 600mg or 800mg dose of arhalofenate in our planned Phase 2b study (the &#147;second draw milestone&#148;). The second tranche shall be
available to us until the earlier of June&nbsp;30, 2015, or the occurrence and continuation of an event of default (as described in the term loan facility). Each tranche matures 48 months following the funding date of such tranche. The proceeds of
the term loan facility may be used for general corporate purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first tranche loans under the term loan facility bear interest at a rate equal 8.75%&nbsp;per
annum. Loans under the second tranche will bear interest at a rate fixed at the time of borrowing equal to the greater of (i)&nbsp;8.75%&nbsp;per annum and (ii)&nbsp;the sum of the Wall Street Journal prime rate plus 4.25%&nbsp;per annum. We were
also required to pay a facility fee of 1.00% on the term loan facility commitment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are permitted to make voluntary prepayments of the
term loans with a prepayment fee equal to 3% of the term loans prepaid. On each tranche, we are required to make 12 monthly interest only payments after the funding date followed by a repayment schedule equal to 36 equal monthly payments of the
outstanding principal of the outstanding term loans of each tranche. After the 36-month amortization period of each tranche, the remaining balance of such tranche and a final payment equal to 6.50% of the original principal amount of the applicable
tranche are payable on the maturity date of such tranche. We are required to make mandatory prepayments of the outstanding term loans upon the acceleration by the lenders of such loans following the occurrence of an event of default, along with a
payment of the final payment, the prepayment fee and any all other obligations (each as defined or described under the term loan facility) that are due and payable at the time of the prepayment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations under the term loan facility are secured, subject to customary permitted liens and other agreed upon exceptions, (1)&nbsp;by a
first priority pledge of all of the equity interests of each of our direct and indirect subsidiaries, and (2)&nbsp;a perfected first priority interest in all of our tangible and intangible assets, including all of our intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term loan facility contains customary representations and warranties and customary affirmative and negative covenants applicable to us and
our subsidiaries, including, among other things, restrictions on dispositions, changes in business, management, ownership or business locations, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with
affiliates and subordinated debt. Until the occurrence of the second draw milestone, the term loan facility contains financial covenants that require us to maintain a certain cash liquidity. The term loan facility also contains performance covenants
that require that (a)&nbsp;by no later than June&nbsp;30, 2014, shares of our common stock must be publicly traded on NASDAQ; (b)&nbsp;within one hundred twenty (120)&nbsp;days of us becoming eligible to file a registration statement with the United
States Securities and Exchange Commission on Form S-3, we must have access to an At The Market facility; and (c)&nbsp;by no later than March&nbsp;31, 2015, the lenders must have received evidence of the occurrence of the second draw milestone;
provided that our failure to comply with these performance covenants shall not be an event of default under the term loan facility so long as we deposit an amount equal to 100% of the aggregate outstanding term loans in a segregated, blocked deposit
account at Silicon Valley Bank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term loan facility also includes customary events of default, including but not limited to the
nonpayment of principal or interest, violations of covenants, material adverse change, attachment, levy, restraint on business, cross-defaults on our or any our subsidiary&#146;s material indebtedness, bankruptcy, material judgments and
misrepresentations. Upon an event of default, the lenders may, among other things, accelerate the loans and foreclose on the collateral. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operating
Activities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities, decreased $6.0 million for the nine months ended September&nbsp;30, 2013, due to a $2.3
million reduction in our net loss due primarily to a reduction in revenues and cost cutting measures and as a result of a reduction in receivables of $3.0 million and a reduction in accounts payable of $0.1 million in 2013 due to managing our cash.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing Activities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided
by investing activities for the nine months ended September&nbsp;30, 2013, of $0.4 million, was as a result of proceeds on sale of fixed assets. Cash provided by investing activities for the nine months ended September&nbsp;30, 2012, consists
primarily of $2.9 million purchases of marketable securities offset by $13.9 million in proceeds from maturities of marketable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financing
Activities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities was $28.9 million for the nine months ended September&nbsp;30, 2013, as a result of
the financing we conducted on September&nbsp;30, 2013, as described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management believes that cash and cash equivalents as of October&nbsp;31, 2013, including the
funds raised in the 2013 financing, are sufficient to sustain the operations of the company through the third quarter of 2015. We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization
of our product candidates. We will continue to require additional financing to develop our products and fund operating losses. We will seek funds through equity financings, collaborative or other arrangements with corporate sources, or through other
sources of financing, including a public offering. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our
ability to pursue our business strategies. If adequate funds are not available to us, we may be required to close our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual
Obligations and Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have lease obligations consisting of an operating lease for our operating facility that commenced in
July 2010 and expires April 2014, for approximately 41,600 square feet in Hayward, CA. In November 2013, we entered into a new lease starting January&nbsp;1, 2014, and expiring in December&nbsp;31, 2018, for 8,894 square feet of office space in
Newark, CA. Our lease obligations under this new lease are approximately $1.7 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities
often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities
involving non-exchange traded contracts. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx608283_8"></A>Item&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Quantitative and Qualitative Disclosures About Market Risk </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This item is not applicable
to us as a smaller reporting company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx608283_9"></A>Item&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Controls and Procedures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Evaluation of Disclosure Controls and Procedures. </I>Based
on the evaluation of our disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Exchange Act), our chief executive officer and chief financial officer have concluded that, as of the end of the period
covered by this report, our disclosure controls and procedures were effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes in Internal Controls. </I>There were no changes
in our internal control over financial reporting that occurred during the quarter ended September&nbsp;30, 2013, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations on the Effectiveness of Controls. </I>A control system, no matter how well conceived and operated, can provide only reasonable,
not absolute, assurance that the objectives of the controls are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been
detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our chief executive officer and chief
financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were sufficiently effective to provide reasonable assurance that the objectives of our
disclosure control system were met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx608283_10"></A>PART&nbsp;II. OTHER INFORMATION </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx608283_11"></A>Item&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Risk Factors </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In evaluating our business, you should carefully consider the following risks, as well
as the other information contained in this Quarterly Report on Form&nbsp;10-Q. These risk factors could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Quarterly Report on
Form&nbsp;10-Q and those we may make from time to time. If any of the following risks actually occurs, our business, financial condition and operating results could be harmed. The risks and uncertainties described below are not the only ones facing
us. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to obtain additional financing, we could be forced to delay, reduce or eliminate our product development programs, seek corporate partners
for the development of our product development programs or relinquish or license on unfavorable terms, our rights to technologies or product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2013, we had net cash on hand of approximately $32.1 million. On September&nbsp;30, 2013, we raised aggregate net
proceeds of approximately $28.9 million and issued common stock in cancellation of $16.9 million of debt owed to the holder of that debt and on October&nbsp;31, 2013, we raised additional aggregate net proceeds of $2.9 million and on November 22,
2013, we entered into an agreement to raise additional gross proceeds of $3.0 million. We refer to these events collectively as the 2013 financing. After giving effect to the 2013 financing, we believe that our existing cash will allow us to
continue operation through the third quarter of 2015. As set forth in the notes to our financial statements, our auditors expressed substantial doubt as to our ability to continue as a going concern if we are unable to raise additional capital
without giving effect to the 2013 financing. Our monthly spending levels vary based on new and ongoing development and corporate activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain
process that takes years to complete. We expect our research and development expenses to substantially increase in connection with our ongoing activities, particularly as we advance development of our lead clinical product candidate, arhalofenate,
for the prevention of gout flares and the treatment of hyperuricemia in patients with gout. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event CymaBay does not successfully
raise sufficient funds in financing(s), its product development activities, particularly related to the development of arhalofenate, will necessarily be curtailed commensurate with the magnitude of the shortfall or may cease altogether. To the
extent that the costs of the planned Phase 2b study of arhalofenate in patients with gout exceed current estimates and CymaBay is unable to raise sufficient additional capital to cover such additional costs, CymaBay will need to reduce operating
expenses, enter into a collaboration or other similar arrangement with respect to development and/or commercialization rights to arhalofenate, outlicense intellectual property rights to arhalofenate, sell assets or effect a combination of the above.
No assurance can be given that CymaBay will be able to effect any of such transactions on acceptable terms, if at all. Failure to progress the development of arhalofenate will have a negative effect on CymaBay&#146;s business, future prospects and
ability to obtain further financing on acceptable terms (if at all). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond the plan of operations outlined above, CymaBay&#146;s future
funding requirements and sources will depend on many factors, including but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate of progress and cost of its clinical studies, including in particular the Phase 3 studies of arhalofenate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need for additional or expanded clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate of progress and cost of its Chemistry, Manufacturing and Control registration and validation program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, economic and other terms of any licensing, collaboration or other similar arrangement into which CymaBay may enter; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs and timing of seeking and obtaining FDA and other regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent of CymaBay&#146;s other development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of competing products and market developments. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us,
we will be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects and on our ability to develop our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future, and
we may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused primarily on developing our lead product candidate,
arhalofenate. We have incurred significant net losses in each year since our inception, including net losses of approximately $11.3 million for the fiscal year 2012. Although we had net loss of $6.2 million for the nine months ended
September&nbsp;30, 2013, we had an operating loss of $5.9 million during that period. As of September&nbsp;30, 2013, we had an accumulated deficit of $344.9 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have financed our operations primarily through the sale of equity securities, licensing fees and debt. We have devoted most of our
financial resources to research and development, including our preclinical development activities and clinical trials. We have not completed development of any product candidates. We expect to continue to incur significant and increasing losses and
negative cash flows for the foreseeable future. The size of our losses will depend, in part, on the rate of future expenditures and our ability to generate revenues. In particular, we expect to incur substantial and increased expenses as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue the development of our lead product candidate, arhalofenate, for the prevention of flares and treatment of hyperuricemia in patients with gout; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek to obtain regulatory approvals for arhalofenate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prepare for the potential commercialization of arhalofenate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scale up manufacturing capabilities to commercialize arhalofenate for any indications for which we receive regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">begin outsourcing of the commercial manufacturing of arhalofenate for any indications for which we receive regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish an infrastructure for the sales, marketing and distribution of arhalofenate for any indications for which we receive regulatory approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expand our research and development activities and advance our clinical programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue our research and development efforts and seek to discover additional product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts and operations as a public company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CymaBay does not anticipate that it will generate revenue from the sale of products for the foreseeable future. CymaBay&#146;s ability to
become profitable depends upon its ability to generate significant continuing revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of additional sources of capital,
which may not be available to CymaBay on acceptable terms, or at all, the development of arhalofenate or future product candidates may be reduced in scope, delayed or terminated. If CymaBay&#146;s product candidates or those of its collaborators
fail in clinical studies or do not gain regulatory approval, or if its future products, if any, do not achieve market acceptance, CymaBay may never become profitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to
become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to generate future revenues from product sales is uncertain and depends upon our ability to
successfully develop, obtain regulatory approval for, and commercialize our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue and achieve
profitability depends on our ability, alone or with collaborators, to successfully complete the development, obtain the necessary regulatory approvals and commercialize our product candidates. We do not anticipate generating revenues from sales of
our product candidates for the foreseeable future, if ever. Our ability to generate future revenues from product sales depends heavily on our success in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining favorable results for and advancing the development of arhalofenate, including successfully initiating and completing our Phase 2b and Phase 3 clinical development; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining United States (U.S.) and foreign regulatory approvals for arhalofenate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching and commercializing arhalofenate, either on our own or with a partner, including building a sales force and collaborating with third parties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieving broad market acceptance of arhalofenate in the medical community and by third-party payors and patients; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generating a pipeline of product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting preclinical testing and clinical
trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data required to obtain regulatory approval and achieve product sales. Our anticipated development costs would likely
increase if we do not obtain favorable results or if development of our product candidates is delayed. In particular, we would likely incur higher costs than we currently anticipate if development of our product candidates is delayed because we are
required by the U.S. FDA to perform studies or trials in addition to those that we currently anticipate. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or
amount of any increase in our anticipated development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our product candidates, if approved, may not achieve commercial
success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if at all. Even if one or more of our product candidates is approved for commercial sale, we
anticipate incurring significant costs in connection with commercialization. As a result, we cannot assure you that we will be able to generate revenues from sales of any approved product candidates, or that we will achieve or maintain profitability
even if we do generate sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to
relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product
revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. We do not have any committed
external source of funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to raise additional funds to support our operations, we may sell additional equity or debt securities,
enter into collaborations, strategic alliances, or licensing arrangements or other marketing or distribution arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership
interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing, if available, may involve agreements that include covenants limiting or
restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, and declaring dividends, and will impose limitations on our ability to acquire, sell or license intellectual property rights and other
operating restrictions that could adversely impact our ability to conduct our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through
collaborations, strategic alliances, or licensing arrangements or other marketing or distribution arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product
candidates, or grant licenses on terms that may not be favorable to us. If we are unable to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition and results of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">operations could be materially adversely affected and we may not be able to meet our debt service obligations. If
we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts, or grant others rights to develop and market product
candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company and we cannot be certain if the
reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company. Under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, emerging growth companies can delay
adopting new or revised accounting standards until such time as those standards apply to private companies. We plan to avail ourselves of this exemption from new or revised accounting standards and, therefore, we may not be subject to the same new
or revised accounting standards as other public companies that are not &#147;emerging growth companies.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For as long as we continue
to be an emerging growth company, we also intend to take advantage of certain other exemptions from various reporting requirements that are applicable to other public companies including, but not limited to, reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory stockholder vote on executive compensation and any golden parachute payments not previously approved, exemption
from the requirement of auditor attestation in the assessment of our internal control over financial reporting and exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm
rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (auditor discussion and analysis). If we do, the information that we provide stockholders may be different than what
is available with respect to other public companies. We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If investors find our common stock less attractive as a result of our status as
an emerging growth company, there may be less liquidity for our common stock and our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an
emerging growth company until the earliest of (i)&nbsp;the end of the fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700 million as of the end of the second fiscal quarter, (ii)&nbsp;the end of the
fiscal year in which we have total annual gross revenues of $1 billion or more during such fiscal year, (iii)&nbsp;the date on which we issue more than $1 billion in non-convertible debt in a three-year period or (iv)&nbsp;the end of the fiscal year
following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement filed under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Clinical Development and Regulatory Approval </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on the success of our lead product candidate, arhalofenate, which is still under clinical development, and may not obtain regulatory approval
or be successfully commercialized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not marketed, distributed or sold any products. The success of our business depends upon our ability to
develop and commercialize our lead product candidate, arhalofenate, which has completed seven Phase 1 and seven Phase 2 clinical trials, including three Phase 2 studies in gout. We plan to conduct a Phase 2b clinical trial for arhalofenate in
preventing flares and reducing serum uric acid in gout patients prior to initiation of a Phase 3 program. There is no guarantee that our clinical trials will be completed or, if completed, will be successful. The success of arhalofenate will depend
on several factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful enrollment and completion of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from the FDA and regulatory authorities outside the U.S. for our product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing commercial manufacturing capabilities by making arrangements with third-party manufacturers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching commercial sales of the product, whether alone or in collaboration with others; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of the product by patients, the medical community and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively competing with other therapies; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a continued acceptable safety profile of the product following approval; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining, maintaining, enforcing and defending intellectual property rights and claims. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize arhalofenate, which would materially harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never obtained regulatory approval for a drug and we may be unable to obtain, or may be delayed in obtaining, regulatory approval for
arhalofenate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never obtained regulatory approval for a drug. In the U.S. it is possible that the FDA may refuse to accept
our New Drug Application (NDA) for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval of arhalofenate. If the FDA does not accept or approve our NDA, it may require that we
conduct additional clinical, nonclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other FDA required studies, approval of any NDA or application that
we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDA.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not know when we might commence our Phase 3 study of arhalofenate or achieve FDA approval of arhalofenate. We currently
do not have the capital necessary to conduct or complete our Phase 3 study of arhalofenate and we may not be able to raise sufficient funds necessary to conduct this study. We believe that our existing cash will be sufficient to enable us to
complete our Phase 2b study, which we anticipate completing the second quarter of 2015, and will allow us to continue operation through the third quarter of 2015. We currently believe that we will need to raise additional capital to continue our
operations beyond the third quarter of 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any delay in obtaining, or an inability to obtain, regulatory approvals would prevent us
from commercializing arhalofenate, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for arhalofenate, which would have a material adverse effect on
our business and could potentially cause us to cease operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on the successful completion of clinical trials for our product
candidates, including arhalofenate. The positive clinical results obtained for our product candidates in prior clinical studies may not be repeated in future clinical studies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approval for the sale of our product candidates, including arhalofenate, we must conduct additional clinical trials
to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more of our clinical
trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have
nonetheless failed to obtain marketing approval for their products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have completed three Phase 2 clinical studies of arhalofenate in
gout. In addition, six clinical studies with MBX-8025 and five clinical studies with MBX-2982 have been completed. However, we have never conducted a Phase 3 clinical trial. The positive results we have seen to date in our Phase 2 clinical trials of
arhalofenate for gout do not ensure that later clinical trials will demonstrate similar results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed
satisfactorily through preclinical studies and initial clinical testing. A number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience, have suffered significant setbacks in Phase 3
clinical development, even after seeing promising results in earlier clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience a number of unforeseen events during clinical trials for our product
candidates, including arhalofenate, that could delay or prevent the commencement and/or completion of our clinical trials, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical study protocol may require one or more amendments delaying study completion; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of subjects required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate or subjects may drop
out of these clinical trials at a higher rate than we anticipate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical investigators or study subjects fail to comply with clinical study protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trial conduct and data analysis errors may occur, including, but not limited to, data entry and/or labeling errors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the subjects are being exposed to unacceptable health risks; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of clinical trials of our product candidates may be greater than we anticipate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the supply or quality of our clinical trial materials or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators to suspend or terminate the trials. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase in connection with our ongoing activities, particularly if we commence a Phase 3
clinical trial with arhalofenate and undertake additional clinical trials of our other product candidates MBX-8025 and MBX-2982. Before we commence a Phase 3 clinical trial for arhalofenate, we will need to raise substantial additional capital. We
also will need to raise substantial additional capital in the future to complete the development and commercialization of MBX-8025 and MBX-2982, for which we currently have no planned clinical trials. Because successful development of our product
candidates is uncertain, we are unable to estimate the actual funds required to complete research and development and commercialize our products under development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Negative or inconclusive results of our future clinical trials of arhalofenate, or any other clinical trial we conduct, could cause the FDA to
require that we repeat or conduct additional clinical studies. Despite the results reported in earlier clinical trials for arhalofenate, we do not know whether any clinical trials we may conduct will demonstrate adequate efficacy and safety to
result in regulatory approval to market our product candidates, including arhalofenate. If later stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates, including arhalofenate,
may be adversely impacted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never conducted a clinical trial of arhalofenate as a monotherapy for the treatment of gout flares. If
arhalofenate does not demonstrate efficacy in the treatment of such flares in our planned Phase 2b clinical trial, our ability to successfully commercialize arhalofenate may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not previously conducted a clinical trial of arhalofenate for the purpose of measuring its effect on flare reduction and control
without the use of colchicine. We plan to conduct a Phase 2b clinical trial to investigate the potential benefit of arhalofenate monotherapy with regard to flare prevention and serum uric acid (sUA) lowering. In addition, our Phase 2b study will
investigate the benefits of two doses of arhalofenate monotherapy, including a higher dose than we studied in previous gout studies, without colchicine. If we do not obtain favorable efficacy and safety results in the Phase 2b trial, our ability to
successfully market arhalofenate could be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delays in clinical trials are common and have many causes, and any delay could result in increased costs to
us and jeopardize or delay our ability to obtain regulatory approval and commence product sales. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive,
difficult to design and implement, can take many years to complete, and is uncertain as to outcome. We may experience delays in clinical trials at any stage of development and testing of our product candidates. Our planned clinical trials may not
begin on time, have an effective design, enroll a sufficient number of subjects, or be completed on schedule, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Events which may
result in delays or unsuccessful completion of clinical trials, including our future clinical trials for arhalofenate, include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to raise funding necessary to initiate or continue a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in obtaining regulatory approval to commence a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching agreement with the FDA on final trial design; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in obtaining required institutional review board (IRB) approval at each site; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in recruiting suitable patients to participate in a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in having subjects complete participation in a trial or return for post-treatment follow-up; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays caused by subjects dropping out of a trial due to side effects or otherwise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays caused by clinical sites dropping out of a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">time required to add new clinical sites; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If initiation or completion of any of our clinical trials for our product candidates, including arhalofenate, are delayed for any of the above
reasons, our development costs may increase, the approval process could be delayed, any periods during which we may have the exclusive right to commercialize our product candidates may be reduced and our competitors may bring products to market
before us. Any of these events could impair our ability to generate revenues from product sales and impair our ability to generate regulatory and commercialization milestones and royalties, all of which could have a material adverse effect on our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit
the scope of any approved label or market acceptance. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Arhalofenate has been studied in a total of 15 clinical trials with nearly a
thousand subjects. The emergence of adverse events (AEs) caused by arhalofenate in future studies could cause us, other reviewing entities, clinical study sites or regulatory authorities to interrupt, delay or halt clinical studies and could result
in the denial of regulatory approval. There is also a risk that our other product candidates may induce AEs, many of which may be unknown at this time. If an unacceptable frequency and/or severity of AEs are reported in our clinical trials for our
product candidates, our ability to obtain regulatory approval for product candidates, including arhalofenate, may be negatively impacted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if any of our approved products cause serious or unexpected side effects after
receiving market approval, a number of potentially significant negative consequences could result, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in a form of a modified risk evaluation and mitigation strategy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications that could diminish the usage of the product or otherwise limit the commercial success of the affected
product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way the product is administered or to conduct additional clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may choose to discontinue sale of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for harm caused to patients; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining
market acceptance of the affected product candidate and could substantially increase the costs of commercializing our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any
product candidate that CymaBay successfully develops does not achieve broad market acceptance among physicians, patients, health care payors and the medical community, the revenues that it generates from its sales will be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if arhalofenate or any other product candidates receive regulatory approval, the products may not gain market acceptance among physicians,
patients, health care payors and the medical community. Coverage and reimbursement of CymaBay&#146;s product candidates by third party payors, including government payors, generally is also necessary for commercial success. The degree of market
acceptance of any of CymaBay&#146;s approved products will depend upon a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and safety, as demonstrated in clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk/benefit profile of CymaBay&#146;s products such as arhalofenate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which the product is approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of the product by physicians, other health care providers and patients as a safe and effective treatment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages of product candidates over alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the safety of product candidates seen in a broader patient group, including its use outside the approved indications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of treatment in relation to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of adequate reimbursement and pricing by third parties and government authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of CymaBay&#146;s or its partners&#146; sales, marketing and distribution efforts. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, health care payors and
patients, CymaBay may not generate sufficient revenue from these products and CymaBay may not become or remain profitable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential conflicts of interest arising from relationships and any related compensation with respect to
clinical studies could adversely affect the process. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Principal investigators for CymaBay&#146;s clinical studies may serve as
scientific advisors or consultants to CymaBay from time to time and receive cash compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of
the data generated at the applicable clinical study site may be questioned or jeopardized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CymaBay may be subject to costly claims related to its
clinical studies and may not be able to obtain adequate insurance. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because CymaBay conducts clinical studies in humans, CymaBay
faces the risk that the use of arhalofenate or future product candidates, will result in adverse side effects. CymaBay cannot predict the possible harms or side effects that may result from its clinical studies. Although CymaBay has clinical study
liability insurance, CymaBay&#146;s insurance may be insufficient to cover any such events. There is also a risk that CymaBay may not be able to continue to obtain clinical study coverage on acceptable terms. In addition, CymaBay may not have
sufficient resources to pay for any liabilities resulting from a claim excluded from, or beyond the limit of, CymaBay&#146;s insurance coverage. There is also a risk that third parties that CymaBay has agreed to indemnify could incur liability. Any
litigation arising from its clinical studies, even if CymaBay is ultimately successful, would consume substantial amounts of CymaBay&#146;s financial and managerial resources and may create adverse publicity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After the completion of our clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize arhalofenate and we
cannot, therefore, predict the timing of any future revenue from arhalofenate. Regulatory approval of an NDA is not guaranteed, and the approval process is expensive, uncertain and lengthy. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot commercialize our product candidates, including arhalofenate until the appropriate regulatory authorities, such as the FDA, have
reviewed and approved the product candidate. The regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval for arhalofenate. Additional delays may result if arhalofenate is
brought before an FDA advisory committee, which could recommend restrictions on approval or recommend non-approval of the product candidate. In addition, we may experience delays or rejections based upon additional government regulation from future
legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical studies and the review process. As a result, we cannot predict when, if at all, we will receive any future revenue from
commercialization of any of our product candidates, including arhalofenate. The FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons, including
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CymaBay may be unable to demonstrate to the satisfaction of regulatory authorities that a product candidate is safe and effective for any indication; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may not find the data from nonclinical studies and clinical studies sufficient or may differ in the interpretation of the data; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require additional nonclinical or clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authority might not approve CymaBay&#146;s third party manufacturers&#146; processes or facilities for clinical or commercial product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authority may change its approval policies or adopt new regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities may disagree with the design or implementation of CymaBay&#146;s clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authority may not accept clinical data from studies that are conducted in countries where the standard of care is potentially different from that in the U.S.; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of clinical studies may not meet the level of statistical significance required by the FDA or foreign regulatory authorities for approval; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CymaBay may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the data collection from clinical studies of CymaBay&#146;s product candidates may not be sufficient to support the submission of a NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased caution
by the FDA and other regulatory authorities in reviewing new pharmaceuticals based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approval for arhalofenate and our other product candidates, we will still face extensive regulatory requirements and our
products may face future development and regulatory difficulties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval in the U.S., the FDA may
still impose significant restrictions on the indicated uses or marketing of our product candidates, including arhalofenate, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the
labeling ultimately approved for our product candidates, including arhalofenate, may include restrictions on use due to the specific patient population and manner of use in which the drug was evaluated and the safety and efficacy data obtained in
those evaluations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Arhalofenate and our other product candidates will also be subject to additional ongoing FDA requirements governing
the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to monitor and report AEs and any
failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing
process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. Furthermore, promotional materials must be approved by the FDA prior to use
for any drug receiving accelerated approval, the pathway we are pursuing for arhalofenate in the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers of drug
products and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current Good Manufacturing Practices (cGMP), and adherence to commitments
made in the NDA. If we, or a regulatory agency, discover previously unknown problems with a product, such as quality issues or AEs of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory
agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we, or our third party contractors, fail to comply with applicable regulatory requirements following approval of our product candidate, a
regulatory agency may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue an untitled or warning letter asserting violation of the law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek an injunction or impose civil or criminal penalties or monetary fines; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or withdraw regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend any ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve a pending NDA or supplements to an NDA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall and/or seize product. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could
require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize arhalofenate and our other product candidates and
inhibit our ability to generate revenues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA approval for arhalofenate or any of our other products in the U.S., we may never
obtain approval for or commercialize arhalofenate or any of our other products outside of the U.S., which would limit our ability to realize their full market potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products outside of the U.S., we must establish and comply with numerous and varying regulatory requirements on a
country-by-country basis regarding safety and efficacy. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, clinical trials conducted in one country may not be accepted by
regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and
additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory
requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we
do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international
markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
relationships with customers and payors will be subject to applicable anti-kickback, fraud and abuse and other health care laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and
diminished profits and future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health care providers, physicians and others play a primary role in the recommendation and
prescription of any products for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the
business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state health care laws and regulations, include the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal health care anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to
induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal health care programs such as Medicare and Medicaid; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal
government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes criminal and civil liability for executing a scheme
to defraud any health care benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
health care benefits, items or services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal transparency requirements under the Health Care and Education Reconciliation Act of 2010 (Health Care Reform Law) require manufacturers of drugs, devices, biologics and medical supplies to report to the
Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and investment interests; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims
involving health care items or services reimbursed by non-governmental third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report
information related to payments to physicians and other health care providers or marketing expenditures. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to
ensure that our business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not
comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations
that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded health care programs, such as Medicare and Medicaid, and the curtailment or restructuring of our
operations. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions
from government funded health care programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently enacted and future legislation may increase the difficulty and cost for us to obtain
marketing approval of and commercialize our product candidates and affect the prices we may obtain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the U.S. and some foreign
jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell any products for which we obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the U.S., the Medicare
Prescription Drug, Improvement, and Modernization Act of 2003 (Medicare Modernization Act) changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and
introduced a new reimbursement methodology based on average sales prices for physician administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost
reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private
payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result in a similar reduction in payments
from private payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More recently, in March 2010, the Health Care Reform Law was enacted to broaden access to health insurance, reduce
or constrain the growth of health care spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional
health policy reforms. The Health Care Reform Law revises the definition of &#147;average manufacturer price&#148; for reporting purposes, which could increase the amount of Medicaid drug rebates to states. Further, the new law imposes a significant
annual fee on companies that manufacture or import branded prescription drug products. New provisions affecting compliance have also been enacted, which may affect our business practices with health care practitioners. We will not know the full
effects of the Health Care Reform Law until applicable federal and state agencies issue regulations or guidance under the new law. Although it is too early to determine the effect of the Health Care Reform Law, the new law appears likely to continue
the pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for
pharmaceutical products. We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our
product candidates, if any, may be. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third-party manufacturers to produce our preclinical and clinical drug supplies, and we intend to rely on third parties to produce commercial
supplies of any approved product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate, and we do not expect to own or operate, facilities for
product manufacturing, storage and distribution, or testing. In the past we have relied on third-party manufacturers for supply of our preclinical and clinical drug supplies. We expect that in the future we will continue to rely on such
manufacturers for drug supplies that will be used in clinical trials of our product candidates, including arhalofenate, and for commercialization of any of our product candidates that receive regulatory approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The facilities used by our contract manufacturers to manufacture the product candidates must be
approved by the FDA pursuant to inspections that will be conducted only after we submit an NDA to the FDA, if at all. We do not control the manufacturing process of our product candidates and are completely dependent on our contract manufacturing
partners for compliance with the FDA&#146;s requirements for manufacture of finished pharmaceutical products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA&#146;s strict
regulatory requirements of safety, purity and potency, we will not be able to secure and/or maintain FDA approval for our product candidates. In addition, we have no direct control over the ability of the contract manufacturers to maintain adequate
quality control, quality assurance and qualified personnel. If our contract manufacturers cannot meet FDA standards, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory
approval for or market our product candidates. No assurance can be given that our manufacturers can continue to make clinical and commercial supplies of arhalofenate, or future product candidates, at an appropriate scale and cost to make it
commercially feasible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we do not have the capability to package and distribute finished products to pharmacies and other
customers. Prior to commercial launch, we will enter into agreements with one or more pharmaceutical product packager/distributor to ensure proper supply chain management once we are authorized to make commercial sales of our product candidates. If
we receive marketing approval from the FDA, we intend to sell pharmaceutical product packaged and distributed by such suppliers. Although we have entered into agreements with our current contract manufacturers and packager/distributor for clinical
trial material, we may be unable to maintain an agreement on commercially reasonable terms, which could have a material adverse impact upon our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on limited sources of supply for the drug substance for our lead product candidate, arhalofenate, and any disruption in the chain of supply may
cause delay in developing and commercializing arhalofenate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently transferring the drug substance manufacturing process
to our selected contractor that will produce the supplies needed to meet clinical development, registration and forecasted commercial demand. It is our expectation that only one supplier of drug substance and one supplier of drug product will be
qualified by the FDA. If supply from an approved vendor is interrupted, there could be a significant disruption in commercial supply of arhalofenate. An alternative vendor would need to be qualified through an NDA supplement which would be expensive
and could result in further delay. The FDA or other regulatory agencies outside of the U.S. may also require additional studies if a new drug substance or drug product supplier is relied upon for commercial production. These factors could cause the
delay of clinical trials, regulatory submissions, required approvals or commercialization of arhalofenate, and cause us to incur additional costs. Furthermore, if our suppliers fail to deliver the required commercial quantities of active
pharmaceutical ingredient on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our supply chain for arhalofenate may be
delayed, which could inhibit our ability to generate revenues. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing issues may arise that could increase product and regulatory approval
costs or delay commercialization of arhalofenate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are modifying the drug substance production process for arhalofenate at the
selected commercial manufacturer to cost effectively remove impurities. As the modified process is scaled up it may reveal previously unknown impurities which could require resolution in order to proceed with our planned clinical trials and obtain
regulatory approval for the commercial marketing of arhalofenate. In the future, we may identify impurities, which could result in increased scrutiny by the regulatory agencies, delays in the clinical program and regulatory approval for
arhalofenate, increases in our operating expenses, or failure to obtain or maintain approval for arhalofenate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on
third-party manufacturers entails risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to meet our product specifications and quality requirements consistently; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a delay or inability to procure or expand sufficient manufacturing capacity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing and product quality issues related to scale-up of manufacturing; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs and validation of new equipment and facilities required for scale-up; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a failure to comply with cGMP and similar foreign standards; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the reliance on a limited number of sources, and in some cases, single sources for key materials, such that if we are unable to secure a sufficient supply of these key materials, we will be unable to manufacture and
sell our product candidates in a timely fashion, in sufficient quantities or under acceptable terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of qualified backup suppliers for those materials that are currently purchased from a sole or single source supplier; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">carrier disruptions or increased costs that are beyond our control; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the failure to deliver our products under specified storage conditions and in a timely manner. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could lead to clinical study delays, failure to obtain regulatory approval or impact our ability to successfully
commercialize our products. Some of these events could be the basis for FDA or other regulatory authorities&#146; action, including injunction, recall, seizure, or total or partial suspension of production. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct, supervise and monitor our clinical studies, and if those third parties perform in an unsatisfactory manner, it may
harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on contract service providers (CSPs) including clinical research organizations, clinical trial sites,
central laboratories and other service providers to ensure the proper and timely conduct of our clinical trials. While we have agreements governing their activities, we have limited influence over their actual performance. We have relied and plan to
continue to rely upon CSPs to monitor and manage data for our ongoing clinical programs for arhalofenate and our other product candidates, as well as the execution of nonclinical studies. We control only certain aspects of our CSPs&#146; activities.
Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CSPs does not relieve us of our regulatory
responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our CSPs are required to comply with the FDA&#146;s guidance, which follows the International Conference on
Harmonization Good Clinical Practice (ICH GCP), which are regulations and guidelines enforced by the FDA for all of our product candidates in clinical development. The FDA enforces the ICH GCP through periodic inspections of trial sponsors,
principal investigators and clinical trial sites. If we or our CSPs fail to comply with the ICH GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before
approving our marketing applications. For example, upon inspection, the FDA may determine that our Phase 3 clinical trial for arhalofenate, does not comply with the ICH GCP. In addition, our Phase 3 clinical trials for arhalofenate will require a
sufficiently large number of test subjects to evaluate the safety and effectiveness of arhalofenate. Accordingly, if our CSPs fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required to repeat
these Phase 3 clinical trials, which would delay the regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CSPs are not our employees, and we cannot control
whether or not they devote sufficient time and resources to our ongoing clinical and nonclinical programs. These CSPs may also have relationships with other entities, including our competitors, for whom they may also be conducting clinical studies,
or other drug development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CSPs, which may reduce our trade secret protection and allow
our potential competitors to access and exploit our proprietary technology. If our CSPs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they
obtain is compromised due to the failure to adhere to our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or
successfully commercialize arhalofenate or our other product candidates. As a result, our financial results and the commercial prospects for arhalofenate and any other product candidates that we develop would be harmed, our costs could increase, and
our ability to generate revenues could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The commercial success of arhalofenate and our other product candidates will depend upon the acceptance of these products by the medical community,
including physicians, patients and health care payors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates, including arhalofenate, receive marketing
approval, they may nonetheless not gain sufficient market acceptance by physicians, patients, health care payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant
product revenues and we may not become profitable. The degree of market acceptance of any of our product candidates, including arhalofenate, will depend on a number of factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstration of clinical safety and efficacy in our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk/benefit profile of our products such as arhalofenate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative convenience, ease of administration and acceptance by physicians, patients and health care payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the safety of product candidates seen in a broader patient group, including its use outside the approved indications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings contained in the FDA and other regulatory authorities approved label for the relevant product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of the product by physicians, other health care providers and patients as a safe and effective treatment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages of product candidates over alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pricing and cost-effectiveness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our or any future collaborators&#146; sales and marketing strategies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain formulary approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain sufficient third-party coverage or reimbursement, which may vary from country to country; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our or any future collaborators&#146; sales, marketing and distribution efforts. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates, including arhalofenate, is approved but does not achieve an adequate level of acceptance by physicians,
patients and health care payors, we may not generate sufficient revenue and we may not become or remain profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish
sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have an organization for the sales, marketing and distribution of pharmaceutical products and the cost of establishing and
maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved, including arhalofenate, we must build our sales, marketing, managerial and other non-technical capabilities or make
arrangements with third parties to perform these services. We may enter into strategic partnerships with third parties to commercialize our product candidates, including arhalofenate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to build our own sales force or negotiate a strategic partnership for the
commercialization of arhalofenate, we may be forced to delay the potential commercialization of arhalofenate, or reduce the scope of our sales or marketing activities for arhalofenate. If we elect to increase our expenditures to fund
commercialization activities ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring arhalofenate to market or generate
product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with
third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the
support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with
third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and
establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or
reposition our sales and marketing personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we obtain approval to commercialize any products outside of the U.S., a variety of risks
associated with international operations could materially adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidates are approved
for commercialization, we intend to enter into agreements with third parties to market those product candidates outside the U.S., including for arhalofenate. We expect that we will be subject to additional risks related to international operations,
including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">different regulatory requirements for drug approvals in foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected changes in tariffs, trade barriers and regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular foreign economies and markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign taxes, including withholding of payroll taxes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the U.S.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from geopolitical actions, including war and terrorism, pandemics, or natural disasters including earthquakes, typhoons, volcanic eruptions, floods and fires. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by both
the European Union and many of the individual countries in Europe with which we will need to comply. Many U.S.-based biopharmaceutical companies have found the process of marketing their own products in Europe to be very challenging. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our competitors develop and market products that are more effective, safer or less expensive than
arhalofenate, our commercial opportunities will be negatively impacted. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The life sciences industry is highly competitive, and we
face significant competition from other pharmaceutical, biopharmaceutical and biotechnology companies and possibly from academic institutions, government agencies and private and public research institutions that are researching, developing and
marketing products designed to address the treatment of gout. Our competitors may have significantly greater financial, manufacturing, marketing and drug development resources. Large pharmaceutical companies, in particular, have extensive experience
in the clinical testing of, obtaining regulatory approvals for, and marketing of, drugs. New developments, including the development of other pharmaceutical technologies and methods of treating disease, occur in the pharmaceutical and life sciences
industries at a rapid pace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These developments may render our product candidates obsolete or noncompetitive. Compared to us, potential
competitors may have substantially greater: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">research and development resources, including personnel and technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory experience; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience in pharmaceutical development and commercialization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ability to negotiate competitive pricing and reimbursement with third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience and expertise in exploitation of intellectual property rights; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">capital resources. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these factors, our competitors may obtain regulatory
approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. The competitors may also develop products that are
more effective, better tolerated, more useful and less costly than our products and they may also be more successful in manufacturing and marketing their products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Formulary approval and reimbursement may not be available for arhalofenate and our other product candidates, which could make it difficult for us to
sell our products profitably. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining formulary approval can be an expensive and time consuming process. We cannot be certain if
and when we will obtain formulary approval to allow us to promote our product candidates, including arhalofenate, into our target markets. Failure to obtain timely formulary approval will limit our commercial success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, market acceptance and sales of arhalofenate, or any other product candidates that we develop, will depend in part on the extent
to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private
health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A prevailing trend in the U.S. health care industry and elsewhere is cost containment. Government authorities and
these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from
list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.
Reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. We cannot be sure that reimbursement will be available for arhalofenate, or any other product candidates. Also, reimbursement amounts may
reduce the demand for, or the price of, our products. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize arhalofenate, or any other product candidates that we develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been a number of legislative and regulatory proposals to change the health care system in the U.S. and in some foreign
jurisdictions that could affect our ability to sell any future products profitably. These legislative and regulatory changes may negatively impact the reimbursement for any future products, following approval. The availability of generic treatments
may also substantially reduce the likelihood of reimbursement for any future products, including arhalofenate. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application of user fees to generic drug products will likely expedite the approval of additional generic drug treatments. We expect to experience pricing pressures in connection with the sale of
arhalofenate and any other product candidate that we develop, due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there may be significant delays in obtaining reimbursement for approved products, and coverage may be more limited than the
purposes for which the product is approved by the FDA or health authorities in other countries. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including
research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and
the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory
discounts or rebates required by government health care programs or private payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the U.S. Third-party
payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to
promptly obtain coverage and profitable payment rates from both government funded and private payors for any of our product candidates, including arhalofenate, it could have a material adverse effect on our operating results, our ability to raise
capital needed to commercialize products and our overall financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval for arhalofenate, we will be
subject to ongoing FDA and other regulatory obligations and continued regulatory review, which may result in significant additional expense and limit our ability to commercialize arhalofenate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we or potential collaboration partners receive for arhalofenate or future product candidates, may also be subject
to limitations on the indicated uses for which the product may be marketed or contain requirements for potentially costly post-marketing studies. In addition, even if approved, the labeling, packaging, adverse event reporting, storage, advertising,
promotion and recordkeeping for any product will be subject to extensive and ongoing regulatory requirements. The subsequent discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, may result in
restrictions on the marketing of the product, and could include withdrawal of the product from the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory policies may change
and additional government regulations may be enacted that could prevent or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative action, either in the U.S. or abroad. If we are not able to maintain regulatory compliance, we might not be permitted to market arhalofenate or future products, if any, and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure related to the testing of our product candidates in human
clinical studies, and will face an even greater risk if we sell our product candidates commercially. An individual may bring a liability claim against us if one of our product candidates causes, or merely appears to have caused, an injury. If we
cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impairment to our business reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical study participants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distraction of management&#146;s attention from our primary business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to patients or other claimants; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenues. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do carry product liability insurance for our clinical studies. Further,
we intend to expand our insurance coverage to include the sale of commercial products if marketing approval is obtained for any of our product candidates. However, we may be unable to obtain this product liability insurance on commercially
reasonable terms and with insurance coverage that will be adequate to satisfy any liability that may arise. On occasion, large judgments have been awarded in class action or individual lawsuits relating to marketed pharmaceuticals. A successful
product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications
that may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily
upon our ability to identify, develop and commercialize product candidates. Because we have limited financial and managerial resources, we focus on product candidates for specific indications. As a result, we may forego or delay pursuit of
opportunities with other product candidates or other indications that later prove to have greater commercial potential. We may focus our efforts and resources on product candidates that ultimately prove to be unsuccessful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable
rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain or protect intellectual property rights related to our products and product candidates, we may not be able to compete
effectively in our market. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trade secret protection and confidentiality agreements to
protect the intellectual property related to our products and product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications
that we own or in-license may fail to result in issued patents with claims that cover the products in the U.S. or in other countries. If this were to occur, early generic competition could be expected against arhalofenate and other product
candidates in development. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing based on a pending patent
application. Even if patents do successfully issue, third parties may challenge their validity, enforceability, scope or ownership, which may result in such patents, or our rights to such patents, being narrowed or invalidated. Furthermore, even if
they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the patent applications we hold or license with respect to arhalofenate fail to
issue or if their breadth or strength of protection is threatened, it could dissuade companies from collaborating with us and threaten our ability to commercialize our products. We cannot offer any assurances about which, if any, patents will issue
or whether any issued patents will be found invalid or unenforceable, will be challenged by third parties or will adequately protect our products and product candidates. Further, if we encounter delays in development or regulatory approvals, the
period of time during which we could market arhalofenate under patent protection could be reduced. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing, and some remain so until issued, we
cannot be certain that we or our licensors were the first to file any patent application related to arhalofenate or our other product candidates. Furthermore, if third parties have filed such patent applications, an interference proceeding in the
U.S. can be provoked by a third party or instituted by us to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. An unfavorable outcome could require us to cease using the related
technology or to attempt to license it from the prevailing party, which may not be available on commercially reasonable terms or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable, processes for which patents are difficult to enforce and other elements of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although we expect all of our employees to assign their
inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such
agreements have been duly executed, that such agreements provide adequate protection and will not be breached, that our trade secrets and other confidential proprietary information will not otherwise be disclosed or that competitors will not
otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third
parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of
operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the laws of some foreign countries do not protect patents and other proprietary rights to
the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property abroad. We may also fail to pursue or obtain patents and other intellectual
property protection relating to our products and product candidates in all foreign countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property
infringement may prevent or delay our development and commercialization efforts or otherwise affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial
success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual
property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter party re-examination proceedings before the U.S. Patent and Trademark Office (U.S. PTO) and its foreign
counterparts. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and
pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of
infringement of the patent and other proprietary rights of third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their
proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of arhalofenate and/or
our other product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties
may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any
molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or
until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such
patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or
at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or
contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a
successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay
royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially
reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our
product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our products or product candidates, resulting in either an injunction prohibiting
our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
license certain key intellectual property from third parties, and the loss of our license rights could have a materially adverse effect on our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to a number of technology licenses that are important to our business and expect to enter into additional licenses in the
future. For example, we rely on an exclusive license to certain patents, proprietary technology and know-how from DiaTex, which include arhalofenate. During the term of the exclusive license with DiaTex we may perform research and development of
compounds and products for the treatment of human disease based on the patents, proprietary technology and know-how from DiaTex. If we fail to comply with our obligations under our agreement with DiaTex, including our obligations to pay royalty
payments during the development and commercialization of arhalofenate, or our other license agreements, or if we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to develop or
market products covered by the license, including in the case of the DiaTex license, arhalofenate, which would have a materially adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be
expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe or otherwise violate our patents, the patents of our
licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that
a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation
or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third
party to bring counter-claims against us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to prevent, alone or with our licensors, misappropriation of our
intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the U.S. Our business could be harmed if in a litigation the prevailing party does not offer us a license on commercially reasonable
terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and
maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for
non-compliance with these requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees on any issued patent are due to be paid to the U.S. PTO and
foreign patent agencies in several stages over the lifetime of the patent. The U.S. PTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the
patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of
the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to,
failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors that control the prosecution and maintenance of our licensed patents fail
to maintain the patents and patent applications covering our product candidates, we may lose our rights and our competitors might be able to enter the market, which would have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Business Operations and Industry </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on principal members of our executive team listed under &#147;Management.&#148; While we have entered into employment
agreements or offer letters with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#147;at will&#148; employees. We do not maintain &#147;key person&#148; insurance for any of our
executives or other employees. Recruiting and retaining other qualified employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our
industry, which is likely to continue. We also experience competition from universities and research institutions for the hiring of scientific and clinical personnel. As a result, competition for skilled personnel is intense and the turnover rate
can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. In addition, failure of any of our clinical studies may make
it more challenging to recruit and retain qualified personnel. If we are unable to successfully recruit key employees or replace the loss of services of any executive or key employee, it may adversely affect the progress of our research, development
and commercialization objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist
us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit
their availability to us, which could also adversely affect the progress of our research, development and commercialization objectives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will
need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&nbsp;15, 2013, we had 13 full-time employees and three consultants. As our company matures, we expect to expand our employee
base to increase our managerial, clinical, scientific and engineering, operational, sales, and marketing teams. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain,
motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day to- day activities and devote a substantial amount of time to managing
these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced
productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to
effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability
to commercialize arhalofenate and our other product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx608283_12"></A>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Unregistered Sales of Equity Securities and Use of Proceeds </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) On September&nbsp;30, 2013, CymaBay
issued an aggregate of 5,366,728 shares of common stock, and warrants to purchase 1,073,338 shares of common stock, to approximately 260 investors. The shares and warrants were issued to the investors in reliance on Rule 506 of Regulation D, in that
all of the investors represented that they were &#147;accredited investors&#148; as that term is defined in Regulation D. The shares and related warrants were sold for an aggregate offering price of $26,833,640. National Securities Corporation, or
NSC, acted as placement agent with respect to 3,483,597 shares and related warrants issued in the transaction, and received an aggregate placement agent commission of $1.8 million in cash and warrants to purchase 348,360 shares of common stock at an
exercise price of $5.75 per share. The warrants issued to NSC in reliance on Rule 506 of Regulation D, in that NSC represented it was an &#147;accredited investor&#148; as that term is defined in Regulation D. The warrants are exercisable for shares
of CymaBay&#146;s common stock for five (5)&nbsp;years from September&nbsp;30, 2013, at an exercise price of $5.75 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) On September&nbsp;30, 2013, CymaBay issued an aggregate of 2,793,281 shares of common stock to 118 holders of
its preferred stock upon conversion of the preferred stock to common stock. The shares were issued to these investors in reliance on Section&nbsp;3(a)(9) of the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) On September&nbsp;30, 2013, CymaBay issued an aggregate of 624,944 shares of common stock to Johnson&nbsp;&amp; Johnson Development Corporation, or JJDC
and entered into an amendment to the Development and License Agreement, dated June&nbsp;15, 2010, with Janssen Pharmaceuticals, Inc. (formerly known as Ortho- McNeil, Inc.) an affiliate of JJDC, pursuant to which CymaBay agreed to forego certain
milestone payments and modify future contingent royalty payments as consideration for the cancellation of $13.7 million in aggregate principal and $3.2 million in aggregate accrued interest of our debt. The shares were issued in reliance on Rule 506
of Regulation D, in that JJDC represented it was an &#147;accredited investor&#148; as that term is defined in Regulation D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) On September&nbsp;30,
2013, CymaBay issued warrants to purchase an aggregate of 121,739 shares of common stock to Silicon Valley Bank, or SVB, and Oxford Finance LLC, or Oxford, as partial consideration for SVB and Oxford entering into a $10,000,000 credit facility with
CymaBay. The shares were issued in reliance on Rule 506 of Regulation D, in that each of SVB and Oxford represented each was an &#147;accredited investor&#148; as that term is defined in Regulation D. The warrants are exercisable for shares of
CymaBay&#146;s common stock for seven (7)&nbsp;years from September&nbsp;30, 2013, at an exercise price of $5.00 per share. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx608283_13"></A>Item&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the Exhibit&nbsp;Index which follows the signature page&nbsp;of this Quarterly Report on
Form&nbsp;10-Q, which is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx608283_15"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CYMABAY THERAPEUTICS,&nbsp;INC.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harold Van Wart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Harold Van Wart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">(Principal Executive Officer)</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: November 25, 2013</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sujal Shah</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Sujal Shah</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Acting Chief Financial Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">(Principal Financial and Accounting Officer)</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: November 25, 2013</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman"><B>Description&nbsp;of&nbsp;Document</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated By-Laws.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Reference is made to Exhibits 3.1 and 3.2</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Registration Rights Agreement</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of 2013 Financing Warrant</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Loan and Security Agreement, dated September&nbsp;30, 2013, by and among CymaBay Therapeutics, Inc., Silicon Valley Bank and Oxford Finance LLC</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2013 Equity Incentive Plan</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.26*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Option Grant Notice and Option Agreement under the 2013 Equity Incentive Plan</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.27</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease, dated November&nbsp;8, 2013, between CymaBay Therapeutics, Inc. and BMR-Pacific Research Center LP</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Executive Officer pursuant to Rule 13-a-14(a) or Rule 15(d)-14(a) of the Exchange Act</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 13a-14(b) or 15d-14(b) of the Exchange Act</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to the like-described exhibit to our Form 10/A, as amended on October&nbsp;17, 2013. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>2
<FILENAME>d608283dex1027.htm
<DESCRIPTION>EX-10.27
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.27</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.27 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LEASE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and between </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BMR-PACIFIC RESEARCH CENTER LP, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a
Delaware limited partnership </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CYMABAY THERAPEUTICS, INC., </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a
Delaware corporation </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">BioMed Realty form dated 10/2/13 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS LEASE (this &#147;<U>Lease</U>&#148;) is entered into as of this 8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of
November, 2013 (the&nbsp;&#147;<U>Execution Date</U>&#148;), by and between BMR-PACIFIC RESEARCH CENTER LP, a Delaware limited partnership (&#147;<U>Landlord</U>&#148;), and CYMABAY THERAPEUTICS, INC., a Delaware corporation
(&#147;<U>Tenant</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. WHEREAS, Landlord owns certain real property (the &#147;<U>Property</U>&#148;) and the improvements on the Property located at 7333-7999
Gateway Boulevard, Newark, California, including the buildings located thereon; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. WHEREAS, Landlord wishes to lease to Tenant, and
Tenant desires to lease from Landlord, certain premises (the &#147;<U>Premises</U>&#148;) located on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>)&nbsp;floor of the building (commonly known as Building 7) located at 7999
Gateway Boulevard, Newark, California (the&nbsp;&#147;<U>Building</U>&#148;), pursuant to the terms and conditions of this Lease, as detailed below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Lease of Premises</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1. Effective on the Term Commencement Date (as defined below), Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, the
Premises, as shown on <U>Exhibit A</U> attached hereto, for use by Tenant in accordance with the Permitted Use (as defined below) and no other uses. The Property and all landscaping, parking facilities, private drives and other improvements and
appurtenances related thereto, including the Building, the Amenities Building (as defined below), the nine (9)&nbsp;other buildings currently located on the Property and each additional building that is constructed on the Property (following
substantial completion of such building), are hereinafter collectively referred to as the &#147;<U>Project</U>.&#148; All portions of the Building that are for the non-exclusive use of the tenants of the Building only, and not the tenants of the
Project generally, such as service corridors, stairways, elevators, public restrooms and public lobbies (all to the extent located in the Building), are hereinafter referred to as &#147;<U>Building Common Area</U>.&#148; All portions of the Project
that are for the non-exclusive use of tenants of the Project generally, including driveways, sidewalks, parking areas, landscaped areas, and (to the extent not located in a building other than the Amenities Building) service corridors, stairways,
elevators, public restrooms, public lobbies and the amenities building (the &#147;<U>Amenities Building</U>&#148;) in which Landlord currently provides certain amenities, including food services, a fitness center and a conference center
(&#147;<U>Amenities Building Services</U>&#148;) (but excluding Building Common Area), are hereinafter referred to as &#147;<U>Project Common Area</U>.&#148; The Building Common Area and Project Common Area are collectively referred to herein as
&#147;<U>Common Area</U>.&#148; The Building is located on a portion of the Project commonly referred to as the &#147;North Campus,&#148; which is that part of the Project to the north of Gateway Boulevard comprised of the Building and five
(5)&nbsp;other buildings commonly referred to as Buildings 1, 2, 3, 5 and 6, together with all appurtenances thereto (collectively, the &#147;<U>North Campus</U>&#148;). </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Basic Lease Provisions</U>. For convenience of the parties, certain basic provisions of this Lease are set
forth herein. The provisions set forth herein are subject to the remaining terms and conditions of this Lease and are to be interpreted in light of such remaining terms and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1. This Lease shall take effect upon the Execution Date and, except as specifically otherwise provided within this Lease, each of the
provisions hereof shall be binding upon and inure to the benefit of Landlord and Tenant from the date of execution and delivery hereof by all parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2. In the definitions below, each current Rentable Area (as defined below) is expressed in square feet. Rentable Area and
&#147;<U>Tenant&#146;s Pro Rata Shares</U>&#148; are all subject to adjustment as provided in this Lease. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:78.10pt; font-size:8pt; font-family:Times New Roman"><B>Definition or Provision</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Means&nbsp;the&nbsp;Following&nbsp;(As&nbsp;of&nbsp;the&nbsp;Term<BR>Commencement Date)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Approximate Rentable Area of Premises*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8,894&nbsp;square&nbsp;feet</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Approximate Rentable Area of Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">178,047&nbsp;square&nbsp;feet</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Approximate Rentable Area of North Campus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">966,271&nbsp;square&nbsp;feet</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Approximate Rentable Area of Project</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,389,517&nbsp;square&nbsp;feet</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant&#146;s Pro Rata Share of Building*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant&#146;s Pro Rata Share of North Campus*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.92%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant&#146;s Pro Rata Share of Project*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.64%</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>*&nbsp;Note:</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Subject to adjustment based upon the Rentable Area of the Premises as of the Term Commencement Date. </I></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3. Initial monthly and annual installments of Base Rent for the Premises (&#147;<U>Base
Rent</U>&#148;) as of the Term Commencement Date, subject to adjustment under this Lease: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:19.10pt; font-size:8pt; font-family:Times New Roman"><B>Dates</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Square&nbsp;Feet<BR>of Rentable<BR>Area*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base&nbsp;Rent&nbsp;per&nbsp;Square<BR>Foot&nbsp;of&nbsp;Rentable&nbsp;Area</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Monthly<BR>Base&nbsp;Rent*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual&nbsp;Base<BR>Rent*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 1 - 12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.90&nbsp;monthly</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,898.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202,783.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 13 - 24</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.96&nbsp;monthly</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,432.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">209,186.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 25 - 36</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.02 monthly</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,965.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215,590.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 37 - 48</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.08 monthly</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,499.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">221,994.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 49 - 60</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.14 monthly</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,033.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">228,397.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>*&nbsp;Note:</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Subject to adjustment based upon the Rentable Area of the Premises as of the Term Commencement Date. </I></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4. Estimated Term Commencement Date: January&nbsp;1, 2014 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5. Estimated Term Expiration Date: December&nbsp;31, 2018 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6. Security Deposit: $50,695.80 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7. Permitted Use: Office use in conformity with all federal, state, municipal and local laws, codes, ordinances, rules and regulations of
Governmental Authorities (as defined below), committees, associations, or other regulatory committees, agencies or governing bodies having jurisdiction over the Premises, the Building, the Property, the Project, Landlord or Tenant, including both
statutory and common law and hazardous waste rules and regulations (&#147;<U>Applicable Laws</U>&#148;) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="61%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.8. Address for Rent Payment:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BMR-Pacific Research Center LP</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention Entity 285</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">P.O. Box 511415</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Los Angeles, California 90051-7970</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.9. Address for Notices to Landlord:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BMR-Pacific Research Center LP</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">17190 Bernardo Center Drive</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Diego, California 92128</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn: Vice President, Real Estate Legal</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.10. Address for Notices to Tenant:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CymaBay Therapeutics, Inc.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7999 Gateway Boulevard</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Newark, California 94560</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.11. Address for Invoices to Tenant:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CymaBay Therapeutics, Inc.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7999 Gateway Boulevard</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Newark, California 94560</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12. The following Exhibits are attached hereto and incorporated herein by reference: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit&nbsp;A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Premises</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tenant Improvements</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Acknowledgement of Term Commencement Date and Term Expiration Date</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[Intentionally omitted]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit E</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Letter of Credit</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit&nbsp;F</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Rules and Regulations</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit&nbsp;G</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[Intentionally omitted]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit H</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Tenant&#146;s Personal Property</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit I</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Form of Estoppel Certificate</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Term</U>. The actual term of this Lease (as the same may be extended pursuant to <U>Article 42</U> hereof, and as the
same may be earlier terminated in accordance with this Lease, the &#147;<U>Term</U>&#148;) shall commence on the actual Term Commencement Date (as defined in <U>Article&nbsp;4</U>) and end on the date that is sixty (60)&nbsp;months after the actual
Term Commencement Date (such date, the &#147;<U>Term Expiration Date</U>&#148;), subject to earlier termination of this Lease as provided herein. TENANT HEREBY WAIVES THE REQUIREMENTS OF SECTION 1933 OF THE CALIFORNIA CIVIL CODE, AS THE SAME MAY BE
AMENDED FROM TIME TO TIME. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Possession and Commencement Date</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1. Landlord shall use commercially reasonable efforts to tender possession of the Premises to Tenant on the Estimated Term Commencement
Date, with the work (the &#147;<U>Tenant Improvements</U>&#148;) required of Landlord described on <U>Exhibit B</U> Substantially Complete (as defined below). Tenant agrees that in the event such work is not Substantially Complete on or before the
Estimated Term Commencement Date for any reason, then (a)&nbsp;this Lease shall not be void or voidable, (b)&nbsp;Landlord shall not be liable to Tenant for any loss or damage resulting therefrom, (c)&nbsp;the Term Expiration Date shall be extended
accordingly and (d)&nbsp;Tenant shall not be responsible for the payment of any Base Rent or Tenant&#146;s Share of Operating Expenses (as defined below) until the actual Term Commencement Date as described in <U>Section&nbsp;4.2</U> occurs. The
term &#147;<U>Substantially Complete</U>&#148; or &#147;<U>Substantial Completion</U>&#148; means that the Tenant Improvements are substantially complete in accordance with <U>Exhibit B</U>, except for minor punch list items. Notwithstanding
anything in this Lease to the contrary, Landlord&#146;s obligation to timely achieve Substantial Completion shall be subject to extension on a day-for-day basis as a result of Force Majeure (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2. The &#147;<U>Term Commencement Date</U>&#148; shall be the later of (a)&nbsp;the Estimated Term Commencement Date and (b)&nbsp;the day
Landlord tenders possession of the Premises to Tenant with the Tenant Improvements Substantially Complete. If possession is delayed by action of Tenant, then the Term Commencement Date shall be the date that the Term Commencement Date would have
occurred but for such delay. Tenant shall execute and deliver to Landlord written acknowledgment of the actual Term Commencement Date and the Term Expiration Date within ten (10)&nbsp;days after Tenant takes occupancy of the Premises, in the form
attached as <U>Exhibit&nbsp;C</U> hereto. Failure to execute and deliver such acknowledgment, however, shall not affect the Term Commencement Date or Landlord&#146;s or Tenant&#146;s liability hereunder. Failure by Tenant to obtain validation by any
medical review board or other similar governmental licensing of the Premises required for the Permitted Use by Tenant shall not serve to extend the Term Commencement Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3. In the event that Landlord permits (in Landlord&#146;s sole and absolute discretion) Tenant to enter upon the Premises prior to the Term
Commencement Date for the purpose of installing improvements or the placement of personal property, Tenant shall furnish to Landlord evidence satisfactory to Landlord that insurance coverages required of Tenant under the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisions of <U>Article 23</U> are in effect, and such entry shall be subject to all the terms and conditions of this Lease other than the payment of Base Rent or Tenant&#146;s Share of
Operating Expenses (as defined below); and <U>provided</U>, further, that if the Term Commencement Date is delayed due to such early access, then the Term Commencement Date shall be the date that the Term Commencement Date would have occurred but
for such delay. If Landlord has not provided Tenant with access to the &#147;Server Room&#148; depicted on <U>Exhibit B</U> attached hereto (the&nbsp;&#147;<U>Server Room</U>&#148;) for the purpose of installing the personal property and equipment
that Tenant intends to install in the Server Room (the &#147;<U>Server Room Equipment</U>&#148;) on or before December&nbsp;26, 2013 (the&nbsp;&#147;<U>Server Room Outside Date</U>&#148;), then Landlord shall be obligated to reimburse Tenant (within
sixty (60)&nbsp;days of receiving an invoice from Tenant) for Tenant&#146;s reasonable, actual, out-of-pocket costs incurred in connection with moving the Server Room Equipment from Tenant&#146;s current location (i.e., Tenant&#146;s leased premises
as of the Execution Date) to a temporary location (such costs, the &#147;<U>Server Room Equipment Moving Costs</U>&#148;); <U>provided</U>, however, that in no event shall Landlord be obligated to reimburse Tenant for Server Room Equipment Moving
Costs exceeding the amount of Ten Thousand Dollars ($10,000.00); <U>provided</U>, further, that the Server Room Outside Date shall be subject to extension on a day-for-day basis as a result of (a)&nbsp;Force Majeure and (b)&nbsp;any delay caused by
any action or inaction of Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4. Notwithstanding anything to the contrary in this Lease, if Substantial Completion has not occurred
by January&nbsp;10, 2014 (the &#147;<U>Substantial Completion Outside Date</U>&#148;), then Tenant shall be entitled to receive one (1)&nbsp;day of Base Rent abatement for each day thereafter that Substantial Completion has not occurred;
<U>provided</U>, however, that the Substantial Completion Outside Date shall be subject to extension on a day-for-day basis as a result of (a)&nbsp;Force Majeure and (b)&nbsp;any delay caused by any action or inaction of Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Condition of Premises</U>. Tenant acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty with respect to
the condition of the Premises, the Building or the Project, or with respect to the suitability of the Premises, the Building or the Project for the conduct of Tenant&#146;s business. Tenant acknowledges that, except with respect to the Tenant
Improvements (a)&nbsp;it is fully familiar with the condition of the Premises and agrees to take the same in its condition &#147;as is&#148; as of the Term Commencement Date and (b)&nbsp;Landlord shall have no obligation to alter, repair or
otherwise prepare the Premises for Tenant&#146;s occupancy or to pay for or construct any improvements to the Premises. Tenant&#146;s taking of possession of the Premises shall, except as otherwise agreed to in writing by Landlord and Tenant,
conclusively establish that the Premises, the Building and the Project were at such time in good, sanitary and satisfactory condition and repair. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.
<U>Rentable Area</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1. The term &#147;<U>Rentable Area</U>&#148; shall reflect such areas as reasonably calculated by Landlord&#146;s
architect, as the same may be reasonably adjusted from time to time by Landlord in consultation with Landlord&#146;s architect to reflect changes to the Premises, the Building or the Project, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2. The Rentable Area of each Building is generally determined by making separate calculations of Rentable Area applicable to each floor
within the Building and totaling the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Rentable Area of all floors within the Building. The Rentable Area of a floor is computed by measuring to the outside finished surface of the permanent outer Building walls. The full area
calculated as previously set forth is included as Rentable Area, without deduction for columns and projections or vertical penetrations, including stairs, elevator shafts, flues, pipe shafts, vertical ducts and the like, as well as such items&#146;
enclosing walls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3. The term &#147;<U>Rentable Area</U>,&#148; when applied to the Premises, is that area equal to the usable area of
the Premises, plus an equitable allocation of Rentable Area within the Building that is not then utilized or expected to be utilized as usable area, including that portion of the Building devoted to corridors, equipment rooms, restrooms, elevator
lobby, atrium and mailroom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4. The Rentable Area of the Project is the total Rentable Area of all buildings within the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5. Review of allocations of Rentable Areas as between tenants of the Building and the Project shall be made as frequently as Landlord deems
appropriate, including in order to facilitate an equitable apportionment of Operating Expenses (as defined below). If such review is by a licensed architect and allocations are certified by such licensed architect as being correct, then Tenant shall
be bound by such certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Rent</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1. Tenant shall pay to Landlord as Base Rent for the Premises, commencing on the Term Commencement Date, the sums set forth in
<U>Section&nbsp;2.3</U>. Base Rent shall be paid in equal monthly installments as set forth in <U>Section&nbsp;2.3</U>, each in advance on the first day of each and every calendar month during the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2. In addition to Base Rent, Tenant shall pay to Landlord as additional rent (&#147;<U>Additional Rent</U>&#148;) at times hereinafter
specified in this Lease (a)&nbsp;Tenant&#146;s Share (as defined below) of Operating Expenses (as defined below), (b)&nbsp;the Property Management Fee (as defined below) and (c)&nbsp;any other amounts that Tenant assumes or agrees to pay under the
provisions of this Lease that are owed to Landlord, including any and all other sums that may become due by reason of any default of Tenant or failure on Tenant&#146;s part to comply with the agreements, terms, covenants and conditions of this Lease
to be performed by Tenant, after notice and the lapse of any applicable cure periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3. Base Rent and Additional Rent shall together
be denominated &#147;<U>Rent</U>.&#148; Rent shall be paid to Landlord, without abatement, deduction or offset, in lawful money of the United States of America at the office of Landlord as set forth in <U>Section&nbsp;2.8</U> or to such other person
or at such other place as Landlord may from time designate in writing. In the event the Term commences or ends on a day other than the first day of a calendar month, then the Rent for such fraction of a month shall be prorated for such period on the
basis of the number of days in the month and shall be paid at the then-current rate for such fractional month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4. Tenant&#146;s
obligation to pay Rent shall not be discharged or otherwise affected by (a)&nbsp;any Applicable Laws now or hereafter applicable to the Premises, (b)&nbsp;any other restriction on Tenant&#146;s use, (c)&nbsp;except as expressly provided herein, any
casualty or taking or (d)&nbsp;any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
occurrence; and Tenant waives all rights now or hereafter existing to terminate or cancel this Lease or quit or surrender the Premises or any part thereof, or to assert any defense in the nature
of constructive eviction to any action seeking to recover rent. Tenant&#146;s obligation to pay Rent with respect to any period or obligations arising, existing or pertaining to the period prior to the date of the expiration or earlier termination
of the Term or this Lease shall survive any such expiration or earlier termination; <U>provided</U>, however, that nothing in this sentence shall in any way affect Tenant&#146;s obligations with respect to any other period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. [Intentionally omitted] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>Operating Expenses</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1. As used herein, the term &#147;<U>Operating Expenses</U>&#148; shall include: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Government impositions, including property tax costs consisting of real and personal property taxes and assessments (including amounts due
under any improvement bond upon the Building or the Project (including the parcel or parcels of real property upon which the Building, the other buildings in the Project and areas serving the Building and the Project are located)) or assessments in
lieu thereof imposed by any federal, state, regional, local or municipal governmental authority, agency or subdivision (each, a &#147;<U>Governmental Authority</U>&#148;); taxes on or measured by gross rentals received from the rental of space in
the Project; taxes based on the square footage of the Premises, the Building or the Project, as well as any parking charges, utilities surcharges or any other costs levied, assessed or imposed by, or at the direction of, or resulting from Applicable
Laws or interpretations thereof, promulgated by any Governmental Authority in connection with the use or occupancy of the Project or the parking facilities serving the Project; taxes on this transaction or any document to which Tenant is a party
creating or transferring an interest in the Premises; any fee for a business license to operate an office building; and any expenses, including the reasonable cost of attorneys or experts, reasonably incurred by Landlord in seeking reduction by the
taxing authority of the applicable taxes, less tax refunds obtained as a result of an application for review thereof. Operating Expenses shall not include any net income, franchise, capital stock, estate or inheritance taxes, or taxes that are the
personal obligation of Tenant or of another tenant of the Project; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) All other costs of any kind paid or incurred by Landlord in
connection with the operation or maintenance of the Building and the Project (including the Amenities Building, which shall include (i)&nbsp;Project office rent at fair market rental for a commercially reasonable amount of space for Project
management personnel located in the Amenities Building, to the extent an office used for Project operations is maintained at the Project, plus customary expenses for such office, and (ii)&nbsp;fair market rent for the portion of the Amenities
Building used in providing the Amenities Building Services), and costs of repairs and replacements to improvements within the Project as appropriate to maintain the Project as required hereunder, including costs of funding such reasonable reserves
as Landlord, consistent with good business practice, may establish to provide for future repairs and replacements; costs of utilities furnished to the Common Areas; sewer fees; cable television; trash collection; cleaning, including windows
(including those of the Amenities Building); heating; ventilation; air-conditioning; maintenance of landscaping and grounds; maintenance of drives and parking areas; maintenance of the roof (including that of the Amenities Building); security
services and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
devices; building supplies; maintenance or replacement of equipment utilized for operation and maintenance of the Project; license, permit and inspection fees; sales, use and excise taxes on
goods and services purchased by Landlord in connection with the operation, maintenance or repair of the Building or Project systems and equipment; telephone, postage, stationery supplies and other expenses incurred in connection with the operation,
maintenance or repair of the Project; accounting, legal and other professional fees and expenses incurred in connection with the Project; costs of furniture, draperies, carpeting, landscaping, snow removal and other customary and ordinary items of
personal property provided by Landlord for use in Common Areas or in the Project office; capital expenditures; costs of complying with Applicable Laws (except to the extent such costs are incurred to remedy non-compliance as of the Execution Date
with Applicable Laws); costs to keep the Project in compliance with, or fees otherwise required under, any CC&amp;Rs (as defined below); insurance premiums, including premiums for commercial general liability, property casualty, earthquake,
terrorism and environmental coverages; portions of insured losses paid by Landlord as part of the deductible portion of a loss pursuant to the terms of insurance policies; service contracts; costs of services of independent contractors retained to
do work of a nature referenced above; and costs of compensation (including employment taxes and fringe benefits) of all persons who perform regular and recurring duties connected with the day-to-day operation and maintenance of the Project, its
equipment, the adjacent walks, landscaped areas, drives and parking areas, including janitors, floor waxers, window washers, watchmen, gardeners, sweepers, plow trucks and handymen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing, Operating Expenses shall not include any leasing commissions; expenses that relate to preparation of rental
space for a tenant; expenses of initial development and construction, including grading, paving, landscaping and decorating (as distinguished from maintenance, repair and replacement of the foregoing); legal expenses relating to other tenants; costs
of repairs to the extent reimbursed by payment of insurance proceeds received by Landlord; interest upon loans to Landlord or secured by a mortgage or deed of trust covering the Project or a portion thereof (<U>provided</U> that interest upon a
government assessment or improvement bond payable in installments shall constitute an Operating Expense under <U>Subsection 9.1(a)</U>); salaries of executive officers of Landlord; depreciation claimed by Landlord for tax purposes (<U>provided</U>
that this exclusion of depreciation is not intended to delete from Operating Expenses actual costs of repairs and replacements and reasonable reserves in regard thereto that are provided for in <U>Subsection 9.1(b)</U>); and taxes that are excluded
from Operating Expenses by the last sentence of <U>Subsection 9.1(a)</U>. To the extent that Tenant uses more than Tenant&#146;s Pro Rata Share of any item of Operating Expenses, Tenant shall pay Landlord for such excess in addition to Tenant&#146;s
obligation to pay Tenant&#146;s Pro Rata Share of Operating Expenses (such excess, together with Tenant&#146;s Pro Rata Share, &#147;<U>Tenant&#146;s Share</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2. Tenant shall pay to Landlord on the first day of each calendar month of the Term, as Additional Rent, (a)&nbsp;the Property Management
Fee (as defined below) and (b)&nbsp;Landlord&#146;s estimate of Tenant&#146;s Share of Operating Expenses with respect to the Building and the Project, as applicable, for such month. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(x) The &#147;<U>Property Management Fee</U>&#148; shall equal three percent (3%)&nbsp;of Base Rent due from Tenant. Tenant shall pay the
Property Management Fee in accordance with <U>Section&nbsp;9.2</U> with respect to the entire Term, including any extensions thereof or any holdover periods, regardless of whether Tenant is obligated to pay Base Rent, Operating Expenses or any other
Rent with respect to any such period or portion thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(y) Within ninety (90)&nbsp;days after the conclusion of each calendar year (or such longer
period as may be reasonably required by Landlord), Landlord shall furnish to Tenant a statement showing in reasonable detail the actual Operating Expenses and Tenant&#146;s Share of Operating Expenses for the previous calendar year. Any additional
sum due from Tenant to Landlord shall be immediately due and payable. If the amounts paid by Tenant pursuant to this Section exceed Tenant&#146;s Share of Operating Expenses for the previous calendar year, then Landlord shall credit the difference
against the Rent next due and owing from Tenant; <U>provided</U> that, if the Lease term has expired, Landlord shall accompany such statement with payment for the amount of such difference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(z) Any amount due under this Section for any period that is less than a full month shall be prorated for such fractional month on the basis
of the number of days in the month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3. Landlord may, from time to time, modify Landlord&#146;s calculation and allocation procedures
for Operating Expenses, so long as such modifications produce Dollar results substantially consistent with Landlord&#146;s then-current practice at the Project. Landlord or an affiliate(s) of Landlord currently own other property(ies) adjacent to
the Project or its neighboring properties (collectively, &#147;<U>Neighboring Properties</U>&#148;). In connection with Landlord performing services for the Project pursuant to this Lease, similar services may be performed by the same vendor(s) for
Neighboring Properties. In such a case, Landlord shall reasonably allocate to each Building and the Project the costs for such services based upon the ratio that the square footage of the Building or the Project (as applicable) bears to the total
square footage of all of the Neighboring Properties or buildings within the Neighboring Properties for which the services are performed, unless the scope of the services performed for any building or property (including the Building and the Project)
is disproportionately more or less than for others, in which case Landlord shall equitably allocate the costs based on the scope of the services being performed for each building or property (including the Building and the Project). Since the
Project consists of multiple buildings, certain Operating Expenses may pertain to a particular building(s), certain Operating Expenses may pertain to the North Campus, and other Operating Expenses to the Project as a whole. Landlord reserves the
right in its sole discretion to allocate any such costs applicable to any particular building within the Project to such building, any costs applicable to the North Campus to the buildings comprising the North Campus (including the Building), and
other such costs applicable to the Project to each building in the Project (including the Building), with the tenants in each building being responsible for paying their respective proportionate shares of their buildings to the extent required under
their leases. Landlord shall allocate such costs to the buildings (including the Building) in a reasonable, non-discriminatory manner, and such allocation shall be binding on Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4. Tenant shall not be responsible for Operating Expenses attributable to the time period prior to the Term Commencement Date;
<U>provided</U>, however, that if Landlord shall permit Tenant possession of the Premises prior to the Term Commencement Date, Tenant shall be responsible for Operating Expenses from such earlier date of possession. Tenant&#146;s responsibility for
Tenant&#146;s Share of Operating Expenses shall continue to the latest of (a)&nbsp;the date of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
termination of the Lease, (b)&nbsp;the date Tenant has fully vacated the Premises and (c)&nbsp;if termination of the Lease is due to a default by Tenant, the earlier of (i)&nbsp;the date of
rental commencement of a replacement tenant or (ii)&nbsp;the scheduled expiration of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5. Operating Expenses for the calendar
year in which Tenant&#146;s obligation to share therein commences and for the calendar year in which such obligation ceases shall be prorated on a basis reasonably determined by Landlord. Expenses such as taxes, assessments and insurance premiums
that are incurred for an extended time period shall be prorated based upon the time periods to which they apply so that the amounts attributed to the Premises relate in a reasonable manner to the time period wherein Tenant has an obligation to share
in Operating Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6. Within three (3)&nbsp;business days after the end of each calendar month, Tenant shall submit to Landlord an
invoice, or, in the event an invoice is not available, an itemized list, of all costs and expenses that (a)&nbsp;Tenant has incurred (either internally or by employing third parties) during the prior month and (b)&nbsp;for which Tenant reasonably
believes it is entitled to reimbursements from Landlord pursuant to the terms of this Lease or that Tenant reasonably believes is the responsibility of Landlord pursuant to this Lease or <U>Exhibit B</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.7. In the event that the Building, North Campus or Project is less than fully occupied during a calendar year, Tenant acknowledges that
Landlord may extrapolate Operating Expenses that vary depending on the occupancy of the Building , North Campus or Project, as applicable, to equal Landlord&#146;s reasonable estimate of what such Operating Expenses would have been had the Building,
North Campus or Project, as applicable, been fully occupied during such calendar year; <U>provided</U>, however, that Landlord shall not recover more than one hundred percent (100%)&nbsp;of Operating Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>Taxes on Tenant&#146;s Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1. Tenant shall pay prior to delinquency any and all taxes levied against any personal property or trade fixtures placed by Tenant in or
about the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2. If any such taxes on Tenant&#146;s personal property or trade fixtures are levied against Landlord or
Landlord&#146;s property or, if the assessed valuation of the Building, the Property or the Project is increased by inclusion therein of a value attributable to Tenant&#146;s personal property or trade fixtures, and if Landlord, after written notice
to Tenant, pays the taxes based upon any such increase in the assessed value of the Building, the Property or the Project, then Tenant shall, upon demand, repay to Landlord the taxes so paid by Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3. If any improvements in or alterations to the Premises, whether owned by Landlord or Tenant and whether or not affixed to the real
property so as to become a part thereof, are assessed for real property tax purposes at a valuation higher than the valuation at which improvements conforming to Landlord&#146;s building standards (the &#147;<U>Building Standard</U>&#148;) in other
spaces in the Building are assessed, then the real property taxes and assessments levied against Landlord or the Building, the Property or the Project by reason of such excess assessed valuation shall be deemed to be taxes levied against personal
property of Tenant and shall be governed by the provisions of <U>Section&nbsp;10.2</U>. Any such excess assessed valuation due to improvements in or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
alterations to space in the Project leased by other tenants at the Project shall not be included in Operating Expenses. If the records of the applicable governmental assessor&#146;s office are
available and sufficiently detailed to serve as a basis for determining whether such Tenant improvements or alterations are assessed at a higher valuation than the Building Standard, then such records shall be binding on both Landlord and Tenant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <U>Security Deposit</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1. Tenant
shall deposit with Landlord on or before the Execution Date the sum set forth in <U>Section&nbsp;2.6</U> (the &#147;<U>Security Deposit</U>&#148;), which sum shall be held by Landlord as security for the faithful performance by Tenant of all of the
terms, covenants and conditions of this Lease to be kept and performed by Tenant during the period commencing on the Execution Date and ending upon the expiration or termination of Tenant&#146;s obligations under this Lease. If Tenant Defaults (as
defined below) with respect to any provision of this Lease, including any provision relating to the payment of Rent, then Landlord may (but shall not be required to) use, apply or retain all or any part of the Security Deposit for the payment of any
Rent or any other sum in default, or to compensate Landlord for any other loss or damage that Landlord may suffer by reason of Tenant&#146;s default. If any portion of the Security Deposit is so used or applied, then Tenant shall, within ten
(10)&nbsp;days following demand therefor, deposit cash with Landlord in an amount sufficient to restore the Security Deposit to its original amount, and Tenant&#146;s failure to do so shall be a material breach of this Lease. The provisions of this
Article shall survive the expiration or earlier termination of this Lease. TENANT HEREBY WAIVES THE REQUIREMENTS OF SECTION 1950.7 OF THE CALIFORNIA CIVIL CODE, AS THE SAME MAY BE AMENDED FROM TIME TO TIME. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2. In the event of bankruptcy or other debtor-creditor proceedings against Tenant, the Security Deposit shall be deemed to be applied first
to the payment of Rent and other charges due Landlord for all periods prior to the filing of such proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3. Landlord may deliver
to any purchaser of Landlord&#146;s interest in the Premises the funds deposited hereunder by Tenant, and thereupon Landlord shall be discharged from any further liability with respect to such deposit. This provision shall also apply to any
subsequent transfers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4. If Tenant shall fully and faithfully perform every provision of this Lease to be performed by it, then the
Security Deposit, or any balance thereof, shall be returned to Tenant (or, at Landlord&#146;s option, to the last assignee of Tenant&#146;s interest hereunder) within thirty (30)&nbsp;days after the expiration or earlier termination of this Lease.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.5. [Intentionally omitted] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.6. If the Security Deposit shall be in cash, Landlord shall hold the Security Deposit in an account at a banking organization selected by
Landlord; <U>provided</U>, however, that Landlord shall not be required to maintain a separate account for the Security Deposit, but may intermingle it with other funds of Landlord. Landlord shall be entitled to all interest and/or dividends, if
any, accruing on the Security Deposit. Landlord shall not be required to credit Tenant with any interest for any period during which Landlord does not receive interest on the Security Deposit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.7. The Security Deposit may be in the form of cash, a letter of credit or any other security
instrument acceptable to Landlord in its sole discretion. Tenant may at any time, except when Tenant is in Default (as defined below), deliver a letter of credit (the &#147;<U>L/C Security</U>&#148;) as the entire Security Deposit, as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) If Tenant elects to deliver L/C Security, then Tenant shall provide Landlord, and maintain in full force and effect throughout the Term
and until the date that is six (6)&nbsp;months after the then-current Term Expiration Date, a letter of credit in the form of <U>Exhibit E</U> issued by an issuer reasonably satisfactory to Landlord, in the amount of the Security Deposit, with an
initial term of at least one year. Landlord may require the L/C Security to be re-issued by a different issuer at any time during the Term if Landlord reasonably believes that the issuing bank of the L/C Security is or may soon become insolvent;
provided, however, Landlord shall return the existing L/C Security to the existing issuer immediately upon receipt of the substitute L/C Security. If any issuer of the L/C Security shall become insolvent or placed into FDIC receivership, then Tenant
shall immediately deliver to Landlord (without the requirement of notice from Landlord) substitute L/C Security issued by an issuer reasonably satisfactory to Landlord, and otherwise conforming to the requirements set forth in this Article. As used
herein with respect to the issuer of the L/C Security, &#147;insolvent&#148; shall mean the determination of insolvency as made by such issuer&#146;s primary bank regulator (<I>i.e</I>., the state bank supervisor for state chartered banks; the OCC
or OTS, respectively, for federally chartered banks or thrifts; or the Federal Reserve for its member banks). If, at the Term Expiration Date, any Rent remains uncalculated or unpaid, then (i)&nbsp;Landlord shall with reasonable diligence complete
any necessary calculations, (ii)&nbsp;Tenant shall extend the expiry date of such L/C Security from time to time as Landlord reasonably requires and (iii)&nbsp;in such extended period, Landlord shall not unreasonably refuse to consent to an
appropriate reduction of the L/C Security. Tenant shall reimburse Landlord&#146;s legal costs (as estimated by Landlord&#146;s counsel) in handling Landlord&#146;s acceptance of L/C Security or its replacement or extension. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) If Tenant delivers to Landlord satisfactory L/C Security in place of the entire Security Deposit, Landlord shall remit to Tenant any cash
Security Deposit Landlord previously held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Landlord may draw upon the L/C Security, and hold and apply the proceeds in the same
manner and for the same purposes as the Security Deposit, if (i)&nbsp;an uncured Default (as defined below) exists, (ii)&nbsp;as of the date forty-five (45)&nbsp;days before any L/C Security expires (even if such scheduled expiry date is after the
Term Expiration Date) Tenant has not delivered to Landlord an amendment or replacement for such L/C Security, reasonably satisfactory to Landlord, extending the expiry date to the earlier of (1)&nbsp;six (6)&nbsp;months after the then-current Term
Expiration Date or (2)&nbsp;the date one year after the then-current expiry date of the L/C Security, (iii)&nbsp;the L/C Security provides for automatic renewals, Landlord asks the issuer to confirm the current L/C Security expiry date, and the
issuer fails to do so within ten (10)&nbsp;business days, (iv)&nbsp;Tenant fails to pay (when and as Landlord reasonably requires) any bank charges for Landlord&#146;s transfer of the L/C Security or (v)&nbsp;the issuer of the L/C Security ceases,
or announces that it will cease, to maintain an office in the city where Landlord may present drafts under the L/C Security (and fails to permit drawing upon the L/C Security by overnight courier or facsimile). This Section does not limit any other
provisions of this Lease allowing Landlord to draw the L/C Security under specified circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Tenant shall not seek to enjoin, prevent, or otherwise interfere with Landlord&#146;s draw
under L/C Security, even if it violates this Lease. Tenant acknowledges that the only effect of a wrongful draw would be to substitute a cash Security Deposit for L/C Security, causing Tenant no legally recognizable damage. Landlord shall hold the
proceeds of any draw in the same manner and for the same purposes as a cash Security Deposit. In the event of a wrongful draw, the parties shall cooperate to allow Tenant to post replacement L/C Security simultaneously with the return to Tenant of
the wrongfully drawn sums, and Landlord shall upon request confirm in writing to the issuer of the L/C Security that Landlord&#146;s draw was erroneous. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) If Landlord transfers its interest in the Premises, then Tenant shall at Tenant&#146;s expense, within five (5)&nbsp;business days after
receiving a request from Landlord, deliver (and, if the issuer requires, Landlord shall consent to) an amendment to the L/C Security naming Landlord&#146;s grantee as substitute beneficiary. If the required Security Deposit changes while L/C
Security is in force, then Tenant shall deliver (and, if the issuer requires, Landlord shall consent to) a corresponding amendment to the L/C Security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <U>Use</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1. Tenant shall use the
Premises for the Permitted Use, and shall not use the Premises, or permit or suffer the Premises to be used, for any other purpose without Landlord&#146;s prior written consent, which consent Landlord may withhold in its sole and absolute
discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2. Tenant shall not use or occupy the Premises in violation of Applicable Laws; zoning ordinances; or the certificate of
occupancy issued for the Building or the Project, and shall, upon five (5)&nbsp;days&#146; written notice from Landlord, discontinue any use of the Premises that is declared or claimed by any Governmental Authority having jurisdiction to be a
violation of any of the above, or that in Landlord&#146;s reasonable opinion violates any of the above. Tenant shall comply with any direction of any Governmental Authority having jurisdiction that shall, by reason of the nature of Tenant&#146;s use
or occupancy of the Premises, impose any duty upon Tenant or Landlord with respect to the Premises or with respect to the use or occupation thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.3. Tenant shall not do or permit to be done anything that will invalidate or increase the cost of any fire, environmental, extended
coverage or any other insurance policy covering the Building or the Project, and shall comply with all rules, orders, regulations and requirements of the insurers of the Building and the Project, and Tenant shall promptly, upon demand, reimburse
Landlord for any additional premium charged for such policy by reason of Tenant&#146;s failure to comply with the provisions of this Article. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.4. Tenant shall keep all doors opening onto public corridors closed, except when in use for ingress and egress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.5. No additional locks or bolts of any kind shall be placed upon any of the doors or windows by Tenant, nor shall any changes be made to
existing locks or the mechanisms thereof without Landlord&#146;s prior written consent. Tenant shall, upon termination of this Lease, return to Landlord all keys to offices and restrooms either furnished to or otherwise procured by Tenant. In the
event any key so furnished to Tenant is lost, Tenant shall pay to Landlord the cost of replacing the same or of changing the lock or locks opened by such lost key if Landlord shall deem it necessary to make such change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.6. No awnings or other projections shall be attached to any outside wall of the Building. No
curtains, blinds, shades or screens shall be attached to or hung in, or used in connection with, any window or door of the Premises other than Landlord&#146;s standard window coverings. Neither the interior nor exterior of any windows shall be
coated or otherwise sunscreened without Landlord&#146;s prior written consent, nor shall any bottles, parcels or other articles be placed on the windowsills. No equipment, furniture or other items of personal property shall be placed on any exterior
balcony without Landlord&#146;s prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.7. No sign, advertisement or notice (&#147;<U>Signage</U>&#148;) shall be
exhibited, painted or affixed by Tenant on any part of the Premises or the Building without Landlord&#146;s prior written consent. Signage shall conform to Landlord&#146;s design criteria. For any Signage, Tenant shall, at Tenant&#146;s own cost and
expense, (a)&nbsp;acquire all permits for such Signage in compliance with Applicable Laws and (b)&nbsp;design, fabricate, install and maintain such Signage in a first-class condition. Tenant shall be responsible for reimbursing Landlord for costs
incurred by Landlord in removing any of Tenant&#146;s Signage upon the expiration or earlier termination of the Lease. Interior signs on entry doors to the Premises and the directory tablet shall be inscribed, painted or affixed for Tenant by
Landlord at Tenant&#146;s sole cost and expense, and shall be of a size, color and type and be located in a place acceptable to Landlord. The directory tablet shall be provided exclusively for the display of the name and location of tenants only.
Tenant shall not place anything on the exterior of the corridor walls or corridor doors other than Landlord&#146;s standard lettering. At Landlord&#146;s option, Landlord may install any Tenant Signage, and Tenant shall pay all costs associated with
such installation within thirty (30)&nbsp;days after demand therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.8. Tenant may only place equipment within the Premises with
floor loading consistent with the Building&#146;s structural design unless Tenant obtains Landlord&#146;s prior written approval. Tenant may place such equipment only in a location designed to carry the weight of such equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.9. Tenant shall cause any equipment or machinery to be installed in the Premises so as to reasonably prevent sounds or vibrations therefrom
from extending into the Common Areas or other offices in the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.10. Tenant shall not (a)&nbsp;do or permit anything to be done
in or about the Premises that shall in any way obstruct or interfere with the rights of other tenants or occupants of the Project, or injure or annoy them, (b)&nbsp;use or allow the Premises to be used for immoral, unlawful or objectionable
purposes, (c)&nbsp;cause, maintain or permit any nuisance or waste in, on or about the Project or (d)&nbsp;take any other action that would in Landlord&#146;s reasonable determination in any manner adversely affect other tenants&#146; quiet use and
enjoyment of their space or adversely impact their ability to conduct business in a professional and suitable work environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.11.
Notwithstanding any other provision herein to the contrary, Tenant shall be responsible for all liabilities, costs and expenses arising out of or in connection with the compliance of the Premises with the Americans with Disabilities Act, 42 U.S.C.
&#167; 12101, et seq., and any state and local accessibility laws, codes, ordinances and rules (collectively, and together </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with regulations promulgated pursuant thereto, the &#147;<U>ADA</U>&#148;), and Tenant shall indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord)
and hold Landlord and its affiliates, employees, agents and contractors; and any lender, mortgagee or beneficiary (each, a &#147;<U>Lender</U>&#148; and, collectively with Landlord and its affiliates, employees, agents and contractors, the
&#147;<U>Landlord Indemnitees</U>&#148;) harmless from and against any demands, claims, liabilities, losses, costs, expenses, actions, causes of action, damages, suits or judgments, and all reasonable expenses (including reasonable attorneys&#146;
fees, charges and disbursements, regardless of whether the applicable demand, claim, action, cause of action or suit is voluntarily withdrawn or dismissed) incurred in investigating or resisting the same (collectively, &#147;<U>Claims</U>&#148;)
arising out of any such failure of the Premises to comply with the ADA. The Premises have not undergone inspection by a Certified Access Specialist. The provisions of this Section shall survive the expiration or earlier termination of this Lease.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <U>Rules and Regulations, CC&amp;Rs, Parking Facilities and Common Areas</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1. Tenant shall have the non-exclusive right, in common with others, to use the Common Areas in conjunction with Tenant&#146;s use of the
Premises for the Permitted Use, and such use of the Common Areas and Tenant&#146;s use of the Premises shall be subject to the rules and regulations adopted by Landlord and attached hereto as <U>Exhibit F</U>, together with such other reasonable and
nondiscriminatory rules and regulations as are hereafter promulgated by Landlord in its sole and absolute discretion (the &#147;<U>Rules and Regulations</U>&#148;). Tenant shall faithfully observe and comply with the Rules and Regulations. Landlord
shall not be responsible to Tenant for the violation or non-performance by any other tenant or any agent, employee or invitee thereof of any of the Rules and Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2. This Lease is subject to any recorded covenants, conditions or restrictions on the Project or Property (the
&#147;<U>CC&amp;R</U>s&#148;), as the same may be amended, amended and restated, supplemented or otherwise modified from time to time. Tenant shall comply with the CC&amp;Rs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.3. Tenant shall have a non-exclusive, irrevocable license to use Tenant&#146;s Pro Rata Share of parking facilities serving the Building in
common on an unreserved basis with other tenants of the Building during the Term at no additional cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.4. Tenant agrees not to
unreasonably overburden the parking facilities and agrees to cooperate with Landlord and other tenants in the use of the parking facilities. Landlord reserves the right to determine that parking facilities are becoming overcrowded and to limit
Tenant&#146;s use thereof. Upon such determination, Landlord may reasonably allocate parking spaces among Tenant and other tenants of the Building or the Project. Nothing in this Section, however, is intended to create an affirmative duty on
Landlord&#146;s part to monitor parking. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.5. Landlord reserves the right to modify the Common Areas, including the right to add or
remove exterior and interior landscaping and to subdivide real property. Tenant acknowledges that Landlord specifically reserves the right to allow the exclusive use of corridors and restroom facilities located on specific floors to one or more
tenants occupying such floors; <U>provided</U>, however, that Tenant shall not be deprived of the use of the corridors reasonably required to serve the Premises or of restroom facilities serving the floor upon which the Premises are located. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <U>Project Control by Landlord</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.1. Landlord reserves full control over the Building and the Project to the extent not inconsistent with Tenant&#146;s enjoyment of the
Premises as provided by this Lease. This reservation includes Landlord&#146;s right to subdivide the Project; convert the Building and other buildings within the Project to condominium units; change the size of the Project by selling all or a
portion of the Project or adding real property and any improvements thereon to the Project; grant easements and licenses to third parties; maintain or establish ownership of the Building separate from fee title to the Property; make additions to or
reconstruct portions of the Building and the Project; install, use, maintain, repair, replace and relocate for service to the Premises and other parts of the Building or the Project pipes, ducts, conduits, wires and appurtenant fixtures, wherever
located in the Premises, the Building or elsewhere at the Project; and alter or relocate any other Common Area or facility, including private drives, lobbies and entrances; <U>provided</U>, however, that such rights shall be exercised in a way that
does not materially adversely affect Tenant&#146;s beneficial use and occupancy of the Premises, including the Permitted Use and Tenant&#146;s access to the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.2. Possession of areas of the Premises necessary for utilities, services, safety and operation of the Building is reserved to Landlord.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.3. Tenant shall, at Landlord&#146;s request, promptly execute such further documents as may be reasonably appropriate to assist
Landlord in the performance of its obligations hereunder; <U>provided</U> that Tenant need not execute any document that creates additional liability for Tenant or that deprives Tenant of the quiet enjoyment and use of the Premises as provided for
in this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.4. Landlord may, at any and all reasonable times during non-business hours (or during business hours, if (a)&nbsp;with
respect to <U>Subsections 14.4(u)</U> through <U>14.4(y)</U>, Tenant so requests, and (b)&nbsp;with respect to <U>Subsection 14.4(z)</U>, if Landlord so requests), and upon twenty-four (24)&nbsp;hours&#146; prior notice (<U>provided</U> that no time
restrictions shall apply or advance notice be required if an emergency necessitates immediate entry), enter the Premises to (u)&nbsp;inspect the same and to determine whether Tenant is in compliance with its obligations hereunder, (v)&nbsp;supply
any service Landlord is required to provide hereunder, (w)&nbsp;alter, improve or repair any portion of the Building other than the Premises for which access to the Premises is reasonably necessary, (x)&nbsp;post notices of nonresponsibility,
(y)&nbsp;access the telephone equipment, electrical substation and fire risers and (z)&nbsp;show the Premises to prospective purchasers or tenants during the final year of the Term. In connection with any such alteration, improvement or repair as
described in <U>Subsection 14.4(w)</U>, Landlord may erect in the Premises or elsewhere in the Project scaffolding and other structures reasonably required for the alteration, improvement or repair work to be performed. In no event shall
Tenant&#146;s Rent abate as a result of Landlord&#146;s activities pursuant to this Section; <U>provided</U>, however, that all such activities shall be conducted in such a manner so as to cause as little interference to Tenant as is reasonably
possible. Landlord shall at all times retain a key with which to unlock all of the doors in the Premises. If an emergency necessitates immediate access to the Premises, Landlord may use whatever force is necessary to enter the Premises, and any such
entry to the Premises shall not constitute a forcible or unlawful entry to the Premises, a detainer of the Premises, or an eviction of Tenant from the Premises or any portion thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <U>Quiet Enjoyment</U>. Landlord covenants that Tenant, upon paying the Rent and performing its obligations
contained in this Lease, may peacefully and quietly have, hold and enjoy the Premises, free from any claim by Landlord or persons claiming under Landlord, but subject to all of the terms and provisions hereof, provisions of Applicable Laws and
rights of record to which this Lease is or may become subordinate. This covenant is in lieu of any other quiet enjoyment covenant, either express or implied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. <U>Utilities and Services</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.1.
Tenant shall pay for all water (including the cost to service, repair and replace reverse osmosis, de-ionized and other treated water), gas, heat, light, power, telephone, internet service, cable television, other telecommunications and other
utilities supplied to the Premises, together with any fees, surcharges and taxes thereon. If any such utility is not separately metered to Tenant, Tenant shall pay Tenant&#146;s Share of all charges of such utility jointly metered with other
premises as Additional Rent or, in the alternative, Landlord may, at its option, monitor the usage of such utilities by Tenant and charge Tenant with the cost of purchasing, installing and monitoring such metering equipment, which cost shall be paid
by Tenant as Additional Rent. To the extent that Tenant uses more than Tenant&#146;s Pro Rata Share of any utilities, then Tenant shall pay Landlord for Tenant&#146;s Share of such utilities to reflect such excess. In the event that the Building,
North Campus or Project is less than fully occupied during a calendar year, Tenant acknowledges that Landlord may extrapolate utility usage that varies depending on the occupancy of the Building, North Campus or Project (as applicable) to equal
Landlord&#146;s reasonable estimate of what such utility usage would have been had the Building, North Campus or Project, as applicable, been fully occupied during such calendar year; <U>provided</U>, however, that Landlord shall not recover more
than one hundred percent (100%)&nbsp;of the cost of such utilities. Tenant shall not be liable for the cost of utilities supplied to the Premises attributable to the time period prior to the Term Commencement Date; <U>provided</U>, however, that, if
Landlord shall permit Tenant possession of the Premises prior to the Term Commencement Date and Tenant uses the Premises for any purpose other than placement of personal property as set forth in <U>Section&nbsp;4.3</U>, then Tenant shall be
responsible for the cost of utilities supplied to the Premises from such earlier date of possession. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.2. Landlord shall not be liable
for, nor shall any eviction of Tenant result from, the failure to furnish any utility or service, whether or not such failure is caused by accident; breakage; repair; strike, lockout or other labor disturbance or labor dispute of any character; act
of terrorism; shortage of materials, which shortage is not unique to Landlord or Tenant, as the case may be; governmental regulation, moratorium or other governmental action, inaction or delay; or other causes beyond Landlord&#146;s control
(collectively, &#147;<U>Force Majeure</U>&#148;) or, to the extent permitted by Applicable Laws, Landlord&#146;s negligence. In the event of such failure, Tenant shall not be entitled to termination of this Lease or any abatement or reduction of
Rent, nor shall Tenant be relieved from the operation of any covenant or agreement of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.3. Tenant shall pay for, prior to
delinquency of payment therefor, any utilities and services that may be furnished to the Premises during or, if Tenant occupies the Premises after the expiration or earlier termination of the Term, after the Term, beyond those utilities provided by
Landlord, including telephone, internet service, cable television and other telecommunications, together with any fees, surcharges and taxes thereon. Upon Landlord&#146;s demand, utilities and services provided to the Premises that are separately
metered shall be paid by Tenant directly to the supplier of such utilities or services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.4. Tenant shall not, without Landlord&#146;s prior written consent, use any device in the
Premises (including data processing machines) that will in any way (a)&nbsp;increase the amount of ventilation, air exchange, gas, steam, electricity or water required or consumed in the Premises based upon Tenant&#146;s Pro Rata Share of the
Building or Project (as applicable) beyond the existing capacity of the Building or the Project usually furnished or supplied for the Permitted Use or (b)&nbsp;exceed Tenant&#146;s Pro Rata Share of the Building&#146;s or Project&#146;s (as
applicable) capacity to provide such utilities or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.5. If Tenant shall require utilities or services in excess of those
usually furnished or supplied for tenants in similar spaces in the Building or the Project by reason of Tenant&#146;s equipment or extended hours of business operations, then Tenant shall first procure Landlord&#146;s consent for the use thereof,
which consent Landlord may condition upon the availability of such excess utilities or services, and Tenant shall pay as Additional Rent an amount equal to the cost of providing such excess utilities and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.6. Landlord shall provide water in Common Areas for lavatory and landscaping purposes only, which water shall be from the local municipal
or similar source; <U>provided</U>, however, that if Landlord determines that Tenant requires, uses or consumes water provided to the Common Areas for any purpose other than ordinary lavatory purposes, Landlord may install a water meter
(&#147;<U>Tenant Water Meter</U>&#148;) and thereby measure Tenant&#146;s water consumption for all purposes. Tenant shall pay Landlord for the costs of any Tenant Water Meter and the installation and maintenance thereof during the Term. If Landlord
installs a Tenant Water Meter, Tenant shall pay for water consumed, as shown on such meter, as and when bills are rendered. If Tenant fails to timely make such payments, Landlord may pay such charges and collect the same from Tenant. Any such costs
or expenses incurred or payments made by Landlord for any of the reasons or purposes stated in this Section shall be deemed to be Additional Rent payable by Tenant and collectible by Landlord as such. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.7. Landlord reserves the right to stop service of the elevator, plumbing, ventilation, air conditioning and utility systems, when Landlord
deems necessary or desirable, due to accident, emergency or the need to make repairs, alterations or improvements, until such repairs, alterations or improvements shall have been completed, and Landlord shall further have no responsibility or
liability for failure to supply elevator facilities, plumbing, ventilation, air conditioning or utility service when prevented from doing so by Force Majeure or, to the extent permitted by Applicable Laws, Landlord&#146;s negligence; a failure by a
third party to deliver gas, oil or another suitable fuel supply; or Landlord&#146;s inability by exercise of reasonable diligence to obtain gas, oil or another suitable fuel. Without limiting the foregoing, it is expressly understood and agreed that
any covenants on Landlord&#146;s part to furnish any service pursuant to any of the terms, covenants, conditions, provisions or agreements of this Lease, or to perform any act or thing for the benefit of Tenant, shall not be deemed breached if
Landlord is unable to furnish or perform the same by virtue of Force Majeure or, to the extent permitted by Applicable Laws, Landlord&#146;s negligence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.8. For the Premises, Landlord shall (a)&nbsp;maintain and operate the heating, ventilating and
air conditioning systems used for typical office use only (&#147;<U>HVAC</U>&#148;) (and not for uses other than office use, including HVAC related to laboratory fixtures and equipment) and (b)&nbsp;subject to <U>Subsection 16.8(a)</U>, furnish HVAC
as reasonably required (except as this Lease otherwise provides) for reasonably comfortable occupancy of the Premises twenty-four (24)&nbsp;hours a day, every day during the Term, subject to casualty, eminent domain or as otherwise specified in this
Article. Notwithstanding anything to the contrary in this Section, Landlord shall have no liability, and Tenant shall have no right or remedy, on account of any interruption or impairment in HVAC services; <U>provided</U> that Landlord diligently
endeavors to cure any such interruption or impairment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.9. For any utilities serving the Premises for which Tenant is billed directly
by such utility provider, Tenant agrees to furnish to Landlord (a)&nbsp;any invoices or statements for such utilities within thirty (30)&nbsp;days after Tenant&#146;s receipt thereof, (b)&nbsp;within thirty (30)&nbsp;days after Landlord&#146;s
request, any other utility usage information reasonably requested by Landlord, and (c)&nbsp;within thirty (30)&nbsp;days after each calendar year during the Term, an ENERGY STAR&reg; Statement of Performance (or similar comprehensive utility usage
report (e.g., related to Labs 21), if requested by Landlord) and any other information reasonably requested by Landlord for the immediately preceding year. Tenant shall retain records of utility usage at the Premises, including invoices and
statements from the utility provider, for at least sixty (60)&nbsp;months, or such other period of time as may be requested by Landlord. Tenant acknowledges that any utility information for the Premises, the Building and the Project may be shared
with third parties, including Landlord&#146;s consultants and Governmental Authorities. In the event that Tenant fails to comply with this Section, Tenant hereby authorizes Landlord to collect utility usage information directly from the applicable
utility providers, and Tenant shall pay Landlord a fee of One Thousand Dollars ($1,000) per month to collect such utility usage information. The provisions of this Section shall survive the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17. <U>Alterations</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.1. Tenant shall
make no alterations, additions or improvements in or to the Premises or engage in any construction, demolition, reconstruction, renovation, or other work (whether major or minor) of any kind in, at, or serving the Premises
(&#147;<U>Alterations</U>&#148;) without Landlord&#146;s prior written approval, which approval Landlord shall not unreasonably withhold; <U>provided</U>, however, that in the event any proposed Alteration affects (a)&nbsp;any structural portions of
the Building, including exterior walls, roof, foundation, foundation systems (including barriers and subslab systems), or core of the Building, (b)&nbsp;the exterior of the Building or (c)&nbsp;any Building systems, including elevator, plumbing, air
conditioning, heating, electrical, security, life safety and power, then Landlord may withhold its approval in its sole and absolute discretion. Tenant shall, in making any such Alterations, use only those architects, contractors, suppliers and
mechanics of which Landlord has given prior written approval, which approval shall be in Landlord&#146;s sole and absolute discretion. In seeking Landlord&#146;s approval, Tenant shall provide Landlord, at least fourteen (14)&nbsp;days in advance of
any proposed construction, with plans, specifications, bid proposals, certified stamped engineering drawings and calculations by Tenant&#146;s engineer of record or architect of record, (including connections to the Building&#146;s structural
system, modifications to the Building&#146;s envelope, non-structural penetrations in slabs or walls, and modifications or tie-ins to life safety systems), work contracts, requests for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
laydown areas and such other information concerning the nature and cost of the Alterations as Landlord may reasonably request. In no event shall Tenant use or Landlord be required to approve any
architects, consultants, contractors, subcontractors or material suppliers that Landlord reasonably believes could cause labor disharmony. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.2. Tenant shall not construct or permit to be constructed partitions or other obstructions that might interfere with free access to
mechanical installation or service facilities of the Building or with other tenants&#146; components located within the Building, or interfere with the moving of Landlord&#146;s equipment to or from the enclosures containing such installations or
facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.3. Tenant shall accomplish any work performed on the Premises or the Building in such a manner as to permit any life
safety systems to remain fully operable at all times. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.4. Any work performed on the Premises, the Building or the Project by Tenant or
Tenant&#146;s contractors shall be done at such times and in such manner as Landlord may from time to time designate. Tenant covenants and agrees that all work done by Tenant or Tenant&#146;s contractors shall be performed in full compliance with
Applicable Laws. Within thirty (30)&nbsp;days after completion of any Alterations, Tenant shall provide Landlord with complete &#147;as built&#148; drawing print sets and electronic CADD files on disc (or files in such other current format in common
use as Landlord reasonably approves or requires) showing any changes in the Premises. Any such &#147;as built&#148; plans shall show the applicable Alterations as an overlay on the Building as-built plans; <U>provided</U> that Landlord provides the
Building &#147;as built&#148; plans to Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.5. Before commencing any Alterations, Tenant shall give Landlord at least fourteen
(14)&nbsp;days&#146; prior written notice of the proposed commencement of such work and shall, if required by Landlord, secure, at Tenant&#146;s own cost and expense, a completion and lien indemnity bond satisfactory to Landlord for such work. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.6. Tenant shall repair any damage to the Premises caused by Tenant&#146;s removal of any property from the Premises. During any such
restoration period, Tenant shall pay Rent to Landlord as provided herein as if such space were otherwise occupied by Tenant. The provisions of this Section shall survive the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.7. The Premises plus any Alterations, Signage, Tenant Improvements, attached equipment, decorations, fixtures, movable laboratory casework
and related appliances, trade fixtures, additions and improvements attached to or built into the Premises, made by either of the Parties (including all floor and wall coverings; paneling; sinks and related plumbing fixtures; laboratory benches;
exterior venting fume hoods; walk-in freezers and refrigerators; ductwork; conduits; electrical panels and circuits; business and trade fixtures; attached machinery and equipment; and built-in furniture and cabinets, in each case, together with all
additions and accessories thereto), shall (unless, prior to such construction or installation, Landlord elects otherwise) at all times remain the property of Landlord, shall remain in the Premises and shall (unless, prior to construction or
installation thereof, Landlord elects otherwise) be surrendered to Landlord upon the expiration or earlier termination of this Lease. For the avoidance of doubt, the items listed on <U>Exhibit H</U> attached hereto (which <U>Exhibit H</U> may be
updated by Tenant from and after the Term Commencement Date, subject to Landlord&#146;s written consent) constitute Tenant&#146;s property and shall be removed by Tenant upon the expiration or earlier termination of the Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.8. Notwithstanding any other provision of this Article to the contrary, in no event shall
Tenant remove any improvement from the Premises as to which Landlord contributed payment, including the Tenant Improvements, without Landlord&#146;s prior written consent, which consent Landlord may withhold in its sole and absolute discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.9. If Tenant shall fail to remove any of its property from the Premises prior to the expiration or earlier termination of this Lease, then
Landlord may, at its option, remove the same in any manner that Landlord shall choose and store such effects without liability to Tenant for loss thereof or damage thereto, and Tenant shall pay Landlord, upon demand, any costs and expenses incurred
due to such removal and storage or Landlord may, at its sole option and without notice to Tenant, sell such property or any portion thereof at private sale and without legal process for such price as Landlord may obtain and apply the proceeds of
such sale against any (a)&nbsp;amounts due by Tenant to Landlord under this Lease and (b)&nbsp;any expenses incident to the removal, storage and sale of such personal property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.10. Tenant shall pay to Landlord an amount equal to three percent (3%)&nbsp;of the cost to Tenant of all Alterations to cover
Landlord&#146;s overhead and expenses for plan review, coordination, scheduling and supervision thereof. For purposes of payment of such sum, Tenant shall submit to Landlord copies of all bills, invoices and statements covering the costs of such
charges, accompanied by payment to Landlord of the fee set forth in this Section. Tenant shall reimburse Landlord for any extra expenses incurred by Landlord by reason of faulty work done by Tenant or its contractors, or by reason of delays caused
by such work, or by reason of inadequate clean-up. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.11. Within sixty (60)&nbsp;days after final completion of any Alterations performed
by Tenant with respect to the Premises, Tenant shall submit to Landlord documentation showing the amounts expended by Tenant with respect to such Alterations, together with supporting documentation reasonably acceptable to Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.12. Tenant shall take, and shall cause its contractors to take, commercially reasonable steps to protect the Premises during the
performance of any Alterations, including covering or temporarily removing any window coverings so as to guard against dust, debris or damage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.13. Tenant shall require its contractors and subcontractors performing work on the Premises to name Landlord and its affiliates and Lenders
as additional insureds on their respective insurance policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18. <U>Repairs and Maintenance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.1. Landlord shall repair and maintain the structural and exterior portions and Common Areas of the Building and the Project, including
roofing and covering materials; foundations; exterior walls; plumbing; fire sprinkler systems (if any); heating, ventilating, air conditioning systems; elevators; and electrical systems installed or furnished by Landlord. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.2. Except for services of Landlord, if any, required by <U>Section&nbsp;18.1</U>, Tenant shall
at Tenant&#146;s sole cost and expense maintain and keep the Premises and every part thereof in good condition and repair, damage thereto from ordinary wear and tear excepted. Tenant shall, upon the expiration or sooner termination of the Term,
surrender the Premises to Landlord in as good a condition as when received, ordinary wear and tear excepted; and shall, at Landlord&#146;s request and Tenant&#146;s sole cost and expense, remove all telephone and data systems, wiring and equipment
from the Premises, and repair any damage to the Premises caused thereby. Landlord shall have no obligation to alter, remodel, improve, repair, decorate or paint the Premises or any part thereof, other than as described in <U>Exhibit&nbsp;B</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.3. Landlord shall not be liable for any failure to make any repairs or to perform any maintenance that is Landlord&#146;s obligation
pursuant to this Lease unless such failure shall persist for an unreasonable time after Tenant provides Landlord with written notice of the need of such repairs or maintenance. Tenant waives its rights under Applicable Laws now or hereafter in
effect to make repairs at Landlord&#146;s expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.4. If any excavation shall be made upon land adjacent to or under the Building, or
shall be authorized to be made, Tenant shall afford to the person causing or authorized to cause such excavation, license to enter the Premises for the purpose of performing such work as such person shall deem necessary or desirable to preserve and
protect the Building from injury or damage and to support the same by proper foundations, without any claim for damages or liability against Landlord and without reducing or otherwise affecting Tenant&#146;s obligations under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.5. This Article relates to repairs and maintenance arising in the ordinary course of operation of the Building and the Project. In the
event of a casualty described in <U>Article&nbsp;24</U>, <U>Article&nbsp;24</U> shall apply in lieu of this Article. In the event of eminent domain, <U>Article&nbsp;25</U> shall apply in lieu of this Article. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.6. Costs incurred by Landlord pursuant to this Article shall constitute Operating Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19. <U>Liens</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.1. Subject to the
immediately succeeding sentence, Tenant shall keep the Premises, the Building and the Project free from any liens arising out of work or services performed, materials furnished or obligations incurred by Tenant. Tenant further covenants and agrees
that any mechanic&#146;s or materialman&#146;s lien filed against the Premises, the Building or the Project for work or services claimed to have been done for, or materials claimed to have been furnished to, or obligations incurred by Tenant shall
be discharged or bonded by Tenant within ten (10)&nbsp;days after the filing thereof, at Tenant&#146;s sole cost and expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.2.
Should Tenant fail to discharge or bond against any lien of the nature described in <U>Section&nbsp;19.1</U>, Landlord may, at Landlord&#146;s election, pay such claim or post a statutory lien bond or otherwise provide security to eliminate the lien
as a claim against title, and Tenant shall immediately reimburse Landlord for the costs thereof as Additional Rent. Tenant shall indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Landlord) and hold the Landlord Indemnitees harmless from and against any Claims arising from any such liens, including any administrative, court or other legal proceedings related to such liens.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.3. In the event that Tenant leases or finances the acquisition of office equipment, furnishings or other personal property of a
removable nature utilized by Tenant in the operation of Tenant&#146;s business, Tenant warrants that any Uniform Commercial Code financing statement shall, upon its face or by exhibit thereto, indicate that such financing statement is applicable
only to removable personal property of Tenant located within the Premises. In no event shall the address of the Premises, the Building or the Project be furnished on a financing statement without qualifying language as to applicability of the lien
only to removable personal property located in an identified suite leased by Tenant. Should any holder of a financing statement record or place of record a financing statement that appears to constitute a lien against any interest of Landlord or
against equipment that may be located other than within an identified suite leased by Tenant, Tenant shall, within ten (10)&nbsp;days after filing such financing statement, cause (a)&nbsp;a copy of the Lender security agreement or other documents to
which the financing statement pertains to be furnished to Landlord to facilitate Landlord&#146;s ability to demonstrate that the lien of such financing statement is not applicable to Landlord&#146;s interest and (b)&nbsp;Tenant&#146;s Lender to
amend such financing statement and any other documents of record to clarify that any liens imposed thereby are not applicable to any interest of Landlord in the Premises, the Building or the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20. <U>Estoppel Certificate</U>. Tenant shall, within ten (10)&nbsp;days of receipt of written notice from Landlord, execute, acknowledge and deliver a
statement in writing substantially in the form attached to this Lease as <U>Exhibit I</U>, or on any other form reasonably requested by a proposed Lender or purchaser, (a)&nbsp;certifying that this Lease is unmodified and in full force and effect
(or, if modified, stating the nature of such modification and certifying that this Lease as so modified is in full force and effect) and the dates to which rental and other charges are paid in advance, if any, (b)&nbsp;acknowledging that there are
not, to Tenant&#146;s knowledge, any uncured defaults on the part of Landlord hereunder, or specifying such defaults if any are claimed, and (c)&nbsp;setting forth such further information with respect to this Lease or the Premises as may be
requested thereon. Any such statement may be relied upon by any prospective purchaser or encumbrancer of all or any portion of the Property. Tenant&#146;s failure to deliver such statement within such the prescribed time shall, at Landlord&#146;s
option, constitute a Default (as defined below) under this Lease, and, in any event, shall be binding upon Tenant that the Lease is in full force and effect and without modification except as may be represented by Landlord in any certificate
prepared by Landlord and delivered to Tenant for execution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">21. <U>Hazardous Materials</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.1. Tenant shall not cause or permit any Hazardous Materials (as defined below) to be brought upon, kept or used in or about the Premises,
the Building or the Project by Tenant or any of its employees, agents, contractors or invitees (collectively with Tenant, each a &#147;<U>Tenant Party</U>&#148;). If (a)&nbsp;Tenant breaches such obligation, (b)&nbsp;the presence of Hazardous
Materials as a result of such a breach results in contamination of the Project, any portion thereof, or any adjacent property, (c)&nbsp;contamination of the Premises otherwise occurs during the Term or any extension or renewal hereof or holding over
hereunder or (d)&nbsp;contamination of the Project occurs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as a result of Hazardous Materials that are placed on or under or are released into the Project by a Tenant Party, then Tenant shall indemnify, save, defend (at Landlord&#146;s option and with
counsel reasonably acceptable to Landlord) and hold the Landlord Indemnitees harmless from and against any and all Claims, including (w)&nbsp;diminution in value of the Project or any portion thereof, (x)&nbsp;damages for the loss or restriction on
use of rentable or usable space or of any amenity of the Project, (y)&nbsp;damages arising from any adverse impact on marketing of space in the Project or any portion thereof and (z)&nbsp;sums paid in settlement of Claims that arise during or after
the Term as a result of such breach or contamination. This indemnification by Tenant includes costs incurred in connection with any investigation of site conditions or any clean-up, remedial, removal or restoration work required by any Governmental
Authority because of Hazardous Materials present in the air, soil or groundwater above, on or under or about the Project. Without limiting the foregoing, if the presence of any Hazardous Materials in, on, under or about the Project, any portion
thereof or any adjacent property caused or permitted by any Tenant Party results in any contamination of the Project, any portion thereof or any adjacent property, then Tenant shall promptly take all actions at its sole cost and expense as are
necessary to return the Project, any portion thereof or any adjacent property to its respective condition existing prior to the time of such contamination; <U>provided</U> that Landlord&#146;s written approval of such action shall first be obtained,
which approval Landlord shall not unreasonably withhold; and <U>provided</U>, further, that it shall be reasonable for Landlord to withhold its consent if such actions could have a material adverse long-term or short-term effect on the Project, any
portion thereof or any adjacent property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.2. [Intentionally omitted] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.3. Notwithstanding the provisions of <U>Sections 21.1</U> <U>21.2</U> or <U>21.9</U>, if (a)&nbsp;Tenant or any proposed transferee,
assignee or sublessee of Tenant has been required by any prior landlord, Lender or Governmental Authority to take material remedial action in connection with Hazardous Materials contaminating a property if the contamination resulted from such
party&#146;s action or omission or use of the property in question or (b)&nbsp;Tenant or any proposed transferee, assignee or sublessee is subject to a material enforcement order issued by any Governmental Authority in connection with the use,
disposal or storage of Hazardous Materials, then Landlord shall have the right to terminate this Lease in Landlord&#146;s sole and absolute discretion (with respect to any such matter involving Tenant), and it shall not be unreasonable for Landlord
to withhold its consent to any proposed transfer, assignment or subletting (with respect to any such matter involving a proposed transferee, assignee or sublessee). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.4. At any time, and from time to time, prior to the expiration of the Term, Landlord shall have the right to conduct appropriate tests of
the Project or any portion thereof to demonstrate that Hazardous Materials are present or that contamination has occurred due to the acts or omissions of a Tenant Party. Tenant shall pay all reasonable costs of such tests if such tests reveal that
Hazardous Materials exist at the Project in violation of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.5. [Intentionally omitted] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.6. Tenant shall promptly report to Landlord any actual or suspected presence of mold or water intrusion at the Premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.7. Tenant&#146;s obligations under this Article shall survive the expiration or earlier
termination of the Lease. During any period of time needed by Tenant or Landlord after the termination of this Lease to complete the removal from the Premises of any such Hazardous Materials, Tenant shall be deemed a holdover tenant and subject to
the provisions of <U>Article 27</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.8. As used herein, the term &#147;<U>Hazardous Material</U>&#148; means any hazardous or toxic
substance, material or waste that is or becomes regulated by any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">22. <U>Odors and Exhaust</U>. Tenant acknowledges that Landlord
would not enter into this Lease with Tenant unless Tenant assured Landlord that under no circumstances will any other occupants of the Building or the Project (including persons legally present in any outdoor areas of the Project) be subjected to
odors or fumes (whether or not noxious), and that the Building and the Project will not be damaged by any exhaust, in each case from Tenant&#146;s operations. Landlord and Tenant therefore agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.1. Tenant shall not cause or permit (or conduct any activities that would cause) any release of any odors or fumes of any kind from the
Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.2. If the Building has a ventilation system that, in Landlord&#146;s judgment, is adequate, suitable, and appropriate to
vent the Premises in a manner that does not release odors affecting any indoor or outdoor part of the Project, Tenant shall vent the Premises through such system. If Landlord at any time determines that any existing ventilation system is inadequate,
or if no ventilation system exists, Tenant shall in compliance with Applicable Laws vent all fumes and odors from the Premises (and remove odors from Tenant&#146;s exhaust stream) as Landlord requires. The placement and configuration of all
ventilation exhaust pipes, louvers and other equipment shall be subject to Landlord&#146;s approval. Tenant acknowledges Landlord&#146;s legitimate desire to maintain the Project (indoor and outdoor areas) in an odor-free manner, and Landlord may
require Tenant to abate and remove all odors in a manner that goes beyond the requirements of Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.3. Tenant shall, at
Tenant&#146;s sole cost and expense, provide odor eliminators and other devices (such as filters, air cleaners, scrubbers and whatever other equipment may in Landlord&#146;s judgment be necessary or appropriate from time to time) to completely
remove, eliminate and abate any odors, fumes or other substances in Tenant&#146;s exhaust stream that, in Landlord&#146;s judgment, emanate from Tenant&#146;s Premises. Any work Tenant performs under this Section shall constitute Alterations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.4. Tenant&#146;s responsibility to remove, eliminate and abate odors, fumes and exhaust shall continue throughout the Term. Landlord&#146;s
construction of the Tenant Improvements shall not preclude Landlord from requiring additional measures to eliminate odors, fumes and other adverse impacts of Tenant&#146;s exhaust stream (as Landlord may designate in Landlord&#146;s discretion).
Tenant shall install additional equipment as Landlord requires from time to time under the preceding sentence. Such installations shall constitute Alterations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.5. If Tenant fails to install satisfactory odor control equipment within ten (10)&nbsp;business days after Landlord&#146;s demand made at
any time, then Landlord may, without limiting Landlord&#146;s other rights and remedies, require Tenant to cease and suspend any operations in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Premises that, in Landlord&#146;s determination, cause odors, fumes or exhaust. For example, if Landlord determines that Tenant&#146;s production of a certain type of product causes odors, fumes
or exhaust, and Tenant does not install satisfactory odor control equipment within ten (10)&nbsp;business days after Landlord&#146;s request, then Landlord may require Tenant to stop producing such type of product in the Premises unless and until
Tenant has installed odor control equipment satisfactory to Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">23. <U>Insurance; Waiver of Subrogation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.1. Landlord shall maintain insurance for the Building and the Project in amounts equal to full replacement cost (exclusive of the costs of
excavation, foundations and footings, engineering costs or such other costs that would not be incurred in the event of a rebuild and without reference to depreciation taken by Landlord upon its books or tax returns) or such lesser coverage as
Landlord may elect, <U>provided</U> that such coverage shall not be less than the amount of such insurance Landlord&#146;s Lender, if any, requires Landlord to maintain, providing protection against any peril generally included within the
classification &#147;Fire and Extended Coverage,&#148; together with insurance against sprinkler damage (if applicable), vandalism and malicious mischief. Landlord, subject to availability thereof, shall further insure, if Landlord deems it
appropriate, coverage against flood, environmental hazard, earthquake, loss or failure of building equipment, rental loss during the period of repairs or rebuilding, Workers&#146; Compensation insurance and fidelity bonds for employees employed to
perform services. Notwithstanding the foregoing, Landlord may, but shall not be deemed required to, provide insurance for any improvements installed by Tenant or that are in addition to the standard improvements customarily furnished by Landlord,
without regard to whether or not such are made a part of or are affixed to the Building. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.2. In addition, Landlord shall carry
Commercial General Liability insurance with limits of not less than One Million Dollars ($1,000,000) per occurrence/general aggregate for bodily injury (including death), or property damage with respect to the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.3. Tenant shall, at its own cost and expense, procure and maintain in effect, beginning on the Term Commencement Date or the date of
occupancy, whichever occurs first, and continuing throughout the Term (and occupancy by Tenant, if any, after termination of this Lease) with insurers financially acceptable and lawfully authorized to do business in the state where the Project is
located Commercial General Liability insurance on a broad-based occurrence coverage form, with limits of not less than Two Million Dollars ($2,000,000) per occurrence and in the aggregate for bodily injury (including death) and for property damage
with respect to the Premises (including $100,000 fire legal liability (each loss)), and Two Million Dollars ($2,000,000) products and completed operations insurance on a claims made basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.4. The insurance required to be purchased and maintained by Tenant pursuant to this Lease shall name Landlord, BioMed Realty, L.P., BioMed
Realty Trust, Inc., and their respective officers, directors, employees, agents, general partners, members, subsidiaries, affiliates and Lenders (&#147;<U>Landlord Parties</U>&#148;) as additional insureds as respects liability arising from work or
operations performed by or on behalf of Tenant and Tenant&#146;s use or occupancy of the Premises. Said insurance shall be with companies authorized to do business in the state in which the Project is located and at all times having a current rating
of not less than A- and financial category rating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of at least Class VII in &#147;A.M. Best&#146;s Insurance Guide&#148; current edition. Tenant shall obtain for Landlord from the insurance companies or cause the insurance companies to furnish
certificates of insurance evidencing all coverages required herein to Landlord. Landlord reserves the right to require complete, certified copies of all required insurance policies including any endorsements. No such policy shall be cancelable or
subject to reduction of coverage or other modification or cancellation except after twenty (20)&nbsp;days&#146; prior written notice to Landlord from the insurer (except in the event of non-payment of premium, in which case ten (10)&nbsp;days
written notice shall be given). Should carrier be unwilling or unable to provide such notice, Tenant shall provide notice to Landlord in accordance with this Section. All such policies shall be written as primary policies, not contributing with and
not in excess of the coverage that Landlord may carry. Tenant&#146;s required policies shall contain severability of interests clauses stating that, except with respect to limits of insurance, coverage shall apply separately to each insured or
additional insured. Tenant&#146;s policies shall contain dedicated or per location limits endorsements so that the amounts of insurance required herein shall not be prejudiced by losses at other locations. Tenant shall, at least twenty
(20)&nbsp;days prior to the expiration of such policies, furnish Landlord with renewal certificates of insurance or binders. Tenant agrees that if Tenant does not take out and maintain such insurance, Landlord may (but shall not be required to)
procure said insurance on Tenant&#146;s behalf and at its cost to be paid by Tenant as Additional Rent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.5. Tenant assumes the risk of
damage to any fixtures, goods, inventory, merchandise, equipment and leasehold improvements, and Landlord shall not be liable for injury to Tenant&#146;s business or any loss of income therefrom, relative to such damage, all as more particularly set
forth within this Lease. Tenant shall, at Tenant&#146;s sole cost and expense, carry such insurance as Tenant desires for Tenant&#146;s protection with respect to personal property of Tenant or business interruption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.6. In each instance where insurance is to name Landlord Parties as additional insureds, Tenant shall, upon Landlord&#146;s written request,
also designate and furnish certificates evidencing such Landlord Parties as additional insureds to (a)&nbsp;any Lender of Landlord holding a security interest in the Building, the Property or the Project, (b)&nbsp;the landlord under any lease
whereunder Landlord is a tenant of the Property if the interest of Landlord is or shall become that of a tenant under a ground lease rather than that of a fee owner and (c)&nbsp;any management company retained by Landlord to manage the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.7. Landlord, Tenant and each of their respective insurers hereby waive any and all rights of recovery or subrogation against one another or
against the officers, directors, employees, agents, general partners, members, subsidiaries, affiliates and Lenders of the other as respects any loss, damage, claims, suits or demands, howsoever caused, that are covered, or should have been covered,
by valid and collectible insurance, including any deductibles or self-insurance maintained thereunder. If necessary, each party agrees to endorse the required insurance policies to permit waivers of subrogation as required hereunder and hold
harmless and indemnify the other party for any loss or expense incurred as a result of a failure to obtain such waivers of subrogation from insurers. Such waivers shall continue so long as their respective insurers so permit. Any termination of such
a waiver shall be by written notice to the other party, containing a description of the circumstances hereinafter set forth in this Section. Landlord and Tenant, upon obtaining the policies of insurance required or permitted under this Lease, shall
give notice to the insurance carrier or carriers that the foregoing mutual waiver of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subrogation is contained in this Lease. If such policies shall not be obtainable with such waiver or shall be so obtainable only at a premium over that chargeable without such waiver, then the
party seeking such policy shall notify the other of such conditions, and the party so notified shall have ten (10)&nbsp;days thereafter to either (a)&nbsp;procure such insurance with companies reasonably satisfactory to the other party or
(b)&nbsp;agree to pay such additional premium (in Tenant&#146;s case, in the proportion that the area of the Premises bears to the insured area). If the parties do not accomplish either (a)&nbsp;or (b), then this Section shall have no effect during
such time as such policies shall not be obtainable or the party in whose favor a waiver of subrogation is desired refuses to pay the additional premium. If such policies shall at any time be unobtainable, but shall be subsequently obtainable, then
neither party shall be subsequently liable for a failure to obtain such insurance until a reasonable time after notification thereof by the other party. If the release of either Landlord or Tenant, as set forth in the first sentence of this Section,
shall contravene Applicable Laws, then the liability of the party in question shall be deemed not released but shall be secondary to the other party&#146;s insurer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.8. Landlord may require insurance policy limits required under this Lease to be raised to conform with requirements of Landlord&#146;s
Lender or to bring coverage limits to levels then being required of new tenants within the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.9. Any costs incurred by Landlord
pursuant to this Article shall constitute a portion of Operating Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24. <U>Damage or Destruction</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.1. In the event of a partial destruction of (a)&nbsp;the Premises or (b)&nbsp;Common Areas of the Building or the Project ((a) and
(b)&nbsp;together, the &#147;<U>Affected Areas</U>&#148;) by fire or other perils covered by extended coverage insurance not exceeding twenty-five percent (25%)&nbsp;of the full insurable value thereof, and <U>provided</U> that (x)&nbsp;the damage
thereto is such that the Affected Areas may be repaired, reconstructed or restored within a period of six (6)&nbsp;months from the date of the happening of such casualty, (y)&nbsp;Landlord shall receive insurance proceeds sufficient to cover the
cost of such repairs, reconstruction and restoration (except for any deductible amount provided by Landlord&#146;s policy, which deductible amount, if paid by Landlord, shall constitute an Operating Expense) and (z)&nbsp;such casualty was not
intentionally caused by a Tenant Party, then Landlord shall commence and proceed diligently with the work of repair, reconstruction and restoration of the Affected Areas and this Lease shall continue in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.2. In the event of any damage to or destruction of the Building or the Project other than as described in <U>Section&nbsp;24.1</U>,
Landlord may elect to repair, reconstruct and restore the Building or the Project, as applicable, in which case this Lease shall continue in full force and effect. If Landlord elects not to repair, reconstruct and restore the Building or the
Project, as applicable, then this Lease shall terminate as of the date of such damage or destruction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.3. Landlord shall give written
notice to Tenant within sixty (60)&nbsp;days following the date of damage or destruction of its election not to repair, reconstruct or restore the Building or the Project, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.4. Upon any termination of this Lease under any of the provisions of this Article, the parties
shall be released thereby without further obligation to the other from the date possession of the Premises is surrendered to Landlord, except with regard to (a)&nbsp;items occurring prior to the damage or destruction and (b)&nbsp;provisions of this
Lease that, by their express terms, survive the expiration or earlier termination hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.5. In the event of repair, reconstruction
and restoration as provided in this Article, all Rent to be paid by Tenant under this Lease shall be abated proportionately based on the extent to which Tenant&#146;s use of the Premises is impaired during the period of such repair, reconstruction
or restoration, unless Landlord provides Tenant with other space during the period of repair, reconstruction and restoration that, in Tenant&#146;s reasonable opinion, is suitable for the temporary conduct of Tenant&#146;s business; <U>provided</U>,
however, that the amount of such abatement shall be reduced by the proceeds of business interruption or loss of rental income insurance actually received by Tenant with respect to the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.6. Notwithstanding anything to the contrary contained in this Article, should Landlord be delayed or prevented from completing the repair,
reconstruction or restoration of the damage or destruction to the Premises after the occurrence of such damage or destruction by Force Majeure or delays caused by a Tenant Party, then the time for Landlord to commence or complete repairs,
reconstruction and restoration shall be extended on a day-for-day basis; <U>provided</U>, however, that, at Landlord&#146;s election, Landlord shall be relieved of its obligation to make such repairs, reconstruction and restoration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.7. If Landlord is obligated to or elects to repair, reconstruct or restore as herein provided, then Landlord shall be obligated to make
such repairs, reconstruction or restoration only with regard to (a)&nbsp;those portions of the Premises that were originally provided at Landlord&#146;s expense and (b)&nbsp;the Common Area portion of the Affected Areas. The repairs, reconstruction
or restoration of improvements not originally provided by Landlord or at Landlord&#146;s expense shall be the obligation of Tenant. In the event Tenant has elected to upgrade certain improvements from the Building Standard, Landlord shall, upon the
need for replacement due to an insured loss, provide only the Building Standard, unless Tenant again elects to upgrade such improvements and pay any incremental costs related thereto, except to the extent that excess insurance proceeds, if received,
are adequate to provide such upgrades, in addition to providing for basic repairs, reconstruction and restoration of the Premises, the Building and the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.8. Notwithstanding anything to the contrary contained in this Article, Landlord shall not have any obligation whatsoever to repair,
reconstruct or restore the Premises if the damage resulting from any casualty covered under this Article occurs during the last twenty-four (24)&nbsp;months of the Term or any extension thereof, or to the extent that insurance proceeds are not
available therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.9. Landlord&#146;s obligation, should it elect or be obligated to repair, reconstruct or restore, shall be limited
to the Affected Areas. Tenant shall, at its expense, replace or fully repair all of Tenant&#146;s personal property and any Alterations installed by Tenant existing at the time of such damage or destruction. If Affected Areas are to be repaired,
reconstructed or restored in accordance with the foregoing, Landlord shall make available to Tenant any portion of insurance proceeds it receives that are allocable to the Alterations constructed by Tenant pursuant to this Lease; <U>provided</U>
Tenant is not then in default under this Lease, and subject to the requirements of any Lender of Landlord. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">25. <U>Eminent Domain</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.1. In the event (a)&nbsp;the whole of all Affected Areas or (b)&nbsp;such part thereof as shall substantially interfere with Tenant&#146;s
use and occupancy of the Premises for the Permitted Use shall be taken for any public or quasi-public purpose by any lawful power or authority by exercise of the right of appropriation, condemnation or eminent domain, or sold to prevent such taking,
Tenant or Landlord may terminate this Lease effective as of the date possession is required to be surrendered to such authority, except with regard to (y)&nbsp;items occurring prior to the taking and (z)&nbsp;provisions of this Lease that, by their
express terms, survive the expiration or earlier termination hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.2. In the event of a partial taking of (a)&nbsp;the Building or
the Project or (b)&nbsp;drives, walkways or parking areas serving the Building or the Project for any public or quasi-public purpose by any lawful power or authority by exercise of right of appropriation, condemnation, or eminent domain, or sold to
prevent such taking, then, without regard to whether any portion of the Premises occupied by Tenant was so taken, Landlord may elect to terminate this Lease (except with regard to (y)&nbsp;items occurring prior to the taking and (z)&nbsp;provisions
of this Lease that, by their express terms, survive the expiration or earlier termination hereof) as of such taking if such taking is, in Landlord&#146;s sole opinion, of a material nature such as to make it uneconomical to continue use of the
unappropriated portion for purposes of renting office or laboratory space. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.3. Tenant shall be entitled to any award that is
specifically awarded as compensation for (a)&nbsp;the taking of Tenant&#146;s personal property that was installed at Tenant&#146;s expense and (b)&nbsp;the costs of Tenant moving to a new location. Except as set forth in the previous sentence, any
award for such taking shall be the property of Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.4. If, upon any taking of the nature described in this Article, this Lease
continues in effect, then Landlord shall promptly proceed to restore the Affected Areas to substantially their same condition prior to such partial taking. To the extent such restoration is infeasible, as determined by Landlord in its sole and
absolute discretion, the Rent shall be decreased proportionately to reflect the loss of any portion of the Premises no longer available to Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">26.
<U>Surrender</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.1. [Intentionally omitted] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.2. No surrender of possession of any part of the Premises shall release Tenant from any of its obligations hereunder, unless such surrender
is accepted in writing by Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.3. The voluntary or other surrender of this Lease by Tenant shall not effect a merger with
Landlord&#146;s fee title or leasehold interest in the Premises, the Building, the Property or the Project, unless Landlord consents in writing, and shall, at Landlord&#146;s option, operate as an assignment to Landlord of any or all subleases. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.4. The voluntary or other surrender of any ground or other underlying lease that now exists or
may hereafter be executed affecting the Building or the Project, or a mutual cancellation thereof or of Landlord&#146;s interest therein by Landlord and its lessor shall not effect a merger with Landlord&#146;s fee title or leasehold interest in the
Premises, the Building or the Property and shall, at the option of the successor to Landlord&#146;s interest in the Building or the Project, as applicable, operate as an assignment of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">27. <U>Holding Over</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.1. If, with
Landlord&#146;s prior written consent, Tenant holds possession of all or any part of the Premises after the Term, Tenant shall become a tenant from month to month after the expiration or earlier termination of the Term, and in such case Tenant shall
continue to pay (a)&nbsp;Base Rent in accordance with <U>Article 7</U> and (b)&nbsp;any amounts for which Tenant would otherwise be liable under this Lease if the Lease were still in effect, including payments for Tenant&#146;s Share of Operating
Expenses. Any such month-to-month tenancy shall be subject to every other term, covenant and agreement contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.2.
Notwithstanding the foregoing, if Tenant remains in possession of the Premises after the expiration or earlier termination of the Term without Landlord&#146;s prior written consent, (a)&nbsp;Tenant shall become a tenant at sufferance subject to the
terms and conditions of this Lease, except that the monthly rent shall be equal to one hundred fifty percent (150%)&nbsp;of the Rent in effect during the last thirty (30)&nbsp;days of the Term, and (b)&nbsp;Tenant shall be liable to Landlord for any
and all damages suffered by Landlord as a result of such holdover, including any lost rent or consequential, special and indirect damages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.3. Acceptance by Landlord of Rent after the expiration or earlier termination of the Term shall not result in an extension, renewal or
reinstatement of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.4. The foregoing provisions of this Article are in addition to and do not affect Landlord&#146;s right of
reentry or any other rights of Landlord hereunder or as otherwise provided by Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.5. The provisions of this Article shall
survive the expiration or earlier termination of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">28. <U>Indemnification and Exculpation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.1. Tenant agrees to indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold the
Landlord Indemnitees harmless from and against any and all Claims arising from injury or death to any person or damage to any property occurring within or about the Premises, the Building, the Property or the Project arising directly or indirectly
out of a Tenant Party&#146;s use or occupancy of the Premises or a breach or default by Tenant in the performance of any of its obligations hereunder, except to the extent caused by Landlord&#146;s negligence or willful misconduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.2. Notwithstanding anything in this Lease to the contrary, Landlord shall not be liable to Tenant for and Tenant assumes all risk of
(a)&nbsp;damage or losses caused by fire, electrical malfunction, gas explosion or water damage of any type (including broken water lines, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
malfunctioning fire sprinkler systems, roof leaks or stoppages of lines), unless any such loss is due to Landlord&#146;s willful disregard of written notice by Tenant of need for a repair that
Landlord is responsible to make for an unreasonable period of time, and (b)&nbsp;damage to personal property or scientific research, including loss of records kept by Tenant within the Premises. Tenant further waives any claim for injury to
Tenant&#146;s business or loss of income relating to any such damage or destruction of personal property as described in this Section. Notwithstanding anything in the foregoing or this Lease to the contrary, except (x)&nbsp;as otherwise provided
herein, (y)&nbsp;as may be provided by Applicable Laws or (z)&nbsp;in the event of Tenant&#146;s breach of <U>Article 21</U> or <U>Section&nbsp;26.1</U>, in no event shall Landlord or Tenant be liable to the other for any consequential, special or
indirect damages arising out of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.3. Landlord shall not be liable for any damages arising from any act, omission or neglect
of any other tenant in the Building or the Project, or of any other third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.4. Tenant acknowledges that security devices and
services, if any, while intended to deter crime, may not in given instances prevent theft or other criminal acts. Landlord shall not be liable for injuries or losses caused by criminal acts of third parties, and Tenant assumes the risk that any
security device or service may malfunction or otherwise be circumvented by a criminal. If Tenant desires protection against such criminal acts, then Tenant shall, at Tenant&#146;s sole cost and expense, obtain appropriate insurance coverage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.5. The provisions of this Article shall survive the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">29. <U>Assignment or Subletting</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.1.
Except as hereinafter expressly permitted, Tenant shall not, either voluntarily or by operation of Applicable Laws, directly or indirectly sell, hypothecate, assign, pledge, encumber or otherwise transfer this Lease or sublet the Premises (each, a
&#147;<U>Transfer</U>&#148;), without Landlord&#146;s prior written consent. In no event shall Tenant perform a Transfer to or with an entity that is a tenant at the Project or that is in discussions or negotiations with Landlord or an affiliate of
Landlord to lease premises at the Project or a property owned by Landlord or an affiliate of Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.2. In the event Tenant desires
to effect a Transfer, then, at least thirty (30)&nbsp;but not more than ninety (90)&nbsp;days prior to the date when Tenant desires the Transfer to be effective (the &#147;<U>Transfer Date</U>&#148;), Tenant shall provide written notice to Landlord
(the &#147;<U>Transfer Notice</U>&#148;) containing information (including references) concerning the character of the proposed transferee, assignee or sublessee; the Transfer Date; the most recent unconsolidated financial statements of Tenant and
of the proposed transferee, assignee or sublessee satisfying the requirements of <U>Section&nbsp;41.2</U> (&#147;<U>Required Financials</U>&#148;); any ownership or commercial relationship between Tenant and the proposed transferee, assignee or
sublessee; and the consideration and all other material terms and conditions of the proposed Transfer, all in such detail as Landlord shall reasonably require. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.3. Landlord, in determining whether consent should be given to a proposed Transfer, may give consideration to (a)&nbsp;the financial
strength of Tenant and of such transferee, assignee or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sublessee (notwithstanding Tenant remaining liable for Tenant&#146;s performance), (b)&nbsp;any change in use that such transferee, assignee or sublessee proposes to make in the use of the
Premises and (c)&nbsp;Landlord&#146;s desire to exercise its rights under <U>Section&nbsp;29.8</U> to cancel this Lease. In no event shall Landlord be deemed to be unreasonable for declining to consent to a Transfer to a transferee, assignee or
sublessee of poor reputation, lacking financial qualifications or seeking a change in the Permitted Use, or jeopardizing directly or indirectly the status of Landlord or any of Landlord&#146;s affiliates as a Real Estate Investment Trust under the
Internal Revenue Code of 1986 (as the same may be amended from time to time, the &#147;<U>Revenue Code</U>&#148;). Notwithstanding anything contained in this Lease to the contrary, (w)&nbsp;no Transfer shall be consummated on any basis such that the
rental or other amounts to be paid by the occupant, assignee, manager or other transferee thereunder would be based, in whole or in part, on the income or profits derived by the business activities of such occupant, assignee, manager or other
transferee; (x)&nbsp;Tenant shall not furnish or render any services to an occupant, assignee, manager or other transferee with respect to whom transfer consideration is required to be paid, or manage or operate the Premises or any capital additions
so transferred, with respect to which transfer consideration is being paid; (y)&nbsp;Tenant shall not consummate a Transfer with any person in which Landlord owns an interest, directly or indirectly (by applying constructive ownership rules set
forth in Section&nbsp;856(d)(5) of the Revenue Code); and (z)&nbsp;Tenant shall not consummate a Transfer with any person or in any manner that could cause any portion of the amounts received by Landlord pursuant to this Lease or any sublease,
license or other arrangement for the right to use, occupy or possess any portion of the Premises to fail to qualify as &#147;rents from real property&#148; within the meaning of Section&nbsp;856(d) of the Revenue Code, or any similar or successor
provision thereto or which could cause any other income of Landlord to fail to qualify as income described in Section&nbsp;856(c)(2) of the Revenue Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.4. The following are conditions precedent to a Transfer or to Landlord considering a request by Tenant to a Transfer: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Tenant shall remain fully liable under this Lease during the unexpired Term. Tenant agrees that it shall not be (and shall not be deemed
to be) a guarantor or surety of this Lease, however, and waives its right to claim that is it is a guarantor or surety or to raise in any legal proceeding any guarantor or surety defenses permitted by this Lease or by Applicable Laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) If Tenant or the proposed transferee, assignee or sublessee does not or cannot deliver the Required Financials, then Landlord may elect to
have either Tenant&#146;s ultimate parent company or the proposed transferee&#146;s, assignee&#146;s or sublessee&#146;s ultimate parent company provide a guaranty of the applicable entity&#146;s obligations under this Lease, in a form acceptable to
Landlord, which guaranty shall be executed and delivered to Landlord by the applicable guarantor prior to the Transfer Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) In the
case of an Exempt Transfer, Tenant shall provide Landlord with evidence reasonably satisfactory to Landlord that the Transfer qualifies as an Exempt Transfer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Tenant shall provide Landlord with evidence reasonably satisfactory to Landlord that the value of Landlord&#146;s interest under this
Lease shall not be diminished or reduced by the proposed Transfer. Such evidence shall include evidence respecting the relevant business experience and financial responsibility and status of the proposed transferee, assignee or sublessee; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Tenant shall reimburse Landlord for Landlord&#146;s actual costs and expenses, including
reasonable attorneys&#146; fees, charges and disbursements incurred in connection with the review, processing and documentation of such request; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) If Tenant&#146;s transfer of rights or sharing of the Premises provides for the receipt by, on behalf of or on account of Tenant of any
consideration of any kind whatsoever (including a premium rental for a sublease or lump sum payment for an assignment, but excluding Tenant&#146;s reasonable costs in marketing and subleasing the Premises) in excess of the rental and other charges
due to Landlord under this Lease, Tenant shall pay fifty percent (50%)&nbsp;of all of such excess to Landlord, after making deductions for any reasonable marketing expenses, tenant improvement funds expended by Tenant, alterations, cash concessions,
brokerage commissions, attorneys&#146; fees and free rent actually paid by Tenant. If such consideration consists of cash paid to Tenant, payment to Landlord shall be made upon receipt by Tenant of such cash payment; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) The proposed transferee, assignee or sublessee shall agree that, in the event Landlord gives such proposed transferee, assignee or
sublessee notice that Tenant is in default under this Lease, such proposed transferee, assignee or sublessee shall thereafter make all payments otherwise due Tenant directly to Landlord, which payments shall be received by Landlord without any
liability being incurred by Landlord, except to credit such payment against those due by Tenant under this Lease, and any such proposed transferee, assignee or sublessee shall agree to attorn to Landlord or its successors and assigns should this
Lease be terminated for any reason; <U>provided</U>, however, that in no event shall Landlord or its Lenders, successors or assigns be obligated to accept such attornment; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) Landlord&#146;s consent to any such Transfer shall be effected on Landlord&#146;s forms; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Tenant shall not then be in default hereunder in any respect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) Such proposed transferee, assignee or sublessee&#146;s use of the Premises shall be the same as the Permitted Use; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) Landlord shall not be bound by any provision of any agreement pertaining to the Transfer, except for Landlord&#146;s written consent to
the same; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l) Tenant shall pay all transfer and other taxes (including interest and penalties) assessed or payable for any Transfer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m) Landlord&#146;s consent (or waiver of its rights) for any Transfer shall not waive Landlord&#146;s right to consent or refuse consent to
any later Transfer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n) Tenant shall deliver to Landlord one executed copy of any and all written instruments evidencing or relating to
the Transfer; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(o) Tenant shall deliver to Landlord a list of Hazardous Materials (as defined below), certified
by the proposed transferee, assignee or sublessee to be true and correct, that the proposed transferee, assignee or sublessee intends to use or store in the Premises. Additionally, Tenant shall deliver to Landlord, on or before the date any proposed
transferee, assignee or sublessee takes occupancy of the Premises, all of the items relating to Hazardous Materials of such proposed transferee, assignee or sublessee as described in <U>Section&nbsp;21.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.5. Any Transfer that is not in compliance with the provisions of this Article or with respect to which Tenant does not fulfill its
obligations pursuant to this Article shall be void and shall, at the option of Landlord, terminate this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.6. Notwithstanding any
Transfer, Tenant shall remain fully and primarily liable for the payment of all Rent and other sums due or to become due hereunder, and for the full performance of all other terms, conditions and covenants to be kept and performed by Tenant. The
acceptance of Rent or any other sum due hereunder, or the acceptance of performance of any other term, covenant or condition thereof, from any person or entity other than Tenant shall not be deemed a waiver of any of the provisions of this Lease or
a consent to any Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.7. If Tenant delivers to Landlord a Transfer Notice indicating a desire to transfer this Lease to a
proposed transferee, assignee or sublessee other than as provided within <U>Section&nbsp;29.4</U>, then Landlord shall have the option, exercisable by giving notice to Tenant at any time within ten (10)&nbsp;days after Landlord&#146;s receipt of
such Transfer Notice, to terminate this Lease as of the date specified in the Transfer Notice as the Transfer Date, except for those provisions that, by their express terms, survive the expiration or earlier termination hereof. If Landlord exercises
such option, then Tenant shall have the right to withdraw such Transfer Notice by delivering to Landlord written notice of such election within five (5)&nbsp;days after Landlord&#146;s delivery of notice electing to exercise Landlord&#146;s option
to terminate this Lease. In the event Tenant withdraws the Transfer Notice as provided in this Section, this Lease shall continue in full force and effect. No failure of Landlord to exercise its option to terminate this Lease shall be deemed to be
Landlord&#146;s consent to a proposed Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.8. If Tenant sublets the Premises or any portion thereof, Tenant hereby immediately
and irrevocably assigns to Landlord, as security for Tenant&#146;s obligations under this Lease, all rent from any such subletting, and appoints Landlord as assignee and attorney-in-fact for Tenant, and Landlord (or a receiver for Tenant appointed
on Landlord&#146;s application) may collect such rent and apply it toward Tenant&#146;s obligations under this Lease; <U>provided</U> that, until the occurrence of a Default (as defined below) by Tenant, Tenant shall have the right to collect such
rent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30. <U>Subordination and Attornment</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30.1. This Lease shall be subject and subordinate to the lien of any mortgage, deed of trust, or lease in which Landlord is tenant now or
hereafter in force against the Building or the Project and to all advances made or hereafter to be made upon the security thereof without the necessity of the execution and delivery of any further instruments on the part of Tenant to effectuate such
subordination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30.2. Notwithstanding the foregoing, Tenant shall execute and deliver upon demand such further
instrument or instruments evidencing such subordination of this Lease to the lien of any such mortgage or mortgages or deeds of trust or lease in which Landlord is tenant as may be required by Landlord. If any such mortgagee, beneficiary or landlord
under a lease wherein Landlord is tenant (each, a &#147;<U>Mortgagee</U>&#148;) so elects, however, this Lease shall be deemed prior in lien to any such lease, mortgage, or deed of trust upon or including the Premises regardless of date and Tenant
shall execute a statement in writing to such effect at Landlord&#146;s request. If Tenant fails to execute any document required from Tenant under this Section within ten (10)&nbsp;days after written request therefor, Tenant hereby constitutes and
appoints Landlord or its special attorney-in-fact to execute and deliver any such document or documents in the name of Tenant. Such power is coupled with an interest and is irrevocable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30.3. Upon written request of Landlord and opportunity for Tenant to review, Tenant agrees to execute any Lease amendments not materially
altering the terms of this Lease, if required by a mortgagee or beneficiary of a deed of trust encumbering real property of which the Premises constitute a part incident to the financing of the real property of which the Premises constitute a part.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30.4. In the event any proceedings are brought for foreclosure, or in the event of the exercise of the power of sale under any mortgage
or deed of trust made by Landlord covering the Premises, Tenant shall at the election of the purchaser at such foreclosure or sale attorn to the purchaser upon any such foreclosure or sale and recognize such purchaser as Landlord under this Lease.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">31. <U>Defaults and Remedies</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.1.
Late payment by Tenant to Landlord of Rent and other sums due shall cause Landlord to incur costs not contemplated by this Lease, the exact amount of which shall be extremely difficult and impracticable to ascertain. Such costs include processing
and accounting charges and late charges that may be imposed on Landlord by the terms of any mortgage or trust deed covering the Premises. Therefore, if any installment of Rent due from Tenant is not received by Landlord within three (3)&nbsp;days
after the date such payment is due, Tenant shall pay to Landlord (a)&nbsp;an additional sum of six percent (6%)&nbsp;of the overdue Rent as a late charge plus (b)&nbsp;interest at an annual rate (the &#147;<U>Default Rate</U>&#148;) equal to the
lesser of (a)&nbsp;twelve percent (12%)&nbsp;and (b)&nbsp;the highest rate permitted by Applicable Laws. The parties agree that this late charge represents a fair and reasonable estimate of the costs that Landlord shall incur by reason of late
payment by Tenant and shall be payable as Additional Rent to Landlord due with the next installment of Rent or within five (5)&nbsp;business days after Landlord&#146;s demand, whichever is earlier. Landlord&#146;s acceptance of any Additional Rent
(including a late charge or any other amount hereunder) shall not be deemed an extension of the date that Rent is due or prevent Landlord from pursuing any other rights or remedies under this Lease, at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.2. No payment by Tenant or receipt by Landlord of a lesser amount than the Rent payment herein stipulated shall be deemed to be other than
on account of the Rent, nor shall any endorsement or statement on any check or any letter accompanying any check or payment as Rent be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to
Landlord&#146;s right to recover the balance of such Rent or pursue any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remedy provided in this Lease or in equity or at law. If a dispute shall arise as to any amount or sum of money to be paid by Tenant to Landlord hereunder, Tenant shall have the right to make
payment &#147;under protest,&#148; such payment shall not be regarded as a voluntary payment, and there shall survive the right on the part of Tenant to institute suit for recovery of the payment paid under protest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.3. If Tenant fails to pay any sum of money required to be paid by it hereunder or perform any other act on its part to be performed
hereunder, in each case within the applicable cure period (if any) described in <U>Section&nbsp;31.4</U>, then Landlord may (but shall not be obligated to), without waiving or releasing Tenant from any obligations of Tenant, make such payment or
perform such act; <U>provided</U> that such failure by Tenant unreasonably interfered with the use of the Building or the Project by any other tenant or with the efficient operation of the Building or the Project, or resulted or could have resulted
in a violation of Applicable Laws or the cancellation of an insurance policy maintained by Landlord. Notwithstanding the foregoing, in the event of an emergency, Landlord shall have the right to enter the Premises and act in accordance with its
rights as provided elsewhere in this Lease. In addition to the late charge described in <U>Section&nbsp;31.1</U>, Tenant shall pay to Landlord as Additional Rent all sums so paid or incurred by Landlord, together with interest at the Default Rate,
computed from the date such sums were paid or incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.4. The occurrence of any one or more of the following events shall constitute
a &#147;<U>Default</U>&#148; hereunder by Tenant: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Tenant abandons or vacates the Premises; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Tenant fails to make any payment of Rent, as and when due, or to satisfy its obligations under <U>Article 19</U>, where such failure shall
continue for a period of three (3)&nbsp;business days after written notice thereof from Landlord to Tenant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Tenant fails to observe
or perform any obligation or covenant contained herein (other than described in <U>Sections 31.4(a)</U> and <U>31.4(b)</U>) to be performed by Tenant, where such failure continues for a period of ten (10)&nbsp;days after written notice thereof from
Landlord to Tenant; <U>provided</U> that, if the nature of Tenant&#146;s default is such that it reasonably requires more than ten (10)&nbsp;days to cure, Tenant shall not be deemed to be in Default if Tenant commences such cure within such ten
(10)&nbsp;day period and thereafter diligently prosecute the same to completion; and <U>provided</U>, further, that such cure is completed no later than thirty (30)&nbsp;days after Tenant&#146;s receipt of written notice from Landlord; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Tenant makes an assignment for the benefit of creditors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) A receiver, trustee or custodian is appointed to or does take title, possession or control of all or substantially all of Tenant&#146;s
assets; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) Tenant files a voluntary petition under the United States Bankruptcy Code or any successor statute (as the same may be
amended from time to time, the &#147;<U>Bankruptcy Code</U>&#148;) or an order for relief is entered against Tenant pursuant to a voluntary or involuntary proceeding commenced under any chapter of the Bankruptcy Code; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Any involuntary petition is filed against Tenant under any chapter of the Bankruptcy Code and
is not dismissed within one hundred twenty (120)&nbsp;days; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) Tenant fails to deliver an estoppel certificate in accordance with
<U>Article 20</U>; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Tenant&#146;s interest in this Lease is attached, executed upon or otherwise judicially seized and such action
is not released within one hundred twenty (120)&nbsp;days of the action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Notices given under this Section shall specify the alleged
default and shall demand that Tenant perform the provisions of this Lease or pay the Rent that is in arrears, as the case may be, within the applicable period of time, or quit the Premises. No such notice shall be deemed a forfeiture or a
termination of this Lease unless Landlord elects otherwise in such notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.5. In the event of a Default by Tenant, and at any time
thereafter, with or without notice or demand and without limiting Landlord in the exercise of any right or remedy that Landlord may have, Landlord has the right to do any or all of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Halt any Tenant Improvements and Alterations and order Tenant&#146;s contractors, subcontractors, consultants, designers and material
suppliers to stop work; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Terminate Tenant&#146;s right to possession of the Premises by written notice to Tenant or by any lawful
means, in which case Tenant shall immediately surrender possession of the Premises to Landlord. In such event, Landlord shall have the immediate right to re-enter and remove all persons and property, and such property may be removed and stored in a
public warehouse or elsewhere at the cost and for the account of Tenant, all without service of notice or resort to legal process and without being deemed guilty of trespass or becoming liable for any loss or damage that may be occasioned thereby;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Terminate this Lease, in which event Tenant shall immediately surrender possession of the Premises to Landlord. In such event,
Landlord shall have the immediate right to re-enter and remove all persons and property, and such property may be removed and stored in a public warehouse or elsewhere at the cost and for the account of Tenant, all without service of notice or
resort to legal process and without being deemed guilty of trespass or becoming liable for any loss or damage that may be occasioned thereby. In the event that Landlord shall elect to so terminate this Lease, then Landlord shall be entitled to
recover from Tenant all damages incurred by Landlord by reason of Tenant&#146;s default, including: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The sum of: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">A. The worth at the time of award of any unpaid Rent that had accrued at the time of such termination; plus </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">B. The worth at the time of award of the amount by which the unpaid Rent that would have accrued during the period commencing with
termination of the Lease and ending at the time of award exceeds that portion of the loss of Landlord&#146;s rental income from the Premises that Tenant proves to Landlord&#146;s reasonable satisfaction could have been reasonably avoided; plus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">C. The worth at the time of award of the amount by which the unpaid Rent for the balance of the
Term after the time of award exceeds that portion of the loss of Landlord&#146;s rental income from the Premises that Tenant proves to Landlord&#146;s reasonable satisfaction could have been reasonably avoided; plus </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">D. Any other amount necessary to compensate Landlord for all the detriment caused by Tenant&#146;s failure to perform its obligations under
this Lease or that in the ordinary course of things would be likely to result therefrom, including the cost of restoring the Premises to the condition required under the terms of this Lease, including any rent payments not otherwise chargeable to
Tenant (e.g., during any &#147;free&#148; rent period or rent holiday); plus </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">E. At Landlord&#146;s election, such other amounts in
addition to or in lieu of the foregoing as may be permitted from time to time by Applicable Laws; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) At Landlord&#146;s election,
as minimum liquidated damages in addition to any (A)&nbsp;amounts paid or payable to Landlord pursuant to <U>Section&nbsp;31.5(c)(i)(A)</U> prior to such election and (B)&nbsp;costs of restoring the Premises to the condition required under the terms
of this Lease, an amount (the &#147;<U>Election Amount</U>&#148;) equal to either (Y)&nbsp;the positive difference (if any, and measured at the time of such termination) between (1)&nbsp;the then-present value of the total Rent and other benefits
that would have accrued to Landlord under this Lease for the remainder of the Term if Tenant had fully complied with the Lease minus (2)&nbsp;the then-present cash rental value of the Premises as determined by Landlord for what would be the
then-unexpired Term if the Lease remained in effect, computed using the discount rate of the Federal Reserve Bank of San Francisco at the time of the award plus one (1)&nbsp;percentage point (the &#147;<U>Discount Rate</U>&#148;) or (Z)&nbsp;twelve
(12)&nbsp;months (or such lesser number of months as may then be remaining in the Term) of Base Rent and Additional Rent at the rate last payable by Tenant pursuant to this Lease, in either case as Landlord specifies in such election. Landlord and
Tenant agree that the Election Amount represents a reasonable forecast of the minimum damages expected to occur in the event of a breach, taking into account the uncertainty, time and cost of determining elements relevant to actual damages, such as
fair market rent, time and costs that may be required to re-lease the Premises, and other factors; and that the Election Amount is not a penalty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used
in <U>Sections 31.5(c)(i)(A)</U> and <U>(B)</U>, &#147;worth at the time of award&#148; shall be computed by allowing interest at the Default Rate. As used in <U>Section&nbsp;31.5(c)(i)(C)</U>, the &#147;worth at the time of the award&#148; shall be
computed by taking the present value of such amount, using the Discount Rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.6. In addition to any other remedies available to Landlord at law or in equity and under this
Lease, Landlord shall have the remedy described in California Civil Code Section&nbsp;1951.4 and may continue this Lease in effect after Tenant&#146;s Default and abandonment and recover Rent as it becomes due, <U>provided</U> Tenant has the right
to sublet or assign, subject only to reasonable limitations. In addition, Landlord shall not be liable in any way whatsoever for its failure or refusal to relet the Premises. For purposes of this Section, the following acts by Landlord will not
constitute the termination of Tenant&#146;s right to possession of the Premises: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Acts of maintenance or preservation or efforts to
relet the Premises, including alterations, remodeling, redecorating, repairs, replacements or painting as Landlord shall consider advisable for the purpose of reletting the Premises or any part thereof; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The appointment of a receiver upon the initiative of Landlord to protect Landlord&#146;s interest under this Lease or in the Premises.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event of a Default by Tenant, Landlord may elect at any time to terminate this Lease and to recover damages to
which Landlord is entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.7. If Landlord does not elect to terminate this Lease as provided in <U>Section&nbsp;31.5</U>, then
Landlord may, from time to time, recover all Rent as it becomes due under this Lease. At any time thereafter, Landlord may elect to terminate this Lease and to recover damages to which Landlord is entitled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.8. In the event Landlord elects to terminate this Lease and relet the Premises, Landlord may execute any new lease in its own name. Tenant
hereunder shall have no right or authority whatsoever to collect any Rent from such tenant. The proceeds of any such reletting shall be applied as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) First, to the payment of any indebtedness other than Rent due hereunder from Tenant to Landlord, including storage charges or brokerage
commissions owing from Tenant to Landlord as the result of such reletting; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Second, to the payment of the costs and expenses of
reletting the Premises, including (i)&nbsp;alterations and repairs that Landlord deems reasonably necessary and advisable and (ii)&nbsp;reasonable attorneys&#146; fees, charges and disbursements incurred by Landlord in connection with the retaking
of the Premises and such reletting; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Third, to the payment of Rent and other charges due and unpaid hereunder; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Fourth, to the payment of future Rent and other damages payable by Tenant under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.9. All of Landlord&#146;s rights, options and remedies hereunder shall be construed and held to be nonexclusive and cumulative. Landlord
shall have the right to pursue any one or all of such remedies, or any other remedy or relief that may be provided by Applicable Laws, whether or not stated in this Lease. No waiver of any default of Tenant hereunder shall be implied from any
acceptance by Landlord of any Rent or other payments due hereunder or any omission by Landlord to take any action on account of such default if such default persists or is repeated, and no express waiver shall affect defaults other than as specified
in such waiver. Notwithstanding any provision of this Lease to the contrary, in no event shall Landlord be required to mitigate its damages with respect to any default by Tenant. Any obligation imposed by Applicable Law upon Landlord to relet the
Premises after any termination of this Lease shall be subject to the reasonable requirements of Landlord to (a)&nbsp;lease to high quality tenants on such terms as Landlord may from time to time deem appropriate in its discretion and
(b)&nbsp;develop the Project in a harmonious manner with a mix of uses, tenants, floor areas, terms of tenancies, etc., as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determined by Landlord. Landlord shall not be obligated to relet the Premises to any party to whom Landlord or an affiliate of Landlord may desire to lease other available space in the Project or
at another property owned by Landlord or an affiliate of Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.10. Landlord&#146;s termination of (a)&nbsp;this Lease or
(b)&nbsp;Tenant&#146;s right to possession of the Premises shall not relieve Tenant of any liability to Landlord that has previously accrued or that shall arise based upon events that occurred prior to the later to occur of (y)&nbsp;the date of
Lease termination and (z)&nbsp;the date Tenant surrenders possession of the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.11. To the extent permitted by Applicable Laws,
Tenant waives any and all rights of redemption granted by or under any present or future Applicable Laws if Tenant is evicted or dispossessed for any cause, or if Landlord obtains possession of the Premises due to Tenant&#146;s default hereunder or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.12. Landlord shall not be in default or liable for damages under this Lease unless Landlord fails to perform obligations
required of Landlord within a reasonable time, but in no event shall such failure continue for more than thirty (30)&nbsp;days after written notice from Tenant specifying the nature of Landlord&#146;s failure; <U>provided</U>, however, that if the
nature of Landlord&#146;s obligation is such that more than thirty (30)&nbsp;days are required for its performance, then Landlord shall not be in default if Landlord commences performance within such thirty (30)&nbsp;day period and thereafter
diligently prosecutes the same to completion. In no event shall Tenant have the right to terminate or cancel this Lease or to withhold or abate rent or to set off any Claims against Rent as a result of any default or breach by Landlord of any of its
covenants, obligations, representations, warranties or promises hereunder, except as may otherwise be expressly set forth in this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.13. In the event of any default by Landlord, Tenant shall give notice by registered or certified mail to any (a)&nbsp;beneficiary of a deed
of trust or (b)&nbsp;mortgagee under a mortgage covering the Premises, the Building or the Project and to any landlord of any lease of land upon or within which the Premises, the Building or the Project is located, and shall offer such beneficiary,
mortgagee or landlord a reasonable opportunity to cure the default, including time to obtain possession of the Building or the Project by power of sale or a judicial action if such should prove necessary to effect a cure; <U>provided</U> that
Landlord shall furnish to Tenant in writing, upon written request by Tenant, the names and addresses of all such persons who are to receive such notices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">32. <U>Bankruptcy</U>. In the event a debtor, trustee or debtor in possession under the Bankruptcy Code, or another person with similar rights, duties and
powers under any other Applicable Laws, proposes to cure any default under this Lease or to assume or assign this Lease and is obliged to provide adequate assurance to Landlord that (a)&nbsp;a default shall be cured, (b)&nbsp;Landlord shall be
compensated for its damages arising from any breach of this Lease and (c)&nbsp;future performance of Tenant&#146;s obligations under this Lease shall occur, then such adequate assurances shall include any or all of the following, as designated by
Landlord in its sole and absolute discretion: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32.1. Those acts specified in the Bankruptcy Code or other Applicable Laws as included
within the meaning of &#147;adequate assurance,&#148; even if this Lease does not concern a shopping center or other facility described in such Applicable Laws; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32.2. A prompt cash payment to compensate Landlord for any monetary defaults or actual damages
arising directly from a breach of this Lease; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32.3. A cash deposit in an amount at least equal to the then-current amount of the Security
Deposit; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32.4. The assumption or assignment of all of Tenant&#146;s interest and obligations under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">33. <U>Brokers</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33.1. Tenant represents
and warrants that it has had no dealings with any real estate broker or agent in connection with the negotiation of this Lease other than CBRE (&#147;<U>Broker</U>&#148;), and that it knows of no other real estate broker or agent that is or might be
entitled to a commission in connection with this Lease. Landlord shall compensate Broker in full in relation to this Lease pursuant to a separate agreement between Landlord and Broker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33.2. Tenant represents and warrants that no broker or agent has made any representation or warranty relied upon by Tenant in Tenant&#146;s
decision to enter into this Lease, other than as contained in this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33.3. Tenant acknowledges and agrees that the employment of
brokers by Landlord is for the purpose of solicitation of offers of leases from prospective tenants and that no authority is granted to any broker to furnish any representation (written or oral) or warranty from Landlord unless expressly contained
within this Lease. Landlord is executing this Lease in reliance upon Tenant&#146;s representations, warranties and agreements contained within <U>Sections 33.1</U> and <U>33.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33.4. Tenant agrees to indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold the
Landlord Indemnitees harmless from any and all cost or liability for compensation claimed by any broker or agent, other than Broker, employed or engaged by Tenant or claiming to have been employed or engaged by Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">34. <U>Definition of Landlord</U>. With regard to obligations imposed upon Landlord pursuant to this Lease, the term &#147;<U>Landlord</U>,&#148; as used in
this Lease, shall refer only to Landlord or Landlord&#146;s then-current successor-in-interest. In the event of any transfer, assignment or conveyance of Landlord&#146;s interest in this Lease or in Landlord&#146;s fee title to or leasehold interest
in the Property, as applicable, Landlord herein named (and in case of any subsequent transfers or conveyances, the subsequent Landlord) shall be automatically freed and relieved, from and after the date of such transfer, assignment or conveyance,
from all liability for the performance of any covenants or obligations contained in this Lease thereafter to be performed by Landlord and, without further agreement, the transferee, assignee or conveyee of Landlord&#146;s in this Lease or in
Landlord&#146;s fee title to or leasehold interest in the Property, as applicable, shall be deemed to have assumed and agreed to observe and perform any and all covenants and obligations of Landlord hereunder during the tenure of its interest in the
Lease or the Property. Landlord or any subsequent Landlord may transfer its interest in the Premises or this Lease without Tenant&#146;s consent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">35. <U>Limitation of Landlord&#146;s Liability</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">35.1. If Landlord is in default under this Lease and, as a consequence, Tenant recovers a monetary judgment against Landlord, the judgment
shall be satisfied only out of (a)&nbsp;the proceeds of sale received on execution of the judgment and levy against the right, title and interest of Landlord in the Building and the Project, (b)&nbsp;rent or other income from such real property
receivable by Landlord or (c)&nbsp;the consideration received by Landlord from the sale, financing, refinancing or other disposition of all or any part of Landlord&#146;s right, title or interest in the Building or the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">35.2. Landlord shall not be personally liable for any deficiency under this Lease. If Landlord is a partnership or joint venture, then the
partners of such partnership shall not be personally liable for Landlord&#146;s obligations under this Lease, and no partner of Landlord shall be sued or named as a party in any suit or action, and service of process shall not be made against any
partner of Landlord except as may be necessary to secure jurisdiction of the partnership or joint venture. If Landlord is a corporation, then the shareholders, directors, officers, employees and agents of such corporation shall not be personally
liable for Landlord&#146;s obligations under this Lease, and no shareholder, director, officer, employee or agent of Landlord shall be sued or named as a party in any suit or action, and service of process shall not be made against any shareholder,
director, officer, employee or agent of Landlord. If Landlord is a limited liability company, then the members of such limited liability company shall not be personally liable for Landlord&#146;s obligations under this Lease, and no member of
Landlord shall be sued or named as a party in any suit or action, and service of process shall not be made against any member of Landlord except as may be necessary to secure jurisdiction of the limited liability company. No partner, shareholder,
director, employee, member or agent of Landlord shall be required to answer or otherwise plead to any service of process, and no judgment shall be taken or writ of execution levied against any partner, shareholder, director, employee, member or
agent of Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">35.3. Each of the covenants and agreements of this Article shall be applicable to any covenant or agreement either
expressly contained in this Lease or imposed by Applicable Laws and shall survive the expiration or earlier termination of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">36. <U>Joint and
Several Obligations</U>. If more than one person or entity executes this Lease as Tenant, then: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">36.1. Each of them is jointly and
severally liable for the keeping, observing and performing of all of the terms, covenants, conditions, provisions and agreements of this Lease to be kept, observed or performed by Tenant; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">36.2. The term &#147;<U>Tenant</U>,&#148; as used in this Lease shall mean and include each of them, jointly and severally. The act of, notice
from, notice to, refund to, or signature of any one or more of them with respect to the tenancy under this Lease, including any renewal, extension, expiration, termination or modification of this Lease, shall be binding upon each and all of the
persons executing this Lease as Tenant with the same force and effect as if each and all of them had so acted, so given or received such notice or refund, or so signed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">37. <U>Representations</U>. Tenant guarantees, warrants and represents that (a)&nbsp;Tenant is duly incorporated
or otherwise established or formed and validly existing under the laws of its state of incorporation, establishment or formation, (b)&nbsp;Tenant has and is duly qualified to do business in the state in which the Property is located, (c)&nbsp;Tenant
has full corporate, partnership, trust, association or other appropriate power and authority to enter into this Lease and to perform all Tenant&#146;s obligations hereunder, (d)&nbsp;each person (and all of the persons if more than one signs)
signing this Lease on behalf of Tenant is duly and validly authorized to do so and (e)&nbsp;neither (i)&nbsp;the execution, delivery or performance of this Lease nor (ii)&nbsp;the consummation of the transactions contemplated hereby will violate or
conflict with any provision of documents or instruments under which Tenant is constituted or to which Tenant is a party. In addition, Tenant guarantees, warrants and represents that none of (x)&nbsp;it, (y)&nbsp;its affiliates or partners nor
(z)&nbsp;to the best of its knowledge, its members, shareholders or other equity owners or any of their respective employees, officers, directors, representatives or agents is a person or entity with whom U.S. persons or entities are restricted from
doing business under regulations of the Office of Foreign Asset Control (&#147;<U>OFAC</U>&#148;) of the Department of the Treasury (including those named on OFAC&#146;s Specially Designated and Blocked Persons List) or under any statute, executive
order (including the September&nbsp;24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism) or other similar governmental action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">38. <U>Confidentiality</U>. Tenant shall keep the terms and conditions of this Lease and any information provided to Tenant or its employees, agents or
contractors pursuant to <U>Article 9</U> confidential and shall not (a)&nbsp;disclose to any third party any terms or conditions of this Lease or any other Lease-related document (including subleases, assignments, work letters, construction
contracts, letters of credit, subordination agreements, non-disturbance agreements, brokerage agreements or estoppels) or (b)&nbsp;provide to any third party an original or copy of this Lease (or any Lease-related document). Landlord shall not
release to any third party any non-public financial information or non-public information about Tenant&#146;s ownership structure that Tenant gives Landlord. Notwithstanding the foregoing, confidential information under this Section may be released
by Landlord or Tenant under the following circumstances: (x)&nbsp;if required by Applicable Laws or in any judicial proceeding; <U>provided</U> that the releasing party has given the other party reasonable notice of such requirement, if feasible,
(y)&nbsp;to a party&#146;s attorneys, accountants, brokers and other bona fide consultants or advisers (with respect to this Lease only); <U>provided</U> such third parties agree to be bound by this Section or (z)&nbsp;to bona fide prospective
assignees or subtenants of this Lease; <U>provided</U> they agree in writing to be bound by this Section. Notwithstanding anything to the contrary in this section, Landlord agrees that the terms and conditions of this Lease may be disclosed by
Tenant pursuant to any filing obligations of Tenant with the Securities and Exchange Commission, as set forth in the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">39. <U>Notices</U>. Any notice, consent, demand, invoice, statement or other communication required or permitted to be given hereunder shall be in writing and
shall be given by personal delivery or by overnight delivery with a reputable nationwide overnight delivery service. If given by personal delivery, any such notice, consent, demand, invoice, statement or other communication shall be deemed delivered
upon receipt; if given by overnight delivery, shall be deemed delivered one business (1)&nbsp;day after deposit with a reputable nationwide overnight delivery service. Any notices given pursuant to this Lease shall be addressed to Tenant at the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Premises, or to Landlord or Tenant at the addresses shown in <U>Sections 2.9</U> and <U>2.10</U> or <U>2.11</U>, respectively. Either party may, by notice to the other given pursuant to this
Section, specify additional or different addresses for notice purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">40. [Intentionally omitted]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">41. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.1. Landlord
reserves the right to change the name of the Building or the Project in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.2. To induce Landlord to enter into this
Lease, Tenant agrees that it shall promptly furnish to Landlord, from time to time, upon Landlord&#146;s written request, the most recent year-end unconsolidated financial statements reflecting Tenant&#146;s current financial condition audited by a
nationally recognized accounting firm. Tenant shall, within ninety (90)&nbsp;days after the end of Tenant&#146;s financial year, furnish Landlord with a certified copy of Tenant&#146;s year-end unconsolidated financial statements for the previous
year audited by a nationally recognized accounting firm. Tenant represents and warrants that all financial statements, records and information furnished by Tenant to Landlord in connection with this Lease are true, correct and complete in all
respects. If audited financials are not otherwise prepared, unaudited financials complying with generally accepted accounting principles and certified by the chief financial officer of Tenant as true, correct and complete in all respects shall
suffice for purposes of this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.3. Where applicable in this Lease, the singular includes the plural and the masculine or neuter
includes the masculine, feminine and neuter. The words &#147;include,&#148; &#147;includes,&#148; &#147;included&#148; and &#147;including&#148; shall mean &#147;&#145;include,&#146; etc., without limitation.&#148; The section headings of this Lease
are not a part of this Lease and shall have no effect upon the construction or interpretation of any part hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.4. If either party
commences a demand, claim, action, cause of action or suit against the other party arising out of or in connection with this Lease, then the substantially prevailing party shall be reimbursed by the other party for all reasonable costs and expenses,
including reasonable attorneys&#146; fees and expenses, incurred by the substantially prevailing party in such action or proceeding and in any appeal in connection therewith (regardless of whether the applicable demand, claim, action, cause of
action or suit is voluntarily withdrawn or dismissed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.5. Submission of this instrument for examination or signature by Tenant does
not constitute a reservation of or option for a lease, and shall not be effective as a lease or otherwise until execution by and delivery to both Landlord and Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.6. Time is of the essence with respect to the performance of every provision of this Lease in which time of performance is a factor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.7. Notwithstanding anything to the contrary contained in this Lease, Tenant&#146;s obligations under this Lease are independent and shall
not be conditioned upon performance by Landlord. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.8. Whenever consent or approval of either party is required, that party shall not unreasonably
withhold such consent or approval, except as may be expressly set forth to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.9. The terms of this Lease are intended by
the parties as a final expression of their agreement with respect to the terms as are included herein, and may not be contradicted by evidence of any prior or contemporaneous agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.10. Any provision of this Lease that shall prove to be invalid, void or illegal shall in no way affect, impair or invalidate any other
provision hereof, and all other provisions of this Lease shall remain in full force and effect and shall be interpreted as if the invalid, void or illegal provision did not exist. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.11. Landlord may, but shall not be obligated to, record a short form or memorandum hereof without Tenant&#146;s consent. Within ten
(10)&nbsp;days after receipt of written request from Landlord, Tenant shall execute a termination of any short form or memorandum of lease recorded with respect hereto. Tenant shall be responsible for the cost of recording any short form or
memorandum of this Lease, including any transfer or other taxes incurred in connection with such recordation. Neither party shall record this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.12. The language in all parts of this Lease shall be in all cases construed as a whole according to its fair meaning and not strictly for
or against either Landlord or Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.13. Each of the covenants, conditions and agreements herein contained shall inure to the benefit
of and shall apply to and be binding upon the parties hereto and their respective heirs; legatees; devisees; executors; administrators; and permitted successors, assigns, sublessees. Nothing in this Section shall in any way alter the provisions of
this Lease restricting assignment or subletting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.14. This Lease shall be governed by, construed and enforced in accordance with the
laws of the state in which the Premises are located, without regard to such state&#146;s conflict of law principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.15. Tenant
guarantees, warrants and represents that the individual or individuals signing this Lease have the power, authority and legal capacity to sign this Lease on behalf of and to bind all entities, corporations, partnerships, limited liability companies,
joint venturers or other organizations and entities on whose behalf such individual or individuals have signed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.16. This Lease may be
executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.17. No provision
of this Lease may be modified, amended or supplemented except by an agreement in writing signed by Landlord and Tenant. The waiver by Landlord of any breach by Tenant of any term, covenant or condition herein contained shall not be deemed to be a
waiver of any subsequent breach of the same or any other term, covenant or condition herein contained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.18. To the extent permitted by Applicable Laws, the parties waive trial by jury in any action,
proceeding or counterclaim brought by the other party hereto related to matters arising out of or in any way connected with this Lease; the relationship between Landlord and Tenant; Tenant&#146;s use or occupancy of the Premises; or any claim of
injury or damage related to this Lease or the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">42. <U>Option to Extend Term</U>. Tenant shall have the option (&#147;<U>Option</U>&#148;) to
extend the Term by three (3)&nbsp;years as to the entire Premises (and no less than the entire Premises) upon the following terms and conditions. Any extension of the Term pursuant to the Option shall be on all the same terms and conditions as this
Lease, except as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42.1. Base Rent at the commencement of the Option term shall equal the greater of (a)&nbsp;one hundred three
percent (103%)&nbsp;of the then-current Base Rent and (b)&nbsp;the then-current fair market value for comparable office space in the Alameda County submarket of comparable age, quality, level of finish and proximity to amenities and public transit
(&#147;<U>FMV</U>&#148;), and shall be further increased on each annual anniversary of the Option term commencement date by three percent (3%). Tenant may, no more than eighteen (18)&nbsp;months prior to the date the Term is then scheduled to
expire, request Landlord&#146;s estimate of the FMV for the Option term. Landlord shall, within fifteen (15)&nbsp;days after receipt of such request, give Tenant a written proposal of such FMV. If Tenant gives written notice to exercise the Option,
such notice shall specify whether Tenant accepts Landlord&#146;s proposed estimate of FMV. If Tenant does not accept the FMV, then the parties shall endeavor to agree upon the FMV, taking into account all relevant factors, including (v)&nbsp;the
size of the Premises, (w)&nbsp;the length of the Option term, (x)&nbsp;rent in comparable buildings in the relevant submarket, including concessions offered to new tenants, such as free rent, tenant improvement allowances and moving allowances,
(y)&nbsp;Tenant&#146;s creditworthiness and (z)&nbsp;the quality and location of the Building and the Project. In the event that the parties are unable to agree upon the FMV within thirty (30)&nbsp;days after Tenant notifies Landlord that Tenant is
exercising the Option, then either party may request that the same be determined as follows: a senior officer of a nationally recognized leasing brokerage firm with local knowledge of the Alameda County office leasing submarket (the
&#147;<U>Baseball Arbitrator</U>&#148;) shall be selected and paid for jointly by Landlord and Tenant. If Landlord and Tenant are unable to agree upon the Baseball Arbitrator, then the same shall be designated by the local chapter of the American
Arbitration Association or any successor organization thereto (the &#147;<U>AAA</U>&#148;). The Baseball Arbitrator selected by the parties or designated by the AAA shall (y)&nbsp;have at least ten (10)&nbsp;years&#146; experience in the leasing of
office space in the Alameda County submarket and (z)&nbsp;not have been employed or retained by either Landlord or Tenant or any affiliate of either for a period of at least ten (10)&nbsp;years prior to appointment pursuant hereto. Each of Landlord
and Tenant shall submit to the Baseball Arbitrator and to the other party its determination of the FMV. The Baseball Arbitrator shall grant to Landlord and Tenant a hearing and the right to submit evidence. The Baseball Arbitrator shall determine
which of the two (2)&nbsp;FMV determinations more closely represents the actual FMV. The arbitrator may not select any other FMV for the Premises other than one submitted by Landlord or Tenant. The FMV selected by the Baseball Arbitrator shall be
binding upon Landlord and Tenant and shall serve as the basis for determination of Base Rent payable for the Option term. If, as of the commencement date of the Option term, the amount of Base Rent payable during the Option term shall not have been
determined, then, pending such determination, Tenant shall pay Base Rent equal to the Base Rent payable with respect to the last year of the then-current Term. After the final determination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Base Rent payable for the Option term, the parties shall promptly execute a written amendment to this Lease specifying the amount of Base Rent to be paid during the Option term. Any failure of
the parties to execute such amendment shall not affect the validity of the FMV determined pursuant to this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42.2. The Option is
not assignable separate and apart from this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42.3. The Option is conditional upon Tenant giving Landlord written notice of its
election to exercise the Option at least twelve (12)&nbsp;months prior to the end of the expiration of the then-current Term. Time shall be of the essence as to Tenant&#146;s exercise of the Option. Tenant assumes full responsibility for maintaining
a record of the deadlines to exercise the Option. Tenant acknowledges that it would be inequitable to require Landlord to accept any exercise of the Option after the date provided for in this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42.4. Notwithstanding anything contained in this Article to the contrary, Tenant shall not have the right to exercise the Option: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) During the time commencing from the date Landlord delivers to Tenant a written notice that Tenant is in default under any provisions of
this Lease and continuing until Tenant has cured the specified default to Landlord&#146;s reasonable satisfaction; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) At any time
after any Default as described in <U>Article 31</U> of the Lease (<U>provided</U>, however, that, for purposes of this <U>Section&nbsp;42.4(b)</U>, Landlord shall not be required to provide Tenant with notice of such Default) and continuing until
Tenant cures any such Default, if such Default is susceptible to being cured; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) In the event that Tenant has defaulted in the
performance of its obligations under this Lease two (2)&nbsp;or more times and a service or late charge has become payable under <U>Section&nbsp;31.1</U> for each of such defaults during the twelve (12)-month period immediately prior to the date
that Tenant intends to exercise the Option, whether or not Tenant has cured such defaults. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42.5. The period of time within which Tenant
may exercise the Option shall not be extended or enlarged by reason of Tenant&#146;s inability to exercise such Option because of the provisions of <U>Section&nbsp;42.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42.6. All of Tenant&#146;s rights under the provisions of the Option shall terminate and be of no further force or effect even after
Tenant&#146;s due and timely exercise of the Option if, after such exercise, but prior to the commencement date of the new term, (a)&nbsp;Tenant fails to pay to Landlord a monetary obligation of Tenant for a period of twenty (20)&nbsp;days after
written notice from Landlord to Tenant, (b)&nbsp;Tenant fails to commence to cure a default (other than a monetary default) within thirty (30)&nbsp;days after the date Landlord gives notice to Tenant of such default or (c)&nbsp;Tenant has defaulted
under this Lease two (2)&nbsp;or more times and a service or late charge under <U>Section&nbsp;31.1</U> has become payable for any such default, whether or not Tenant has cured such defaults. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Lease as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>LANDLORD</U>:</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BMR-PACIFIC RESEARCH CENTER LP,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware limited partnership</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin M. Simonsen</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Kevin M. Simonsen</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">V.P., Real Estate Legal</P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>TENANT</U>:</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CYMABAY THERAPEUTICS, INC.,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware corporation</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harold Van Wart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Harold Van Wart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President and C.E.O.</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PREMISES </U></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g608283exa_pg071.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TENANT IMPROVEMENTS </U></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CymaBay Exhibit </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Storefront glass on full front entry wall, wood double door with full glass vision lite </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Storefront glass on all offices, full width, no vertical mullions, wood doors </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Gypsum ceiling in lobby; drop ceiling in rest of suite </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Meeting Room </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Glass wall with glass seams(no vertical aluminum frame), full width glass, no mullions, wood door </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Provide at the wall power and rough-in, ring and string for tel/data/AV, actual tel/data/av cabling and AV equipment by Tenant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Provide at the floor below the table, power and rough-in, ring and string for tel/data/AV, actual tel/data/av cabling and integration with furniture by Tenant. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Board Room </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Will remove jog in wall and align to column </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Provide at the wall power and rough-in, ring and string for tel/data/AV, actual tel/data/av cabling and AV equipment by Tenant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Provide at the floor below the table, power and rough-in, ring and string for tel/data/AV, actual tel/data/av cabling and integration with furniture by Tenant. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Secure File Room </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">BMR will provide (1)&nbsp;2-hour rated room in a location to be determined in lieu of (1)&nbsp;office, the glazing shown on the plan at that location will be eliminated. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lobby </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Floor hardwood &#150; BMR will provide (3)&nbsp;options for Tenant to select from. Tenant shall make selection within 1 business day. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Decorative rock or wood accent wall behind receptionist &#150; BMR will provide (3)&nbsp;options for Tenant to select from. Tenant shall make selection within 1 business day. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Spot lighting to logo </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All office </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Double drop electrical, phone and computer on opposite walls </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g608283exa_pg074.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACKNOWLEDGEMENT OF TERM COMMENCEMENT DATE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AND TERM EXPIRATION DATE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS ACKNOWLEDGEMENT OF TERM COMMENCEMENT DATE AND TERM EXPIRATION DATE is entered into as of
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;], with reference to that certain Lease (the &#147;<U>Lease</U>&#148;) dated as of
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;], by CYMABAY THERAPEUTICS, INC., a Delaware corporation (&#147;<U>Tenant</U>&#148;), in favor of BMR-PACIFIC RESEARCH
CENTER LP, a Delaware limited partnership (&#147;<U>Landlord</U>&#148;). All capitalized terms used herein without definition shall have the meanings ascribed to them in the Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant hereby confirms the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Tenant accepted possession of the Premises for use in accordance with the Permitted Use on
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. Tenant first occupied the Premises for the Permitted Use on
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The
Premises are in good order, condition and repair. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The Tenant Improvements are Substantially Complete. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. All conditions of the Lease to be performed by Landlord as a condition to the full effectiveness of the Lease have been satisfied, and
Landlord has fulfilled all of its duties in the nature of inducements offered to Tenant to lease the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. In accordance with the
provisions of <U>Article 4</U> of the Lease, the Term Commencement Date is [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;], and, unless the Lease is terminated prior to
the Term Expiration Date pursuant to its terms, the Term Expiration Date shall be [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. The Lease is in full force and effect, and the same represents the entire agreement between Landlord and Tenant concerning the Premises[,
except [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. Tenant has no existing defenses against the enforcement of the Lease by Landlord, and there exist no offsets or credits against Rent owed
or to be owed by Tenant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. The obligation to pay Rent is presently in effect and all Rent obligations on the part of
Tenant under the Lease commenced to accrue on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;], with Base Rent payable on the dates and amounts set forth in the chart
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:19.10pt; font-size:8pt; font-family:Times New Roman"><B>Dates</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Square&nbsp;Feet</B><br><B>of&nbsp;Rentable</B><br><B>Area*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base&nbsp;Rent&nbsp;per&nbsp;Square</B><br><B>Foot&nbsp;of&nbsp;Rentable&nbsp;Area</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Monthly</B><br><B>Base&nbsp;Rent*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual&nbsp;Base</B><br><B>Rent*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 1 - 12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.90&nbsp;monthly</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,898.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202,783.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 13 - 24</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.96&nbsp;monthly</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,432.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">209,186.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 25 - 36</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.02 monthly</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,965.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215,590.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 37 - 48</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.08 monthly</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,499.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">221,994.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 49 - 60</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.14 monthly</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,033.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">228,397.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>*&nbsp;Note:</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Subject to adjustment based upon the Rentable Area of the Premises as of the Term Commencement Date. </I></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. The undersigned Tenant has not made any prior assignment, transfer, hypothecation or pledge of the Lease or of the rents thereunder or
sublease of the Premises or any portion thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Tenant has executed this Acknowledgment of Term Commencement Date and Term
Expiration Date as of the date first written above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TENANT: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CYMABAY THERAPEUTICS, INC.,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">a Delaware corporation</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Intentionally omitted] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF LETTER OF CREDIT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[On letterhead or L/C letterhead of Issuer.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LETTER OF CREDIT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">(the &#147;<U>Beneficiary</U>&#148;)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">L/C.&nbsp;No.:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Loan&nbsp;No.:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We establish in favor of Beneficiary our irrevocable and unconditional Letter of Credit numbered as identified above (the
&#147;<U>L/C</U>&#148;) for an aggregate amount of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, expiring at &nbsp;&nbsp;&nbsp;&nbsp;:00 p.m. on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or, if such day is not a Banking Day, then the next succeeding Banking Day (such date, as extended from time to time, the
&#147;<U>Expiry Date</U>&#148;). &#147;<U>Banking Day</U>&#148; means a weekday except a weekday when commercial banks in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are authorized or required to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We authorize Beneficiary to draw on us (the &#147;<U>Issuer</U>&#148;) for the account of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;<U>Account Party</U>&#148;), under the terms and conditions of this
L/C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Funds under this L/C are available by presenting the following documentation (the &#147;<U>Drawing Documentation</U>&#148;):
(a)&nbsp;the original L/C and (b)&nbsp;a sight draft substantially in the form of <U>Attachment 1</U>, with blanks filled in and bracketed items provided as appropriate. No other evidence of authority, certificate, or documentation is required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drawing Documentation must be presented at Issuer&#146;s office at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; on or before the Expiry Date by personal presentation, courier or messenger
service, or fax. Presentation by fax shall be effective upon electronic confirmation of transmission as evidenced by a printed report from the sender&#146;s fax machine. After any fax presentation, but not as a condition to its effectiveness,
Beneficiary shall with reasonable promptness deliver the original Drawing Documentation by any other means. Issuer will on request issue a receipt for Drawing Documentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We agree, irrevocably, and irrespective of any claim by any other person, to honor drafts drawn under and in conformity with this L/C, within
the maximum amount of this L/C, presented to us on or before the Expiry Date, <U>provided</U> we also receive (on or before the Expiry Date) any other Drawing Documentation this L/C requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We shall pay this L/C only from our own funds by check or wire transfer, in compliance with the
Drawing Documentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Beneficiary presents proper Drawing Documentation to us on or before the Expiry Date, then we shall pay under
this L/C at or before the following time (the &#147;<U>Payment Deadline</U>&#148;): (a)&nbsp;if presentment is made at or before noon of any Banking Day, then the close of such Banking Day; and (b)&nbsp;otherwise, the close of the next Banking Day.
We waive any right to delay payment beyond the Payment Deadline. If we determine that Drawing Documentation is not proper, then we shall so advise Beneficiary in writing, specifying all grounds for our determination, within one Banking Day after the
Payment Deadline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Partial drawings are permitted. This L/C shall, except to the extent reduced thereby, survive any partial drawings.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We shall have no duty or right to inquire into the validity of or basis for any draw under this L/C or any Drawing Documentation. We
waive any defense based on fraud or any claim of fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Expiry Date shall automatically be extended by one year (but never beyond
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;<U>Outside Date</U>&#148;)) unless, on or before the date 90 days before any Expiry Date, we have given Beneficiary
notice that the Expiry Date shall not be so extended (a &#147;<U>Nonrenewal Notice</U>&#148;). We shall promptly upon request confirm any extension of the Expiry Date under the preceding sentence by issuing an amendment to this L/C, but such an
amendment is not required for the extension to be effective. We need not give any notice of the Outside Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficiary may from time
to time without charge transfer this L/C, in whole but not in part, to any transferee (the &#147;<U>Transferee</U>&#148;). Issuer shall look solely to Account Party for payment of any fee for any transfer of this L/C. Such payment is not a condition
to any such transfer. Beneficiary or Transferee shall consummate such transfer by delivering to Issuer the original of this L/C and a Transfer Notice substantially in the form of <U>Attachment 2</U>, purportedly signed by Beneficiary, and
designating Transferee. Issuer shall promptly reissue or amend this L/C in favor of Transferee as Beneficiary. Upon any transfer, all references to Beneficiary shall automatically refer to Transferee, who may then exercise all rights of Beneficiary.
Issuer expressly consents to any transfers made from time to time in compliance with this paragraph. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any notice to Beneficiary shall be
in writing and delivered by hand with receipt acknowledged or by overnight delivery service such as FedEx (with proof of delivery) at the above address, or such other address as Beneficiary may specify by written notice to Issuer. A copy of any such
notice shall also be delivered, as a condition to the effectiveness of such notice, to:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (or such replacement as Beneficiary designates from time to time by written
notice). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No amendment that adversely affects Beneficiary shall be effective without Beneficiary&#146;s written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This L/C is subject to and incorporates by reference: (a)&nbsp;the International Standby Practices 98 (&#147;<U>ISP 98</U>&#148;); and
(b)&nbsp;to the extent not inconsistent with ISP 98, Article 5 of the Uniform Commercial Code of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[Issuer Signature]</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT 1 TO EXHIBIT E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF SIGHT DRAFT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[B<SMALL>ENEFICIARY</SMALL> L<SMALL>ETTERHEAD</SMALL>] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Name and Address of Issuer] </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGHT DRAFT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AT SIGHT, pay to the Order
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , the sum of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States Dollars
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;). Drawn under [Issuer] Letter of Credit No. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Issuer is hereby directed to
pay the proceeds of this Sight Draft solely to the following account: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Name and signature block, with signature or purported signature of Beneficiary] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT 2 TO EXHIBIT E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF TRANSFER NOTICE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[B<SMALL>ENEFICIARY</SMALL> L<SMALL>ETTERHEAD</SMALL>] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TO: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Name and Address of Issuer] (the
&#147;<U>Issuer</U>&#148;) </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSFER NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By signing below, the undersigned, Beneficiary (the &#147;<U>Beneficiary</U>&#148;) under Issuer&#146;s Letter of Credit No.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;<U>L/C</U>&#148;), transfers the L/C to the following transferee (the &#147;<U>Transferee</U>&#148;): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Transferee Name and Address] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The original L/C is enclosed.
Beneficiary directs Issuer to reissue or amend the L/C in favor of Transferee as Beneficiary. Beneficiary represents and warrants that Beneficiary has not transferred, assigned, or encumbered the L/C or any interest in the L/C, which transfer,
assignment, or encumbrance remains in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Name and signature block, with signature or purported signature of Beneficiary] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RULES AND REGULATIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOTHING IN THESE RULES AND REGULATIONS (&#147;<U>RULES AND REGULATIONS</U>&#148;) SHALL SUPPLANT ANY PROVISION OF THE LEASE. IN THE EVENT OF A
CONFLICT OR INCONSISTENCY BETWEEN THESE RULES AND REGULATIONS AND THE LEASE, THE LEASE SHALL PREVAIL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. No Tenant Party shall encumber or obstruct the
common entrances, lobbies, elevators, sidewalks and stairways of the Building(s) or the Project or use them for any purposes other than ingress or egress to and from the Building(s) or the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Except as specifically provided in the Lease, no sign, placard, picture, advertisement, name or notice shall be installed or displayed on any part of the
outside of the Premises or the Building(s) without Landlord&#146;s prior written consent. Landlord shall have the right to remove, at Tenant&#146;s sole cost and expense and without notice, any sign installed or displayed in violation of this rule.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. If Landlord objects in writing to any curtains, blinds, shades, screens, hanging plants or other similar objects attached to or used in connection
with any window or door of the Premises or placed on any windowsill, and (a)&nbsp;such window, door or windowsill is visible from the exterior of the Premises and (b)&nbsp;such curtain, blind, shade, screen, hanging plant or other object is not
included in plans approved by Landlord, then Tenant shall promptly remove such curtains, blinds, shades, screens, hanging plants or other similar objects at its sole cost and expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. No deliveries shall be made that impede or interfere with other tenants in or the operation of the Project. Movement of furniture, office equipment or any
other large or bulky material(s) through the Common Area shall be restricted to such hours as Landlord may designate and shall be subject to reasonable restrictions that Landlord may impose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. Tenant shall not place a load upon any floor of the Premises that exceeds the load per square foot that (a)&nbsp;such floor was designed to carry or
(b)&nbsp;is allowed by Applicable Laws. Fixtures and equipment that cause noises or vibrations that may be transmitted to the structure of the Building(s) to such a degree as to be objectionable to other tenants shall be placed and maintained by
Tenant, at Tenant&#146;s sole cost and expense, on vibration eliminators or other devices sufficient to eliminate such noises and vibrations to levels reasonably acceptable to Landlord and the affected tenants of the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. Tenant shall not use any method of heating or air conditioning other than that approved in writing by Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. Tenant shall not install any radio, television or other antennae; cell or other communications equipment; or other devices on the roof or exterior walls of
the Premises except in accordance with the Lease. Tenant shall not interfere with radio, television or other digital or electronic communications at the Project or elsewhere. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. Canvassing, peddling, soliciting and distributing handbills or any other written material within, on or around
the Project (other than within the Premises) are prohibited. Tenant shall cooperate with Landlord to prevent such activities by any Tenant Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.
Tenant shall store all of its trash, garbage and Hazardous Materials in receptacles within its Premises or in receptacles designated by Landlord outside of the Premises. Tenant shall not place in any such receptacle any material that cannot be
disposed of in the ordinary and customary manner of trash, garbage and Hazardous Materials disposal. Any Hazardous Materials transported through Common Areas shall be held in secondary containment devices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. The Premises shall not be used for lodging or for any improper, immoral or objectionable purpose. No cooking shall be done or permitted in the Premises;
<U>provided</U>, however, that Tenant may use (a)&nbsp;equipment approved in accordance with the requirements of insurance policies that Landlord or Tenant is required to purchase and maintain pursuant to the Lease for brewing coffee, tea, hot
chocolate and similar beverages, (b)&nbsp;microwave ovens for employees&#146; use and (c)&nbsp;equipment shown on plans approved by Landlord; <U>provided</U>, further, that any such equipment and microwave ovens are used in accordance with
Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. Tenant shall not, without Landlord&#146;s prior written consent, use the name of the Project, if any, in connection with or in
promoting or advertising Tenant&#146;s business except as Tenant&#146;s address. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. Tenant shall comply with all safety, fire protection and evacuation
procedures and regulations established by Landlord or any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. Tenant assumes any and all responsibility for protecting the
Premises from theft, robbery and pilferage, which responsibility includes keeping doors locked and other means of entry to the Premises closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14.
Tenant shall not modify any locks to the Premises without Landlord&#146;s prior written consent, which consent Landlord shall not unreasonably withhold, condition or delay. Tenant shall furnish Landlord with copies of keys, pass cards or similar
devices for locks to the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. Tenant shall cooperate and participate in all reasonable security programs affecting the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. Tenant shall not permit any animals in the Project, other than for guide animals or for use in laboratory experiments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17. Bicycles shall not be taken into the Building(s) except into areas designated by Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18. The water and wash closets and other plumbing fixtures shall not be used for any purposes other than those for which they were constructed, and no
sweepings, rubbish, rags or other substances shall be deposited therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19. Discharge of industrial sewage shall only be permitted if Tenant, at its
sole expense, first obtains all necessary permits and licenses therefor from all applicable Governmental Authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20. Smoking is prohibited at the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">21. The Project&#146;s hours of operation are currently 24 hours a day, seven days a week. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">22. Tenant shall comply with all orders, requirements and conditions now or hereafter imposed by Applicable Laws or Landlord (&#147;<U>Waste
Regulations</U>&#148;) regarding the collection, sorting, separation and recycling of waste products, garbage, refuse and trash generated by Tenant (collectively, &#147;<U>Waste Products</U>&#148;), including (without limitation) the separation of
Waste Products into receptacles reasonably approved by Landlord and the removal of such receptacles in accordance with any collection schedules prescribed by Waste Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">23. Tenant, at Tenant&#146;s sole cost and expense, shall cause the Premises to be exterminated on a monthly basis to Landlord&#146;s reasonable satisfaction
and shall cause all portions of the Premises used for the storage, preparation, service or consumption of food or beverages to be cleaned daily in a manner reasonably satisfactory to Landlord, and to be treated against infestation by insects,
rodents and other vermin and pests whenever there is evidence of any infestation. Tenant shall not permit any person to enter the Premises or the Project for the purpose of providing such extermination services, unless such persons have been
approved by Landlord. If requested by Landlord, Tenant shall, at Tenant&#146;s sole cost and expense, store any refuse generated in the Premises by the consumption of food or beverages in a cold box or similar facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24. If Tenant desires to use any portion of the Common Area for a Tenant-related event, Tenant must notify Landlord in writing at least thirty (30)&nbsp;days
prior to such event on the form attached as <U>Attachment 1</U> to this Exhibit, which use shall be subject to Landlord&#146;s prior written consent, not to be unreasonably withheld, conditioned or delayed. Notwithstanding anything in this Lease or
the completed and executed Attachment to the contrary, Tenant shall be solely responsible for setting up and taking down any equipment or other materials required for the event, and shall promptly pick up any litter and report any property damage to
Landlord related to the event. Any use of the Common Area pursuant to this Section shall be subject to the provisions of <U>Article&nbsp;28</U> of the Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Landlord may waive any one or more of these Rules and Regulations for the benefit of Tenant or any other tenant, but no such waiver by
Landlord shall be construed as a waiver of such Rules and Regulations in favor of Tenant or any other tenant, nor prevent Landlord from thereafter enforcing any such Rules and Regulations against any or all of the tenants of the Project, including
Tenant. These Rules and Regulations are in addition to, and shall not be construed to in any way modify or amend, in whole or in part, the terms covenants, agreements and conditions of the Lease. Landlord reserves the right to make such other and
reasonable rules and regulations as, in its judgment, may from time to time be needed for safety and security, the care and cleanliness of the Project, or the preservation of good order therein; <U>provided</U>, however, that Tenant shall not be
obligated to adhere to such additional rules or regulations until Landlord has provided Tenant with written notice thereof. Tenant agrees to abide by these Rules and Regulations and any additional rules and regulations issued or adopted by Landlord.
Tenant shall be responsible for the observance of these Rules and Regulations by all Tenant Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT 1 TO EXHIBIT F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>REQUEST FOR USE OF COMMON AREA </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[TENANT LETTERHEAD] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>VIA
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Date] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BMR-Pacific Research Center LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17190 Bernardo Center Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92128 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Senior Director, West Coast
Operations </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"><U>Notice of Request to Use Common Area</U> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Whom It May Concern: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CymaBay Therapeutics, Inc. requests that it have use of the common area as described below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Event&nbsp;Description:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Location&nbsp;at&nbsp;Property:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number&nbsp;of&nbsp;Attendees:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Open to the
Public?&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;YES&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;NO </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Food and/or Beverages?&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;YES&nbsp;&nbsp;&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;NO </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If YES: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">will alcohol be served <I>(Note: Proof of an insurance endorsement for serving alcohol must be
provided)</I>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;YES&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;NO</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">please&nbsp;describe:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Other&nbsp;Amenities&nbsp;(tent,&nbsp;band,&nbsp;etc.):</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Other&nbsp;Event&nbsp;Details:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please let us know at your earliest convenience whether such use is approved. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[Name]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[Title]</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>To Be Completed by Landlord</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;APPROVED&nbsp;&nbsp;&nbsp;&nbsp;DENIED&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following conditions apply to approval (if approved): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BMR-PACIFIC RESEARCH CENTER LP</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT G </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Intentionally omitted] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT H </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TENANT&#146;S PROPERTY </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF ESTOPPEL CERTIFICATE </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">BMR-Pacific Research Center LP</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">17190 Bernardo Center Drive</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">San Diego, California 92128</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Attention: Vice President, Real Estate Legal</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">BioMed Realty, L.P.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">17190 Bernardo Center Drive</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">San Diego, California 92128</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Re:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">7999 Gateway Boulevard, Newark, California (the &#147;<U>Premises</U>&#148;) at 7333-7999 Gateway Boulevard, Newark, California (the &#147;<U>Property</U>&#148;)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned tenant (&#147;<U>Tenant</U>&#148;) hereby certifies to you as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Tenant is a tenant at the Property under a lease (the &#147;<U>Lease</U>&#148;) for the Premises dated as of
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. The Lease has not been cancelled, modified, assigned, extended or amended [except as follows:
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]], and there are no other agreements, written or oral, affecting or relating to
Tenant&#146;s lease of the Premises or any other space at the Property. The lease term expires on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Tenant took possession of the Premises, currently consisting of
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] square feet, on
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;], and commenced to pay rent on
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. Tenant has full possession of the Premises, has not assigned the Lease or sublet any part of the Premises, and does not
hold the Premises under an assignment or sublease[, except as follows: [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. All base rent, rent escalations and additional rent under the Lease have been paid through
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. There is no prepaid rent[, except
$[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]][, and the amount of security deposit is $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] [in cash][OR][in the form of a
letter of credit]]. Tenant currently has no right to any future rent abatement under the Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Base rent is currently payable in the
amount of $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] per month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Tenant is currently paying estimated
payments of additional rent of $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] per month on account of real estate taxes, insurance, management fees and common area maintenance expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. All work to be performed for Tenant under the Lease has been performed as required under the Lease and has been accepted by Tenant[, except
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]], and all allowances to be paid to Tenant, including allowances for tenant
improvements, moving expenses or other items, have been paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. The Lease is in full force and effect, free from default and free from
any event that could become a default under the Lease, and Tenant has no claims against the landlord or offsets or defenses against rent, and there are no disputes with the landlord. Tenant has received no notice of prior sale, transfer, assignment,
hypothecation or pledge of the Lease or of the rents payable thereunder[, except
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. [Tenant has the following expansion rights or options for the Property:
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;].][OR][Tenant has no rights or options to purchase the Property.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. To Tenant&#146;s knowledge, no hazardous wastes have been generated, treated, stored or disposed of by or on behalf of Tenant in, on or
around the Premises or the Project in violation of any environmental laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. The undersigned has executed this Estoppel Certificate
with the knowledge and understanding that [INSERT NAME OF LANDLORD, PURCHASER OR LENDER, AS APPROPRIATE] or its assignee is acquiring the Property in reliance on this certificate and that the undersigned shall be bound by this certificate. The
statements contained herein may be relied upon by [INSERT NAME OF PURCHASER OR LENDER, AS APPROPRIATE], [LANDLORD], BioMed Realty, L.P., BioMed Realty Trust, Inc., and any [other] mortgagee of the Property and their respective successors and
assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any capitalized terms not defined herein shall have the respective meanings given in the Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated this [&nbsp;&nbsp;&nbsp;&nbsp;] day of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
20[&nbsp;&nbsp;&nbsp;&nbsp;]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CYMABAY THERAPEUTICS, INC.,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware corporation</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>d608283dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Harold Van Wart,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Form&nbsp;10-Q of CymaBay Therapeutics,&nbsp;Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for
the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of
the registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November 25, 2013 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harold Van Wart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Harold Van Wart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>d608283dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;31.2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Sujal Shah, certify
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Form&nbsp;10-Q of CymaBay Therapeutics,&nbsp;Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for
the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of
the registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November 25, 2013 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sujal Shah</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Sujal Shah</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Acting Chief Financial Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>d608283dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;32.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to
the requirement set forth in Rule&nbsp;13a-14(b)&nbsp;of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Harold Van
Wart, Chief Executive Officer of CymaBay Therapeutics,&nbsp;Inc. (the &#147;Company&#148;), and Sujal Shah, Acting Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Quarterly Report on Form&nbsp;10-Q for the period ended September&nbsp;30, 2013, to which this Certification is attached as Exhibit&nbsp;32.1 (the &#147;Periodic Report&#148;), fully complies with the
requirements of Section&nbsp;13(a)&nbsp;or Section&nbsp;15(d)&nbsp;of the Exchange Act, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Witness Whereof, the undersigned have set their hands hereto as of November 25, 2013. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harold Van Wart</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sujal Shah</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Harold Van Wart</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Sujal Shah</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Acting Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This certification accompanies the Form&nbsp;10-Q to which it relates, is not deemed filed with the Securities
and Exchange Commission and is not to be incorporated by reference into any filing of CymaBay Therapeutics,&nbsp;Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the
date of the Form&nbsp;10-Q), irrespective of any general incorporation language contained in such filing. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g608283exa_pg071.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g608283exa_pg071.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@#*@)R`P$1``(1`0,1`?_$`*```0``!@,!````````
M```````"!08'"`D#!`H!`0$`````````````````````$``!`P0!`P,"`@<#
M!P8(!!<"`0,$``4&!Q$A$@@Q$PDB%$%187&!,B,5"I$6%_"AL4)2,R3!8G*2
M&!G1LM)#4W,T);0U=;4F-B<WMX)C1%9VMB@X&O&BLZ15A95&.1$!````````
M`````````````/_:``P#`0`"$0,1`#\`]_%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%!)[]?(&.6F9>KHZL>W6]HGYCZ,2Y/LL`BJ;JL08\J4X
M@HGH#9+06[@;QUG<[:MWC99;6K<#<R0Y)N#%VM+;42`R3\N5(6[VVW'%8C-"
MIF9CV(*+UH+J1)3$V+&FQ76Y$66PU)C2&3!UE^.^V+K+S+C9$#C3K9(0DBJB
MHJ+0=B@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@E]SNE
MOM$9)=SG1+?&.3#A@_,>!EHY<^4U"@Q0(R'OD3);X--`G)&X8BB*JHE!WT5%
M1%1>47T5*#ILW*WR)DJWL3H3\Z"H)-ALRV'9<176VWFTE1@,GHZN,O"0]Z)R
M)(J=%2@[BJB>JHG5$ZKQU7T3K^*T%KMWN*.E=O.-I[A#J_8"@`\DKACBEW5`
M%!Y(B(DXX3K03G6!*6M=>$J=JE@V)$J=4X5;!;U5.%ZIQ05S0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!06"\D&T=P"P)U[DW)H/V^`5S
M^*6Z<$;:Y%%1>WW#3E47E$ZI^5!;\O-G05HP?%,\R;)+KB]@S4,FE8L%UQ+*
M'KS?+1B4@@O^6VZP6BUW.^.X+%;=9=&[E&"&K,ADE(5<%*"=Z\+'KGO[/LOL
M-HL\T,MP;$I(YY9L=9:"\VV(Q'6UP)F:P\@E1<A7[>7]U&CN0&I+$5X5]Y6D
M`$"[NWKG(LFJMDWJ)+*!)L^`YE=6)X%V.07[=C5TF,3&B[@07([[(DBJJ(G%
M!RZVE2K_`*OU]<;H?NS;Q@V)W&Y$Z'N^_+GV&!*F$X#_`+G<KDAXE7NYZ^O-
M!7P"@`("B(("(BB((HB"B(B((H(HB(GHB(E!%0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!06"\D64>U_8@5PV4_QBT&OOBB$C"_XU8&@O
M.CRBJRT2H1<<+PG14]:#6#@=HV5;H&:>1FO/'&R0M2[>Q&[Q;/E6MMV7/(O(
M?5VKGY$^\7MG#M7[2QZYZIM:S[S`_F+^,622TV4E2$O==:::$,X/%M,-M]TA
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M*!06$\CP9+`+$4E7$CM;@T0\\K0^X?MM[EP9506O_.GSQVBG53XXZT&J&^6C
M*[?L;9=HGZVS.QO3+]DT[+[+X#^:5HD2[_*NSDV0Y>L@\;LS=QRZV;.+M;R,
MI@6OH^\?/UG_`!5#/WQBB1+;>[=:;-:\AQ3%;5J#`K;BF!Y9A&1V'+L.LMNM
M-M.VV3-+U+N%ZQU_+[;!NPQ[A%;E??)+:=(@]L.5#(K=T"'==0;-MUQ:1ZVS
M<#R^-<VEC,S!=MKV/7)N>T<220Q90.Q",5:=_A.H7:7"+R@3'4KQ2-5:SD'!
M2UF_K_#GBM@PFK8-N5W';<?V(VUAU]FWI$[O;1@#,6NWL0E1.5"X-`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H+#>1SBLZ^L[Z-BY]O
MM[0K_!#W`/M[LP$A(NY4;'ZN$0C^@%5"7HE!HIL^/8D&-?X$+KOPB\M+C:[A
MF=LM67:]W9#T/YJLY2[D=UN[U]2VY_:;=D-VSV'=B:D)+@7N.C\F.))T0>0W
M->-&"[3MEHPG/MLS%CYWE&E-;P-G8](B1TN4?:=MQZSL9/<;G<[5*.RW*4;\
M9QEQQMLN#'AMSVN`H+J^030/Z+W#'=(&XTG6&?QICKKD5IJ/#D8E>&94EUV:
MT_#;9CL&1FKC;H((KR!I]"A/-111@ZGUC!"5%FA#U[AD0)L%06%,"-CEM9"5
M$5IB*VL62((;?:TV/82<"*=$"XE`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H+$^1@N'KF`TV!N(]M31;+K;2D+CC3NZL!;(!(>$#N4D
MY(E$1'E55.*#7!F%LW/Y*:U?RR]^+7B-YC8!FT"\E@.88OD]ZTWL>Q@4B?%L
MTZ6NQ\9N\W'KM8KBV"//VR]1)L-R.4AD4=0!H-HND<?S7$].:MQ?9&0AENP<
M=P#$K)FV3-G[K=\RFUV.%"OMR!Y6(Q2`E7)EPD<)L"<1>XA155*"4^13+<G0
MNYHCT*;<69FK-A1'[?;B0)TYF1B%Y:=AQ"ZD,F2!*#:BA%WJG"+05AK5EB/K
MG`(\:&Y;HS&$XJS'M[R=KT%AJQ0`:ANCR7:Y&;%`).5X4:"MJ!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!064\@E>37`K&;%V0.PM.$R
M!DH@I!M_!B)3X154!;0E5$ZJB+Q0:>L*L'A%C>KL,R;&[-Y4ZVS39TC:$_#[
MUI;(-@6S<NTL;UY=9*9/OJ]8%J?(+OC;UJ!^4DA7[Q:4D\FVR<0E-L"#=-IN
M=8[GJ?6]PQG.+ALW'Y>%8V]9MBW>5'FW?.;>5JC?;99>)46+!9>N]_;1)4I4
M887[APT)MLN00+CF`N(B%ST,#3A5%4("0AZBJ+QRG5/Q3HO2@B%.U$3UX3CE
M>.5_2O'"<K0?:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!064\A&Q=UD^!<]<YU"2=I$!=P;=P8Q5"%17H0HO'HOHO*4$CLOBYI#%Y6:
MWS`\'MVO,LS^W7FUW[-,([K#E;46_P`]VYW8K!=F$<7&7)]V<6<XD`([1S>'
MR!7$0D"ZFNL`Q;56!XAK7![8%FP_!<>M6+XW:P==?^RL]FB-0H+)R)!N2)+R
M,M(KCKA*;KBJ1*JJM!6=`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%!8KR=W#)\??'G<N[X=CCY+*U5KS)LY9
ML$N>Y:HMW/'K<]</L)-R:B3W(#$A&>#=1EQ6QY7CI0:QM3?(IYR[KQ6SY?KS
MX^;=D=CO,"QW*/=+?OW'0AK;<JM4._8U>&VKG8[9,=M5QL=Q8E*X@)P)&`J3
MK9`@7'/RU^2XWB6+\:3212=46BE^0F#,R$:0NWO>:!LT%>BKTYZ<4'R3Y:?)
M@S**,S\:T*6/"*,AKR$Q(&D_AB9"1.VX&27E>.CGJG[*"8::\[/)F^>4VLO&
MGR*\/&=`GM7"]EY?BN6?XO63-UN8ZSA6B7=XT6RV2SD(!S>V!,WY31#WHHB?
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M=8-5QVXR!7Z_J&%-?XX]M`4-H;?U@A$*H2\]PJO42150AY_%$5*"/M3]/'Y<
MKQ0:MO(QJ1_WHOQW28X'V,:J\PQE.!Q]$4L7P12]WKS[*R0;Y_#GB@VBQDX8
M:X043L3H/"#UZ].WIQ0<U`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!9;R!3
MG64I$_\`PSU1_P#97PF@O./[H_\`13_1014"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@EE[N26:S7:[K%F34M
M5LGW)85OCN2Y\Q(,5V4L6#%9!UZ3,D(UV--@)$9JB(BJO%!I$\=?FA_[0^]=
M(ZTM/C->L8U]M"=;L!R+9=VVGCDB18=Y9%@U]V?$UC@^+#88#^V6]9X386PV
M'=+5(2%B-[N\.W&4AX7>0SN^2RRS\C\`/+^RVMN(]-GZ"V*VRW.<1J*0MV&2
M\_[SA&V@(,=HU155.J)02;XUK9;Y_P`<'A]9Y+$2YVZ3XTZVMLJ*8H4.7&<Q
M.'%DQB3HA,F"D'/XIUH,L=?N2K5'>P>Y/27I^(H$./-EN^\[>,><0RL%R]YP
MS???2(GVTDB52^YC&I+]8JH7(H-7GD1[:_)_\>P..L`BZN\N#8:<?<;>=?#'
ML%-Q&6F#$WE2,)KPXBL?[77MH-G[7^['JI(O*HJJJJJ*JJ/*EUYXH.2@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@LOO]>-9RE7_`/#/5'_V5\)H+SC^ZGZD
M_P!%!]H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%!36926XF(Y3)=OQ8LW&QR]R',F!J.\>.-LVR4X=^!F6)1'
M2LX@LA!=16R5O@NG-!Y(?!':.R5\J_!WQ_=\FQO^`ZURC)]U3-I6MCS*S39V
MV;/Y6:CRC(]?:.\E)6XL2MF&Z6D[GN.,S]A6ZQ7Z[7:8(0X#=J;BL-,.2@])
M'GTZ^QX/>7#D56PD#XZ;@^V)T/<;1TL%O8M*8JBHJ=Y)ZITH*(^+H'0^.?PH
M1]&D=7QLU09^R/:TI.8I;W.0'\$+NYH,LLSB7*$];<LLD-N9<K*^,:7'*0,7
M[K'KD8,7A%<<5&7';4"#-9!Q10S84$(5<7D*YC.H_'9>$D,7&Q)'$041Q%3H
MX*`1CV.)]2<*J<+ZT&JOR:?N3'RC_&X#`6S[23@?E\U(D2FR.<VB8/B[P,PU
M;X(`=]OZE7IPG%!M7:3AL$_(43^R@Y*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*"RGD(BKJ^=VJ@DF7ZL45)4%$4=J862*JKT]4H+TA^X/_`$1_T)014"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@M+M6WYH;>.9!CVQK=@F(XA(R>_;1MLW7K.=OYQB`8)E$*)9+>\5V@R<
M:>LV3RX%X<>8C3WIS%N.`C0I*5UL/(_X/S\J=W!X"999K*4O56Q_*(\X@95C
M?Q#6_P`2=,9%D^P-1[`DW'9.";YO6S+[?17+[+;(T>V/KCT61<;=Q!8.&T+C
M(AZ8_D>O8XWX#>8=Z-@)(P?'C::HPX78!^_B=QBCW$BIQV*]W>OX4$C^+LW3
M^.GPF5SCO'QKU.VYVJ))WM8G;VBX).A)R'14]:#.YYM'6C;7JAIVKRB*BIRG
M*$B]%%?14_%*"BL74K+,DX9[$L(EJC,SK-,EO%*&7:YCTM3@,2B%LW#L<A!9
MX).X6":155?J4-<GDY"-SY/?CAG]@^U&P7RZ8[B/@DD2,$QI&.QM5Y-.U#Y5
M$X3GK0;4F_W!_501T"@4"@4"@4"@4"@4%I-D;-?PB\X=C=IP_),WR',/Y]*@
MVC&Y6.0GFK9B[5M>N\V3)R:[V>%[39W>,WV-N$Z7N*J)P)*@2!O;&?F/<?CY
MM%LE]&TO^G#[?T=P[()%Y_6M`3:^P$1>?'G:ZJB+PB7O3G7IZ?\`UR.*"8#L
M[,U>1HM&[0!HE93[I9VK2;!'!%7#5H-A'(5(ZDJ$B"JEV_2B\I0<+FT\P9FG
M%+1^TG6.SN;GMSM6_;FO*CV>R]G\68V2\<\J"BB+Z^J('99V/FSS3SAZ3V*R
M@D8@A7?6:O$""BHX#<?-Y#7*JO1")%Y3JB)0<`;3S!"1M[1^SFR541""5K1[
MD?P-4'80EW+^2#S0=]O8V3NJB%J/9L;N+M_B-8`O:G'[ZF.=.`*+^I?U4':#
M.<C(T#_#/8HJJ\>X?]P^P>BKROMY:?1/^BM!]<SO)6G%:_PPS]U$`C21W8-[
M9*@$:`G.8,JA*H]J<BB<JG*\4$UQ'+KGDDB4U<,*S+$BB-17>_)V;"W'FK,1
MP28AE9+[?.]V$K'\12]L%[T457F@K^@QY\J#;;TE?S=FOV\$RG5?,R,W[KS*
MKMG!Q!0;[2[N\U05Z=$55H,@VT1!X0>U$-SISS_YPNO/_.]>/PYH(Z!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!04KG*(N%Y@AWEK'6EQ;($<O[UP=M+-C%;3,0KR[=6%%^V-6Q/XY2`5#91M3
M3JB4'BR^-+1&-XMEGQ=YPUBOCO$D3]]91AL'>%CVEYT2LLVAFVK=6[*+,8D/
M#=RVB%I.'D.QK9,/(;7_`,-`:OEF:DS[+_"]H2#T_?*7"FW+XY/-2';HK\Z:
M]XY[-]B+%#OD/$WCDMXA:!%3N)`!5X_10?/BP`F_C@\)`/\`?3QKU5[GX\N+
MBT!37G\>355H,^J"C\J@NBTQD$&*[,O&/$_.ML9DS0YB/L#&GV_VU<$'#F0P
M46T7A/=[>.O"T&KSR+R&%=/DS^,B1!GB_`O&!>6TZ&VK9^[(:<P7'3CODJ\*
MT@`)(HDB$*_2J(J+0;<&TX;!%]43C^R@CH%`H%`H%`H%`H%`H,<-A&PGDAX[
M-.(JNOXCOP&>BJ/TP=<$ZA=>U$4$_%%H,B?MV?\`T8T$/VL?_P!$/^?_`,-!
M]2+'145&AY1>4]?5/VT'(K8+Z@/]E!"++8_NCQU[E1")$5?S5.>%H/I--GSW
M`*\IPO*>J?E0<?VL;_T+?_5H.06FQ'L$4$?R3E/\_/-!]]L..U1Y3]/*^B\^
MJJJ^M!\!IMM24!1%(E)?5?J7U7JJ\?LH.2@QG\O^Y/'_`"U07AP<@U>39?B+
M@[8P<@).>G(FB+09+CZ?M+_QEY_ST'V@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%@O)[>VG_`!PT=G^UMY[`
MPG6FOK+9)$&;DFP9<:/C;ETO;9VNR61Z+(:E'>95[N4EN.W`98D/2U-0%H^5
M2@\ROQ+:1RK,@\&?+K_L"V_+9^0W*5(O?E"GF^YM?4^NX5RP?(<(OVQ]-^+4
M?-;QC.K\@^UQ>V8FD.*R,K&8/N02;$(J``>C+SRBO3O"/RSB1WC8DO\`CMM]
MN,\!HV;<G^XU[^W(7"X$%1Y!ZKPB?CTH+<_%D+T?XXO"9B0T^#T?QNU;'<!U
MLA=$F,9A,]IH2(O*=GK^*=>O-!GQW_\`-/\`ZJT$#BB0=1->%143M)%Y1?7G
MHG2@U">0^/2H7RH?'8K<86[&6+>6MSM"LQS:8@7"?@UC6]Q);W45=GO.+)83
MHG)O)QT2@V^LFCC0&/*(0]R(2<%PO5.4Z\+0<E`H%`H%`H%`H%`H%!CEG[*%
MY)^.SY"*BQA^_.%7]X3=BZT1"%/_`%8DB_KH,C"X0255[4X7E4_!..J_LH+.
MS-KJ&R+GK"T8=DM[N=DPS&LVN-];D6.W6`;=E5XR&R6B#'EW&Z1Y,V[+*QB2
M;S0,H#;:MKWJI]J!4_\`>;*$%57`;RJIRO'\XQCE>$]$_P#>HIRM!"&3Y2XB
MDFO[V'"\<'=\7Y7\>?INKB<=?SH(ER/*N%_^@&]+^A+QC(\_HY_F:<4`<ERA
M15?\/[T*]>BWK&3_`/WOYIPE!]3)<G_'`KQ__E\9_P"2Z)02.YYKFD-\`CZG
MS*Y-N(G+UNO>`HRTO:2\.#.RF$^/5..4%4Y5..E!*YFP\YA@PZQIC/;D;X"3
MD>/D6L06&I"B]DA).9Q^UT/0NTC'N]%6@J'!<PR/)I=W9O\`K;+<$&#]I]K)
MR*Z8C<HEX]]M3<2V)BV27XVOM%'M=5\6/J7IW<T%RJ#&CR_!QSQ]S(6E07/Y
MSK8@)5X[2#:.%FB\\+PJ=M!DLG''3\U_MY7G_/0?:!0*!0*!0*!0*!0*!0*!
M0*!0*!0*#@DOI&CO/D#KB-`1J#(][I(GJ@"JCW%^U*#A2<P+[<4E/WS95]$4
M"X0.4Z$?[J$G=Z4'<%4)$5/1?_V4'V@4"@4"@4"@4"@4"@4"@4"@4$OF27V/
MMS991QI7Q"4O^N#)(J=S8I^\7>J>O'2@F%`H%`H%`H%!B3Y?>,U_\F\7U9;,
M3VHSIW*M3;DLNX\<S)_5F![@1F[67"L^PQF*SB.R8T_%&YB,YV<AB>Y'?D07
MXX.1T;?['F@Q&TS\?7E+I+,->2K5\A><Y;JVR;]RC=^QM-R='Z@UUC^?.YVN
M773++&-^UQ:+5?K393R[)ANL>U-FEJ)^.@O-&BH2!L_V#@F-;/P7+]<9E;QN
MF)9SCMWQ3)+83CS`S['?83UNN<178[C+[22(D@Q[A)%3F@P5M7Q8>(]C@6RU
M6*V[DL-JM$=(UOM5E\C-Y6NV18R`HA&CV^#GC,./'91?H;;``'CHB)00SOBX
M\8IQ)_[Q\@H7MS6YC;D+RAWPV9J#8A]N\AYN??#+M^IE2(2557IS02UWXK/'
M)4,(^9>4D,#A/P#")Y9[U8:=CRW'RDB32Y:Z(FZU()I21.?:X#GA*"NM4_'?
MHS46U\6W-9[[O#*LUPV+>H6-O;+WML39%KM+.0P'+;="BVC+;E/B@X[%>+A1
M[515YH,\6Q[`$.57M%!Y5>57CIROZ5]:".@@5>[HG**B_J].GX4$:>B4"@4"
M@4"@4"@4&-VQ'>WR2\<6D)45[%=^)V(O[Z!;=>EU3\40N/VT&1Y_N%_T2_T+
M06#L43V/(?/GT5XO?U+JJ.Z)<_:@368;2=_@KS_O%&3U3A.B(M!?I&6T5%1%
MZ+S^\2_YE+B@B(!)>23E?3U5/]"T$/M-_P"S_G+_`,-`]EO_`&5_ZQ?^&@^>
MRW_LK_US_P#*H.,V8_"]S(&O"JBF`FO]I\K0=2+*CNRI4$8KK3D)&#[S9;!A
M\9+?N=\4T)5<%I5[7.4%4/IU]:"8]@=PEVIW"A(*_DA]O<B?K[4_LH(Z#&SR
MZ-&]`9B9<\#=]=*O'5?_`*YV&^E!DB/HO_2/_P`<J"*@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@*G/1>J+T5%_&@ZA`\LL31U$CHT8&PK8JI.$J$CGN<\IPB>E!V
MT1$Z(G"?DG2@4"@4"@4"@4"@4"@4"@4"@4"@XP3GN1>J=/\`EH.2@4"@4"@4
M"@4#A/7CK^=`H%`H%`H%`H(25`0C5.@HI+PG7A$Y7_10<``CCH2A=>028[49
M4_X7U$)HXK?5/<1$XY_):#LT"@4"@4"@4"@QEV0`%Y.^,QJ1H88GY!H';Z*A
MVO7*%W=?PX14_309,DG<*CU3E%3E/5.4XZ?IH+16^`<?=>53U=4FKAKK">&5
M,E%IRU9'F[+A`"IVC[H307]*HO[0N]0*!0*!0=*2?VX2I3I?P&HZN<(JJHHT
MA$XJ"O"<JB?G0<K*(8(2@J*)EQW(G/(JH]R>O14]/T4'8H%!C/Y@?_H]YI_\
MK:Y_^R=AM!DL/HO_`$C_`/'*@BH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`X3UX
MZ_G0*!0*!0*!0*!0*!0*!0*!0*!0*!PB>B<4"@4"@4"@4"@4"@4"@4"@4"@4
M$)CW`8IZD)"G/Z45*"%D%;:;;5450`154]%5$1.G/%!R4"@4"@4"@4"@U:_(
M1LS9VL-W_'J_JJ^X?8;OLKR*GZ5R.7E>.2\H-G"=A6BV%?IECM\>[V9AJZQ7
MK#&%'GG5`!=5..21:#**^[3V+I,&[CNFV6?)->C'%;MM374"^,)B,E7)2NW3
M.->2%O\`<K1AL>(T/W%WAW*>$1Q4]Z,VV2O"%:V*_0KKO;)(\*5]W'8T_@4X
M7&G!>A/-WC,,]&+*BN`9LO!*:MZFC@\H;9`J*J+07SH%`H%`H.C<XQS;=-B-
MD(N2(KS($?*`A.`HHI**$2"BKUX1:#MM\H`HO543A?V=*".@4&-7EZJ)X^9M
MRG/-RU^*?H,]DX@(%^CM-47GU3B@R1:$A!4)>Y>]U>>57H3ID*=>O051*#DH
M%`H%`H%`H%`H%`H%`H%`H%`H%!"9=@J7:I<<=$5$7CE.5ZJB?2G6@PGV!\C?
MA1JG9V7:>V5Y!85A.?X,S:W,DL^0%<X;41Z[P@N,6WQ[FEO<MEQNK4%P'7XT
M=UUZ.)C[@BJ\4%.I\HWQ]E(1L?*[5J\?2O%PN2M(?9WH"NI;?:0U!>>.?PH.
M_:ODX\!KW(<C6ORDUA,<98.0Z3<^Y(PVRVY[)D<IRV!%$D=^GM[^[G\*#F_[
MS#P,60<9/*+5OO-KVFA7.<(<J/=P+RV[V7%X_(EZ]/6@[DCY(?!:(8MR?)[5
MK+IBIBT5XD>XHH/>I("0N]40.J].B4'5;^2_P(=`7`\J=2*)<JG-^,%Z*HKR
M)Q1(>J?BB4'*/R4>!Q.PV/\`M4:@%R?("+$]S)$:!UYQQMD4)UV.#30(XZ*$
M9J(`B\DJ(BK079:\NO%-[N]OR8T`:@)D?;N+7A((MEVF7<.1**B)=.>>*"!K
MR^\4'VT=9\F_'QUM7'&4(=S:Z5/=95$=;_\`IB_?:54[D]4YH.1?+GQ3%HWS
M\F?'T&&U47'RW/KA&FS3_4,UR1.T^B]/T4'5'S&\2#%2:\I/'1Q$:<?)4W;K
M7@8[+:NO/JO]Y5X:9:%2)?1!3E:#E;\P?$MT0-ORA\=S!P1,##=>MB$P)$42
M%1R5>X21>47\4H*>O'G3X:6*$]<)_E-X_E#CSPM<AZV[:PF]%&GNM^ZU%E1[
M->)\J,X;:*2J8((BG*JB4%/,_(CX,O\`^[\J](%R*$G_`-'EF'D2_=5%-X$5
M%H.:/\A/A!*0E9\IM)J(=%)S.[*QU15141)$AI23IZIRBI00,_(?X+R)`Q6?
M+'1!R"7A&O\`$3'D)%]/J4IB"/7\U1%H)FWY[>%K_=]OY0:3D]G'?]KG]AE=
MG//"N?;RW?;0N.G=QSQ01RO//PNA0CN,WRBT=$@-*(NS).Q\898;(N>T7"<N
M`DVI<+QW(G/%!"7GKX6`HBYY2Z+;4VVW00]DXN*DTZBJVX/-Q_<-$Z+0<S'G
M;X929,6*SY1Z')R=,AVZ&1;1P]MJ1/N,IJ%;H8/.W8&!?G2W4;:0B'O/HE!<
MXO(;0C9(#V[M0LN$O`-N[,PD3->4'@1_GG*KW+Q^N@YBW]HP%05W-JCE4(NN
MQ\,1>T%%'"X*]HJBVICROX=R?G0<H;WTFXO#>W]6FO*(J#L/#B5%)>`14&]*
MO)ET3]-!U)GD-H:WR`B7#=>HX,MUI'VXTS9F$1GS85U&/?%EZ^MNDS[Y('<B
M*G>J)ZT$W#<FJ74)6=E:]?3N3M]G.<5-"!0$T<54NW`BJ+^/X=?QH(0W3I\Y
M<>`.U-;%/EOL18T(,\Q0I;\J42A'C,1TN_O/2'S3@`$5(UZ(BT$UN6R]>V=#
M6ZYQA]N]H&W'/OLIQ^&H`\9ML&:2;DUV@\0*@*O0N%1.J+027*=W:@P=BU2L
MSVCKK$HE^/V[#*R;.<7L3%[<$>]P+2]<[I&:N'LI^^K1$@_BM!(A\F/'-R5;
MX+&_-*OS[M+:@6J"SM7`SEW2<Z;8-PK='&_*]-F&KPH+3:$9*0HB<JE!<:%F
MN+7";<+9#OMJ?N=H<;;NUM;N,%V?;/>128.=$9D./16I"?[LS1`/T155%2@Z
M-YV3K[')D.!D6;XAC\NY"Z5MBWW)K)9Y5Q2.@K(*!&N,Z,_,".ACWDT)B*KP
MO%!P+M36@KP6P<&']*YACB>OIT6Y(O6@EO\`C7J%9<J".T-<K*@C'<G,_P!_
M,0]Z&U*Y^W<E,?SI9$<'U3@%,!0U].:#OKMG5PA[A;'P,6^5%3+,L:0$5"45
M126Z=O/<BIZ^M!TG=TZB8<89=VCKAF1+(@@L/YWB;3DXPX[AB`MW4WE3GJ@H
MJI^-!,CVCKAM$4\]PD.>$^O+L=!.5_#E;EU6@INY;_T=9W?M[QN74]H?X;)&
MKCLG#(3RHZ;C;7\*3>FG.'3;41Z?42*B>E!!8O(+261_;MV;;.L[A->9:=*V
MPMAX7,N+"N-MN(V_%C7UQP'.QX%X3GE#1?QH*T+/<-']_)\='KQPN06/GG\N
M$N*KS0=-W9^O&)B0'LWP]J<K?O#$<RO&VY1-<<^XD8[J+_8@]>>WCB@F+6;X
MD\B$UDEA=`A0@<:O=H>`Q).44%9FN*J*B^OI0<C.9XF_'=E-9)83CQW"9DO!
M>K6XS%>14_@RGVI9L,.DB\H)$A?HYH(ER_&$1%._6<$7T4KK;N%7\>%24J+Q
M0=D,CL3O/M7FT."/5P@ND`D;'_:+MD%PE!'_`'@LG_\`5K8GZ[E`Z_V2:"2W
M786#V.0S&O.88I:79#!R6&[GDUCM[KT=I11YYEF9/8==9:4Q[C%%%.Y.O6@U
M$_))M?7R[\^+V+#SO$G9%P\SL?BHW$RJQO&XW*M0>PRX$:>Z9,RWA#MY3L(A
M3KRB4&XQZ[6.0T\VY/M+H&VXT:',M[C:@X!@8N"XZ0J!`:HJ*BHJ*J*BT&"&
M@+KB>(^2N]=3P,BM[[&N\#U7#QR,_?8#[UMP7)KQL++,8LC+2S'9;K>/NW&9
M!B&7[MMB,"O4%4@SP/([$V*.'>;0#?=VDX=T@``\?O*I+(X^GE.4]>J4$27^
MTJ78EQMRF)*C@I<81>WV\]_<J/+P0HB]%X7HOX(M!%_/[*BAS=;9_$-&FU_F
M,'ZW5]&P3[CDW%Y3Z4Y7K0!O]E)Y6!NUK5P>_N%+E"4T[$Y)%;1]7$41157E
M.B4')_.;2O=VW.W$C8][BI.B_0/^T7\7@4Z>J\)02W^^&+>V;BY'8$!LB!SF
M^6K@#%4%6S+[OL`T)>%15Z+016_+L8NJR`M=_LMR.&\$>8U;KM;9QPWW$[@:
MEC$E/)&,AZHCG:J_AZI03EF8P^9@T2&H'V&H$!H!<<\&0$0@:I_JJO=^B@[5
M!C'YCNNL>.>?O,"!OM2L%-D7$Y`G1V+B2MHO1>O?QQ^F@R;147TX7JJ=/S1>
M%_:BT'V@4"@4"@4"@4"@4"@4"@4"@4$*DB=%YH.,7A)TFD1>1`355XX5"7CC
M]=!$[W(V?;QW=J\<KPG[51%6@\6?GI@MKV#\P-ST7(5W',7W5O3Q?QW*)^&!
M&M&01K?G=CQ"WYA=F)\B/-C1;[?&FVP==0%-UON+CN1%0/0+`^'[P=%UN:&O
M\M!]M40#7:NP'R#VXR0Q1$=O'LFC;*=@JK?[O'X\K03*%\1'A3;@<;AX=F;8
MN&9HCNQLHE(R3A=SA,A,E2`!355YZ+ZK00G\0WA2X^,@\-R='/J1P@RZ:#KW
M<"M\N2Q828BBB]%;<;5$3CJE!(+E\,_A%.9,6\9V%&DDZ)A+:V=DY2FF5)M'
MHK<B4Y+(([@`O3A5^I4Y0>B!RP?AI\&X-O8MO]T,\DL1R<<%R1L_*TD...F9
MDKIQI,85$>_A$1!%./3GK02#-/A5\+LCQB[V6SV_96)72?!?AV[(;;L;(+A-
MLSDD>PWHL.\OS+>^KC:J!`Z"HJ%RBB2"2!R8Q\9/QZQHMFUML#Q,UDSE=MM8
M6^URY29%-A9P,"V+'?N]LO#E\8.XW=R,XK\Z')]N:VX9.(A@@O*$^UO\+WQQ
MZWPR#A,'QNQC*(,)VXOC?<XO&49)EDD[G.>GOA/OSEZCOR18<>]IE01M&H[;
M;7"]O<H<69?"C\:N:6+^02O&/$K$RMWLEW=N>+W?+;/?GOY)=HEV_E#MX6_R
MI:V&]+%^UN,45$9<)UQI51"Y0(;M\)WQFW"SS;7;O%#7N*N3(,F`W=<1F938
M[U;&93),&5HN(7R0W"<;:+@>6#;4?I4%1:"KX_P_?&O&88CCX?:=>1AEIA'I
M%INSLEU&6Q;1V0[_`#D?=?<0>3+A.XE5:"E;M\+'QQS;C#N^/^/%DUO=(<JX
M2CGZPO618=)N?\SA-P9+-X=C7.2LQ@6F^0!$`1+KPM!TP^&#PD;9:C!9MH*P
MV^\\8.;4R-WWD>4?X+Q/>ZX3+?;]*(0JGYK02^3\)_@[(8)MFR;/MKA(QP_!
MVE?3D,E'DI(`V7YS$LN3).TN45%#Z>.*#B/X3/")TB-ZW;4?(UY(GME335>J
MK^-LZ)ROIZ4'99^%;PEC\^U:MG#W=O/;L66/*#SPB]EK'GU_&@E<SX1O"N:D
MMIQO:OV<R.ZT[!3.HWVZNJZ;C3Q*6.&\9,^XJ"JDO"=.J4%L,?\`AR\0\42%
MBNRX>SKH:-L0+'GZ[`&/:<B+DT&WSHD:Q--XM>A!P0:B&9QY:BJQW"=4FJ"N
M+_\`!9X2WJQ3['">W'CB36NP+A:-@Q7I41Q%'AYAF[XU<8/?P/'U-+^CKPJ!
M)X7P.>&L2*Q%<R;=DQ68[,<Y$K*,0)Z0++?MH;A-8&THN&/[Q)U5>O/-!Q/?
M`SX=R'V9+F7;Q!YE.SB/E6)-M.M"8$#;C9X,Z7':V(DHD*F@HJ_5UH)NY\&?
MB*XRL=<LW:#1.@ZX+>4XM_%4%%4!PW,*==5KD?W4)$_'UZT%!7_^GR\+\DE,
MR+CE^[%!A'1&*M\P28PHN$#B?_&>OIKH*+K8EP)(/(HJ(BIS03`_@2\6%F2Y
MS6QMSLORH8PT-JYXFRK0-^R+;HC%Q>,RKX-M=O?V(JHOY)Q02Z;_`$__`(I7
M"X66;*V;O!!L\^'.[(MVP^+*D'$>1X%&Y!B)3XDCN3Z'FS1QKE>Q45>:"O;G
M\&/B-<D:YSCR)9,!07G#V?'F%,1F,<:%]Q]WC;A)]B!IV(!"BJBDOU$JT$EN
MOP*^'=T_EBN9QY$&5K5Y8X7'8]IR","R!;1]8L?(\0NR6KW2#DTAK']Q>.[F
M@Z;_`,!?AW+.TG*S/>3Q6>>W<H+J91B3,F%,9=:?9F6V6S@P2;;.9>8;('F2
M!P"`51>B4%R;Q\,_CLZESO%@VGY,6/-I6,'C,/+UW'<Y\^,RIF]&=G`4"*5T
M9B2W2=]HC;15(E!0->Y`LF]\.7CIE62XN.P-E^2=BV-C;<X+!++;K&1VJZQ)
M;*A=WL.O656&?<6;;<D)0F02,+@*$B$B@"/D%WF_ADTQ'^\2W>0/E):FIL=6
M%CQ-@V(FXJDV+2N1%E8G*<CF+:=J=I<)Z^O6@H/(/@7\7LJRE,RR+;/D)>\D
M_E\6UC>[GDV%2[NQ#@DI0VXUQ=P,I3/L=RHG!)PA%QQW+05"/PB:-">Y<6_(
M[R\9?<?<?5&-J6=IH2=-3,`;3$%06E5?W?3B@BO'PC:(OMQLUTN?D!Y429>.
MS!N%C?<V#CCDBVSR10ERHLA["W78[TUA5;(FU`P%54%$N%0+@0?A\\>[>(#%
MVMY01^QLV>8^Z9P=[3O<A`XIV5QTR:$R[#4^Y27DN51*"C+S\'/B'DF1OY=D
MF8>0]]R-R#%M35VN^TX]SEQ[7!=5Z+"8=F8NX33+;Q*YQRJHXJDB\JJJ'3G_
M``5>'<LK3)C95OFV76PW"3=K+>X6?6<;K;[I*9<8<N+,@\25#F"VYVH3B&G:
MB=.B*@5+`^'755ME,RXODUY>=P,M,OLR-E8Q*CS.P15XY(2,#<,BE/#[A\$G
MU=!X3I04Y/\`A&\?[SEENSJ^;N\E;EEUMQF9B+%_',,)BW,K+-?;D$Q*E_X>
MR'9WVQ-"C/NJJ@B=%H)ZOP^X+$M,^VV;RA\G8GW$$V(2S\AP2<Q%G"O?$N#X
MQ\#M\N44=11M6P?8`VNBIRG-!8NS_#MX\7S-'9.P-E^15FVV5WA91-DR<SP^
MY6O+I&,>VEMO>)/RL(?;G6EH>%*,307*,1*+P$*"XH7_`(?Q":]MZ]]O\F_*
M>+S#8A"+N9XI<Q5F-)&0PZ:7?"II?=$@(CACVJ:*J+T7B@I^^_#CBE]O..W]
M[RQ\F(MVQJ-=HMLNL.[X;'N\%N]LM,W$+5.;Q81MK$M([7NA[;A$#?:)ASR@
M<P_$#;V>4A^9/E!'%0%M5*\XQ)==;;1?;]]U^R%WF*DOU(@JO/7\*"W-^^";
M5&67Z3E.6>2>]\ER.;;H5FF7N[#B$FX.V:W]Y1K6#Q6;EF*#I(J\)WFB=I$2
M4&MEKXN\`B_+3I'0KFR<TDXIJ+3T[R9Q'(9T/'H>27S(9)R<2<P^3+QUO&+C
M&L=K4DN,=^),"5&EL@G/MJJT&^1_XX\!<>"4WL79(2FFG&F7'M@;>DMBCG7Z
MXQ[7%AU.[JO</*ITY2@Q)G?!W@%S\@LVW_-\D-SQ[GG&%XAA-PL5AO>7V!]B
M#AUTGW:%/;SB/L.1G;L^1(N+@."<Y8R,JH(TG<JT%Y)/Q*:^D6[^6EO??<EE
MIE8\4KOL[9M[)IDY4"2ZV_\`S#8;GW@K]BB"I<$*F2\KSQ08^WSX'<!O6Y2W
M,GE1O6VW1S9Q;&.T0'66U5E[`I.!R\63,TNP[';M,B+**3R%W#L>0>`X154+
M^X]\26#8\[#<#R&\C;G]O":8D)==O[5EC)EQW1=C3`9+8B-QB84$^G^(CB<H
M?<E!1,;X8<#C;:M&V%\CMYRIUMUM<-:2+/+RG*B8N%NNMPM5WFW-V[1LTBWP
M+@MQMB]B*^;(QGS:4%Z'073G?%=KN1:+M;1V[M]M;I;9]M=?#/MF*0-SXCL0
MG%;_`,2$1]6!>4Q`E[")$0D4>44//?XA_&+G>[0WSA;.]==XTUXS;JS'15H>
MO&O+[<,DV9_<.T0[VF5&Q"RNWLA<&X]R:.8Q$:D*9]QNJG(JH;#_`!^^">-:
MMEWS=63>35HR-B]8\[C+-KT]8,DPZVR;W:[B<:7?+QDEEV*2WN?:I<-R(C"L
M\L$!#[B$*H@;E?&#Q0A>-1Y0%MS&\9'!R,[<]]G<[AE5P2/*AC(61.4\DRG(
M56;-=DDKA@C:D/"+SPE!E_08O^9@D7C?L`1+M+[S`E0NJ<<;(Q`O5.OX4&3Z
M<?@G'5?T=>5Y7]JT'V@4"@4"@4"@4"@4"@4"@4"@4"@^<)SSPG*]%7CJO[?6
M@XI'_L[_`/ZEW_Q"H/&AY<Q?<^?7!'A66BQ/*WP;%]4+VHKC,BSX040`(G41
MTV7V'%,4%5X-$3\:#V615Y:7C\'74_L<*@[-`H%`H%!3V3XO:,MM3EHO,5'X
MQN-OMN-N.QIL*4SRL>?;9\8V9MMN40U[F9##@.MDG1>.44+8P,AONMY+=IV%
M=2OM@>D,0+!GOVYQR%UT6A8MF>(*K;+9='#)!8N#?V\6:1(!`#Y()A>T"[P`
M^..\1+CKT[D1>.J(OX_DE!%0*!0*!0*!0*"7W*V0;O#?MUQBQYD&2T33\62T
M+K#HKQP+C9="%%3E/147JBHO6@MSW7;7H]MPDR+[A8-.J,^0<R5?,<0"3[6)
M.2+$>6[6!H"5/NW.),4!3W2>'ZT"YT65&FLMR8C[,J.\V#K,B.X+S#K;B=P&
MTZ"D#@DG7E%6@[%`H%`H%`H%`H''/KU]%_LZI_8M!),@Q^V9-;'K5=8P/QW2
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M=;R9KK0QK=X87AJP1VP("<:GR\M2]*\H\-NMB\PQVHO[O]E!O,H%`H%`H%!;
M'9&I\9VG'M43)I>816K+<F[K;W</V%GFO)K4L6B8,GI^!9%C<V>R3)JB-2''
M64+KV<]:#S??']X(ZQWIOWS"SG,\_P!WV:;XM?(WMN?@D7"=S[,Q&+=F,EU/
MCEH%G+9-FRF+<KG<6QO1E+N+3T>?<P$&9+KC("*!MMT1\8>B=#:IL&IL:SCR
M/DV3'\ARK)6+DWY+[QQFX7&9EN67S+IPW2)AN=8_9#9";?G!4&8S(/"*$X*N
MD;A!G-K;7UIU?B%JPJQW7+[Q:[.LO[:?G>;Y9L7*'DF2WYAC<<OS:[WS)+HC
M3CZBTC\DT9:06P00$40*\H,;/+L4+QZST51%17\+]414Z9_BRIT7\E2@R3H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H('![FS'GCN$D_M2@\F>=:OQ?9?]1S>7,NC
MOSH^N\1TOMW%83,E^''8SBP7/2^.V6[7..P2)?V;;!R:9[3;W#,9TA<%%-*#
MUD1D(6`0E0EZJBH/;]*DJ@BI_M"'"+^'-!ST"@4"@4"@X),9B9'>BRF&I,62
MTZQ(CO@+K#[#S9-.LO-&B@ZTX!J)"2*BHM!9L+==]5$9V5FX9)K\2(G<=9?2
M3>\)9=<%!_NRRZ2/WG'FD[C_`)<I%+CIR,4G`0(R!=2R7NVY!;XUTM,MF=!E
MM^XQ*C.MOLN"B]I"IMD7MO-E])MGVN-ER)"BHJ4$WH%`H%`H%`H%!"8"8D)(
MBH0D*HJ(O(DBBJ<*BHJ*BT%L9UDNN)3OYEB,9)EEDFT5TQ$G1:9:<`U-VZXT
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MDL/`K;C#S1HH.,N":\HOX\*G5.:"TQO7W4PHY.EW3*M=MHO=(*/*NF2X5&;'
MA/NG1.5<<DQME2Y]SL<G0614G2DMH3C87?@SXMRBL383[,F)*9;D1I##S4AF
M0PZG<V^R\P;C+K+@]1(25%2@[1<H)*GJ@KQ^OCI_GH-#FZY;K/SW^'45N#,%
M)?C+LA^7<`>CMP7(S>.;49$#57P<>5N<K0HUVD2DHF@\"JH&^6@4"@4"@4'Q
M?3]H_P"E*#1K\3]]CWC8GRMXPA0ANUI\_<T2;(8%X9*L7[!<=.U+,`A%LO8:
MA.("@9*HCU1%H-W[LN+"9`Y<J/''M54.2^VP*HG'<O<Z0IP/<G/Y<T%M=?;R
MU!M?(-B8EKC8^(YCE.I,E_NAL[&K'>8LO(,$R(XH38UOR6R]PW&UC<(;B.Q'
MW&TCS&N38-P154"ZU!C1Y@N^SX[Y\YPJ\2<('A%X7Z]A8H'//Z.Z@R7H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H.&1_[._\`^I=_\0J#RNMNOQ?ZD;<;J,%Q+TOJ
M&"$KW/H&.N1^-SC[/MNBV/).DB\MD9=.HT'JD9Z-@G^RBC^OM51Y_;Q0<E`H
M%`H%`H%!\X3GGA.?SXZ_VT%H;_AERQZ?=,NUV$1N[W9Y'[_B,N6Y;\<R]_O8
M%9IO!'FA8LF&.T0A-;9]F02B,L#%$<`*JPW,H.5PG?8C3;=<[63<.^6.[,I$
MO-FN'8BE%GQ!<D-]I\*33[3KT:0WP;3ACRJ!6J=41?SH%`H%`H%`H%`XYZ+U
M2@HF^8I*E2#NU@N8V.]*0D^OL')L]Y;!4_X:^6Q7VPD*30"(26R;DL\<B9#R
MVH<V.94EW-RVW*)_)LAB(GW=G><5P2;1.D^US$`6[G:Y*)W-."($B?28@2*B
M!6%`H%`H%`H%`H%!\X3GGA.?3GCKQSSQS^N@MK?<1N<&<_D>$R(-NN3DA95W
ML3X?;63+?X*,\7%YAIU^UWAL4_@SXX>XO"`\+@>@3[&,JC7X7(AM2(-X@"@7
M6U7`6X]SA/<JB$[&%?XL9]$[FY#7+#O/TJA(HH%6T"@4"@4"@4"@4%I;Q9,E
MQ":5]P=AFZVIQQ^3D&#.$L<Y0$"*]/Q"5Q[-MO`J*+]FXHPI/U?[MXD<H*XQ
MO)[9E=K2ZV@R-KW'8[L=]/MYL.6PJB]`N,0_^(M\^.:=KK+@B;9<\IQPJAY[
M/(F/!8_J"/$._P!RN$08,3Q[N@/>ZXU&BXY<&+!O'[4KG<'58CM2KRS)XCHZ
M2JJ(B(GUHM!OS/;&LFW'&CV)@0.-+P\V>9XX#C2\<\.-K<.X%X3T7B@DCN_]
M',ONQ7-Q:K;E--DX;#NQ,/;<$!Y[E(5O*F*)QUZ=*"CW?+SQ?8?**]Y":49E
MH7MC&>VGA#3INHG<8`!WI'"[!Z\H*_JH+C:^V]K';,*YW'6&?8=L.WV2X!9[
MU-PK([5DT6U78V6)(VZ<_:),MF/+^UD"ZH&0FC:H7'"HM!<>@4!>O]J?YEYH
M-!?P["\WY*_,8$AE6R3SS;(!4D+N;_N`VRVZG1./<1KG]'/%!AS\QEGM&6?-
MQ\'F(Y1;(&1XCD5[V/`R#%+]%8N^-7Z"Y?K(KD.]6&>$BU76*XK8JK<AEP%4
M4Z=$H/2'I_QET)H*]9WD.E]68KK6X[,F6J;F:8I$>MMNN3MC;GMVEB%90D%9
M<>MT(KI)<&);8\2*K\EUTFU=<,U"^]!C)YCISXV[+_\`48PJ+^2IFF-JBI^E
M%2@R9'T7_I'_`.,M!%0*!0*!0*!0*!0*!0*!0*!0*!0*#B?+L9=/CGL;,^/S
M[14N/V\4'E.NA/A_49;-_C_P7M>Z7X94?W57*/&XU5"4OQ4N.B)0>K%CHRTG
MY`/^B@Y:!0*!0*!0*!0..?\`+]G^B@H;*L.:O1-7B#<#L64VUHVK3?XP`7:P
M;GN+:KK$=58USLTIS@7F202X^ILVSX-`DF-9]+6YMXCF=G'',R%F0L.*U+&3
M:,LC6\&BDW/#YKOMG<&VXY^Z_#<09D/JAB8\.$%U*!0*!0*!0*!0*"07ZPQK
MTRTIJXQ,A*;UOG15!F=$D]BHV<:5VJ;*=W'</[C@_2:$*JE!3%IRF;;;FSC>
M51684J2X0V>^,J35GOHCVHL?MX-NSWYLC1#AND@R%0CCDZG<@A<;G_+]71?[
M%H%`H%`H%`H%`H%!2U_QB-=5"X0S2VY%!:E):KXT*%(B%(#ZV'D)""3;WR%$
M=9-%%1Y[>TN"0)5:,OD-W!G',EMZVN\KV-1)R.BECR3M!$-^PS'21#E(0JKL
M%Q4DLHJ<>X/UJ%>"2&*$BHJ+^*+RG1>%Z\)Z*E!%0*!0*!0*!0..?]%!;+*\
M,FO3RRC$9C%GRR/&#N*2X^-CR-F*/ML6G)XT;N?.*VV9?;RF$23#/@A4Q[FS
M#4UOWXN_'OS2W7D&Z[_D^R=(;CNV)6?%=E8ICKV+2X]W''6685FR80O=LF%<
MHC%E:8AQKC;2"+(C-MJ8-O\`N@@6E=_I\M$O<M%OW:_V8H1`RF+:R25]P2]Q
M2'[F&-C/DG[G7@CX_"@[47X`-*QY4F2YO_9LE7XK,8/=P?5*.,HRO/=[PXRB
MO]Z]5]Q"+_G<=*#CN/P%Z<;M\9V-OC8*RK,LB<R4C7VJGFY*`U)/[5UIK'HI
M^VX3G"\.(O']M!._Z>J'&B^(NYHR6>SVNXV?RSV9CUREVJWM0'[F=JQ#6[K:
M3U:5?=2WK-*.PBJJ-1FP;1>!H-]=`H/B\_@G/5/QXZ*J(J_L3K0:"/B$<&3Y
M%_,<`%^[YRL1B+U[7%P1#+IRG^[][C]E!BA\MO3YVO@B'\LCV!U__O5E3_DH
M/5*'[J?M_P!*T$5!CAY;A[GCUL).>.!Q=STYY]K-,<=[?P_>[./VT&1C?[J_
M]-S_`/B%01T"@4"@4"@4"@4"@4"@4"@4"@4"@X9)=C#I\<]H$O'/'/"?GUH/
M'[N>!EMX_J-[-&P9R\M2;)D>IKIL"5$N4"+88VO5P7`0A-Y':WSBW#)8Y[.G
M8X\U"B/*ZV3"O.*#:JJ!ZU[!DBRWUM%S@N6F^,MM.OQWB<*',%YOW5?L]P,?
M:N;8IPAB*HZRO0Q3HJA6///5.J4"@4"@4"@4"@4"@IK*\3L^96HK/>XZ/15<
M]YMULCCSX,A&G60G6FY1S:FVBYLMO&C<F.;;S?<O!<*J*%LPRVZ:P[XV?OI<
ML14X[$'90@`*W+?D-Q&H.<PH+*LVB03AB(W)L4@O$O\`&2*70@O<V:.`#B>A
M@)IPJ+T)$5.HJ0KT7\%5*".@4"@4"@4"@4$KO%FMU]M\JUW2'&G09K7LR8TM
MGWFG`3E1^GN!1,"7E"145%].%H*!*3<-=G$8E_>W[#D3VBO#Y+,OV,`O`-%=
M#7_B;S9^Y!;62*%(CHHJ\A`A.H%S&'VI#0/-.M.MN(A`XT:&V8DB$*B2=%Y%
M:#FH%`H%`H%`H%`H)9=[/;[Y".WW*,W)C&J$*%R+C#HB0MR8KP*+L68QWJK3
MK:BXV7!"J*B+06[;NUSU^B1\FE/WC'B?=:B90K`(_:VS<`8S>6A'[R7N(T;&
MXM@+*BB%)1HE)Q0NDP\W(9:>:,#;>;!ULVR0P-MP4(#`TZ&!BO**G14]*#EH
M%`H%`H%`H%!1&9X1;\L9BRD?=L^16=)+V/93;6V$O5CE/-\$<5YX#;?A/J*)
M(B/(<:4"<.`O`J@23&\PN$&?!Q3-V85OR&;WMVJZ0F7HF.Y2L="<>_E*R%-V
M#=48%7#MSQ&Z/!$VXXWPHA=*@Z5R:)^W3V112)Z%*:$4)`4B<8<!$0UZ`JJO
MK^%!HY^`5J,UXP^13<57E;;\UMPL&K\EN22O1,/U;#=X-I5014H_/"]>5H-Z
M=`H%!H9^'N-'@^17R^>P"`#WG.;ICSPB.'ASWN&JK^!*G[*#!GYM\MM.H_EJ
M^)'R3SYJ]6K1GC=#S386^-CP,;R')+'JO"+KGV+8E;<HS`,:MEVN%ML\[)KM
M%@-.^R2.2GP;%%,A10]'NA/*75ODDW(G:LA[.?QQ<8Q;,[!F.9Z=VAK+%<WQ
MC,&YKMHO&#778N*8Q_>>'[<+N<.."HC;S3@J;;@G09'T&.7ELR$CQXV0TXG(
MK$L))_S3;RNPNM'^GVW`0N/QXH,BQ'M14YY^HR]./WC(D3U7T1>/TT$5`H%`
MH%`H%`H%`H%`H%`H%`H%`H."5_[,_P#H9<7_`*HJO_)0>4:='>7^H]VLX%P$
M&?[@Z2FDW]L3BQWCN_CE"<@$ZCR()7%EL30NWZ4#A>M!ZI;I9(-\8%J<"K[1
MNN1'VNQN9;Y?<0MSK?,0?>B2VD]"%>%]%14Z4$DB7F98S"W9('T./JU!OK8(
M$6:J@3GMSQ'Z(EPX3GE.&GNJCVDA`@5JBH2(J*BHOHJ=46@^T"@4"@4"@4"@
M4'6E1(TZ.]$F1V)422R['E19++<B/(CO#V/,/LNB;3K+H*J$)"J$B\+06>_E
M]ZU@^3EB8>ONO?;<)[&T-]^_8<#:N2'WL73B0Y>,?:`D_P#=IDCD05XBEV(D
M>@NQ:[K!N\&+<(,N/*BS&`D,/L&I-N-FO;T[Q!P5$_I(2$3$T5"1%3B@F5`H
M%`H%`H%`H/A)W"J?FBIU1%3KT]%Z+06ZEV>ZXK(EW?&$<N$&0ZU(N&)&K(-N
M$"$DF7CCB]@0;B^*IW1RXCO*(\>T7<1!6%GO4"^04GP7D)GW'&'0/EM^+)97
MLD0Y;)\'&EQG44#`NJ*G/HJ+03:@4"@4"@4"@4"@@<;!T";,1,#$A(#'O`A,
M5`A,%Z&)"2HJ+T6@M<MKNF!/J_CL5VYXJX4IV3C0^\_<;29@3SCN*][JME!5
MQI"*WNF*<D2QR$NUDPKNR7R!D$)FXVR2S)B.B8J8$:.M/M*(OQI##H-OQ)44
MU4'6G1!ULTX(46@G-`H%`H%`H%`H)#D..6O)[>];+Q';E0G@)#;/O$@<1%5B
M5'?9<9?BRXCB][3S9"ZT74"%>M!0$6_W37[[%KS"1)NF/R784&TYHZT\Y*CR
MGB)H+?F`18JQXR"B(C=W^B*\JH,A6G%0G`NTAB0JJ$*CPOU"2$G''//*?H7F
M@T8?`,\KWC-Y.`;1L/6[S\\E;$^PZBBX+V/KA=H=<-%3Z??<B*:)UX%4ZT&]
M*@4"@T$_$B#T_P`@/F5AL@GOGYM/0V4(N$,RP9U04E5/I0E.@Q=_J?._'?%J
M7?0@?_3YX^;ET]=+@PR#A#V;E\3]S66+*D=BO-QA<U3<.Q.1!3/ZN5(4H-^/
M@RBKX4>':\K_`/HL^/O3\U_PEQ+K^OK093T%@_*)A)&@=FMJ2@B6)E[N1$7K
M&NMOD(/"JG0U:X5?P1:"_0EW)SQQU)/["5/\_%!%0*!0*!0*!0*!0*!0*!0*
M!0*!0*#@E=(S_P#ZH_\`.G%!Y0)!+_\`K(>X`*/+!&L%THTU(%[VHTC[B[^-
M\PQ[`53>5@C[5$D[>G//-!ZPFOW/_MC_`/'*@XI<2//C/PY;0/Q9+9,R&'1$
MVWFC3@VS$D5%$QZ+^/Y<+04I(D3\7-A4CN7#'0$&9!M^X4ZS@(%V2&V>3^^M
MZ$@@0!R^WW=W!"*T%51);$V.W(8>8>;<[NUR.\#[1*!F!=C@=%5";5%3U%45
M%ZHM!VJ!0*!0*!0*!0*!06?ON"7BRW-W*]<S&8EQD.^_?\/N#CC.*Y6"R%>>
ME`$;VUL.4BV2H$YK^'*5!"8#@JAMA5N'YM:\OBRRCH_;[I:GOL[[C]T8.#?+
M%.'N4F+C!=]&G!'N9D-$[$D`BFPZZWP=!6=`H%`H%`H%`H%!1-ZQ<S=D7NR3
M&K7D/M@7O%&$[9=#8Y*/'OD(!-93/N\</!Q*8Y56SXY%0BL&6I<91V>[Q?Y'
MD4='"DV>68B;K#+8]]PM$A51N[VAQWGA]OJ'[C@"2+05HBHO5%Y3]']M`H%`
MH%`H%`H%`H+<WS$I,6;*R;$'XMNR:2@E.CS$<&QY*$4"-B-?&6%5QN4V@]K5
MP`7)$=%ZBX"("!,L5S!C(#?M\J*_9;_;FA2ZV*XHC<YD_I%9D0D06+G9Y!?4
MQ+CJ;3@JB%[9HK:!6B*BHBHO*+U14ZHJ+Z*BT"@4"@4"@4"@XGF6Y#3C+HH;
M3K;C3@*B*)MNBH&)(J*BH0KQ06:D0+QJY]VXV=FX9%K\0?E7.P,-2[CD6)#R
M)(]B4:*U(DW?'FA$U<M*"KT=%[HGN?[B@U<?!C)=D:(\M"&);HUK+Y"O)N59
M'(;;T:9-MER7";HU,N\%]2=A3G#FD@B1>X4<6R,6S4FQ#=C0*`O^7X]/Q3]J
M4&@KX<GG`\A?F%D.G[KB><[Q$1<#R(8K)8#G\$%MH$3]E!:3^JIL$N[_`!2W
MZ\V_(4L[F$[JU;D]SMHRXC#N28_=';UKVZ6HFGY<=^1#BR<YC3'19!\N8P]P
M(/+@!N7\`KW9<@\&O#VX6"\6N^6\?&31EO6?9[A$ND))UJUEC-MND+[N"\_'
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M7.KD9Y"3G@@5MQ!-`ZN.YO+E2_[OY7;6,9RH!?)B,Y*-RUY!&B@CCMUQF:XT
MRL^*+2H;T8NV9$1>'@1.#(+AB0ESVD)<+PO:J+PO"+PO'HO"T$5`H%`H%`H%
M`H*8R;%K9DT>,,X'6Y=NE#.M-TA.+'NEGGH'M#/MTM.5:>!LE0@)":=#Z7`(
M>E!)8.17&Q3XF.Y:J.'('LMN6-1OMK/=2[D;:A7`A56;3D#J?5[*\,/\_P`(
MD+Z*"OT(5540A517@D14547UX5$]%XH(J!0*!0*!0*!0*"FKYC,*]DQ),WH=
MTA(Y_*[M"46IUL==%1)R.[VJILN(O#C+G<RZG[P\]:"G;1E=SMT\K!F<1BWR
M2)B-8<D1YIBS9:ZK9J;(,E]=DOC:A_$B.\@ZJ]T8W1[D`+B":$@]4Y(4+MY1
M51/Q_3PB]*".@4"@4"@4"@@=<%IMQTR$0;`W#(R[0$0%2(B)>@BB)U7\$H-'
M/P.9)_>O17E_?&I\&XVZY_(/Y!W:RRH#2"P]9;W8-:7JVOB\*JDI)$>>AH:\
M%PO"IRE!O)H%!\5>$5?3]?5/\U!H*^'N,COD+\QD(T<:%SSD?8$B[%,VGL3E
MN)(!$Z*!&X2#_P!!?Q1:"MODU^-C;WF9Y;?'/Y!X,FDLAU_X>Y[F&6;2UCN2
M;?6&]CVC(;W@%Q:L=CBPL(S.P2'#BXK)0CN0`RT\3)=CB(2(&7WAEJRTZPSO
M?L.T>"ED\.X\Z\X[*+(<'S[#<FUCN)^4-[F2+K@^*XF[:/[EA:3?1RX"_C]D
M*5.G&7:^8FZH;`J"R7D>2!HS9A*J(B8T_P`JJHB=7XZ=57HE!>IO_=A_T!_T
M)01T"@4"@4"@4"@4"@4"@4"@4"@E5TE.1&B<1"5#)A@"9;0W&3>,Q)]U7'6V
MQ8;1$553N5.J\+T2@^L7`/OUMBBZ3P0(\\GO;+VC"0Z\P@^XB(VKPDPJD*=4
M%47\:#OOBA-&A=W;QRO;U7Z50NGK^5!XTO+&"+?S\:X>BW+VY%Q\KO#R9<(@
M`K;#\:#C6&LQ@<>!'BER2981P!5&P!M%556@]E$->6$_0;R)^KW3X7]J4':H
M%`H*1N>+M.70<BM;[MOOP`;+K@D90;M&($%(=ZA(OMSFVNQ/9=7AZ-U]LT!3
M`@Y+%DG\S.1"N,,K+>(*JDVV2WFR-`(R%B5">#EJ=;I(@J@Z*H2<=I@)=*"J
MJ!0*!0*!0*!0*!04YDN*V;+(*0;Q'5U&3^X@RF35B?:IP@0,W.TS03W[;=(O
M<JM/M*+@<JG/:I(H4!!R.ZX)*BV+-'Y5RM\PH<.RYVY"1MN=*(EB,VK*FH9?
M:VF^R%$?:DBVQ`FD7`HV\OMD%X>Y%]%1?P]4_5_IH/M`H%`H%`H%`H.E.M\2
MYQ)<"X,,S8,UE6)$22T+L=QHDX,#`D^I"]?S14Y146@H0W[G@R*)I<KYB49/
M<.2+3UPO=AC(@",=6663D7BUL)R2F)%+8!$3VW0Y(0KBV7*%=H46X0)<69%F
M,C)C2(;[<AAZ.XI>VZTZV1"XV2"O!)ZJB^BHJ4$PH%`H%`H%`H%`H)3>K);,
MA@/VN\0X]PMTILFI4.4T#S#[1**J)B2=%$@0A5.HDB*G5$5`H`9MXP!":N#T
MW(,3;^Y4;Y)]^3=\<8:-LA:O/:CLJ\6B.V9(,P!5U@!_C]Z<NB%RXLV)-CQI
M425&E1Y;`28S\9]I]B2PX*&#\=UHS;>9,214(5451>BT':H%`H%`H%!":=P&
M/:)<B2=I]0+E%3M)."Y%?QZ+TH-%/]/[B=ZQ'Q7\B8V1P[7:;W,\[/)`;I9;
M7)8>8LUTL#^*8A<[6K3:HY"*)<,;=$&7!`D90"0>PA50WK(8*B*ABJ$O`JA(
MJ$O/'"+SPJ\T'WE.>.4Y]>.>O]GK0.43U5*#SB?'9N/!/'G:OS";5V7(R&/@
MUN\Y[9;;O=\7P[*<[>Q]I_&[L"W>_P!KPVU7N[6S'XLF2@2)QL?;1>\5>(!5
M20/07K[.+'LK"\<SW&6L@9Q_*K8S>+.&4XKDN$7];?)4EC/7+$\QM5CR>QNR
M&D1P69L2._[9"2@B*E!6-`H+$>3HJ>@MHB**2KC+W""BJJ_\5%YX1.5]*"^]
M`H%`H%`H%`H%`H%`H%`H%`H%!PO1VY`]CR=X<HO8O';W)SP7IRJ]:#Z+0CPJ
M?O)PB%P/=VIZ!SQRHI0?7>?;/M157CT11%5Z]>I=$Z4'C2WQ%8O/]0OB-E_F
M"A.3RG\=I4;EM#1MG&])1,L*WA%4VWWU.'9B57`7L9;)2)%XH/93&'L:0.>>
MU53T5%_2B\]%X7GJG*?IH.Q0*!0*"17BP0;R41R2AA)@R$DP9C*J$R"]VD).
MPGT158-T5[3Z*)@JBJ=:"3PLBF0)S%HR1F)"<FR'FK+=(_OMVRZ-@G+,8O=0
MTMUW5%Z1W3X>1%)I25%`0K1%Y1%_R_3_`)Z#I7.YV^S0)=TNT^#:[9;XS\R?
M<;E+8@P(,.*T;\J7,F27&H\:-&8;(W'#)!`!555$2@[+#[,EAF3'=:?8D--O
ML/L.`ZR\RZ".-NLNMJ0.-.`2*)(JHJ+RE!RT"@4"@4"@4'3FP8\]AYB2V#S3
MS#L<VW6Q=:)MX5!P3;-%0A<!>U4_%/RH+0HSD.L77SB-W/*<$-SWG8S@G*OF
M$MKW$XY`-%.3D.+,FI$4=$*=";Z@CX_0(75M-ZME[@0[G;)\.?!GQ8TR'+A/
MB_&DQY;:.QW6'DX0Q=;)"3HBHB]:":T"@4"@4"@4"@@<!'`4%4A0N.H$HDG"
MHO(DG"BO3U2@MW/L-WQI]^[X1'COL.O+(NF(/>W'AS2<5"E3K!((@:M5Y<#U
M;)0B223ASVR_BH%4V'((-^@#,8(V'!,VI4&8V4.X0)`$J%&GP'E]^%)1$1>P
M_4514515%4)]0*!0*!0*!0*!0<;C:.=O)$B"JKPG'553MYYX5>B*J<>B\]:"
MUYXI,PN1(NV"1R6!)>-^ZX2*M-6^6[(-5D7&P./(H6:ZD2H9,BHPG^U>0!PN
M]0K.PY'`OL4Y,<G6O8>*+(9F,'!EQY3*J$B/*AR.UZ,^R\!"J*B@2)W`1@J$
MH5#0*!0*!00FO:!E^0DO]B*M!I(^/?3\NW9%\A^*Z]V/GNKH>$>>^XF,9@64
M<<OUF[LGLN'9I=)]TL&58]=2O3UXO5]?)XED`3S*-B)`K8E0;&\6VCF-DR^R
M:HWA;K)"R')W)AZYSK&0F,XAL]BTQDG7.V.VJ8]+G8-G5LM7,E^U/R)<:7';
M<>A2G$!UA@,CV;=!9?*2S'9%_M1M70'ASM!5^@C15)115]%Z)0=IUMMP5%U$
M("X`A+]TN21$%4_'DE2@\E&J<.S?/]5?U%%MPG:^8:3N=KWGG^5R;_@D6WQ<
M@EVO"-3YM?YV'A.D-?=V"!F<BSMQ+E-B$W<5M[CK;#K)NHZ`>G+QRQ"^8#HK
M5&'Y%L#)=I72P8-CL!S.\QAV"%E%^C-6R/\`8/7QO&+99K,]<(T%6V7'VXS9
MR%;]QSN<(S(+U4"@LGY'*@Z-V6JJB(F-2.55>$3^/'_%:"]+?^[#]`"G[41$
M5/UHM!'0*!0*!0*!0*!0*!0*!0*!0*!0*#AD**,N=ZJ@J/:JCT44-4'N15Z)
MV\\T'E-=QO$\A_J(=C7B[6.VSKY@[.C[KCEPG##*;8\CN&*XCC5UO-L:<%9#
M4JZXY.<ADYU56#+LXY5:#U;#^ZG^7ITH(J!0*!0*"772U0KS"D6ZX,A(ARA0
M'V7!$A,.4].4Y!Q/43'@VR1"%4)$6@H\YESQ`FF9(.SL499,3O4J0_)GV;[9
MI5`KMW][TNVFTVB?<MH;C1<D\G:G>H53-AVG([8Y`GLP;G;+G%()$.0W%GPI
M\&4RH/,OQGAD1)L.0P\HF)B;1B7"HJ+03*-':B1V(K`H#$=IMAD$Z(#30H#8
M(B<(@B*(B)Z(E!S4"@4"@4"@4"@4%LI^+2\;G3[]A$9E2NCR2[]B[A_;VRZR
M!``<N5L41]FVY`]'8%LN>V-+0`1[M5$<H*LL&26_(89RXA.,DRZL:7#EM_;3
M[?,;1/N($V*9*XU)C&O!+^X:<$"D*HJA4-`H%`H%`H%`H(3'N%10B#JB]PJB
M$G"HO"<HJ=>./U4%+7?'!=E%>[.__*[^#0M_>-MH4>>PVJ*W#O,9L1<N,-OA
M>Q.Y'&E-5;)%7A0Z]BRUF;.=L-U9*TY)$;;=EVN0I=C@/"\[]W:)C@MM7BV'
M[1()L\N-<=KP-$J(H5GSSU3JE`H%`H%`H%!"1@*B)$(J7/:BJB<\*B+QS^DD
M_MH.I!N5ONC+DBV3X=Q8:DRX3K\&2S+9;F0)#D2=$-U@W`&3"ELFTZ"KW-N`
M0DB$BH@=M3%$55(41/555$1.B+U7G\EH*&RC#_YI(:OMDFE9,IAQ_9BW9IH7
MXTYA%14ME]@=A!<[4\O7CZ76"1#:,5YY#BQ_-AEW!S&\B99L&6QXXR?Y4\Y_
M`NT4&^9%TQJ49HEYM3!HJ.*"(_%7A)#;:J*D%<1Y<26*G%DQY((X\RIQWFWA
M1Z.:M2&E)LB1'6'$43'U$DX7A:#L4"@4'`3[2M.F!MN^V+G*":%]0<H0+V=R
MHJ$G"IZHOZ:#03\=&Z<.U+N7Y%+1N';>,WW-<H\OK[E7\TPVR7^XXK+9#&H+
M5S;M$>PP;XU:8U@*)]G(;ER/NW'8I$?'<*T&>.\/*'QFS36622`V#,>O&&K;
M\ZQ&1;<&V9_-H&<8=)2_XM*LK;.*K+E/OW&&,9UMD31V-(=9<Y;=(5#//'YQ
M72RVNYFRY&.Y6Z!<#BNB8.Q2F0H\C[9P'/J`XZ.=BHO7E.O7F@G"]47KQT]>
MG3]/7E.E!H`\&M6V39NQ?G.U7*G/8K`V[Y%YA@5_N\!V%<)5FCYOJK(\8G7R
M,R]Q%^[B-7(I`LO+V>X'!=%6@WTX_;0LMBLUF;=.0U:+7;[4U(<$0<?;M\1F
M(#S@!R`FZ+/<J)T15Z4$WH%!8OR9Y30>U"$/<,,3FN`VK@LHX;9LF`*Z?T-H
M1"B*J]$H+WLJJMHJIPJJ7*<\\+WERG*=%X7ISZ+0<M`H%`H%`H%`H%`H%`H%
M`H%`H%`H.&0*&PX)<\**\\?HZ_\`)0>6VP,#!_J&_(&4Y`]TKYCV@F4D*C`$
MT<"%C`BXV3C+AF/M16EX%1+A'%YX]`]2Z)PG%!]H%`H%`H%!`XV+H]AHJCRB
M\(JIZ?@O''*+^*>BIT7E%5*"@)%JNF*/NW'&VBN%H-OF=C`B".1R5T.^?CSA
M>V$=0;4W'8//M/$G\+L-5[@J^UW6%=HH2H4IF2UWN,.$TJHK4J.7MR8S[1+[
MD:3'=11<:-$,"3A4YH)DBH2(0KRA(BHJ>BHJ<HJ?K2@^T"@4"@4"@4"@+^OC
M]*?A^GKRE!0&1X7]Y*#(+#.<LF508ZM0K@VV3\.X-(CI#:,BM[?MI=+(1$G`
M(3;L=4[F7&U5>0Y<:RR1-E+8LEAMV+*F6">>MHDZY!N#3/8#]TL,]\6BN5M,
MR1>.P'8ZEV.BBHA$%=<\^E`H%`H%`H%`H%!3]ZQJTWUME)\?N?ARDG6^>R2L
MW"URT$161;Y;2(^PX8AVFB+VN@J@:$*JE!3UKO=^L\I+1F+4(&",V[5E$(4C
M6BXB3J!#A3H[CB.6B]D"\$':L5[CEHT7^%07`1>43\^.:#[0*!0*!068\B8F
M23=%;@8P_*KO@V4IK/-Y&/9A81B+><<O,3'ITJW72VE.%R($R/(93L4Q41YY
MY141:#R<_'/ISSD\M]!WC=&'>9^^,1PJQ[1V-A]XPW7^5R+CE_\`.F%LV97[
M*685RO6-XYD,_([UE[\Z2'W<>:<EYXD%YQU10-C.M?"KR,VB=W8Q;YF/(:6_
M9T?M.68PN-%:,_Q"6X,)IEC(<2RC(8E\Q^5'D1@4')41L7E)>PC`N5#'_;W@
M_P#*=K2]7H+#\FUSR;$+G/>DX->=@;BV=BN?7QARW1.^TQ]989KG-)%ROD>\
M*;(LVV7)%UM6U[&G"4*#7-N^V_*OX]W755V\B=];3Q/'LWS&YKKI3W9DV>9@
MEPLDNS8S_>YZ+=+=99VMFY*Y0Q,8A/&4I\'S;DM1R;5J@V?_``$[5\E-KYAY
M9W[;VU<PV-@47,KAA^+P;TV__*;!G6*9%,OV995#)M9L:%=MDM;!:F36GI!O
M"4$!!703D`]-U`H/A=15%]%1?]'Z:#0;<8GD]Y&_)?YBZ(P_S0W)HK!=,:[T
M=E&/8_A=CQ6XV..[L>Q"$EMEB\M...26Y$!R2ZXKB\N/^G'2@V&>"OA-:_"G
M"]E8W'V9DFT[UM39USVIE.3Y!9;7C;[M]NMIMEK?%FVV8CBH;S=M1U]U24GG
MS(E1%]0SD]L>47D^4_\`NCG'[44N%_;0?&VT;'M0B+E>54N/541%X04$13IZ
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M"B+GB`-7)S(L<<_E=^?+FX"/<ELR%D6E;2-?([:HAF`)PU+%"DL=$3O%/;4)
MW;;['FR9,!Q'(UP@IQ+BOM&T0\=O#S#CG`S(C@KW(ZWR`HJ(?:72@GU`H%`H
M%`H%`H%`H*8RC%+1E,5INY,N?<P'%F6FX17%CW*T7$`,6;C:I@@X[#FM(:IW
M"BH8$H&)@JBH4S;+W>,8^VMF=7&.]]W/)BV90U`<BQ)S`-=[4:_H*?8V2[F*
M=J$CA1Y'MJH*A+V(%RP,315`D5$(@7\T(5X(51>J*BT$5`H%`H%`H%`H.K-@
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MOL#1VX=/[.T]CV%;>V=>(^P[!M7'\TVI:?[C7_R4N;5EQ`+[!NI.[(Q;(L2O
MDRWS`1Y&[4-J$39;;BVPD(^T-&'RF>+KV'O^/?D)+\_=]>2=WM6\+/J=O7>_
MAQ]U_6+.PAR?+[I)N.&8#BN#2<>=-<`A165NUK]L2C.O"_[2BV(;5?@!QW^0
M:M\RXA21?_\`STMA$@,6M^RLQBC6''H*15BJ#++CC(,(CA`/8KGZ4Z!O_H%!
M"?[A^J_271.$7T7T5>G/ZZ#3EXX6G[+YA_D0N2SXCI771WB>:VL69238X,6R
M>RW,<D$*P38>45'L`E)%!5]%H-Q]`H%!\7HG/Y=5Y_+\?\U!H_\`BNLL>P>0
MOROS&KJ4J3>?->\7F5$=@K&6V&;N9Q/85Q77?N@<;BDO/:WVJ*]5H-WS:HH"
MJ+SRB+_:B%_RT$=`H,>/+5EI_P`9=Z,OF;;+NM,I!UQL/<,&RMKR&8!_KD*=
M43\:#(1M>6PZJJ]H\JH]BJJ)PO(+U!>?P_"@CH%`H%`H%`H%`H%`H%`H%`H%
M`H%!`ZO:V2ISSQ^"<^J\>GZ:#Q,^8,/?CGSLY5M#1^0V&T77Q_S?062Y"[DM
MCRR\Q#P7.+'AVM,DL<#%\<M]V;S">W"S";-8-UL"@N(W(:3W`)%#VI66\6V]
M6Z+<K5.C7"WSD]R#,B.(\Q*95.1=:>#D'D5.JDGHO1>%14H)O0*!0*!0*!0*
M!04]?<>B7J.*$]*A36#1Z'=(!H%PB&+@N*#1J)B[&=4>'&#0F71_>%5X5`ZU
MJN]P8?&U9$PU'FFXZW;[A'14M]W;'O<;1M.JPYXQQ^M@^JJ*J"J/H%4`8N")
M@JJ))RBJBBO"_H)$5/VT$5`H%`H%`H%`H%!TI\*'.C2(\V,W+C/QWH\B,ZT#
M[<B.\B(\P;+B$#@.H*(J*G6@MPRS?,`X:8^[O6"M$2BT\3T[(<6CB0_2P\I.
ME?;`V/<7\9P9D1OCJ^*=HA<6VW*%=H$6YV^2Q+@3F@?B2H[H/,OLNHB@8.`J
M@O/IPBKPO3UH._0*!0*!0*!0*#XJ<_GZHO1>/3K^'7UH+;W*R7O'IYWS#^Z4
MQ(-#OF+23;"WW%.@'/LI(/?:KZTT*<-IVPI?':Y[1+[R!55CR*VWUATXDD5D
M1'4BW."^/V]PM<]`!TH-RAFON1)8MN(7:O*$*H0*0*A*$^145$5/14Y3]2T'
MV@4%K]V^VNG-L"XXK0KK//N7$7M($_NG=T(A7A>%$%5?V4'GY^`GQ_TWLOQ5
MS#96;ZX@77.K;O+,,6M^2W)RZ,WJ%85U]JF<_984V--C&]:%GR''1-?J>(U4
MU541:#?:UX[Z89:89#!+=[49D8[`%-O+B-,B1&+8*Y<B5!0B5:#7UY&_$9I[
MR-V.UG]XW!Y"X5$A.0[A9<#PW.WQP7'+\Q:)%@N5^Q^SWH;F-JE9!;I!C,;;
M)&G5)24>5Z!C??\`^GI\6LGN7\XONW-^7*].6ERPO7R=-P.;>7;.XT_';A.7
M27B$B6+<.-*-J.2$CD=I>UM1'I02C^G;@N630_E;B[ESO%Z_NGY=9OC;=VOD
M:6U<KFS8\>QNSQ[E-ERY+W\RN%QCP`>DOM@TT<@S5$554E#T*T"@@<Z`:]/W
M"_>YX]%]>.O%!IP\;4$OF'^1,E>E.J.C_$YAAMV)/CM16&+1+><;C.NHD*2P
MX[)[D(>31>Y%Z)0;DJ!0*#B>_P!V7"\=1_L[DY_S4&BWXGGY=P\G/E^B39$I
MY@?..^L1H[@"#$:$[,V"J'">1>XE?<$N_G]U11$H-Z@#V"B?DB)_U404_P`R
M4$=`H,=O+ASV_&+>[G*?1J_+215].X;4^H\__;)09#A^X*KZJB$OZRZK_G6@
MBH%`H%`H%`H%`H%`H%`H%`H%`H%!`XG<!)Z=/]'7_DH/)Q?E:M?SJ>3<M7')
M9W5WPXDL,QK@,7[=P\UU-;WV7HXN-NNR&6WU5"]%'IU]*#T\S\:N6/3)>2X0
MRRY-FN%)NV,R7AAVG(7^&VS>:DJ+B6B_O(W],E1]J0JB#_"(AB%58SE$#)(A
M.LJY&G1W2CW*TS&OM[I:98(BE#ND3O=2-(1%Y%4,VG1^ILS!46@J>@4"@4"@
M4"@4"@EUSM4"\P9-NN4<94*6V34A@B,$<`TZHAMD#K9(O"H0$)"J(J*E!2[\
MV7BC<.-)6=,L;;*1DO#BNW.XPE[Q_P")N[(`CST9M%$$?%"45)%<3MY6@K)F
M2P_R+3H.$"`IH!(7;WB)@JJ/T_6!(J<=%1>4Z4'/0*!0*!0*!0*!00D*&)"O
MH2*B_J7I06YE8S-QN8]>,,!&V'WY%PO>,*K;=OO<IYIH7IEO(N&;+>.V,*]P
MBD9]?WQ0E[Z"IL<R6W9)!^ZB%(9D-N*S.M=PC%!N]JDJIJD.YVYQ2=BO"(_2
MJ\@Z/!@1`J*H5%0*!0*!0*!0*#XJ(OK043?L127+&_6*2=GRF.VK+-Q;1LH\
M^+[A/C:;]&(.VX6=7R5>/]^PID;)":KR$5BRK[AT[3?8Q6*^Q%('84IP3C7$
M$]I!GV*<I"ESMQ$YV]W:CK9<@X*$*J05JG7JGHM`H+5;S;<=TUM<&A[C766P
M11.1%.X\.O0!R1J()R9(G*KQUZT&G#^G@998\(LX!F2S+%?(G+25Y@R,$<76
M^IT<:7DR[2:).%3ISZITH-\E`H%!H)^`RW';,`\YV$>21$_[=&TRMQHZKRMP
MBM./&,53(S)?MI!N"B+QPG3T2@W[4"@A-.0)/S$D_M1:#3-XSN,O?,-\C2A'
M-EUC3/BBRZ9.O$CYE:9'+@-DX38!VM"G`HB<HOYK0;FZ!0*#AD<^R?'5>$X_
M:2)0:*_BO?6W^2WS!2(X(\Y$\TKN:-*:)R\#VQ7B;(O]7ZRZ_DE!O59,G&T,
MT%%4CZ`JDB(A*B=51/JX3K^F@Y:`J<]%H,<?+X57Q<WV(IS_`/4NR[I^JU/J
MM!D8'[@_]$?]"4$5`H%`H%`H%`H%`H%`H%`H%`H%`H(#7@"7]%!X_MM,R%^;
M_P`D;C#98:6VY9X-6LI*N.>Z['N&U=*MN((*OTOM(A@/"<$/*JOI0>O]M.6T
M[D_>53X_6:D*I^7X*E!2=[Q4)=R')+0;=KRF-#6%'NJ-*ZW+B]WN!;[O%;<9
M2XVT7E4D$U]QE5(F";(B4@AQ_*UG2'+-?(9V7)XR$<BUN&+K$J,!$"7*S2Q$
M`N%N=04(D3EZ/WH+HCRBJ%9(J$B$B\HJ(J+^:+0?:!0*!0*!0*!00D`EQS^'
M*?K14X5%_-%_*@HL+-,QQZ3-L:OR8$AM2?QH3;]EJ8<@"?N%H<D+Q$4FB(BB
M"H,&2<B@$JJH5!9[[:+]'.39[A%N#3+[L60L=P3.-+8)6Y$24US[D:6P:<&V
M:"8+ZI03:@4"@4"@4"@4"@^*B*BHO5%147]2]%H*(ON)+,FLWNPRG+'DL)A(
M\>ZMM@]&EPN4)+1>89$'\RM*N"A<=PO,E]31HO**$-CRQQR6EDR=G^19*+3S
MJ6]QP'8%U88[%D3\>N'M,%<X,9%[G.6VGV`)/=;']Y0K@#$Q0A7D5]%X5.4_
M-.43E%_!?14H(J!0*!0*!0*!04MDF(V?)H[03V7@E1)/W]MN,&2Y"N=KN(-*
MVW-MT]I?=B.H'(F*<LO`1`Z#C9D*A(+1?KQ89#=CS:2RXKCGV]GRAMEJ)!NZ
MFYVQH-R8;1&K3?B!4%`3_AI9(I,D*K[(!<85Y1%Z]4_%%%?[%1%2@M[MP8[F
MK-DM2_\`V1W`,T;F=`+_`(0L9NB/KPXHMK]*_P"LJ)^?3F@TG_TZ<^V3O"?9
M(VF!]C%MWDQF=J553ZICD+6>H1669(JH9F)(*JG*+QT7B@WZ4$)&(<=R\=R\
M#T5>5_).$7JOY4%@[WY1^/N.W>-8KKMS#1N<K++#@HQX-Q6\-LYCD]TBV6PX
MU.F6=F?"MMXN=UFM1VV9#C1^Z:"O"\T&HGX$'+>S@?F];(Q!]Y%\U-C39P")
MCREQM]K2.^O<B`B/+$<1$%>G9U1.E!OTH%!`XO#9KQSP!+Q^?"+TH-/GCE.M
MLCY>?D*BQVV@N$+2?BB%P-"DH^\KMLFO,&C9`D7V0!SM[A7O4D].*#<-0*!0
M0.JJ-FJ`IJ@J2`B\*2CU015>G<JITYZ<^M!HH^)>/;7?)7YAH(!)<DAYW9`S
M>7G'7?9>D3(V4S_:@H2H01F&+@B(O"?6I(G04H-ZS0H`((IPG)+^?J2JOK^E
M:#DH%!CEY>J2>+V^U'U_PMR[^S^4O\_YJ#(IOCL#CT[!X_5PE!'0*!0*!0*!
M0*!0*!0*!0*!0*!0*#C>0%:<0^>Q0+NX547CCKPH_4G[*#Q1^3VQ;]B/SP9A
M9H>/3KE:=A[_`/"W"9]^9%MJ-C$JR91I[+8K\F,3;AW:+>6D=B*0^U]HYP:J
M:*B('M;91$;'CGA4YZJOX_KZHE!RT%-9+BUJR>(#%P:>21%D!,MMPAR#B7.T
M7!MLVFKE:I@<E$FL@XO"HBB7H2$G2@IZUY+<;/=TQG+6D91Q4&QY./MA:KXK
MQ&L>W2B5P5MV2"`*GV_;[<E!4V5]6Q"X;;@N@A@JJ)<\*J**]%5%Y0D0DZI^
M-!'0*!0*!0*!0*#XJ(OK04K<;"L>0]>,>CQ8U[=5'))&*`Q=E:9<;88N9`B.
MFB\H"/(JN-)]7!HG:H=ZUWQB:X_#D\0KM$;%R9;'55'V6BY1)#7<`+)AN&)(
M+P(H%V^O/2@GM`H%`H%`H%`H%`H)%?<>MN01P9N$?W2CNMR8;P&3<F#+:(3:
MF07P('(TQKM^DQ5$7T)"'E%"E85ZO.,36[/EKB2K29`U:LS%&VFY#IF^0VS(
M8K8*-NG-1FQ)9G(19"EPB-E])!<0'`-$45Y1>J=%3E/SZHG14]%_%*".@4"@
M@5P$4DY7D..Y$$E7ZO141$7E/U4$GN638[93M[5ZOMHLSMVG-VNU-W>X1+8Y
M<[F\BDU;;<$YU@IT]P4Y%EKO<5.O%!.$<%>.A]?S;<3^WD4XH.%R9%:>:CNR
M&6Y#[;SK+!N`+[K4?VDD.-,JJ.N`Q[X=ZHBH/>//'*<ASB8F*$*]PKZ*B+U_
M#\J#J384*X1GH4Z.$F(^)`_'=:5QIT"Y[A,5%4)%YZ?BB]4H+57"??=;F[<I
M(3+_`(&V0@Z+#3C]ZPF$O)R[C)=>>5V_XS%[$<<01&9"90U1'FQ50"89M>L?
MR74687B'<8%VQJ[:ZR>6ESB/)(M,VU2\:GN%(;F-\LN13CJ7)(O3T7A>E!I(
M_IO)`R/!W9XMJ'LQ/*K9$5E0;]L76/\`#_4CT=Y$[151)EU$15ZJB4'H)H,.
M,L.^^16P\QU'%E72T:9UP=KM6V;I99]PLUTV/EM[@LWDM4V;(K:_"D6_%,>L
M,F,]DKT5P)<UZ:U;1..T,PC"V_G!C>(ZU\>-;V;#\.M5GQRT^4GAS%@8UCD*
M/9[1:XTOR>U9;WID*UV\8\-HHGWRO%V-]Q'RYPI\E0:__@1^EKY`FQ5%:#RU
MNW"BJ$GO_830EBIHJ_6#X*BCS]/ZEH/0?0*"!SCL/GT["Y_5PM!IO\;YHK\P
M_P`B4(8B&BZ2\3I!S0%`1KV[,\VU%<+IWF\KY.)ZJB-<?CPH;DZ!0*"$EX%5
MZIPGJG'1/Q+KZ]J=:#1E\6RN1/*CYAHC3D-"C^8PRRGMFGW4B?)@Y:1N28!]
M&66(S;<=LT!!>)AQ44B0E0-Y3*$C8]Q]Z\"O/:@^HHJ]$_2M!RT"@QP\P'09
M\6]_.N%VMMZJS$S+@BX%+/)Y7M%%)5_0B*M!D4PJ$PR2>BM-JG14Z*"*G1>%
M2@Y:!0*!0*!0*!0*!0*!0*!0*!0<#QDTBN<$K8#W&@`KA<#RI=H"A.$O'X(B
MJM!P-7&(_+<A-F:OM,-R#167A;1MTB$41X@1HG445[@1>\?Q1.:#LO\`/LN\
M=O/87[W=V^GX]OU>GY4'C;\E["WL#Y\<!Q*V75RS/R_*71USF7'[*VR>Q_6V
MJ;3L5R$[`>D1)<R/<AQ(8HN<JC?W'N)W=G%![)6D-`3O3@E4E5.Y#X525>A(
M#?*?LH.2@4$HN]DME\A2;?=(;,^)+!6I$>0G>VZTJBO9RJ]S7:0H0D'!MFG<
M*H76@I%N;<<*;:9N[DB;BS2&V-[D.',N=F4G`2.U>B:;,YEL$57_`(XD0VT_
MW_HKBA7D67&F-`]%>;D-.`!@ZT7>V8&*$#@$GTD#@KR*IT5*#LT"@4"@4"@4
M"@4$CN]CB7-&GE]^-.C*JQ;C`,6+A'[E%7`;?7CEI[M3O`N1)$3E*#JV^\/M
MOO0;Y[,62+S@1)(=Z0)[`H1M.-2#$6VIA,)RZPJJHDA**D/H%2"2$G*(2=53
M@A45Z+QZ$B<HOX+Z+014"@4"@4"@4"@4'6EQ(TZ.]%ELM28TAIQB1&?`78\A
MET5!QI]DT)MQMP%X5%1>BT%O6V+WA*J4<)5YP]D77%B*7OWG'&A`G/;@K_$=
MN]F:[>T&5_XE@>$!3!.T0KN%<X-P8CR(DIB2S*;%V.]'+W&7FSY42;<3D33A
M%1>OJBT$PH%!H;_J`<IOV+^*NK4QZ;DT&=D/D?AF/-IC&1/X]<ITRX8KEL>Q
MVYM]FXVUB0U.R"1&#VGW4!72$EX[>4#15>?CV^2N_A;7<@\:=Y9(W!N+=QMX
MW?,]7W*]X[+A^^,.=:I,O;3RPKC!+L^V?9(7!150RZ)P%4.>$WRG+-:9/4?E
MR]:@BHBQPV7@C3Y/H#2*\P__`(V*R(1R>5`$P$C]M5+JJ<A8/=^D/-73%UU5
M-V_IOR)L=VV3G,?2>F)%]SC$I<FX;6V$!/V7`[)=[9LJ\S;;,SI^PC[DR0B0
MXX1_<=)$:05"0ZWA^;V>RL\UO'T7YBR]EZYNUDMFR<2P6[7'-+Q@8Y3!D2<4
M3)+E:;^MN`\K8ARYL>2TKD7[1H")P5-$((<G9\K=?9#:\1RG!?-^P7O[06UM
M$V0S='W0C&K4N9=)UGRBYPL>**Y)8:<8N!PWVU[%<`4/D@J3/\=\S\:PK(W\
M_P!`?(-CF/*P]$>ON289DD>V%!6&^$N.\RY,)J6[<(0O(K(MN.^UWGP@BI($
MBP3"O*K-<**ZZPT3Y\9-A616QML$Q+&LCF6-YNZQ)02&$9A/S4LWOP9R2C]Z
M&R\7O"?V[B."[09K^"'GQY`_'=A&4>-TGPVVKDN69GLJ_P"SX%DRW%,IQK-G
M)U_L>.XD-EDVFQ6J\V"U#$G82H_\3)CO</"CH`9(BAGYG_S;^6VIX5JOFU?C
MDV#K'%+I?;5CZ9+L0<SPZTQ[U/:FW%C&2F73&?;<R._VJVR/Y:TB(!OM$+BB
MB4&X/P,M>S8GC]!R3=^`?X7;FV?GFU=L;*P$Y\6[OXI>\^V3E-XM5@E7B'*F
M-7-VS8@5LBB[WHGLLM@@-H'MB$O^0BR[!O'C;=KCJ7&5S_9F`9]J+;.':S;<
MBL3-GS]4[2Q'/96`6V1,D1VH=SR6VV%YB/(Y)([Q"XHEV]JAYY/CMWWY9^%E
MI\A(L/P0V?L&5M_<V1;!GM,6W*\7+'+ZKCC+^.'[&"7H+HUV31(9IFVIF#G*
M=O9P&S*T?*!YG7!5-[XQ]KLL-RG8CR1[SE[[Z$VV:^Z(GJQD%;]X1!/7N[N4
MZ(M!WI'R.?(.<,)=L^*+:4E2(55F5G%QA/JWRBG[;#NO44C0>>.XA^K\*#GL
MOR*?(;D,5R3"^)?:]M;!UUI5R+8\6RN$K2JA=D.;B#,XP/CZ7!;5LOP6@LS\
M=6:[!V'\J?GYLK<.I'-&9S?-'^/ENN>`W?*8]ZO5J@V8QC61UQD+=;5^TG1I
M(/(\**/\4!+J24'H19FQ)!=K,EETO]D'!)?[$7E:#LT"@@<5$`E+H/'"]%7H
MO1>@HJ_C0:+_`(PBE!YI?,=97K1]M!7RHQN[1KNA12D71^YL9ZS+@L&+AN)'
MMS<%3074%0=DN*"<$M!O/;44;%4[N$1$^KCNZ(B=>WZ>?U4'(B\]4H%!CGY>
M*@^+V^B5.4#5N7GQV]_*A:9!#]"(O=]2>G"\T&0T<D-ADQ]#:;-.BCT,4+]U
M411]?3\*#FH%`H%`H%`H%`H%`H%`H%`H%`H($;;0E)`'N5>57A/WO]K_`*2_
MGZT'TT%0+NZCVKW>OIQU].OI0>/?+LC9D_U'>(8L<UH+HN]K/+BP?M6R?FPK
M7XIW"9<3:=2,2HW;VWD)T^]%1#%%7ZD2@]A5`H%`H(";`T(3$3$Q43$D[A(5
M3A1(5Y$A5/5%H+;3;;>L0G/73'AD7'&7U<>N>*-_QYT24XB(L_$SD21;;'@>
M7+:2"R:JILJ+G\,PK*Q7^T9%;V;C9I[%QB&3C!NL'W$S)CDK<F++;5`=BS([
MHJ+C3@@X!)PHHO2@G5`H%`H%`H%`H%!U9<*+.9*/*9!YDN%[#1>T2$D,#'A4
M4'&S%"$D5"%4145%H*)_F5QQ)\6+U]Q,QMQ66H-\4E?>M3CBBR,*_P#'N.N1
MO<52&?P+8#P+J"J(1A7C3K;PH;1BX!")B0*A"0&G<!B2<B8&G5%3E%3TH.2@
M4"@4"@4"@4"@*B+Z_P"7'5/VHM!;ZXXY<[+.>O\`ASG#IMLMSL4D25;L=V%H
MW"5RW@2HU9+T[[RHKP*C+ZH*/@O"."%0X]D4'(8KKL;WF)<1\HMTMDMM&;A:
MIH\D42:PBKVJ@JB@X/+;P*A@1"J+05!0:$/G^2X_X`>+TB#V>P'G#I"'+(S:
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MNB_8>M]E;L(2(<F"1&BMG*>$`SO\JY>L-B8'X\VZS[`UUY#673+D^U[.U7E.
M66BU/;3QR_:GNNMG<IM$S*XEUQ@]B8O>YK=XMP79?MGW#>;-X24"4(O`*\:M
MTS)S^7,F8%HW6\S"M+ZXU;J1W,<8ON;+:-/X[=<?NFS]E?W"#^X%IS'/9-R9
M;=C6HG15BWMF\0FJ-B&'.ZM$XM.OFT+KC^)ZQSK>.4VWR0Q/5?DM?<YUH."X
MOBGE+FMDR&W9GLEJY,_XP6S.M'XR,J/C5OM34N),C-N![@_<JHA9/YJYD=_`
M?'C+<>\PQS:SVC:>BM?R=+1KF,IC-\E@Q<GM]WVA>K?"O[=KF2WG"%]SBUN7
M!)9HTCZ1W/:H/6*VRVV*``HB>J\)PI%PB*9*G[Q*B=57K0"9:/A3!"[>>.[E
M415XZHBKQST]?PH/J-`G[J*/`B"()F(H(<H(H(D@HB<_A00K':547M5.%YZ$
M0HJ_I1%1%6@Y>$Z^J\^O*JOZ/Q5:#A-EKM,NSKVEZ*2<].B+PJ=.G[$H-*OC
M:Y)D?,Y\CC:2XJQ(^EO%ELH+MO=2='=7&[`^V<*>AML_9.(XXKS8@9NO*V1&
M/MBBANL%AD2[T;!#X[>_M121.J\(2\JB<K0<M`H.)XFQ:,G4Y;$>3]5^E.JK
MPG5>*#1!\7TB27G/\T;HREG-P_)7!&HRN,M-$S)1=LMR8J*C;9F#:MMBA*JH
MJ>B^M!O>80E8:]P>TU;!7!1>40U%%-$5%]$*@YD3CHE`H,<?+Y]8OB[ON2)=
MA,:MR]U#[4/M5NTODB]JH2%QQZ<+09#QE4H[)+U[FQ)/^B2<C^KZ52@YZ!0*
M!0*!0*!0*!0*!0*!0*!0*!0<;J\-.+_S"_T=:#RX:QM]I>_J(_)24^P`3(=I
MU3)A.RHJ2B"9)P%V%(=M3C@DY:G)<1GVGW&U!'VP03[D1$H/4G0*!0*!0?%1
M%3A4Y3_)?\RT%LKUA4V!=W<NP1Z%9[_-DL'DEO?9/^39A#:^@TN3;+K*Q;\S
M&Y&-/'DT+@7D-M?I"HL7RR#D3!-(U,MUX@@T%YLET:;CW:T2C'GV9S#3S[7:
MXB=S;S1N,/#U;,DYX"JT7E$7\_V4'V@4"@4"@4"@4'`_'9D`0/-`\!-.M&V:
M(0.-/`H.M&)?2;;@]%0N46@H!(%YP]TI-I;F7;&S-M'L;909$VU>X[P4JQ//
M/BH0(K")WV_ZA%!58Z]Q>W05I:KO;[U"9N%M?]^*^B]A*VZRX!B2@;3[#X-O
MQWVS%4(#$2%4ZI03*@4"@4"@4"@4"@>M!1=]Q4YLD+Q9ICMFR2,IC&N@(+K$
MAD@;_P""O<'W`&\6M3:3Z"-M]GDE9<;5550AL64F]/.P9$Q_)\G::`TAJZCE
MONS/#A+/Q^48ME,C?1]8+_&854%Q.?J4-'_]0!/<9T5XE6=D'3D7SSMT<Y&:
M8%LO=?MK&1R$CO-N&+A!(8,Q,FR0AZ*GXT&QK6'F[AFP<*QC:DW7&X<)U'FH
MSG\=V9D>.6.Y8@U`AW.XVM;GE3V'9%D][P:`Y*MI\R;O$APV1(5><:3E:#,.
MS9#8\CAQ+EC]VMU[MEPB,7"!<[1-C7*VSH$D>Z--ASX3K\65$DHBJVX!D#B(
MJBJHBK02[+,*PS.+>W:<UQ'&LQMH2VIS%LRJPVS(K:U<8S3XQIP0;O%F1&I;
M#;S@@Z@(8H:HB\*M!(=>8#KK"H<K_#_"<(P]FXO+_,?[DXQ8<:CSW;:X[!BA
M-&PP8#<IZW-`30HXA*T/(IPE!<?C_/S^*_C_`**#[00H*)Z<\\<<JJDO"?I)
M56@ZXPH@FKB1VE<4T<5P@0W/<3G@T,^XA).>BHO2@IS*,!P7.(<2W9KAN+9A
M;X%U@7V#`RJP6K(8,*^6I]95KO,2)=XLR/'NUMDJKD>2`H\R:]P$*]:"K:!0
M*!0*"!SJV:)QRH%QRJHG[J^JHBJB4&D3QOMYN_-QY^7AOWE`/'K1EJD?<I&!
MQEYJW:\?9&`;:#*>M\F*TIFIK_O>15.B4&[Z@4"@@=%#;,"3D2`D5/S147I0
M:#OB@20YYU?-/[ZH<:3Y7XDK(\CU;&3MT%0D1$(5]QO\:#?F*<"B+^'3^ST_
MS4'V@4&,WF:2!XG^1#A=!;U'FSAJB<J@-V249*B?BJ"*T&2,-46)%4?18["I
M^I6A5/\`-0=B@4"@4"@4"@4"@4"@4"@4"@4"@4$#@H0$*J2(J<<BO!?L5?2@
M\RNO[LQ*_J`O(F']AC[#T&Q:8$;HK$P;W/21A\[_`((B1Y8J-Q6E[P)13GN5
M/PH/3;0*!0*!0*"$@$T1"3E$7GCKQRGYI^*=?1>E!2V08R%S#[VU.,6K)(K#
M[5IO?VZ2/LU>(7#:DQ>]H9MO>>;%765(4+U14+K02^P9<3L\L<R2-_),E:,V
MV&'B5(&0LM(J_P`RQR2?\.8R0"INQT)9$5.C@HG"J%<@2&(F/42%"1>47HJ<
MIU151>E!%0*!0*!0*!0*#XJ(2<+Z?K5/]'%!2=RLDF$Y,NV+MQ8MTE.#*N,0
MQ!N%?":%!))*BB+'N3K8(#<I.5'C@T(?0.S9<FM]X<EPQ5R/=K<3+=TM,@>V
M7;WW@[A`N$09$<U1>Q\.6C1.A<]*"I*!0*!0*!0*!0*!02>[6.W7D&AFQQ<<
MCOMR(DD3-N5!D-+W-R83X?6P\!(B]/I/C@D5.E!Y[/G6N^06+$O!N#?\;M>3
MP(_GIJE8N4S8JO6^$U*ME]BL'<&4NMMDV[((B2P-'&_<BOLJXO"$!)0;-/C+
M1FX>!?C@Z[;X<07\.N3GV<9LPB@G]\<C,3!IQ^20(_\`[PA4RZFJ>G2@KJTV
MJ#X_[KL]CL$0;1J/=S]_BVK%;>PHV;#MR0(3N32',>C^Z$6R6C96,VR:\Y;H
MS3<8;Q;7I`)[T^0JAEL9]S(N`A*A")]G'!$"IW*/'JA*'X?G04_B;[C]GC&[
M"&WF9SO^$!.``6[C*`7>$_UI`\$O/55ZK05/0*!0*!0*!0*!0*"7W&Y0;;$?
MESY+4.(TVI.RI#K;#`(J%SW.NF`CVHG*JO"(G7GA%X#2AXLY[CF8_-!Y_P!N
MQW["[MXSH;0[,[*[&Q(D6Z6=UM6).P;8_>V5>LUPE,)$>3B.9$W[1"?:HT&[
M^@4"@XW44FR$24"7A$)..>>Y.$ZHO0O1?T+0:$_BNND]WS.^9R),M-DMDRT>
M5-K89F6D'?NKG&=N&VW[1.NCCCCC13!ADBD(BB"1*B\T&^J/W^PS[B\N>TW[
MB_F?8/<O/X\K0<U`H,=?+GL7QAWPCD:/,;+5^7"Y$F"11)+96I\38DB!`91W
M051-$5%457A4H,@XHH,9@4XX1EM$[441X[4X[15541X]$Y7A*#GH%`H%`H%`
MH%`H%`H%`H%`H%`H%`7C\?3]-!Y?-0W.U0OZ@SRFCRIUOC7*ZP].6R#$N$J*
MQ+NCD'75PFR(UCC.N_=7!Z"Q[;[Z-!_!:(3-414H/4"!B:=P+W)SZIZ+^/*+
MZ*BHOJG2@BH%`H%`H%`H*;R+%K1DL'[*X0VW>R8Q/CR0-R/.@3XY\L7.W3F>
M)$.Y0^55ET5117Z5^A510IF)DERQ:6S9LT-7(#SC<6R9CRR$&8O"-A#R,D5M
MJU7LS3@3^F-*(D%OAWZ""XX&AHBISU1"Z\>B\?DJ_G01T"@4"@4"@4"@^*B*
MBHJ<HJ<*B_BB^J4%+Y!CC5V.+,C/R+9=K>VZD&\0G$"3'`E$RBO,E_!N,"00
MI[D=_EI>$+H2(M!U;3DKX2OY+DD+^4W?WW68+R.B]:[\R!*H2K3*(U)'S:X,
MXCG$AKKPA@/?05DA(7/"HO"\+PO/7\J#[0*!0*!0*!0*!0>?S^H)ARYVE?$9
MF),2`[_VU=;A&N7V+%T&T7.1C>5Q;5=3MLA^,U/6USI(R$8,_:>)M`<0FR)*
M#<IXVZ0M/C=HO6>C;)D%YRNWZWQMJPADV0A`9O.02EE29]QO$^-:HT2V0W;C
M<ICKJ,1V@98$D;!.T4H.CY#Z:R#<^)8Y:L.V=>]/9CB.PL5V)C6=V+'\>RM^
M#<L:*8R[`FX]E++UGNEJO-JN,B(^V?:0B[W@J$*4&O\`WSL/R-\)KQXY;*W1
MYAWC9FG\TWY!U?M3&E\9\%8>@XS>=4;8RQN\VV=K*.UF$,[1D6&0?=D,LRFV
M81/./->V)&`;7,:R&R9-:8-XL,]BZ6Z:RZL>?'429D_:2'8LA0,1`2]N6V8K
MPB(JHJITH+-N^4FCV_(?_LJ+G#"[Y3!9.R2P0;9=E>;PZ,XT!W(KS]C_`"!9
M)"^#B0TE+-]DD<5I&_JH,A$Y5$545%5$Y1>.47CT7CIS0?:"T^]-G6W3.H-D
M[2NDFU1V,%P?*<ECA?+O'L5KGW*SV2;/M5HD724]'9BG>;C':BM+WH:N/((<
MDJ)08[_'=Y095YA^*^"[TSG'K#BF9WJYYOC668_BKUQ>QB!D&#9MD&(SOY&=
MY>?O!6^0W:&W1^Y7W>XRY1$X2@Q/\H?/OR!TEY!X%BV)8+IR\Z#R+R0U'XOW
MG*<CON6M;`CYAG5BLF397D%K"VR6L92W8G#R"/;DAR!^\.X_6XHM*B*&Y"@4
M"@H78F>6S7>-2;_<69,YXG8ULLEE@>W_`#/),DNKPPK!C5I1X@:*Z7NXN`PR
MA$((I=Q*@HJT%O<?U2_DS+>0[C^RS')Y90IA8U+?6ZX!A4A(3(/VK%;'+BI;
MI3D0S-MRY2X[LV6?)H3(*#+07CMV.X_9Q(+18[3:@/L[PMMNB06S]L>QM""*
MRT)"V/[J*G"?A03F@4"@@=0E;-!7@NU>U?R+CE%_8M!HL^+8&C\X/F.583+<
M>1Y/XH!2E1$=FRF9NVHL@7![E51:)OM1>G*+0;U41$3A$X1/^3I_HH/M`H,<
M?,!Q&O%O?KJJJ(WJO,7%5/5$"SR"Y3]/2@R'C+S'97\VPX_5PG']B4'/0*!0
M*!0*!0*!0*!0*!0*!0*!0*"!P1,"$N>U>.>/7HJ*G^=*#QE[-\<K+Y'?U!V>
MS+YD%^QR%HS9^D-IOQ,)@PH6:9+<[/@4*Z8["C9/WE=+;:FI6-A]^PV)M76W
MNNPS:'Z7E#V16JY0;A#9DP9`R6'7#;16^\E8>%.YR,^"BCL5UDN4)MQ!-M?I
M5$H)K0*!0*!0*!0*#ISH$.Y1)$"=&CRH<QLV)<:2RV^Q(8<14-IYET#:=`T7
MA1)%1:"W`L7;7J$BG<<@P87&?:%'')=^Q!@G1$P'L;!Z[8O`:3N^HG9<=M%$
M4<`400N+`N,*YQV9EOD-3(<EH7XTR.XV]&DM&(J+C#H$J.A]7'*=$5%1>%H.
M]0*!0*!0*!0*`J<HJ+Z+T7]M!++G9[?=H;L&;&;>9<'Z>>X#9=021N1'=;4'
M8\EKNY%QM1,?P6@I8KM(Q`E:R%]HL;;"*U!R$E-'(AN.*S]I?&T[A;;'A%&9
MT!>[AQ![5)0KH#!P4("0A7A4)%Y145$)%1?1445147\46@BH%`H%`H%`H%!Y
MZOZC.))E>+7C\];W)H72S^5^!W^`%L1E+C*.R8?GES<B6]]WL6-<'2ABC1HX
MVB.J'*\*O`;Z\%RJTYWA.(9Q82D'8LSQBPY99"EMHU+*T9':XMXMA2FA<=%N
M24*8"N"A$@GRG*^M!55!JB^6')=:8CB7AO>MQ6F7>-9/><6N\/RUB!$CW"5%
M8VSIW?&F[-=4MDD^VYQK9D^PX+TE@6Y#A11<(67.Q14,@O"G(Y-@UM%T3GAR
M(FX=,-S<=S>)<60B2LAM?]X;L&)[*LT82(9.'Y_;%&3&?!2"-*1^&ZH.L**A
MJO:R5AS^HYNN(QP'[N'X<3\[N#AG#`';)<L:Q;&X3<!LG_OI=Y2Z6DE-H6NT
M8G!]_J*!Z*&^U&P04010![1145$'A.$14Y141/RH(Z#3)\_[3$CXL?(B-*CL
MRH[[N`BZP_#&<R?LYS8I;9&P;+X]S+\<7`+MY!P!)%141:#J_'7CODQKCQ.P
M'6N&ZKLF)GE]]V!M*V[5S7,;!<<)M6(;>S&\Y[ALR!B.,S)&99CDC^,WJ.Y]
ME,"SMLRC0'WU$"$@Q,^9B-C7B%I[P.N(G*N&*8CYQX]M?;6;9%S=[S<(5O6Y
M;#V3L3(O:'NDWF;<0>FFD9H190&X\=M`;8;0/2)9KU;,@ML"[V>6U/METM\&
MZVZ:PO>Q,M]RC-S(4MAQ.CC,B,\)BJ>J+06:\A/)O1_BMB%JSS?.=0L`Q6^9
M/;<,L]SFPKI</YCD]WBW&=;[/$B6>#<)KTI^':9+O1OM$&2552@Q>A_+5\>D
M]\8\?R/L?)(O\5[#MDQXPK_JB<E_#6V0,_\`51515H,>?(SY4?$-B5K:[8#M
M+#-C2L.S)_)[UBMR78&+A[<7&<@MUAO#,]-=7V.I6S(;FR1"30EQ]2+R"<A:
M\?G&U4V[(:<MVJ678K$:0^0;4V$,9E)1HRRU(?\`\`VXWNJI_2"*1$OX<=:#
M)WP)^3[$/.;9FW=76;7.0XC=]56Z'D4;,(=YBY5JO86)72[?RJW7/"<G>M^-
M7R1=([W`W.+*M+(PG?X8.NK]5!M3H%`H('$)6S05X)17A554Z\=.J=:#0'\6
MKJEYY?-HX!O?\!Y+84T'N>RBLRC_`,8Y"G'%@`!`[WQ7N)/<54^I5X2@W[Q"
M(HL8C52,H[)$2KRI$K8J2JOXJJT'8H%!CMY<QAF>+V_H[CC[39ZGS8G7(L<9
M<@66K%,==]F.1MBZXK8*B(I(B>OX4%_X)HY"B.)QP<9DTX]%0FQ5%3]"\]*#
MM4"@4"@4"@4"@4"@4"@4"@4"@4"@XW?]V?Z!5?P_#KTYX3F@\PVI[7(=_J!?
M*JZ-$3R%'T6S*<=LSD=IIG_#[*'08<N*`O9/C!`;!E#X^X:<-47A.H>D&Z8O
M)8O2Y-8+A_*9?0KI`[06SY"*`@`MVC]B*S.CHB^S,:,'!Y[74<;1!0)Q8<CB
MW@"85J1"NL9>VXVJ6G$J$:\\&I*+;<B&ZJ*C+[?+3J)]*]%1`J2@4"@4"@4"
M@4'PA0DX)$5/R6@M=<L<NF)R9]_PE@9(SY"3;SAZNDQ"N;PHI29EB<)Q(UDO
MDL413Y08<DP3WD0E1Q`J_&LHM.4PEEVIQ[^"7L3H<MM8URM4X!%7K;=H+B_<
M09['<G<!IP2?4*D/6@J.@4"@4"@4"@4"@XGF6WVG676P=:>;)MQMP!,#`Q42
M$P-"`A5%ZHJ*BT%KG8=\P0T>LD1RZXDV3LJX6",X;]YB/O.*^_(Q=N0ZGW,-
M5[U<MJFBBI(L;A/X)!<>WW.%=8K4V`^$F*]^X\V0D/<G".-EPJJV\PYR#@%P
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MT5?\RO\`8\>T5Y";/F:#R"[VW*O(/24]_`<KU#<G+[+L&6L8CG"G$8N=LM5]
MMCMGO;-RFPK%(F1GHKJ2EA2RC!BQJ@\<3Y[=*YKBNR,OVYC_`)!_%[>ME6G,
MLTL6.1[XVU9LV'';#!.;8<<Q=VVL?R%AW[F)+BI+&X`ZCQ=R("!Z;F^K;:_F
M`_AQ_JI^'X4%)8CG^'9ZF0'AV06W(FL5RK(L'R%ZV2`DM6G+\2GK;,EQV68=
M&[I9)Z>U):]6C^E>O2@U+?/Y_P#\L?(PNO+8X6ZBHJHJ>UE]H,N%3KSV"J4$
MNT_EF]LUM>E=,Z^V?!U%BN)^&>D<M@S4L4&1=[U<DUI@;]UG.R9(2Q<@6Y,G
MBM^S'!&X#<5YUX)2R&!9#7YYZ[%O'DQI#XZY>T9-ERB<SYQ2,(O\['HDA^R9
M3%A:MO%Y9F7>VOQ&8#TQRR218N4=MK[!RX(\C8M#_":#>_\`'?PO@UXEN?8I
M;>[QXU3VP`?62D5D<5A^RR+O<2&@-JGIZ>GX)05WGEOL.R]R:YQBXXU9<GM&
MM(-]V%D!7VU0;K%M%\R"T2<1P>/%;FL2V`N<^#<+Q()4$7&8T='.4!Q%4+L#
MJW60(J!KG!!0OWD'$<?%%X_-$MZ(OK0<0ZFU8)$0ZTU^)&G!D.&XXA&GY$J6
MWDD_70?9>K-8204I6M\#E>T'T(_A^//J*-IW`(([;B1.U4Z)^"T&DOPEMT&R
M_-/\GUGM-MB6:S0,"TA_*K7;8<:W6N*U*PK6<F2=O@PP:BL-RIS[CKB@`^XZ
M1$7)*JJ&_.@4"@X9'/L.\*HK[9\$*\$G1>J+^"I0:$/BF3W_`#^^:_OC(,=S
MR>PQI54$1F0;([*%5+\#<%'%1>?S_30;\FT00$11$$4[11$X1!3HB(GX(B)0
M1T"@LQY&CWZ!W4UT57M69XTG/[O+F,7,4[O^;UZT%V;6B);;>@HB(,&**(G1
M$06&T1$3\DXH.]0*!0*!0*!0*!0*!0*!0*!0*!0*"!SN[#[452[5[41!557C
MT1"5!Y7]*\4'F5\?9"N?/AYP-DW]HY`F:#8+V!D`4N/,U=DCD9Z2K@!'EB\2
MFJGW*3:CP*<+0>FQ4145%1%14X5%ZHJ+ZHJ?BBT%.WC'V[B7W<1W^67EEAR/
M;[S%`%EP@=(7'`('$./,C..#R33@]JISPHEP2!U;;D@C,:LM[;&UWF04@H3+
MKJ?;W6.R1JKUM><4?=<;;%%=87^,USRJ*"B:A5O^:@4"@4"@4"@4!41?5.?U
MT%"7S#ON;FF2V!]FS96U%;B)<^UUQBZ06GB?_E%_C"8C/@.&2]KB=LB.2]S9
M>HJ';QO)DN2R+?<H1V:_Q)#[4VUOOJZ+@M&HM3[4^?:EPM<UD4=;-M.0$D1P
M0+E*"L*!0*!0*!0*!0*#XHBO541>%14Y3GA4YX5/TIS04E=++/BNE=,8<8AR
M_=]^;:W%1FUWM51!=^Z06R^TGJV*($EM$)51$<0D1.`[5ER:#=Y$V!W+$NL`
MT2;:9*B$Z&"J+8.NAW*CD=Y[E&W04FW/]55X7@*DH%`H%`H%!YY_ZCYMTO"[
M7"0X2SGF_(S&GA:=NBV^![[FN-H-`Q/_`(B*\$UTQ;;X`T9<5#7M]:#63L[Y
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MZID7;9EYN>Y6]D95:+G-M>!(Q8LZN+T*XS(\U;A&E-QV`9F0S*0%X;(QJO1W
MS/>%&21=Y:8N6FK+\7>VM)NYX&S]?0VI.=XILW'<KR$LDB1L@%JSEE4C,VKE
M$`VFV'55\6E[HYB@;&M5_,SX2[5S37..VO:&.VFS[@O.Q,?US?[UE%CAN3KC
MK5^^C=)>7V)UQF7@%CR")CDA^RSKBZ#-P:<C)P#DID2"U^A_/#Q?\?\`7.V;
M[E6V,"5S9OR'>6.)81`M>:XD:7^[WS:F9W:VWBXW!+N<"R8?_+K.Z_(N\K_A
MV6U;X[S=:`PQ=^4CS;T'YA?%AY16K6FR<)MN5XUL7&];99CLS-,4NL^#+LVP
M\99O&08\<.Z/-9KB'\FN`SV;E;A>CN,`^W],B-(9;#7AY=[B\LO([QC\9K'H
M7PF\K]9;?P'7&M<(D[0A1LP<Q+,=52-8'8\OMRVG',3B2_YV]"]R7CL]75&W
MR9!D?O`H-*'-N7RIQO;U_P#C]\0-=^,FTO'FYZ)\C,6OAV#=%^!<MR6]9I89
M=BB'<1N-AM-[N-]R^Y[)6_3[W*%J/*>*6B(JJV@!Z2/$S#/)K7?C-IC0D[`;
M3JN^ZHU3@6NI^<Y=F-CV`S.GX[9F;3=[A8L3PFXF4\D.+[T-RX7"(CB%RZR*
M(K9!FCK/65DUI:+C;K:LRX3KY=Y61Y-D=YFNW/(,KR6Y=IW*^WR:Z#8+*>(!
M;:98!J)$C-ML1VFF6P!`N50%Z(J_E0:2/D8^3[:/AIY$:OTK@F%Z4OMMS_6;
M^;S+_N/8<G6L*V35R7);0VQ_>BX2K;A=MB1X&,2'A"XS8KDYTA8CG[B()!8_
MXDV-Y[G\RO,'S=V+CFGH>';KPC7&&VVZ:3W;A>X,0A9GA$6QVNZ8HDK%<ORE
M\;A'LUECS7G7_8$?N!$$(50U#T3T"@4'&ZJ(TXI)R*`7*<<].%_"@T,?%HX2
M>:'S.M(B,2VO*6.Z2JZW]PHN2=DNQ'B;;)7FP1DA0")$1>WZ>B4&^*'W+%C*
M2J1+'94E5555)6@[E55ZJJEUH.S0*"S?D02!H;<IDG*!K'.#5.BJJ!C=Q,D3
MGIRHHJ4%U;6O-LMR_G`B+_;';7^V@[]`H%`H%`H%`H%`H%`H%`H%`H%`H('`
M0P(2YX5%YX7A?SZ*GI0>1'%-HYA8?ZC;,+/98]N'$]I;@MNL<O&8$VX71E-<
M>,F<9C89-G))C<6V,R[DCOW)FT\GMBV`>VJ*5!Z\:!02R[6B%>H3T&<RCC3P
M$'>)$U(8[Q4%>BR6U%Z-)`27M,%146@H4+[-Q";%M^5/G+LYDU!M^6JA"*2I
M""#,/)HS("S"DR#$?;FHB1W3515&E7A0N4!=X"7"CW(BJ*\*J+^*<HJBOZTY
M1?PH(Z!0*!0*!0*!04SDN+P\DCL@;LBVSXAF[;KW;#&->+4\?M][L&7[;G:+
MJ-"CK1B;+X)V."J<*@4];,KF6:='QW-!9C3Y+HQ+%?6%[+3E)-@TBH*$(,66
M^%W_`%6\W%)TA-8ZN"G"!<>@4"@4"@4"@4"@4%)Y#B[%Y>CW!A]ZTWJ`/_N^
M^V\16XQD)T#>BFV8*S-MLL`[7F'4(2%54/;<1'$#J6[*C8F-6+(F&;?>77#"
M$XR^"VN\M"1</6R2^8K[X-<&[%/A]I%^E'!3O4*WH%`H%`H/.Y_4MM-%X`8W
M*-&VW('D=A$AI]SWU=7NP38L<XK,:&_'N$QJ6KZ=X-$@\#R7HE!EABGPV?&W
M/Q7&)[?C5%9*;:HEZ1],^VU'GE(OD./.F&\ZQG8=AO/.J1`/TB71/2@G!_"S
M\:YB@N>,\1\0>*0/N;#V\9E(<52<><)S8(H9]W455>4Y6@Y5^&3XVR5E7?&2
MW.K%1S[0G\[VW).(;K1QR<C^YF[R,NJRZ0]XJ1"BJJ=41:"3X]\.'QL2+*T,
M'QZ8N<4U5F1<Y6=[2<EW&3;94J*@RW6\S0W'+6XV3'441"#C\$6@J!OX:_CF
M$_<+QMMKQJVXUS*S?:LG@'U57A1',U%11Y57N3GA?Q2@@;^&_P".YE6!9\<6
MFFX@.M0P8V)M5EN&R\\$AUN$T.>($1MQYH#413A5%.4Z)032#\0?Q\0",X7C
MK&@O**H$MC.MEI+:(D!"<9?'.`<9><%H4,Q5%-!1%Y2@U=_,+\;WA[X]_'_M
MC;FG-(,8KLS"YVN+=CV7,Y/F%VNT>!D6?X]B]XCR/[P9%>HTJ&_9+N\R8N`J
MBV7:VH\T'H$\5W'7/&OQ_-YPG'"T=I\C(C,U4SUSC1.%W&I$JD:JJJJJJJO*
M]:#R6?((S//YZM;R(@R5<8V[XDM@+9F@2&I.-Z_.:JH)<.-M-Q4[^?\`:3UZ
M\![3U$5]1%>?7E$7_+UH/M`H/B^B_J7_`$4'C;_J!XN>W;Y"/$2T:PUB&W<^
M:U38,BQ77CL>VRH&7S\3SW=.73K->(EQF6]B5:1L6.2WGFR=[2;`Q%%,AY#*
MOX`/(G$RR?R*\>\CU/L#1^SMB9/;=ZX3@>1ZKBX!B<K6&L-)^.&C;Q=+--L[
M[^+RLH>R&'&N%RA07)!-!<FGG'/<=)$#T]4"@4'#(ZL/?A_#/K^7TK0>;;PU
MVQ<=*;C_`*A?<4>TMWZXZ8V'F.T8./7.0XS#N[F"8/N++85KDOM$3K$"[NV<
M6B(/J$#54ZI0>AC6>5.9WK?7^;NPV[<[F6$8IE;EO:-76H#F16*!=SA-.$B$
MXW%*8K8DO54'F@K>@4%G/(<%<T-N9M.$4]7YV*<^GU8Q<TZ^O2@NG:?_`(KM
MWZ(,4?\`JL`*K^U4H)A0*!0*!0*!0*!0*!0*!0*!0%]%H))=9P6Y(Y/M3I0R
MI#45MJ'%?DHVX9+P\^4<>]EE.40B+Z!2@6VXC,G7".TKK@PDCMO.'P(-276_
M>*'V="1UAHQ(N?P-.M!.37@#7\A)?\RT'C8L3('_`%'RJ!/*ZOE+>S<;9-6"
M!F-X=["<1TB50%Z.XZ[PZ`\J7T\ITH/930*!0<$AAN0V3+K;3K3G`NMN@+C;
MK?H;9@2$)B0JJ<*BIUH*$=_G.(//S.Z7?,85R7)D1_I=NMB:[1-%M[3:(=SM
MH=J_P>CS"<J/>*\"%:0+C"N<9B9`DM2XDIH'F),<O<9<$T[NA)^Z2(J<H7"I
MSZ<\T'>H%`H%`H%`H%!)[S8K7?K;(M-TA19EOE-(T]$D,][!B)";:H@$VXTZ
MPX"$V;9";9HA"J*B+04&MSN6OU;#()$Z^8P^8LQ[^BN3+G8"4A"/%O[0`+LR
MUDIH(3VP[F$3F6BBA25"YS+[<@`<:(3;<;;=;,#`Q-MU%('`("(#;,4Y$D51
M+\*#FH%`H%`H%`H%`H)1=[);KW`>MEPB1Y,)\0%QEP"1$[5Z&T;1-.QWP!51
MMQLA-LEY1:"AG;Q=<'E,1\A<*X8HH`#&4(/;(M)D\XVW&R..TB@U`8CHT`3Q
M3@W"07D!>"4+F-NMO#WM&)@J\(0KR*_CRBIT)%1>BIT6@Y*!0*#SV_U(<)V;
MX$8Z4:$W<)<'R0P6<Q&<15&0ZSA6RB:8)$7AUMXA1LFS10-"[53\4#2=Y!^'
MF^M=9%C%DTWO7:^Z(-VUZSOG,;>&.9V%VPC3600[->;%KXKM8=@S+9DNX(EJ
MRIDWKBL3'<;B0@AOSY<+[QM*#8=J7X4-J[:L&'[`LOR!74-?YC(L5^&X8[@.
MRL?S^%8VK@KF48XRMXW-<[=9<E5(KUO?27'D_P`NF`YW-&32"H<?R+_'OKCP
MUQ#QVV9;O(CR^R+&LZ\M-1Z-V3C![FM<"XWK`]J)E,-T,?G2;!'99OMIR.-#
ME(BKS*AC(CI]9M*`8;^67BUDFIO*W66NM+;.\O<KT1J8/YAYT7*PYK=+],L=
MJN&46.Q8EC.G),6WP+;!R^/:[Y$N%U"Z.M6T6I:,PS64,E@`OIDOA9HR3\AW
MC5XP67R;\KWM3YKX>[5\MLOS^?N&SC`NV.6JY8K`P6%8W8N.1ISD%NUOW.=<
MYCRJDAMR/V]AMER%C_%K0%SV)YD;`P_9^R/.+%?"O9V57C7'B/LN9E\ZV95-
MS/`KGC\'(2VE>8T:;8+=B.9W2_/M8@Y;V4<4V?M[JD=U$5`K;;/AI)PWQ<WU
M=]>>1'F)F?DE#\L]Z>/OCECG^(3]\LTE_`-ACA>-7;.K)`LCU[EX/#M\N)(O
MLB"#UQ-YYEB&RY)D--&%H\^\.<2RCXOMG;YV#MKRM;\B=,R<>PC>FI]JY)[6
MNF]AR<ZM&,3[]9L8EPHDF1KR5%ENW2PDZ;-S;1EL)+4:X-/,M!L@NOR_>3WA
M?XC^.NS=O>!"XEHV\87IG7&%[)O^Z[?[N076]X*RN"!,QVQ8K>;K:Y676ZTH
M;8NCVLNN()D@HI(&(7D=@_E9E7R1^-GDSY`Z*;\=X.T_(7Q_PS&K/.S:TY7%
ME73$8V&1;Q`B7JSHS+]YZUVF3<&O^#!'/MU9[EY5%#V@4"@^(2%Z<]*`7HOZ
ME_T4'F"^6^S9_C'R8>(.[,8P38&26O!=(9:LF[81K.?LE8YOL[MQ:;"*U#<[
M!;+A,%K9<9X(;EP8=<$5)!-$XH*6^&VQXEDGF+->O.7;RNVX?'KQRS3%K@WM
M[46)ZMOF1V[;>;:QN.3W_,6;)MK/I9WP)^'VQ(,9FTV**,,A45?[.:#U3T"@
M4'$\G+3B?F!)T5$_#\UY2@\FERNV88/9OZFVY8;B>+3+P_\`<0I=IS3/XV)6
MU_&,SUGLV%E61Q<A:M^1,#D$>Q7Z3/L]F?;86XRVV()NQ"D(Z`>CGPRN^4W[
MQ)\:KSFUKQFRY1<=(:SDW:UX;DQ9EC$-P\2M21V[-E!VZU+>XI0T;+WTCMB1
MDJ#R*(2ADO0*"SWD*BEH?<PHO!'J[/!$O]DBQBYHA?FG"T%S[.G%IMJ*O*C!
MBBJ_FHL@*K^U4H)E0*!0*!0*!0*!0*!0*!0*!0*#XJ(2*A(BHO145.47]:+T
M6@^(`"I*(B*F7<:H*(IDB(*$2HGU$@BB<K^"4'QPD!LR+GM05YX157C]2<JM
M!XP\@NM_Q#^HG)_%=:W_`&5F0^1L&ZNV2T?;Q&++@F9^/[V(W?.[M=WV)D*-
M"Q"SW6Y7'[=7(\J2$-P6Q<)41`]FT12)E"(_<4R,^_@QY0C51_AF;BM<#PG;
MSPGY)Z4'9H%`H(2`#X[A$N%Y3N%%X7\TY1>%H**E6&599TB^8S[:%,>]V\6!
M][V+;<S-10ID0E$PMUXX%![T3VGO0T[OK0)GCF36[(XSKD)T_N8<DX5T@R6C
MC3[9.$$=6'-BFG<V\C:\HJ*0$G42)%YH*DH%`H%`H%`H%!`XVVZ)`ZV#@&)`
M8.")B0&*B8$)(J$)BO"HO14H+13+/=-<"[,Q&)(NV*D3[TK"X:(_=;8;SYR9
M<O#0>,$DLF3IF=L-P&QZDP0K_#4+F6F\6^]QDFVR2W*BJO:CK9=1<3E'&7FE
MX=C2&23M-MP0<`D5%%.BJ$TH%`H%`H%`H%`H.O)C-2F'F'0$@?;)EU"$5[FC
MZ&*H0D)"HJO1445]%3B@MN5MN6#/(_8FG;GBJ$\Y/QEDW'[C:4[77DDXFT7)
MOM.NGP=N(^!3JQU^A0KFRWJ!?8+-PM[X/QGOI144Q>:=[>XX\J.Z#4B)*:1>
M#:=$'`7H0HO2@F]`H-"']1"'N>"=N`'48DIO?$'H+I'[8C,C:_V/+!%ZHIDX
MTRX(BG7O)%_!:"L-!Z+WM8\$QS;&N[1A^>VWR(\0=#VV;-NTV-!N^%Y3'TY@
M]FN:JU>)$1N399H0#>9%'76O=<::DL$$5OO#9)XC:9R316C\2P7,<CB93E;;
M^39!DES@,N1[:Q>,OR:Y9+)LMF!QI@WK-8&[@W!8>-MHY`Q4>5MKW5;$-8GS
M_N`QXQ^*C[CB-@S\D7AN1+U3N[\LOK*-]/\`TBN]OY*B\4$>Q-3>=.NLZ\H[
M'IK%];YWJCR/F95DT'8N8;`A6:]ZGEWG(LC=R>PWR)=[J46U1\23(+J=OF1H
MUU@G%6)[L1N3%?9E!A1#UY897S'^+OCI;=DXWL"^V;X?-\:[S3.[)<+=>K9'
MR+*,_DH;Z6R$[(2(U'D75QR-">?]Q+8VP)(J&I4&P(/';S#S*W>,VG;AC&M\
M.P75&=RLKS?9+=ZL=ZN$FVV_*!O+SF,VV+$<E72Z91#D2&H"E%MWL/O?=3'4
M>B"W)"@L.U+N7()-^W#IG',7V%>]._(OYOSKK@=_OQ8S)NEBR;;$80NM@N,A
MV/99MUQUVP](4I^%[HR!?9E`Y%2/*"RWR(:DV;B_QQ?('L;=EDQ+'Y^V)FNE
MMN)87,=E%;[9;MG1+C%NUZN2D^RY>7;MD'\-MI]__AXHNOE]R^Z(AWHFC](^
M1ML\2L7\ILFG'KW`O`'6,S`K.ETE6ZWMW7,M"V+'\QS&+R_+B7>^R<:N5Q[0
M<C&Z@VEGV27^,T\&.FR[C<[KHKXB+',?GWFRXM\B^/X/AEVR1;NY<GL/Q_&[
MA)MD8)TZ5.>N;.+73[FS,N))DM+'MZ-&X;@.4'K+H%`H%!\7T7]2T&A?Q'BM
MROG)^3>Y.&Z<BWZOTM;&T,R)M(DO"M.3$!`4E1%:D044.G`]Q<<=RT&^F@4"
M@@<#O`PZ?4*CU]$54Z+^Q:#RWWO`\&V#<_ZE[%<UQ"R9M986'V3.0L656UJ^
MVEW,<*T-L'.\*O*6UX'4<EXSE5B@3H:HBFU*BMF'!"-!Z"/$+`L,UAXL^/."
M:]L5DQK#<>TYKYBQV7&XI0K%#8E8S;KC(6UQ3;:-B+*FS'7D%0!>7%Y%/1`R
M+H%!9[R%7MT/N8__`$>KL\/IZKVXQ<UX2@N=9NMIMJ_[4&,?7_GM"2)^Q%H)
MG0*!0*!0*!0*!0*!0*!0*!0*!0*"$UX`OU+0>7[1+G?\_?F)`*1!&(YF^AYY
MA+=CNN,SX7CIM[[1N%%,Q?CR9Z"XO>*+SVJJHOK0>H)$1$X1$1.57A$X3E5Y
M5?UJJT'V@4"@4!4145%3E%Z*B]45%]45*"C+]B[DU]+K9I3=FR!ML8[=R!A7
MFY<(3)Q;9=F$=9<F0#7]SL-MZ,?U-&B(HJ'<L5^;F'_*9[!6N_QF5<E6I]WW
M5-L"03E0)2@T-RA*1I_$%.1[D0T%5ZA4]`H%`H%`H%`H(2$23@A0DX5.J(O0
MDX5.OYHO%!;.[XC+M-S=R?#I+,&Z/JCE[LK[BQ[/ES3;:MH=R<!MTK??(X*G
MM7)L%<(0%I[O;ZH%38[EENR+[EAH)$"Z0#%JY6:X-*Q<H#I(2C[S*\BY&?0%
M)A]LC8D-_4V2]>`JB@4"@4"@4"@4"@^<)UZ)]7[W1.O3CK^?2@HF]8Y.:F/Y
M!B[\>+>'`C).@35+^47UJ(3J@Q*01/["80/D(RVP5Q%04-"!.V@F>/Y&S>FW
M&78TBV7:&X35RL\U!&7!=1$)%'CM25`<$T5F2">VZ*IZ%R(A4E!H3_J&823/
M!JT@LE(ST3>^+W"(9*/#DN/KC:"L,()?[Q7"?_<3J2#TH-P7C=;(]G\=M"6>
M/[91K5I?5EM8]OJTK,#![%&95OGE>Q!:3MH+THB"G`H@HGHB(B(GX^B=*#39
M\U&J<@WCJCPPU1C%TL5DNV6?(YXQO?S;(RE!:H-LQ"#L;/;ZZX4)B3)24=BQ
M62$?M!1^X,.]0#N<$+ZZ<U'*\E;2UL_>$B#D^KKS=<EN^F=(O`_(U^[B#^9W
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MM<8GJ*3N#,<1Q3,,'M>8:IQJR:ZV!<.VP72^YGA&)%>\??`9]PM\*&Y%;!Z2
MK(=O(6T^9.^8AKS%OCFS^TE;;5K?5_F'@68^WB5OC383V"67![[)6!BL.U*,
M5V*_:.PXHQ_X;K8MBUT).`R`C_-[X+25C"-WVJV<Q'3BMN:QNW>\TTZ;1/"(
M23X;(@7CGA>/5$7I0=9KYR/`]R8Y;SO&VXLUM55(TW4V11'76^.1D,"^0*]'
M<1/I,>46@[,GYO?!.$9A.O6U(/8VP[WS-77N,RK4D5-IU)#SH,")"BK]1"OY
M)01K\WG@?PT8Y)LAV,\)$,UG6]W=@H(I^\Y*!XF6Q->@J2HBETYH.!OYP?`V
M0JM,Y%LQQY04T8:UK=WY"M]45P66)#CA"*^O">M!B[\;^V\%WY\J/GKNS7,^
M?)Q+8.MM>OV./>K4Y8[\C>.6_6N)WG^:6I]YR5`.#>+0X`"\@F8$A(B(M!Z'
MZ!0*"$T[A(47A2%41?RY14Y_90:,/!_&;/E?GM\U^%Y)"8O>/95G&D['?[5/
M1S["X6+)]<YG!NMI=2.XS)^VG6V:;+RH8FJ%]!#TH-W&/6FWV"PV:PVB'&MU
MIL5K@6:UV^$W[,.#;K7%:@P8<1GDO:C18K```\KVB*)03F@4%H/((D#16Y'5
M3N%G5V>O$/3ZQ:Q:ZFH=>4^I!XZ]*"Y5B7FRVE?SML+_`.#-T$UH%`H%`H%`
MH%`H%`H%`H%`H%`H%!QN_P"[/]"<_P!B\T'FE\>OL9'SV^;,@H\9J5!OFB(*
M.E=BCNR#=T+M)T#*$K1MONM@2B#:<$8\EW)PJ4'I>H%`H%`H%`H)!?,<@7X&
MED^ZQ,BJKD"XQ7G8\V`_ZB]&?8<;,?JX[P55!T.0-%%:"0V^_P!QM5S>LF4Q
M&F#/M6S9''[&K9?X[3+7N)*'A&K+>&GW"18YFK;K:=[1KU;`*[$NX1)./J1%
MZ+RG7KT5415_LH(J!0*!0*!0*!PG//'7TY_'C\N:"DLCQ=;R3$ZW7*18;W!3
MF#=83++I(B."X<2?%<1&KI:Y2"H.QW?P7N;)MQ$.@Z5ARE]R:5@R.)%LV1JL
MEV+$;FD_!O<-E1)RYV.5(%HY,8&W$)YE1%^,7*$*CP9!75`H%`H%`H%`H%`H
M*2R;&V[RT$IB?*LUYA*I6J]6_P!M9<-TD[1!QIT2;N$0U)>^*YRTYRO3NX6@
MEUKRDH<^!CF3LQ+7?9:NI`<C/.?R>]M-D2(_;),H&B":XB=QP24Y#:JO"N`B
MN4&D+^HE-?\`L)X\ZB(;;?D%99#W#[D?M:9U#N)%(3#M?<-EWM)&P$C,A011
M>>4#:KX.Y;9\Y\,_%'*[#=(-ZM=Z\=--2F;E;9P7&&\^WK^P1I[;<UM2%]R+
M<&'67%Y[D=;)"X5%H+Q;3VUK726'R]@;:S?&=>83;YMKMT[*<NNT6R62)-O4
M]BUVB(].ED+:2;G<Y34=AM.3=><$43E:#2KYY^4NDO+D/$#2GB5Y-Z3R;<^1
M^8.+);9..W#_`!-DX19WM)[XLU]SN7BF/W6R7%^'C;%W14==D1XS<AQI7U)M
M2;,-T^J\>@8KA..8W;HT./%QZTL6-H8+3;48SM1N09<IL&A%MIR?-9<?=:'H
MR9]G*\<J&LC?WQDY3N/Y`M5^9EHW%8;%B6%W'45XRC6EUPFZ76^W>[:BR-R^
MP'L>RR+E=NMUKCWEN+$COA*MDLP$7U`^'400V>;2P.+L_66<:XN$S[*+G.&9
M)B,FXM,>Z<$<BL4ZS+<&(WNM=[D,IGN@*.`O<"<$B]:#7O\`'QX';+\3MD^2
M^U]P;BQ+:V=>0L_%93[>"X-?<&L%CBV#)MG9?-==BW[+\OD3KA=K_M&67(NM
M`RTTG0S<<-0EGRI>&6RO*G1^2Q-3;`QK!<GC:XV!C^0+D.$WS-W<LQ1Z9B^?
M6O&[):;)DF/\7],PP.(W%<?26"-SGQ%DG#!4"1_"5:W6?`7$`G8_=[$U<]D[
MNNT.V9+9;K:ISEKO.Q[Z[%D_87^!;[@L.6PI().,A[H=>%%450U6?*TS>,*V
M%XH>+V'8]D=U8Q#SHU#M;4]C@V3)7[+;]3;`LMQ>R#&+;/MMD=Q^'CF$[`L=
MRB1()R5.)!GQ6U;".(%0>KD;)9AX4;1:Q5$X3M@1$X3UX3AKHE!&Y:;4Z8N.
MVRWN."*`)N0HQF(IZ")$VJH*?EZ4$+MFL[X*V_:K:\V7"$V[!BN`2"G`HHFT
MHKVIZ?E08G>4>O,&NMLU8]D=IN4?#+7M2P1<I8P^\Y!AK@6W+K?>,'A72[3<
M/O&/R7K'9+]D4-^0CY/1V`_C$WR`F(?6O!GQ]:(B:M>R&#%?X;S>]-SHYTX7
ME/\`Z.E1.TD]%147\E2@J'2OAIXX^/>;9=LG5&N(UCV)G[+D/-M@7?(,MS/.
M,CMI2X\]FTS\IS*_WZ\%9X<J&RL>(CJ1HXAVM@*=*#*&@4"@+U_M3_,O-!I*
M^/N:#GR3?,2R0"VD79GCPIONR72`D<P7+N`1DU^WCMM_;]R**=Q&7*KPG%!N
MQ:,'`0@,'!ZIW`2&*\*O/!)^5!R4"@M-OHT;TAM\U'N0-9YP2C_M(F-W+D>J
M*G5*"O\`'`4,?L@JO*_RJ`7/_2C-EQ^SGB@G5`H%`H%`H%`H%`H%`H%`H%`H
M%`H('"[&S+IT%5ZKPG[5X7B@\GNK]HX7J7^HE\H;%F,E&)6W<GU4SC5R$7G+
M7$/'?'?-6KFESDML/)#=B2[Y;F.206Q.<*N&V*(IAZP@,7$515%X517A>511
M515%_:E!'0*!0*!0*!02V[VF#?+=*M5RCLRX,UDV),=]L'6GF7!4#$VS115>
M"Y%?42X).J4%'),D8-';:N3\N\X^V_\`;L78@23<+!"43/B].`B&]:H+;0B4
ME4)T41"=4EY-`KYAYN0RT^T8.-O-@ZV;9BX!MN"A"8.`I`8$B\HJ*J*E!RT"
M@4"@4"@4"@I_(L?AY%!*'-5X0$7'&'8A#'GQ)G:BQI]NG(/OP9\0T[FS!4Y5
M>"0AZ4%+0[]=L7?C6?+2":Q)<CQ+5EP";+$]TNUEJ'?F6VC8M5X(0[O<11AR
M2+@%!Q5;H+D(O//Z%X_R_MH/M`H%`H%`H%`H''/K^N@D]]L5MR.W.6RZQFY,
M9PVW1[NX76)#)(;$J+(:)N1#F1S3N:>:,'6R1%%4H//I\[SF96/Q6UQC5X8=
MR#&#\A\>_EN9J]`>NS,D=;[8AQ;+DEK-V+(D7"2Y+!R+<XB.=XLNC);;54(@
MRX^#4Q+XK?#%!5]1#6^1M)]SQ[Z^QL_.F55Q$Z(O(>GX)TH,L=PW.#L'=^G=
M*V\8EUFXA=@\@=A1O=5UO'\;Q)JYV77+=S:;%U&IF7;#N;;D%EQ$5Z/99KP\
MC'*@RJC6Z&RC+HPX3<D!3N?9B,-$IJ'8X0*`J0(XBKZ$O1>*#KV6V_RJ._%2
M4],1VXW2?[CRHI-_S&XR)WVH=O1&8BR/;!/P$:"<4"@4$)"A<<\=%14Y1%X5
M/14_)46@BH(5'\NGJJ\)ZJO"<_KX2@BH%`H)'D>/6G*;+=K!?8$.Z6>\VR=:
M+I;I[`R8<ZW7%DH\V'*8,A%QB0RO!)R*_DJ4&,]J?VGX]6!K'UQ[,=_X#;)!
MQL9N..R;'(VUC.-1V_\`@+#DT#)KS98^Q$LL=I8[%SB3%NTID6_?C/.]TAP.
MWJKS*T9N#=.<^.N,7?);;N[6N&X[GN=:WR_"<JQ._8YBV5%'2Q722[>;7'M$
MUJXI,;5O[23(_>Z\(E!E30*!0<;I^TTXYQW=@$?;SQSVHJ\<\+QS0:1_`EM]
MSY)?F4$G?^'7,_')EIGV^K;CV";`<<>[^[Z^5:3IPGZZ#=G"3B)&1$XXCL)^
M7_F@_"@[-`H+->1<C[3Q_P!X2_XO_":BV/,X8<1EY?M,/O,GM:=4'$:,O:X0
MNU>U5YX6@N!ADG[S#\4F<&/W>-V.5VN&CCB?<6R,]PXX@@CCB=_4N$[EZ\)0
M5+0*!0*!0*!0*!0*!0*!0*!0*!0*"!Q>`)?R3G^R@\N&H=76'./ZAGR.V-=Y
M\E9^KIMIQ:SXX#[$FQW:%MKQBR*%E#^36J7$=203<7!H@0_:<;`0=?\`<$_<
MY0/1&Q:KOJ<I#EE"X9%KYD1=7%HK)R[WB,=L/XSV+I]4B\645-5*VF9/1Q'F
M*I_[E`NU9;S;L@MD6[VJ9%GP)C?N,28CPOLFB*HD/>B(0N-DBB8$@F!HHD**
MBI036@4"@4"@4"@@<;%T5`T0@+E#%4Y0A5%115/R6@M]<[?/Q,SNN-0W+G!>
MDD[<L8%P/?5'4,I$O&G9+H-1YO/\0H9+[,A45&T!PN2"H\=R&W9%;VI]N?%Z
M,K;2$I@<:2PZH#[D:?"=!MZW36CY$V'$1QLDX)$Z<A4-`H%`H%`H%`H.M+AQ
MIS+L:8PU)C/-FTZP^V+C3K;B=I@X!<BX!#T5%3A:"V@L737I,M,?>7_#0X!&
M`"1-OV+1NY\@+E779%\L+*=C:#P<R/\`O<N-\HV%Q[=/BW2&S/A28LN))'W(
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M_LYH%`H%`H%!`:]K9KQSV@2\?GPBKQ0:8?'PNWYK_.X.SA'_`!:\:'17CA!1
MJ);FU$>G454_PXX5*#=#0*!00'QV$J\=$[OJ7@?I^KJO7A.GK0:6_`*8^_\`
M)+\PC3\>:B1-C^.+#4MU@6X;K)Z_R5P6F'4-5-R,)<FG'[BH7/7B@W2A^ZG[
M?]-!%0*"RODD7;X[[X+CGC3.T?T?_P"BWZ@JK!KG;K;KG`WKC/A6]I</Q04<
MFRV(K?>[9X#;0(;[C8J3CBH(IZJ2\)UH*_$A)$(50A7T45147]2IT6@^T"@4
M"@4"@4"@4"@4"@4"@4"@4$#B<@:?F*_Z*#S4^-</WOGD\X)1NR/^%S33)LL]
MZHQ_%\8=DMN'V<<+RLA>OYI0>EA414X_2B_GU1>4_:BI06HN>&W+'KW,S#!#
M+[R8/?D&(/R`AX[E+R$*I<`1N.X-DR=&OH6<T*-21[1E`YVBXV%5XGEL+*81
M/-L2;7<(I,LW>PW06X][L4V0U[X6^[0A<=1B2K2H0&!.,/A];1F*HM!5M`H%
M`H%`H%`H**O&+=]P&^V5V/;KN9MMW!7&N85ZAIVI]C<XS?8,ATR$4;DKR^QP
MG:JBG:H=JR95"NLJ3:'0*W7ZW-$<^S331N:VTV[]O]_&`_JFVB0Y_N90<MN)
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M9MVWIAUA*Z08N)R7%Q"WX?L//,R9?7-+==+&S!&Q80Z\_P`M>^\TR3+)"ZZ*
MT$AM'EA+8U+JV]Z)WO&\ALEVMM6_X+@V,Z[U7CEN_O'=;C9Y^V[H5RON>WNP
MMXEB&+:\E!?9E\E$[$.VOLE%20+C)D%T(OE=F4;!-IY7M#)GM*Y-HBSXUD6P
M]>R-?8;LNZW_`!O-FE;U[?M=9'B^=1\<S*'L&Z*D"`<4PXNG,9P05.:"JL6W
M9NJ]YYAF`Y[/?T;?LRCY26,+?\)UUG]OR"7AUJ@Y#D=AN5VP[94L,'RV!8)O
MW)VN6!&3+3A`X2APH6<D^<>>N6;$MC#;<DL?CEF69X]B-G\BIV%ZU<M:0<OR
MW_#[#-@W?5[^S(V>6K4^79BXW'B7MX![F7F'T94'D[0KW(O)W<-DR;8.#Z_M
M=]\A[CI*;'L>W\CP_"==8-&MV5.8_$S*=AN(63,]CP)NP<SLV&36KC+A6ON`
M&G6FD<5]SL$-?_R-^<^\=6>.V,;`\=O++$;SL3."U_L7&M?6C4F(8KGD+3-\
MQ^^Y]>KW<UR7(<S@J5JQ;%WI4B`<-JZN-1Y'LHVK1$H>D1E25II3_?5L%/E.
MU>Y112Y'_5Z_A^%!R4"@4"@XW4Y:=1?16S3\O]5:#3CI!1_[Z3S'_P")CN)_
MV1="*,=LU5Z$/WMF1&Y(DB().E]8\<HHJGX]*#<E0*!0?"]/U\)_:J)S^SF@
MT7^"UP`OE;^77'U??`IA^/UX^W5U7(Z=UAR6QC*:CJ@HVZJL=I*BKW(B4&\N
M.G:RT'K[8"WS^?8*#S^CGB@YJ!062\EA[_'/?K?7^+I7:C?*=53OP2_)SQ^-
M!JZ\W?`?:OFC;_'R/CF)^*UUU;9-78O#V++V;`O5EWSDOVPQ[C"P;"]LP-;[
M,77&N)2'[MQ.V0X]^DO.N#'FPT_B&&T+QMU>WI?1VMM7,X1@.MV<)QX;(S@^
MK[SD>18'CS34R6\W$QZ_9?;+/E%W8=!Y'GI$Z,W)=DN.$?<J]Y!?"@4"@4"@
M4"@4"@4"@4"@4"@4%G-N[:3508,JXY+R)W/-BXIK:W-Q9\2W,P+KEBW)(ERN
MLR8A-Q;5'.W(TJB)N./R&FP'E55`X[UF^U8\9E[']36J^*3BC)1W9MNM`16@
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M/62^1#M\I/\`XLN*J)V[(&FV^YPX3HK_`,//8+H[%-$-%5%!2%>:"KA)"1"1
M>B_VI^A4_!4H(J!0*!0*!0*!04A>\9<E.'=K-*:M61-LN-MS%CJY`N`+RHQ+
M[!!P/OXG*)]2*+S:IR!IU%0Z]BRYJ7.>QZZQQM.31.#=M+KP*DF`A"R%YM+W
M*_?V=\O0T^MIPD:<023F@K?GG_+]O^B@4"@4"@4"@TH?.K@>?[$\-H]IUYA&
M5YQ<;7M:W9!>XF)6>?>Y=DQ>#K39<*Z93<8]M()35CM+]P8&2X/<3?N(O:J4
M&OCQE^<+&M$>..AM,CHL\RFZ]UYA&OTR*)LI^UQ;\_9;*Q`=N,>VR\#N$Z$+
M915%UMUTU%Q>A$/6@NP/]1GC)3'(P^,+Z@*RA!PMR,@9E'9><1%:76:J*F;7
M;QSS08'?(3\K3'GSX_6#4^-ZZ;TE?K/L6VY\SD\C9K.4\Q8&$YWB]PM,NU1M
M;M.A;<AMV7NLN'WB:,*0<B1HJ!9#>'R59;G>!XSC>NO'GQD\;+K@4Z\9)KC.
M]2[`V/'OUFNN<X!(P?/XPX["UI:K%?/\1,5NDJUM1YJ2"!MJ,X2*3`=@=;1_
MR'9)ANE\XU_G>F<(W>.78Q@6KDS"3M/:6/9I9\`T';HSNI<.A?9:QNUNM=PP
M&]13DI*#[=VX3S4W10^*!X\_(KO72NSQSS8.&6#>)KF>PMGP;3D&=YQ:&[5M
M?8V)6S%L\RR.<#3[DB>\YCT=N)'8)IL(C4V41.FXX+8A;"%Y5[3C[68EO8A=
M+[HYTL!QE_Q[D;"V+<&YFK=39Q-VIK_6C.7Q-41KBYC]IV!=ILDC0WB=AROM
MD9!665:#(K(O([S2\M-O1_(/Q1\:-EX-9\,WQ=LWSM=87C9^=8M)\AH6KY&G
MLXE/Q)6L8,_%,ADZ?RL($L0C-*W+$'O;>-![0JWRV7RS\F](X1IO`?BZV+HS
M*,$A8-B-IW06*[$R[.+MK##[;>+!)P*7=KUI?''1MV8P,E?8E3_N0E1VY4CV
MVB!TVZ#U9^&7DQ)\L]&6W;MSUQ>=/W]<OV-@65ZMR:<=PR?!\KUCGF0X#?[/
M?I!6RS\33FX^LA&_MP)II\0/ZQ*@J/RO\@[=XL>/^RM\7/&[EF@8#8VY=KPB
MR&\W?LZRF\7.WXYAN#6`V(-S<"]Y?EEYA6^*OVSZ([(15'B@U(ZM^;?.=OGD
M4;`_C[WEF-PPZ[2[#FD#"KW<LLDX7?XRS`/'<J"V:S+^37QF3#..ZRXO1YEY
M!4D;6@O2'R=^0X1ON9_QA>5#*J!.-M1(M[FDO**3(GSKN,0&YPB*B"7:J_VA
M+(ORM[I^V5;O\7OFK%N)R3&-`M>$Y#>&SA)[8A+>EEA=M]APS54]KVRX1.5+
MKQ01!\K&ZG2<:_[K3SD;:&",AR06"W0&0=<=..47D\:1Q71)LE14%44>%_&@
MQS^/[?E[WW\NOF/E&4ZQS+2=U<\7]5P`U/LRP/6;/+)$QN\8E;DOMSDN18C4
MFS9)_,1DV\5`35I%54%>40/170*!0?"ZB2?H7_10:$/!)1<^9'Y:'U(1./CN
M@(J-\C]39ED[A/%RJ$B`H<?EUH-]P?NI_:BIU147T5%_%%H(J!06<\BNGC[O
M5?RTWL[_`/(F]T%8ZYZZ]P1?SPW%_P#YD@T%94"@4"@4"@4"@4"@4"@4"@4"
M@4%F=^ZQN6VM6Y-B./7Y,4S)?Y5D&O\`+'(Z36<5V#B5W@Y-A.02(1<I*@6_
M([5'*6R/U/PU>:3]^@I+0N^8>V[7>K!>+)(P;;^"2&+/MG4]\_AWW#[ZZ#0I
M.@JXOLY'@61%WR+'>H/W$"?#X17`DMOL-!KR\27HK_S`_*,]'BR(:1=:^),"
M6<E4[)DYO%LB??GL'T1([X/@(IST[%H-T%`H%!2.78;8\P@##N[+R.,.C)ME
MQA/O0KO9;B'^YNECN48@E6VXM)_KMJB.#]!HH$0J%(6;++UBS]OQK/15_P"[
MD!!L.=MQ5AVK(7G5-8\.^QFF!:QC)G^B>V2#"EGRK!B2HP(789=1P$+N!27N
MY0%_=45X453E50PY1"3\%H.6@4"@4"@4"@Z<^WQ+G'<B3F0D1W!(3;-/S3A#
M`TX<:<#_`%2!1)%ZHM!;F)<+UA+TIC(Y+=SQ9>Y8&3.A[$ZT(UV,M6_)E4B2
M9'04X:N2=B*B(+R(2]ZA<UIYIX`<:=;=!QL'0-LQ,3;<'N;<`@(A(#'J*HJH
MJ>BT'+0*!0*!0*!0*"E\HQB'DD1$==>A7&$CCUGO$)09N5FFJ!",R#)45427
MGAQL^YEX/I,52@IJSY7<;&];\<SQV,ESD/Q;=:\I:99MMERN2\TI@#4<I#J6
MB_D(\N0G%$7512C*:+V"%S45%]%YZ\=/S3U3]:4"@4"@4"@X9$=J2R['?`76
M7VR:>:<$7&G6C3M<:<;,2!QIP.1(514(55%Z+04-$U7K2W^V4#7N"0G&1[&G
M(N'8['-L>.%`%8M[?8''X)Q0=O\`PZP1.HX7B`FG423%['R)?[2?\#Z]5_MH
M!:YP$VS9+",.)EULV7FEQ>QJV\PX*BXRX"P5$VG$7@A5%14]:"T+.J\/U:;(
MV;!;#=L`[X[0V$<:LUPF8&VPVK3#V.-?8A*?Q>.R*DY$)UUR"*D4?^'RS07@
ML5IPF=:HL_'[=C#UIGMI.BO6JVVE8+H/<D3S2L10`E,E7N54[D+E%X7E*":C
MC5@3Z@LUF%2X52&TVY%)/5.52/UZKS04WF%JM-KQ;)+A&C0;5(AX[D,AJZ1(
M,:/)MQ-V2>7WC+L9D'A<8_>3M7GE.G6@T4_TXMU=O?B=Y&W:5.EW2\7+S,V1
M<<AN<]V9*N=UO]QUOJ";=+O=I]PD29D^YW62\4AUQ3[45SM1$XH/0KV_\XO[
M:#$77\Z!I3<.;ZNN48[?9MT91D&W]9W8F18LL_*;K&@O;-P%9G(`&4!=XCU_
MBL$A'-A39#@*11G44)%\@+SB>-ER**K9.CMCQI5.YL)(CSY,Z=5>]I>X23LY
M7]''/X4&K3X"(42/<?D>DPWC1B9YD9HC<)]UMZ2PW%RK8,?[DR`$)MJ6\)H`
M*1=6B<7@W#Y#T24%OMK8W><PUIL'%,>O#U@OF28/EEAL]ZCONQ';7=+O8IT"
MWW`)L<FY,-8DM\'/<:(7`[>15%1%0,.-*^,>A]AZMQ/)/Y;LZ!,>M+4#(+-(
MW?N"1/L^5VH/Y9EU@NH/YR^0S;-D465$,"Y%4:[DY`D50UJ^'V>:JUK\Q?E!
MXOZ\UU`M>:2K5?+SG>V+\^_F&>Y3@F/:]\=K[@.-R-BY->L@S61%M][S6X@W
M;9;P0&XT4UALAV>Z8>C*@4'420X4IZ.D=]!:;CN(^0"+#WO&X)@R[WJI.1T;
MY,5%.A)PJ_@':7T7]2_Z*#01X)0&GOF-^7*2KI(9XYH2WD"(*H`24RDO<Z_5
MW_3T1>BT&_1D$;:;;155&P%M%7U5`1!15_2O%!R4"@L[Y$"A^/V]!5>$+3NS
M15?R1<*O:*O[.:"K=:JJZYP!53A5PK%55/R5;%`Y3]E!6M`H%`H%`H%`H%`H
M%`H%`H%`7T6@A15X553KUX3A?RH"<JB\IQ^'Y?Z:"T&T-$:TV^]9YV:6>:=Y
MQT_=Q[)\>OU^PW+["YW&1+:<NQ"Y6/)(L9WO7W8OW10GT7^*R=!Y2=3;JW=@
M']0WL/6&*;2OS.#[9WI$U'L^U7NUX_F$_+<0UWXY7_96*6]^Z7BV.7BP.6V;
M9A`94)YGM8E.$0D9B5![%&Q401%4BX4NI?O<*2JB*OX]J+Q^I*".@4"@E]SM
MD*\09=MN,=F9!G,.1I<22V+L>0PZ*@;;K9?O"HK^"HJ+U146@MI[ETUS(5";
M?O.!ML-,C+4W'KSB#$<"4CN)&)NWG&XC`_2\*E)B@BBHNBO<(70@SHEQAQ)T
M*2Q*B3H[4N))CN"XQ)C/MHZR^P8JJ.-.MDA"J>J+0=N@4"@4"@4"@X7V&Y#1
MLNHA-N`3;@J($A@:<&!"8D!`2=%%45%3U2@M\W9YN$J;N/L2KGCSANORL<)Q
MUZ39FA%UYU<4$63)QM]\^?L77$;!5[6%;#^&@5?9K[:[_#:N%JFQYL-]OO:=
M8(E_=,VW0=$Q;<9?9<#M<:,1-LD5"1%H)Q0*!0*!0*!0*"5W6T6^]09EMN<9
MN7!FL$Q(CN#]+@*BIRA"HN@Z"]0<`A<;)$("$D14"W41VZ:X3[6XR;E?L+CQ
MVT9O4OWIEXQMAI%3B_.]7+O;FQ1$^\;'WV&Q19`G]3ZA="'+8FQ(TR._'D1Y
M3+;[$B*Z+T9]IT$-MUAX?I=:<%>15/5*#LT"@4"@4"@4"@@,$<1$7IPJ$BIQ
MRBI^ZHJJ+PJ+UH+93\:N&*3I%_PB(,L+C(%S(L04V(4"ZD7"R;Q:3;;:8MV3
M.@`B9.*,26(H+OMD@NH%68UDUKR6W-SK>^*B)NQI,9UMR+-M\R,HA)@7&#(0
M)%NG17%[7&7$54]44AX)0E^Q1[\%S%OE4]S$\G#IZ_58;@G3]-!H>_IOBBKX
MA;W"*Y%=Y\LLU?E''%U#&6_K34ZN,R3-5;<>;:`%Y#IVDE!Z%:"B=@:\Q39V
M-R<5S&W%<;3(-N0TK$N9;KE;+C&)'(-ZL5XMK\2[6*_VMU/<B3H;S,F,YU`T
MY5%##W9GB_M_.=?Q-0V_?!S\'<S;5&53+SL["8V5[+A0-:;-Q39#EI:RW'KO
MBL#(9.0+C`P5E72W.2F&G3===DN]5#6E\!C\9Z]_(X,:4LD1\MLI=<0H20R8
M<EYOM:231<&7N]JN=.>%1./SH/1+0?%3E%3E4Y14Y1>%3GIRBIU1:"RU^UG<
M+7<;[E>MLABX=DF0*P_?X\ZQ-7S$\GN##01V;E?K''F6>:MZ6*PU&6=&F,R%
MCM@!]_8BT&IOQW=M$3Y@/(3`<UUU9<?VI;--6_>+&:8AF+][QC*Y^>VW4^N\
MLEGCEVUU:\DQZ2-FQFU-,L2LAGLM>RY[+2"1.4&\Z@4"@A-50"5$Y5!7I0:!
M_`E]/^^,^7E%4?IMGCZ;J(O)@D9C)%9^GGE%?1TN.?WE'I^-!OSC/!(8;>;Y
M5MQ.]M51450+J*JB]4546@YZ!06=\B$0O'_>8JO"+IW9J*OY(N%7M%7KTZ)0
M5;K55+76`DJ<*N%8JJI^2K8H"JG7KT6@K6@4"@4"@4"@4"@4"@4"@4"@4"@4
M$#G*`7"<KQZ?H7HJ_L3K0>*2V6FY-?U.D1ERT26!B>4-]R&9?K:<MYB+!R+P
MASIK'8%YN#$9IF,F2C;)2-Q'$,'%AGPYW`J4'M>H%`H%`H('&Q=!0-.4517\
M%X450D5.>4Y14H+272R7[#9$C(,%C?S.W+,E2+U@CCOL,S/NO<=EW7%73;1+
M=?DDD*E%,BA3&T+L%I\D-0KK%\JM&76L+I:'S-I#5B5'DLN0KA;I@B)/6^Z6
MZ1VS+9<HRD@NQWA!ULNBIZ*H5)0*!0*!0*!0*"VM[Q&X6R5,R;!7(T.^R3%^
M[V:8:MV#+NP?94+B`-.!;;PK"H+5Q:#W54!%]'6N40*EQ[)X-_;D`@NV^YP3
M1JYV:>"Q[C;G27@4=:/Z7XSI?[F0TIL/CU`O5$"I:!0*!0*!0*!00F*&*B75
M%3CJB+^KHO*+U_!>E!;EO&YN)3G)N+M"[8C)R1/Q86A]MAUY"*3<,9+W&P@2
MG7.2>A\>Q(Y10]MQ550K2U7>!>(J2H4IF0/>33H@JBY'?;1%=C26'.U^/)9Y
M^MLQ$Q_%*":4"@4"@4"@4"@4%OL@PXCGGDN,/-VG*C!MF1(,3.WY!%CHI,6K
M(8[2<R6!ZBS*_P#:8:ERV7;R"A(+_E(7?"\TM\QMNWY+:\,ODJ[6(WP>D1AD
MV*\MQI;3@((R[9-<BN>P^(C[B"O(@0J-!HP_IH6'&?#3>QN/LO\`W?EIF,KE
MIEYCL<+4^FVI#/M/D3B>P\TK:K_MB2?A0>B^@4"@\X7P`MMMYO\`*'[3[;C9
M>8=[5MIL7P%@6\FV<R2*C[#*\N.M$2<<_3POZP]'M`H"T&B_"!&/_4";B<1Y
MXENW@E;F?9&6\K#06[*M3NNF<`32.KDC[EM`>(5<1`(17CN2@WH4"@4$#G/8
M?"<KVKPGKST_)*#0!X$-!_WROR\&)*I3+-H)7$3A>TK6.1`R@<)S]:R20D7G
MJB<<4&_:`U[,.,VJ$B@PT*H2<$G:V(]4X3A>!H.Y0*"SOD0B%X_[S%5X0M.[
M-%5_)%PJ]HOK^24%6:U+OUS@!]/JPG%2Z>GU6*`O3]'6@K:@4"@4"@4"@4"@
M4"@4"@4"@4"@4$))R))RJ=%ZIZ_Y^:#R&X;]TS_41[F%QUXV'?*;0YMD\`<`
M)^#'DT@Q&7>Q%^W$R]P1Y54,U7GK0>O2@4"@4"@4'Q4YZ+06VR'!B"[O9KAQ
MM6?-7&6(\UX_=&T93$B(?VMMRF+&X62#2EV,S1`ID05X%2:3VE";8UEX7E]Z
MU7&&5CR2!'!VZ6"6^#DR,AODP$J*X">U<[/),?X$MI5;+]PT!Q#`0K2@4"@4
M"@4"@+UZ+Z+04W=\=CW!^'/CF<&[VX3&'<F$3W!8-$%V');7AJ=$>#HK3J$*
M+]2=I?50=&U9)).<5FR",W:;NBN.1E%'#M=XB`)&K]HG.*VKCS37!/L&*.,%
MRGU#P:A62*BIRB\HOHJ=4H%`H%`H%`H%!"8]XJ/*CSPJ*/JBHJ*BIRBIT5*"
M@KYBCZ7%S)L6DK:\D;!M);#XNN6#)`;%4;8O,!GC_B6Q,D;G1T&4SRB$KK2>
MTH=['\LC75V3;YJ-VB_6\6BN>/RW`^^@-N^[[4L30Q&9:YA-K[$H!]DU$AY[
MT44"L$5%1%145%1%147E%1>J*BIT5%2@^T"@4"@4"@4"@MELK!H^5XW<HT2X
MS<<OB19_\HRBTA$6Y667+AO1BDJU*;*+<X)HZ7W$20ALOB2\HBH*H&A[^G%M
M5YLVA/+2+=?O7HK'EE<X%KNL@0:A7D+7JO6UMG3[:PR`L,-N7..ZC@"3BBZB
MH1*J4'HNH*)OVR]<8K<&K3D^?X3C=U?CMRV+9?\`*K%9KB]%>-QMJ2U"N,^-
M)<CNN-$(F@J)**HB\HM!(PWCI1TNUO<&K7"[4/M#8&)F7:3BM"7`W=5[2=3M
M1?12Z>M!H._I]+A$FY+\G01U;-UOS,RJ2XX,V--)R-/RS9KUN<%R*JMK$>@B
M#C!=4-L^X55.*#TAT"@^+Z+SZ<=:#1[@%K1[Y]=Z7<'P)+5X+XM;WV.\%=;<
MNV6:\.,XC?[R"86TD)>./2@WAT"@4$)*J"JIZHG-!Y]?`-E(OS3?+P\;C_!8
MWHAU&2X[``EO[BNMAVH7\157KRJ=*#T$,N@^V+K:JH'U%?S3\T_-%H.2@4%G
M/(A.=`;RXZ__`%'MF_\`Y$WR@JK6'_UM=>?_`(C8E_\`,%OH*YH%`H%`H%`H
M%`H%`H%`H%`H%`H%!"?/:7'5>U>/U\+Q0>16%D%HM']0EL:'-=;CQIOD_H7W
M+JZ`K`A7-?"KR-AQ+;<KH4AN-;)EW<E-MP6'!]R2;;G9W+PB!ZZA,2Y[21>"
M(5X7_6%5$D_6*IPM!%0*!0*!0*!04EDN'VW(5BS#61`O=K5URSWZVD$>[6MQ
MU>]T6'NWMD1)1B*/Q7NZ.^*?6*KUH)/8<JNL6>WC6;1HUOO!DZ%JNT07&[)D
MK(=QL+$)PC6!>_MQ4G[>9&0]A&RXZWU`+AH0KQP2+RBJG"\\HG'*HJ?ERE!%
M0*!0*!0*!02JZV6W7F.D:X,>^#;K<A@NY0=C2F"4F9,9T>"8D-DO0AX54Z+R
M/*4%+0KK<L;-R)D\A7;0V?,+)I`LL"(.O_;LP+RVCBI'DHX0BV^/+3R=51M5
M[:"O45%]%1>O'1>>M!]H%`H%`H%`H%!3.0XO!OS:.$[*MUS81?L;Q;3^WN,,
MR1![1>!$)^&YPGNQW%5AU/WA_%`EEGR.3'N0XYD44;9<S_\`BV8V"C9;^B?<
MN.!:7W%%P)\=EL3?C&(J'/+:N!]2!7///IU]4_LZ+_8M`H%`H%`H%`H)?<NL
M5P%_<<:D(:_B*#%>-%1?1%[@3\Z#R*?!7J;*=T8_YKWJP;:VCA=SUUY'#8K/
MA5OV'G+6F+['R;`L5R&ZS+IA^*9#CETBY"Y(8(&;M#N#,IA'2$A>'^&H;Y&/
M\/L*D);?(:W;4TRZLR/;X&;RO(+;]^TSD#TITFHZP]A_WLC-8?,?4/\`V'(H
M]I>[B06CD<=]!@3Y9>.GQF;O\EM%X]G=^7)-CY/G$C'\SV#;]N97*:L=CP'4
MVP;YB>OK_LF[7ZZ8K:$>O-M5]BRK)6Z3)'>ZK:(1F@:V_ET\.?CG\;/&=-A>
M,>38_+WA:+U`B0L1MFY;?L"1D6O[TQ=X66R9>$R+A>6[DU;W),=]J6#".PWP
M;,3$5-"#.7^G<:A6Z)YXX]`LZ6F+8-Z8A"A@:/C)2W+8<B_E\.0W(DR7&OMH
MP(X@_2G=()43A>$#TF4"@^*G**GYHJ?VT&B/`5@K_4&;Q[FS_FB^"MA!MX>.
MP(*9%JIZ4PHJGU/'(1DAY5>T>[C]Y5H-[M`H%!\7A45%Z(J*B_MZ4&A'P51Q
M[YB_EH'V0;(<>T?%1Y6C`B4H]X=:%PB5.]$;?0AXZ*)=*#?)`8<C0HS#RB3K
M30BXH<H"FG[W:B\KQS0=N@4%G?(<A#Q_WF9D@@&G=FD1$O""(X5>U(E7\$1$
MH*JUB2%K;7I"J$)8/B9"J=45%L-O5%1?Q14H*XH%`H%`H%`H%`H%`H%`H%`H
M%`H%!\+]U>/R7_10>0J#ENAK5_4#;PU_N^]GCY;'W1J.=KJ1+G+;L9O&<XKX
MV999(V'7>_`<84N.5O[!BQXME>5YJX&\;:"IDBH'J<;"]:];8&)[EVUW`@]B
M@^%QN62XTTR:F#S3PK*E9#8FF'/;]LA27$;:%45UM%5`N;`N,&Z0XT^!*CRX
M<QM'HDF.Z#K,EDOW7&C`B147\O5%3A>%1:#NT"@4"@4"@4$GO5@M&107+;>8
M34Z$\0FXP[W(BF!=[3@F"BXT\P?!-N`HFV:(0JA(BH%`C<;O@4L(MY.=><0<
M%N-`R5Y3E7.SNB1HU`R7M#OE0S1P18N7"]J)Q*5%1'2"YT>0S(;:-IX'D<9;
M>`P5%%QMP!,7`45(2`A)%Y153JE!V*!0*!0*!0*#@D1F933K$AMMUEYM6GFG
M6VW6W6B14)MQMT#`P7GJBI04$U%N>$`[]HLR\8H+[TAR*2')NN.QS[31FUAP
MKERL\=!7ELB.0TA?0IBG:@5G:KK`O4"+<[9*8F0)T=F7$DQW1=;?C2`1QET2
M!5%$<!>4ZT$QH%`H%`H%`H%!*[M:H=UB.19;`O-D0F(K])MO`J*W(8>#AV/)
M:X^AP2%17A:"@DOEVP=/8R=YV;C1R!;M^4%"(G;4$B5[<>!E217WE3ZG@;;G
MMM^R2)R_V$O*A<X#0TZ<\\KZIQRG<J(2>J*)<<HJ>J4$=`H%`H%`H);=#1N,
MXYSU;9E."*]1(DBO"*$/^LBD:)Q^:T'D'^!'R6UQHJW>?6&W^[0(^QKUY"V+
M*K1A&47NQZ^==L36O(-D+(+MD&<RL?L-DL!WJT26"=5Q]YOV#1&C-1$@W:WK
M,M0;:)T?+#S-T1&PV?!8>E^-VJ=PXKC^O;E;+PX46)"V-F17R'L?;,5]9"1G
M(HK9;!,1.UVVN@J\A@9G^V_B3Q7:%WPC3.QM7V^[ZGM`1KUKH-/0O(7Q:M<3
M-HTNX)8+!8+A!=M>!7J8-N[9[>"W*U=GN$W.C2'B3L#1S\H^9^"^Z,6QF1H/
MQ-P30GD5C4W8\E=@:TQ"Q8IAVVK=>L2Q)FWS\&R&Q6_'[E>DN=LM[T9R!?+1
M;;C:S8DM-B8.*](#;]\%FZ]%:WN?G9<\QW=K*P1LXW+BN0XR]D&9V&QA?++`
ML=]"X7BQ,W2;%>FV-FZ7`V4D"BB3P&G3A$H-]COG!X:L2%B/^57CU'DHTP\K
M$C;^!L.(U)4DCFHNWT%[7E!4'\^*#DC^;?AS+4DB^5'CW)4$0B2/M_`G^U%]
M.?:OI<*OY>M!VF_,SQ(>C_=,^3>A7(Z\\/CM?"":54YZ=Z7KA5Y%>GK0:7\&
MWSHZ/\YVZMKW+<NK8>MD\-<=Q.T9V_FN/L8G=+W-NVM)CMK:RERX)8YUVYMK
MJ!'![WN&CX%>U:#T#X9L'!-C60\DU_F6+YMCS4V9;7;YBE]ME_M+=QMZBD^`
MY<+7)E10F02-$>:4D-I5X)$6@JT3`^>PA+M)1+A47M(5X45_)45.J4$5!"7'
M:O/'")SU_1U1?V+0:&_"*+]A\S/RTJ4B<^V[BWCC/$94@G_:5^Q/NNLQ>Y$]
MJ(T2)V-IT%%7\Z#>]%DM3&&Y+"]S+PH;9_@8$B*!BOXB0KRGZ*#L4"@M'O[M
M71>YQ,1)L]3['%P23D2!<,O?<A)^(JB=:##OR/\`,#,/%'2FNKMBWCWGVV2E
M:LAWF3E%LB7-C66&G:,;MZQK=F5[QJR9CD\&Y7B08A#9;M"Q7$Y]V7'1.Z@S
M`T/FEXV%JG#LRON5ZPS>YY%#GW!_)=-2;C-UM-;*ZS@B1L:FW:;.N<P;3$!N
M)+=?)IPYK#RJQ'5?8;"\%`H%`H%`H%`H%`H%`H%`H%`H%!`X78!%VJ?"?NCZ
MK^'"4'E(P+0&LMF?U!.\<SS_`!)C)KOKK<&OK]AR7%LYMFMEU>\5<VO4*_OV
MEYPK:=]LM]Q"W2;?.-HY,)^*'M$"*?(>K86A1OV^25.555(E4U)2[U+NY147
MNZ].$3\.*"V=QQN[XS<#OF#`+K$E]V5>\.=6.Q;+J\338++LLDT$+'?GE;1.
M2[84CT<]LE]Q0J['LEMN10$F1'E1QM]V)-AO,O1IUOFL*2/0[A">'WHDEKMY
M5%[@5."`S!1-0J*@4"@4"@4"@XW&FWA4'0%P%0A(23D2$A42$D7H0D*JBHO1
M4]:"USMFN>!&_<,6CR+CC1>X]<\3;,G7[4*KWNS<160O:##(HI+:^4955+[=
M&R)1(+@6F\6^\PHLZ!)"2S*91P2`3!1)$1'FG&S^MAYAQ>UQL^#;+Z21%H)K
M0*!0*!0*!0?"3N%17G@D5.GKU3CISSUH+>7+';E8YG\ZPLFV5-]V3>\;?56[
M7??<!5?DQG$^BUWXNSE'U167BX1Y.O?03_'<HM^0Q%<;1R%/CF,>Y6::*LW.
MUS%Y0XDN*7\3D#14%T45IY!4P)1ZT%2T"@4"@4"@4"@XGF6Y#3C#PH;3H$VX
M!(A"8&BB8&)(HF!BJHJ*BHJ4%L'XMZP(WIEF:E7K#6O<=E8X+3\R\V9.$[G\
M8-")ZX0D1>XX+GUHJ*K!+RHT%Q+9<X-WAL3K?*9F1W@Y%YA5[>X5[7`(5^MI
MULT43;+@P).%3F@F%`H%`H%!`;8N(B$G*(J%Z)ZBJ$GJB^A(B_K2@P@R?XVO
M!_-\JS+-\R\=\*R;+,_R2Y9;EM^N[M\?FW>^W=J,S<9A^W=F68K<D(8*K+(-
MLH7*H**2\A0R?$9\;GOA*+Q'U@[+:[$9FR$R.3-81L_<;&--D7YV5&0'$141
MLQX5$_)*"9/?%+\>3Q"1>+6OP410$2/*RJ**IW$:D0QLB9$W#<,B(EY(S)25
M5)550ZS_`,3GQVR`09'BO@4KAM&NY^?ESSJMCU`%<<R17#1LOJ!%7Z"1"'A4
M1:"W-T^)OP>L^33\P_[-6)Y-:KDQ&"?:WI>5.7?&8]OA1H3"88,.^1W'+,XS
M&]Z5;G5<>.43CK)J3BC0=X?B,^+[-[<-U/Q9U_?(=S"*^DL[UG3;C@QW''(R
M$;>5M.B;#Q&BBO!`:*"HBBHH'$U\*7Q?M.MO#XDX>CC2J39KE6R%5LB11(Q1
M,S1.Y17CG\J">V+X<_C6QI$2R^*^(0T%HV43^\FPI`H#BDI*@2LO>!#Y->"X
M[D_!:"H[?\3WQX6TGUC>+>`&$DB-Z-+D9-.A$\IB;<G[*7?G8J2XZCPT\@(Z
MVBEVDG<7(:[O@&A"QJOSFUBX-['',"\[<\3%;3,FW'[>PVV_ZVUU>'K7;9WW
M*22)J]_<E(9[U4'3[BY(E50V^^(FM<5U9J[(L<P]J[Q[9-W5OC))$6\Y#>LD
M=BW;(-MY;/N<>%+OTV?+AVP))K[$0'/9CBO`(B4&4=!QNHJMFB)RO:O"?IXH
M-'GAY#!/F+^5$P7AR;@/CC[9^X)(G;CTAMU";1>Y.'.U>5_"@W<6N(4"W0X1
M$AE%CM,*8\\%[0("*G/7T2@[]`H+/^0A*.AMUDGJ.H]E$GY<IA-\7K^CI08/
M[I\J<MTK:M$6?&LDQ&P6:[:CPS*,\R+*-7OYM9\,L5UN6*X;:\KO%S'?&H9+
M%D*[794.';(%\N",1WY)`VRU]09D^-^OI&L]4VO&9N6X]G-PDY1LO,[ED^)V
MDK%C5PN>Q]E99L&XLV.TG?<F<A6VV3,F.*T)SY1J+')'W*J(%]Z!0*!0*!0*
M!0*!0*!0*!0*!0*"!Q5$"5!4U1.>U%1%7]2K0>;;Q_AK<OG/\N;@5SCDMCVK
MJR(MO:9?;?0)7B'MIUM7G45&'$#O7UH/290?%%"11)$5%]47TH+<Y9@IW20.
M0XS<7L<S:$RC,"]`KDB#.CB7N#:,FM?OL-WRR$Y_J$82&.56.ZTJDA!W\<RP
MYCX6+(H[%BS!N.4F98!EI+8<B@I"5QL4]8\7^<6LB0?J0!>9[NUYL"Z*%;B2
M$G<*\HO/"IZ+PJHO'YIRE!]H%`H%`H%!"0]R<<D/IU%>%Z*B^O7UXH*'O.,S
M(T@[YA[S5NOIOA(GQ7E)+1D;38*!Q;LVWU:EDWPC,T!5]M11"4@Y&@[N.95$
MO3DNWNB];KU;!!+E9KBK87&-]7L_<H(H(RK<^^)(S*;[F7^%4>%Y%`JV@4"@
M4"@4"@*G**GY]*"AK_AT:X3F+W;#>M62Q&AC0[S&!ISB)[RREM]SBO.`Q=K0
M3X<^RYR;!%W,$V76@^V/+'G9B6')X86/)``B!A7!6WWIMOA"G8\][CBRHQ)R
M1,D7W,?A4<'A$,@K4'`='N;)"'\T_/A%X5/5%X6@CH%`H%`H%`H(3%#'M523
MG\151+]A)U'E/RZT%O;QC]TM$US(<*98&XO/`Y>;(Z81;3D;`]K9(Z7!+`O3
M,=.(\H4]LSX%].Q?<`*BQ_(X=^!\&D>B7"`H-76TSA!FZ6U\TY!N9%$R[$<0
M55MP%-AX?J:,PX*@J%%Y1%3GA?S117]J$B*E!]H%`H%`H%!\7N_!.?S_`,N4
MH/M!\5$7U3F@M_>,:N-LE.7["O98G//J_>K$\[[5MR-"X]YY#,7`MN0(`(C,
MSA1+A!>0@X40G>-Y/"R*&Z^V$J'*C/+&N%LN$<H=QMTQ.[NB2H9J3@&@CW"2
M*0.MJA@2BO0*FH%!H@^&"X2!S?Y/[&(PHUHM'GIDUQ@QH:ERR]>,*L`W*4:*
M`_5,;MK1$OXEWKPBT&W70J._W*O9/#VFYM3<YCT1.6?\5LP&.:(BKT-@17]-
M!>J@A-5025$Y7A>E!HQ\-R,/F7^5%3%DD#7_`(WDQ(!A0/VW;"X7L.O>CJM&
MG3\N:#>/$>^XC,/<H2N--FJHG"*I@)\HGX(J%0=F@4%LMU")Z<VP!L+*$M:Y
MT)1$'O66*XO=$**@(BJ:R$^CM3JO/%!A!DT^+=,ITSA]W\.+9Y(V-KQEQ7)X
M5T?QC44BZ83<RN%OM+]C.^[ER'&K4W#N<)6W!A0GCE`Y'-QUOL(20,V=,0[7
M;]=8]$L^HUT3`%;PXUJDH>%0"Q5Q^^W)^4GVFNKM?,,;2\RG#N"+"E.B:2NY
MSM=4Q$+IT"@4"@4"@4"@4"@4"@4"@4"@4'PEX%57\EH/-%XWW%J)\ZOF?"=`
MFWKGNS54=@R0NU_[7PKVI<%;;Z=G<#2$2KSU053U%>`]+U`H%!2^38C:LHB>
MQ,^ZC2V7$DVZ[VY\HEWLTT1(`GVB8G*PIB`:B1(BHXVJ@XA`JC04Y:LAN]AF
MQ<?S(6P!TPBVC*H[0!;<@D&A=K$]F.R+>/WPUX(V3XCOFJJPY_YI`N.CK9*"
M"2+[B*H<<JBH/[W5$X3B@Y*!0*!0*!0*"C\HQ5N]BW-@R7K/D41AYBV9#!;8
M*X01=^KVB%\"CSX!.H*NQ7D)IP>[CM)4)`EV.Y7-22-BS%ABRW_VFTAJ!"-J
MR-MMH%=N&/N&2O\`!JJJY#>0)4;T43!$<(+@(J+Z+ST1?V+Z+^WB@^T"@4"@
M4"@4$BO^.VS(X2P[DRX788OQ),=TH\ZWS&_]Q/MLP/XL*:PJKVF"IRBJA<BJ
MI04)"RJ\XG<6[%G*$[;74CI:\]4668,UQU596#DC$849Q^YBZ@@T\O$.8O05
M;<5&U"ZH.`X/<!=P\JG*<^HJHJG7A>BI01T"@4"@4"@4!4YZ+04??\6&X.A=
M;5).U9)%0DA75OEP5`E4U@W.-R*7*SO'PAQR5$'E3;4'>"H.O8\J`[@&.7YH
M;)DB,.FS:W'/<C7./&[%?N%AFFB%=(;8.BKH]'8RKVN#T0R"MT5%1%1>45.4
M5/Q1?1:#[0*!0*!0*!0*!04C>\=.2ZW/LKY6B],]G%Q9;`QE,`ZKWV-S`U[I
MEO><_?%%%U$X5LQX5%#FLF0%+<*V7EINU9"R)F_:R>%P'V@5$6=:GE%M9UN)
M"%>Y![VE7M<X7CD*F0D)21%ZBO!=%Z+PB_CZ]%H-`WPHR&9&R/E/0C0GO^W/
M<6)"(A)PBX9!`!]..5#NZI0;EM%JXN&WE'$X0=F[>1OT_P!S_B=E:MKT_-%_
M'K07EH('%5&S5/5!6@T7>&_M._,I\JK0HC;X8+XWB3B$IK[:6$B9Y:4E04%4
M7KPG/Y]*#>1`9^WAQV5+N5MIL%5/S`!!$_8(HE!W*!04#M9AJ5J[9,9\5-B1
M@.8L/"A$"DT]CMQ;<%#!1,54"5.45%3\*#69OS1F>;6;TI>K#H#5&^[.QX[8
M;9(UMSR_8A99N)WAS*<+O>1S8C63VBZ2GK=D&%PWK>VY&)%C2C$E[55#0-B6
MB,5@X5JS$L8MNK+7I2%:8]R;CZPLMWMU^M>*C(O-PE$Q$NMH$+=+"X&^LLO:
M1$`I"BOU"M!=^@4"@4"@4"@4"@+TZT"@4"@4"@^<HB\?BM!]H.)]5%ETD]4`
ME3T]43IZ\IZT'C)T!L&^W;^HXSF2E];DO7'RDWK@V2X^U(*T6AV!K[QFS7&<
M+NKEM?D=ESR.RX^+[3;K7<IMR'E5.3*@]G=`H%`H)==+3;;U!DVVZPHUP@S&
M7(\F)+:%Z.^TXG!`ZT7TFG*(J?BBHBHJ*B+06V<G776<=M+@ESON%`\TQ_-4
M;DW:]XNR1*B.W0`<?N-ZLB$:#]P`G)B`G+J.`BN"%T(DR/-8:D1GFWFGFQ>;
M-HQ<`VSY[7&S#D7&CX^DDZ$G5*#M4"@4"@4"@4$DON/6C)(:V^\P6I\52!P`
M=4D*+)9+OCSH3PJ+T*XQ7/J:D-*+S1)R)(M!1L.[7K#A.'E\H)5E51"V9>Z+
M39,&9H#4#*0!QMD))&0@S,:%ME_E/<%IQ>""Y+3K;P]S9H:)T7A?1>.>%_*@
MY*!0*!0*!0*#H7&!$N423$FQ&9T:2P4>1$D`TXQ)9-44V'FWA-IQL^.J$BI^
MV@MJ\MYUPT3D>/<[[@D5MQY]ALTN%^Q6*#1N&L8GW#GY!9HO':+?US(X"B#[
MK:(*!<JW7&#<XC$NWS&9T9]D'F9+)@;;[3B?0Z)-_0HEPOIQU1:#OT"@4"@4
M"@4"@I^_X[;K_'!N8RXK[#HR(,R/(.).MLL!)`FVZ:TGOPY(\I]0*G>B()<C
MRE!2]IOEYQZ9_)<VEQ7(SCC,:PY1VMQFKHK@\,Q+V(J#%OO[BB7/MBD1_A/;
M(7"5I`N(#H.("@JJAA[@KVDB=OT\<JJ)VDO=T1>%_L6@Y*!0*!0*!0*!0*"1
M7G'K7>0C'-C$[*ML@I]KF-FH3K=.0#`9$&3U)ESM-1X7D"%>"%4Z4$@@9'-M
M4V/9LO5B+)N$MN'C]P8$0@WE7$(VHKJ(;GV=^%L"5QI21E[M56%+@D$-%_PB
MB+FQOE.DL\/B_P"=-Q>0FR[1>1O%6V>]LS51(4)M1X[4ZBO7GG@-T6A9'W6%
MWQSM[!#:NYXX(OJH1-K9A%$_5?\`>(SW?HYH+U4$)(BB2+Z*BT&@7Q8GR8WR
M_P#S`OP@9B.VW3^@),>Y,DY]\Y<`PZ?($R0T5D!@&V/M\)U5>O-!NKT??+KD
M^E]2Y)?9AW&^9!K7!KW>;@Z+8.3KK=,9MDVX3'`9!MH'),IXS)!$112Z(B4%
MT:!04/L[_P"MML+_`/$?+/\`YAN%!IS\G<VG:ISGQSSAN?LJW-7CQ5LF)1G=
M8>0'CCI6YNO1;M9[S/:O4/?5X@N9!`%LXZL.VUHACN>X+Q_6"(&SCQ.S9-B:
M!UWF"3LEN/\`.8=\7[W,,[USLW)'_L<FO-O5;IG6I9,S7M_=#[3M`[<Z0LM(
M++O\=MQ$#(R@4"@4"@4"@4"@^+Z+^J@^T"@4"@+Z+QZ_A0=1U)*FPK?HCX^]
M^Y_N.P^[UZ_[SCTZT'R0W,(T*/(%L4%/X91P=%215Y535YLT14_!*#J.!<D`
MC>E15902]QL8AB9#PO*"?W)H*K^I:#Q`>/4IEK^HVR5CO]UP_/\`\G?<9[2_
MX8W?'+8'VSB'V^CS2/<HB\?G^%![E17E$5?\NM!]H%`H%!`8"XB(7/"*A)P1
M"O*<_B*HJ>M!;2;9+OB4U^^8LV<RTO./O7?%!4.P&W$1UR?BXNN-,P+A[W).
MQ%((LI54_H=Y(@K2RW^UY!&^YMDA7D'Z)#)MFS)A2!(P=B3H[@HY%ELN-JAM
MFB$B_H5%4)U0*!0*!0*!0<,B.Q*:)F0TV\T:*A-N@CC9HJ*)"8%R)@0JJ*B]
M%152@H-8UQPT`6WQ9-SQQH"]^WP063>+=WRAX.U@\0A(M4?[DW#CD9/,M!PS
M[B\-T%9P+G;[K%:FVZ6S-AOCWLRHQHZPXG<0D@.#R*DV8*)CZ@2**\*BI0=^
M@4"@4"@4"@A(1,5$DY1?5/U+RBHOJBHJ<HOJBT%M9^-W7'9\F^87]NU&D/+,
MOF+R")+9>7U!L7;A;W#<[+%?>UOE71'[:4J?QQ0OXR!46+9=:LIA$]#*3'G1
M'?M+M9[FP,2\V:>@H10[M"$C2*^0DA`J$3;H*A-D0KS0550*!0*!0*!0*#I3
M[=`ND1^WW&(Q-@RFS:DQ)+8O1WVW$5#!UHT4#%>?Q3HO"IU1*"W)E+UNRA$E
MRNV%LMJ*/F<B\WS&6UD*7;),U*;<\:AL$I(X1.R8@HO>IM]6PN/!GQ+C':E0
M9#4N,\`.-2&"0V70-MMT'&S%5$@<;=$A5%7E%H.Y0*!0*!0*!0*!02J\6>U7
MN!,M]XA-3X$R,Y'E1GD)0<9)%5>.Q1,'6U^ILQ5'&S1"!4)$6@T*?#'`>L6]
M?E<QRS1VVL.L7FT=KMSLN[W2YWN/+A8@$>1#?.Z1GW;C&^V:9<6:Y)1]V0;O
M>"JBNN!MZ\;Y%RD:^R8Y,2/&>:W3Y!1X@-R5>!^'&W5G;$*2^7M#[#LIEM#(
M$0^SGCE5Z4%]@*Y*J>XS%$>>JA(<(D3\Q$HPHJ_K5*#G/[A&G%!!5Q!7L0^$
M!5_(E'JB+^B@\[FG2GV[Y2OF8>C9)>[&[(T!HBZ1W[%B@91>;-*E8>XU'=MU
MK9BW5W(CDR&7`^V^W[D%5X(>1,0W)^(S]R+QJTXU-N%^NUQ@X19K?+3)L>/$
M;M!?@1PBK87+6_;X3@P\?;;2'&DDV938[`/JXXKBFH9'@LHE%7`1M.O((8.<
M>O"]_:"KS^J@Z5]O]CQ6R7/(\HO-JQW'[)"D7*]7Z^7"':;-:+;$`G95QNET
MGO1X-O@1614W7G3!ML$525$2@I?8,J+<M6YQ,M\EB;#G8#DTB%+BNMOQ9<:1
MCTUR/)C2&B)I^.^V:$#@JH&*HJ*J+S0:W/)?3^^MS:]\<[+KA<QO.KPUE87=
MC8'886K6\:SAURSV);;:\YN66;3UCG-PL`L"9N6BVRV;?.1.V:3S9>S09J>)
M\V/-T5AS<:+;;<%CD97B3EFM.MK7J"%CDW#,RR#$[IBX:ZL639C8\==QJXV9
MV"Y]E=)L.4;"R&'/;=$4#(Z@4"@4"@4"@4"@^+Z+^I:#[0*!0*!0*!0<$D%<
M8=%.>5%53M5$5>/J[>2141"XX7]"T'B-M>E,RLO]0EM_+<+V-CV$XKKSRSM>
MW-C9WD-O"3)M,/9&F+AD%RPQBT.*XT-HRO%8]_L3UZ)?9M;CC$EP04D,`]N,
M1X)$=IYLQ<;=%'&S`P<`VS3O;,'&U5LP-LD)"15147E.G%!V*!0*!0*!04%?
M<4FE<VLCQ:?_`"C(0!6I?O<NV._PQ57`@WV`A*IN]P`#<UE!F,CT0R;[FB!B
M6;1\@>E6:=&DV7++,A)?<;N)M??QA-U6X]RA$TTVS=[!-4"^WG,)[1\=I(+B
M$`A7J*BIRB\HOHJ=4H%`H%`H%`H(#;!S]\47A%1%]%1%]414X5$7B@MY<L5N
M5IEE><(-BWR'Y"2\@LCR"MNR81;1@B1QPC_E5];83EF2VB`\8B$E#!$40GV/
M91`OD;GN<A3V`9_F%HN(MQ[M:7W45/MKG&!QQML^]%0'0(F'^.6B).M!5%`H
M%`H%`H%!\(4,2$DY$D453]"IPM!0V08<$V:%^L<C^194PRU$CW]MOWT.`!"?
M\LNMO4VV;Q:R)%5`<(7&7"4VB%>>0X;!G`3;Q,QB_P`0L>RF`!/_`,MD&+D:
M^6T>Q/YYC$P!0;I;!(T1U$_CQ"7M?!M>U2"OT7E.4]%H/M`H%`H%`H%!`;8N
M(B$BJB+RG!$G7CCGHJ<\<].?1:"V\ZS7K%Y+EUQ!AEZ#)F*_=<3(V66IHNKS
M)EV!PU1BV7I$$G/:(DBS"X0O:-.Y0JNP9-:<DBI(MCSIDVOM3(DEAZ+<+;)$
M15R'=(3X-R;?,;[DY;=$2)%[AY%46@J"@4"@4"@4"@4$#A=C9GP2]H$7`HJD
MO:*KP*(A*I+QTX1:#27\3EGD6???RR-3(P1WW?/*Z.&@2/N1<]W#;?)$^X0`
M1+LE(*HGHJ4&S'QE>-[7^3D9=RAO'R)9%>$3AMG>>P&VQZ(G/:`HGYT&0U!`
MYW=A=G[WX>GYISZ]/2@T?>(P1A^9GY0'4#^(>J/&$7"X,N8J6F>C2$/4>T14
MN>G/'K0;M[<\Q)A1)$=E6&78[+K3*H">T#K8N(W_``B)I>Q#XY%5'GT6@[M!
MK7^8ZUN7GXJ?D(MS3,!\W_$O=1HU<Q(H:I&PJZ2B)Q`(2]P!84FEYX1U!5>E
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M7+$^I`0*BPW633V'0NIC.5V++;3$O5@GA<K=-4T9D`#K)"X"FCL:5&DML2X$
MZ.8*+T9X`D,&BB8(M!4E`H%`H%`H*5R3%(%_%B4BO0+Y;_<<L]_@*V%SM3QC
M]1,*\BLR(SRBB.QW4)EY/WDY1"$*<LV92X-X'%\S:9MMR)Q8MDO#*$EDRU4:
M1Q!@GT2V7UM&C5VW/)[BB0DP3K?)(%S$7E$7A4Y1%X7U3E.>%_2E!]H%`H%`
MH%`5.45%_'I^7^=.M!1-^PZ+<)D>\6MU;#D,*.$=F_PVVRD.P&I7WBV>XLGW
M!<[2\ZI*K3B<M$:FT0'U4.U:LD%V<Y8[JR=OOC;:R0BDJG&FP>1%9UJF*@)-
MBMD2>XBH+S*KP8IT50JR@4"@4"@4"@*G/1:"G<BQJVY%#%B6RX,F*\DNVSXD
MAR%<;9/`/;:FP)K)(Y'?`5X7GN;<'Z7`<#D%"BK/DE\QB>QCV?20E))DQX5C
MS)AAB+`O,B63GV=LO,)APPLF0D(H*&*!"G$BJU[9<MH%UD7E$5.>OYHJ+^U%
M1%2@^T"@4"@4"@4$*BBJ*KSR//'!$B=4X7D45$+I^?-!0^1XB],ELWW&I@6+
M)V";YGJV3T&[1VB1?Y?D,,'&2N$56^X6G.[WHI*A!RB*"ASX[F,2\3'[+/9=
ML>3PP4Y>/W`FQD.,"O"7*T/HJ-WJSN\_3(8[A!?I<[#11H*SH%`H%`H%`H/A
M<J)(G/*BO'"HB\\?@J]$6@\^?A9O3!/'?9WR?[&RBV['NF%95\E#>'_S/$,%
MR?8DBU2[GB4*-)R6?9<4AW*_Q\1MTFWN,S9C4=\(IJW_``U0E6@V[^*4E)FM
M<FDBBHV]O;R/=9[A)LU8=WML%R.3C1B+C+A,F*J!H)@O0D0D5$#):@X9'N>P
M[[2\.>V?8O3H7"\>O2@T7^);K[GS8?*+&;9?6V%J'QH828`\M1Y\>P04*(2_
MO(X)3R?X7HH'RO3B@WEP8R0XC$835Q&6P;[U1![NP4#GM3@13@?1$1*#MT&N
MKY>&G'OBU^0@&D-7$\/]^NC[;;;IHK&N+^^I"VZXT!=B-\]23HGX^E!D/A9]
MWB/B+O5?_P`W.PN+RG"ESK**75$].>?PH-:OD'=\?Q_(_&1O94_Q8=U\GBE9
MGH;OE-A[N56.'EMMG8R3M_MDBRQCN>(.#;'6F3F3W(]MD/O,L,&LO@"#9)XE
MOX]+T7ALK$X^O(^/NNY$5N_PIQK+,3P!]I<DNPG,QRU9LTS?W(DQX2<662%'
MFF2O1R-@VR4,E*!0*!0*!0*!0*`J\=5H%`H%`H%`H%!\+H*]%7HO1/5?U4'F
MY\:09;^<GS>!S^,\[M33<EDV)`N-,#_V2MMB0/MHB$T^G'"BJ_BE!Z1E%"3@
MD147\%3E.B\I_8M!:G),'NT2Z/Y=KN5#LN1/OI*OEHEDY'QO.O:8]EJ-?%BM
MN.VJZ#T1FYLLON@OTO-/M\-H%28GF,3)&W8KT:59\A@F35ZQVY>VEQM<A.J_
M[HE"7;G>?^'EM\L2`_=7N0@$*SH%`H%`H%!(;]C=ER2!)MMYML6YPI?:K\:8
M*FT9M*+D=Q"ZN1WHKX"ZRXVHN,O")@J$G-!1[<N\X(C#=\FR;SBHJW%C7N07
MO7&R"ZZVVPSD!-QQ.X0H@)PEQ50<[5_XE#/AV@N2T\V\($V:&A@AB0]0(5XX
M(#12`A7GHJ*J+^=!RT"@4"@4"@4$MN-JAW-IL)+(&<<_>B/=$?B2!14;D1G%
M0E:=!5_2B^BHJ=*"DXM[N-ADQ;;EKB^P^ZS%M>1H38Q9S[S;++$*\BU'CL0;
MM)?]Q10$^W+A$0D)4%0KU%Y_R]?TI^B@^T"@4"@4"@4'0N-NB7.))B2XL64U
M):]IUJ4RCK+HHO<(NBO51$T145%Y$D14X5$6@M<3N0ZT[B?.5DNO@=,U<-Z9
M<<JQ!)3S2-L$I`[(R7%H9.G]?6X0F1%%20V*DV%S[9=(%W@P[C;)D>XP+A';
MF0IT)]J5#EQ7P]QF1&E,&;$AAT%11(")%2@F-`H%`H%`H%`H*5R#%+=?6XQ*
MR$:X07SDVZ[QU)FZVR2X@(;\&6'\0%=4!]ULE5J0(]C@J*]`INQ95>;3,CX[
ML)(<6[2C-FS7^WMNM8]DJ`@_;M-J\J_R3(WFN2<MSAN(9(I1G70Y$`N=0*!0
M*!0*"$UX`U3U025/V(JT'GKTAJK>&<7/Y.\,\9\ZPS!,\_[QB-?)\C.[8-ZQ
M.?A,*RV>_P!_PPHIV;(@@2K\7[DK[)]8SI]_:7;VJ&WSQ/%\=;97]S[/W!;\
M\DU>]A55I'4WSL(302)MHC1"'CE45>/52]5#)J@XWD)6G4!>"5L^U?T]J\4&
MB+Q.=MS?S=?)J34R6,X]1Z+]Z",CBVI&AX_A1O3GH?;W)<$<EH*.\\$S]*)T
MH-ZT"4S.AQYD9T7HTIEN1'=']UQEX4<;-/3H0E0=N@UY?+<*G\77R%CR*(OA
MMY$H?<A**M_X69-[H\`0ER3?*)PJ=5H+]X((_P#9!PT13@5\;L>$$5>>$_PP
MAHB*J\\]*#6YY*ZOLVV;_P"+>M)V88]IR_7?QAB3KEM#,MF;"Q/'LQLF*W77
M\^/J6TX9A.?ZUA9]=VLE>8O$F1,N!E9HP-N,QGCD=S(;&_#_`"D\R\?L*OCM
MQ.]2$FYQ8Y>0?W^O&TH.22L4S_)\6?R2P;`O[;=WR?%+^Y9UF6E]]%(;:\RV
MA&@(9!DU0*!0*!0*!0*!0*!0*!0*!0*!0<3ZBC1J?[O"<_2I=>4X^D5%5Z_I
MH/+KHC8=HQ[^H@\D=7LLL/W/:610LO&:S(]S[!G4?BO,MMXMTIDFP,)ERE[.
MA/-*"J`M1G4+DC2@]1]!\(4)%$DY1?5/U+RG^=*"W><X`SERV^?"N,_&\FLL
MIF39,JLKS4>[VWM(5DPW!>COQKO9+F`HW+@24]B0*(O(&(&`="P9M=(UTC8K
MG<.-:\F-):PY-K.3(QK)&XZ=P.6*=*!MT;G[!=SUK?(IC2IWA[S*>[072$D,
M4(?1>J?Y)RE!%0*!0*!00&V#HJ#@"8$A"0&B$)"0J)"0KT(2%5147HJ4%KYM
MKOV%/O7+%(\F\8ZZ\4FZXD4@2D6]LU-V9/P\WC'A\>5<*VN*C+Q=&2;)>%"N
M+!D%IR6V1KI9I:3(;X)P:@ZT\RX(C[L:8P\(/PYT<B[7671!ULNA"E!.Z!0*
M!0*!0*#KRHL>;'>BRF6I$=\%;=:>`7&S%>%X(2147@D14_)4Y]:"BNRXX>,E
MP!FWBP.RP=1B.)2;E8FY#HBXC".$1S[3'_>5%7WF0Y[4(41*"M8TIB8RW)C.
M"\PZ*&T\V0FVZV2(0.-F*J)"0K^?Z^M!V*!0*!0*!0*"`VVW!4'`$Q+CN$Q0
MA+A45$5%145.4H+57+%[WB4F3>\!;9=@.O%(NN"'(;A6Z<X^:))N>./O-FS8
M;\@$7\+_`-@F$2^X#;B^]05CBV5VC*X"S+2\ZZL=]Z%<(TAHF)UKN$8B"3;[
MG%<(G(DZ.8\&"JO'14515%4*GH%`H%`H%`H%!);]CUFR:VR;/?;;#NELF@(2
MXDQD'FGD:,'655#15%QEX!-LT5#:<$3!1)$5`H)N9D&`+V9%/?O>&H:-QLC?
M<!V\6`77C5J/DG9%;&=;`5T&6YXHCC("BR>]>Z0H708DLR10V#%QL@!P'`(3
M;<!SE0-LA)>]LQ3D23Z21>BKUX#GH%`H%!":=P$*>I"2?EZHJ>OX4'FX\8K#
MY_O>4_RA'XG[+\1[9BQ>;=\'(X>]]?[5ON06^^KK[$)-KC6@L"RBQV]+8_;)
M*#(<D(3WO@KC:]KBB@7WT!&^7*%@NSOY%L_XZXMGQ[<GD+'GS<EUEY#I)8R*
M+M#+;IDMU1^W;%9ACC_\UE//1FS:)YN+VBX9&BJ@;A]-7[*\IU1KG),Y9M+&
M8WW"L8NV3-6`9X6%+Y/LL*3=#L@752NK=G?FN&Y%&4JR18(4<53154+E$G(D
MB>JHJ?VI0:(?%"*8_-?\D[KA,(DG56H'6.TS^Z2.Y8-:-(J@B('8,AESU5>%
M)/P6@WJ061CQ&(XKR++0-)T1$X`4%$1$1$011.$Z>B4';H-??RQL#)^,/Y!8
MYN(R#WASY$MF\J\(T!:LR=#<5?\`F#RO[*"^F`(@^(>$BAJZB>-^-BCJ]5<1
M-80T1Q?TFB<_MH,"?+[!<YV7I;Q>QS#]1;/V5<)V`VAR?EN.NV*[8%J\%Q/'
M$/*,CU]/N]FNNP,OF(Z;%IAQI-O802?*5,::_ANAGKXEXS>\.T'K[&+_`'7;
M-ZNEBMLBTR;CNRRXAC>?/);YC\*.$G'<#)S%K%9&8S`#:XL8W%9MZ-"X9N=Q
M*&2-`H%`H%`H%`H%`H%`H%`H%`H%!":]HDO5.$7JGK0>:31V`VG_`+_[RCRN
MY-VR=E..WW6[]BFG'9"XV7&-D>)^P"O5M@NHGNJQ<[GA4$I:]$>*&RJ_N)0>
MEV@4"@IS*,8M.5V:=9;M";E19XM>XBF]'?;=8)#C2HLN,XS*AS8CB(;+S1@;
M9HBHOYA;"VY!D>M7HUFV'<W+_C!2)$:U;&>$&7[;#[1.V6_8+;0-QQFJ/<V-
MZ;!J)(44^X%AX_K"^`&+@"8*A`:(0DBH0D*]1(2%5$A).J*GJE!%0*!0*!0?
M%%"XY1%X5"3G\%3JB_K1:"WEXPR8%S<R+#YK%@O[ZQUN9.@\_:LD:BB0-Q;_
M`&]IQD7'P:<,69S1#)854[O=!%;4._C68PKR4^W26)-KR.T$@WBP3'!>G1T,
MB"--B=G"3[1<4;4X\ID?9<3E%[20A0*U3JB+U3G\%]?V_IH%`H%`H%`H/BIR
MGZ?P_'A>/RY3F@HF189UE?>N.,$"-ONNRKG87W59@7%YPA)R1$=026UST0?I
M[/X+O*HXG[I($]L]YA75EU8Q.H[$>6+-BR.4EPY8EV.QI#1K[J$T:]#X]MP%
M0P(A5%H)U0*!0*!0*!0?%%"11)$)%]45$5%_6B]*"W6480],G.Y1B4N/C6;A
M';92])%63'O46,2FS9\F@`XP%XMBBJ@T1$DF&I=[#@_4!AW<9S#^:/.6>\VV
M;8,GA-(4VTR^'FI#8JV"W&R3FD1J\6DC-$]T!$VB^EX&S^F@K@5[D1>%3G\^
M%_4O(JJ<+0?:!0*!0*!0*"!QMMT";=`7&S$@-LQ0@,#%0,#`N1,"$E147E%1
M:"U<BT73`W')^,,++QMT7GKEA\9%5RW.%(]T[ABI/'V!WHZ1/6Y.U)#BJ4?L
M<514+D6ZYP;M&&7;Y+<E@D#D@544"-L7/:>;+AQA\1-.YLT$QYZHE!WZ!0*"
M$T50-$7A5`D1?3A5141>?PH-0?Q^7"%;/(_Y:ITTPAP8/FK`>ES'U9CQ([#>
ME\"E.2'Y+IM,@RGW*JID71>>?PY"L_'B^_X^X%N/`]>W.1)UWD?E'Y,Q<ZVG
M9S8D669CB[GN[5QPK!ISK;L'*Y.6VY'X,VYP3>A6J&;RB\LQ6P;#:!!A,6^*
MQ"C-BU'C--,,-@G`-L,-`RRT`IT$&F6Q!$_(:#DDDHQWR%5$A:-45.BHJ"JH
MJ?I2@T(^*#RK\['R4L.$9@SI'321FU7D&12S:L=?$$7H*.',%?TKS^T-]L1Y
MN1';>:14!Q%44)$1>A*/5$54YY2@[%!KX^6=6O\`NOOD)1Y'5:+PU\C6S]@!
M<=1'-4Y0WW")(0_0I<JJIPB(JK07EU++"1X6ZPF]S3[4CQ@PJ43D>1$?9<:>
MU1;7B=CRFB<A2&B`N1,"5HT7E%4:"BW,_P!9Q/%+6F$;*W19]-WK;OCI;[/8
MLB_O5;,9RN$4S7-EM]WR;#G'),=TY^).W^,^C["=D=XV5(A[QY#)[6^6X=F^
M%6'(,!S&TY]BSL3["WY;9+M$O=OO)VAP[5-?"Z077HLJ0,V&X#RB2\/"2+U1
M:"N*!0*!0*!0*!0*!0*!0*!0*!0*#B?549<5$YX!5XYX_P`_6@\Y^@%ER?G8
M\S7Y5K>@2&,GT3$9D3+@ZZLRRL>*VW_L)5M:'O;^QDR%>0XY=@LNHKB<D2\!
MZ-:!0*!0=27"BS67(\J.Q)9>;<:>9D-`\R\RZ!-NLOM&)`\PZ!*A`2=I)06?
M<MUUU-%.=96;QD6#LR6C>Q"$X4^YXI!!@F7'<29-O[VZVA@41P[6IFZT@D49
M23AE0N=CV0VG);9$NUDG1[G;9@$Y&GQ'4<CO"!J#B)WE[P.L.HK;K9H+C+J*
M!B*IQ03V@4"@4"@4%*9%B<*^^S+9==M-_@-RAL^10!9&Y6IR6"`Z3:NMN-2H
MSG">['=0F74_>'NX)`D=IR\K;<V<6S`D@WY\8[=JGDK+-GRY_P"V1V5_=[EY
MPF)K781NP'C]\$Y)I'&40Z"XR+RB*GHJ<_VT'V@4"@4"@4!4145%3E%Z*B]4
M5%]45*"D[SC#<N<S?+6\5IO\5L`&?'[^R?'97N"VW:*)"S<(3G44[T5UE%56
MB$NM!V;9?5??&W7*.Y;[R8D^L!PVW!<C`HM%,@N#V_<0_=X14ZNMJ7UH@\+0
M5'0*!0*!0*!0*"G<AQJ#D,$8KRNQ9,>2W-MMSAN+'N%JN#:_PY\*0**HO-BJ
MHH$A-N@JMN"0$J4%)6S++G9;TUBV9,--O/MBEDR:&B#9LC<Y]L8*L*O=9<@%
M17NBFI,R$^M@^.6@"YR+RB+PJ<HB\+ZIRG/"^O5*#[0*!0*!0*!00&V#B<&(
MFGY$G/'Z4_):"DKCC\N-*>O6-O-Q;J\HN7"$\I!:[\C8("-3!:%7(LM`3AN4
MWR8+^^+@\C0,=RN+>%D0WV)%MO\``]H+O89KC93+>\8_00N#[<>7;GR7M9EM
M<LO%]/*&BB@5A0*#B?\`]R]_ZIS_`,1:#1#XW^+_`(]^17E%\F:;EU9BV?7+
M$?,.QR<<GW!VZ0;W87)VI,&E"_!N-FF6Z;%$Y5H`Q47%Y)I>G3J&1_C9>LI\
M=L:SO^]>5.Y;H*!Y0;NQ&!-O,9D<MTT$K<L^UV1F?.M$-EC+-:!-G`$BYSFV
M[A9/<%Y]QV&CA1PVHMN(XBJB$G"]JH2<*B\(OI^I:"%\%<9=!..3;(4Y].J*
MG7HO2@T/^*C33OS@?([*;;$'/\'M2QG2041QYJ78=0>V\3O"D)Q5C$@BG1>Y
M%Y1:#>[%9".PVPWS[;:*(=R\EV\JOU+^)<K0=B@U\?+,K(_&!\@Y2&Y+L</#
MCR).0U#<!F6ZP&K,G)YN*ZX#C;<@VD5`4A(4)4Y14Z4%UM'%%7P9T^L2.]'@
MEXGZ_6+%E>R4AB*NG[2K,>3[(-L$\TSP)]@B"DB\(B4&%NRO-3$_%75_BC)N
MFLL1S/*1\7L8RBSWK+<_M.N+O_+)\'6F+W7$M:W.YXKD8Y!D5TD2F+C=H92+
M;%CVRV@^\Z9>T"!LCT3L9_;.L<<S]^3K>3_>!+D\R>I<^+9N#MQH]TEQ(T>W
MYHN/XN-VGQ6&!;G($)H&)@NMBIB*&07@H%`H%`H%!#POY_ZW/JOI^5!%0*!0
M*!0*!0*!0*#AD(A,N"0$XA#VJ(]W<O*HG111214YYZ4'G1T5$=A_.=Y6R8]T
M2XQKEF.K6G`)UB3)MC[/BGL.?.L[C1.]\5B$4]AP%'ZQ^X5$'M,EH/1I0*!0
M*!00D(FG:8B2<HO!(A)RBHJ+PO*<HJ<T%GL@PB\V&Z3<RUJY"@WF;*&1D.-7
M!YQC&LR`R[Y#T@604;%DZ!R#%S9%>\5[9(.#P8!6F*9E:<J9?;AK*BW2VD+%
MZL=T9^TO=EDGRK3-SA*O>V$EL>]A].6)37!M&8KS05?0*!0*!0*"2WK'[3D$
M1R#=H$>;&<%.1=0D)MP"$F7X[K1-OQI<<DY:>:,'6BZBJ+06_8NN0X*]]OE]
MQ2\XFX;GV.6]BA<+$*$A,PLL9`4:=@L-EV#=!1$41190@2JZ076;=;>1";+O
M;40,'!ZMN`XG<)M&GTN`H]>4Z+0<E`H%`H%`H%!*[I:F+FT`F1L2(Y..PY<=
M0"3$?-HV_>8<(#0#1#_%%%?Q14Z4%/P+I=;7-&UY(`.-I[,:TY$TZ@1[L1,N
MN$W<HWTMVZZ",55+_P`RXI)[:HJ]@A60$ACRGZE3E%[5_%%455.4H(J!0*!0
M*!0*"5WBSVZ^VV7:KI"BSX4UM`D19;2.L.]JH0*8]"[FS%"%143$D11(51%0
M+2/WZZ:BCO.93+N60:\C>T$?($!RYWW#HJD#9EEJMDY.O%C:)5/^8MM>Y#CC
M_P`2)")2*"\<&=&N,:/,AN@_%EL-R8LAIQIYB3'>;!UF1'>9-QF0PZVXA"8$
M0JBIPO6@[E`H%`H%`H%`H*5R/%X]\1B3'=6U7J`#W\KOD4>9<(W47O9<9518
MGP'U7^+'?[VC]>U"020.C8<E>^\6PY"U]G?1`W([XD2VZ_1HW#<B?;#,1&,\
M!_4]!)5D1Q(57O%4-0KB@A/GL/A%5>PN$1$557A>B(7TJJ_IZ4'G8\<?('.=
M&>:GRI)9?$_R7\@[5E'E%@;S-\T79=?W:!8Y5NU3;V9<"]N9WL;!78TO_B&C
M1N*$@4!Y"4D[J"\&EO,S,+YK7<V-7;XW//#(K%GVZ/)!B2W:L#T@<1+5D&QL
MIM$VTW=+OO:`ZU>H:@XS-%MJ1'!X5]MUT4[J#;9H69D$_3FMI&66"[XME/\`
M<O&6LAQO()4:9?[%=F+)`9DVN^OPYMRB'>H:@@2_:D/MK(0U%PT5"4+KR%5&
M'E1514:-45%X5%[5ZHJ>BT&A3Q1FFGSF_)9;1$!4-1:;F,J71%99Q;3YNB':
MG*"CCOIZ<DM!ODMQ2#@QCE*VL@VT-U6E)6^XE4N`4A$N$1?Q2@[M!KW^6AYR
M/\7GR&2&B$76/#+R/?;4FQ=#O9U/E+@H;9_2;:J/!)T54YX5%ZT%Q?'20].\
M`M$3'S-U^7X?:PDON.J!...R-*V1QPW%;;:;4S,U5>T!'GT1$Z4&(6W\NUU@
M.D/#?(]]'E5QT>6A;':W<<P7:P:SO\C9#N%X#,QZYS(#.R-:7C-[5'L4.XM-
MM1)4A+9*<&0\PH&+\8,Z_$8\ED:$PJX9+<'KD%Y<R6^X@Y.RJUY[>HNM+UE%
MWN>L;;D>>62]9%9LVR.VX'*@,S+G&G2VI+P*OW$@D*0Z&2M`H%`H%`H%`H%`
MH%`H%`H%`H%!Q/+VLN%QSP!+PJJG/1>G*=4H/%[XR7FY7C^IGV!=;A>7Y$Y=
MQ^5F'%$/N9%['\:T+(A6)GL8(F93=EB6-AL#?_B\F7:G;0>T>@4"@4"@4'Q4
M1?5$7]?7U3C_`$+06_R?!0O,J)?+-,3'LLM1R#M5]B@X2=CT=UI;;>833L=F
M_6)YTA<<AO\`(BXGN-&VZ@N($NQ?/56[_P!R\QBC8LX:8$VV@*6=BRF.R/8Y
M<\0N4SA+BTVH\R8Q*DV&I"CH*)`X8711>41>%3E.>%3A4_6B]46@^T"@4"@4
M'`]':?!6W6FG6S`VS!UL#$P-$0P(3$A(#3HJ*G"IZT%MWK3/P9`<QJ"_=<=<
M>><FXXS)+^8VF/[9.N.8JCYK[T5'A4C@$:(GN%]NH\"VH5U9;W;<AMS%UM,A
M)4&2A>T[VDV7>V2MO-.-.(+S+S#HJ!@8B0D*HJ4$UH%`H%`H%`H.M)AQ)C3K
M,N,Q):?;]IUMYL'!<;Y5>P^Y%Y%"7E/R7JG6@HQM+AB`J+I3;KCC?+OO$12[
MG:4(T[@-P5%VX6YOG\6_=;#U4D3H%:QI+,QAJ3'<!YAX4<9=;(3;=;+J)@0J
MJ*))0<]`H%`H%`H%!`331(HDVV0JJJHD`JBJ7/<JHJ<*I<KS^?-!96YXS?\`
M`+E_/\!C%=,=FS5<R#7+#C$91.037OWG!WY;K4>VS0!GND6U2&),%%5I8[JJ
M1A<C%LLL.96L+OCL]NXP5-QAQP0<9>C2X[A,RH$Z&^+<RWW"*Z"BXR\`.#TZ
M<*BT%2T"@4"@4"@4!4145%3E%Z*B]45%]45*"4W:S0;Q"=ARHXF)^V31BX<=
MV.^R7N1Y,9]GAV+)CN(A`X'!(J>O%!13-WNN%R6X>63UN5AD."U#RUUII@HK
M[[GMQ+=?V6%%MEXR7M&:+8,.KQ[G8:]0N/WB;9$G45!514X5"%1Y115.1)%1
M?5%XH-5?@G+)WRN^5"`0PR6%Y2ZZD>W'(TD*U,TOB:"],9(19%7"BEVN"JFY
MVDA=!&@S"\6G&Y6!9JYV?0._O(U@1<05[4B[LSB*:"G5!`C9541/P6@R61..
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M]R.LJ-)8?%J0VA"PX`9">$UTQB[:.]_$L@MV5VYG:&[(<W),>8M<+"KUD4?;
M.7#DT[7%MLUZR&VVO6SM]5]+$P$Q]P+:C2O&3ZN$H9<4"@4"@4"@4"@4"@4"
M@4"@4!?1:#B$#1PB4^1411!Y5>%1555Z].O-!\D=6'4_^YE_HH/%%XR/6JT?
MU(VS<BN\N/;K?#W]YB>Y/N4J';;9%?33\^`(E-EOQHR/2OYDB"CA<EV$@HJI
M0>R9-HZY5@G_`._>&=HFC:I_>[&^$<5%(05Q+I[2&0(JHBDB\)0<#&U]=2N5
MC9MAK[:<I[C.8XJ\/>BJGM_PKP?U<"J]>/2@C':NN340#.<,<=,T`&0S#%U<
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M%DVND>?$L2*LN/%A63/''+:Q;<<R&:ZZTU#E^X$"[O&C;2`^A-J%W2\B=(MN
MN,.;,Q07VB('6/YBBO-&"]IBXW[:&"@71>4Z+0?3\B-(-$T#NS,5;-YE9#0G
M/[5<8$T;5T$5OJ".+V\_G00.>1>D6>$>V9B;1$A$(G<5'D!3N4^K/*!VIRJ^
MB=/SH/FI?([1&^++)R/36W->;-L,.Z2+),NF%Y=8[ZS!O,5MIR19[@U#FG*@
M75D'44X[K8NBG54H+K?SB`2$K<J&:MJ"/C]]#0F"<3N:%[A\D`G`7D4_%*#X
M-ZMY<]LB.YQZ^U+AN<<\^O;(Z>E!$5QCKSW-BJ\<?4]$].47CE7_`$Y3F@H"
MZV&:ER>R/"I5OM]Z?-LKW;),COLV0,@(!VW%N*\XL*[(RG:U<&Q]P13M=!YO
MZ4"0.^1&J++:KK<\ZS#']9+CURM%ER6'L;(K!B3MANU^DNPK'%E2;Q<HMNE,
M7Z8T3=NE17GXMQ421APR;=$`O'_,8W<0$8B8+VJ/N,JO<@B1)_O/0>[CGTY1
M:!_,8Z?OD@+^`JZPJKT1>G:ZJ?C0?0GM&7"(J)_M*XQZ_D@B\I+T_)%H.198
M)RI":)SP"_3]?Y=O))ZT$*36UX1!+O4N/;)00^U%^L^$-4X!.55/6@D.3YMB
MN%VB5D.79!8\6Q^"C?WU]R2\VRPVB$KS@,L_=W&[2HD-A'GG0;!2/ZW#$4ZJ
ME!.V+E%DL-R&31QAX`=8=;(#:?9<`7&GF7!)6W6G&S0A(5421>46@XY=UB0F
M'Y<QQJ)"C,.R94Z6ZU'B1H[#9.OOR'G#0&F66Q4B)51$%.5H*1EVR[0)B7K%
MW_?8D.*[<+&_V%#GMN`TV,FV/F\(VJ>WV]R]O_#R`7ZP[U1R@JNVWF-=(46<
MRU+9"4WWBS+C'$E-*BD)MOQG^UUIP#%45%_8JI0=X9'=RBMF)IZBJ=PCU'A'
M##N`"430N%7GMZT$MO606G&[5<+[D-QMUBLEI8<EW.\7FX1K7:K="93EV9/N
M,\X\.'%:]3<<,0$?J542@[5KNL"]6Z#=[3+BW.UW.(Q/MUQM\J--@3X,MH7X
MLV%,CNN1Y<24P8FVXV1`8$BBJHJ+0=[N7_8+^T/_`"J!RO\`LDG_`%?^0J#[
MROY+_F_\-!\Y7_8+^T?_`"J#HQ9\>X`Z<<3>:8E289DK:AVRX,AR-);['D;+
MEE]I40D11+CE%5.M!;/)L'O+5TDYC@,N#9,PD(TW.9FM2$QW+XS`N?;V_*XM
MN_BA(91Q0CW1D?O(PH@G[S7\*@F6);&@9'<)^-2(,JQ9M8V!=O>(79Y@;G$C
M$Z4>->8*MH@WC%[D^"C&N4<2C&2$V7MO`XTV%R$)51%["Z_]%/\`22+0.Y?]
M@O[0_P#*H'=^@O[*"6N7BWLSV[8[,AM7%YER2Q`<EL-SWHC)(#\IF$9I)=CL
MKSW&(J"<>M!,^[]!+^Q?^7B@^T!?\O\`).5H.!AY7D(NS@4)4`T,7`<'E40A
M(?I7E$Y7A5XYXYYYH/K[#,AIUE]EE]MYIQAUI]L'6G6G147&G6S0A<:<1>"%
M45%3UH+27)J]:\)N5;K;-OV"M,$DVU6I)<N_8LX;A]]PL\)$=>OE@%@B]R"*
MN2HJ\+'%T541#6S\?63V_*/-'Y85MJL*D/R#TTBN-,(!S[?,TW"D6>XC+9FF
MS(9,VI0JR;#<AD@537G@`#._Q5X#7N8CPJ+_`-H/R8%>14?K#?FP@)5[D15^
MH?6@R8H.)Y%)ET17@E;)$7GCA51>O-!X4ODGP_+<@^=C!L9QIO&[ODF6^0V@
M`LEBSJW6ZYX))QR]8[HFWY'9\EMER@7B%<H>0V.W71L$D1#;"4]'(?J%5$,W
M_#?7'DC@GSA^:./8>QXLX/?W?$O`LCPBV6C6.46K`H&D;_EV%OXPP[CN*Y)C
M-[A[+D7'O+(),F3):E/MBH%[8M"`>GC5L'=4>%./=-ZUE=KTEP4;0>L+!EE@
MLXV4HK*D%RBY=DF3SW;N,]'%1QJ0#/LJB*WW)S08J?+,JI\7GR($*J)#X5^3
M!(2*J*BCI_+E145.J*G%!7?C89G\?&@7#,C<<\-M6&;ADI&9EI"QD1F9*I$1
M%U55ZJM!CME6L_(+*=$>-^5Z:O&D[59[)XQX);\DN>XK_?,?_NBL>'KK)Y62
M8W-MF"YE!C)/QJQ3K;<'I)108B2._P#B(*B@;`=-6_*;7KZQQ,SQC6&'Y`BW
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M^#'<QFAP/."39509@M?RW5]U`XANMNI%?C.%LON%UIZ0;I<IPIJGY4'VQ?`Y
MG_\`+KI9,K\YLNDVJZ1"B3(F.Z[?MH7!'7@<?D7%J;L"=&<E.,BHH;8-J//3
MTH)&G].KC]OM$&Q6+RFNT:VP9#"M!-U!C\EYNW,^PG\M!_\`O1]PZV\TP(..
M..$XYPA$JE00)_3K6N/=K??+9Y;WZS7JRNW-RQWJSZ<QNV7:W+<T?]YQR9#R
MAMZXN<OJG;(5P.WKQSUH)SE/P7[ODW(9&(^?.:VR"3I*_$N&.9"0FTX7NN^S
M'C9\<"*92%4D1MI!%%X'A*"3_P#<5^10&#T3Y`,IA26'0>:?:Q[)C)QT'YR*
M;HIF[()WPI(`HHB_6'//%!1TS^GDV7+R"5F<GS3*\YE(M,VQ,WK)M;W2^K!M
M,A\Y;42*Q-SMQA%9F+[JN*'>2JH\]J(E!U"_I_M\&Q,C2O+77%U9F0W(<@+A
MJ#(E9D#[[3K3Q0PSPX41SEOW%1D`07N"'CA*#AQ3X!O*3"K0Q9\8\]HF/P6.
M]MF)9\%REAN)#&1(DLPFI<K-9EQDM+(<1TU==55-51.!040)I,^"[S2D$PO_
M`'B$::+3*H?\VP#(IBF9A(]QD>,M#VHONO(2=O!?3^=!*G_@8\R+A;I-NN7R
M%6N2Q+]QEX#UID+H_828BPY<$2+,FWDC/L$0$/>G<"^J$B$@2*T?T\WD!C;=
MIC8WY7Z9L\:QVQFU6K[+0UZC28L5@U<`5EL9V,F0Z*K_`+YPR>5.BDM!-X?]
M/]Y%P,JL^90_+?5<;(++$F6]F>.GLGD!,A7&)'A30N-JN.>3K).?5EE?:=>C
M.FRJ\@H]:"]K7P_>;4:3+?8\Y]>FU,CD+D21X_V(V$DGT4VU5PC9:!/W4#CB
M@YG/B'\W@@LLQO./`%F,)(-J1)T?:3!N0JR'(;G8`(K@,ON`I"7*$(<4%DLX
M^!SR<SG);?EV3^4VJ\QO\&%<K8S.N>&YAB+46#/N`SU2-:L-N$2T2)RO\N?<
M/L..M<JVVHMET"G,L^`7?^P6;O"RKR#TU?CN+DBWW9;EA&=/M7*V+9I<%EL'
M;C)N2VY;6]/5^("$^++QNN-D!FJJ%Y;+\0/G#8L9M>&V?RMTS;L9L4:QVJQ0
M%UY=+L_:K98I,5V$?\VN&/K=KG-9`'D59K\CWE>5'"441*">K\4?R`LN(L7S
M`T(+0PUC?;IIL8@/*/NMM*2Q[6JLFHDAFZ*$9&BCQVT%%9!\.'GUF&)7C#,K
M\Q]%7&R7V&Q"N#$74LVT2%B]["3(\>[66):[]%?-EE?:E,RVG6S+]WIRH4O:
M?@2\@K4(.M^36#C,9AW"VM.-2-LG%*URB?::M[\2;?9@."$)Q!)WE'>]5453
MI03D?@P\DVQN7L^3N!1UDP)%IALQ@V2PU#MD@&0^W%T;@KZ/,!&;`'D_B]J*
MJJJJM!15]_I^-Z91:[C9LF\A=99%:YMTAW+^6W[_`!/O5N>^Q895B/<[?<9T
MB#<H@SHX.HRXUV(J<HO=PJ!,)/P/^4*I+(/*;7L<7ABD@QUVHVT*,D*G%&.L
M]^,S"9'^&T(!RC0"BIRE!AWX.?'W<_+7R'\V?'//MQY?C,3Q;RJ#@]]S/"(U
MSE1,LN\_),NQXH\%K);TJ,6*4SALTN"8]QU>X5Y%%2@SOV;\.?CMK*5&QW-?
MD>R;7-SGLQKA'MVPLTQ&P7&5:R21$":S'O\`G]EN#L%7XC@@0+[9$T8IR@&B
M!3EF^)WQ/>M,F:ORBE/B($AIJZ8WG6J8S/WC;9F4N3*F9]D*.3(K0*O#3C0(
M@]17JE!BGYB^(^`>)-Z\3K7J;SVV#EL'='D!8]0Y:L?9-HF)B6%7O&[F3N9.
MM8[E341"@"VR"E/((;C8JIN=YHBAGQ?/B7T'>P?L=_\`DSS^_6N5Q#+$+WL3
M`+Q8'(S_`&-NVXL>ON8SF)T2;$1([K$E'6W&25%%4X2@FD'XI-.V:%:[7;OD
MWV[9H-HBI9[5;+7L[!;/:($9`5ABU6ZU6W-8<>$Q$95`88:0&V@1!$41$2@^
M!\7&HQ9:B-_*SMU5%76?;?VYATEU$<%YEQ"]W.3,WF^\E'N(NTQ3HO'%!@=X
M'>-<?RI:\@+IL#SXWGJVXZDW?E.H\0-S:+%MBYUC.*2'QA9PD#(\PMRW"/</
MX:*Y#)8I(7"*2=1#/5CXP-9)(G=_RK[??F2?MUDL-;;Q5K[<6>Y&U"*FR32.
M+G=UX7ZN*"*3\86KF6'57Y6]P00$D.09[>Q4381Q!$1-QW8J-M,O.D1"G55)
MQ4YX[40-3_DAXX:>U7Y]:#T+DGR);IN^BINB]Y^0_D#M2W;#R"[_`.%-FP2[
M6'',2M[ESP[8.0>R.2Y1>(\)Z-*CN<-FP++*F]R`7`?P+X@8\\K<U\OOD\]*
MB3`ANM0[IO.Y%"DN3;9;F0;.#:#"*;DB\QO:<!.TFW44>16@E;>O_ABN-T&[
ME\NN_#R4K7+@V2\S9VX(U_LE@=BM76]6^V3;E:&9[%MNC5O;E2V^Y&I/M@?:
M2^VJ!5-EU-\3=U=C76V_,_O:YV9QIIF#'BYEM63!?:5Z4!&](1V2<M\G89$C
MJ=B(R8<<@0JH5@WJ'XKB?MUU;^7/?C;,UU&K=&<R+:Q.29C97)&5BMHS]Q[D
M8[2\1(HJ*H@]W0P[@[,W6?QDW4`)OYF?(V"+,V;#<=9R[9L9#E16[:<AM]/L
MQ)IMH;FTJ&8B'U%POT%P%.1='?$:YD%JRICY?=I2LRQQ'K=;<Q+(<JF9=;H;
MG\RC.XS#RE^VOY1#MI2&WE.$,SL=->%'DAY#-'4GAQX^[XUS9MN:?^3_`,U=
MBX1<)MXMEGSW#;ML*+">FV24_CEY2*,6W6^2`P9]B.*XX8*#:QT15YY(PG#7
MQG:S*U0H'_>&_)1[]W17HMU8S?<82'?M9,6+)-]0>=:;=?>N#7(KV<BO(CVH
MJH%86OXT]51GFR'S\^2*`$.).F.G)VALR`;@08\6:9&Y-AO>V0L/\@TX/+W8
M:")()<!(;#\:FD+#$M&$8C\AOR/XM!L$0H,"P1-F;$01C!<)C!.6\$L`-1VC
MG,2"%`%1(^]T>YM1)06OXW<6R?:..8=C7R/?(Q=+#=K;F5KO4B1Y#9O`O%MS
MS&K1AV6Q+9(&4U:VVADX7EY2C:]APB[!7HB+072SCXK&M8X?D&>99\F?G#CF
M-:[LEVS.^9=>=KWJ>Y:L?L5KD2[E+GO2KNY%E!!@PC=[!CHA'Z-J1(BABC_3
MBX9>-]>+OF!O;:V7YGL>)Y`>4$W&K=><TEW.UYI><4TGC=KQO'[Q?K]:;NU>
M3ODYFZ^U+<:D,FV]%-K@50N0]$VD=`ZT\>;#D>-:LM%QLEERO.<HV+>8=RRG
M*\K5[*LQEMS\@G1I>77N^38#$R6VA_;,N!&$U(T!#,R(+TT'7ENM1XLB0^2"
MQ'9<?>)51$1ID5=<[E7H@]@KS^B@\$_C98-#>2&9YSY>>2'R6WOQ^WT&^,N3
M"W,PPZXY7M"W6*QJRN`Y#8<L?N48;-#2S+&:A0H39-L0[6T@H)$:D&<N'VKP
MCL^WKQN-OYP,Q?W/E&+I@%USE<7RFSY;-Q>QOVNYQ\6EWAV4DIZQVV7$62W'
M50Y)U%$^P$2@V6>`^6:^G>300,8^5W+?+N7=-?98_#T7>8%[2')@6Z5CHR<U
M=E7FYW5IN3BDE[V1^W2/WC<.#0U1%0,S_E>[?^[#^0KN[NW_`+%_DHI(#:ND
MHIJ'+5)!:'ZG"5/04ZKZ4%<>-3@._'SH%T$)`<\-]5N")#V$@'I*PD*$"_ND
MB+U3\*"T[FV8D/QXU?H1C4%_W#D&Q/!^'DMNP:)D5NPV#L6T1+'KK`,GP"V9
M)->1Z->W;1G9S9+C`$<*`RKG[YMT&4/C)M.1N#4-GRR7BMHPZ1`O^<8*]9\;
MRS^_F*JYK7,[[@+EPQ/-/Y385R?&[BYCJNQ9:PV","X454>Y0O\`T"@4"@4"
M@4"@4'SM3JO"<KT7HG7]?YT'V@4"@4'Q5X15Z]/R3E?V(G5:#J1YH27)38-/
M@L24L0R>;5L7#1IE[W&%7_>L]KZ)W)T[D5/PH.PZ:-MF:\\"G*\>J)^?[/[?
MRH.G;II36/>*,_%17GFP;DIV/DVT:B#QM^K:/(G<(JJJ@JG/"\H@3"@A[?J[
MN?V?LXH(J!0*!0*!0*!0*!0*!0*!0*!0?%$2X[A%>/3E$7C]7-!QMMH"%^ZO
M<7<O")U7CU7\UH.7A$]$XH%`H(5`2ZD(JOIRJ(O^E*#Y[;?_`*,/^J/_`(*!
M[;?_`*,/^J/_`(*"3Y#=(>.V"]Y!+%!BV*TW&\R5`4[DCVN&].>XXX5>6V%Z
M<IS0>`7XZ?C7WSYU>$ODAYZ:4\@?('!_(S='DGMP[)K3"MHIJ#6FWK;;,WA2
M;F6:7^*$:\Q)=KN.1W]F)-%\_MUBD#0_62T&</A=\#.VO('=>U<N^4K&MXXY
M!QC%M<VW7PP?+>[[7<SF^MWG+9V0NCG+Z3[^SAMGLIQ(K5G-8J19,^6ZT:F[
MW(&R&!_3-?&U`EPYC<OR9<=AR9TA!/?E_:;?^]`VA;D+#ML5]T(;1=K1$:NJ
M(HCAN?4I!VK;_35_'I:6Q"%E/E<VH6VX6@#7R`NG<W!N;JN2``0L3;0N`!$V
M!=J\-KPJ$JJJAQ__`*M%\<B..F%U\G@]QJVH()OBZD#,JU*I1;DP)V8O;N"F
MB$9IT)4]*#D?_IJOCQD/M/.Y-Y5&#$UFYM1CWS--D+DTHJ4[W%QW[LGW>WZN
M75'\DXZ4'=#^FU^.QMB/';NWDX+<:>=R9_\`J[W0NR4X#@&:"5E4$15<4DZ+
MP?6@Z;_]-=\?<HFRD9GY:.DPCJ1B<WTZX45'4)"&.3N+.*T*=W/"=%5$Y1>*
M#IR_Z:?P&E*R\&Q_+V/,8:;9:E!N^W.$H@@I_':=P0VI2$(\*CB%Z\^O"T&L
MCY4/@0UMX^>/]HV!X7XMYE[IV!=]UX!:LYPVP9W$SJ;"U*42_2\QG0+0QAS4
MQB7]];XJ1[D8S2MLJ2+B,F"**!9[X$?'C")7R`;"SC%</V#9K)CNF<9Q?)7-
MT7_&LZOU^RR[;<S;+Y20X<+%K$Y8K=$QW4MFC*,N+&E!/@27U`5D!P'N,;Q;
M&AY<_NY8$=<5LW3;L\`5-QOVE`U+[?N)05@.U5ZIV#^24'4<P7"GGON'L0Q9
MU]&T:1YS'K0;R-"V+(MHZ<,C]L610$3GA!1$]*"TZ^*'C*3SKY>/>D5-^0[*
M=(=684)./ON$^\\:I9N%==?<,B+U7E/RH+$ZX\9_':Y6765PN^C=*,W,+]EP
MMFSKS7Q#+D">1&C++SN--NNO(%L%Y&X_8Z(M$I$38DBA*<6\;_'5Z%J!Q=(:
M0DN7W9VS+?<#'4^*1UN+$"+M20RT0)8U;[H*VMON]W@75;Y157M%0HW7WC=X
MX%CN)/.:'TJDJ1Y';*M$IR/K3"!==C6[*MGVR+`FM0\2=;9.+&@`TAJ#!BC0
MD3S9\HH95:&U-K/%,+O&,8_K;7M@L-NSO8T6#9K#B&.6FT,PUSG(74`;;;;/
M!A"X;CQ$X2@9N&2D9F2J5!?1S$<6=0!<QK'W!#E0%VRVYP6U5155;18Z("JH
M)SQZ\)^5!UI6#8=.[?N\2Q65V-&R'W>/6N5V-.`K9M![T8NQH@)444^E4545
M.*"F+_B6M\7M%]RE_"<.:>LMEGWA^<F,6-IX6[7&E3`1)00XY(HFIJ**:<$9
M*BIW*JAIXTIKW8>'[EUYN28.PH&H(^U,1M6'VY[/<9N6MUO6:V7)=!9-*+5\
M'%;3E.$W>$PMFBPUCR%M)($B1([WB[U#+_S0SBVY8N4ZA(W_`.Z>MM193Y';
M^E129%RWX9@D6]W/66(2C>9=B]VQLVQM^83!F#IVO'Y"**-R.Z@\FGPI>,WR
M!Y+;+]AOBMY_[&\=;9@>G?%?R-R7%LYP2Q;#U;?LV\G(FS<KN.+W+"KQ[CMI
M=<Q*T6N[//,*T[,DW,U?!2;;<H-^-UO_`/4$Z.MLZ;=8?QV>5>/6-FZWBXW<
M;WL/0>23;+'C3);CD@G8Z8W9AM34=MP^Q'T-M"0B_%`HG7'R[?(',PO#<ZV!
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M<)$>?".V/"W94)N6HN<+%7[A`RX\;%4OCVT"O*\EX:ZL7G\>ND+&O7\Z#!WR
MDL..YEXL^$6%WG"]BYE+O.#X`[;I&+XKAU\P?`PCX#B;%PS_`&/=+SJS:N9V
MR):(4LV8,/'883+NX^['>5&.YUD-C'B'9"QCQZUOBY9M-V$N-6F18ARF9JV!
MI<)86V?)CA"MNMK98,9A8W9+0(_:P0&().160,S=<(G3#):@4"@4"@4"@4"@
M4"@4"@4"@+U14_.@A0>$X7KUY]/\ORH(J!0<0N]SKK7;Q[?9UY]>\>?3CIQ0
M<M`H%`H%`H%`H%`H%`H%`H%`H%!")=W/3CB@BH%`H%`H%!@M\FFV_P#`[X^?
M,_9P3!MTO%?&W:KMJFJX;9L7R\8I<L>L*LFU];<C^=76.C9?@X0JO1*#&KX$
MM5+J#XB_"/&WP3[^^:ND[(N+BL"PXY*VCE>19^S[R(1JX[&MN1,,>XJ]S@M(
M2\<\(&WU$1%541$55Y541$55X1.5_->$H/M`H%`H%`H%!;C<&;1M::JV1L>8
MZU'AZ^P'-<XER7NY6HT?%,6N]]??<;;$W'0;;@JI"(DJCST6@\Q?]-SB*W%C
M<>U;G93A7K+KA;GIL^*<QFV/7&#B&-9=<W66YKI2YPW.Z;VF'RZ@K%<C$T(H
M/""'J[3HB)^5`H%!C=K:XK!M&K(+LU7"O63YU&:)%22DH(;.<7#V7YCUWE&\
MZPD=%`P5\D$%#M`>XA"5XZ^Y)9T,[!1]I@]O[:%YMM31/LVK3N8>R1W2^Y8Z
M2&VUX(G>30/I_$0H''&^S'=<L18[2BQY>;,DNJ)S'0!LLRV^DJ0G\NN,1I7!
M>/E??60R)JJN,JZ@]H9":8$&[#D[0-RA[-E;+(SE7!;@KCSF;7LY"L&O/VD4
MGE4FX_/\$2XX_,+OT"@M%N_V2UOE3$F5%@L7&TG979DM\XS3;5[DQ[5(;20T
MB.QW'V9:@!(J?42<<+PJ!A]N1NS:@^/_`"O.KM)AVNS:>U='WU*ER9LQ!MRZ
M[N\/=$PH\N%/D2GE>:LSC;#0/E[[K@,J9]ZJ@87^<^673!OB!\V/(7)K2=IV
MSY1:<>N5QM#3S4R\65[=;=BUII;6D9OLD,RY^$81D\"&49I2:D73[PQ_WZDH
M</PO838,+N/R)[#)ZW0;7'\H]<>-ELNLB6U;K:>/>'/C%IC4?\N9CW`H\6$U
M:<T6^-JZ*_Q'")$3Z$H-F&89:7DBJ:XU\3SNHILJ*FS]L1R$\=R&P0+L`WO5
MN!N.("9+<LJ&(4&\7%@7;7`M+S[8O.RW@!H.QX:O?W8U)'T;<(0V_)/'J[2M
M42[8T9F!8;:'WW-3Y1#66K<EVR91K9;=(9<[40)`OQT1"8(1#'??$"T;/^4K
MPFUY<'H4IG2WCEY:>14VQ3(:SF)<[+)FI_'W&I<EEPQB(TQ`S6^H`NB:.$I=
MH]P]R!D1FW@-X6;&>ES,T\5M`WJYS1,9-X35F)6N]/\`N_[]';S9[;;[N0/_
M`/G$5]>_A.>>$H+TZ5TIJ_QWUEB^G-,8=:\`UGA;-PC8MB-F*:Y;;+'NMVG7
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MNMRM%:OR736L)4I+[<AG2<<USES,?(,?61+[SE(^V"/RR<>`1;<%$#+F@4"@
M4"@4"@ZT26S-8:DL+W,OLLR&3].]E\$-LE14Y'E%]*#LT"@4"@4"@4"@4"@4
M$/;]7=S^S]G%!%0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#05_4NYY<,/
M^)'?-CM#<B1==J9=I?4\5B*/<\\&6[-Q^9-85$Z^V[`Q]SN7IPB<_K#<9XWZ
M\CZB\?-':IBPQM[&M-1:VP-N$!=_VO\`=3#++9%9)?\`T@%"5"]>5Z_C07IH
M%`H%`H%`H%!K8^7[8$W7'QM^6%TM4E(MZR;7(ZOLKJ/(Q(2X[>O]FU@!PG5$
MT&='CY8XZUTX[F^O2@Q$^`[&&(_BL&6?RIQIV\9%L9YB^FZ,@[W&E[/R>R1W
M)4A6(CKLK^[V"VEWE6A%6WA42-/J4-\5`Y3\_3U_9ZT"@QCU@5]6Q::61%DR
M3_O)GS=XF3&;6[+BPPCYT,-U]UZUP78WW$EEAM"@M1W"$D$S-M7/<#I6(G'V
MM!.6J4VS&#<>V?O4CQWV69D1NS[H8?C"TMO@JC97#VW4<)H&S5M"$S[@(PI'
M`91QL;PIZ>+[C\[RFVI#1A\!=^UXS+;OVKS9!:Q(&2C-H0J2#[:$B>ZG^L%^
M--RKM*L^5K=6A:)C96R8T'M][^+:6<VO@VM[A]IHD[X?:GT=[?T_21=:"[]`
MH,8_+"=-CZL?A6J#.N-TN=UM\6/&M[WLR$;;21+60:?RJ\&_$:EQF$>`&5+M
M-%51%%6@LYO?"K?O;.<$\1G[>W=M36?&+9L'R&5YQH+9.QC'+BVQJ35MRBM-
MJ$L=CYG!*Y7&(J`R]8[`^R2"DMI%#5G\BCLS;W@-X%^,<)O^:7C?_EQX]^.>
M1N+*CQ.(^DLHO\;,),QMSM6:L*\:T%P1`P5U\6U[D1:#>Y%\=-(1KI<+U'U'
MK>-=KC?5R.?.3#K&\[<<B7N]S)YPN1/;DY)*$U5Z::+(=,B(R(EYH+SQHK$2
M.Q%CLLL1XS+3####+;##++`(VTTRRV@MM--`G`B*((IT1*"R6S]*-YMD-HV%
MBN43-;;5QJW.VBPY[9H#-Q*38I4MF;/Q3-<?F2H]KS7#YDAE'4AR%:?B2$1^
M)(C.J9&%@M2>/VUXGF7MSR>VY<<`E%>]"ZFT)KFWX2_D2NP[-A^:[`V!G.07
MF%?;7%2SOYA?\HMZM0VI5R1ANV\%)/O3L#/*@4'$\X+3:N$G*"H=..Y>IBB<
M(GX\KT_*@\IORD1,CRF;\B[#VMKUK:R8_P".?DQGPY06L_(C(,&VN]CGA]?,
M&:OR9$_?GO&K%=DY3C%]FVUC)6;4%X8LMC.WI*25(`"#?AXP$A?']XZD(]HG
MX=ZE)!^E.U"TG82XX$1'I^A$2@L/"RG+8=M\2\?LWCKA&]++#\2(>:3+CDDW
M#L>N^%76WQ-76F+*M>4YN$BWQ+=/MEPE_=QX[8O&333AN"VWVD&P#6N4W[,L
M1M.0Y)B+>$W2X!((K`QE%AS**S&;D&W#E0\BQIUVTW"+.C@+@*VHJ"%VDB*E
M!7]`H%`H%`H%`H%`H%`H%`H%`H%`H%!#W?5V\?M_9S014"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@\V/]0;'>VMGWQ*^)-NF,1I^__D'P2\W`7G7Q!<=U
M;;UEW=Q]ELA9>:&+E1(B'R7<O`JG/*!Z18JH37>*JJ.$1HGIV(75`1/P04H.
MS0*!0*!0*!0*#0U_4)9\S8O#+6N%,=[\[:'E+J>Q-QAC!-8<MV%1LIV=>9$N
M&ZGV\N!!'"&_>`U1$54)/J%*#7=\,&%66-XZ[)N>3[]P'!;_`"-][,PFP0\O
MQ.^#A%TQO!+/A>)P+W;LBM&5:VD2)7]YF;DS(<"XD;LD7%5U7&TH-H7D=ENY
M]8:J9OFN')N]8&4Y3CNL6(7BQY3Y1C&<P)>?S5Q>+>[%:-MR=JXB4N%D$Z.U
M'CM7!'RE/M<JTT#SC89(XH7D-C>&89"R")Y4MWF#$1V9D,DO'#;]QO*I;13W
M[]$&UX1>8:R'Y"/'&C6^,3#H>TB(*J*!8/<VT?(S*ML>.FKM=;RR37A9+L"0
M]E5HR3QAS[`+Y=<1?;;MT*)*R8\IM=AG_P`I*/<9KHP"9]\X[*.(+)?4%^K3
MX0[GM#>'ML>96Q$CX;-N<ZU,#9[Q[9NW9BXQGTE<[`(9+8Q[FX@BJ<(J\IQT
M1`ZL3P4W!#8Q1B)YE[*;'$+WD.26S_W5=43^=Y*,T+A*=[,\;5]HPNDQ4;-2
M1"E.*BIRJ*''<_#W<N+XXW*<\R\U8A8I>+_L`)$G&;LZ+%R=&Z76Y/O>WL-H
MGXA!<IQDV:\>XX!?ZG!!9CP!\[-)1=3G9-X>2EOC[`GYCD,V0NV[/F>L3LQR
M&(=QN>.'?-EVR';9C=GO$B7VNC>+BVHN`(.H/8V(;6<4VUJK/"4,&V9K[,S%
M5$@Q3,\<R(A(10B%1L]RF*BB*\JGX)07`54%%551$3JJJO")^M5H,8_)+9&/
M:VM5HR3+I5KA838!F9-F-RGQ&)SEOM&//P;PZL2-(+AYVXVVW3HK8M";QS'8
M[0HBNHM!)O$3!,YQ_7N2;#VXRY;]Q[VRN=MG/[.\\<I<!9N\&%;\!U:RZXZX
M)-:OUW;+7:Y"@7M2+JS,DC_[0JT&G_>$&+D7RM?&[X[6Q0FQ]8^0?G%Y47^)
M'1&0@6N1KC&KGC*RVT(^8W][ME27VSY5"?C@BH*D%!Z-J!0*!0*!00GU%?7\
M/1>%]4_']-!Y5_F(\Q-BM;.\OO$2-#U;?\9A?';YC7:/,L]O=OVX<3AW[Q:O
MF579+[;<4W),:P3`E=M,(7LARO%HOOR942#;F3^Y^^4-\?BPA#\??CDCG[Z>
M'&H4/GI]2:3Q[NY_+K08`^5>5:4UQXU>*N6;AMNY<ALEX\>+/CF3X=KMC"K9
M@VQM>X_CNNM@W[`-IY]GK<.W8C9L@N>.PP:@VZYP;KD[?OVUL)#;AB`;#?"3
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MF^+=DKF7ZZR6-9LG?M&OL*SK-2C#-G83':992?"A2$_]_BTX:(/!*2'09`):
M+-CC1VQ-;>:&K&&1]AF1KS*;]L#'F2!E4&?:H-CS'8(HTC(]BMO6P40N$%LN
MBT%JL)DCFOFM@3,/8F<9U"UKC5YN!1-FX])Q7(+1*<Q*^17`9BEAV"?SA%'-
M;03\HV9WL&\+*."1$*!ME3IT_*@4%L]QR78NL,Z)AK[A^1BUXMT>-]NLKW7[
MO%*TM*L9`=^Z!LIW*M**B?HO"=:#'W3+DJ'J_$L6M62:TR#^;6^Z7+^Z&51V
M[1,>@3[X[=76Y$"US+FR_)9"]-)(+[/V>]07L;0T`0ZV<^,FA<_BQW\S\4M3
M9-<20)+[^,6O$;?=OOI$AN=<C8NY0,3N@J4P3,72?1Q\4<#I[S@F%)7O36KL
M$EVIJQ7'RDU/%CC9\?MW^'^=;4R3%HC:G(C0(KUG2;L"TQ;<W]LGO&]&9%&R
M;520%H,-M[>'V5>8>Y(V`7/SFW9&U]KJ3BN>NXOC..X-CV36#)+5$NE^LD?+
MLIMUKQZ[9'BPGE%NEQK9<(CW,EAMYTB002@N,_XE?)Q@+C*:I^2&W9[:F(T1
MA;5OW2F/7^3)<A^Z;K[MZLG?/F/W5HA:<%2;%KCW$4EZ4%L?$[P8\P;'\EV?
M^<OEI>M%WHKIH!=0X@>F7<H"UR94*^8P%OOTK',H3C&[Y(QRUOLSCAN#%DHC
M(H'>UW$&]6@4"@4"@4'Q51$Y7HG*>O3U5$_Y:#RG?,'@VR<]ROSPOVR,"D8O
MK+7GAEY`WWQ\VSC&HL#L=VR>\VOQ-S&-G^OL[\@Y3SF;WO`LM&]S#2R0@;;9
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M1DQ8[\I6"-/1]IP%1"!4H*JH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%!Q/\>P]RG*>T?*?FG:O*)^E:#0[I#QIWM=?
MGI\NO+W9&LKW9]+8UXNZST=X]["O42$%GR-VY'AUWS-C%C:N#TY#MERM]S%]
MQYEKG[M1'D2/@-\]`H%`H%`H%`H%!Y)_FU\?_*W<_F!.RS67CAMW9>"XMXPV
MG5^'Y#A6$CDEIN.99G><\N]Z]F=&FC(@?R"3,MRS'7FD;914=12]LAH/0+IW
M0NQ],Z"U'HNT9+KK,,8U9JG"-;VVR9WK64Q$<MF%8A:\<M<65/LV12(CA>S:
MT&0ZL)U5)5)`7GB@L/>=!7:X;[UOE5_\/M07(L%P/*[_`!\XU/E#^%SVLTR*
M=C%I;MT1R?C&')(D6ZT0KB(,2YZ@]%D@2BG!<!>,8%JQ=@W0L?E_@+D@#8?&
MWW6\[0ML'@_>1`:9N6T6(\-IU$%%CLI]"=J)VKQ0='Q[UQLEKR#W%L#8SEVO
MMA*QV>R:RR2_VEFR7.1C\]+([)AO6Z)9++%"3'_NG#>-SVFWOXR`X"$)4&>J
M)PB(G/1$3JO*]/S5>JK0?:"R'D!+N\37EQ_D5H*\7:1W-06QMUTNHQ)++9W!
MF:_#LL*?<SCL.04Y1IHB,^T$^HAH.OC^'Y?9;+B]FN3.#Y!;[%BMALS[CM@N
M5LNDJY08$2))?;,)=TC-6^1]J*HUV$8'PI$O8-!T?Y2EH_F#@:JOD62^B,.W
M+7]_AL2'V)$N2X+H,.W'%7V766F0-Y4;X`GE;;)SM):#[(N8M31,+QM[%I`W
MFT0`;N&.2KW;Y;MU*&,:.+I62]-.6H7G%;D/MO@$924G#%!7@+?ZLL6<!Y![
MKO603;G+L[\>P1;.]/Q%BU,NB;<6TJ-IOK<<&[I!")B*2'&AY[79O*JB""D&
M8E`H%`H%`H%`H.O*4$CNJYPH=O"\BI)U5$150>5Z*O[*#Q+?+3=[WE7EQYY_
MR+!H<_-\!\/_`"ILV6[!LEYRBY69OQOD^(1S+];<HQ/)(%XPNS7?'\BOELLS
MTZP/6NYE<[O!3MF`<[V`WS?'/CV%V[QYS_+L7*QC?K_JO4:YT$25B$[(IE\L
MGC+B$((V3IC[,3(K0%@?63`AL7MM9)@PX^T;K<A'""^,O9P6C0/CWINXZ.V%
MNC$-N>*+A;):UK<+$N1XU@,3!]=XC>7XV,7*\V&^95_-#V$#*M69YVYL`!.-
M,/%PB!?\-CXCL+4.)Y3J*/>,GLT^X'8,:9/%;S!*P72PQKM:93.=VK),-O&6
M8:WC<BUO19GNVM)[<M`CJ"^\HD%T]46=^PX9;[8_-8F*Q)NI-)#PW^X<&`T]
M<I+PVN!CBPK>\U"MYF3;<AUM'9B)[YJ2FJJ%R*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"'M_
M27]M!$G3I0*#XJ<_FGZJ#[0*!0?%3G\53]5!]H%!\5.>.J]/R_']=!]H%`H%
M`H%`H%`H+6;;R/9F-XVU,U;KO']DWYRZ16)=CR;8(ZVMK%C)E\[C=/[PEB^6
M`4F*8MB$98PJZAD7>*!PH>6GY4_'?;V>!Y)^8E[P+`;8L/PN\J<7N^&Q_)+5
M>;8WBUFR#QMS?%,DSG7=AM&J=<9W<-IC:V?N`D3Y]^8=C+)CH,1LVR9#.#XI
M=LXMGN&^06%VW5TO76?89X_>.;>U;@6:WC*+)F=VAZ(NF"8UD&-VJYZ\P>+:
M6Y]CPWW%F19-[9N+7`C+5(Z]P9EWK?\`DVD-,^.3$>ZZIP6S97XDQ&L1V?N)
MF^6_7UHW#:;/JE<:QS,\TMTJ/;\=LETQ:;=IS<)Y69%Z?MOM1Y#1LJC@7TT+
MLC(M\ZIPB_9[C&,9[C.<.[.D)D4/`[]C>.9=CF+;`8LVL<VA8)F,N_RK%:LX
MQ;FYM,3YK\AQL&WX_<T:HV&3.#,VUBQ^W:L-E8)$:N%Q8&P2[?9[62+'E''_
M`)BS$L<^Y0!B7(&1=95'$-6B'O`"Y%`K&@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@ZTV)'N$23!EM@]%EL.QI#+@-N-O,/`K;K3C3H.
M-.-N`2B0D*B2*J*BI0:5O)7X@/$W%O##S"Q+Q:\6-;AO'.=+^3/^#MP6PV6X
M9?CNPMM:TRK'6,:UYE.2G]QAUAF2KTY$@0`ELV^WMS'&P0&"4*"T/Q8^*WE!
MH3+/.#)M]:IN&#-[,UOX_P!EPC)+OE]ARTLWE8#JS*\6N_VEMM-^O,W6MJLH
MO6UAVR@JV]9J29K)H<EUL0NKY@7B9:?&GPVQ6V1[24NZ:^Q<;E?G]]W/5%_Q
M[&[9A>(I<YN(8:N8X3AVQ,@F2#98:D7R3(AV-")X8LDG?:(,N?'FW)E/C+K=
MS6EYW(L-(V:8K<)=QW3C.WLW6).RA#R6=<-D.YBU:9N0M.65R%:)L.3[F/MS
M"%F(TK:`T%<W/)+SJ+1^T,KU*S=\IF8MLN3/<PC)+%?;^[BMI9RK'8.=8?:(
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MHKB`<J.%R=8Y#E_N;WUME.62]CKK25;8MHSBX6ZPVN]RX.4X0Q?RQ;*@Q>W6
MG&I.58P\XI/2(L6(CL*;$5Q@7.YUX,2MBZUVAL7!?$MB%J/+-T:9L6B6KAE&
M!8CO=G23\K93UBU^&!W;(9K-\QF=E%HM%G8NR1XP30CQY<I)#K3QML^V'=TI
MDVXLE\?_`.ZSV.O7C+<+V!OVRXWC^0;"8SW/;*.HME1+9K?7V?Y5:<ZM9Y)>
M[9&GMVV^7EF[248;AM$\\^\^IN!EY<L.DS]#W?'<;AY!BET:^[O+$:SXIC,3
M)9%XLV4?WDF-VVQYBYEF//7+*9D$VVIES<N*NE*24Z;SB]RA=C7:3TP?$2N?
M\_2>YCMJ>E-Y3;[#:LCC./1&G?LKY;<7@6O'8-S@B:,NM0H[,<";5!%$H*TH
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H*.SG7V$[+L3F
M,Y]C%GRRPN2XEP2VWJ&W+9CW&`Y[L"YPC)$?@7."XJDS(8-MYI57M).5H)?;
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M`KBU">5S[0A]HE:4+I:!R6[9?IK6^2WR_P`S*[O>L3ML^Z9+-MU@M3E[N+P+
M]Y<&(&*FYCT>WR'T(HB13<`HOMDIF2D2A>&@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4$ER->,>OR]W9_[FNGUJ*D@_\$_]2BG"D@^O
M%!IC\C[5L3-=-^),K6>K<VV#`B:&MEWCW7&$WJ]#=N4^/K.W0\<O$73.Y-3!
M;5;QZ1/NX2KD-R24];`@M)&"2\[09:^-6&9&UJ'7T*#J#'\;8Q*\;K;C8]EF
M/9SJRV7ZYO[$;C6+9-VQ/-[AGF?6"]9_8'KG='`N(WIXGYKBE*!'0(PR`SC:
M]DT?H_.MG9C:\4@Q-:VB_7&?BV"Y#;'8,R[0"-ZV8G9[GD$/#K<SE.1W!]B,
MPQ);C)]]*`.XE)"4)_H':H[OT_@>V&K<-IBYW:';]!MR.^\Y%MS]QF-6QN4J
MD1-SBM[312&EX)E\C!4115$"\5`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H)5?"0;+=R)!41M=P4NY.1[4AO*O=_P`WIUH,.,0O,FS?
M'5:,BCS7[1+M7A^M\C7*!(D0)%M?A:A<N$>?"EQ#"5#>B&V+K3K1(XV0H0JB
MHBT%Y;3?\JNNH-;Y):K!*R+(KUA6*7MUI<HN%@M[-TF8M#N0'?;E;V+E>Y=N
MEW$T:<]J',+ZU-P$!")`M;<K/_-/%3*HEOQ*ZY!>=D8]<9.58O:IEWSRZ1LI
MSEIIJ]VR<F2WJS7F]CCLJ4,6='*3;G48CF@!%04%L*R\/\#NNL?'/6&!WJSW
M''KIC=KO,*?8+G(E37K#*<RF^2SLD2XS)<QZZ66U?<>Q;Y?<`2H#;+P-,@:,
M@&2]`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H)-D7_T
MOWW_`.1KG_\``GZ#6P6]L8TWXG>*6*;,Q9[)=>[@T3AFMLAM^)9&R>V_N[[@
M6-V8(V%:MB^QF&QX;L"YR?O_`.[CDF]6T0!YN&\"FXT%_K_E5EF:TQ>?K3*M
M@ZQL$#7F>62T,WG6>56R=CN-8HUCL%_,[WB6Q',)OL9<#;M#/VQ2A*1.B37E
MCMNJZCHA?G64'+HEFNKF;W-VZWBXY->[HRZ4`+5$C6J4\TEMA6JVCE>9N0K6
MQ';Y:!R<3BJ1$K;7*`@7)H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H)-D2\8_?5_*S7-?_P"2?H-/>X,EV9BGBKX>Y-J;=/CEI;.G
M_'5RW6VZ[?N>$8?GU_?=U1BMXBP=8Y]GN.YE8;'9[9<K:U+R."Y:S_F,(6A"
M7#=;;<(,I/'7)K3FOC[I_&[Y:;GLQS8MOS:ZY//WAGN&[0CW"3B]U(<JR!S(
M;3<<LQW*<:DYI<HT:RP[:C;,*WOMC[$1(I1A#+/6&16[(L>DI`L,7&'+!D&0
MXS=;#;W(K]L@WFT7-X+@Y:Y4./#8FVRYFZDQA[V6'7&Y"*ZTV[W@(7&H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H)-D?']W[[SZ?R
M:Z<_J^R?YH-$/EM%U]C_`(@^)NP,EQ#R:RIVU>-=HMD8M)W;&<<U_&L-EQ_6
M>R"C;9S++<.S:#B9R[YA%N?LKS</WI4R&37*HG%!EEJ:WWH/%7")S.6:;R%S
M9CVW,QFW?*\F8W):7-@[&R23M&W3QO%OU7;K=D=TLI,7-N\0(]FM<6,\X9MH
M?V@`X&343.KIA.F,PS?'X^K(#+><R6<,@Y%>_P#"_7[%CN65VG'H4:Z7Y_#K
M2]!FNB\\K*_RY]R5,-ID7'>]#H+Y:VR>X9E@^,Y/=&K$S-O=K;FOIB]['(\<
M>[G'`:F6*^)'B%<K5/9`7V'#:;<]MQ$,1-"1`KF@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$ER5.<=OW7C_P!RW3KQS_\`>+]!I.\G
M<OFX)X<>&,BS[7\I<`R(-.XH5NLOCWC5RN&)9LC&`82#D#<V56S^22L&QQF<
M]':C38]_M,WF4_\`;C)-%$`R>\9QDSO$G5N/8O=L)B9+G\_/+KE5HBR\F\@+
M9?;@&27B;GMO=S+*K3CUR=F-R7ACS[A=[9,:C37DB@,E59<<"L]ZJU-\.\BA
M3\A>LSL/),;MU\OTG*\B>E6*X6O:=E*;)E#FC5@NN0OQG6!7^[1,MP[FA);H
MK+L5UELPO3XAWF/D/C7IN\Q;U_>.//PN&XS?5NUVOBW4`DR64F?S2^8[B-TD
M^Y[?_G+7`%OCL;8;;$!0,D:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!027)/_I=O_\`\BW3_P"`OT&K0==W+=.->!6`8EGA:@RZP^.5
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M+(B/`3C$IER,\`D@D3+X*TZ*%RG;RV2]4Z_EUH+!9OXM:1V'@^#Z]RK#7)5A
MUI!AVO7\RTY)E&*99B%LAVV/9AM]ASG%;S9<RM\*5:(C4:6T$Y&YS30?<(ZH
M"J!4M@T%I[&=?XUJZQX%9;;@N(V>78;!88Z2D;A6JXR69UUCG-^X_F,T[U<(
MX2I[K[SKLZ6/OODX[R=!/+EJG![KB-[P>5;)R8YD=Q*ZWV-&R+)H4ZYS7+C$
MN;YR;["O$:_^W*DP6A>;&4+;L=%8,58(FU#KY?*'5^J[O(Q2(TVWAV.\66%,
MD3)C+;$`6VH\=V1+?DS7@!E.$4W#+HG*T%RP52`57U44Y_7QU_ST$5`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!3N6XY$R[&[Q
MC4\WVX5ZAN091Q2$)`LN\=RM&:*(DG'X_A03]M%$!1?5$3G\_P!O'3F@CH%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g608283exa_pg074.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g608283exa_pg074.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@#*@)R`P$1``(1`0,1`?_$`*\``0`!!`,!`0$`````
M```````)!@<("@,$!0(!"P$!`````````````````````!````8"`@$#`@,%
M!`8#!0(O`0(#!`4&``<1"!(A$PDQ%$%1(F$R%18*<8$C%Y&A0E(S&+%B),'1
M<H*2-!GPLD-3<[,E-28V)R@:X:)CDU1T1CAXN/'2T]5VUC?"@Z-$E$6EM5:F
MME=W2%BH*1$!`````````````````````/_:``P#`0`"$0,1`#\`W^,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,`/\`H_LP.JBV%)99;WUU`63;I@BH<!12%`%0%1(O`"51
M?W/UCR/EXA],#M8#`8#`8#`8#`8#`8#`8#`8#`8'332*T%=11RLH"ZQE`]\_
MF"7F(B"2/`!XI%_`/7`[8"!@`P#R!@`0'\P$.0'_`$8'[@,"E_YE#_X2-_YM
M^S_XX?\`P7_@_3]G^O`JC`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8'X8/(./IZX'Z'H`!^6`P&!1'`_D/_`*\>/[_R_MP*WP&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!27(?F'_KT_
M,,"K<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#\Y`?H(
M8'[@,!@,"C/8#_>'_P!>GY!@5G@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!SS]/7`_.0YXY#G\N?7Z"/_0&!X=FAW4_`R<.RL,[4W;]O["%C
MK/\`!_X]$G$Y#?=1G\P0\_#?<`4HE_[0S<)^)A_3SP(!C;NUAL+5^F=F[!@-
MV;%?3=%H=CL\4A.PNHG48\D(**<2#9&619:OC73EFY5;@5<J*Z"AB&'P.0W!
M@#*_`8#`8%)__53`JS`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`L=V%V--ZLU_'6F`;QSIZZV?I:FN$Y1)95H2(V)MRE4&;<<(+('(Y:1-D650
M,)O`JY""8!+R`A>5NLB1$H&63*)?(QP,=(@IB/*HE$"@0"@0@_B'/CZCS]<#
M'"D[,O4_V2VYKA^:I%H%*A*R^KP)Q%XB+VI)3<7'.'_W:\K'$HMEJQ5Q7%%_
M&/57)'`_:JMT1;G46"_MHL+"I5J?M4H)RQ=;AY*>E#IIJJJ)1L0S6?R"Q$4$
MEG"QD&;<YP(F0ZA_'@I1,(!@>%>*E#[8UO:*5*K/&\'L&HR<"]<,^6[]O'V*
M*5:*+M_N$N4G2*3KR*"A/0P<&+]0P*[#Z!R//[?S_;Z>F`P&`P*5_3^?_P"=
M/'ZA_P`7_P!-_P#A?L^N!56`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/@XG`2>/CQY<&\N>1#CT\./
M3RY_/\,"/>#^2#5ERCK)8-=:7[=;,J->M=OIA+E0>LFQ;%6IZ<H5HF:7:TZN
M]1;HN+`RC+-`.VWW*"/L*&2'P,8/7`[\9W]AY48X6O5'OA[,H=X+1R\ZGWN+
M2!%BW]]8[Q.3<-7,6)S?H2^Z31,N?]*9#?7`Y4OD$H"=JU14+'I3M7KN0W)>
MHK6]1D]E=>+M4:NG;IUG*O89C8+,[!2)KY7Z<*N4GOJ>1E`*0`\CE`0SW#U]
M0^@X#`8#`8#`8#`8#`8#`8#`8&+O<$!'3D=P"9@#>/5\5$U?(4UFX=E=3BZ;
MB4H@)Q<M?-,"\"!A,`"`A@13Q-M[1/'NQ])R'9^6A[;U_@-KVRTO-`[7T/OS
MM)V-VU:'SI[28ZL:<ND4Y<ZKUI184!6+5W;1FHL\,FR(NFS9BX<!FMU+C]CO
M-LK6W>D:G&;QD](:Y1V/&5N.G6E*@[0>ITI>=B$WS>S3=(FI1I.`]0;KIHMY
M!-NV43*0&O@LZ#+SL<DY<=?MX-F3A9J[=:BV2V;N6L<ZEW:"JU+FR$59Q3(!
M=R+I(1\DT4P$ZA@\2@(B`"%QJ>JV7J5779F=':+5V$5:F>E,5Z9LI&-CH&=E
M/P<KH4A`5`'U`_/.!46`P&`P*-\#_P"Z;_V<O/\`=']S_>^G[O[?I@5E@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,#Y,'/B/^Z8!#_67U_N'`C>^*0R2'3"#(*H`@QWIW);^X<X<$3:
M]P=Z%$53>A2F*4G)OH`8%F9OYSNA[5%T]I"W9+=,2C,+PS:?TOU,[!WVKS"S
M)P^92+NOVAI0VM>G(Z.DF!VJBK5RIY+B`)@H7DP!DGW6>H2+#I?)D!RV;/.[
M_71ZF1^W6CW217R-J%J@]:/").&CHRS@B9D5"E4*J/@(`;TP,]"CR4H_F4!_
MU8'U@,!@,!@?@B``(B/``'(B/X`'U'`^`53,`B!RB!>!$>?H`AY!S_</.!^@
MJF(<@<H@'_6#`_0.4>>#%'CZ^H8'R95,O'DH0.>>.3!Z^(>0_P"@`YP.3`<_
MA^.`P&!BSW(,J322*J1#*"ANCK&Y/P0J@$3;=E-3+F4.0P@`D)[?(_4`^H@(
M`(8$0*^N:&TU-.:*ANDD%W82J[^[K:O[&=7=H=?T]K)VA[9K%*0U@OD_.WC7
M>S-.[,K=@D46K^99R$PV5<MSN!,4#&;$#.WIA%2;#91PVS)Q,_V8B]"ZRJVY
M)V/@W:`/;/`UZLM;@2.LQJW!1]DA&]E(4@KIJOU#N>2@L"*2:*896=NV$K+=
M7.P</!`D::FM.[%A(D%Q=@@60FZE+1+15<&*:SLR+=9Z"A@(0X\$^@X%Z:@W
M;LZG6&C-5%PT:UZ%;-7#=,J+==LA'-DD%T$BB)4D5DB`8I0$0*40#`J+`8#`
M8%.>9/\`?+_[,?A^\'[_`/N?7][]GUP*CP&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!^#^']H?]_`B_
M^,[[=+HU-I&C%;`@UWGWN16@T##]S+E2[:[\]Z'(*8"8KA_^I`.`Y`QOIS@1
M-_'J_P#E!MW2C0LMUE[9?'YI_2_\(LS+7.H]NZ^NNP]F:@HS*VR[6KZMO]SB
MKA4&UDMVMF"0P[M0\4P<J"S*9PHNN=1;`F/[[&62JG2L9L6LRZ_Y^.GR4BYC
MVID&;J36N"J!)-BV.N[4:,R2RA'!2BJJ)$2^(G-ZB(2*A]`]1'T^H_4?VCP`
M!R.!^X#`8#`8%"[1E9&"UGL6<B'(LY:&HMNE8MV#=-V+61CJ_(.V3D&JP@DY
M%!RB4WMF$"GXX'T'`UE_CJC?DI^0#JS1.QL5\KD[3I"?D[#`6FE!H37LJZJ]
MC@)==F9@NY9KQZ2@242+200**?H@[*`&,`<X&=P=#/E'%4B@_+Q:13#CS3+U
MQH:8F`.>0#F6$H"(?B(#@>>E\?\`\I/V[5-3YB;V=1%$R3A8G7'7B9W2AU5#
M)+E(I(&]D4RG`I@$1Y`O/(<X&,6^*%\B?3'<'1>P7GY+]G[OJ&ZNZ6D]'W2A
MJZPUU281U6K#)2<G*%=NF3>4?K)3#.-!DJ1$Z)^%/(#!@;++4`!$``PF*`B!
M>1`>"E_2!0$/P#C_`$X&NAU^^<[9^[^_VD^J<WU+IVJM7;_L&QHG6]ML?8V`
MF-\24%K]GV88KW60T1%51):)AB7;J[.1$N@:347KSEVQ3>#[SM%,P;&^`P,6
M^Y'D&BGAR(*N#I;2Z\*D(B<""02=A=7"+A03)+E%!J7E10/`1,0H@'!A`0"`
ME:ETGM#<=C[G0U_\;+^^1UOV2UF^K;%>Q=:.[<,UK%VGX5!O+[YUWL:-EEMI
MWAA#'?(A+5].(4</4!,J5(QUQ"6/I_;=;7/9%0G=?V[:$S5+!UFHEMU7"WF=
MV')K-J!*5S6K)W)6YS:HV4C['L-LLTCFKQ__`#`X7`3F\VGW"CMZX#,'M!,(
MUSKEO6QN3*E;5_4>QIMP5%5%!15O&T^9=+H$6<+-D4Q613,7DRJ0!SZG('Z@
M"XVO7#9W0J2Z9))H,G-3KKADBB)1219KQ#15HDF)3JD$B;<Q0#@Q@]/0PAZB
M%88#`8#`I'A+_>_^.OS_`'@_\T?^F_[?V?7`J[`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`C&^+59
M@CT[L)I(40CFW9SOH$E]P`&1*R;]QM\'=@X*;](I@W,;S`?3C`UTG'7?KG,:
M8DN]<'\%_6^:^/).K6F\N9M7L[<&G:>1T5#2,S)2^Z4=?J+DIB;Q>%C#OVT)
M_&CS(-#%;%>%3'@H;$_=^<K3C3'1RRTQN+FG..[O0V0J2+`AA(:L3FQH!I"G
M1()E3`@WAI1-3U,/!"\B(\>H2?X#`8#`8#`MENMNF[TUMMHMP"+K65\;JB(B
M4/;6JLJF?DP<"4/$P^H?3`@C_IY&:52^.7JY:BM4D([8+S<-(LSTAV#=L2;J
M&ZMD!KN16*5+WG*CRN'7B2J&/R1)!HE]/``#8H`0,'(#R'YA]!].?0?H/H.!
M^X$-GR\PPRDS\93@A2BM%?*#UC=I&4%/VRE.:U%5$"^X18RW@3]'B!B@//EZ
M8$Q+(>4"^@AP90/7\1`X\F+_`-41P-6;H#&_(?N'O..UIN&N5QZU0W;/L)9W
M7::R[0T98M:SVIZI']H])R^C=$T.(@F6X==P,MN-W4I!U`.&##["1J4DY?R+
MY5VG[X;4>`P,>^TR0*Z2L112(OXV/6*Q45#B0BQV^TZ6NFD8P>H`H=,`_;SQ
M@0O;:H.N-^6#9:*/:#X]>[;VHV2V,I#2/;[46L:WM2K*5^2D$I2D1NW:&\K%
M\KCJ(61<-6DD]@'I$0`BAS*)AYX$R'3^<UE<>KW7BY:<J+C7^K9_4%'E]>T9
M<.#U&HR=?9.86M>9CKF6;PC-0J")BJ&243(!R\E$O`>EVQ>OX[K+OQ_%M%7\
MFRU!L5S'L4$FSA5V^1J4N=FB1J],5D\,9R!/\!8?:7X]LW(&$,"[=(*N6EU$
MKE4%G):Q`E<+%;HM`57"*:@LH#1N!4&H'4`1]L@`0G[H>@8%48#`8#`HG@/S
M_P#CVY^H?7\L"ML!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,",OXI0(;JI:DU03,DEV[[Z-U2J@44_
M#_G(W?[Q%0-R42<<@;GTXP->2TV[0:,+:=;0>\?EOBOAI-<IZK7$]=ZS4^1Z
MGM:8K=UFUSK$!V;.1+?L7U74E`=LG"C2-<"G'**((.A0$#8&Q+WY)"QNI.GQ
M:L=LVJS'O3T/;0ZD:J"C%&O&W-4X^&*U6Y5\V9T%D")&Y-R!BCR/UP)*L!@,
M!@,!@6\VYZZHV<'D8O.O+I^HA0.<O_L-R7ZB%$#`8P?@`@(".!"#_3^10W'X
M8-,1K=R8DJI,[T4C'IXY%H$79(_=%VD(-^@'MF3>EC9=!!<JPDX4$@E$H@`@
M(3IT68>3M6B9&3:@PEU&J))R.!=)Q_#9U-%,)N-]Q'@G_K.E/=1^@<^'EQZX
M%78$*_S(*O4I/XOO8,JDT4^4_JVG(+I#XB0AE;01N0RG/Z`56/X_0>>>,"4K
M<^Q9W4.F]E;-K&KKUNRP42K3MCA=2ZS0C'-]V!(Q;8ZS:KU5O,/XV/5EI%8O
M@0IU?(?7P(JIXIG#3V^*O;&GNP7RO(N(C2_6'XX;A6&%KWW(==YIWV!E^V^V
MME[67V96;SK>VLMXS&FZ)6;S`1I!MDR%0I=E(:-D&8)2`)>\=`-V?`8%@NSI
M6QM+V+[T"BT+/:Y4<`I_PQ22V93U3@H'T.D($_44?0Q>0_'`B(K^N^Q]LH[4
M.V7QFZ2[BQ[JY[0DFMCG;CK)SV+2IX[3O;FFDM]+W'2*Q!KN&%2)&(,`8V99
M-9BF@`@0PB`!-?J*31F-7T"3;:^F=3MGE3A%&NL;#$Q$#-:_:@Q1(VI\C"P#
MM_!1;BO(%*U]AFLJU3!(`2,)/$<#U=@4R&V-1[;0+$DLO7KK7)FJSR#<XI++
MPT_'N(N3026*8BB"BS)T<I5"&*HF(@8H@8`'`]R$B6D##1$%'E4(PA8QA$L2
M+*G76*SC6J3-L55=0QU%E`01+Y&,(F,/J(B.!ZF`P&`P*'_^SC`KC`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`BH^-FUTVB]/=LV2_P!GKE-I5=[A?(`I9;-;IR.K=<A([_G*W2BL
MYF9Z7=,HZ-:@9T!1555(4!,`<\B&!$;M2M=@]2=#)/K$P[^?&37?BQO=7NVJ
MZ=VZMD]:7N]([KU/2SEE,4*MUR$EWFK-F[*K]8EW,.D\8."G.*95EDD''/B$
MM_=1I68GJOTN9T^:=V.EQ7;OXVVE8LKQ55Z[FZNVWOJMG`SKUR*"2KA>5CO8
M645,F03'5Y$`YXP)6L!@,!@,!@45LHH'US?R")B@:E6HHF)SY@!H)^`B7@0'
MR#GT]0]<"%K^F_DVTQ\2.B$VJCA9./MF[(<5'@K'5.+;;%M$!.99510_DFL4
M1'GU$1P)>X<Y*CLN6KGNK$B]@D<7&&3.@<$$+#&(L8ZSQ:"YN42_Q!D1O(E2
M*`&$Y72G(^0\!=_`AA^9QXX8U_XZUDV@JI'^5GI.@H]X()(T3W.7$%%.1`WB
M\\?9#@!]3>OI@3+-_P!U3\A77X_;_BF`?_>@'`@8Z_?(?,=R^X$-7S==^A]=
MI.J.Q&^]15NX[5[@46?[M0$QIV:V#JV>DJ/UH:Z@=6BCV^U2E96<ILSV)`XU
M9T9<ZQRJ%*<)[\!@6"[/@C_DA<#+E4,BD[IKA0J1?,YBMKU65Q#Q'_9'V_U#
M^!>1P(SO^2+LZI_,M'N=ZM[C1\%?-][M<.]#[WO5*[#=HMF[$N[R<UO"WB?F
MOY>A-6UC6U<.DV,PCYD8F2D6;0YB(LBJH'"3SK/'[FBNO^HH[L/(-I3=[.BP
M2&SG[1>+=IKVPC4H2/N/H1C%PTB[2-P1=TT:MFSE<IU4DDR'*0H7RP&`P&`P
M&!0__P!G&!7&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&!K&3&B]J[P^/I.G:PTBEV?1IOS&]BME[2
MT*O<JC18?:VJZ#W2WU9;%49Z4O<A'U=Y$.9;^&BJT=`X3643((HJ`0>`QHU7
MT][-:E[0[O[#M_@*U_?:[;):HRO7K3UF[8];&E%ZR?PVKQ+;81M?4Q=.R:_C
MI[9UZB233J281S!P@8"I`(_XACA.K\@KF9ENNO6V2FX@U*FW?<[X]Y.?K(2;
M22"MR"_9?5+F6K9Y:/`C&4+#.E#MQ70`$G'L^1`\3`&!)K@,!@,!@,"D[Z3W
M*-<TP\>3U.Q$#SY\?U0[POZN/7Q]?7]F!"#_`$UQTQ^*35:21$"D;;3WVV*+
M<RATS@EM2Q<'Y5*4W(@;U_LP)IMC03F0B49R*0*O8*>\;VB!2\U$3.'T65P#
MB/%9'_$]F6B'3IH8G[IO?#GZ<@%45N>8VB$C+#%J>]%S3!E*1JPE.0RC)^T0
M=H&43.4IB*@5;@Q?]D0X'U`<")7YDTFAM=]&7;U!=RC&?*=T1=@FV-XJ@HKL
MMTR3']XH"`J.BA^KT]<"7QL81(L`^(`5RY`HE$1Y#W3&$1Y]0,!C"`_V8&I5
MH9'?<)\L-.:6*!V]$[_>=N>PK7?$?8>K_36E=-6O4)RTW!.:FL.AM[1E'8[Z
ML&S[5%*TAPLDG87EFE),TL>6:$:MA.(;;^`P,?>TXJ%T+?C)!^HB5=./T'A,
MEM@#JFX'T_2D`C_=@7_*7@H@(?4YQ_TJ&,'^GG`^P#CT#`8#`8#`8#`HKP/^
M0_\`LZ>]_P#>_P#>_P#0]<"M<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,",GXK%%CZ+W<10>!1[[_
M`""HD]"_I1'MOM-5$/3Z\IJ`//U]?7`M3US^;?HOL;586#??8_KOUUW!7[C>
MZ'LG4%IW#70>U&Q4R]3=43".E)(T62V0<O&L&K]"48$6CU$W(^*H^V?Q"ZGR
M+2]?OG6C0=MK%@CIJHV+N+\?MM@;)"NDI&)GZY+=G]22<)*1$@T,HB\CIEH\
M05072,)%$E"F`1*/.!)Q@,!@,!@,"FKF0%*?:TQ]`/6IT@CSQP!HMT`^O!N/
M0?R'`@R_IJ_$OQ84!!,`!-MN+?22?U,/`[&E5C"*PC_VD146-_B`1(#_`%!,
M@>F!/<L4YTE"IF\3F(8I3<\>)A#@#`(<\"7ZA^W`LYKTJE1L5JUJNL1-@R=?
MSC2D1*(J#5;2^54D(WW/#P,-=M8NT2%`PBFS<M@$`#QP(]_F#62;:DZF.5T#
M+I(_)-T66,4"F']S<;`"F`P!^@2G$/7T_P!>!+*U#@JW[73D?[.53"'^H<#4
MU^.[64%!_(CO&6ME$Z_U/8KSY!^XEDBQVK\7O8:V=G9.K2%^V@XK,[1?D:F#
M06KV\!*P[U1W%/"M'(,H1P,1[BA/MC`&VH`\^H8#`Q^[3F*30.QU##P1.,C5
M3CZCXD3L$0H<W`<B/B0HCZ>N!D``@8.0'D.3!_>41*8/[A#`_<!@,!@,!@,"
MF/;'\O\`XX>?K^/^G`J?`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`C.^+@I4]/]AFQ0$@-OD"[\)E
M3'GR2(?L]L%T!3>7Z@,8'`&#GUX-^6!#EHWN)==C/-_[$OM#Z(1&O)?I#VR[
MA=9:#&Z=J:J.CKMIK<[_`%XTB-T763<-GENN]EGB!)6%%DA%"D\%8A?U\'`)
M1^T=]=;7Z`=.-J/*\W@'&Q=S_&/LF4K$>@=HSK@6G?.B+.]B6K8P@HV90JK\
M4"$'U(0@%'`EWP&`P&`P&!X5H2]^LV)'U_QH*72_2`F-_B1[@GH4.1,/K]`]
M1P(.OZ;Z/-&_%[1VYA./.Y-]'("A!3,5,-C2J1`$I@`WZBI`;U]?U8$\6!:/
M9:1(5[5]BB"I2TM^L$N=$Q^#U&:1*RL?W:9$CF5;10%0D^`$``6`_B/J$:GS
M(J&-HOJZ^00"0%#Y&^C#M-,`*4QD?\XXLWDF(>(F!,I_(!^H@&!,$EX?XGAQ
M_P`4_EP;R_6(\FY]1\1Y'Z?A@:E_1'<=GO'R)[Q8;`O&CK.^KOR.=L=?QRFW
MOE1[`U?M#`P%5OETBM?TVM_'ZA+O-&6"$AXDC5E"-&96K)["D3<J-Q>H*'.&
MVF3]T/[_`/I'`^L#'KM<9,G7C:9U1X23KZ2JIAYX*DE*QRBAAX]>"D*(C_9@
M9`I`)2B`AP/N+#_<94Y@'^\!P.3`8#`8#`8#`ISD?_T[S_?@5'@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@1G?&29(:?V_03!X4[/Y'^\C=;[M-),5E!W,_<`L@=`YVRR":+@A`,E
MP7R`Q3@"A3X$"?</7_7?I)NZ3[$_)]\9?4/:E?N&QV=@0[`]5]VR=:G+5-+2
MQG+>=N/2;;5_K:-MF7`$16FPBE)IBZ=IK+NA.54,"<[O/?J_M3I+H7:].+,1
M%5OW83X[[_7$)J'<0,TVK-M[/Z+EXUC,03HGOQ#XT3*$37:G#E$_)?\`9YP)
M3\!@,!@,!@>3/^804U[8^*G\)DO;,'^R?[-;P'U]/0V!`Y_36OGCKXQX4C]=
M1PJQ[!=A8]-57T4,DWOSD0,HF``*)SJ*&,)!`!*)OH`8$^_F7\_]0_\`>P.C
M)M6LE'/X]V@#IJ^9N6CEJ8"B5RW<(G17;F]P!)X+I'$@\^G`^N!!S\J2]@'J
MQH&L+*N2V/7GR-=((%Y(*)"E]]$QVZX!Q%2QEW'*9P?U-9`JJH#XF=@H!1Y$
M`P)P968AZ]#R\_/2<=!0,&QD9B<FI=VVBXF)BHQ!9Y)RLI(O%$&;&.8,T#JK
MKJG*FDF0QC&`H".!JP4:1[2PGR/:KORDQV2!#L!W0L[F)V!(7;J<S^+#<72V
MU5O9&P-3?Y#1<;[FV+9V5D=0QT0Z3!H8\^]G6,E(.';B-`Q#!M9$_=#^_P#Z
M1P/K`QX[9``]<-O>1/<*6HN5#$`0#S*FY:J&+R80*')2_CZ?GZ8&0B8B)>1'
MD?-3\!#C@Y@`/41_=#T_(<#[P&`P&`P&`P/!^W5_W0_]>WW'[Q?^%_O?7Z_L
M^N![V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&!&3\8[]HX@.ZT>S%HF6%^2ONXQ59M$Q3%HJZV>G.
MF!P4Q0\7#LLT5T;Z^17)1#@/0`@KZ%]Q/B'UR:6V3V:UE-/N^\-L[=T/?-DV
M31O:#LS:)AM&;,LK>MV+7]YMD!M.;:UEQ1FT:FW3(>/<,_:42^V03X`X3J?(
M?:X"]=,-=[!KAUWU8M78'H1=H$9"/D8-U(0D]VJT5,PYGL7,-H^7AW*K)ZF<
M[9RB@Y0/R14A#E,4`DVP&`P.,ZJ:8")S`7Q*)Q_$0*`@'EP'(\<C@?)ETRF`
MHB8>0$>2D.8H<?@)BE$`$<#Y*Z2,;Q#S^@CY"F<"AQ^`F$O'.!UWWM.V3QJ!
MQY<M7#</$H^7^,D=/]/D`!S^KTY$`P->WJY\>7RJ]+M?3FFNOG:[J!#ZO=[(
MO>P(AI;=%;"LMD2<WJ7&6D%'[XL^T:^][WT12("*8^A3"7C@,F2:@^;02&!7
MN=TN(IR(%,EUBN8``<!P;Q6M8B(@/]V!Q'TS\VQB'\>[W39-02B!!_Y6[.H4
MI^/TF$!M9!$`'UXYP,?]B_'1\G_827J2?8SNEUNME-B;YI>X6.!I&@K92'LN
M;3FQ!O$0[82#>TN"1TZ!'SM$JP)B54`0*</!+U";K<.K*[O'3FVM'W4THG3]
MR:YOVK;2M#K`SEDJSL6LRM3G5(QXLDX*UD21LPL9!0R9P34\1$H@'&!$/K3X
M\._DG<>IE2[5]T=';/ZR=*-BT_9VN(75_6A_K+=.U[+J>K6*G:F5VW:WVQ;-
M28-I"QUA^YDTJW$,R/UVI4R^T10Y@"<<BA3")2@;@O`>7`^(\^OH/U]/VX'+
M@8Z=N3D2ZR[P64'@B&N[`X-Z&'D&[45Q#@H";]7M\>GK@9$EX\0$!$0$.0$?
MKP/J'U]?0!P/K`8#`8#`8#`\[WT_]X?_`#1[?T']_P#+Z8'HX#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`_!$`^N!^X#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`B_P#C%D))^R[Y-Y$"&)%?)OW(81ZZ::)4UV!K/6I$O"J?"K@6
MKI^LV,94`4*9`4P_00N!#?K?Y/K5#[.["6[LE\C%=HJTYUL[Y_9Z)>PFKJ2A
MU)W;J#?,#K72])@ZC)P[B]WW:CFE).I=FA/"[4G^3*-VBJ'D(A(WV2O.Q=C_
M`!+]5]F[C:K,=I76?^,NY[,;+1A85TE=K%V$ZYRUH%:%22;IQ2ZDP[5,9J5-
M,K<PB0"%`OB`3:X#`8&,.XX]Q:MQZ2H:UQN]8A9BN;9L;YE2;5)5)S-/ZHOK
M=.,"0?1!DGSEHP3GW'^![A$S>\(FY$"A@5BIHZ'63,B>[[B(4P\B9#;UZ;G`
M?R`4I<!$,#H?\OE=,04U+SN]4HCS^K=^QR"'IQP`HSR0\8'P'7>J`4Q!MVZ5
M"G`0$3[TVEY<"'`@!BV8#%]/R'G`XR]<:8!#$&Q[B4`P"`BMO7;BA^!#C@%/
MYP(8H?V?CZX'ZAUSI#<OMEE=J*@)O(5%MX[=54*(\!P7W+B<>`XYXY^N!WPT
M'2P`"_<[#,`!QY&W'M@RAO\`K"?^<0X$?[!P.,W7VC*#R9;8(CQQ^K<NW1'C
M^TEU('X_E@?:/7W7Z)@.(7E8PB)3`YVWM5TF!!`0$1(XN9_/D/P'D,#V$=*4
M5NFT300LI/L#&.S.&P]A"=`YP,!A`3683J?I,(!YF$`Y].,"JZY2HFL.G3J.
M4FE%'A2$7&5L]CG4P*F4"E^W0FI.13;"/`>0EX$?K@5C@8Y=O2F/U>WR0IC$
M$^K[87S*82F3`T6L`J%$/7R(`\A^8A@9$I"`I)B41,`ID$#&_>,'B'`F_:(?
M7`Y,!@,!@,!@,#H>TG_N%_X_G]/]O\_[<#OX#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`<`/U#G`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`UR:
M#V!V;U@TOWNOFOFU<2E;1\XUTUA(6RWL#2U'UK0]H[,TS5[EL.Y$83$.JUAZ
M]!O'(>ZJN@FV=N$E%0.F`^04EV-D9;M)V3[1[:Z>:KZ'&J?1VF-)V^=EMS]:
M*?N63WIOF&A9&^6#4]5V4T<,EHAI0:3#LD'\T@NZ?Q\A)%*7@J9"@&8W;C<(
M]D_BRTIOY&*+7T]M6[X\MKN('[H'9(@+/V:T!/O&#=V!C"[(T5>'32./`JD*
M41X$1#`F=P&`P,5MF<%[8=6U1]!_D7LHB'J/D?S9ZD6%,H?0W/VWE_XN!E3@
M<2BI4^>0,(\`/!2^0CR(@!2A]1,/`\!^S`^0<$$>/!</3GD6S@`_UI_7`_!<
MA^"+D?V@B;_N\#@?@N0`!'V'(\?@")N1_L]>,#[*L!@Y]M8/3G@R8@/]G'YX
M'U[GISX*?V>`\X`50#Q_2I^H>./`1$/KZF*'J!?3`^O,/R-_Y!__`*'`_/<#
MR`!`P<CP`F#Q`3<"/B'EP(CP'/H'&!]X&.W;D!'J]O\`$OH8FI;RJ4?R,E`/
M52F#]I1)R'[<"_D=Y_8M!4-Y'%!,PCSSR!B\E_T%$,#NX#`8#`8#`8'3_P#I
MF!W,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?'N``B4?00^@
M<E$3!^92@83>G[0#`^\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@17N^D?8VM'[+
MP.K]S]=EM7=C]T7K=$YKK=G622V>R"1V,UJS>SURQ.6&WZFQLT*L:OG,F91F
MFJ4ITRB/"?J'1I/23L_4]76?K^QVCTOJG7R7B)FKH:FH72^8@ZS*5BQM56=B
M96.-+OQ-FJ>>9.5$'8)E-[Q!Y$_J)0"QW>O2G:^B].)I"<W3I"TZOU;;NNMD
M+J^@]=9#4IU:EK'?VJYUI7HBR$W+:FE<CHV(A2`!B1YB))MP+QXF$2A.>`\^
MH>H#Z@(?C@,!@8B[9%4.W?4+Q.((_P`K=F?>(`\`<0KNN!3$0^@^`@/^G`RZ
MP,1+[JNO[3[$'1M<]L(L?`:6B1BJ]5=K;%H,.DZG[O:&TM+O8JCV2":R<@[:
M1C9`'#DJJB)$0*D)?(W(>^3J3J$IA,;_`#27#CT3<]@-ZK)@;\#@![^;Q.7\
M!#Z8'6_Y.]'"90YXB_JG5.)U#K;ZWNL8QA``$?(^PO0.`^@>F!S)]0-'IE$"
MP]X*`B(\#NS=Z@B(@`<@J;80')]/P^GUP.1GU%T<P5.NTKMG!90.%%7.W=R/
MSJ!_N',]OBXF3_ZOT^OYX'I!U=TX!@-_+$H8P?0P[&V?Y?Z36Y0?3^W`]5EU
MVU9'F#[6NR)"F'_$\[]L1P`!^8)N;*J0X_L'C`]DND=;)!X%KKHX!Z^1K/:A
M'U_:I.'-_KP*CK6O*I4GJ\A`1)V#IRB#9=565F)$QFX&`X)$)(/W220>X4!Y
M`.1P*XP,>>VI#*=7^P)"\`8VH+_QR/`>E;D!^H<_@&!?J.,!X]B<.>#LVI@Y
M^O!D""'/[>!P.Y@,!@,!@,!@=/\`^F8'<P&`P&`P&`P&`P&`P/$F#2)3,2QI
M@*9P^;).U5.12;,4S**N5"%`#`+A0``A>0X'GU$.,#L$?`4#G<(.&I?N!12*
MOX"9P)@$2F2`BBG!1`!'@WCQQ@>F'KZX#`8#`8#`8#`8#`8#`8#`8#`ZCM<[
M<$3$;K+@=8J9Q1]KA`I@$176]Q1,?9()>#>(&-Z^@#@>2:,$[DSA---HJ1^T
M7(X;KJBN]02_XR3X1(7])Q.8/'DP"`!R/X8%0X#`8#`8#`8#`8#`8#`8#`8#
M`Z3ELLL=L=-TJA]NX,N=-,P`1T06[A$&SCDIA]GS6*?]/!@,0/7`XUI!LT79
M,E/=%P\,*3<A2'5\O;3.H<YU!$P$(4B8B(G$!'^W`]`I@,4IBCR4P`8H_F`A
MR`^OKZA@?N`P&!8[LIJYIN[0NXM/OBN1;;,UA>J2!V2H-W:#RQUQ]&1SEJY\
MB"W=-G[A,Z1_(OBH4IA$..0"AND&W7&]NIG7W:;_`-PLU:-5U0+6BJ<ZBK*]
M0#/^5[_&+B?]17$7<H1\W4*/J"B9N?7`RJP&!B+MPHE[:=15Q#R)_+/9=H'"
MIB"5=:L:_=)G%,`\5">RP4+R(\E$P<`/(\!EU@8S$D3!V_EHHI"@4O6^K2!U
M`]#',?:MH:)IF$/42)AYB`?@)A_/`R9P&`P&`P`^GK@=7V#F=`Z!=4"`@"/V
M_F((B/N"<RPI^I15XX`!_+`[6`P+`=K2B;K'V"XX`0TWL<X"/_ONIRJGI]?7
M]/I^W`O7!G!6%B50Y\5(UBH7GZ@51LD<H#ZCP(%'`]3`8#`8#`8#`XN`_(/^
M)^08'+@,!@,!@,!@,!@,!@?AC`4HF'G@H"(\<?0/4?J(!],"EH@RCF3FRN2O
MS`UD@013>"D#0I$X]@?[AB0H>:Z"YEQ_6H)C%4`P`!0XP*JP&`P&`P&`P&`P
M&`P&`P&`P&!\F(0X`!RE,`"!@`P`(`8/H/K^(8'19E4*J_!4_GR[%1+D1,":
M)DDRE3#R_=X,0P\!Z>N!Z&`P&`P&`P&`P&`P&`P&`P&`P&!Y,29V<CHSPI"G
M+(R)&XD."GFT*Z,#<QQ`1\3^`?NCZA^6!ZV`P&`P/P0`>.0YX'D/V#P(<A^W
M@<"-OX\OLZ%-]UNLZ/W3<-#=O]B3=>C7:A#_`&NONR;"&[*58\<(-VYC0Q9C
M9<PU0$0,!#LU$0,8$L"27`8$?O:W;.M-,]DNG%LVQL"HZVJCIOV,@DK!=['$
M5>#6G9"CU9>,BBR4T\9,U)-\DR7^W1`PJJB4P$`?7`S0IFPJ1L:*+/T&V5FZ
MU\YSHDGJE88:RPYG"?'FU_B,(^?M2N4RF`3$$P&+R'(<C@8\"X42[RR:)@`6
MZW5"N+%\?^("K;<\\F?R^GZ1*\+X^OX#_>&7.`P&`P&`P&`P&!8;M,05.LW8
M8@"`".DMI"`C^`EI$V8!]/7D!#TP+O5HP'KD`8.>#0L6(<_7U8H?7ZX'MX#`
M8#`8#`8'SXC_`.]^7]W_`'\#ZP&`P&`P&`P&`P&`P`@`@("'(#Z"`^H"`_4!
M#`X0,F942`4IE$P+Y>A>4RF#DOU]0`>/PP.;`8#`8#`8#`8#`8#`8#`8#`8`
M?3U'Z!@==!1,YURD$!,DH4BG''/D)"J!S^(_I.&!V,!@,!@,!@,!@,!@,!@,
M!@,!@,#JMBI%][V4B)%%=83@0A2>:PGY45,!0`#&4,/(B/J/XX':P&`P&`P(
MQP,KJOY5P%9^LUK';[IR9)HBIXE:26W.J.PQ<.4VRJ"!`+*O=6[M,J<JZIS"
MVBP]D`(FI@2<8#`@T^:$#A=/BE6%M&N4"_)UUW;+$D6J3PO$C*FCSD*@JDL4
MQ%FCE8I_3CU#GTYP)*MA]:(%XLA<]*GBM);;@E'4G"6NIQ:497K&Z.4YEJYM
M>HQ!6,9L"ES9O$KLBX$D6WB"S)TW7(4^!CYI'93O:':E27FH<:U<H/K0K1MA
M587:C\*S?Z?OE_$V>.;/%R)+O8=TX]M]%NCE*=[$.VKD0`5?$H228#`8#`8#
M`8#`8%C>SJ8J];>P*11\3*:3VH4!'G@!&C3OUX]?PP+J57UK%<'\X*('_2P;
MC_W<#WL!@,!@,!@,!@,!@,!@,!@,!@,!@?AA$`$0#R'\`YXY$1X#U_#`AEEO
MGAZ%QEDL%81=;MFG=:LEDJLB^A=/3[J(-*521>1,L+2077:IN682#%1-)4``
MJI@_3@4@7Y^.@L2$NZD3;[;*![S\C1WIV12>+1C)D41D&R9I<P*,%A1/[9Q,
M7U*/(!@514_G*ZNW&OLK$RU=V)A6[]1^BE&6VIT.O3[9>/DGD2LWD89;9+AT
MQ6,]9'*4#`/)>!'@.>`J-W\T_6!,$2Q]!WS*+':$6<)HU"K-4V;PSQ=H$4HY
M>W=N@[?&%N*A?M1<)BF8!$P>H`'DVCYNNL]0JEDN,MJWL,K%U.'>STVVBJA3
MY&52C(PB"TDHT8%OJ0O%VB"PG]L#`)@((`//&!2:7S]=+7$&A/-Z-V5!HX$4
MRIO-8P$>X3=%*C[C-9)W?$Q(Z176]DY?7Q5(8.>`Y$*5DOZBGHK6D4Y2\5+L
M93JN@^9,[#;'NM8F:BJ<D_`WLR5G8U6X3MC:1:1_`%E4&+CV04*<X`3DP!F+
M9_ELZ'5*N25HE=Z5)2.B*](6=^VB[%4Y>:2BHN.5E7H)P$=8W$RXD4FB!N&:
M:!W1U/T%3$X@7`]ZF?*'TSOM!IVRZ[M./_E6^0479:XM-N8:KRCB&FF*$C&N
MGD'9IF)EXT[EJX*/M+HIJD'D#%`0P+<[/^9?H-J(*D-OVVW,%UOT-K.#_EY2
M`LY@MT\112/;2I(*POCPD7XI#[\B[!&/:B(>^LGR&!T=O_-3\>VD]=6+9UNW
M5$24!5B,59:/I4I4KK:@1D)%K%H+,JM7K2]F9%$CUXF"ID$C@B014/XIE,8`
MK2/^6WHG)1S&01WC2DOO6Z:YF3J\ZT;/F/N$(H"#])2\@D@Y*!_4@',("`_E
M@8V;U^?7HSIJP56GP[JY;FM=GB9ZQFB-2.->61.`KE=,1L^D[!*EOB<7'K*R
M+IN@BR%47JOO@H"7M`)\"UP_U$_5TAF_EI+?@IO%`*T5(.JE2N2"B=8JB!2[
M&\E/=\?$A0#R.80X#`I6?_J3>L$!"N9M?KOV3622=1K-NR*.G&T@\<RKU)@W
M(DW>[2;@D1%PN05CJ&*1),1.8>"CP&4]>^8:FVJOQUAB>L/8_P"VDHB)F@9/
MJ5*ED6;>8CV\@V1>DBX>69IN2IN/$P$74)R')3&#@<#T2?+1$*I-W"/5GL(9
M)S[WM%/5K*FX-[!2F.)4/Y5,"@!Y!^X8W'X\8%JMQ?-]4=)U9_<[AU5W[&UR
M/<%:*2<LV3JC!5R=F_D2HDE+K#0<.FH=G%KB0#N4Q45*1(H"=0H8%EVG]1OH
MQ^HDW;==-PK.3I-U%D?YOU0@FW!X41:D5<.[`U1.9<P>(`43!Y>@\8%'2_\`
M4L]=:2C.S-GZZ;M:03)W#N)%S'6[3DO)I-I223KY3LX@+FDI)';N6PJ&235!
M8Y5`!,AS<@`9NL/FGT?*%058==NX+INZ;*.6KI'2CD[=R#=!55T5%0)CQ.*"
MB0DY#]\1Y+R&!3]^^<?0>MW^L8ZR:`[6INMK[`_RTK;='5"@.RV8T6ZF$DW#
M9S)-CN&RC)BL8/M!<N#`D82I&*4QBA54?\Q^L9=VHSC>L';U44T&K@'+G42S
M%FLD\>-F*)VZSJ23,L0%G("<0+Z$`1#D?3`QPWQ_4;]4.MLW'0FV]&=FJRK/
M4.;V!7%)2J4ZM*2T77Y2*BI%H1C>KK4'PR!%YA(2H()N5S!_Z3]0P*M_\_OU
M`:;CH$G4[MT5U*MF3M@X<4&)19+HOH]M((?XY9Q8R8F3<>/)B@03!R!A`0'`
MX[7\^VE*;%PTU.=7^U",9/WJFZ^CET:5%F4/.7ETQ8PQC(JRJ`G;D?2*:*Q4
M16<D4`X%2/X".!>A'YAM=NGCQ@RZR=K'2S$J@K.!U;)-X\ZJ:A"&;-WSHJ)'
M"YO<`2^`"F8`']7H.!8W>WSU:ST?8J;697K!O9>3O`3ZL0-A=U"@1R32KLF[
MR7>*O;2Z1%?DKU$K<C<J_P!P)C\>/M'X#'&P_P!3;I>KN(9Q,=6-LJQ,K-52
M!,[A]EZZE)!%Y;9QK7F8H5YNN@[DDVK]\B*GL\F,0_Z`.?@@AG1_Y]%II1PH
MR::#[1KKME)9%^L736P3-H]6.;JKM0<G)5G#D23!TO;1$B!Q()P%4"%Y,`4;
MLKYQ=6:TL&GJS(=:.R;Z=W)89JLP46[H%KJDLVD8.K.K<[5*UM]5@$9QA_"F
MHE\X]5PH50Y`,F!1,<H5%#_,;&3RBG\/Z:]K$!(Z8LA-)5))J15R^.L0B#?V
MVSY0ZB22/NG!0$^$C`8.?I@8L=COZD#6O6"T#5-C].^PK9]_ER[V>D)Y2H1B
MRM;93(0;@2,)4C)ZJZ(\,`^"1%!%+DP?0<#)J`^90ED2@W$;TL[('2GV\4Y:
M/2$@OLCH3+9!VS51<K%3*Z3,@X*(^V03<\@`<A@4IN'YP8?2L35YFV].-_-F
M=GV#4-=)NW3V!B$&$M<_8-'.G:THU;D.U035,94J13K!X#P0>0P*VA_F$>3S
M@J4/TG["NDU""JWDSR5.1CWS;[A-`CELH9T=P9-?W2G)Y(D$2_7@?3`QVWQ_
M4"16A;95ZG8^G&T&\C;HB<F(U2R[/JM225-7UHY*3C&J4C$JD>/$RR2:A?9$
MY#$`>!P+!1G]2O7*K.Q]:L/56SS@V?8$/7H92L;IJTU.*/-AV5HRKS(8EW3X
MU%5M%GG$&[D47*AF_@)CC[93'`)8$?DLG53@@?I9V;:+\*"!';&OD`P(E$1%
M,Z,FX,N!N/T^V4PF#U#TP,=-L_.'5M/[YTQU_M'4+L<O9]UPUSFH<S>/9KOH
M=E2FXJR*SV$8Q[IV^;*N`]@#-5%E$3B45R)E$1*%R&?R]Q3Y4R4;U'[%'*0K
M8175C(]),?N%'J12`!2.%`4(+(PF`Q2\<A^/(8&&V^_ZCC7W7N]RFOKCU`W:
MI8$HO7LQ6&RU\I-==V-'8LLYA&)/X58S1DBFG'/D"%54;(/D_P#'3#T,(X%[
MVWSIT1TY.T#JAV3:K)N5VJBKQ@FFS%5N<"*&14*@JLJB)AY**:1Q\>!$`YP(
M\?D!^9*I1&U/C^W)&=<]I0%CTWV>FY!VO9'81C23UM=M96O5^U(1O[D"H+ER
MZB+,T=-U`X`JS,@>O(\!)VO\T5.0?IL":,MKLBIO%)]&WJJ2#%3@0`PE4;>9
MR%+Y!^^4OI_8.!AUN#^I"A]<;/+K6O\`55U*G"LQ]B5G;;NZ"KK9P:06DTAC
M(R-;U25<JNXY.*.JO^KA1-5(R?D`C@1D]N_G!LO;/<71&I0/4J)E9W5/;W7V
MY6U?JNT7MNL=D6I+%Y,#7(=FM1X-.-?/T"")7RP*M6IB%,J)`X$0FH#YH.QK
MTA",?B@[&/7"YE2@W-M:L($*D#A1N1958U1,0$E`3$X`!3G\1]`$?3`CV7^7
M;L'KKN_N/;,/\:>ZE$9WK?15[32I*QS27\O+0-OG0G=DRLY':Z=L3*3M9C85
MH6(3:)2"2D<=PH4Q3@80RX2^<;N6^;IO6_Q2WO[)1J@X2>N-L6-)%47"0*$(
M@FGI8ZKDH',!1,0!`0'D/3`ZC?YZ>S;A->(=_%GN./N:9&KI*OK6N[N&RC(P
M"Y75-*1>EG+9)T#(GN)MCB"YC&`AB@(X'RC\\/:I=H#I'XM]M-2J%4,FG*3V
MRFJH^V<R8G.DYTFFL1,3$'C]/J'K@4M+_/EW%CWT5[?Q7[&6B7GWB+V21E-O
M2!&*Z:'O)>X:/T0LB5$Y2CYB80$OI^>!5KCYZ.RK1NU.7XO=R+^2K;S*TD-A
MJ^;)4%%#JMBCIHKDRZ:*7D!!2$1\R!^(\!88G]21N!>0>HN>I^N:[]FE-MW%
M=EML71Q9H^29R`L&@RC9A0!-'IH.@5;/$5&I7*;QNJF0IN`'`J'57]0MV>V=
MOBGZCKO16MW!G/P,[+3<E3]IVYL\K(0!2%-*3#RZZ_K=0B8"776*W:*/9%F9
M9R0Q$S**?X>!,/TT[N[W[+;<L5*V1U2?Z1J,%35I]G<7.RZ?<Q>6,DG'L4Z\
MLRK$K)%!)]&/57*2P#XD%N8AN#"'(2@X%D>S`^/7+?AA_P!G3&T#?W%I$X80
M_O`.,"XM&5]^E4];U_QJO`*@!AY,`*130X`8?Q$`-ZX%4X#`8#`8#`8#`8#`
M8#`8#`8`?3UP.FY?M6@H`X4]H72Z;5OR0Y@475$"II\IE.!/(1^IN"A^>!R(
MNDUQ6*0JA107,W/[B9D^3D*0PF)Y<>:8@H'!@]!]<#F/]`^O[Q/H/'^V7_5_
MTX&BA\0FHM+]LN_&\:AOO6L+L.H0],[5;$AX*P.Y0K2-MS+MS#U7^-(FBG\8
M8SQ6*F7"!?/R*4IP$/U<C@3IZD^./HQN?8&^M<;(^/3250::WL,=5Y!\SV=>
M[HYEU[%3X6T18LVQ8JJIQD/(U:T"H!T7BHI.@71$@`!3X&9T!\5G1VJ0K2N5
MC44W7*_'^Y]A78'=W82(KK(%ESNEBM8./VNWCFY5G2IEC@1,`.L<QQY,(B(5
M*'QM=/!'R/JZ5,82D*8P[=WF<QBICRF!CGV>)C>`AR'//`^OUP/&FOB]Z2V*
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MC6$`2@4:7AW)6U8F&:;U[,-ID7SERO\`]I.N\.54I1*!0"5JQ?#G\?%Q1AFU
MOT<YLZ-=EX^PU_\`C.RMGN%(&>B15-'2\2=.W(';/VQW"AB*E$#$$X^/'(X%
M1;%^)SH5MFI2=&V)H6/M55G$F:,[#2%ZVBFVG",%TW;09-5I=T'#A1)\BFOY
M',83*D`3"(^N!5T7\;/3J&9LF##4#<C>/9(,&I%KSM!Q[;9NFFD0ODM=S',8
M2I%\C"(F,/J81'UP+0:B^/[IE=T]DM[YUOU5L)Q1-X[-@*G,;$JB=SL4!!NW
M47+_`,#B[':CR=@)#-U7_":?W(I<%#@."EX"]33XU>A+)=LX;=/^NR*K(Y#L
MSIZOKW+8Z0\IF1`S8Q4S)_[(@'H/TP(./Z@/J!U@U/U?ZV3>N.O6E*:ZG>^_
M6.I6IW":_KL8XGJ9:+))MK)69-VB@@NZB)Y,A$W2!C&353Y`Q3`/&!.TX^/#
MI(Z,45^K.C#E223:H%-0(LR:+-`O@W;))![:2*2"8`4I2`!0#T```,#I$^.'
MHR5;[@>J.@_?+Z$6_P`NHHRQ0'Z@"IC>9>0^O`^N!YTM\:W0-\DJG+]/.M4J
MU<*MUEVLWJ:L2$:HX;*`9J<6L@W<L@<)JGY3'V_+R]0]<#T;%TLZ4U>OSL__
M`,HW69;^#0LC+"U+IO7Z)'1(IBYD"MA44B#($.I]L($,8!`@CS@18PG8'XWB
M;TU3J1I\92W\;V9U<C>V!;/3NDL+>(VO,5WE27A*=$2%,I$FC:YZ,5G!4?.&
M2BK*,>%0;G.+AQ[90DQTANWKIMRS!2:QUEVKKT\57UY-*:VWU*M6GJ>1DDZ;
M,U(EC9;?3XB&-,+F>%,FR(<JBQ`,(`/B.!%'\S];HS?M_P#!NT@ZQ2D"O/D"
MBXMZ1M'0K9)2->JT=NY8+M6Z1&[MN_26.B**J9R'`XE``$WJ&PB35.KD/<30
MUG1$B+BG[Q4*76TTUO:4*HC[X!'@"OM*$`Q>?W3``AP(8'4D-*Z<EW1'TMJ+
M6DH_3`02>R-"J3QTGSP(@1PYC%5B@(E`1X'\,#Z/IC3ZWA[^I=;+"FH*J?N4
M6J']M0W'*A/*,'Q./'J(>N!RH:?U*V.F=MJK7;8Z0`"*B-(JR1D0`2B'MBG'
M%,0`$@#Z?D'Y8':'56L1$YAUS0C"J50BHC3J]RH18>52*#_#A$Q51#DP#R!O
MQP/(DM%Z5F4DV\MI[54DW;\"T2D-?5)\FW,`*!RDF[AU4TAX5,`>(!Z&'\QP
M(*_DOTSJFM_()\++:N:QUE7&4SV9VA%S[.,IE6B6EEB4Z#%.4(^1:,XULUE"
ML7@`JBBJFI[9N3EX'D<"?EO1:.=))0:94Q,9,.3?RY#@/`D%/CT9AP'MF$O_
M`((\?3`L+VVK=5BNLV_;`VKL(RE8'3&QGD9,,:[$K3$2=K4I90B\.H=L"B+U
M`.11\#%$%.!`0'`[->ZE]:C0T,Z_R8I"BJD5'*"LO#>+A7EHF)%7*9U##]R(
M'Y,)A$P'$1YYP.V?IQU<.J[6'1&L3*/D2-GIE*NT4%XV3-YD;//(W#IN0X^1
M4S@)`-Z@'.!VB]1NM29$R)Z4UVF"(`")25]$A$>!Y#VB%5*"0`/T\>.,""O^
MHPZ_:0US\7VR[93]4U>"L;;9.GD&<Y"1"!7D45:XM43.DQ7<D(W0]G@BHD`Y
MC%$`\3<!P$]CE2I4;3C.X_Y:.K>G`46+E2U6ATN,G[=-E9PC=P6,K%>3*S_B
MDJJ1/A!L0Y!.(`4OKP&!&IV2[VZPJ&D=K;$4^.OM)89K6.O;OL2%9;,Z<.6%
M-)-U6J2DTV//6A^1ZPK\:)V0$=2"0JBW0\C@!P+XB&.>E/D8HCW>C>E3'Q?[
M0H<0IU]@>Q]-E:GUVIZ]QEF.Q+C+15==(K*/(*%8"PK#)-.14*^.]7DGY2@D
MFD')@E=TGV9U]NV;EH1;K_N/47\(@T)<9C>>M*O0X21!=Z#$(:)>ELTR=W-)
M@`JJ-_;*!$"B83?0!#)%.2UJF<QTW-&24Y$3F(ZKP*"80$IO(4U!/R("(#S@
M=<TSJ8IBIC)Z\\S'$"I_?5@#"H43&'@IE@$3@)Q'TY$!$<#6V^6R/UW9OE&^
M&:OHQE,L</(;O.RGX5)I`3,4Z8.KI7#D;2\8FFZ9KMUC>1@(L4Q1$!$`Y`1P
M-CLNC-*E\?#4&K2>/J0"Z]J1?#D`#]/$2'CZ`'^C`QJ[D=/]6;HZI]B=5U[4
MVO6UIN^EMCP-0?15*K4?(L+>O69%>HN63YK%IKMUF]G2:JE\3`!A*(#R`\8'
MF](V&E.P_4?K?NY73^J_XELC2^O+%/`.O*7[[:TK5E@WN$:Z!&&*5%[$VI!Z
MU72_])JHF+P'`A@5?M+1>DVVP.O*R&I-6M5QV596Z2*>O*D0CTQ].[&.""H%
MAO$X%(T`Q`'Z'(4P>I0$`ANVS"5^M?U*'2>!K];KE=AC])-O22#&O0<9"H+3
M;]IM9N\<.$HYJV275691Y"F.8!.)4B%$1`A0`-ESCZ\^O/[/P_+`ZSAL@LW<
M('11.BNFN59%1%-5)8%TS$5*JD8/!4%2&$#`/[P"(#@6BH$@]KLQ,ZP?13A)
MI7%$7=)?_<`X;25$=B*;0J9US>X5S57IOX<LGR8Y4?84$1\\"\^`P&!:S:U]
MMU"@V<E3-2VO<4LZG(N,5K%/G*/`R;.,>J"1]85G5]LM5B56$.0/)5))PHZ4
M`?\`#3,//`:4WQX=C^PNB>XO>Z<T;U&M?8&S[3[@:]U[L6H,I&M14CK>FV_L
MAV+;6.6?3[N6%@,A%++B`.B%4AFJC4RCQR1,Z?`;'.B.YW>6Y2^[65X^-'8]
M9&D;LL%!I@)[DT)%.)RA0M>KCZ"LLD_FKHP:S[N;7DG"HN8T58LH'!%%0YT5
M#B$B>HKYL"^P3N1V3I>;TM.-9E1FUK$]<*+=GCF/*U041G"R5"F9R);).%%E
M$RI&6]X/;$3``&`,"\&!9?L@3SZ\;Y)Z?JTQM$/4.0_51IT/7_3@5KK@>=>4
M,?SIE7'U_;!L<"L\!@,!@,!@,!@,!@,!@,!@,!@,!@?@CQ_I`/P_$0#\?RP-
M)'^G\<-U?E)[-P0+-A=1>JNW[=^FW<%448KAW6IY"-7K8H)K,U%2H@<$U`(8
MQ#_0,#8QMO6S6T9V!TO46LGMAO`W^1WG-V:/#L-V%;A(OXRL526B!;"SV4@5
M%&'=.U?:3`Q$TTCB0A0*!2@&1ZG3#22A!(<^WE"&XY(?LEV4\1X$!#GPV\4W
MH(<^@X'$7I/H4O`F9;15$/J5?L7V.<)#^TQ%]L*'-P'TY,/`X'Z/2?01A'RC
M]G^(\<I$[#]B"(AQQ^ZE_FF8"^H<_P!OK@6TI6KJYICN?2JQ0'UU95NV]:=P
M6&PP-@V5L>^1;V9JVSM(14%)HM;Y:[(C&R#!G:GJ8*M2HJ*$<'*H8X`0`#/[
M`P6^3XAC_''WJ*1(RRG_`"F[[,FD42@)E":TL9T_WQ`@@4Y0$0$0`0#@1#`B
MI^!+4=OD>@5$90?8/8%4A&R%%=H1-+@M9)MFB\YIW7-AF4SOY^FVN2._<2DT
M<%C*.E@\$$02!(I1*(2_HZ%V*XMLHE_S?=D4HM"$B3-HA)/18(MW1W<J@X>"
M]6TJXD'2KHK4HF`ZG@00_27U]`J+_EXNIO0_;3LJ(?4`(OI!(>?_``D])@(A
MQ^'TP.%7KC<E``"]M^SJ7`\\IO\`2?(AQ]!\M)&#C`N5J'5#?4<%)PR-NMMW
M=3EDG+=/6:[NHAY8YF>GEFYG+EVI`PE=AT4&S9FDB@DV9H$(F3U`QOU8%VL#
M7A_J54"K],>LQ5/1$/D@Z:BL8./(J1;?-J'`/Q_Q"IB7^T0P-A[`8&%/92N0
MURW[TWJEHCVLY5Y:U[M&7KTB!UXJ5.TTI8U6(OV(F^V>%9JB8Z8*%-[:G!B\
M"'.!<@>H_6LS=TT4T?K%5J].Y,Z;K5-DN@X^\*8CD%DEC'(H5<AA`Q1#Q$!$
M..,#E;=4>N2#9HU)I#58(1C=5I$-OY%@@:Q+)=%H@X8QR7VHG:,G!(]#S2(8
M"#[1/3])>`I\O23J64GM!UMT<5$WJ<A=<U\OD)A\U/HUXX\_4O\`NX&L)_4/
MZ=T_K+>/Q@QU!UA3J85UM"146=5>,"OJG;->P/4A@1H4(-2+.BN1M-.B)NB*
M%<HD<*E*;@X@`;2)^I_7UZ<YW.M8EP9(YD"F<R-F<&`A1$_B4RL\82EY/]`]
M,#KGZ<];53E44U37CG+P!1,ZL(@``/(`)1G/$P<C^.!SI=0NN:(@*>JZZ00'
MR#P6G2%Y_,2_QH0$<"A+9UITI2I75U@JU#BJ[,5S:M#=0TQ'.)8L@@HYEQ9.
MVH.7$DY$[5\W="DLF<#$42,)>`Y`0#,_`8$!7RTI>7?WX,G/(<->Y]Y2\./4
MQGFO&:0&*;Z%\`#U_/G`GN:F\T$S`'`"7Z?EZB&!3UVJ,-?ZA9Z/8VXNZ];X
M*4K4\T*LNW,ZAIMFM'2C8CALHBX;J+L7"A2J$,4Q#"!@]0P+6H]?X9NT29([
M*WHFB@F5)+PV_<2G(F0?T)E,#X."$*`%`/P*'&!9NR,-"UF_-M563LUL*%V0
M_A%+@UI,EVAL,-;%JJFL9@I90@G5D9/BP!'R1T2KE3%$52&#GD!P,==B_P"6
M=X9ZW<:0[2[@M3=MVJUGI[9*]`[26RQ-XY234D26.G3*\197)XZ0*F=`RB9P
M27_=,7]`^0AA3\]76VI4_P")'M'97%ZWG<W==2UK9XIIL#<NPM@1B,RAL"J0
MK=RI#S<W]DX*DTDU1`AP%,JP@KXB<A<#8*UP/GKNA&-R(FI=6,/ER)A$8-B8
M1-Y>HFY^O/KS@58Z:MGS=9H\;H.FKA,Z+ALY13<-UT5"B11)9!4IDE4E"&$!
M*8!`0^N!@?O6KP%GW_U"C+36H:RQ9]L;X*+"PP36=9F%/25R=LE/L'R:S;V6
MQTQ%,YRF(0_`E`#"40#*4FE]2@/)]7:Z'T]/&BU<A@$>.?U!&>O/'K^>!]):
M7U*@8QTM6ZT`QPX-_P"P'5TC<<\\&.G%>1QY_/`[ZVJ=:KI>RMKJ@+)@7Q*B
MI3X`4BAX^(``"P-P!0]`X`,#6E^;;65'A>XGPSO(2C5NMA(=Q:O`3CVMQJ=9
M75@)3;^D851D]>5\(N35:E"7,(%34`Y3B`@(`)N0FH[=:=UW7>LN]K#'0;II
M+1.K[5(L7\?9K>P>MG3!A]PU<-7B%@!=NY153*8#E$!Y#UY]0$*,<6SH.\V/
M<=<+.FDQ?:,^387:,BFFY;0T@;(\BDGZ\"_G($DE5$I]")DD5';`KPSIG[Z8
M.$DCF*&!B-\7]!ZQ;+ANX6C*O%#8*SUA[G[=J=31_B.PZVG!4/:2,%NRLU=M
M!N9:NR\.E3WMZD(86[EJD)31HF+R!A,(2LUKJYI.IV2$M\)0HAA9:VL^<0$U
M][89)]#KR<>XB9!:-&:FI%!FN\C'2B"BA">0HJ&)]##@0;;[-Q_4V='`_P#3
M?1[8Z/\`XSQOO90IP_+VRLA`?Q'R_9@;*&`P+=;`A'+E"-LD,Q!Y9*<X4EH5
M`JI6XODU`*A,PAE!*8/&:C#'3*`@(>\4AN/(`$`JJNS4=8X9A/1*IUF$LV2>
MH**$.DIPJF7S351/ZH+H'`4U$_J10IBCZ@.![>`P/DP!^(%']1?KQ]?(.!]?
MQ`?I@:E'P/J';_)!\Q#,#%`P[!E78*H*E43*#3L9OXBA>`#Q]Q;W?7\OQYP-
MKJKK+.JY".7)P57<QC)PL?Q*4#K*MTU%3^)0`H>2HB/]^![_`!@,"SG8D.>O
MV\R_[VG=G%Y_+FDSGK@5=K4WGKF@'XX\Z553<?EY03`>/]>!6N`P&`P&`P&`
MP&`P&`P&`P&`P&`P.)8>$C#P`_3Z@`AZF`/H/("(8&M)\8U'J<5\N_R=W&#J
M%>BYZ4V/?&DM8V46@A,/6DA']>YEU&J.DO`B48>6]QX9$A"@=VL981$PCR$T
MVZHA6Q]@NM4:SL4_652,=ZE5D:TO&(/TE#5&J*$2.,I%2J!BF26`X?X8#R`#
MZX%K=X5'86LI;2*-?[';U6:[/WU5-86="6D]>OQ1K$Y5[_.NC0!R:Z;*QLU_
M$H1J!'`BMP@0R0$Y,!@"M;,37C!LH2P=U;C5&\0\=Q4@Z=;CTO`N$)*,!7^(
ML9-5U3BE2?,01$RZ1A241]0,0`*.!6,=U_<RC1E*L>SW9"08/D&[YDZ9W^DN
M6#YHL4JS5TU<L]?`BZ:.D1*<ATS"10A@$!$!YP*II_7Z(JVRVVV)"];'O5NC
MZ?.T**<7>=CI!G%5BRR]=L$TU8,(B$@FB;I]+U5B<RZA5E`3;@0HE`3<A?W`
MPD^2I+WOCT[O(\@7W.JF]R")O4``VM;&`^G^T/`_3\?I@1\_T\2[@_0>#0.S
M<,6:;ZB/(Y-PW;MQ,WE=!Z:>',F5`B9CI?<>8E,?R-P/UP)G[-<JM15+':KK
M88&GU2NUMM)S]IM$PP@*_#1Q'CP%7LK,RBS:.CVJ)@`!475(3R.`<@(^H6WA
M^VW6.P3-?KD'V'T/-6"W2)(FIP4+N+7\Q,V635*<Z4?"1<;..7TD^532,)44
M2'4,)?$`$P@&!D00WD4IA`2^10'Q'ZAR'/`_M#`^L!@:_']2`HX2Z6Z`.BH4
M$C_(!U,;O6JA/-%\T6LTV)VRWJ!RE!1,IRF*(&`Y`_#D!#8'P&!:O9>GZEM5
M6KNK&M98Z2I<D[EZS-U"UV&F3\6]?LCQD@5";K4A'/\`[*1C53H.$#&,DLF;
M@P>@8'@+Z'K0E%12[;G`J:(%-QNK9:8>"93"(B(64O`\#ZB.!BS#;BZ4$AK!
M.1?;=9[!QCDT1.RY.TMSG8QB\0>"T%`)%.VO4&Q@>IF3,JD8.0*(";CD,"IJ
M5`J3793:<*CLC:$M1XK2^@;14V*>U[>ZA#.;E-;J2E9YBLUE@!V>;:0##R6]
MU4BJ:)?'QXY$((OGZU1#)=EOB_C4[1=E@N6V'=5?GE[G99]_&1CWL5T_^X=5
MA6:DW[."D5"K&`RY4#G-X$_W`#`V)]P:Q/7]-[?F([9.XTYB/U_>9Z*E";.L
MK1]$24=`2LHP6C%F#AL1L#1TD02E$A@,4H%,`E],#DJ"]7C->ZLEKOM*?AI*
MX5.IK).;-L]6'4L$\\J;"3=MV!I*08#+R*B:9U5$TA,H4A3'$`+@5=!)4"[/
MI*-KFU96?DH="/4F8VK[=<2SN*;2I5U8UQ)MH>;<N(].1104,@HJ5,%RD'P$
M>!X"I%M25]TM!*2$M<99.NV*.M4<WE[I:7[?^,Q1P4CUG**DL5%XV:J_XA4%
MRJH>\!3B01*&!=/`8$"?RS*E1[V?"*"OZ2.NZ]C025'_`.&"45FX*CQQSRHD
M@;UY],">-GZMDQ_,3_\`JP^!V<#\$>`'CU_9@0--X_3?77OM\C6W^Z-J@M(T
MS=DQUILVCM@7;9T]3*?;M>4W2,;KRUI&L,=-Q$+#2,)L&-=I&C73A)ZE[Z;D
MB?LNR**!;Z.UW"1_<2U;7T6PFIGK]L39WQKPC#:<E;[9:8V[;1IVT-[6:_-J
MZZM<B_<SL;#:]V374C2;;_L*2@G8D.95LLFF%\/ZACG_`,YG[C*_N^Q4=?K^
M//J8$]KT,?'G\/,!_NP)@];?_:[H/_UEU;_]1L<"M,"@[?KNI7\L8G;H9M*'
M@97^-03I%S)Q<A$R)6[ED5VRDXIZQD&S@S-XHD<2*`51,XE,`@.!YZFM:<R*
M=3[643(<ZSA4W\SVGVRJJ)I%4.<ZD[PFF8$2_4?$OJ(\!R.!B1!]LNC=F@+!
M:JQN-"RUJKN)%M+3M>?;5FHTQHEZK'2"L,M').?YF9(OD?;(XC0=MUA,`IG.
M4><#O:YA-4;(W_<YJJV=>XU*=Z^Z3MM<4CMB7.8KSF/GKEN$$K'#LD[*:(2_
MC3./;I*.D2@LN1L1-4?)+C`A7^:B@UBG=T/AJGH!@];JN>Y>OF4LY<6"QRJ7
MM([[ZXF01(UFI>2;-3%.<3B9$I#&`.!$0XX"?'O,)2]/NR1S&\2IZ>NRIC<@
M'!4HA90WJ(@`<@7ZCZ8$>6H_\C^I4EORL]MZVRK=F[#=Y=F[(UO:(6A["NU5
MVFU[`V<9G44,RM53JDB0+A'L4CPSIA(_:+-GC(Q4/=:F16.&/O0>C7WK9\IO
M:Z2G::WUOHOY'FE]W'HN"<OABY]>7ZQR-*J+R:L%)=,6@4Y]=:A?',NT*=15
MXYC"HG>E05*"10V-P.!BB/\`L^//("`\E$.>0$/3Z8&MWV/(S1_J4OCF42(B
M#]UTHW(+TR8&*L=NBWW:6/%P(B('\2F4`OH'`<_G@;)&`P/@Y?,ABAX\B40`
M3`!@`W'Z1$!^O`^N!9J*75HE^"G*&=*U^[ED;+6E3-SJMHV>0<>_:ZZ5R!C%
M:H/P>!*,T3^(<@Z(GR!"D`+T8#`^3_0/3G]1/_1R^O\`=@:C?P*G;+_)G\OX
MI'%PB:Z6!%4$R#Y`HEV=[`M5TP+R/D8!2YY_;@2O_+S\E%Q^,33W7"W:VTU6
M=O3^^>S=%ZV1L+=KK+T*%K9[K!6A^SLCN0A:M;)!TBS?P:*2B)&X#[*ISE$Q
MBE(8,F=$QGR")]BKM,]B9_1(:`E-<0AZU3=8HS4L[K^SD'+)J]2A+-8&-<LK
MB"7C$'3A^:29J%6<+MRM"-BI+BL&=V!:/?X>6B]S%_W]4;'+Z_MI<Y^'XX%3
MZU-Y:ZH)N./*E54W'Y<P3`>/[L"M<!@,!@,!@,!@,!@,!@,!@,!@,!@<+@/)
M%0/S*(?]\?[@P->OXVDV;CY/?D]=HR"@G-M59,6H`!4RG5I&I4E/3R$QA*HC
MZCZ<^GY8$L-I;O&O9O1ZCM#V2R$EO5PR'S\_<:%UUKMN58/TAX^2[)0/']F!
M2O=XCHS'K<1@15216[0U!&,30<"U7-)K:RVVA'%0<`=,R2XO%">V8#I^)^!\
MR``F`(\.G&G^I\1U`T"Y[$;:)4=LTC7-*BM]5?8NW*_$3U<W#7V3%CLB&N$%
M8EEY(98]M2<IK@=5<7Q50,DHLFJF<X9Z?&+$V6M]+M50-JKUAK+AO8=TN*S'
MV07QWZNN93>&QYW5LBB2245E6$5)ZUDXI=BU>E;NFK0Z:*B*)DQ2*&?V`P,'
M/DV%4/CJ[R@A_P`8W5'?*:?[3*:UL:?'/X<^7&!A;\!34C?H%KL_V_VJRM>U
M.5P@)_=%,S70VK&A"^YP7RX21+Z\!],"J?F$ZQO-TZFU%=&8;$FH+6':;JML
M+<-*J<^[1KTYI+7>Z8:S7Z=L=2:@9_9ST>O+O)$B+`1='(F8?8<>T0I0PL^0
M2*ZG=B>JFR]8=(]SH[P[:O)/4U?U!K3479:P2ECC]D1^P:C.1LU.P,58%F]:
M0AH2&=S$@_GDDF*"#4RBIA'P`P2^3&K9_6EMT?9VN[=[6$]BV/%5.R52Y["1
ML5.DXV:IEN=/4W42G`QY57#5_'I+-U4CH>"B8#QX\D$,XBAX@!0^@``!_<'&
M!^X$!W]19"(6'I1I:),H!7[GOAU()$)@FLLJM(K7MRT)[*2!3'.=N@Y.L(>@
M""0AR'/(!/C@,!@6)[+TRW;(Z][VH-!(U-=[SI/:E,J'\0>C&QYK-:Z/.P=?
M^[DP27^P;A+/4146]L_M$Y-P/'&!$'T]5Z,4#JIH+K]MD\K1]X57K)K:&V/U
M[DKMO0FS0=TJJ5V@WU%E0(U_&3=GAT+LW69_<QS`L<N9PD!0*1<GD%WOBST[
M>^O-=K.D=EQAH6ZZXZ6]48"=AU)7^,JQ3DVU.TTFA&*OP`Q%U8J-DFS8X`HL
M*9TA3$YP*4Y@P._J!P58]G?B4F12`K<G8(D>#DY@*F=ZKV(Z>KHL1'@1*=9J
MDNH`\#_PN/QP-C?=8$/IK;95%"(IFUE?2G65'A)(@U:6*950W`\$(7U$?P`,
M"%C9.G*];>_W5+8G8)12"ZUT[XVU82AWRU6&`8:L1WTXVA0I>;C@1LZ+R#B+
MBIK9@BY2=N"-5'31$2(+*>PLD`7&UQH34\'\C?7+;O6%^6^4Q/KGV+C-QW.C
MVJM35`B8VRSFGD=2LY!:H(1E=EI*<FZO-J-$RE=O$A1=*F$B0@.!-<`\_4.,
M#]P&!`?\NYDR=WO@V,H<"%_Y[)HGD/T`QJ$4Q/\`RSD`O_C8$\S+U;)\>H?K
MX'\P]PW`_P!^!VL#`';53+L[NQKS6MDLVP&%%)UBVI?#5^E;%O>O47-OCMH:
M@KL?-R#BCV*`<2*[*%FGB"9%S*)D*X,(``^N!6-UZ#]<-DU";U_L2,V9?:/9
M6I65BJ-SWQN^RUN=:$<MW96\M"RVP7,>^3(Y:)*%!0@^)TRF#U*&!4;?IKI-
M"=I]B6)LN9?4&U1=VJ+.T;MW)::]$6>#0<(0LJ%8G;V^@GJD45TH9`BZ"B9%
M#>?B)@`<#`+^H6:^[\-_=9J!_$`HM0`#"'GP">SJ08`'U`1]"\<B//XC@2UZ
MK'G6&N!_.AU`?_W>CL"O,"F:ZF9)2P`)A/[UCD5PYY#P**3,@$#D1Y`/'G\/
MK],#P]J1+^RZXOU7A'$>C.V.EVV`AS2;M5FP3EIFN2<?'&?.6R#MRV:%=N2&
M5.1)0Y$@,8I#"`%$(1^FTETXZU]<^J/2#L'4E:WV;K.@(2EV[4#37^U;2^MD
MYJ&(CX38$_6'=9K\M7;-674DBD^3D&CO[<49-H*OMG<$3P+^?&#H9YUO\-2S
MQ()E9:MUWI3AQ`5M0RT55H6Y=E>V5XKU9!;W%2'?04//H,W)0'A-P@<I>2\#
M@8/_`#ML9+_FA^&^00$A8UKWJU^UD#B)>3.)'=6@%F2/'("`<`(\X&R1.P<3
M98B1@)Z-CYF#F&+J-EX>69-I*+E8]ZB9L[82,>]379OF+ENH8BB*J9TU"FX$
M.,"RJ_5CKNNR91I](:D-',7J$HV8+:^KRS5M*M``&DDR2%L4&;YH'()*D_6F
M'[HE_$,"._V@M#Z[:=7]_'U7KI%CIWM;J6+N:JM+AG+=SK+?4DKUTMD=)D]I
M,QXQB_VE&2ZO/F4O\)!0Q#`GQ@9R]38>'@-$5>O0+=)C$P$SL6NL6;4ZPM&2
M$+LRYQWVC%)=586K)FJ@=)%(!\$4B%3+P0I0`-?+Y3-A[4ZX?,)TP[54G0MO
MW5":[ZF;$KBT;4X:RE+).K)9;O"O6CJTU^JVK^%J1D?9$G*3=5(HF$QP#D#^
M1`NW'?/;LQXY134^-_?""*RPHBX%Y<E/;/[9E"`*8Z>+Y>7'X&#C`YW'SP[8
M;++@K\:N_P!PDT!-R)&SRY"\>,O=!-P,>@?4`$7>I@!A!(3``\!R8.<#WR?/
M'<'!&IF?QL=JUCO`4!)!=C.M5BJE3\TDEBFUNH"1EC"!>1'@!'`RZZ1_(15?
MDN@MYUB$UE<=&;(T%/TQ&9B+6Z+)NX:8LS*<D*I)).1BZ^[;/F,C69!I(L7#
M5)5$A?0QBJE,`2;4FQEL\"A(*H@SDT5W$;/1WN`J:+L$>?[>6C1-P`B#5T40
M(/`<IB4?QP*NP/DP\!SP(^I?H'(_O!@:AOP((D9_)[\P)4S/`,;8MP*N5803
M2$Z?:O>@(K(H<&]K@C@>1$P^?U],"M?ZHE=5UUO^,ERNH=59Q\GW7M90Z@^1
MQ,K`7]00$>`]"^7`?L#`VO\``8%L]TM3/M/;79$`@F>:VO+0ON$%5/EU6)1`
M!42`Q153#W.1+R'D'IR&!Z>L"&3UIKQ,Q2$,2C5(AB)E$J9#%@(\HE(41$2D
M*(<`'(\!@5S@,!@,!@,!@,!@,!@,!@,!@,!@,#\'D`]./[QX``Y]1Y]?H&!K
MY_'`#57Y0_E$7091[)9MM<\<Y1;)K&5373H>HU5U`7<.%E`*[$2'4```@G_=
M`..,"6'8<FR'L]ULBRN%!?"EN]8S8RGM%!-M0*H94Z:9P`'*:82"/(D$?`RG
MK^.!=;;.G:GN>"CZ_<%9YLWA;%%6ZORM5L,S4;/7+1"E<)QL]`V6`>LI6-D&
MZ#QPD(D/XG17.0P"`X&-\S\?&CK);*I?;':-]V"[T,+`6E6V9WULJ0L%6+:X
MMG"60(>17G#+MQFHF/1;KB(G$4TB@`@(`.!Q;1ZMP5=U7L69B=T=J4I6"HUN
MFXMZX[.;D>F;R<7!R$DP<G1=6M1!R#=VW(;VU"F3,4OB8HE$0$,K-4/GTIJ[
M7$I*.C/9.4HM3DI%Z<A$U'C^0@6#QX[5(F!4RJN7"QCG\0`OD8>``/3`K_`P
M7^3LRA/CE[T'1'A1+J=OI4HC^`I:TL:G/]P%P,"O@_>W*I_'_P!=I9AKV:ND
M!L[66M;A#6B'G:BS2"/8:XK54>FE8J;FXR6:O2S=?73!-%%P04_$_N>HA@9[
MS'<VR1VQ;+JV*ZD]B;O:J9$5V9M?\DGU!*0\`A;22*]=:O9F4VC",S24DSC%
MEO82%0R:?'GP(\`%K:AVFJ4;L?C5O2S:+S:^^H>Y;!V$G5RZ0A+,J325NBM)
M3"^SIF9V/",G,Y7)99K&MT4WCT0;E'VA,F038%YE[EL'=;_71UM-676"NM-W
M,)RZ1=_LM+7FF$)$TNQG9R<8VHDW<XV;3FUYYL5NFB\!4I/=.H4@IB40S1*(
MB`"(<"(`(A^0\>H?A],#]P(+_G[9O)'JSUOCVBZ#'[OY`^HY5I4RZ3=]&)H7
M1^[]^+65,0$W:IFX)B(>OM',''K@3H8#`_!#D!`?H(<?Z<"/71^@M:;4B=OV
M2\L;3/3,EV+WFQ>.G.R=EMD_MJULF>@X9DQ9Q%OBV47$Q<6Q20;,VR:3=%(O
M`%$1,8P7+4Z,]875D:6I77+E>U0T=*PL7:7M_P!IO+%%PMB<L7\Y"PTXK>OX
MI$PLN]C&RSIH@L5NNLW2.<@F2((!<S4_6[3FD)&Q3&M:B,'+VMG%1T]+O;%;
M;3*R$=".Y=_%1ZDG<+!8'Z3&/>S[Q5%%)1-),[@P@7`UZ?ZB=E*(;H^*BRI,
M@<0T7V.+&O7'W*:1D9"2WCU/>QZ((G_4I[[:'<CY%Y$OM_3UP-G:5BV$_$RL
M+*MB.XR98/XB1:*^7MNF#Y!9B[04\#$/[;ANJ8H\"`\#Z#^.!BB_Z(=9Y>O+
MU"7I,Y)U%PS-&J5=]L[;3N`5C5&*T:JP7BG5[79N&AV+@R94S$%-(H_X92X'
MET_X]NI6N:M&4N@ZO<TRFU^&1@H&J5;8FU8*OQ$0T3$K1C'Q4=>4&;%-KR/M
MF0(D<@?0>>1$+\:4K493*@_J<(,@$)7K?;HZ'0E)B8L#QG'A-.7"3,\O/OY.
M8>)H'7,!!774,0G!"B!"E*`7>P&!`1\PG^%W+^#]?])_=^0)NT\50\@2!6LL
M%O=0'D/;4#[;@?KR!AP)[6?HAX_[JBI?[?$Y@YP.U@8WVG6]J4[+4G=D.I`/
M(6N:2V-J^2A7[V082BLE<;IK>TQTDS7;1<DU,S:I4I1)8A_%3EP4Q0$"FP+=
M[*[&[JJFX*#IJ@=>(#9%AM]`ONQI1^ONQK2(JM0-'FZ;7?9%:5U])*R\M,RE
MV;"FW3(G[+=)14YAX`HA5VG=W;;V(\V7!W72$-K.T:TNK.J/8G_-9.YLI=C*
MU"O7*'L$;-QE%C6PHO&4_P"RHW,0%&Z[8Y3";D,"*S^HLNU]A_B([9(+4Z#"
M%GX[7-9E)-G:WSN4AVTSM"GI_P`5;Q)ZJT0D$FBZ:8*%^Z3X3.8P"(EX$)N-
M2',KJK62A_'S4U]3#F\#>1/(]<C3&\#"!1,7D?0>`Y#`N#@<"8![AQ`Q1]3`
M(`(#P/("(#P(\&_UX&".M.M.B=F.]K6K86JZ9<+"_P!Z;F;O9F>AB/9-RC&7
MM^UBD3NU%>?88,4B))%\>`*4./VA<]?I+U,>G9K2'7?3SY>/4=JL73JB0SAX
MS.^2;H/!:O7*3AV@#INR1(J4IP(H5(/(!#T`+JZ_TOJ?53Z;DM<Z[I%'?V-"
M.:SSRIUB&K[F8;0ZCY2(;R:\8T;K/48L\FY,@50PE3.Y6$H`*@X$!?S:Z^L.
MP^WGPQP-?G0K#F2[FG%&<?U]S/0"+^K2VNMFQ[&3!E(1SE(TDXH1$"`59`3E
M7,8J@"GXF"<U[']AE!7%E;='(`<I10%[K^[O3)J<B*@JF2V0R!PGZAX@`$$/
MQ$<#&E?9?<R?VU?]0ZX<=5GDKJBJZTF[3.7:%VO%I2#S9I;BO&)0D/7K!,BS
M:-&E2,)_?<BJ8ZGH4"`4Q@M'V#I_8OMC\??8RFSSS41KY9-=;PJC.N4ZO7`(
M]ULK6$K:6E5>U2U2UX0?1AUK?363EF[=-DU&;CQ$2CX!Y!D!\:4R-KZ-=:[X
MK/)61]LS649M.=DD&AXY`MLVA)2^P;A&MHY1[)'9-8.T65VP3(9PJ?AK^H>?
M0`SJP&`P/P?H/`\#P/`_7C]O'[,#7C^(MJNE\AWS4.3"/V[K?^O$4!.83B"Y
M)W>3A8!\N3&`?>\@$?3UX_#`FZE#+TK8D=(ILU7%5V`X0B[`L0OFG!W(B*25
M=F3AZ@W8SR#06"Y@_P#QHK;G]X,"\?/^KTP/P?I_9P/TY_'_`*<#4H^#:.7C
M/E2^7E)R4QS+VFTN`(`<JJ(#V<W28OD(B'N*K$5XY]/3C`JK^J?\1T!\:8D0
M4:D'Y0>O0D;*D!-1`HUZ^B"1R`)@`Q?[<#:NP&!0>TC^UK/8:W*H"C1K<J'L
M^Y[W)*](F_P?9366!7T_3X$.?GZ`(^F!QZF5][5FM%O\3_%U_35?\45!5_Q*
MY&F_Q!5(FJ*GKZ^12FY^H`/I@7`P&`P&`P&`P&`P&`P&`P&`P&`P&!QJ\^`@
M`<\B4/[/(P`(CZAZ%`>1_P"[@:MOQ::[MB/S@_+5ME1./0I<M9+G2$S-)":4
MD9&>-:-;6F.=SL.Z<KQ+`S2$!=JT71`IU2(G*8`*!0P)X-RT"_+;BTYN"AU6
M(N3S6A=IQSVO2-G)4CNFFQZE48E&1;2[B)ET!49/:D1-5$$A-[2H'#Z<"')_
MF;VR,L($ZL:_5:^8E!=/LVV\Q('(>0HGTZ3@X?B7SX#\!'`]]>_=E2LB':=<
MJ<M(F*(G;.NP#5JR3-Y<%+]^AK%ZN;R)^/VW[WI]/7`MQL*S=P+90[E4F'6K
M5#)U::G9*VB_?]FWAF<>YG(I:*;.W:3?18N%VR"CTRBA2>)Q(D(%]3!P&56O
M(5Q6Z%2:X\536=UZIUZ!=+HD6317<PT2TC5UT$W!$UR(+*MA,0#E*<"B'D`#
MR&!6&!A%\EQ2F^/#O"4Q2G*/5'?7D0X>13E_RSLG)3!^)3?C@6/^%"24E/BL
MZ+O%4D4%'6AH-<Z*!/:13,$K+IB1-(``"%#CZ?A@7$D=8=O([MAOC8&NK%IF
MNZ<V'0M)M8,]RJUBN]N<7BAENT;;SGCHBU4YG#P@0LTQ^U]U=P=PY*?@$RB(
MB&.52Z__`"0563TO:ZI:NJL%<8JJ]IFVZ5;'6K]9:L]LFX^R+#:U-2UQ$1$[
M$2L8P;51LHF_5>.UO9<"5$A50_Q`"07KC#=AHR/OKKLDZU`^MTK>%W%7=Z;B
MK5$0QZ&V@*^QB"SS:VOY-]_,G\4:O15]M;V"H"B!2@/D(ADC@,""WY_$3GZM
M=<5T')D7;7OYU..T0!NHL5XLI<7R1D%#I<F;E*@8ZGEP/(DX_'G`G2P&`']G
MJ.!&$^LW:#KI?8;3NLZ5H_;*N\=F]B=K5]S;MD7+6+^O5).<C[O.+3?VU!NR
M,G(1\E?FL>BW8I"59,Q5S*)AYE`/!LG:?N/4)^7J:VFNO*U]?;<U;K:MUESM
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M*2BU@3IDI,$C6L\$&CHQ1LH_,Q72>_9?>@()&%,50.&![+WLCW`5;[&GZ]U6
MU18*%1[5L&!;6-7LTK"R4M%:[E9&)EIIY7E=0/AAUG2L2X,FS^[74(!0!0Q3
M"(%#+G3Z4V>I*3<^$,1Y;YN5N39""7?N6+:*LJB<G$-SN)%LT<*ODXY9/[@0
M3!,%A,!.2@`X%T\!@0(_,2@53MM\(RYC^'VGR%1JX`/'!S!6VP%3$PB'B)N?
M3ZC@3S-0X2#_`,(X_P"DPC_W<#L8#`P0[$]>^P^P-]:WV[H??55TJ:HZHV5K
M2RI3>LF>R)&?1NULUG:XMS&H2KU"*B4X]:AK)KG.1158JP`0"@41P*QZIZ;W
MEJ9;<LGO[;T#NFX;-V:E:(FSUVBLM>-8NFPM"IU.KU=D(".,HS4F&RL"Z66<
MIF$BH+$#T$O&!'5_4E>`?#EVO,HX5;D*&J1,9$WB<X?YNT@/9$W(<%5$>!^N
M!,;IXR9]1ZL.EZI&US2#)CY>?^&:LQ@D_7_M_I$/7\<"XV!3L"R48JS@*>OW
ML](/TQXX`$UDV9"A^W_AX&*=:UMV1H4SLM"JW?2#VJ6W:5WV#`I62@[`_F*,
M;7*2_BJT/+NX2[L8V3/&/#J)I.$D$O<2X$Y0/SR%D8S<O>Z^--MKZOI?3SC6
MFT+UJQL\O-QW!&DGY"BHQZ;Z;>L:[7)TT*U?2CTR1&8N'2J1">9E!$0+@9`U
M\_:J?@8>;3N/6L$YB+CY,A6NK]MNFQ2/VB3H"H.#[4:'72)[O!3BDF)@]1*4
M1\0"'GY,)K:,#WK^$2"V#+4Z51F^Y$V+(U'@9^`C?XPUKD.V<*2$5/6B?,*2
M<=)*?;G`2J(G#CR/Y\`&R`4`````X````#\@X]`_NP(\ML])=F7O?]QWCK3N
M1MWK\VO>NM?4BT437%1UT\CI:6UY)6IS$W-W.VJ%F9=22/%6I1@#<O@@FBB4
MWZC"(X&276C2LMU]T_"ZQL&T;7NF;CYN]V*:V9>FL6SM5JD[W>K)>7SJ8;PJ
M3:(2.S6L0M4P0222]E`H@0O/`!A3\5[TE-J_;3J^8Q4&_4[NANS75,C5!,56
M.U'L)Y'[\U8T2(HFCS&LJ_M0[-H8A/9]EGX$$03'@)4L!@,#Y/\`N&].?TF]
M/S]!]/[\#7(^'R1=._D4^:X')A6,GV(I39-4?3VVR%XWZR:M^`Y#_!0:EX]?
M4#8&PW8H)A88B4BI$IQ:R+%1FL9$XI.$B&'S(NV6$1*@\;+E*J@J`>:2I`,`
M\A@4MKZQ.I!B_@9<3C:ZG)%@[![K=5N#WP1*I'V!J0_*AXV=CB`JDJ/Z?>!1
M(1\DS8%Q3?NC_=_TA@:EOPI+ND?F"^8)FY7,Y3+9+0\3$Y`)P1?L=L(A4"EY
M,!BI!R`&^H^7TP,R?G:T)5>Q/5#K\[V)8;1!FUEM[9VW*M.U%W',9.)V[KGJ
M'VCONFY552382;%Y'1^S*C%)KM5$3D>)J"D;CS`0#W/@3M6_>V_2?KGW^[)=
MJ-];7VSM2K;;@;#K^2?ZZK.B&;:*W/<:U'/XK65#US54`L#..J33VI)T[=/4
MO)9--0C=91$P3WX%';$;)/=?WEFN`&0=TZS-EBF$X%,DO"/DE"F%,Z2@%$AQ
MY\3E-^0A]<#S=1"0=3ZP%-,$B#KRE"1(ICG*D0:W&B5,IE#&4,4A?0!,(F$`
M]1$<"X>`P&`P&`P&`P&`P&`P&`P&`P&`P.-40*3R-Z`!B"/X_P"V7\`]<#7C
M^,W[DWRC_*O]L\,,4AN;[91JJ!$U5W)JS43+.02$?<\&[E`R8&`!#Q$HB/Z@
MY#8/2>MU';EJF?R59K((N"B'C[9W+;[E("F'T4$R0@/`>H<X'HX#`8#`8&$7
MR7!S\>'>/_Y5#?@_Z-964?\`N8&/7P<.!>?%#T5<F*!#'T3'G$@")@`5+)/\
M@`CP(\>U_KP)8L!@,#\$0#CD0#D>`Y_$?KP'YCP&!:_8FYM::K4A&MZN,)`2
M=G<*,ZO!KK*/K)979!3*9&O5>+3>6*=%$52BJ+1JJ5$I@%0Q`$!$-?SYHNR>
MLNPO3>E_Y46)Z^=:J^2_J=K39D=,U"TU&PU6[1<Y%W%Y67T+=(:!FHUPO`6&
M-=$<$1,11H]+X&'R$`";_8W;/3&K=IQNE+3-SBFSI37<MMEO5*Y1KU<GJ.N8
M>?:U=Y:Y`U.KD^C&QA+`\(T`RQB&,KR(%\0$0"\E%OU.V576=MHMG@K;6Y#R
M!I,5^10D69E4^/>:+*(',+=ZU$0!5%0"+)&_2<A1`0P*QP,-NSFA-R;2V'U]
MV/I/<%6U#/ZBE;^WL:UIUD.S6]RI6PH6'C9BJ-F7\TU4L&LJ\@6CK[WW%3$%
MN4"D'D<#$ZR]'>U5O0MTU*]S*T&YG/833&Y*;M",ZW1+:(I=:U139BKIT5QK
ME[>Y.%L#N82M\BM_$3/4BIF6+Y$Y+@9!Z(ZU]A*'O*Q[LWWVA8;^6D-55[5E
M-C&FE*YJI2JI-[>XM=HE%#UB8E$9P]F6*V(5-1%(S0K;@#G`PC@1Q_.<;PW%
M\.QP`I#$^234ARN@_0JW`DY63G]M<.!1*HD4P'X']1`'\,"4;7??7K+MB`KU
MIJ%\=$IEU<N&E+O5GIURJ5"MZC=[*Q:Z=>NUDA(NJR`ED(5TD!OO"D,=/Q`1
M,8`P,"*QT7^1N$J<!KUG\CNL5=.P]DB2-*0TZ@TYP5?5+2^)V="E(W)*Q$F$
MWQZ85..)(@8ZIUA%S^(%`+FW3J7\B;A#>U4U+W5TG0M8;2NFT+'2JO,]836:
MP4B!VM+RMBFX:7M([#0"PRC9W8G0IO"(-B`44P!+]`B8)5*?#'KM5K<`HK[Z
MD)`P\.=QX^(N314:UC_N3![BH@*_VWEP)A$`'@1],"H\!@0%_,HB5?M%\**:
MBGM$-\CE3+Y^/D'G_"&)TR?4``RAB<!S]/K]`P)'V_>[1REJVI546^T'3+26
MQUM2[.OC#4&P)77%0OS6&A[$]@Y6V0\/(MR),(:PL5G3X$PCVA7)/>6)SQ@9
M;5FSP-PA&%BK4U#6"#E2*+QDQ`2K*9BI!J551(J[.1CUEVC@HBF(&\#F\3`)
M1'D!P/?P&`P(,/ZDHB9_AE[B>XI[0EC=6G2.")5Q!8-S:_\`:X3/Z>IQX$?]
MDHB/X8$ONC3IJ:3T\=$>4CZMU\=(0("?*9JE$"0?`/0G)1#T_#`NE@<*9BF.
MH!3%,)#"4_B8#>!@X$2FX$?$P`8!X'U]<#FP(Q7'1+=\3*]BW&M.]NU=50F]
MMB;(V7!5VN:FU1)--83NQ8U@WDU(UY98F7?V)9G-M%)!)1T=,IQ7,F*8%`I@
M#)BR;AU)U/H.L*+?;>=[/I5Z"IM0J]<@96T[)V"O`QK2*5>5?6=)CIJT28*J
M-P5=*MF?\/CP.(N%T4P`PAKT_(QV5K&[ODP^(2J1])VI0I_1_;N/E;[$[.I9
MZK(MD-E5NM3%0=1S4LC('D8UU%U20,NJF!CMED/;.0O(B`3;ZE^2'0>W-84+
M=C6(VMK_`$YLUHB_IFT]GZ[DJ[K^08NWOV$>]DK=&.I^"JS.3<`)4%YA>/0,
M/`"<#?IP,^&CMN];H.VJR#ELZ;HNFSALLFX;N&[A,%45VZZ0F26053,!B'*(
ME,`\@/&!V<"+2MQ49IOY7]D`K(F0C^\/5BH7:.AQ!<R:VS.HMG6HEIE$&Y6P
MMR+26L-P0!5%143'VXWQ\3>GB$I>`P&!\G]"&]>/TF]?R]!]<#75^)YJLU^3
M7YO#G4\$W._=1&!@5N5LD@8)7;1RN2D`?(3.BG`PF$``_/(?7`V+,"S=^+_)
MMEB=IMRJ_9HMFU5O8$\SI)U!=ZJ[;V`R!3<"K6)54#*G`HF!DY6'_8`!"[Y#
ME5()@,0Q1Y`#$,!B_3CZAR`^O^K`U*?A7139?,E\P+,AE5"-+/>TO-PL990P
MH]D;:L4_ZO\`A$,+D?$@>A0+Z?7`EU^9QA68'XW-Y7:>(X;5[4`U+8TB=BDJ
M=TPK4?;XN'O"[4&[&0=>X2B626]4TC'X,(!Z<@(8[_TQ13$^$/I20P<&*SW:
M4P>GH8O8C;`"'IZ>@A@3W8%.V\"#4[."A043&O30*)CZ%5(,:Z`R8C^1P'C`
MI_4:I5]4:Q6*F5$JVO:6J5$HB8J15*W&G!,IAX$2D`>`$?RP+A8#`8'X(<^@
MX'Z'IZ8#`8#`8#`8#`8#`8#`8#`XU#`4GD//`&)SP'(_OE#Z!ZX&NQ\<0-1^
M7/Y3SMU_<*EL=8H^8D!859&O:T<J%*0H^0I("W`HC^`CZ^N!L)-67VTE+.RI
M(",BY9*F,F;_`!A!"/2:^XY`WI^CVN"@7Z@.![.`P&`P&!A3\DB0+_'QW<1$
M1*"O53?28F*`")0/K.R%$0`?01#G`QG^"PXC\371(OCZ?Y&MDN?7Z-[59DB#
M_:<`YP);L!@,"P?9+;+W3FL'ECKT4VL=_GIB"H.JJF[6.U:VO:5WDV\#2H5^
M\3Y48PG\4=`YE%R@(H1+9RKZ>&!Y6D>NE?U:#FXSTNYV5NRU-"'ONY;.T:FL
M\XNNJH\5AZ^FF0$:1K^-67%.-@([V6+1`H"<JJYEEU0UEOE*2*RUUW;<)"D/
MM_-KT=?>R1+V2'74ZQ]:15,?@A!,<Y2\G,'/D(<B.!.*LG[/R_'.41`RGQK+
M>)_$H&`Q.TY5?`BG'N`!S..#%`0`W`<@(\<!D!M?33ZOS7^>>F$$H7:<4'W=
MQB8]-1G";JJ35;[R9J%OA&A@BWMJ<1X*#!SID@D(^1(D05C,U%VYPR.IULA;
MQ6X*V5UVF^@;)"Q<]#.TQ*(KQLJS2>-CJE*)BH+@17Q.ER)DSE$!]?0`J?`\
M]LBDW7?*^\`G=K)+*$,)`]LR;9%L!0]>>!*@`^OKR.!W043'Z'(/]ABC_P!W
M`U]?G2(4^Q_B+6`W)D/DDU%XIEX$#@HZ8@<1`.1X(7U_9^.!>/X%(2-L_P`.
M'4J&L3)G-14I7-S1LE$RS)I(1C^/5[![<1.U?QSQ%9H]041#Q$BQ#D$/]GU'
MD,ZJ/7T^N6SH'5$6^>GU!M49`=25]1%LG%ZFLU3@R24UJ^OK(HD>%I%A@6;N
M9AVKA58(MPQ>-$3%;*M4$0S`P/P1``$1$``/41'T`/[1P'(<>7(<?7GD../S
MY^F!\^XG_OD_/]XOX>H_C^`8$"WS()@MV0^%Y4G*@H_)-15DRD#S`_$#X^YP
M7D1*D)O+D/0!#UP,D?C?0\-N_*WXB8OW'R3W/C])1]L1ZW=;!.H7R*8#^?N!
MSR''TP,H+C"1'7"=2VQ6&IH37,O.-X_;U3AVR+2K-I"Z2[*-8[A9P;1$"1\W
M%3SA!&=5;"4KR*<J.W!%%F93X&6R!SG2(=0H%.8!$2AR'C^H>`'D1_4`?7]N
M!R"(!]1`.1X#GTY$?H']HX'YYD_WB_\`E!_W\"#[^HY(U7^'#N$#EP*"18C7
M)@4)X#RJ7;-']M,?(>/\0X^/Y\CZ8$L77IPFYT%H]P0Q1*XT_K1<O!@$/%:E
MPBA1`>?4!`V!>#D/S#_2&!35?(8CJQ^13$]RPNE$_(HE]P@L(PON$Y`/,@F*
M(<AR'(#@5-@6IW=L1UJ?5UQV&PJL[>9&KPSI]$TRLLWC^=MLXJ4&-?K4>W8M
M'S@IYN==MFYEO:,FV(<RJG"9#"`6LZX]??\`+)G*WJ_R*=U[![*(E,;@V.\1
M*X=+R2QSK(T"ENEFZ"\'J*@^X,?`Q*)4VX-DON5B*.W#A=0-?WO+IG=$S\U?
M6#9E;U)LRPZ[8]@NIKB=O$!1;-.5&OL82HWAO.RTS.1L,YB6$=$HK';KKJN4
MTD#N`!0!Y`,"7?XD*/-U?XU^J="OU3EJQ,Q6JG$-8:5;81Y$R+--2UVU(\?-
M0,NT:+D0=L%@_P`!=$"F24`1*)1#`O#K6GV/KGN(^L*O%V&6Z];0AK';J0T3
M;F?P6A-A0;YFYL]%;.R`52#UOL9I-?Q&`8F%9*,E6<@V1%)JNT02#-,/H'_S
M_P#7^.!&/\AYQUG?.A_:5FV1]S3_`&VI^J[E(*J(H$:ZF[9Q[W0=G!VJL=),
M6+6[V.L2!BF.4`5CTS?4O`A)Q@,!@?AN>!X'@>!X'CG@>/0>/QP(`?C39_:_
M*O\`-2B@W0:QSG8W79=%)(3>X5XC#[#=/UC`H8QS$?N5Q4$P^GN&$I>```P)
M_P#`ZC]ND[8NVCA)-=!TV6;KH+$]Q%9!=,R2J2R8B'FDHF80,'XE$<"V.N'S
MJ-5F-=/@7%U23L$XUXZ.8RTU4)%`RE>E4E%3F47.T32-'NC'_69VS5-QP<O(
M:S?P[JN!^9WY@FIA04CD;9=#"N8$@=?>F[#3Y_MS*E`ON($*?@2F]2#P'XX&
M4?\`4==NWO4[XHKVU7U]!;32[26!WU$F4[1.OZ^A5&&XM?;0/_F`U"+:.5I:
M6J#BM(K-F1CMDE3@!CJ@!/$X9#?#1U?[`=#^L.N^ENP;AUPW%K34L-:I2F[@
MU+;;C'7J04N]WF+PYA+EJV>K\K$IE;25J>%3EV=@03%NBW2&/]TRBV!,I@4[
M;B^=6L1?]Z%DB_V<M%0Y_NP*:TYP&H]6@`\@775*(`_GX5N-+S_JP+CX#`8#
M`8#`8#`8#`8#`8#`8#`<A^>`P/A0>"\_CR4"^H@`F$P`0!$H"(%$PASZ?3`U
M*?B:[#2>POF^^2&`DZ4>!B[U(;NM-)ECNT2R"L1IG9VN]-/V]B@TR>42[EED
MOOVZ@**%62,'[N!MA-'K=S)RC9`PBK'JMD'@&#@`.NR0>(>T(>AO\%4!-^7.
M!Z^`P&`P&!C3W-UW:=O=1^S>J:.P3E+GLG0NVJ-4XQ9XC'(R-EM%$G8:"8K2
M+KEK'I.Y1VDF9=7_``T@-Y&X`.<"`#K3M?Y<OCFZ+ZZU-*_')1[+2^L&HGA[
M%?7?8>J'D7-:KO\`$[/9)8:Q`.)%VL^9)N5P3:-Q4,HFW]P#_K*F`5+&?+9\
ML5_ZRH=L=/?&MJNYZAD:E.7V)GU=Z`T,\J%=<R*,K*!%N#,9DJB*4,Z.")T$
MEC>`%\`,/&!)?U'[%_)5L]&X&[,=$-?:43C"U%2G2;+L''.B6HTNR0<6AH:$
M90%Q>QY:TH8WM.EUT"O3B"0))"`J8&;1[7O`#F!/3U0.3R$"&/M]1,3E]?$?
M#_+@XE,)0Y$.1XP,-MZ2G;FR=ANH1%.L=>F.OM+V'?\`8NU+?4-FQ%SNU;L\
M)JBW5K5B+.G6&(H"1HIW9+:NJX>-7#]RB=L@`(%(8Y\#,,NV;*(B`:/VX(!Z
M`<65$+Y!SP!O$U_*8O(>O`@`A^.!J]_)1U[[\VN?[&Q>I.M4K/:.W'W#ZT]J
MVM[NLQ0HJW1NTZS1M::89:\:5T=IF17UT:5IL<91^=-N_`\FH5-,Y$O/`D(Z
MQI?(!=OD`M':SMCU/L.J(F"ZHL>N5!K>L;/K:V5FVJS&VR[,L]NL:\GM0TI7
MY6N_PA!HP1(55-ZD[.<PIF)XX$P?^9MP`0YTELPX#]?%371!)Z?CY[$X,/\`
M8/X8&!76R^=\Z+K;9-8N72B'C24G9VPFFC6P;MHK:4OFFY"RS=BHLA9F4$-F
MB*7:&49*)LG+$CIPE[B(F*)>1+@7OF-V=UVB::\/TP@)@BA70E;?Y_UMD\`4
M3)E2!8'5?(U0]SR'T%41'@>`'`Q>O.ZOF><["2-JGI3U;B]9.ZJ@NY5O6^74
M[=&MW0EG*#M@]5BWM5BTX%W!*-W+51LS=*%4!0BI@$2``42ZVY\]2RY@;]0^
ME""*7"155]JSCHRY@]%'*::=\:`FB8P<D(<!/Q^\.!''WBUY\T?8!]U>LVXN
MMW5N#E-%]G=>;!TX376QRME)S9:CEDA78*XA,W.:^VJ,D[;K)2#EJ=)=!`H&
M*4_J)0GH^,#K1:>GW0_KIUVO(E+=J#49%W<FB3EH_91-OOEHGME6FO1<HQ44
M;2\36;!<7,<V=E$/N46I5.`\L"N^XU?[%RU`JDSU6AZ'8MT4G;.L+=!P&TII
M]6]?RM90L!H#932<L,9$34I$*_Y=V.35:J-&Z[DSI),I4S@)B&#MC/\`=LP\
MI:SZOH$Y,!BN=R[6,H`^X8I1**6C/$Y3$`..?'D>?PX'`XG\YW=&+D@::^ZL
M#*"PD`C".=L;85CSR96BPQR;X2Z<:J_:F>@0%@*8I@3\A`P#@1FIW_\`J"%D
MSK/M#]!XY43&!1LA<K#)-&0I\$429R+JYL'+UB"Q3&247;MU_;,`*)E.`\A]
M#>/GZ,B8Z>I.@0*A^Z@K9)\HG$!#](J)7-=,A3E_M'`C[[CZZ^:#<6V^CUNV
MM3^G4#,ZA[.1=JU!#TRZ_91ZVS?Y5GIR+8VG^-V)1S,UU6%I;Q0Z359NZ%50
MJ8`<!X$)N?C<TEV"T_3]^7[M<KKJ)WAV4['V[=EQJVKI523US5T_Y5INM*\2
MMRCY563<+6"K:\92+Y-P<X-WKA1(@^!"\AF+O]A.VW2&VJSKY2KO]@S.OK6Q
MH;.RO3IUU>[JPKL:B2P'8K%?(P@V$K;[HZ/*A$/(Q0$0X$++:REN]RM"IG^9
MT=U&:;'5@HQ:[-JK9=JK5LD\=),TQ_+XOX(C]2.%R8P(G4#U#@?4.!$+K&G=
M^^X1L#;1OW0E`P(!8+UY'X2%413$M=X.02AR'U`2X$:MALGSMI6RT-J[0_CI
M>U1"W2B%6D%+9M1!U(4LQ@5AY!VT<)BX;2Y4C^#@AQ\3'()B@!1#`P'^2K57
MS!=G.E6[M-;UB.D->U-9(F"?WIQKRXV=K<!C*O:X6S)MJ\^M(J0;60=/(A$@
M*.TQ1(41Y#`S2HL'\Y57HE.J,*AT":,:G5HRK1[APML611495N%:1,,N99HY
M4.K]VDQ+[H`4!`3?IX`,#VDEOGH#Q(X)\>13BF!CJ@ZV4"9%/3R2]H4#*B(C
M]!\A`.,"X76Z>^75_LVZGWY.]!G>J8N&=Q4>E1S;0&VL]AM569CL%7/DW8IP
MS-J<XNBK`JL*BI`3,3Q,40STI<KOP]F;)WV2T.K6#H/U56M,/<R6A4Y6XBP*
MU-.O31HD(Y(;[@3$Y!/C@`'`O[^\4!]0Y`!_(0Y#Z#_IP/K`_!#GT]?[L``<
M?B(\_G@?N`P,)/D?U-,[OZ,=H]<5DCE2X2FG+=.T`K'@K\FQZ(T+?=>+QZWM
MJBW>H7*LLC)'`/,B@`)1`W`X%W.J^Y8WL1URT;O>'5!:.W!J/7>QT3`!B^"U
MNJT=,OVYDS\B@JSD'2J!TQ'E,Z0@(!@7_P`!@<:QO!)4_B<_BF<W@F`&4/XE
M$?$A1$H&.;C@`Y#D<#7)^)-]/.OD^^:!M9YZ)L]@:[8ULD_G(-%%&+5;-)K9
MJ4+%HE1.8"NX"OG:,7)3`!RNFY^0$1$1#8ZP&!;#8Z4E%-VUY@VBKV5J0&>.
M&#=)1PXF:V95$]FAVZ"8B*L@I'-_>9<%,8'*7B4!]PP"&KY\/)@=?-9\L3J-
M,DZK+I2]R*<HFY;+)RLC)=@PFVSQ-%`PBF@I'.R<&,'/("`CR`X&T!LW2FF=
MYUAG3MU:HUIN.GLY9O8&-6VC1ZML*MMIUHB];,YQK"VN+EXQ&6:M9%PDDY(F
M"Q$UU"E,`',`A9O5'0SICH;9*.W=']9=-Z=V$C675/"?U=28F@E6KSQ<CARS
M>0U51BH%^X4.0`^Z7:J.RIA[8*@3].!EM@>-8DP6K\XD81`#Q$B41#CD`%HM
M].?3G`HC2*GNZ:U2IZ?KUU33>@\AP-?CQ`0'\0$,"Z&`P&`P&`P&`P&`P&`P
M&`P&`'Z#@>2_?*-%&0`F@8'3U%J;WE_MC%(<#F$Z`"13[E;R``!/]///UP.Z
MDX%8RQ025("*XH"*B9B`<2D3.*B0CQYI""G`&#TY`?RP.P8`$/7T]2C_`'@8
M!#_2(8&DI\.D\J\^=+LNL*;</N*EW^2=BB8?^#&=NZ"U1$QCG,!>$6X''GT$
M?IP'T#8FZ0]L-R;Y[`]N]9;+LG3V2C^ONQT=>L6G72U6^U7E_(K145/)2NP4
M+%(BRKA8F`E6\4Y;MD71?XZT?(@X*#,4SA*-R'TY]?RP&`P&`P&!C!W:=_P_
MIUVID`.FF9AUUW2[(=42^T4R&M[*<!5\N"BGZ>O/X8$%/QG:'U1=?@(U_9WK
M"T.U;+UD[!6-\>/VUL\D&XEYR?V(C)JL(N.NS>+:(E_@Z)2MT446[0Y5/:(!
ME5C'#8.A=*Z])#PI08V`?8CH_P!L1OE^$?T-$B%$XC9Q%3T_WA'G\<#`?>^J
M.\$EO!8^D-?=??\`(N%@B)Q,GL/:6Z7.S;%;!K-A<H2`QL4_;UNM5V'O"L0C
M[1S/'3UDBZ5%0I#%2$/5J6G^X*VYNO*UTKNED=,,-,M4>QSJ$MNV4+H\W<Y@
M7ZP_Y9,E+&NSC:-79]NBEX+N50D&CU4X@BJ@FF8,\?\`)77J@`<T;+<GX.(?
MS19?03>HAP$L`!QS@6TV-TQZ[;8;1+.^TJ4G&L)88&TL4!OVPV"03-9E6<W#
MK."1MJ9E=(-I6/07%%0#)'.B01+^D,"X+70&HV*"+9K3T4D&Z?M(I_Q>PJ%(
M03F4'_B2YA,<QSB(F$1,/XC@<QM%:L4\`6JR2P)+).$O*4G?T+(\^!@$)3D0
M#GZ#R`_B&!BQVST9OI>F0+#I'"Z$K>RGTZX;V*X;Z1OEEKM;IZL)*)N7-<K-
M>E&RDU;CS!VAFQ'3QHQ*5,_OBH0PIB%D=G=?>ZDIH9Y!U"*ZPR6\Y#8]?<-)
M-X2^1="B=4L_X(>30>MY1*=2F[X\?,WJ!3)M&C9%F[253\56H%6#,:I=8=.J
MQJ1;'JJL-ILK.*-+%CGE@.U&34CD?XH0KAQ+BX>))21%2HJJ%()FWM>@<<`%
M5_\`*MUZ'@3ZKK1Q#]T3A('$OKSZ>;XPAZX%$W'HEU*O[RGO[?I*I33BB6=E
M<*S]R$B5%G/QZ+E%HZ<MDGR;>310!T8Q4'15D"J@50"`<H&P/?<]3.MI%2`3
M1%!=%,`"90T0UY*(F$/$/>5\N./7T`<#E2ZB]9E"B971.O4C`/`%&#:FY#@!
MYY(/'U'`P?[I])]M6)CKF,Z+4CJ=K5ZC8Y-]MRT;@H;JT/7E0)795I%5NCP:
M<!+Q`R\E//DE%GKE5(6:"(^":_F9,0H>>Z4]D"4^M,:AKGI6ZNO^==XF+#+V
M&D+,(ACH,KNR?Y=TQBU;4:6-*7-_'/(MM,.O%B*`,5E45UA7\0"1M+J5UJ`H
MKGT1K0ZPF]PI1J\=Y#R`<$4%5,P'.0/01-^\(<\!@=E/JEUL$2F-H;6"9O7T
M&HPQA#CGCU*W$OK@4-=NC'4BZ2E%D[+UMU;9'%`L1[/4OO*O$@WKTX:/>QXR
MB#8$DDW"P(O3"0%`4!-4"J%`#E*8H7!2ZN]=S)`4VD-:(E$3<MSTZO.$O4PF
M$QR*L%DU!.;]0B8!]?7ZX'('6S0,4DJK&:/UB1SYHG(9I2JRP7,H10@D,1PE
M&$3(HC^\4P@'`@'J'UP,(4>I/8QU9;W-23GJFU@G^VZS+:[KB&GG,D%8U!&;
M"AW%KBY.;=Q4=)O;I:-7L'+9,XBJ@RFE2+IJ_;E`N!>[6?6N?C=JW*2V'4-!
MFU0)73+5E7INNV#:Q0[$C>#31DK1/2,(V=)24BX;R:KA@R769(&=I%34.4#<
M!DZ33&K4T@0)1*P5`J0(@@6&CBI>V```D$"-RCX&X]0YX'`MY>^H/639U6E:
M1?\`1VM+349LB1)6`D:G%?9/2(+D<H`J=!!%T'MKI@;DJ@"(^@B("("%<Q^B
MM/Q:":$?KFHM")D!,H-H1@W`"`'[I2(HD3(4?R*`!@<QM*:I$QE`U_404,(B
M90T#'JF-S]?(5$3<B/Y_7`PX[`=5-J2-"DH+J'*:2T;>;#MS^;;1>;QJB/OJ
M7\J.?ME)Y&%K*34L6_G9<R)4RF>\)E(3D3E,`"(5EUQZY[)UU>=C6O;,WK&]
M??VN*?:=7J^NX>K.]=TW_+:DUJV0ZCLD4VDCRECO,-+2PBFLJW!M*>T`$]L"
M@&<Q0`I0*'T*``'U'T`./J/(X'[@,!@,!@?@E`WU]0X$!`?4!`?00$/Q#`C"
M^+!`FO=5[[ZMG<$$.HG;'>.H:TT6>*.9-IJFSSR6\M.IR!%E%#-TV>O-LLV3
M8"C[8MF1/'Z"`!)]@,#X5Y]M3CT'P/QZ@7U\1X_4("!?[>!XP-;OI7)GZ[?+
M_P#+)7IK3%R@66U3:;V[67-`IYK)$2M6D#3*!]@S#6KI+.&2ESL\M("HHL47
M"BT>OY$\B&'`V#J1L>D;$9/WU.M4'84XN36AI9O'.R#(P,P@'^-!V&+6,22A
M)M#@1.U=)(+@40'PX$!$*YP/A0`$@@)@+].##Q^DP"`E,`&_2(E-P(<_C@:>
MOQJ&0KGS!_-9#P876*BXVK[C_A[34L<E*7B-)&[<B")+42&69R35[=!5DE5(
MY)1NL11P!2^V8H>.!L4_'A??\T.LU7OIYS>4^ZL4Q.N7[O?RY'MM0=HKIM3,
MH23:URK1<O3FR2)`9.V;7V5S^Z(G%4%`*&<F`P/)G@,,),`7CD8N0#UYX]6B
MWY"&!;O0@@.CM/"!R*`.L:*('3,!TS`-9C!`Q#%$0,40'Z\X%VL!@,!@,!@,
M!@,!@,!@,!@,!@?!R`?Q$>/T&`P<E*;U#\O(!X_M#@<#[P/PP<AQ]/4/7^P0
M'_3@:2OP[MBO?G4[DMF\>Z8O:_$][8ZW0JS4[9:!=R':&@J09G3-RB*Y4YIJ
MDHJ3RX35#R]#!]`V2^H>NJ?4NP?R#S5;I])@'/\`S+51E&N8.KUZ(?MV+[K%
MH";G(Q>1B(QM)),)2R.5)!5)50Q572AE>!.H8PA2NM.]&Y=M[9W_`#NK=&1>
MV^HNFK4UU4PO5%GED-Q6K95<:*N-IR5.JDZ=K4]A4NLNE6[)!)G(,I19P;E$
MCKR%-(,DV?>'K+(5BKVMAM*.DV5NKS"T1L;!UZXV2R,(.48+2C&2LM4KE?EK
M15&RS-N<0-*,V0&,00*(CP`AYLYW`K<M*5ZHZ%BD>P.P+=796SPT'4I9I#UF
M"@8IZSBW5CV3>I4QX^C1#66>IMCM?MGTZHL<"I1YP`QP"G>HO:>Y;@N&[]([
MM@J?2NPFA[@5M:ZK35YIQ79*@6L'DCKBXUIY8A1E96/DHUJHBLX,BB"JB1%O
M9;?<?;(AG7@<:JI44S*GY\"`(F$`Y\2@`B)A_(H`'J.!1MY9Q-CH-K8OVK.7
MAI>J6%H\9.TDG<?)1SZ$?M7C-VV5`Z#MF\:+'343.!BG(80$,"'&B;IZ]::Z
M.Z3Z2PR[.D[(V!\;-BV-JC7T75Y!E7Y^L5/60C>',9*,(\(-K)1#]\H\?HK*
MIJB1T54ON'5`HA-A!G!2%AU`XX/%QYPX$!#@S1$?00Y`0]<#U,!@,!@,!@,#
M\,/!3"'U`!$.?V!@4]#OE'4G8&IR(`#!Q'ID42]SW50<QK=V85Q.4I.2G5$"
M^(!^GZ^N!46`P&`P&`P&`$0#U'TP+7Q^Z=22CNPQS#:FM7LC4YMY6[0P9W>M
M+O*W/L"HJ/(2>;)RAEHF7:)N$S*MUP(J0#EY*'(8'>-MC6!!$#[)U^40^H&N
M5=*(<_3D!DPP`;8U@;U+LC7X@//`A<:Z//'//TDOPXP.9MM+6;LQB-=BT1RH
M0"B<C>WU]8Q`.!S$$Q4Y$XE`Q4S"'/U`H_D.!VR[$U^<#F)>:<8$QX4$MFA3
M`01'@`.(/1`HB/IZX'*G?:*L4YDKI4U2IF`IS)V.'.4AA^A3B5X(%,/Y#@>!
M8]SZ@J#!24M.T]=5V.1<1S55[-W:M1;5-U,/48V);&6?2:"8.)21<)MVY.?)
M98Y2$`QA`,"HE[Q2VG'W=NK#01+Y>+J?B4#`'XB(*.R_3\<#RS;5U>0@JGV1
M0BIE/[1E#7"O%(54.>4Q.,B!0.'`^GU],#R&6[-./5'Y6VV-;KC'/5HUZ4EU
MK0&;/D2H+JME0_BHB51-!XB/`\#P<!^A@P/8B-IZQGY1*$@=C42;FER+J(0\
M/;J_)RJQ&I#*.3I1[*07=J%;ID$QQ*00(`"(\`&!78"`@`@("`AR`AZ@(#]!
M`?Q`<#]P&`P&`P&!&=26*&HOD[W5`L!1;1';KK10-W%:*"FBN78?6VV)Z@NC
MQ-,JOFN27H%_JPJ&%/S$6'!C#^D`"3'`8'PH`BF<`'@1(8`'@!X$2CP/`B`#
MP/[<"$W0FQ:=L/YL^X):-<J_9&-/Z9:?H5W2B)9%8T5L"N[4L(2\`Z22;B9U
M(UYJ]*1R=-8A&*KD$S$.=4WM!(UMG4Y6DHWW+K`G\`VK5&ZTB\4BD6#=IMFM
M1C5TX<:TV"4C)=67BY``*:,>^)G\3((I*(*@F9PBN%\:3:X^\U2`M\0<58FR
MQ$9.Q:ADQ2.>.F(]M),A53,8PIK@V=%!0O\`L*`)?7CG`JDW''K].0'_`$"`
M\C^P!P-4CXIXM2.^>'Y;#K%*0TBGL)Z/MAPF`#O*L`D!/J/D)!`3?M'\,"?G
MH,RF8SI_HN*L$2ZA)B)JSR)?1CWD'3=2+L<W'D.J4Q2F3%RBV*J!1#DA3@'K
MQS@9?X#`\J=$0A9;CCR-&O2%Y\N/([=0A0_2!C<B8WX!@6?ZP*-UNN.B5&@N
M3-3:EH'VYG8\NC(A6(T$S+C[2'*@E`.?T%_LP+ZX#`8#`8#`8#`8#`8#`8#`
M8#`8#`XU?'VS^7'CQR;RX```/41$1]`X#UP(#ND3>,=?*#W1=(F*W!"6NT<W
M_P"R-F;I9X?9MX<2'MN!1^^>)>ZD<YQ.H<@G'D`#Q*!0G!8TJLLG=N.TBVB"
MMS?)2=L53;MR+6%[_`(ZM`O+*E1!1X?^!13=J`G$1!)(H!QP'`1=;SZT[HZP
M]:-J4+IQ=:C6-!1.N-DOC:NN-7?2EJUE%N8V=ML^&B;I$`=S,R-@D7#M`D;:
MT9%-JL]*N@_33;E9+!F_U+T_K_3.@-7U&@"U7CCTVMRC^S-ACA>WF7?0S)P_
MN,G)1J9$I1S.*J&63,4?:0;'(@@5-NDDF0,2>T&GYR+[>===E]=)ZJ4+?MUC
M]OPT^:PUZ0E*1L"M5FF0<JJ39\36743+R#%H'VK/^(H+$?E<JQ9!5,5H@F`9
M2:FZNUZJ;&_YA=AS;S:'9"2I8T)]LR2BV=;805*6E!FW-'U_2HLRD?4Z@I+E
M37X<*R,PN"")73]<$R%*&5F`'U_]#_O^F!3=K%,*K8BBH4.(*7(`F\2@!C1S
MHA?+@"E*`B/Y`&!KC[,B]8V/7/0JU.+]5(';$5\;FY936=1EH5RXO4C#,NNT
MFQM[ZARRL['1[=VNE,((R*"3-VN#9$5G!"IIIJ)!LA5L1&NP(B<5!&%BQ%02
MB03B+%#DXD$1$HF^O'X8'HO':#!LL[='*DV;IJ+.%SB!$FZ"1#**K+',(%32
M3(41,8?0`#`P2)\GG0-<1%MVRU$Y3'DQ%6LPX=H*)\_I50<-V2J#A$X>I5"&
M,0Y1`2B("`X')_YYKT,__P`JM5__`)>^_P#J?@<2GR?="@_<[0ZP$0$0-PXG
M%?I_ZBAQ\?\`6&!TP^4?H6955NEV=UXY<-RHG<MV;&W/'#4CDISM5';=K`K+
M-4W9$C&1,H!05*41)Y``\!^C\H_1`I3''L95/`G[_C6]A&4]?IX)!4A.K]/7
MQ`>,#F2^3[HRL<A4NP]6,*C5N\+YUO8*)10<J"F@<53U($RJ','ZDQX.F4!,
M8``,#B=_*%T18+LFTCV0I[!232:+1X/X&]L$I`90Q48N*8NG573;NK'(K*%(
MWC"":0<J"!$T1,/&!\,_D4Z6,I:4%KO1DX<R*:<@N0E!VFNW*G&M4(X2(NV]
M(4;'6-X`<J0'%94.1(42@(X%8I?()U*74]M'<\0J?_<3IVQ3&'UXX*!:N(B(
MC_;@=)#Y&.G;ML+MINA@X;`X<-/>1H^SU4P=-$EEG+<3$I@_XJ":!Q,7ZAXC
M@>"R^3SI%)E\XS?,-)$_]:'^)'TC:CY+F)=N&$H7W&M(5)YQS]HJ@N7GE)9,
MQ#<&*(`'.I\F'2])51!3=S$BR+,L@JD;7FW`.FR.FDJ1T8HT7D$3)KD'R^G!
M@_/`X$_D[Z3*)JJDWBQ531,D551/7FWC$3,L(E2*<0H)@`5#`(!^>!4D'\AG
M4:SLIU_![IAEF]9_@IYL751V,P7:H3[MPQBU$F4E5(]Z]2>.VBJ0*MTUDTU"
M^*@E$0Y"NM2]P^OF\=B6'5>K]BM[7=ZM4X6\S<0E6[;#)-JK/2TC!L)1K(V"
M$BX^3`TM&*-U4VZRJB!S%\RAS@<E^[>=<==[;3T+>-OTRK;9<U*-O;2AS3MZ
MRL#VI2,J]B&MA8)BR,@\B_XM'J-U5DE#?:K>V"OC[J?(8`_'N\^/?LY.=P7V
MGM=Z$V#8JOVVVHOL.>3U#"#+.7MMDEY",FGT[8*RFM84IUQ&2`D60671(9(Q
M!!,Q1(`22K=9NNH$$R6@M*^[R0"F-JVD@``)RE-Z$@1#]T1_#C\\"/0F\?CV
MWQJC;K/JW:NK47LF%+LG6<98;!HYJ^CZ#M"M2,I3Y->;JZM1B7DTE6+$V.(I
M)"+=Y[9#`<Z2@"8,:^ONI)#63[^.;?[[:+W0HRK=Z!>+9].M;:YK\G;9_P#R
MV7I$HYBZQ5!D(:&HIJM/(_;,W/W3IO/B<5DU6R8B'9K/R!?'=U>EI[0?:?LC
MIG:^_P"M#&S]REJCUBF&K&&@['%MEZ]!/4:Q4YM@*B"K)RX0`[LRY$')"J`)
MBB.!70_,#\-;1L+@=I:Z:(#P)RFZ^WMJ!C<\`44S4E,H*"(>@8%D-Y_*Y\,M
M_H0QK"[ZYFI4ENUC/1A3]=[JFJ@YJ6S:I82R2$BOKY5-)W$(Q:JJ0@8#<E$`
M'@1P)P=,6?078?6%$W=JEG3;IKO9M896JGV9*J,&O\6@)/D4#G:2$6VD69TS
M)BDJ@NF15)1,2'*!BB&!3'8JW=6NK>E[WOS>T+K^EZDURR9S5VL[NAQLHVAV
M;Z680;9\LPCH5Y(.S&DI5%,?;3.<`4$>.`'`Q+GIS2EHCX&2T+9]*T%A,;KK
M%[OL_,Z#?6]:[ZB<Q4/)61AKM9"N1[:(E[>R(U:(2SI)^U1;@X)[!E!(9(.]
MI26I^L]M;)O5]WI2+?4)-"17UG48'K;*4J6UQ`QB8J+N7=R80+A_8IF7@VQ_
MXB**;%LNY$QD&Y"G*D`6DB_Z@CXKY>.0DH_L#-F9JA(`05]*[H9K@6*=N6#U
M4[-Q1$G"*"3EHH41,4/$2"`@`AQ@?!OZ@CXN!:HOD-]SKMFL@NY!PQTQMYXF
MDDWY%0RXHU(?9X3#S_5P/AZ\!@4K7?ZB/XT9IY;2+;7M:4?!R:J$`^8Z?VS*
M#:H=K#0K]W--VS>G$5CA2EI96.!LMRL99H)@]%"A@>@__J&_C)C4VAW&T=DG
M5D?;"-8)Z#VNE(2!E2K'(DS;NH-$RRPE;GY+Z"'@//TP/II_4&_'H]?/8U"2
MW7]U&``RI5=02S8(HIFP/"#(&=2*0-O<:C[@`/KX^H@&!1EB_J1/CBKYF2(N
MMY2+U\_;QS>,9ZL31>J.'AC$;#S*V>-0324.40`1-^H>./VA[W6C^H/Z%]@;
MC?JI9K1(=>FU;C&ECI5HW:I$URM['K2Z@,GBL-*,G\BT;62$?@!GD8H?W4VR
MZ"A3'\C@0+8=L?DBZ-279'X[^PFJ.T^H+4^UMOZUZCV:G!V,PN4='=AM:6"M
MV6Q/_<:$!6I5#8E<J\H\4,(H-@;@L8X>`\A)^U^2[H$\+[C3N3UT7)[GAS_F
MA64^3B!3`0OD\Y.(E.'T_,/SP.%7Y-OC_(BHZ/W$Z_I-40,*SD-A0JC5,"K"
MW,)W7NE1)PL'AQS]<#&C:_SD_'YJ^VGI:>Q;'M)P>&3E1G]*5DNQJLB+@[E$
MD/\`QN/DVJ:T\4&WN"W3(IP10@^0\^@1U=#]]WWO7\GW<S:^B-E,]*ZU;:*T
MW'5!`^K*Q+6:Q5-.R.UDG5[J=BD4G,1=%;:::.J[3*<OLG2(8QN$Q`)TI'3'
M:9TU=I->YLG'JJMEB(+H]=M4.1:K&(;VW!$'0+$7,B?@P$/R4XAP("`B&!?G
M3='E=;:TJ-&F[7(WF6K<2A'2-PE8N+@GUD?$#S>S"L'"-VT1"%?.SG.1FV*"
M#9,2II@!2@4`N8?]T?7CD.`'Z@`CZ`(_3T#GUP-2OXM'2Z?S^?*RFL[5<-21
MNVS("ND=NLU(GOG7J:J"A3B)56QE'!C%4\0\B^(E$``>0VM*F9T:!9?>F6.Z
M`[TJAG`^2P@5\Y!(5!$I.1%'Q$/0/3C`J+`8'ES0":)?@'(B+93@`^HCQZ!_
M>.!9+J@<5.LF@3&X\O\`*&@%$`^@"2M1Q./J/J'C@9`X#`8#`8#`8#`8#`8#
M`8#`8#`8#`XU0*9)0IOW3$,4>/0>#`)?0?S]<"`KHA!,"?)IW:=BX,N]A[O>
M?;4%83![-BV#L=_["Q..#JI%3-[8^GBF`AZX$]""GN/7A2"`"BLBFKR'/D4S
M-)8GAZAZ\J>O[`P.TY02<H*MUTR+(K$%-5%5,BJ:J9O0Z:B2A3IJ)G+Z&`0$
M!`<"*]=]V?Z_;-L>B.J-!AMU:KI54K=CCZMLNQ0-+)J%"^.KS_+M&IUY_FE*
M8LU0AE*TH+2)?00FAXSVFK>3.F":*`7HZG04U?YVQ=B]N2[Z4W>H]N>F9*ID
M+',Z/I5E1;I*QUEI&O8>.D[$@<]@E(MD]EIQ>4>OID4&@"#9NW(U2#._`8&-
M._\`?SK4RM3IM(J#S:6Z]F/'S'6>KXMXC%!))1`,C6.X7&SNB+L:/K2EMY!%
M:7EUD7*A#+(MFC9X\60;*A1TKUTV1MVFS]=WUO[8:!KBP?,YJ!Z_OU-+5N%C
M)9`R*D!`V6/0?;1=F8HJJI&DE9EHLZ*8#_;H#_AE"TNS.G^@]`=+KA6:%3E'
M)NOW47<NK]36FZR\G?+Y4Z&YI,VY<5MK>+8XE;*JP6]A)(04<&-]NDFD`@F0
MI0"06L"(UJO"(B(C!Q(B(_41%@W$1']HX%/[0`1US?.#F((4RVB!B#XCS_+D
MH`"`^OJ'/(?M#`MQU5;H'ZN];3%)[91T'IWQ*DHH0A"?Y=UP"D(4#\%(4O``
M'X`&!?,09%$Q3+&*8H^)BF<*E,`_7Z"<!X_;],#\,+-02%(],0QP$Q?:>#R<
MO/CSZG-R`#]!_/`QIUF*0]HNSW`EY&G]=#&5*/!S@,9LT"B90O`'*`D-QZ^G
MK^'&!E+^D?7D>/S\QX_Z?7`_/`/P,</U"8?UF'U'CT_4(\%]/H'H&!'C\CQ3
M$H?5X4P,<3?(;T1\O(RA_;`_8VEE,H0!/P`D\_T@/)"B`#QZ!@9W1C]R]D["
MQ6.!4HUS')MC)@)5/!S'(.U/<,83`8?=4'C@`X#TP*A$O("'D8.1YY`>!#]@
M#^6!^>'J4?,_Z?00\@X-]./,./40_NP,-^ARQE^M[!5==47!]O=H!7\CF%0J
M@=GMQ`(^!P$P',`>0^GJ81_LP,OB*ME2D53>>29C@0@E6)X&4`WJF`\<F/Y!
MP(<\\^F!S>:11\17X$3%*`&4#GR-^Z3U_P!H_P"`?4<#%I?@.[D:4..3=5ID
M1/P7W.`VY`!P!N/("_X@^GTYX_+`Z=<3`W>/<G/D8W_*]UPX,)A\O!#:_9=0
MJ8#SQ[93JF,(<>HF'GGTX#QUV+?_`)_W3\6X_>*].HYHFZ`4TQ%NWW<^45:^
M[X^Z)#'=E$Q!$2#R'IR/.!&?TNUCKS57S7=]$]?U^!K)]G]<ZOM"]DKS9Q'(
MV&\/^QFSH]]/2S(PD:J38,4D4UEDTR@H)A-R)CG,8)MMO7]GK#6MQO;E`\@K
M6H5S(QD*V`QW]CG2^*5>K$4BF4ZKB7LLXHW8-$R`)E'#@A0^N!1G6#4Y-+:!
MU7K=5HV8RU?J4<:T)L2MD4UKI+%/,7-XLI'E21?/'=GD'1UG)O)1PH(J',)S
M"(A?D4P].#J``?@!Q'G^T3<B/^G`M[/Z@U9;)%:8MFNJ+:I9P@U:K2EEI];G
MI)1LQ.LHS;GD)6+=O#MVBC@YDDS'$B0F'Q`.1Y#Q!Z]Z)/Z+:9U.N3T$4EM:
MT<R8B'[H\!`%'DOX>N!"_P#/KJS4>O\`XTME3M7UQ1*B_:[+TLHE(5>GUJO/
M@.KL>&(9O][$Q35T#=Z544EB@</=2.8AA$IC`(9F?$J9D'2JD(1S4S"/8;D[
MA,6S1)%)JU1;M>W.ZT44FC1!%%LUC$B\`W10(FBB0`*0H%*``%S>UQHS;=VT
M)U>2CV-D5N>S*SN?8,<M%QL]'0.G="S[.ZNY>QMI1L^C6[6U[-CJ_7V(*I^X
MX4>.3H^K142!F3$M6R2KXK=XY5,1P0KAM]XJJVCU0:MB$9M&Q_TL6Y6Y2'*B
M7@I1,(@')AY#V/8`0*`J*CXF$X<G]>>!XY'CG@HCR`?Z><"F"T"C$]`IU5X_
MQQX_EV&XY=*F7="``R`"BZ<',HIQP!U#F,/(B(X'TWH=(:)BDUI]7;)"!@%)
M"O0Z*0@;]X!329$(/(>@^GJ&!K<=`.LFB.PG>?YQ*1M_6E7N$?2^Z6J9NFNG
MT8V+-4IY+:S>O3#5)A-(KZ";*"R1,=L@<K9<O)54U"&,40E)NU)USU5K,U?+
M%JC1MZUA7'/W365'7NG=>;(KS8_@1)A'"_8UNE[`?F3%4&R*+F$E'AQ!%NB[
M6.0IPPPV;-_&QVE<U'9LOUOTI(QME5;ZX8;;W9H*T)V@I$8F=F(ZELM+QM6:
M[`:33<4':;-G;$:^*YDE3,R/D2E.<-:'Y>X_XQJ;4H>&Z:Z/VBPWM:K/?GVY
M-QV+KMNS4E4C*["T-DD@QBU+S5:#3JO7'EL+&^"58:)IIO3F575%=85%@R>^
M%"/@+!\IYJI98.)L<3+Z'W1(!$V*OQSUFB,,^UJ:)5%B_;+(*E;,)0$D#F()
M@(3T$>1$0VO^\W6&E;(ZB=A:91:%28:^N]4VJ7U](QE6@XMVSO%/;I76G>VZ
MC(]L\!JK::XR*ND4W@NERF<!*8<"Z^A)'36ZM,Z@W%$TK7C=AN37-'V-#-4:
MU5SJG2N%5B[$HV3,G'B+Q:.%Z=)02@(D]D?(?0>`ON>C4O[0S/\`E*L_9>V8
MOV7\!B?LN.?/D6@M!;B('#G]W`UL-SZ>U'M7^H-H^EME:IKERUI8>B=FL'\O
M.&J3>#CK+".D6D;+#$-"(H"Z2BW;M!NJ7Q,DHIR`\E+P$[G7[76OM0I26N:_
M0J?1IVLM(YF1S5:E!UM2WTWWE&M8L#Y6'9I#(.S%1%!\"BBOM/T53AP"A<#)
M_`8'R8.2B'YA@:E7Q>+HA_4&?*BFE[ZBAHC<)7*I41,T;"&\=<';H*K_`+I%
MW)DE!*`_@0<#;.:.4G:!5T%DW"1C*$*JD8IR&,DH9)0H&+Z"*:I#%'\A`0P.
MS@,#IR!0.R=%'Z"B?GC]@<_]S`L#U$.=3J[H`Z@`!QU-2/(`#@`,$$S`0X]>
M/I@9%8#`8#`8#`8#`8#`8#`8#`8#`8#`^%./`W/TX$?]'J'^O`UX>AMVJCWY
M9^]]08VV"=6)M/69R^K#.2CG,NU",NEW(_7D&23DS]@+`\\T*8%$RAPZ3]?U
M%Y#8-:I@1Y(*^X4X*K-3>!?WDC%9II#Y#]#>8%`0`.?]>!Z@#R`#Z^OKZ@(#
M_>`\"`X$>.^M"]S+!N6R[(ZN=D]8Z2A[;3*!6+#%W[1A=MN'TI17M]<A+,UO
MYNJXM&[AM<T42I>8CYM5!'GR(&!?SJQJ6_:;U0WK.V+M`;(VE,W/8]]V!>:I
M45Z+6K'8;]>;!:0=1E37DYL\&FSB9-JS,D+Q?R4;B<#?J\0#)`QRE`1,(@`!
MR(\#P`?V@'&!^"<H``B/H/''H/X_3\/QP(7%_D,ZCZ0[;=K7?9#94G0=G0%O
MJ^FJ/!O]2[<MKAII^KT.L7$DK`OJ31;&R_@-TV#=95PNJ58H*KL$B'`?:3`H
M760^9_XWU/?,;L>LT;,FSAZ_>R.BNQ4/%1C%HB9=T_E9B5U6UBXJ-9H$%15P
MX53233*)C&``$<#(_>.RZ%MWI%O>_:ONM6V/3;-UYW$[@+;2)=E8JY.((4>R
M-'"T5)Q;AXT=E2>('2,!%#"10ABCZE$`#*"HG!6J5A0!`P*5Z%.!@^A@/&MC
M`(?L'G`\C99?/7MW(`"(GJ%H3``^HF4K\DF4`_:8Q@`/VC@6XZG<AU8ZT@8.
M#?Y`:;\@_(?\NJYR'^G`BIW+MWLQ5]*:2VM$]J=HQEC[']N:/UUC(V.J76U*
MEZU9;&W#:*$2>8L;%I^6G;,C4("`$X,U9`J[IYXK++%;D7`0JKMK![DZ?:EL
MF_JIW<[*W/\`BNY]&-KS3;0MUF<).X'9]XUYH=W'ZS-*:4&.UTM''L+><09H
M$)&.)!NX]TA`=*'*%S>Q^K=D=5].=G.VD'V7[%WN[4_3KRXRL"\-UBK,?9TM
M2P$](0K=>2=]?9./@F;5O(NSNEBMCKG0$Q4P\Q*`A^WK46[J+I"Z[L'Y&MX/
M-VUOKPY?/79VO7!723Z=IT1*7EQ)1^H/\GRPT<G+R"B[0S]%R$N:,,BDH\5!
MNEP%TNOMHV5/Q?4';$CN?;UCK_9#7;2XS.LMD--%/FE<)9]/ALJ,;)3^M--:
M]EG,O`/?!N*Q'(-7"8J"9$>2"0/WY&C`6A=83"(`4/D)Z'^0C]`\NR-%(7G^
MTY@#^_`R'[/6.=U]UN[%7JER:L!<*YIO8]DK\\@W8O',38(*DRJ\+*H-9-J]
MCG"\:Z:)*D3<(K(&.3@Y#E$2B&"-])>*AW#TIUI6[@]D*W5[_P!?]Y[KLUNG
M)W1+A>8;ZTGM84M&FQ:[K2:!*DX36V;_`!EQ+E$JOMQY6R`%]U51,*-GBSVK
MNRW3'K'1>YW86_ZNWE4=RT9DJELC35DNVOI_1NOH_84;:9F]OM162T[%3M,*
MBO'/23;I1ZF[40=E>&#W4%0Y=XZRLO4<_5W66J>T&^:="[\[0R=#D[!9[1JB
M2BZ0UML-MSL+L.=9PDAID&<W)VAY59-JD9VY;M8I:4^[-[WLI-5`HSLW%/=$
MQ6EI#27=OL!9X??'<K6U`V-6&6[M4SLU+!V,M7\CO;+2;E+:SN,K0XS7]D7;
M2B4-%-PAEF[5>/1;LB+>^B&>W7U[=X??W9'4-AV/=]D5O6\1U_E:D_OSFO/;
M$S&\U^\+6-161KE;K";EO(/ZT@(%42/X&3.)1`IQ#`Y+[;X:B=M)2X3BKDL5
M3^EUYMTV6/8NI21)!5W9\#)R:[&,9)+/)!T1FW4]M!(IE%E``A0$1#`I;KUN
M#7F]>R5RW#K"?/9:'=NJ&B'\#.*0TY7S/VS';_9*,7.$)8XV)G6(I2#=9+P<
M-R',8O(<E$HB%;'D/_;^5F@(-3-S].DW@O\`Q$729V^ZUFYFJ9P$1*@<%A,<
MH!R)R%_+`PDT[J7=-=^2[M'V@KU%)==<6K5K/0$,=M8H"NNHF[5;:DSLB94F
MTIQVD^7@I&!MS0[-ZS;.B^Z51,2#P`B&=\+I:_7K8$!LOL+-1<JI49A:6UMJ
M.C'>EUG0Y0K(C9I<K'(R:#::V7L5HDHJ1F[<H-(F)%4YFC('0%>F#+%%$J"9
M4B<^)>>!'CD1$1$1'@`#DQAY'T^N!R\A].?7\L!@6QV%MBI:U5K[:R.)K[ZU
M/I&-K\9`4^UW.5DWD5%.)M^FA&U&*EWB2;>+:**^:I"D'QX\N1`!"##Y\]Z4
M*R_&#M6)4@MH?=S]FUE_"6LAJ39-:4!_%W&+G1^_?V&J-8V$!LE&F%0SA0@C
M_P`,G)S%X#,#I[KKN)I/K;&ZDA:/JD9EOLG>%NK^R+I=I!Y52TC;6][[M&LN
MV5(J42M9I>0CJC<T/-F[?1(K/$CH'52(;W2AF9H/KQ&Z=5M-RG[1-;.W1L[^
M"N=J[;M*2#27LJ\"R4:P]?@81J96/H^NZV=VZ-$0#$XMF0NUU#G<.%EG"@7U
MB4$D7DXHGY<NI(%SB(B(>163-$>/0/#T('H/U^OTP/<Y#\\!^7[?I_T_]`8&
M+[?M90GHNE(ZJ[TD63=R_;%DV/7/<Z\4[_ASITS<+QLD%1*UDV@JLU!260,<
MBQ``Y!,4Q1$-=KX[>PNYY7Y)?F=K?7?2LE8)"_=AM1W6;N.P$6-7::P@F%0L
M-0BS6'6EAL-'O\].6<D8LX9M`^P1031$SAP'F0#!.)5=)JLK7%;$VAJ':6^]
MJ5]1RY@K_L:PZA4CJR\>+@NZ4UUK9G=FM$UX!#D`B#EDQ-+>R(@L^6.8XB$;
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MRQ.&B[VE7-)H`O:W+I^XT0DT@1?(J-7!S)A!U\/-S-NS>7^7S"MWB)U)\;M=
MWU2*`RO<%)5*;A[9V5WY;)&CUN7@I'AZWL.GNO58&ON6ZP^R@9TI[!/;%)00
MV=5/W#_^`;Z?V#@:V]C</%/ZFO51?XXU2:)='+FV+'I!X'>(JQJ#U.)=%X$5
MGZ+GW'Y##X\-@XP)_P"_0CW[B)N\,F=:9IH.7!F2`%!:>KSDH'GZ_P`FX(=5
MVDU26;>0@!':!/P,;`K>$EFD[%L9=BK[S20:MWC93VS)>2+A$BJ8BDI_B)&$
MIOU$-^HAN2C],#U<#C5,)$E#E^I2&$.?IR`>F!J%?&$D"']1A\GH_P`4>HBY
MA-\>W$@*(L7A/\Y-3*O'*HC_`(OO,S"B)"\<`"QA_P!H<#;;K39=I#H(.4C(
MK%=29Q3.4I#`164>K)#XD`"@!TE"F#]@X'O8#`Z[L/)LL7_>()?[A]!_U8&/
M/4$PFZN:#$WU_P`K*>7T_(D2W*'^H,#([`8#`8#`8#`8#`8#`8#`8#`8#`8'
M`Y$005,'')2&.7GU#R)^HO(?VA@:-55Z;;DL_P`Y/;*PZ7[86#0+RV]E;Y7[
M?,ZXIRB=R=U/;-)G=@JPLG8FDI%)RS.!MFK(X6[9X)DO`ZRGD!B%*(2V;P^-
M#N?6ZTE-1GRW]O'@KW+5E1L";))]&/1A;ML.I5:Q2;1RVV(#5HI'P\VNJEXH
M&,`%`H>H^0!<%O\`#7O]JNDJU^7COZFW0_2@U-<Y%9,J0`)2)\*7,Q52%*;C
MDY1,/'(B(^N!Z,C\.V\YA,B<A\L??0YR`("HUN<E'"?Z>(G%I<$@$Q``.!Y#
MU#`\<_PM[H*P49&^6KY`#(F253,LOL.76=`543#R#H;H"_FF)_T#SR4``/I@
M4%0?APW':()=S-_+!WZ5>1E\NC%-9CL29:?<L*W892O1:"YD[68YE%8^,256
M#S,!E#FYP+DE^%S8PKG7-\I'R"C[@&`2AM*QD,'D''('"VB(<<?E@<;OX3[N
M_1*W=_)]\A3A(@)@45-OSHFX3.LH`<JV90W!U%Q,("'J(%^G&!8;LU\-$[K?
MK3V!O9_D?[YV9M5M,[&M4M4[)M>3DZQ:VM:I<W+&K]AC%)7EU"20-O9<)%/R
MHB8Q1Y`1P*-^/;2[G<O]/Y6+"PW?OB@LIGK7VA5+7M>7*$J];;%2M6X@5(BP
M/2GDBE'O#)^;A'[H3JE54#S`3B.!LP:PC1AM:Z]B!DW\T,71ZG'#,2JB2LG+
M?90+!M_$I%5!!LBH^?>W[JIB)IE%0PB!2AZ`'-L0!&C6T./T?RU8?<'\@_@D
M@)/]*WB']^!;/J?YCU9ZU"J'"G^0&F_<#@`X/_EU7/,.`]`X-@8ETOK)JWMC
MTCJ>H-LQ+F1KI-BV&\Q#Q@HR3E:W=*'O^YV>JV.,&38RD:JXCY2.`IT7+5RV
M<MU%$5DCIJ&*(4_*?$)U!G'E=7FZ]-2\/6KC5+TUJ)8'4U>A%9RDV6,N%91*
M^JFLZW:HV)C['#H+&;,I-L5=,HHJB9(QB"$C6S-<4_<.N+UJC8D06?HFRJ?8
MJ+<X0[ARS+*UFU1+J%G(_P"[9+(/&IG4>\4("J*A%$Q'R*8#``X$?9OB1ZF*
MZP<:C<Q+E>J/J\[JLDL77W75A8'\)(I*-9)`\]$Z,CW[-\^8K'2,^:&;OTQ-
M[R2Z;D`6`,EK#3(VB77IO1J*V:URET*5M57BX`A5GB;>FUS0UOK\!`LG3M5P
M[3&-,BQ,"RBAU#I-C%,81.(B%F?DC`?\L^N2@?\`I#O_`-#%N?P*(=GM=%*(
MA^(>1PP+M]P7;Q?JGV];KMS)-F>B-H$8K"!`*X35UM+JN!*)3"8WM.A.4?+C
MZ<!Z8'6[%=).O_:JQZPNFVJL63M>IRS;:JS2+.O/EOX#:DHTUDJ\BTL\#8XQ
MS!R[J'9+J"1!)XFJU)[2Z9#K$5"@=,?&QU=T=M^O;UK-65D]DTR%L4'1IJ4B
MZ+$$IB%P:DCK<\AFM!I5*2<R=BB44V:RTA]Z9%J02-O8]YP*P7X[&=:-6=H:
M=$TS:<6[=M:S;8&_U":BUV[>?IUWK7WI(BS5MR]:2+!O*(LY)TU5!=LX0<LW
M2J*J9R'X`,7(_P"++JBQNFM]@34%/725U'98V\TN.LY::6%:6^`<!)UN=7:5
MNEUUR+FMS:1)!LDFNDU,^3(JLDL*9`*%T-/@8.Z/<@.."_R!U),F'X>U_"-Q
MEY#]GF4P?W8'2OT7)3'<L8>`GW-5L,[TDV9&Q%H9LVLD\K4H;;%&;PUA91K\
MBC!^Z@Y&2!R1!8ID5SIE(<!*(X%J.N6NKMJC=-PUILR_,MCV^O\`3G4:$[?*
MQ43ZY0G#.=Y=G7C5W$U5":M)X)PU9O$T?\)VX]Q=,52`'F!"A8OXV5=AREMJ
M#S<FW;'NC:45U[V)6GUWM-4L=)GI>L)=E)=:K-9V!ME&US,M96JQ`-HIPLE'
M+-79FYER/')E!/@6]^&'<&R]F[Y^7R#O.P[?>J_1N_$^VH#2WN$EEZC"O(=Q
M#J5^((BDF1E!MFU4:)H-R?H*5+SX\CG$0GJ5,)"&,7CD.`]?H')@`1_N`><#
M$*L!O;8%TVM(-MT!4ZU!;+G:96JBPUS3YE./B:]#P7#Y>=DS!*/I"3>R1W*@
M*?X:0<)%#@/(0[(-MX47:NGF]AW:-UJ%PL5KKUCKLCK2GUXRJ;;7ENLD2]83
M<$<9!J[93$"W\BCRBHW4.!@\O$0#+'[E#P\_/]/B4_[I^0(8PD*82^/D!1,'
M'/&!8O893&W#U[!/S,BK-[+,N(**E#@NNI0I3?H4)Y`"@^(<^0``^G'UP(L?
MZBQF97XGM_$1^X_3-ZN.?VEURG!(NP((#\G(H!Q(8IN#!R("`\#Z8$R.L0,&
MMM>@<3"<*/4P,)AY,)@@6'D)A_$PC]<"T_9F]W*C5K6R5&E6T'+WO>VHM:O)
M=>+93"L?`W*T(1\ZNP921@8&D1CBG*D=4JA4Q-Y`0Q@`,#PX6C;*D96YM8+?
MLY$2+*PMVUB<_P"5^M%@>2BD%!R)'*`GB"E,JE$/F[;S.4Y3"D)A+R(X'O=5
M[];-B:>AY^]RC69M:-KVS6'\JSC$8@DHVH6WKS08N06CFB:3)L\<Q590,X]@
MI$!<&.8A2E$I0#(D%"'/XE,`F3$!.7G]1`,0WB)BC^H`-^`_C@6ITHW2#657
M`"^(BU?"(@/`@;^,R@>0#^!BCSP/X8$`_P`4R"#?YIOGE(GY@JK<^N#E8#G.
M/ZEV.S%.0*/"?CX&*(#P(@`\<_A@;*>!QE3*0QC%Y`3<>7J/`B'/!A+^[Y\>
M@CQR(`'/TP`)\"81.H;RX#@3<`7Z_N^(%$!'G\QP-./HXJ!?ZC[LX)'2X@YL
MW<%F1(RZJJ;@6:]*54`P*B<PG:KB)"^H%*0H%*'&!N/B`"`@/T$!`?[!]/Q]
M,"WU5U1KND638%PJ=3B8*T;4G8JS;%G&"'M/[A/0=?8U2)E)M3D2N7C&MQC=
MF4_`&,BD'D)C<F$+@FY\3>/[WB/']O'I_KP-9V?C&#C^IPHLB1T5N^C>IMB0
M,!A7.1PY=:Z\$V7B4P(E<%8&,XY,'[A/KSP&!LP*?N']!'])O0``1'T'T`!]
M!'`M)$J'HES/5CHG+7[RYD+!`/#J',@PLYC`ZLE;\E!\$$GZ1AD&)`'C]#E,
MI>"%X"[A3D/R)#%,!3"41*("`&``$0Y#TY#G`XG7(-EQ#Z^T?C^WQ'`U#?CQ
M5:-/ZD?OBR13."CVH]IS+&$X_P"(NGM+KI(F$0'CR(4DCP''(%Y`,#;Q:N$'
M2)5FZI5DA.LF!R\^(G06405+Z@`\D53,4?VA@=C`8'R<I3E$IOH;T'UXP,:^
MFYU#]5]""KZ'#659(/``'HFQ(0OT]/W2A@9+8#`8#`8#`8#`8#`8#`8#`8#`
M8#`X'/\`YG6Y'Q#VC\CP(\!XCSZ!R/TP-6;KTA)1WS1]H7BT61=I(=PZ?$IR
M3YZ#)=LW<]=]V3Y%XQFT*X1D@!=P1HH1<4%$P*"O)O<*40V$NTJ=B#3LY_)1
MJX6W*W/3RT(G;G;UI7G3]MMRBK$9R"\<BY?IE=MFYTR>PF=3S$!`HX&,/93O
M!)]/5*4Y[`V31M7C]@2BU<J,1!,=^7VZ3L\5XDW3+&UC7FL+A*JQ0*/&[87"
MB")#/G"+<#BJLF0P>#IGO9=-Y0D5;*"?4$U!QVV:/K?8<!-0/8'4^RX!G>+3
M%5YA.QM$VUKBLSYVBK64*[8NG+5-A)IE-[2I1*8N!*"OY?;B!N/+A,#<?01\
MB@;CZ>@X$:.EUMZ[.+VH_E[?:FOF%`[/[MUS28B&UIKVQHQ+2%&)G47DLZL3
M-Y(2LDM*6-8ZP*JHD!`2E*4``#X%[^A.T=B[AZIZBO\`MBU0EUV#.M+BA9K5
M78-C686?=U_8%KK;>0C(&/<.FL8W.PB$0%(BBG`@(F'DV!F1@8O=W$E5^FW:
MUNCQ[KCKENM%/R`#!YJ:WLA2\E-^D0Y_`?3`B)^)1L9O_3XZ[8G$ISJ]=>TZ
M"PIE!,BH&MVY$U13*4`*D`A]`#CC\,">RACS1Z8/UYJE='_3$,\#K;&\AH5T
M`GJ<:I9!3#\U"PKXR?U]/^(`?7TP+>=6R@GUDZYDXX`NB=0D`/KQXZ_KP`'/
M]V!0W2TXCH*JDY#@)W:H!^?^%NG8Z0_Z```P,L,!@,#&[;\S_#-U]3F7LD5_
MF'8>RXDQS*"0S8C?1.QYX7!"@4WO#YPI4A*(E``5$W/IP(6*^1\GEJC1"@A^
MAOWMZ'+&-_N?^W4:Q3`P_B(>:@!_?@7A[H>PWZC=IC>0$.OH/;(F\A'@YQH\
MXF0I>?3R-]`*'J.!DZV.51$AB"(@!2!SP8/4"%YX\@#G@?3^WTP.Q@,#Y.7R
M(<O^\4Q?Q'Z@(?@(#@8<:G2]KN1VX4,`%,XUSU14`14*/N-TF.ZTRJ%3#]21
M0634+P(B(^//TXP.>2`![[5%;R)X#U$OZ8#[A/+R#=.L3_N>7GX\%'UXX]..
M<#Y11.X[L;83:J*)N7'4723=%5NK[:R:AMO=AO;.F<!$$S$,;D#"`AZ>H#],
M#&7IKKK?.DMP5_5'8:_US;>R7FBMJ7:P7ZL5]C7&KY*:['HR<*U6180%>1<R
M`L[*NXDG)D06>/CK*B)@$GB&''PBOA>]I_FH<%,Y/]UWP5<*"\(U(\#AM=8_
MVW*;0?MTCD"-*)0+Z^V)>?U".!L/.1X1./[2?ZSE#`L3I9,"2FX`('[N[KD*
MOKSXG<5ZGKF_\HP\^GT#`Q<^2;>M@ZYZLJ^W:G3[)>[-3YK8;F%@*M$-YN2;
M28Z'V@X8V=W'.G+9-Q7:JL@5])^/O'*Q34$$5N!3$,%NV_3:+Z_ZTC-XT/M=
MV]C]S1-@M>S1NEP[.;=LU%DKLSUK:[2\G)?3CJ<_RD"JJR,45VO7DHIO"),D
MSM$4")"0@!,7=U`/M;KTJ1;WTSS>QRD6$"E\RJ:\FE``"E*4``#("`>G(`7@
M1$?40C>_J!07_P#.I>RQT$RJ'11HJQO,A#E(!+S`#[@@?](`4_'K^&!+1K(Y
M5-;:^4(8#E/1ZF<IBB`E,4T"P$#`(>@@(#@6"[<)"I$]?S`41!#MIUZ5.(#^
MZ`W1-$##^8"HJ`?WX&1=?AE8N1M#M18BA9N:))H$*0I3HIEBHR/$BIP#E8_D
MP^H\B`<!],""SK-K.`[MW3L+J+>[+?M3U?U6W)=6VJ8JJ[8O&E(F_6*^;S[$
M3T[MAO9-)W2N6VU1:#4J<#'H2DBFT1^R<G_AY5S@N(92_&939+6#[LUK-#9V
MPM@T>M[*AI"C,-F7FS;)L-22LK.9>V%@VN-WD)FWO(:1D6Y%T6SMXN1J;S]K
MP*H(8$A>HB%2H-?1(5N4J:<F4`;*K+I`0)R4!+P56`#G$2\^?/T/R'TXP(&_
MC1.Q-\U7S9_8B4?,W6TS[@IRB+Y$VS6JG/F4HCX`CX^G)1XY#ZX&QA@,#\$0
M#Z_C@:;_`$G:I)_U'G8(Z7`%6M'=4%P%4/,3+O*<H<4TS&!3GS2^I0'Q#^T,
M#<AP&!^&'Q*81]``!'G\N`YP-8E<Y1_J:X053&]UUUZ<G3`?(2F*30Z9C>'`
M>"8`/F/'H(C@;.^!25TJC.WP:\<X.HV>(+M)2%DT#"1U"ST6K]U$2[-0OZDU
MF;H`$P!Z*)"=,W)3F`0XZ59"V&)\G0)M9QBZ=1T_$@HF*L7,,C)@];B0@^16
MZ@K$7;B8`,=LND8?4V!5;G_S.MS]/:/S_P"2.!I[=$?-E_4V=S$""44GM$[5
M+*$,7R.DJK=.MBXB0X\B4BY6Q#>(#QR'YX&WO!-56<>#=5,4C%>22A2"(&'V
MW$BZ<)FY`3?OD5`?SX'`]C`8'&H8I`*8P\!YD+S^TY@(4/3\S&`,#&SIL"H=
M6=$E6#Q5)KJ!34+Z?I,FB9,2CQR'(>/&!DO@,!@,!@,!@,!@,!@,!@,!@,!@
M,#@=<@W7$/K[9^/3GUX'\/VX&I5K*5DF'S@;-8-Y-%Y%V3O]&LEP16$R;8T+
MTXW;,.F:Q4_\(7!'!6R9B&_4!D2F$.2\X&S#N\(Z4J4@S?KBDC%7[3KCG[)@
M]`KM#8U,?LTTR.R*`BN_66(B57@#HB/F02B`#@1L_)KM/6.BMP]/]E;<,XJ=
M3#:5,@UMGO*_,/:K`N&&\M*W9]$6"P1#9^G`"Z@JJ\DD1>@BU42CS^)A6(4N
M!]77;M3[?[%T+OKJ7V)8VG2VI-HTVI;F6K%&9V6F;8?3VYM3&A]>([%LK6/E
M*Y8Z([9_Q94L-]R)$EO:<`F#GD0F4.;R9^8F\O\`"*?SXX\N.#>?B'TYXYXP
M(W:.IH5LZWY.&UAL2P3#/;>Y(W:4I1JG>GT/)3C.=6D)%)VR@Y1"&FI\M>*R
M(J\3:F<'(!$/<$0\<#(CIE(Z"FNM^KYSJ]51I&B):*E'NO:NI59:C'BH]>P2
MPR28U.<20EX@[B=*Z6,1P0%#&4$_T,&!E+@8R]TQ4+T][4&1*8RQ>NVYQ1`I
M1.;W?\NK'[?!0`>?U#^/I@1%?$4!E/@"UZDH!O,-&]I4S%$!+P(W+<X&*`CP
M''F(_3TP)Y*(`!1Z:!?W0JE>`O\`8$0SX^OK],#UYF-2F(M_%."F,WDF;E@Y
M\#B0_P!L\1.W<`F8!#Q4,@H8"F_V3"`\#Q@8:U/K)OJBU:OTVM=U=GH5RJ5R
M,JE<8NM0]>'KB-AX./:Q<*11ZMKU)=\Y8L&9$Q45,851Y,<!$><#(+2>JVVF
M=>UW7K6=FK2$"A*G=6:?1B&LG.2E@L4Q:IJ2<M(-I'Q34[N7G%C`DW0201(!
M2$+P&!=S`8#`LEM[43O9<EKR>B+Q8Z#8M;3LS/P4U7(^H2JQEYRLR=4D&KIA
M<Z[88XZ*\1,+D!1(B*Y#&]#^!CE,%B]L]1+INF!KE=O7:+<#R+JVS-8;7C$H
MVIZ%AUPM6I+O"["J)UUV^I%S.(Y*R0#51PAR3[A(@IB8`,/(>G;.N.R-CUF^
MT*X]JMGSM8N4.O6)N(0H_7]@X:P4O'BPFXS[EGJPC@?XRU56*8YC@=--4?;,
M40`0#,!@@+=$J/"O"1$4BG6$IU%"D2+^I0Y3F!143"/F;@O)N?[<#O8#`8&*
M%\ZR3%AVK8=M:_[!;BTK.W"I4ZHVZ,HS#4TY`3S>AO+,YJ\F=KLK6MX=QTHQ
M2MKY!46BR"*Z9TQ.F)TP-@4<CU&O!+8[O;WMWV#DKZ>G)T6(N2M?Z[-GM=JR
M]F:6B;BH^+9:00@'Y[!(1;0%UGS5RLW2;E!L=(3JB8+?ZAUE<Z/WPV":S[]V
M?M8%.INI#@TO49J]DD<3;EW&5NJ1.AZYIY&PQ!4E2)B`^2X2"@JB;V41(%\7
M[)+_`)V(R43E5B/4NK$VP+!`)/8=-U]O5IP:8'G]8*1RC<$?P*8KKUYX]`BD
M^&I)%+N9\WB:"*+=(.\D6H"3=(B*0&/"VTIS^!``OFH(<F'ZF,(B/J.!L!N@
MY0.`_F3_`-6%P+&:7$!E]U@'X;RL_P"?_P"RE,_[HX'WN?7DM=U:,]C8&OVA
M&KVB=D)>LV9^:/C9Z%LFM+I0))FH[".EBID,G9R>:8H&*LB"A1X$0'`B7MOQ
MA[/O<G&H[&VCVLV7IZ"LDC88[K#9.Y-;-IQQ`_:2$?'ZJEWB'7)ILJP:_-"S
M"T8HVD+`NJYCR`DX7.4P\AG_`"5BW,ZW[UKB;9J6L4^IA,;.(O-P^T$+2NV7
M:ZNL?\(CDH$:5`+"U=HB;S7!P`H*(^'MG*8%!#!3^HT?*,?B1[%*IJH)&6D-
M9(&.O[P#X*;`KYC^Q[)1*#D0+^GW.$_S'Z8$QVJA$VK];F$>1-0J>(C^8C7H
MX1'\/K@61[9E4&OZ1,D')D^U?6\P_3T3-LV&36']7H/^$H;]OY>N!DTS<@NY
M?I`F)09KE0]P1`05$Z*2H\!SR7P$P@/Y\X$,.R>AN^KDNB6M.[7IZT5V];??
M1N\.MW;VQ:*OU]U[?=I;(V+`TC8E;-H#8%:EX.%>WL'2*+C[IPSD$E%&[DB;
MA=,X73Z@]9M\].J_:*]3M6US84G=)T)VW[.W%V]MU[V5;%&Y7803.9F/^7")
M9(L:PB]50:H-VQ$RD54./D<XX&;_`%B5LZ^CM>JW-I&Q]I4B7REB81$FI-1C
M&<4GI4THTCI92/BE)*/;.N2(K&;(&.4O(D+SQ@0A?&9R?YK?FS7.9H8YUNO:
M13,515;"5LML5N*9A-^L'B"::8.2CZ$<BH`?I\>0V.L"WFRMDUS6%;4L5A<.
M1!5RA&0T1&-1D;#9Y]^H5"*K-6ATS%<3-CEW!O;;-R<%YY.J9-$BBA0P7[*[
M7[J4OKANK>\*UU'I0==:TMU]KE%M$*_V_=GZD%`GE6;"XS4'9JO2JXZ4<)G2
M7:QJ4^FF!0,1ZIR)<"!7I9X?^Y$&X7JI&I)&7M';]1R5(ICBDJI"4IR)&ZJP
M>:9%4TR&,!1`O(>OJ(X&XK@,#X4]4U`'Z"0W_HH_VX&K22RBO_4Y04,JH1!1
MGJFQQZ20LO%1VS3ZQ0K]HF5SYK@;V#NE5!/RD)@'Q$H\!@;3.!\F*4Y1(8.2
MF#@0]0Y`?P],"S]R<Q^O)QM?E!39U^07CXJ^*`02I-4E3DCH.UN3%*(?^LMT
MJ1JZ6,/)&:WD;]*?(!=L3I+)+``^1`\TSB`&`.0+^H`$>.?'G@>/Q`0^H8&H
M5U'C7-?_`*HSMJR5!`$I+4.\IALF@<RHE;SB?6^8%RJ8XF,4Z[H%"F+SXD,7
MQ``^F!MZ-E2+I`H0P'+YJD\@^GDDH=)0/H'[JA!#^[`[&`P.NZ*8Z0`4.1]]
MJ/'I]"ND3&'U_(H8&._4`0'K)I4`_P!BCQJ8_L,D==,X?M\3E$,#)#`8#`8#
M`8#`8#`8#`8#`8#`8'YR`#Q^(X'[@<:I/<3.GR`>91*`B'D`"(<`(E`Q1$`'
M\.0P-&SK#ONZ;#^?0(R:CHI"C;0[K[ZME/CV[9PG9J=+Z+T]M#4R[B5E6Q5(
MRQ,+5'HNQ,@8&PM#.BJ@=0R!4U`W`^Q,2#VDKC$BF=XGM?0<G,HJ'<D(",=M
MK7RJBJ@M3$5,4D2W$P$'E,QB_J#ZX&0Z:+=RD<3E*NF=50#E5`%$S'1<&`#"
MF?R3$Y%$@X$`]!#TP+"]B*[,?Y9$5H=/>6&5A]EZDN+BMUA"'1EY6-KFUZC8
MK2I&-Y5[$1+F5"#9.EP*JX1%<Y.//S$N!Q-]U32[=5/_`"*W\B4I6X$(YJU+
M3\DQ>$;JIH>%W.<5$VYQ5,*@E`2$_2(G$"F#&[4^ONS]<@NP2]<H.LHR-W%M
MG<>RZDTV/=;-7;I%#>C(1L>SML%6:;=8%FB`PR;CR;R+E11NN03)IJ%.F(9!
M]0=8;+T[U[UMKG;\I5IO856BY)A.R=*,_/5C@M/R\A'MX<\HQBI!5%K'ODTQ
M45:HF.)1_2`<8&36!CAW%3%7J5V>1(0IU%>OFY2)D,!1*8_^7-C'@?+]/T`?
MKZ8$.7Q#3$*G\%&H:-_&(8+2MUS[0R;.MEDV0S"T(WV#MV/4D$F'O_=K,T'K
MI-`ZP%$I5A\!-Y%,`!/C1#$/1Z:=(>4SU2NF3'U]2&B&8D'U]?4H_C@57@,!
M@,!@,!@67WQV)TCUAHQ=E;_V56M5T12;CJVE9;4Y5;1ZT_+D<J1L0A["#A==
M^\29+'(F0AA$B1S?0HB`8=N/EW^,F(+)O7/;[4;/[=`SZ57%2>*9-!N@*QEW
M7A!B;A)MY']0Y\"F'Z%,(!(?6;+!7*O0=KK,BC+UZR0\58(*5;`H#>2AIN/;
M2L3(-P6(FI[#Z/=IJD\B@/B<.0`?3`]W`8#`8%&[&?3\7KZ]2=4>0,=:(ZGV
M5]6Y"U.2LZNQGFD,]7AWEE>&$"M*^VD$TSO51$/;;%.;\,#`7JW;]DW[L3_-
MVX(ZC1>Q)7IEJ@EE;:UFY.PT923CMZ;SCUY"NR<Q&0\M]C+%;).OMG"'N,C+
M"W%1?VA64#VMD[[USK;Y!:I2+6-H;6*>Z?6:PPRT70K99F#V+CMQP24J@A)U
MF&ECI.X[V2*N4%`*4"+(<F*=9(#AK[]`ODCT!T][>_+8]WB_NHGV_P!P7]FI
MJ%&I,Q:7`P58E+S`/7,\T<,X*2@GXG<H%*BNW*!B)")1,/D(A*H]_J`^@;9N
MFLN;L&+=<3%25+I.6,F<Y#<`03E><)F,H'B7R\0$P@'.!:[3WS@]4(JQ;G3G
M*GV*2;3>V)ZWU-S&:.FEVTC3W]2I[6.<N5U9+DLJX?L'8BF``0$BD'D!'@0N
M&?\`J">DQ5!1+1.W1U?<!$"DZ_.AX$3>/N`<T\5(2%_>^OT_#G`]`OSY].16
M]C_+GM\54`^A^O[@R(@!0,!O?;SRR8^91Y#Q$>!]!X'D`"S^P?G?ZCJ;#TY/
M%UQVG)!5.PVEW8Y-WI8L:6.)-TB;KD2D4LA9FX.EG<O(I%_V"IIF$1$1],#`
MOY;/EUZQ=WNC^T>M^D(S;Z.P;@ZI<I!.+M6F-5JKUO7K01[*M7DI#V295'],
M:<H)*H"W7-X_JX]<#/2A?U"W2BOTBH5M[2^QGW];JE:@Y!<M%I1&ZC^+A63)
MW]N*NQ!752,X0/[9A2+YE#GTP*/W3\[O4O9,#K_^7->]AC$I^\=17>9,_IM(
M;&&'J%G1L3Q-FF78YEU9!VBPX;$.FFFJ<>#'('K@7!AOZAWIRJX?KFH_80R4
MN^*XAFT?2Z&H^403BH\'B3Q)SL;Q*\;R";@#%(;@I`*'J/J(>T7^H?Z:',"9
M:'V.`WME5_Q:MJY(WMF\0`3E-LT!3.(F`/$>!`?3`\YY_47=.V8R!4M:]CWR
MD>9$3I!6M9(@9!5$%#+BJ.R?;3`AQ\/U"4.?7`I_5?\`4#=*:[0H>-E:?OIG
M),&,L^?1[2H5210:JN920E1;`_"]%14\&ZPB!BF,43<E`PCX\A8KX6MSU3?O
MRI?+)O:HDE(VG;=J77JV5)G9_MVUD4BV\YM",<F>,4'CU%-)F\3\$P0461`B
MA0`_(@&!M)E?M#<<+%#DGGZ_7Q\CD]0^H#Y$'_1@8K5UL?9W9K8$Y*N$7D-U
M]A*Y0:=$_;MCDC;ML6NLKML*TF=`4ZIY96I2$)$M?$R1FK11Z`?^:C"8*7^2
M5Q]ET'[A.Q6;H%:=<=L+@JZ61;MTU$ZH_,0ZRRQBI(I`(?J,80(4/4<#5TZH
M;$JE!^?/8.P]IVVL:_JZ4OV8)(3]LL$17Z\SD)C7&M7"1%)>1>-6)EI=X^-[
M!0.8%/'A/\L#:S-WWZ0D`3&[==;P`I1,;_VLVO\`])`^IS!_'N0)SZ<CZ<^G
MUP.BI\A/11(RA5NW_7%$4C^VI[VX*,B!%."F\#"I-%`#<'#T_;@?A_D%Z,&`
M"AV\ZZB"@"!!+MNE']T!].4/&7,"W(^@>'/(^GUP-<C56T->[N_J5(?8FMK5
M7+=35:Q=8NN6NKS#6;A+,E%=6H"/>NX^09K*MU1:/069JD`>2*-QY#D>1#;[
MP&!T9-@UDX]]'/6Y'3-^T<,G;97_`(3ALZ2,@X04`0$/;52.(&#CU#`MO1I)
M>'+*Z^EC.E9.HHM$XIXZ.14\]5'QW:<!*^^":157J"+0[5X4``2K-Q-QP<HB
M&JQU'<GD_P"J"[3RAU3`H.M.P4"#80]4T8!OUT9(""O'JFOXBL!>>"BI^88&
MW'`LSL&!D%$S)&%_*+^)SB<?%S(NG!#>0F/Z'(H`@'/ISQ@>U@,#X4_=#_PT
M_P#U87`QNZ>__(S:=_95"%#^PLB_*`?W`&!DI@,!@,!@,!@,!@,!@,!@,!@,
M#R7!9)`$S-P"1.I(MP4*JJFS!JP54(5PJ02I'!P9JGR8I!\1./IY8'H)J"IS
MXCR!3B0WH`<"7CD/]>!RC_W0_P"D,#0Y^/35?^8GSOW2-6G[9"!0+M\@]]K$
M[574?'R4-.MMC)5A`J*LW$34.[:+,KZ]1.DJU7'W!*H(AP`8&XJRT+9YARX9
M7C=VYK9!M;%5)E"O2<OKAHS$M;7A[`Q8S#JLZ]A).2:N+!&@LN9-1HHHGPD'
M!`,)PRH9$430`JI0(?W%C"`"3U!18Z@&$"`!"F-Y<B`<@'YC]<#G43(J42*%
M\BB("(<B'J40,`\@(#Z"&!Q?:H<\^`\_^I%/RX_W_P`L#G*4"@!2^@!]/41_
MUB(C@?N`P+#=IH>>L76CL)7:K$N)ZTV#2.UX.LPC3P^ZEK!+4&P,(B.;^X8B
M?O/7K@B9?(0#R,'.!K)=`>OUC8]*/BLVS:-+R#6UZJZL=^#2%IL$XZJ-IJ$?
MLD-EV5G#RE$-5Y-Q:ZEL6)7(Z%)P\A_:#V543J*'%(0VNJ&J*U&IBPHE;BK5
M*ZH+<J?M%0$\0S-[)4@.I[94^>`+Y#P`<<C@53R("/E^[^'_`'/IZ_3`^15`
M/7P4X_/QP.0#`;Z8'[@=5N9Z8RGW23=,H<>T*"RBHF]1Y\P.DGX^G'TYP.U@
M<2BQ$N//S]2F,'BFH?T+QR')"B`&'GT`?4?PP-=+^IS2</?CRU\NS20708=S
M.N"\L5\FA]FG"*OK4SEU':,A[:"C,6;D2+B/H5N93R$">8X&''RQZLZ#5GXZ
MN^,]HICIMAL%/5E;'4KZ.@J1''CV8[*I;242I<C'UMH<7K4%W:3#[=59T2..
ML9`#MQ.J(;-73POCU-ZQ%$.!+UXTB!@_ZW^6%6\OIR`C^W`R/P&`P.LY45(0
MX(`4RWMB*(*`I[0J>O@"ITR',4@B'KQZ\8'B2$<QLD#+UVX1D3*Q4_'24-,0
MCEN=_%2\)),U&4E'OVCQ#P=LWK-PHDNF8IDS)G$!Y`1P,(-+ZIUKI+MO,ZPT
MW2JMKG75:ZC:[/"TNJ1J4/"Q/\3WKN)^Z-&QB`$101</5'"BG@4`]U3D?WL"
MY\M'I&[M5V7*D@+AKU<M#%1=04/>*S<;?H[P4T>#_>AY*L/(0`HHF$A?,0$"
M@(1"_#36T8;NO\W<"[4+,BR[KP3Y->113=*HDGT-FRAFJ:K@AS@DV(<B0``\
M<)`/XB(A-OOJK0\EJFUMUVE78,BIQ+N4>SKE*`BVL9'3T5(2#AY--Q;FCT$&
M34YCG.<J0@'BI^@38'H&V1K4CQ02[$U&1@8I_8*-GKQ7OW`*#Y?<*!+`W.@5
M,.``I?(!XY_'`[@;5TTD0H.MDZJ35`0`WC<:HD7R$?T@7RD@.`B''X^N!UT=
MPZ9*X.DOM?4Q4EO`\<B2]U<KA1$P>(F,`S`^[Y*E,`"4./3C\\"-3YFKGJFQ
M_&SV#8Q^QZ.=T^_RO4ATHVQUZ46FI)IN*@.&D4@T1D#JOTWRZ8)J%3\C`F)C
M>@`(@$.7QG?#=KCM[TPTIOV_;JVU3;1<&M_9OJ]0F6K6%>8-ZILJX5R+-#IV
M;6=FEU4I%!AYKJN7:PF'@2#P.!($A_3K=:R)E^^WOV1E7;ENW923Q:1TZGRW
M:D4!-1FU0U&V;H.E!.'F<"A]`X`/7`PI[\?!KI'J=TD[1]B]8[CW]-W[2>F[
MCM&IL+/)ZN=PLO/4V,4DXZ.M;9AK*(<O8,Y$S`Y\':9BI@(E.`@`X$*"?6KK
M[K_M-T^U'?M_[^U/JOMKU;#?]QGK1JVMWN4@IN2UA0+O6XBF1G\I/T!J\A/%
MM2ZSE=D)T&$:D)@$IDU3AG7VC^*1U6MQQ^CNLMEW7N1_3]B]>*1O6YV1#K_$
M$C'&_P!M)S%?8UVKH4RNJ1+)C"Q:+T),RSIJW.LJDX$"I$$X5I*?$CJDW4!'
MMM`]B^R;NQSM@8:YC=+)4O0;9>P[8<;=)IHNLUK(O1O$%7]V0.Q;R7'M)E,5
M8"K#XE,%C^A'Q7QO8^?J%;["7KL%JE[MJ<[*JZ7M=6BM&/HF>J_7Z\0%3E&M
MEK5AUI+.(F4=&=+JDDDQ",=G1%%`ABE,H8*YWM\1VRJ-V`CM:=-KONS8:T!N
MK7^E]S[*O!=/5QU4@V#K5[M&.-1V<#0F?V,16Z4U1!1^[.E$K/WJ"1%B.0.4
M0H[MWUUZQ=;N@E6[B:^[E]Q7UZVM62.-24BX,J+(UZQS\3LJ(I%HJMND:K0(
MZ0:PSZ8?.F:#@KQ(KU59%3S\#!@;3OPY]>JIH+HEIZ0K<[<++*]@JQ3^RFP)
MJ[6'^99%UL#:FNJ2YGFT2\%JW,PJD4G&(M8UD8RXMFZ0![AO+`D/V70H+:-&
MM>NK7'-IBIWFMSM/M,2\+YM).N6:,<PDXR6)Y%\A<1;U4J?U`J@E,/T#`@L4
M_IP^CJ+!TT@[;V4@W2H%%I*+[4A9Y9BKY,Q<+"VD:?X/EW@-3<J+G4,F94PE
MX'U`+6H_TS77@CTSEUV/W=(-BN5E6K)S!:\/[#4QRG;LUW!HGS=F0\>#'_25
M0W`B4.,"E+C_`$]>M4;K$01NS6T8R&M$4N2N2J]3ILFG'W%BN5T_@9*)4^V9
MN6<[7$5%H_V5$E4U6+KR\Q,D&!7C+^G-J#-J9H'<+9HI@`D0]K7%40^W()1#
MA,`FSAR`CR`X&/\`ICHO!="_FSZ34.)VA.;-1OVDNP%Y7DK'78>$?-I!O3+)
M63,$0BA<)JHK(LDG`G,<I@,CX@'`^H;9^`P&!:/:L+8OL6-PIJ:"]FI[H))&
M+.)$@M,&8$D[!4E%U#`1%Q,,T@.S5$>$I!NV$0\/,<#5)Z3.XY__`%+?9"3C
MI-*22E:CV5?`<@I>ZT3D8WKB\3CG)$3G*FY:'(<%"#_B(GY2/P<@A@;>T`!"
MLUR$<N'7MR+\AE'(*@H4Y7!_)(/>_4*:0^A>/3CZ8'N8#`XU/W0_]2)?^K"<
M_P"K`QMZ=&\NLFG1X,4?Y6\1*<HD,!BR<@4P"4P`("!@P,EL!@,!@,!@,!@,
M!@,!@,!@,!@,#Y*0I.?$./(PF']IA^H_VCQ@?BARD()S>A2\"/`"/H`A^`>H
MX&F9\7D!-0OS^]JZQ-PLTR<:[D>[+>1D0BW*M:2E=A[#T_L&NP:-C1YC7$F\
MHMA;R8-P,*A$EA`P`8@@`;CS=))&5DE4T7)5G9F7OJK&X:J$1;"0GV@?[Q/H
M</KSZX'L8#`8#`8#`\Z5_P#,*P?@8ARC_P""=,Y#!Z?3DIN,",UEUPHFP-&Z
M,WM/+39;SJ;K'9H>D.6T@"D,0UIUV]8_>V"/^V4?RZ\,1RH+,".4RE]Y3W//
MD`P)'*2424RHD,<JAB5B`*8Y""F0XEBF@"<J8E**93"'(%X#@/3C`_;BX?,Z
MM87L:X%J^90<R\:K@!3>TZ;1;M9JH8IRF*<B;@A3"40'D`XP,,=,:*F;QIS6
M=OFNR/9^1E[KKREVN5D4]H,XLQI.PUV/EI!5DQ8U1NUCVIWCH_MHE#Q2)P4H
M``!@7\ZTNK*YTU4BVV9L%DFF"MHA5K):GD6_L<ZTK]TLD#$2LT[AV$6P<R,A
M#1K=910C='R%3]1?,#8%^,!@,#&C>J<Q+WS0%/9V:X5J&M%PNI+&I3+(M6)"
M1:PVM;-*QS%R^:(G>*-"RZ"*PD341_6D43&$O)#!';\JG5#7E[ZUZ_A-@VK=
M=F@B]P^I*1VKW<%K*JDWO^^*7J6?(V<-G2#A$JM+V#*M4?$WD@=R"P<J)D$H
M6EW;\#7QM5K3FU91OJG8ZB\=K*[K-Q<]A=TOFZA6U?=JB9VT<V\4%1)[8"4H
MD.41]1#GC`G0U[7(2GTFIU.LL2Q=;JU8KU;KT6FJLNE&P4##LXJ'8IKN3&<J
M@UCFJ2?DH(F'Q]1$?7`K/`8#`PM2@I:_]J=Z5Z<N^QT:Q5=6=>']=K%;O<[4
MHB#D;3*;R+9)%!*O/(U1T]FPKC`BQUC+&\6J8$\``W(=VP::3=W^+H[78F\H
MN!FZ7-V"0/%[MO;2:"7KUGIR,8=G-*2;F2CV9V;]TDY2;K))N"*\*$.(%$H6
MRU=J&-USWNMKMI<=K6)5?J71$ER7S:=MOS=<5MR[#!(ZS>S.G8)JQY$N&AD#
M)%3!=?W"G,8ABA>V2<R"?<B&:?8MU(=UUCLJRLG]NJ+EG(M-JU,B+,[H/\$C
M9\U>J*`0?7R;";Z`.!$Y\0Y@4[\?.,I[2R(J=Q*(/MN$C(K%\8G9J0"=(W(E
M!0B8&)_O)F*;Z"&!/O+Q$5/QCZ$G8QA,PTHV592<3*LV\A&R+)<HD79OV+M-
M5J\:.$Q$JB:A3$.41`P"`\8%GGG6GK6J@;[WK[I%PBF4!,5QJBB."@4OT_2I
M`'YXXP,$C;T^,9+=6U-#1^KM(J731YX1ALI5'3NK8ZNUFT33%A,I4?\`BLLS
MC5)*X-X279N7;5FBN1JD\2*=4JHF(4*0H%YZ+=F-B:L0TYJG4K6P:PWS(TO:
M%(?ZJULPLU87L6@-M6"C?QQG!-YN,6@[9%MADXI8'2J2J9!-PFND8A`K7Y3-
M(:6:?'[V+DF^K]:PCRMTJ,E86984FLQSVON(VWUUZB[B7K.-0<1BQ#)CP9$Q
M!_4(?01P*`^`QPFX^+CK=[2AU4DI'>3='W"B`I(-MZW]-NV(!O4J+1$P)D#Z
M>)0P)F,##KY!M!6KM/TF[/\`7&DN8]G:MU:;NFNX1S+/E(V,2?62*68)_?O4
M47"C=JH"@D,8$U``#<B4P<@(0(=</C*^0N3[F=7-P]DZ#TJD->]1.I<EU9@X
MLMAG-CQ<ZPCHRHQM-<SE1D*^50MGCP@@E"O`%H1(RH%*0AA#@)D=E=/-M[2M
MBVP'-\J^KK](03&I62XZ,L&VM=SMWIL0Y>.8BK7=9"SO6-B81JDH\,T74;%>
MQX.E"-EB$,;R"IXOJO<8K1K;K4WK'7$FC65?"MM:,WA]JH'(Q1DC2[5Z%@6N
M;V5)9$Y@W\2-+!S('E>7?N`L(FP,<],=+[WUQWJM;VM]K=\N%PJ=@B:'>-Y.
M=L[;?T)L\ETY_9&NJ,JYN]=2K[2ZR()3SYP)%'DJ*!TE#_;L$0$+];CZ@;'W
M-*NIU]L6-H$U)5D:O8Y33]BV_K`U\A#M7J00UZ0JU]:+S+!@J_5!BN5PF_:(
MJJ)IK@4Y@$+"=W^@>YM]="+QU!U0VZKU]"/U[`5;2\4ZUU<(F.IIJ>ZAGL3%
MQ5DD+=<7-<"2:P)(]61*Q=K%174.JFN)C`(9^]1-2V+0W5SKKI.VN(MY9]2Z
M0U?KBQ.X)9PO".9VG4V(@Y=>'5=HMW:L8H_9J>P=5-(YDP`1(7Z8&1F`P&!3
M-JKR%CBG#)0XH."D*O&OB%*9:,E&RZ#R-E6W)@X<1SYJFJ'''D`"7Z"(8'/7
MI!P^9B1\HW/*,A(SE2-52*(HOTDDQ4`I2F%5$CI,Y'"95`*I[2Q1$.!#`A"[
M2+)I_/#\::0BZ`[CKQV/*/LJ^*`D1KUS4`'!`X$0%7QX_,?3`G<P&`P.-80!
M)01^@$,/[?0!^G'KSS@:B_66L0=:_JD^RS6`AV\,T=:@W!8GK>/!)LR<3%EJ
MO6V;FI86A`Y,^EIB4<N72A>/<<KG.;DQAP-N)FF9-,_F``8ZRJ@\<>HG.(^0
M\>G(X':P&!QJ@`D_48Q0\B#R40*/('*)0Y'TX$W'.!8KK&=!31=!%JT68-BM
M9E)!FX+X+-T4++-(II*$Y,)1*1,/01$0#Z^N!?G`8#`8#`8#`8#`8#`8#`8#
M`8#`8'"Y'A!80Y'_``S_`+O(C]!^G'K@00]/:]`PORQ=XETT@1?S=F>SJ:23
M,4T3RCJO5]K(O/N`*4JZRL4V0\UA\N3F,AS_`((%*$YC)RZ6E)ENL7Q;LU60
M-!Y`?=(X8I*JB(<<E$BX&#^S`IC9FR:?JBDV"^WB93A*U7&I'$B_%!P[5]Y=
MRU91L8PCV8&?RTU-RCYNR8,6Q5'+YXX202(910H8&-C7;';R?8I6N#ZT4^!J
MBI7SM.K;'WNWKNVWC9/VPC"GBZWKFWT.O/7I/)11F[G1.W,`$553$3E(%\]-
M;BKFX:X[DXEI/0,Y7YR2JMVI5M9HQUPHULB_:6>5ZRL6KEZT*N9BZ0=LW3=9
M9E)Q[E!VU55;K$.(7?P&!\G.!`\AYX#D1$`$>``HF$1`.1'Z<>G(\X%KMF[=
MU=J^OR,QLG8=+U[%-8YR_7D+M9X2K-09H(**+*E5G7S`%`)X^`^/(@H(%'U'
MC`Q9ZG[3UWN_X\]6;`U/;(RZ4FQ=?S%B+!$J+?9N3Q-?D8279C[R:+A!]$S$
M8X:.43E*HBNB<A@`0]0S9J0@-5K(A]!K\,(<_D,<VX^OK@<=R#RJ5G#\!KTV
M!@'\2C%NP$/[\"U_6),Z/7'0**G'N)Z6U@D?@>0\T:9#$4X'TY#R'T'\<#L=
M>'39[J:!7:+IN$BS%Z:F43$1*#ECL"TLGB(\@'ZV[M`Z9O\`K%'`O9@,#\$0
M#ZX&/&V#%)N7K`)OH:Z;()].>1'3]R.7^X#I@/\`=@8]?)J(!UXHW_RX71#_
M`%]Q=+<?]&!DAV2.?_(K>')OTIZGV#XA_N_^PJ_,;CT_'C`N]7%/**9&Y'Q,
MS8^`#^`?9H\_V<C@>_@,#\Y`!X_$<#%;7ZB?_.%V92\R"J73O5A44O(HJE3/
M-=CR)JF3Y\RIG.F8"F$.!$H@`\@.!="2.!-WU(#<\JZRO($``YY%*R48Q^?R
M]#AQ^>!:%%0J?>.R&'D`_P"4VEJF#@>1(VW%>C?3\R@J/']N!V7,A`27;BI/
M6[[[EU(=:;>M#&;^"T>^B4=H451^_2?(*'15(5=PS]D2B8JJ:IA(/'ER$2WP
MY,9E'O-\XCN0K-X@4%^YU00(O<XMPU4DGB,=L=\=Q&2(H$CY2-<5^8BWK0R!
MU`3C'S3S'R-ZAL,8%O;EL[6]).FQNM^I=/<NR@HW1M=I@ZX=RB4Y?)5`DO(L
M%5T.>2^XF!B`<!#GD!``A5AKSU3Z73_;K96]);5&^ZQV&[=H[EIMFU]"ZDV/
M8Z^EMYGJ/64!K:=KO\S/K4*]6O$0@8TDBFHP%N]^]6%J5-<Q`[/6^D:HKW<6
MY[CILOI.LM.SO936KK76GM?2^M7-HKU,T+U!V?K=6S3++7DU-1[-O<)]Z_>I
M,$@XC$3)F7<&<.3H)AF+\M1#N?CC[1HI&$#+TV#;B/`<%(I?ZFBKY@/(`0A!
M'SY]``!YP(F/Z=6,W=>/CTLK6O;[L-4-K3LUN>A4*$>5&CVZF,*]Q4]A.&<E
M%O8F*LC[^)66\OW#@Z<RV7(58$DU"`F`@$\6L-T6LER'3F]86-INUDHZ6G(!
M]!NUY/7^V:S'.DRO)[7$HZ30DDG]>(\1+,03](LI%@<BH&>,SE>B&4!#D5(4
MY1`Q#`!BB`@8!`?H("`B40_LP/!C'1%IB=:)H@F,>LU*NJ'B`.E7K8CDAA*4
M`-Y((^)!,;D3?AZ!@5#@,"@-CU-S:Z\*<0X*QM$,]:V&HR1S&!-C9(GW58\7
M''ZA8/R**,W90]3M'*I>?7`].E69"VUR+G$$!9B\;F!U&F.556*D6:ZL?)1:
MRA?$!6CW[51(X>("!B#R`>@8%68#`8#`8#`M59&2U:MC"WQJ94HN8(U@KLF4
M/!,Q1<))U^PCX\`*\:Z/]JZ,/ZA9N`-S_@$#`AT[1D1/\[_QI+F7,F)^N_9!
M,J/`<JBWAK4/B;Z\>"J@?3Z^N!/!@,!@<2W'M*<_3P'G^SC`U4=),&Z/]47O
MEZ4P_<+]>=AHJI^(^!07I?6I1(X&^AC*$9#Y?EXA^>!M5-7*3DAS)"80276;
MG\B^/^(B<2*`'/U+Y!Z#^.!V<!@<#D>$O7CCW$>>0`0X]Y/GGGZ!Q^/U#`L]
MUZ9,H[3]08QR;9)DU_CZ2";-=PY;$`MHFO,$UW?_`&A3_$\N1-Z^7/X<8%Z,
M!@,!@,!@,!@,!@,!@,!@,!@,!@<2P"*2@%'Q$2B`&#ZASZ<A@0'=,74B\^5W
MO"Y4D7"S0+L^:$9*N43%:-T8!1!%LB@<_OE:@Z8*J_X9?;]Q3DWZC8$QF\M[
M:BZX:ZM>WMU7"-U_K^ID8'G;++`Y!#[F1<-8N&CV2+-%R_E)>7DI!%FS:MDE
M7+ARJ5-,@F'`CB[*]DKVP>:*N^W]&/\`6_6I#LCJ&13N%ON,6XOT<X9+R`0T
MSL?5\.UDT*K6'$I*)R<;S*OY-NO#&,^;-!.W*4):8N0CG4>U68'3>-'R?WC9
MPP43<-G;9X<RS=^@Y14%-PV>)*%436(8R:A3`)3"`A@1/5;L;/F[F]L'N@]*
M26ZJ9666E8#:TU6;5$UDK2?I]9LA'AJ$M/`6I;)OCEK:DF*\6$E%`BTK:@G<
MG44:(J!)!J#>FK=Y0TE+ZSMK"R_R]/RM1N,2F*K6R4*YPBQDIJDWZMOB-YRF
M7"'4_2XCI!!!P0!`Q0,F)3F"[^!AQN_95]LVR8CK+HN=:PNQ)>M*WO:>P#)1
MTDMI#4[F1<0L3,Q<.^3<1K_9VPIB/=LJJW?$,R2)'R$@Y3639@W7"J=>]0M!
MT8/XFXUU"7F[.T2$G=F;3*GM'9ED7*!14>35WN#9]+*G<J@*@H-_MF:1S#[2
M)`'C`NY<HJ+A=:W-A#1K")9(TZTD;LXQFW8-$`/#R2Q@2;-4TD4P,LH8X\%#
MDQA'ZB.!4%0$!J=7$/H-=A!#^S^&ML#JWM<C6EVUPH?VTTJQ8%#G_P!P"1#P
MXG'\>"@4<"WW6IPW=]=]#NFIO-LYTUK%RV/P(>3=S2H15,W`^H>8#SQ@8`[%
MVWM#5'3O4[;4$K%5^Z;>[>M]$-K))"U^ZK<;M7LY>J_+3==+(0EGBQLC)B8W
MVQW<9)-VX&,N=JX]H$C!X_80>[_66B&W7&[I=W.&HUQURK9H&_WS7UAA)VI3
M^P*O4['%*UJK]0M832S]U%SZWVJR%ECA:."$6$5@**!PS"[_`.]K5UAZ6=I.
MPU(3AE;AI?0FTMD55*RF5+6EK/5:J]D:^C._;J).5&!Y5-(3IIF**Q2BGS^K
MU##:0H/?B$ZOL[6P[,2$[L.&U*EL.<M\G;J9'1DA9F]/?6N12;0B'5)^BM7#
MS9"E3CQ.W5!@8J(N2"7S,%W-8[FLF[ZK\6VV[2A$M++NZD.=@V1K`BN:#;6&
MS=6)VU224/[GNJA')/WJWM>X83E(`%$1$.<#W/D^5(WZW4Y<_/BEV\Z)FY*'
M)@,/<;2:9!`/3Z**A_9@90=CD@5T?N%$I0$[C56PR&#C]\3561(0!X]1]1P,
M`>R&T.QLMW!ZN=4-$7N!HD?9.NVX.Q=]47DOX/99L=87/4%#K=>2D5J7?T6U
M>?*[&=*NDOX>DHY4;$#[@@$\1"G8R]]X],=Z^L5"W3>M=SNHNS[+<E'&KP-Q
MDK4]C++JO6`[-@[-#*2FJ=4IUQ\\"'?-7K=->;,^16*H5%$$#J$"\'R8;2W-
M5:]U7T_H._(:UV%VD[9T?2B]N,HW;/X^C-Z+L?9UX1A9$\7/O(25E(K7Q6:;
M]O'NEFP.1$OM&,"Z88Y[VD^_O7";TQMBW;FU[_EP/:3KAK&S1"-VL-E2L=,W
M7M:IZ>GHN0K4MJ>F1K%R=&X!(MWQYI=9@^:)^R!B*'1,&=.N1#_G][6\AR(=
M:>F0<\!SQ_/7<(0#G\@$W.!=+9L>G)WM%HXBI"=:N](;>CW,'$.DV4O,IOG5
M-2/%13M9PT2:R$BF(HHJF52*FJ<HB<H!Y`&`'1F%E8"V42!D2]@F$E'],_LE
M$>TAI!;>;<&W8B^`Q9W,TO9[F\419M52MHTQY%P4T<5$Q?$@E(`>3\;%4AZ@
MU@HA+3MQT1*$J^]UUM?VVP6VQM(-5;<U,5=L*M-7J4D+3*51HH#=O%N3)LD%
M46HF(U3#@QPS[T<U.UV)V<3$GLJ+[U82"9?(0!1@?1FF6A3@`&$H@51MX\<?
MI``X],#)W`Q15K57LW:Z\Q]DI=?L2*6B-6R2,A.5^*F"H'->=M,A9(KR+1P9
M`QP#W#$((>0%`1YP+WI:GU8B8#(ZUH"1B@8"F2IM=3,`'X\P`2QP"`'X#G\^
M,#T(K7U"@GB<C!TBH0TBBBJW1?Q-;AHUZB@MS[R*3MFR1<)I*\_J*4P`;\<#
M!GY:%/MOCF[6*%,"7CKUKP84_=`HJ6VN%$?;Y#R$1/\`W"/.!&=_3$/&@=&=
MM,P'VE7/<+<\DR0%`[?[AHG4=31CR1;$'R*=H:99.43*%,)063.0>#@)0"9/
MN4R0AM+R&W6#9`EGZ^3L7O2N/S`H06@4LZJEX1.HB9,Y6E@UJ\FH]UR/MBD[
M,8X&\>,#A:]]^CRR#,S?N#UF<@[^U(W!'>&LS**G>&(FU(")++Y%.NLJ1,I>
M`'W#`7ZB`8&2L4T:)S,\_;OE%U9,T:NX9F\@39E08)MFXIE,4HE%R0@G-^W`
MJ3`8#`L@W05U_LQPW`/;JVV%!=-U`<<(QFRHU@J>2;D;J<E12NT$R*Y+[7'#
MV/7.?R.X#`NK#V"%G1?DAY1A)GB'JL7*E8/V4@,;*-P(+F,D#LG#DC63;`</
M=0.)54_(!,4`,41#S;%>Z54!9EMMMK-6-(F63C0L<_#P@R*S8A5'2+`))ZV%
MVJT(<HJ@3GP`P"/I@5.BNDX(51(Y%"'(50IB'*<IDU`\DSE,0QB&(H00,40$
M0$!`<#EP&`'T]?\`HP,:;WMI.Q2]BUCK.I);9LT>4U<N\:,Z6N4RE.IF.(L,
M??[G]N^)&/U(>136+&QK>3F3$63.+=!,Q5A#`Z'Z/[POO?;KUVOVSMNCM!ZC
MZ_V'KB!H%<K4[,3NR8#8:<TTA+38+W.2<8SBUHV+D@3<E90PF=OF)_(4DSE$
M`F'P&`P.)?\`X*G_`(!O^C`U7-0D22_J@-SK>XY]USHJ\-_`BB/VP%2UKH1<
MWO)B7WRB/Z1`>1`3!],#:7C6RC9-R53QY6?O'!/$>0]I=8QT^?0.#>(^H?A@
M>C@,#@<_\(1$1`"'14'CU$03634$`#\1,!>,"V^G$56^NX5%;[?W"/;,`@U.
M4Z`%&U38IE(8I2AR5,0`P<>A@$,"Y^`P&`P&`P&`P&`P&`P&`P&`P&`P.)90
MB22BBG[A"&,;TY]`#D?0/K@:O?4'M!I"I?,[WOU=<=D05%M,1;[7)R3>[OHV
MJ1;Y%DP8J)I15BG3M(R6%%A<8Y?[1LY%X3[D5%$O:*!@":O>NP^E>^-3[-T]
MM?=^AI77VSJR^JMA:O\`:=`!,T4_8B@X>H'6FS$0>Q:IO?;JB'^&X3*(8$>6
MAVRLKI*@:'[H?(#U@L]'U:_;1K:NZQV?3/YQW'3]?W,KW5UAVWLJ<EOO8QPG
M&1D:#^*K;)@L=9N7WI90#+)"&4SR&^-IJDNB;?M!K-5<K@X<42L]OK35=7.B
MF4(!FPZY@=JQ].19+$#@S1!HDT.41`R/B)@$,>ME;%U;HNL;;-T6[<].(67N
M!'KQ/K_>]F:YJU&KMX<U1I!LIW4UWKY#OJ).-8:(;"TAYAK+UQ8[9-)-.,2.
MJJ`7RZ67/I=U0T57*0Z[4]=YF_/D"W'<U\'9U$1D[[LZS%!W9+5,O3S1GKWS
M=+`S8"NHH*<>V1(4?41P,HG/?CI(S!N+GMEU[2%V"QFQ#;9I0J+D;F`JYTDB
MS`J'32$?4P!Q@1(O?D9A=0=@.R-MU?)=*-]1&X;_`%:RQ=ZEOD&UKJ.9A:/6
MM;4RB52H.JE,:WM3E)"-FXN9>>:;U1$RLHHH4I3**<AZD[\UMVKD#-6*6U#T
MS4B(6#GYM1.!^3[5L[89-.!:JKJQD#"MM+I*R<Z^<%(W:H`HF59PJ0@G*41,
M`9W:4[\:9[)])@[.OWX:8K-MUUL:5>UK;MGJ,39JDUJR5EA9->Q&:3CN.3:J
M'AU72*I#_P"*U.0_'`A@9WZXE8R=U]19J%D&<M$2U.K$E%RL:Z0?1TE'/X1B
M[9/V#UL=5L\9NVRQ5$U4S&(<A@$!$!YP.W=TR*TZUIJ>B9ZU/D.(``F*!HEV
M43%`?3R`HCQ@6WZS^R/7;0_V_E]O_DSK'V/,H$-[/\G1/M>1`$0*()\>@>@8
M%D+QT;KMXI#[7+G>6]H:G*7-:_P,1$.-/>[2;8-Z<;&CYFFSTGIV2M,+(P5I
M='68N@?G=H$_P_=,43`8.G*=,;A<9MXZV9W"[&7:KQ]TJ-PHU**UTM`0D&K3
MFL8\BF]N18:F5:;'51N+(\L07R"30J@-BF;'4:E7.%%/M5W3;VW.Q_7R\=@M
MH3FN4-5:A?.*S)UC1,M&/F&TW>W8JT,)-K,Z:D&<JQ>(4U$@-U4O;(7G@`Y]
M`H8OQHWDD3%:U_\`/".[*O7^.UN:@N-5*V;3AIF4*B_8I,4GFS@TX%L-54J>
M@M#+QXF,Y=(*@H=[Y%$#!E?5^K,37+/J:P*WVY2T?I).8;ZWI1FU#KU*KS6;
MJ+FC*H(0U/HE>-]O%UEVH@R0*J1%'RY\1X#`L+\K*OV_5*%<\B'VW;'H@MY%
M_?*`=T=$E$2>H?J]<#.6U0]?V%$W;7\@_,JG(P+F!L#2,D"-IB.C+5&2$>!R
MG\5CQZ[AL=19NH8@@8R0#P(`(8&.MVZ=1%VF]?VMSN'=L1<]8'ES4Z]0%BI,
M;<X]C8((E=G*RM-J:Z>_?U&79$(X<1[A-1L>2;H.O'W4DS%"GM1]-K33'M8N
M6U^T6]-_[6K%>G(%A=;J.M86,C0L$D+Z2DJI2J]K]"(J$T]CT6\:X=MUE5EV
MC?Q,;P.9/`H:L]?5.SFO[3$;:W9NR6_D;L9L9.JR<3*T&N3U9EM2;AF3T"=K
MM@B->I3,-.5I.*;H%=M5T3.VY3IN"J)K+)G"M&G2![)V-I-[0[4=D]NQM8V:
MPV5KJI6V7UJTK%1<P\$U804?*1D%K6.2OBD!/F>2[%W+`NJU?+MU$P*LQ;+%
M#)BIZ=JU0V)>=J-'5@E+OL2N4.I666G)E9^F>NZV=7%]4XV/C4TFL9&D9/K]
M*K*G21*JX.Z_Q#&`B8%!+G*7<U)3$/U+4.^<>GH)$YBD&,4P_P!O&!90I1_Y
M]GY3<&04ZA0Y?9'@0,<FZI@!.)!#Q$"E5#U_;@53-`HV[74TB1W!&+GKWLQ1
MTDDQ(9D5VUV/J@S-=W)>R*R+M8'2I44`/PL4%!\1$F!XG7VSU^8VMV\CX:;B
MYE[7MYP49.1T7(-)!Y`2)]':C6^QF&[9=4\2Z5)^H$E_;/\`7DH"!N`RR(<#
ME\@`0_88/7T_L$0$/V@(@.!9:T:LLDGL,^PJGLN<I3Q[58ZIS$6T@ZM-1DFT
MAG\U)1#TX3L0_>MG;-Q8'(>*"J2:@&#S`PE+P'XE0=MEX]W>\PKQY<\4.@$Y
MY$?'Z07IP&`/K_;"AA#_`#[GT$Q]0%O1-<BL40`.``SBNKIB41^O).?RXP(^
M/E2U[LTGQ^]E3R&]I1]%-:G#O91I*TFBHI2\6UN=8<.X9=U$P3!:/2?I)"D*
MZ)3+D`_)!*(8&,OP'%?L_C0UO98POBK5MR]D_NF"`J+&D*LOM267F(Q%0Y4U
MP72,(.TA-R(N$./]L1`)_4P82\<@H8K:08O6Q%R>8%<-G"#I'GGA0#%41615
M$.!Y`Q#<#Z#@1L?*IK6DC\<_;UM$TFI,I%?3%A:Q;EI4H155F_769(L'2+<J
M+/WS-'BA%`3!5+S\?'S+SY`%X>DVUMG;%H<U7]S2<'/;7U19+!K39$]5:J>E
M5Y_;*I/24;[[:L*RLPI!JR5?38/_`+0'"Y$TG9%$S^PLAR&._P`BO;K=W6S;
MW0JDZ@7JJ,/OSLM!T+;`VFN+V%PZH#JW:SJ3V+KJR,Q%!6I1=;9`+EDC%=E1
M^T!/V#>[Y$"5P@"!"@(B(@4H")OWA$`#D3<<!R/XX'U@8Y=N)1[6^MF[;M%-
MWCF<UWJ^];%K1(YRFRDB6FBUB3M%:6CWRI#D9NB3$6B'F("7P,8I@,4P@(0<
M?TZ5RC[OKOM)LX8:(KLYM*_0>S;Y#0BP.F\=?+=<]VR-E;/Y!04UY21BR@BU
M,]=`#I9BU;^X/B0G`6C^?.,JF\.GG8#?:E;C;)3M+AJS5FI+T\81\@G*6N=V
M:E/;<LE*E#BOYP$:]B(:O*O6G@1TX9OT_=5(CP(;,>FU`/JW6_J(F'7E%4.(
M^OD8]6BN3"(B(F,(`'K^S`N;@,"UFY)R?@-?SZ]67,TLTDW;5RKO@3;JIQME
MM,BSK,+)K)N1,DX+&/I@CKVC$,10$!`WI@=[7M(K^LZI%5B*,LX(S;@H]EGB
MI7$I8I=83JR]FFWGER]G)Y\H=RZ6-]55!`."`4`#CN*YFH1]I@DT9%S`J)_Q
M5)LL0RCNKN#`I,-B'3/P+MN@F#MJ0XA[BB(D*/)QP*^9/FTBW2=LU`6:KI(K
M(+D$IDET7"*;A)5(Y3&`Z9TE2B!@]!Y],#MX#`XE_P#@J?\`@&_Z,#4ZUV_<
M(?U3^Q(]!-1!!YI*[@Z<!S[+P?\`)74;@K7\DUDSMDU1^OD4@#@;7$9((2*3
M@Z'N\-'SR/5]TH%'WV:HHK"3@QO)/S#](^@B'X!@>E@,#A<?\(WX\B0`#]HG
M+Q_KP+6Z2370UQ#HN2'37"6N1C%.)3"`'NUB.3D2F,'JF8!#U^F!=C`8#`8#
M`8#`8#`8#`8#`8#`8#`8'"XY]A7@OD/MF#Q^O/("&!JAZFZ$=8=Z_,GVZMN]
MM=OMG2<]:MA2:-5NTR_<46'5,SC8-M8ZY78XT>>.G'4!4628O!<K`JW=K%.G
MR9$4@D7W)\3'QY%V-USA&W5ZAQ,19]F6F'LC"-D;;')66-;:8V1/LHQZLSGT
MW)VK.<AVSPI0,4`7;D-]0P*/[*_#3\<5:I]+M%=ZS5V"DX?='7Z(,JQN.Q%4
MI*NV;>-$KMAK,HP?6=Q'/(:=BIM9NX\TA6!)0WMG*8"B`9?H_$_\=)DDB(]1
M-/D1147%N0T9,#[1A]QNL8G_`*V`\/<*!@'C_9'`^S_%!\>(MW+(W4731VKM
M;[AT@>+F#).5_#P]Y<AI<P**`0>.1Y'C`^4?B>^.QFU513Z@:7(V4]PZJ(0\
MH8AS"4?U"!Y0_P"L`#T'ZE_#C`MSJ/XKOCN%E<`+T_TN95ILW83)-=S"/7KD
MJ+2SOB-DBNG;]9<$4&W@0A`$"D(0"@'B4,"[X?%I\?"91(3I]HLY!+X>*]8]
MY,2>95/'V53J$``.4!#\A#`M3V)^-[HQ7>O^\;%#]5=+PTW7--;/F8.7C*T1
MJ]BI6+H\Z]CWS9=,R9DE&CI(JA1Y]#E`?J`8&)GPI4NDWCX9-4.9VJ52T2$G
M5>S31Q)V2NQ,NN]:J;1VO%_;N73QLY<K,P;>*`%$Q@^V*!/W0`,"=/6,?'Q.
MM]?Q<2P8Q<7'4FJLHZ,C&B#".CV36"8(-63!BV(FW9LVR!"D323*4B9"@4``
M`P.S?DCKTFW))N!:'4JUC(5X"H)%:"I"ODP<F,8JA.$!/Y!Y%,`"'/'I@19]
M9^]<\RZYZ&C8SHK\@-I08:4UBT9V%IJK52+*SBUID.@G)Q[R7W7"%%E*)I"Z
M17<)M4CI*$$/$QBD$+KG^0&_>Y_@_&W\B"R!B>9''^7^CF_D/NG)[9FSCL*D
M[2/X$`_ZB`'!@#GGD,#M(=_;NJ=4JWQS?(>W!,0`APUOI!0%@Y2`3E_]N%*(
M%`5/QX-P41XX]1#'FD]U+@S[9=@Y]3HEWI7++Z=ZU1Z<$PUOJ-Q.QX14SOQ=
M22F@6W@W;-FDBK*B@S!)=85#,US&*3@OD&2G_/K<Q_<^.SY"S_G_`.TXT,EQ
M^7_&[')\\_L^F!\F[X;"'C[?XXOD#5^OE[M-ZZ-?'_=`/>[+!Y\^OT^F!@9\
MC?;79=YZQH1,ET$[E4ENCV1Z92G\9NB/71E#F5A.V^EYIM%%4A.PLR^-)V)W
M')QC`OL>T:0>H`LHBB*BR89MLNY>Z4Y.7>)_&7W:2*\%GXN"GZG-Y!T9`B_D
M1^<_9_VE46XJ\(>(F\2F-Y#R.!ZW_.OO,?0/C2[NB(^@`,CU'*`B/H')O^9O
M](?M_#`XS=S^P`\^W\9'=,X\#X_^Q9U"2*)O7Q`3'[0AP41_'@>`P+#Z#[7]
MB8>LWM-E\;?;*9(^WAO*8.Z:7GJ1%`1Q)[.LKE:-=(2G8:,7_B48J;V')RIJ
M('6(8R:JI!`XA?1'N!VB73,*?QC]ID?U"3Q?;?Z:M5A'Q*/D0O\`S&+<D]?0
M>?J`^F!^#VV[8<^*?QE]FC`/XFW9TPYY_L#?RJG`?L`?[,"F8OL]OZ6W+7B6
M;H5V!J$K&:UN+^'AGFS.M,U)6AJ\N&O(F5-&*0NX%*^T"O)N4W+C[]ZV643.
M!6R:P^8%#]USMO8-S^152+MO7+;.JF9NGJ)V,W;9C3\K'`5+<CA1]_%#4/9-
MLD&ZKMS]LBP3*DKY@5RHI[!"D,L&7<@<@=I*ZB"J)5EM"VU0J0NDP6.DWV)1
M_<5*P$X*+)HF5*`K`4?:,H4.?U8%*+](>K!;M==F1&DZ95]D;(G$;-L&_4I.
M4H-TNUC014;HS]GM%(D8&7FII%NL<A'+E154I#"7G@>,"R6Z-F;*Z0"TV/<[
M5,;8ZI2EMI%4N;^SO0'9/70;I8&=83V+(6Q!E[^QM.M9.303D6SI$)Z(6637
M(\<L_?(U"1-J(F0((^8#Z\@HH"IP'R'DHJ%$P'X'Z#^(8'8P&!'/\MR"3GXX
M^UR*W/MFUZS,(%]?(4[=6U2%,'(<D.<@`;_JB.!AK_3JN`>_&K5#E!,JB.[^
MQZ2Z10#P!57:,DX,DB4.?\(A5@#GT$`_#`F-JA@J$\\I#I^FK&.2OIJDMO:6
M(LRAD#M2RM?,<I#-G9H-VZ*J@!1*H1DY(4Q1]KR$,-?EY=R3/XPN\4E#/5(J
M98==-@24-)$(BJK&2[&+%W%2*9%2+H*+1T@DDN0IRG3,=,`.4Q1$HA:[KC9=
MQP.B=&=LZW4C[8-V4TUH+9':.C4F,BHG8TC?);450C7.ZZ(U]V%B+=8EXR-0
M;SL,91JN]8M$%(X0<-P:.0C)^8C?<)>.YWPGU_75OLT>N\[CIM-@5I[5YRL2
M"\7)7_K^_BXJTQESK\>^8IG?09CE.@4KDBK42D.!1,.!M3!]`P&!C'W3."?4
M'M(8W(E)UUW8J<`_$B6MK(8P!ZAZ_E@:XWQ+0?636_Q\=2]S;VL\K'4OLXE?
M=46FE*66R,:W=]F:YV]NPE*7F:350%];2S-23=Q<DD[.M%?]D9@X2$%`P,I?
MG!V5I#:7PZ[8<ZDDXI;7K&ZZDI0QM=CW-4&MG97>$8)UAW6QCF$O456C,4P(
MW59(G(U.F=-,R1R"(2!_$3NC:^^N@VC;SN]O&$VA&,;-K2V2,*DBUB[&]U-<
M;!KIO:6L>BU:$B1L,=7$7)VI2B5%0Y@`1P,@.Z<_NZ`Z\W7_`);;-6Z?OB??
M46FZLLEPB0GJM"VNZ;#JM80?SL.+*2!Y'HQTFY,<!;J`7Q`?3CG`P42TQ\XJ
MI$T77<WINV*4W)W;#1$ZJ\.4#`/@8CM@+(0,`<")4R"'/]^!1>R^I'R_;AJJ
M]!V/VRZ=VFC2RL>K9*W(Z(FRLYC^&2["78D,K'-8V4:*,GC`BZ2K=TB<%2%Y
MY+S@8ZH_$_\`(>FDZ(&\^C!0/Y$CB&T'=W9(T@+B9,Q#/)A85Q.AZ&((%(!_
M7UP,.--:+[-]/OF_Z1:ZW5N2J6=UN756R925@]!,[/J_5<I`UFE;28P:-[H9
MW2<3=9^*>0Z"C9XZ1.=(P`<!`Q`Y#;"J2;NFV&0HKU4%(>05<V*CK`/B+>-6
M<@I-53D0(90T`_<^\W'DQC,5P*/_``A#`NW@,#B7#E%4`^HD,`?WA@:H-"<M
MQ_JD[^W$W^*36-C]I,2#^E13KE0#KJ$-QXE%5)$@&'GD?`/RP-K"+9?8INB^
M*1?N)!Z]_P`+Z#]TL*OD?])?\4>?U?7UP/3P&!P./5(?_"3_`-'N$Y_TA@6D
MT*8#ZQB3!R/$_?R!Y>H@5/85J3`O/(^A0+P'[,"\6`P&`P&`P&`P&`P&`P&`
MP&`P&`P.!SY"W7\!`#^TIXB/T`?$?K^S`A`ZROFCGY8>U""383K-T)`HNA<$
M7^V!)(&AVXI%.<C(%A;@)2AP8Q"AY@`AQ@2'[A77#>76$JJAA03WI/(MTU#F
M%/P6ZS[A,<J1!_2"@.!\AX_MP/9[=PH6+4#2'&1EH@'.X>O!OXE!/OX;,,U&
MV^=<NV[B.>B@Z30<).$""`G24(/'!BB`B&!AQVHL&Q]%6/6E!U?-]C-R[#V<
MY.NQCYW?U,U;3XN&)>*#KM1PYM*VIK:^<2XVO9\,4C)*-$GV1W"YEBB@1)8.
M-Y;-_P!"4UJQV6YV+K78LENW0+)&*:;NB]W:ZNFM+5N76NO[PR<3#K5>NWC.
M>11M?V[IH>.1$OW8.6;E4I3`W"6)0.4#%_WBB0!_(3#X@/\`KP+6:G;G;M[R
M4XE$3;3V&L'CS^ZXGE7!`'D`_4!%@`?V@.!=K`HK9%6C+SK^ZTB;(HI"7.JV
M"HS1$%S-G`P]FB7<')_;+D*<4G'V;\_@;C])N!_#`C;^.#253ZO_`!5Z0UK5
M'LY+PL7H.Q6U25LLFU6D7$M?6T_L"R*.7YTX]BU9A.3SD40$I$VS4I?(1\3'
M$)+*`7PHE*+YD4\:E7"^XF;S(?B'9AYD/_MD-QR`_B&`OI`4I-O3,`&*>K6,
MIRF]2F(:&>E$I@]0$H^7TP+!=)U$9#I]U57,D4X*=<],JC[R9#&'WM>UI5/G
M][D2E-P/[<#*7V$.3&]E+R.;R.;VR<F-XE)Y&'CD1\"`'/Y`&!T6LG#2#N5C
M&;^,>OH5=LUFX]L[:.7<2X>,D)!FWE&B*AUF"SJ.=)KID6*0QT%"G*`E,`B&
M*=&:"'=?L8X!H/VA]!=8$0,9+Q3.NE;NR!A\2G*!1,1-;^WUP,HQFX7^)E@S
M.V7\=%B,H$'[J!I@(H'!6@RH1G/WHQ@.S`B+@$Q1!4?#R\O3`])/VQY$&IDP
M#CU%),!'\N`()C>G]F!'C\I!P:]68Y\F5D"C3LYTG4(>0]LK`OEW#T<B;[D5
M"F(1,Q%1_4(<`/'X\8$AH(I^ZJ8Z9%`,("0!*!Q`0`?+CR#T\A_+`^#'0)]&
M2AA_ZC8H\<?M]``<#S(6QP-ECFLS7GS&P0SXJIV4S"N6DM$/"(J*)+&:2;%5
MPR=%262,0PIG,`*%$O/D`@`6IZ_$.E6+N4Y!*4=W;P,D4!(<`0/L^S'2*'MF
M,!`(4WB)1X$H@(<>F!=J)GJS932P04S!3YZ_,NZY.EB9&/E#P=@8)MUWT#+@
MS67&,F62+Q(ZS5;P73*J03%`#!R'L`BB40$J211`>0$$R`(#^8"`>@X%B[$!
M`[':U.*0&$VIMIHJ'%0Y?T&M>JE4A]L`\%#$62_VOH4QN/J(8%MED!_Y^(]4
MO@!/^4*3)X@'`^1-U0J@CP`<<>)AX_:(X'/9[A!,.[.NJRM+L494W67;4Z[C
M3NHA-PG&$V;IYC'/7OO.R2K1LL].NFW\4A;.#D6%0Q3-T_(,-=N?-GU&U?NW
M8>A(B'V9M.\:ED6D-LA2GJ:EJD!6IMT#OW(=O)[JVQJD;6[C_MB?=*0J<@T;
M&7(FHL57R(4,:MW_`#/:&VCK>9H4?H39[J/M\G`5RP'MVR^G,175*P\F&AK(
MWD'"7;`JSI-W$-W+<S9,WDL502FX(8V!FIU5[_=6(OK?IMGMCLYI2IWQE2XZ
M+G8"U[FUJ_M4<I$F6C6#:R/(.VST6]L18EH@9\HW>.DSN1.;W#<\B%^5_D5Z
M'-R`=7M_UV*4?H/^;%-$`]>/U"$MP01'_>$.<#RE/DP^/I$YR+=R^N"1DQ3!
M3SVW3/T"J0QR>7C+&$/(I1P,#/DS^0;I%L;HEV'I&N^TND=@7.VUF*K]7J-,
MV!7[+8K+-+W"M"2'A8B)>.WDB].F!C"1,AO%,IC&X*4P@$:?PNV_8TOUQZ_]
M<H79K[3U8NFX.VMHE+!%E>(3ER>I[%NB+&#KDLP=L%T2PY*P'MI)K-A<G7%4
MPK%3315":SJ;<MM;5@]XU&RVYGL"=T#M8K#5&W'!08JS8MH]V]3K5E5%PX&5
M!5D=1!1^)A66A9=O[P&<MS*'#T_E`LD=</B@[O2;9!XD"_5?;A'C%Z44GT7*
MLJW)-)&+?'(`%0E(B5;*(K`7@2*I\@`!XX$;/7*Z;5WA`=,.GU:W=/:*U8GT
M$ZY6QK.4R3?1=]D;+,Z8_BWV:LVR<P4F=&%9UY91LD5ZDEX-7RSCW5!8@F&/
M'8[8^R]G:L^*938UW0VE-:O^9C1U";['(9$LM;X!A72RL=*V(5"I*GGRI3?M
MG.'BJY:B@JY\W(KGP-NX!]>.!]/V>F!BE1-WV>Q]Q>PG7Q^VA0JNJ]+]=ME5
M]ZW*H%@5D]O6+>D3/M)8QG8I*,&B>L68L_!N3Q%14#*'$0`H>OW+4:I]2>T!
MWJ:BC-/KMNXSI-,I3**-_P#+2S%4*F!S%*8P@;D`$0#D,#5:ZCDI=<^&KH5O
MW8L?-2&C]1V_LAKK<!F<9'RJ57C+CVAN24=M9^^F';6!AX6C6V(82:TS(+HL
M&:[1$SDX)>7`4KNNWDWK\4/;'N+(UQGK:B[QW1UFB(2M(1?\';NH_6VSI@ZV
MRTX%H9PUC:KL1K<&[R%%`I4'$<8JZ7N-EFR@A/\`_#F\:5WH'4G,FY0;1379
M78-Z:7<RB"L>BP#=U\,HZ=2CD&;1JW2\1$1.8``!_MP,L(^3;]C;U#RD$J5]
MI/5DR,RRG_-X5ILC:#(RC>(7K:AB%0F*+0&YU5S/P%9K)3JB7VYC),#F5#+?
M`8%)VZ]TR@LVLC=[76J?&O7B<>UD;3/1-=CW#]5-99-DB]F7C)JJ\.@W4.5(
MIQ4,0AA`!`HX&NKVFV+2+?\`/]\7#ZE62K79I_DUN2*<R=1F8FT),'9Z[MU;
M[1X\A7+U)B(-U/=X4,7DG(AZX&Q!>(%[+1@/8;V4[)!'&6KCE=02$3E&R:@%
M;*#XB!6DHW44;+^O`IJ\B`^(8'IU*QL;9`L9Y@5PDF]*H#AH[3.B[CY!LJ=I
M)1CM$XB*+J.?(*(J%Y$`.0>!$.!$*CP/A0.4SA_U1_Z,#55IRI$?ZH2W-P9H
M>3K5=E5%V!C%6\D^O5(Y\B`4"&'@`+R(\\#@;3T>O[Z:X_K_`,)XZ0'S_-%4
M2#X^H_H]/3`[^`P.%<ODB<OD8O(``&*`"8HB(<&`!].2CZX%G>OZX.-8LU`1
M(W*%PVFB5(AC'*4C;:ET;D,`F`!#W"I`80^A1'@/0`P+T8#`8#`8#`8#`8#`
M8#`8#`8#`8#`X7''L*\_0$S"//KZ``B/^K`@&Z3HE'Y5^ZRP&(DJ%XO(+H'_
M`,-=PFH^<$;."<@`.$2@V,'("/ASP/&!*GO7A/<?4(3H!POO>TA[P&2`2^UU
MRW**1S`)@.)C*`8GIR/`?E@57V-;KOZ37H]NQ-(@XW#HL[IN5R#,X-VNW:6]
M.LFL8Z?/VH-`5,4H\G`HE`!$>,#&GNKJ[?,_L#0&V]%ZZBMKGUW(I,;/4E+U
M!46=+$'W)H;:RDM#N[6@2O2158O3KN,,DJ[;+).9)NN4%4TU2@%!;VIU]W,;
M0F[=Q:)B-2V73?8G1C#7\),WJ%OESAQN78'3S.UVI&6ICQ:H1S24@HP&"38%
M'CU4BRICBW``*J$J!@Y)P'^^'^I0/^]@6KU4=0Q;^51-4@%VE>@3,IQXJ$_B
M#<0,GZB($Y'C^T!P+L8'1D0\FIB?[YB%_9ZF#Z_LP-;>]L-DPZOQB6ZIWG<\
M#3VW4OL#5-A42IUN]V'2FQXLFI32L0QW$YAXP],JQ8:;8HO8YS*N"?<)(+M@
M)[*IU4PV)M>"4U`HQB>'@-/K(E]M0JJ?B,*R$O@J0ZA%"<?0P&,`AZ@(_7`[
M-U$H4ZU>7'`UN<`1'Z%*,6Z\C&_ZI2\B/[,#'7HH[:/>F?5!RR4(LV<=<M.+
M(*I<>V=$]!K_`+?B(?@0H>/'X<<8$3':&Q,->](-;[.E;Y9:2XW'WC@]'[HW
M"O?]CI6FKZ:V1V^N%)O$E3K`TMB8T.PQ]2:ILXV3:H**1+</%FDFH")T@X>T
MTGT'ZZZQMN^.KMJ+6NPRNSM&RPO#['WP]1W),GO=-UC_`"[MEG9+9]CL]D\U
M_..H]%.546<(`FW.V535;H&(&?/?BOUOKAU*[B]JM2T6JM-Y:[ZR;#M->LDD
MSEY;^)2.K*E9K+0HVPM$9A@K.P\-*.7"B3958$TS.51#]\X&"/BD53XK3=:J
M5LUU>F$GN$G6>/!+>SG9N\YO;:KIU66^P'SE+8+N37E748K>@"6!H?SBEE2E
M`S44B@G@9.=;K/(7ZA_$QN]^=K%W?L#7%KQM)6GO)J(J]HEK;U`NUT<D4K19
MMW$&B$YM-!VBU,0Z39TD51'VS%Y$+_\`RBJJ->J1'R)P249=D>E"HJ`JFDH!
M%>Y.B&YB)'6,1$#G]W\1`>/IZ\8&66^'JT?IG;;YLNNV79ZMV*X17;**(KHK
MMZA+K)+HJI*)*)JI*)@8IBF*8#``@(#ZX$)?9J)T%4>[7QZ:9VLT3@-&;/T-
MV!VB^@HDFU`D-A[MUFTU*TJ$1//J/+.Y&PUAC5KY/2BD$JB9FJ\9H.UQ.#9-
M,P>K)073+6G<WHQISK!KFG4>!W"]W;1MJ:^@M4[1J=7=Z[JVJ;)LFO2D+`JL
M*]5JQ)1.QV+8CB<01,)4Y,6CKU?(&(%Z>^FAM#:CI77R(@-?U77^O-M]S]04
MK=SBLL;%&2<K3K@_L%CFF[.7K,@VE8.0MEO@F+=X];A]XX3>+HIG(HZ,H(4E
MV:U)T7U52J3;]+ZZI=;V&IV#T+!1[-M5[A_"+O\`YE[<I.NKQ$7"(D6P0=I6
MEZ).OS%7D`,Y;NVZ#E%4KA%(<"3/56NZ+K+:^T8#7M5AJ="NJ3J.5=14"T*P
M8+RCB9VZS7D#M4A]G[M=HQ02.H``8Y$2`//B&!S7AVY8;]UZZ9,3RCU+3>Y5
MV46FNDU/)/6T[JX[1@5RO_@-SO')R)E4/^A,3>0^@8&.6C]KJ[J[-4/93JAV
M[6;VQ=1K:WD*/>"Q`62O2T!O:%A)IB[4A)*5CG35*7163;KD5*9=),%#))";
MP`,L+EH+35[O<7L^Y:JU[:[]`U66I</<+#4X:9LD?4YMZQDI>MM9%^Q<+EAY
M%_'(K'0$PD!1/DH![A^0UK/CRZ5=4^P??;YJ`W-HFFW1"B=JH.N4V/?LYV%:
M5:O69A=W<ZW@V4=,LVS8TS(M?N3JI(I#[G!DSEX#@)$NO/Q8]&%YGL"SLO6'
M6DPPA^P]IA:2#U.P/?X13(^AZ[5C80JCVPN5A;LY9Z^4`#>HK*&.`>H&$,EG
M?Q/?'6^*B5WU%U"N#<3BCYQ\MR45.?,1,$IY&Y$1^O/&!UD/B3^.-LH=5#I[
MII,RG'N"$9*B*H@``'N@:3$JGB`>G(#Q@6#W!\7/Q[1NR.MT>VZC:=3967:]
MGA;`U3AGA6\O%_Y'[3F$F<DG]\(/4&TI#-7*13<"FX1(8H@'D!@Q7^6;XY>C
MFB_CVWUM_3G6#4.MMG45SJR=H]SK5>68R5;GG>Y]=P)I-F*#](/>6C9)9!8/
M0%DE3D,/!L#6YT2U^27;O3:)U1H30KZXT+7.]]B7;4>[J-J6[V&Q56U3$DNW
MO4&]?H6!Y5+"1L=][`Q[^+?-&YD&JP<N6R2Q0DWT!V"^;#K/J:HZ)TOTDF8R
ML5""8M335OZY[.G):QV)"(2:R]JMT^\N/\1L$E,RB29E%3+@<&J*2")$4TRD
M(%V.RG:+Y+]Q]6=UZ'L_QI;4B)CM1J(-0W:P0K:]-HN*VC;JH\@KWL&EU<:F
M]>LTI]FW!9K'KNA*BY:)&%<ZASE4#%SMU3^XO8?KA3>O>@/C+[.:#N6H(K6%
M7HFVIA:3OLTPU[`ZM1U=*U*TUUW0H1M8`M5)CVRI%WKE16*FVJ+Y`2*I@4P7
MNW2R[77W2/2O3>M_B#["ZV)TM[)Z%WUKZ2_G:<E331];6`DAL)E<'[NLJ2<U
M*[%B'+[[F0>.'*YI%P5P<3F+P8*ZV5V@^>6[WRZWJF]0=KZ\;R]HHTKJ6KI-
M[BO#ZUK%=_@[BQ5BQPC9U&56]+WM1O(?Q%W-1KPZ/WZ9&Q6X,DQ.%<6/>'RX
MRVXNV>X]3?'K=]8;%WSHC3FE=?6F8=*6`FHG^I'6WIY&\N6TW#L&.P?XA)[1
M,1!E_P!C(V4:D,852B(8%MU=W?,U4]9]FHS:W3>_6C3NQNM5MITA$6>^6"0>
MZ\L*M5M#2T;=_FF\V2Z2SE):MR'_`&R$9@V8*.FH."$2,<Q`"TWQ8_#C!=V/
MC?UM?9SM_P!C:/0]OO\`:IK-H^ORQG6J_<8[@ML++(FK$C.N8E_'61O"`L[;
MK(&05<N%%C$%0?+`P_\`F'Z/C\959U#2J=OO9^T-7[?K]S/*4R["9&LU9'34
M168:B!'UZ.D7,5*J1;2PMT&95T2(QZ$<D#<J?'`!N7:'ZJZ,<:=UD5W24I.'
MD:Y![%6J$W-668HR5QO3%M;[1*MZ3(3;BL%"4L<HY=BBHV51146,"12E'Q`,
MY&[5JT11;-6R#9NW12;H(-T4T44$$2@1%!%),I2)HI$#@I2@!2AZ`&!SX#`U
M>OZJI=:.Z9:&G$F3:1_@78QO)J1[A=9$DFDVUI?%5(E7[5TR>&9R(IE37^W5
M2<%3$3)J)'*!L"P_Q+4G333Y':W1O\INK"UKKW7/:F]J3L+K;9.P3E*C2U8V
MQ'Z,E*Y/?YI;+N-=MK2UP-O=NVCIJT3]@`_0J<GB(AM^&*!@$I@`2F`2F`?H
M("'`@/[!#`MH[?IU.YLFSLRH0U[=_;LE"@8&T?;&S<RR3-0$P`$B3\<V.8IS
M#XF<-?#]Y0`$+E@/(<^O]^!\*_\`#/\`^".!J=P;DJ?]5%(-A]]$RNI[""9T
M?,6KL#=:X=95N\)XF*5P06Y3IGY(`E3\1`P\"`;2=,L]-LA;,G3[9`6L:[<9
MZLVK^`S<?-_RU<XTZ"\Y4IO[!RY&(GX8'B7W#%?VW#<%2>9"^0<A6N`P.LZ)
M[B/A^H`%5N)A*)BCX%<)&/ZDX$`\"CS^''U],"RW75P1?5Z!B%;D\+]N5L<K
M58ZZ0*M-Q7QNMY**%*(.!52'W2`'@FKY$+^DH#@7RP&`P&`P&`P&`P&`P&`P
M&`P&`P&!\*$*J0R9@Y*;T$.1#TY#GZ8&HOT"V#LY_P#/KV@B9R^/I"G6>6[>
M#_(/\-;_`,$@UJ-;Z/&U%W#RH-B/RJIQ;V0,\(HH*:KAZ)@#]!1P)4XZ[/EN
MZ^R4+=9W!H:I?)17*W4TYZ4!.+@HAQ\3M0LBL%#"^639QK9Q8)UX],D42`LZ
M=**!Y'..!(IN:Q0,G68-M&6&M.)8=FZG5B683T9]R[52V%65%$$2E66,=P9#
MW!(4H")O3@0YP+_H@'M%X`O`AR'B7Q*/(\^A>1\?K]/SP+*]@]:VW:>NTJW1
M+1$4^U1M\U;>8F8GH=W.PAUM<['J][4BY2,CY*'?K-)A"OF:B9!TBJD94#E-
M^G@0X/X/V*",40+:-,!(@9(R"IJ7>CL0,"ON+&50_P`P"N3%'U\2@KY!^)A^
MN!4NJ*E<*I77*5\FZY/6N6L%CGYA[4H22KU<!2:EW3ULVBXF7F[%)-R-61TB
M*G6>+G65*8P>)?$H![&QMET74E1E+YLBT0U.J,,+4DA.SKY%@R3<2#E)A%L$
M#*F`[R5F)-RBT9M42G<.W:R:*1#J'*40QL<[1[+;(:6-34>D*]2(I5BY)1[C
MV+N\M5W<P^,F)6\LZT_4Z[8+1%P:)Q!8B4H]C9%=(2@=LW$_Z0Q)I?1K<%"Z
MY=?9+=_9&<F=N=3-#[@I4@WT[',8+2VV6T_`OF4?+6^G7N(N%G//Q=:9(MB.
MHV2BW'NK.03,1NN=`0E*UBK[^M=>K\*%]ZCU-7A4I2*A[D!'GX5(3]!5`Y_4
M`>@#],#T;J`#3[6`@`@-:G@$!#D!`8EX`AZ_@(8&,7Q^I%1Z1]1$TR$3(GUH
MTJ0I$R@0@`.OJ^?])"@!2A^K_3@=W3>NZMM#KF^H>U*/5YRO3>P]XIS52=-4
M7\&4[??FQ';!RR$"E.TD&#I%)VU=(&2<M'9"K(J$5(4X!7+CJ[H5X>$/):WB
M9M.O2T3.Q32Q/IRQ1J$U`.T)""E5XJ<E)"-D)"%DVB+MHJY25.V>(IN$Q*LF
M0Y0O5,PT78(N1A)J.8R\1+L7<7+14FU1>QTG%R"!VLA'/VC@BJ#ED^;*&353
M.4Q#D,)1`0$0P,=(OIQUMA*<AK^'U#4XNF,UVZ[*NM%)HD8T*S536:-&R)9-
M-1M%MO;!--D0X,R(`"0)>U^C`I+>#!A#;TZ%146Q9QL<SW#LQBQ81S5!DQ9,
MFO5G<Z#9HU:-DTF[9JW01(0B9"@0A"@````&!17R<13F9ZFOX]I*'A5E]_\`
M3+QE"(MU_L_:[CZ'4%0R;H00\3E`2B8WH7GGZ\8&3>^FYC:6W.)U@]M35.Q"
M@0Y0]M`%:=,I&/R'J8!']1N?I^&!X$KI+5&Z:7K)/9M`J5]2J,57YFKK62(1
M?N(*35@&B*S^#>_X;V-._:G!)P":A2.$@`BA3%P/6H?7+2FLK*ZN-$UC1ZO:
M'D8M#+ST-`I-97^$.7+9VZC4GJBSA9NP=.62!U4DA3(J9%,3\^!>`N+=:-3=
MD5J2IM_J\%<JI,%;EDZ]9(QI+Q+T6CI%\S469O$E4179/FZ:Z"@`"B*R95""
M4Y0$`M/`]4.M%7LT#<Z]HO6$/::N9NI79UC4(=&0AG#1!5LU>1RP-O\`LS]N
M@L8"."@"Y?(1`_/K@51"AQNW9''_`/+?3O\`_$>Z,"EK@1J^[!Z[A'+8#C*Z
M<W&4'@*JIK-&Z=@U6V=)H^R=,Q3N/OR#Y@8#$%,!`0'C`QQT[J2/T;VHI6LX
MFY;&OD;`]4+JHRL6UK<YO%T4;R&\ZH[2CGED>(-W+R/B2']AH0Y1,D@4"B8P
M\F$)#CE$Q#%`0`1#CD0`0#]O!@$!X_+\<#%[2O4#3>@=I]CMR:YC)QE>>U5U
MAM@;A<RMGFIN+D[/`1CJ*CG$#$R+A9I661&[]83MFH`F<Y_+T'`]%YUP0_F>
MX62O;?W53"WFS&MLW`U>UP;:OIS"T1'0SQ6,8252EG#%-\VBD5%"E7_\T@*@
M"`&,00[R>A9),K@O^?6_U0<Q*42(+W.O&%O[1#A_%&BB5+1.E,',8/)8WF4W
M'[G/&!5;#5CQBU;M1VGM5[]NF"?W+^PQ+AVN``(`HY5)7D?<5'GU$``/V8&,
MVX*8_K^]NE"I[]?IM(VZ-CB[C)N9:.XI[[/6;=1DCKMDHQJK[C94042X4X*8
M!$0'G`LW\U1"?^=?]FON/:$B3;42ZGN`(IB"&^]7+CZ<>HCX>G/IS]?3`@V^
M'OY<.JG4'J9*:6VXGLM>X5S;NVK:^=5J`K,C!C$76U-WL&F#U_<(55&071'R
M%`Z!"CP(E.;UP)6O_/\`KI69NNZ"B]BC(I%4,94U&H'M*)I)&7,H*H;2.4B/
MLIB;R/XE#C@1`>,"T5P_J$^@=QUO+OY:@=J6M2<Q2<BZL8:H@TD81L50RS"T
M-I="].&**40[01=I/`5%N42E,)Q+SR%.UW^HZZJU:!=3NXJ#V*K46T95N-),
M2&M(&*BAGGJ*S/SD)-_<V;&/&ZO4DG4:DN9(PI+@7CD!#`N=9?ZB+J14(1M/
MSNB>X3**7E8J&^[/I^)1;).YIZWCXSERZNC9LJD[=N2$3]HYSJF.4J93B8H"
M'4>_U%/4AC9XVEN]']J&URF_N3UJHO*#4&EKLB+<AS"YK]>7OQ965;\%#W#H
M)J`W*;E7P#G@.FR_J(>M<E*OJ\CU7[IA98AE&R,Y7%]/Q`S$(VEUWS2/-*,V
MUK=*-1=OV!T$Q,`%45*<"";VS^(69V+\_/7KL1UQWJQU7UJ[5S\3.ZTVC0S6
M^+HU9E8"$FY.B+1KU&;4@+5+/FKF`7LC<[UL5$SE!(#J"3Q(.!EQ_3O$*Q^)
M;KBT(8'@-;!O9N#AJFL"*P)[YV/PH0JZ2*Q"&\O0#%`<")K^JU\_N.EXN_XN
MWA@A>PBL@,44AG3DK='60D;$1`JASE,HN7S$?$A"_J./B'(!L^=-['+3G7O5
M#*R'8J6NO:PU;&3Z\4S6CXB14<:ZK,K&3<*S=.G[E.+F(I^BH`&65!)P"R'D
M8R)AP,I<!@,#64_J@8N%F^KG6N*L)"EAWO8\K5Z]^]7CG$>B]UW;HYRYCWC<
M!.E*&CWJZ;<?3Q.?S#U(&!&[U1HVG>N?R*TTO3#8_:&0I3/M1K?K$UAQVFXG
M]9M=22VT-LS]EJ[.LW&MRMTNV@E:`RK;AI,QTP2,;3[;W`44(DJD4-XW`\*Q
MP32PQ3J-=&41]TGDW=(<`X9.TN3LWS<W)1*X9..%"#R'!B_7`\"B6-Y-0YD)
MDC<+1#2*T%:&S)0%46\JS(F(.@Y*F";:4CS).TRE\BE*MX`(B4<"N5/^&?\`
M\`W_`$#@:DI)0(K^JG(@JN!47>M)ITY.N<&S1E'*=37"PK'7,)2+*)KP1S'`
MPB"29@-Z!R.!*]\2VPJ+=7'R)$J5LK<XX'Y.>UDX+*(G8>2?&@7JM&CXFR?:
MQKYVJ-?L)XQ56/>"'LO$.#IF'D0`)?\``8'$MX^V/D4#`(E+P(`(<G,!`'U_
M(38&.O5GR#6$H0YA.)=R]B?U"(C^DV^=BG``Y]0_XN!D?@,!@,!@,!@,!@,!
M@,!@,!@!P/&E7+YD1!1E'J2JIW"29VZ3M!HHF@)P]YT`N.2J@@0>1(7]1OPP
M/1;KE7!7Q!4/:6,B(J)G3\C%*0PF3\P`3I_JX`P>@B`X'*?Z!_X:?_JPN!IT
M]`ET@_J#-_-A.`+FG>\Y2%$.>"M[I1%A'Z?NG))$X#_J#^88$A/QO4FJ7[O1
M\PC*_P"J.TLE'?\`-K5)",8=MUVE[U.FFII;7"[9[K:#EY"891<C)M5R/X3W
MT!>,=?N8-D!T/:4;@$XL?IK4<2^82<7JS6L9)Q3A)W%R,=1*RR?QKI#_`(#F
M/=MXXCADX1_V3IF*8OX"&!<HH>(<?V_L^H\_]W`_<!@,#!'^63=@^V]@D+4S
M</-8]/7,3&T>&>H^<'/]A]@4UE9YC8+A#S!M(/M4:XLK&-A@524!F_G7KHO"
MZ2)R!G00H%`O*8>8!ZB4OT$?KXB/ZN!_,?4<"U6^P`VCMP@(<@;5NP`$HAR`
ME&HS`&`0^@@(#ZX%1:P*!=:Z\*4H%*6C5(I2E`"E*`0$>`%`H<```'X8'J7%
M+WJG9DA,8H*5^:(;P,)3>)HQT!O$P>I#^(^AO7Q'UP,7/CY!L/2'J.HS;KM&
M@=;=-D0;.7[B3<)$&A0)^%I!R5-9XH(CR)S%*(<\````8%T^N1U3ZR6%5`[<
MQ=H[[2*0ZB2@G21WOLA)!R`I&,4I7:)"JE*/ZR%.!3@!@$`"^N`P&!B!V%;F
M4WYT7<%,``UWELL3$X$3*`OU@W>D`%X]`\1'D>?P#`I7Y%X]"6ZQ.63I(56R
M^^.GA54O$/U_^WA:(``$P@<..3?02B`X&06\DG/^3N[S'7,HV6U-?"MVXH$(
M5L):?/E6'WBB)W'W)S`;]7[O'`?4<"M=>"'\B4P`#C_V$ZV/I].#0K$P?Z`'
MC`K+`8#`LI!G$.P>SO%VX4#_`"GTDB,<5,!:MS_S7O947YE@((E<.4S`F8HF
MX\42#P'ER(>;:4E/^9#4"P%("8:SW$D8XJ%*H/E,:N/X$3']:B?)0$PAZ%'Q
MY^H8%O)'S+WVJ_(#[*_42[B/`&#_`!FFZM<>W^K]T0`'@\A]?].!F!@,!@</
MMG][W/>4\./^#P3P_=XYY\?/Z^OU^N!RB'(<<\?MP(G/E>W!>-$5?JSL;6ZL
M$A=4^T%6I4&[LL*ZL4*R5VA4K9K9P^?PC%VP>2:+1M:C*BBFN@)O#_B%#UP(
MPOF+VSV@A^I,[KZP]@-'[,J-LV'`4G8_\F:1G:G-&DZ1V0ZZU>2JKI>2V5,M
MXMU%/[PFL=XU(8QC(IHF2,F<RF!&+\>G534'=/0FJ^KTC4M=P4[<>T^_-@;3
MV1,T&'EK-:*C29B+L;#3X2D<]@KHM`+M(Y9=46<M&B1<S5`5!:IK(.0GU^.;
MI_H0*QM+KEM[3.@-P6/KA<F=;CMI2.E==*2%PJ3I6;:UUM8UVT$9-[,UF4KT
MFU17.H+M>&&/,NJLN+A=P&9GR?5R'KWQ==Y*_`1<5`P43TZWA$1,1`Q[:&CH
M>+::SG&[1C#LHTC5",;,FR8$0(@"94`*7P`/$,"#2S:T8]X='_';H_=-Z>KZ
M\VCTNZL;;[+NK(T0MZFVIB/HT\TU[;KHS56AI.PLM;VI`CE^JWDT%SJ2!WCO
MWDXK@`[?8C=6TY_JST"UO=MC6.WRFL?EPZAZ"M%SBY(L>PV7$4FV-9V"=60\
M4E'-K65%X#0QS'*#=Z:.:O12$Y_=5"^_8/KC>^PO9O;7R`I]A7U)N/2VW0VO
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M7_3U=N;(BR23%6LJ4:O/HR=>BI_B?<U&37.8/#U4:.UBFX*7D`S9`>>?00$/
MK@?N`P,#N_7037/R#4'7FN=FVRUU.#U[LMALYDYJ`L4Y-]+1U>L5>;-#N7R*
M_P!DDFC8U%TUT`*X1<(I'3.42\X$+&R]0;$Z0_*?\7FM(_N#VQVA1]^WO;KB
MVU^^;/E9"$=JUBF32L1&ST7_`!`D3-0TC*6%'WR*-16]UJ@8AR@7Q$-IC`_#
M`!BB40`0$!`0'Z"`AQP/[!P+-6>*&IW2-V2D\63BEVR->N[,OC]N,:*QPK<Z
M"(%$2*UY\[504.'U9O5!-R*9.`O$<!.F</W>0,`#]?3U`#>GX"&!J/3[B3:_
MU2\:BA&1+TLQ0O&+-)D.9(BQ>F5V,X;"X12<+1@2+E%-%PM[2Y?MA$03.?T$
M,Q_@.TQM+43GY'4=D]?.I^F74EW]W6B=_P!;OXXT<FEVJD/)/=?J,9O7U55<
MZFJ,?.-7%1=D<H^:,BZ*:*8CP98-A[`8'$O_`,(P_P"Z)#_W$.4XA_:(%P,<
M>K1_/7,Z0.0%ONSL:D81'T,)=\[$#D/R`>?]6!DG@,!@,!@,!@,!@,!@,!@,
M!@,#\X`1`1`.0YX'CU#GZ\#^'.!^X'X;CC]7TY#Z_L$./]>!I!:HTKW;C_G(
M[12_76'U_4[4POG926AMI;;5<R='E:;LEW#RX0<948X?X\C."ZB%DR/%VPME
M2QJXD/X&3`X9\&'YMM.;-W@^83_65:][DWCK>&9IHZMG9"&O,_\`Y#PZC>0H
M+U1*`3&MU.B:Y%K*KOESF1ED#E*(@<I<"NK+M#Y]J5&QLI:5>OY6\I9*K4D`
MCM7,SI?QJZ3S.M0!')U;2?[./-,23<B[@QC%2`XF\1XX$+N)$^?,2%.K:NJG
M)B"/VW\I,B)`)@_0(K'>``"41`PAS]?0,#I)MOZ@,J+CW[OU*57,("T1:TIE
MY)\#S[9E#R:B9Q.'ISX^G.!QDC_Z@05"JJ;"ZG()F41#V5Z$Q$P$,8I%1(J1
MX0#+)G'@H"(%$?J(!ZX'K:O1^;#:5?G9YCV5ZFU>1AKS<:+(UFTZB?F>P\K1
M9^1@I=,[Z!C9:-D$71TDUD%$G!B^VIP(^0&#`QDVE\0G?_=FT9[<NP.PG5UU
ML&X'AE+@:ND[%4NMS)X2(9P+*04J]+L]:@BV!&'C6S91^5$BCM%,`5`?$O`6
M8OWP>=T6U0MKMKO3KBU&/KU@?$/"3?:V-F>&T.^5*#604V(\;-GA#@!TE!3,
M4JQ2&$!`.!#)WXQ+MVUWI\-,W>97?+2V3DC2>U43%6O<%?LFS]DH)UN?O4%"
MLY6R#>J^RFTX-FQ^W8B9`@)I$1\BGX.`A/KH-&81T;II.PNVTA.IZJUZG+OF
MC55BV=R)*C#E?.4&2[M^LT2<.BF."9EUC$`>!.;CG`N@^9HOVJ[-R0%&SI!9
MLY1/S[:S9PF9%=$X!P(E43,(#^/`X%DZ9UYH^NJE7:%17]TJE+J$3'0-6KD3
M?;DE'P,)$M$F$7#QY3SACIQT<S0*FBF(B!2A_9@7'I%*A]?P*%9KQ'"40U<R
MKU$CQ\_DWIW<W+OIV3<NY&3=/'SQ=Y*2:ZIC'4'@3\!Z```%88#`8%"W+7-2
MOCNKO[+%`^?TN7<3M7?IO9&.?0LJ[BWD(Z>,7D6[9NDCN(B1<-U`\_%1%4Q#
M!XF'`M7?.JFG=FQ2T%>HNUV2$7EJY/J1#_9^TRL"3U/GHZT5:6;(-+HU2:.8
M&Q1+9ZW]LI0*Y;IG^I0P/J5ZSZSL)'T?,FODE&N&Q&KV-<;?V^5G(HG(N"S6
M013O8)N6+E-;Q52,`E4+R4P"4>,#(!@Q1CFR#-J0J+5JW0:MFR0`5!L@V3!)
M%%$O'Z4TTP`A0_`I0P.Y@,!@6-OG7+4>R;>%[M=;>K6O^`,:NI-PUOO%3>/(
M*-D'\K'1DF%0LT`A*M8^0DUU4`<D6%(RQ_`2^0\A20]/="F5=K*5&36</HY&
M(7D7.Q-I.IA.+3EF4Z:.CYAU=UY2(9.):+;++IM5T2NO9*58#D#QP,?ZOH?7
MFMN_]4?TN.E8E0_4F\"J+BXWB=!P#?<VO@*FY1L=DF$5TDB2*P)%,`D2,L<X
M%\_`Y0D?P&`P&`P(0_G0AIR9Z\Z'+69=*`L33MSIEU!6%>-"7&NRW\179QTT
ME&^12O0BGZZ;DR)N06*F)!X*8P@$,GS;:F[=+4K1MGOW;!UV4I.N=WC6K=`R
M^AX_K$>(E6.Z^N4`69BV=>=?8;GAQL<]'^V1V`0B9?-ZV<**("G@9M_`]UTH
M.Y.D^P%;O"NFL[4NXV_2U6TM%FJ%CBVKV&H)#D:*I,PC31SL/`YV;ANNV`Z9
M3>V"HG4,&PKIC0^O-"U]2M:YA6T.P>/'$K-.?:1/+6&9<^":DQ.2223<[Y[]
MJBDB4!*"***1$T4TB$X$,?/D^9.Y+XY>\T>Q:.'SQWU1WPDW9M4P5<N#AK6Q
MJ&(BD)B>X<$TS&XY#T`<"*CIM4.L>TOC5Z$R6Y8VQ7>?0ZN:;K^IJU060.-G
M69>6H;YK9*O#0#4BS&?KZZ`'6>&FC*Q$0`B[778$.900PK^3&6L^B:?\9NG)
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M!51=`@NC&.4`*$#/PJZ=VI:_BVTAL35C>M2^QM-=L^W4XC5;H5E[5A;3&[5W
M,H1M*NQ339SB;F&3.4WW+,JC==8H.$U`2.`7R[RZ/W[7?CG^3C?_`&!0J41L
M?<]"H45`ZYIYVLDPIM7J>V&"K(\G/-WDFVD):7":;F*V1<ND6:;7W#+*.73C
MP"=CJW&MW_5?KY%2*1'K1QUVTVR?-EP\T7B"VM:^@X25*8>1*L7D!]?4!'G`
MN/KZ4<-%)BD2::B;ZI*,DHLZJRCA66J#Q`_\OS`J';HB9P4&RK1PGY*'36;"
M)AX,43!<_`8#`UZ/E.A!7^5#X2)Q,A/=:;QV2R.JH<J7#<\#&+'33,8/\10W
MU\`]1X#`V%\!@=-^R:R#)VR>H)N6CQLLV=-U2@9-=NL0Q%43@(#^A0AA`?[<
M"C*:]<,T7=1D%CN9&L@B@BX<*#]Q(5]<I@@Y0PF`164.@D=!8X>GW"!OIY`&
M!JSV2'L/_N4K39=FW!""2I\(20D3+(I@Z,OU'V$C]@1)13W%3HJ>SSX%`1!4
M/R'`V">H.L[?KF;[@O;9&GCV^S.Y>R]FT\ZA'!!DJ?,4#5,$PDB@X00$4UI*
MM.R%,3S3,"?)3"`X&9V`P.)?_A&_9P/]O`AZ?WX&.'6#_P!D*S`'IQOGL80?
MV^.ZK]S_`*1]<#)3`8#`8#`8#`8#`8#`8#`8#`8#`8'6>?\`F5QP/`^RIZ_^
M*.!`SU7F$?\`SU7LNQ%F`K.KO>6I70F)YI%CFEI<F^J?N"1;[@`\0,`!X\^O
MX!*3OTX);+ZG&`H"(]@E4@$.`$`=:*W<4>!XY\0]CU#\><#U^UUE8T[33JS2
M328?,8C8NCUW#2`AI*PS*Q%MVZ]:%!A"P[9Y)R"I#N`,)$4CG`A3&XX`<#O)
M;_K#5(S8U(W<Y.V*?W!9Z,VH\3.!3F'E`R-6.+@A@X\#$`2F#@0$0P.FMV<H
M;-Y$M)*J;C@$YJ=@*TSEK+I39U;KJ$U:91E"0+22L$Q5VD7&%D)B20;@HLH4
MA5%0`1#`OX=3[ED50Z92B90G*?D54"&(OXB'D`>(F*)?P^@X&+G4LHEA]Y`8
MQE?/M?V0,`J_J%,O^8;\"II?DF`!@9:8%+7=7V*=:E_;55]FMSRGMHE\UC^$
M0]-X)$Y`3JG$."A^)A`,"`GX.II.W?"=%RR1'K2.=H=OUF2T@Q.R74C3[&V6
MFBY,V.(&,FH(G\3<B"@)"//KZ!.]J50BVJM9K)CRFKKZF*$$/Q(>N1IBC_>4
M<"OCG*F'D8>"A]3#]`_M_MP`'`0`2@)@$`$!X,`"`^H"`B'`X#R'_='_`%_]
M[`^A$0^@".!Q%5\N2B``H7@3I@<IC$`PF`@F`HB(%/XCQSQ]!P.;`8'3=O46
M)05<J(H-^2%,X772;I%.JJ1!%,3K&(G[BZZI$R!Y<F.<`#ZX':`>>?T\?3^_
M_5@?6`P.FR?-GY5S-EVZX-G2S-?[=PDX!%RW$"KMUO;$10<(F'@Z9P*H0?0P
M!@=S`8%(W";CXV(EFCJ:1A7CFOSSQFL13W)0C6-8&4DI2,C4BJ/I`\,FJ10Y
M4$U#%,=,!#DY0P(I.C6R$]F[;T984]_I=H"_\HV[X(-U#68ZGRMG_E/?NIX?
MPM-?B3!'MK>U`0"1.DFW*=<1'VPY\C!,3@,!@,!@1M?(?I%CV,<=3]2S%BLU
M0AYSLA_%7=FI[I@RM$+(TS36U[I596%/*Q\O%K*L[7!-#G3<-ED5"$,4Y!#`
MP4^8+JE:F_13;NU[3V6W+L]UJB+I5@B*O;874;:-E19[PU%:E&+AY5]>5Z6:
M%D9.H,06.FN/^"F)2%+S@<7]-I-I3W2C=;Q%,R::?=+>+<`,L9?S,$'KM10X
M'.`'_P"(80'GD1'D?QP-A7`PE^2=S$-/C[[K.IUHK(13;JOOU5ZQ;@`N'2`:
MJM95$4/^T-!(J8AAX-[J7CQSY!Q@6T^/?6>JHZJK7+6T3`LJ5K^"C^KNCHJ'
M1:.(ZCZ:T@"-5=PL+)`YD%EU;/L*+DGDFL1<P.1:LTCF5*S2/@1N_P!1#1*/
M-T+J5;K#%P8V6H;FM+VH6.0`4)&,<C74'SB*9N4G;,73:12CS*'9J^XBLJBF
M<2>1`'`ERU=J>I[LZ;]9H6R"<CIGH[3%@J5UA3HM[92[2AKBO*0]TI$\":BL
M+.1K@P*D43\DG"?**Y%6ZBJ1PA]KNTY*[?-CU-2M$M`.MF5[K)O35^RV=??-
MT$"VW7KW;\/-RQ((5"RC&/GEZZUD&A5DB@BB\*4IA(*9CA+SVOD8G2M/G=H)
M.X>OU>XMYBA;10?J,HF!=KW:NS,)3KB\>*&9M&D\QN"\?'+.5E"%<1[Y0JAA
M.1(0#7E_IGU+AN/KUO.!8;CV+2(BJ6%G:*,A3)R">P,/*WS>'9@UHE/X+,U^
M4K]D/,'H\8W75=MU3`V9E10,B`G,8)%_DOVE<8?XZ>Z&G]UNZJ_VY3-:4N9:
MR=43?U>O;=UY9-L5JKQ-SC(0Z\E)55^J_$8RP1Y%7#>.E?!1%<6SI#P"RW6G
MI+\D6U^K/7&ZUGY4+=K^NV_0VH;)`5>$U6R#^686;HT++15>+)&G6RKTT%'O
M$F8K^V3[@$/,2AY8%7;8Z$?)U7X]O?6ORLW^9G:U]H,HE':J38&/1G,S$)W5
MVSB(.SQS21?0T(@:010,`F450,4IB^92B%<L_CC^1R9B4'"'S%;.<LI0Y)9-
M[%ZV53(X:O$`69FCGI-C"N@R716*H!"F,F/(>(`&!1.]NE?R0:DUHZN\!\I6
M]K6[J0P8(5BNZQ@I"S6QU(3,;`MF)%K;M*&@EQ^\EBKK&>O$$BH)G,<WB00$
M+1Q/7'YD$VR9'G:#MD;VQ%1T+^N];"NG"RR_^(=NHV[-J)H-PY]$OW"?ND``
MX#`I&B=`/DWN?>'IOMK<U]LE^U/URV&;8EML/8:>I+>P,SOB/V#F&TQ"Z[ON
MTE7+^12%-9\,N:/100131;+&,H8@!M1X#`8%K]AHK0XM-@,453N*>U>+S"+9
MN=RO*U`2?=S;!!NF("N_:F:)NFI0Y-[B0@4!\\#5TN<LBO\`U.^H31KE-Q$3
MU5KTJDNT<J\.@5ZD["49JK%`1;G24;G(H4I0Y$IBB(\^@!MI-2>"8ASSRH<W
MTX_>'GC^[`[.`P.)?_@J?^`;_HP,=>LYP+3+:3C]_>?8/@?0`#QW#<@Y_M'P
M_P!>!D?@,!@,!@,!@,!@,!@,!@,!@,!@,#X/^X;]H>/_`)7Z?^[@:]_5=5%#
MY=>RC85!,LO>K^N!1+X^`+PMC-P'J//!67U].?+]GJ$LO8H.=B]0A^G'9LG]
M_P#[;[OH<"MNR"I$M8HG.H*0#L[1B93A]?<5W;KU),H>H"'FH<"_WX$>WR3Z
MWI&[]C=3-+;4E)EYKNP6F1L,YK=A<+!58JY2L'M'KM6(IY/J5>5B)EZTBH^]
MR#-)#W1;F/)',)/=*DHF%E-H:FJ'1O?_`%MT;U;U!;H_3&_YN*N&Y:U$[$>2
M=+UW9-;;ZZT1=5V\YA=DV:4FAE)U&Q*0C\D*L9Q(@9NNLV4%J94`G;$O$>)/
M+GP(;D>#``BD83"`>0`(EY)P`_00]0],".;2R6S+5"]MCT?:C>CFK_:#L'&P
MGAKZ%L98B2B'4;*+.7:TU)@$@#Y](^2I1!$H)\D)[?[V!=;X^=I[&W9U%T;M
M?;-E@[;L&^U60G+'.5N!CJS!N7(66;9)$C(>*D)5FV;(-&B2?HX6$PD$QC"8
MPX&:"@`8"E$`$!.7D!#D!`.1X$/[L"$:H=M]4Z&ZU]7^LEFC+G$77LIH[>\7
MIF:CJDXD:&XMM41LCHU0G)M@(IUZ9D8IVO)-3.4B-%&4>Y,=8ABD*<)==-JF
M6U#JI8Z@*G5UO1E3J@4I04,I6(LQE`*0ZA2@<1YX`P@'/U'`K"?9MY"'D(]T
M*A6\@T<,%C(J*I+>T^14:*E16051706.DL8I#D.4Y3"`E,`@`X$8?1/JCIF7
MZ?\`6:0L5)L*,_(:/H+N82D;_M9K()/QA&H+"]:#>A!NZ<";R4_VCJ`8QN1'
MT#]V1U/O`;JBR:MU7JPV@6.J;L_GGENW9OQOLVU;L,NU#7D'`LXFRA%5>C,R
M,5BRKU91TJL=^10K<?MN%`NMH;I]`FU%K93L/2*VWWVM2(%;;J&L]E[G7UZC
M>E&:1[`C31E[LD_&OIR(J%;&7*54Y`Y$/7`MK6.INAQ[J[?C!K<HHU3ZTZ#?
M-V*E^V>HH@97978%D=RU>#=P50;+%CRIJ(!R4RB0*>AA-R%<]D^HI?\`)J[,
M^L6OJ4_WC(QJ+2A+;>VINF/UY%2:DBQ!6:LG\`GYB6?-(AB*K@K-(B0/54R(
M'4(FH8P!YE2ZFR:N[[:YV+0]4+:%9ZXU\%#)`6K:X[#>;>6=68=HS,\VD[,$
M3&448M]'M(=F*SMP"J)UN2"?P*%L>]G3702/6BS,H+5LG*/G.RNO#\L97[%L
M&1DY#[+?6IX]RU.T//S0.(52"*M_$$56RS(6A%5G"8@4QP#)M7I)U5?RJS-S
MJ-F*+7V'R"Y[=?TTG3I<'Z8E3$EP*1<B`&X.02B4#B4>.2D$H8)7'X[MLJ%[
M/!K2C]7J^,M:-=)]1AM-F[`S+BK5E+^!J[5F]SN#3YS2T[+.VCE:&C&21D&Y
MA(07)`\SB&>J/0GJ0Y*JHIJ"-.JJ?S5,2U;`$/=422,854UK3SYF`0'Q,7CP
M$`$!P,<NL_0_J7*5_:Q)/2M<?*1?8[?<6@NXDK4=<S1ML68,W(X7/8#N'IT4
MU03*=<ZJH(D33\A(F0`#M[F^/FFN+KI-OHS176^,HY;H^6WU.;*0N<W9BZ__
M`)<ED&<1K*$:O3L'-D=695FX47?.D$46S4Z8%,*QA*'H:1Z':F;5FR&[.:-Z
MPENKS:.REZ<VUY'RY81GJ1:UOS:LBIA>=<L'<O<F=1^W+,+@D5%1[Y@D'M@7
M`ZZW5'K=K+NGU<NNNM/TBN'@M;=E5%K!7XA0D;`RSP=,L8MXZ>"_<1D1+OV3
MI^U:JG(1==!1RF0P@`A@7Q5=P1.^]`8Q:\60"]0=N'(UCUX\"!Y[HTL)A*V;
M*`<!$2B(B!.!]?7G`S5P&`P&`P,'^XA)II+]:;=5(R3LMRI'8-.6K5-CFS1<
MMO6E].;6JLG%O7;VPUIG"MX^%FW4@DY567*+EH1+V#^Z`E",;Y6=R]AY;X^>
MQL#L/3"NL:]8X!C%DL3E5@F[]]&QQ5G91D>M7]@6E9M+//Y?.B9RNW(U34-R
M?P+P(A;?^ETG%7W3?LA"K-U"+0W<_8[Q1RJ'M*.#3U!UFY%([7@?94:"U\3'
M\S`L(B<`*`\8&PKN6Y&UUJK85_3:LWKBDTVT6MHRD'/V;!Z\@(&1DVC)VZ`B
MAT47CAL5+DH"?DX`7U$,"*W<NL?E3[-=;]G:7LQ/CXH<;O\`TS:]=6-_'R'8
M^8L-28[-IKV$E5VC-U$(Q[Z6@R3!S$!4X(&52#S#P$0P))-!:SK.E:A#:CI4
M!7ZM5:'3J?%1M?J<'%5JMLWAV3M2<>1<'#,V4>P&:EP5>./$GDJX6.<PB(X%
M9;0T]JG=D`WJNX-9Z]VK6&DFVF6U>V32Z]>81M+,RJ$:RC:+LK"18MY%NDLH
M0BY2`H4JA@`>!$!"FJ&D77]A7UDBR1:5/[%Y,:Z^S;(L8^*B6[DG\5HR#-`A
M$69*V=TFM')E`I#1JX)E#_LAP`.U'=?=(0VT9;=\'J#5T+N:?:*,IW:\;0*J
MUV---%6S1HLRE;LC%)V9\S6;Q[<BA#.N%"(E*/H'&!7-QI%1V%7G]0O=7K=U
MJ,NA]K-56W04;9:Y--?)-0K:5A)EN\BY!`JR13@19)0H'*40#D`P,&NDO0:)
MZ8[-[;W2N6N#?U/L?LUK=Z=KRN4!A1HC45?1F[]:E*>V/&S,@RGDPL6R)`45
MD&D6B@R3;H@W$Q#*'"GOD=^/^P=ZJ7%52I;M9Z*=+56VZYNDVOK0FR5;+KFW
MV#75P>P;1DK<J>A%2;6SZOC5$7:HO"%;*N4@2`RH*%#-?0VJV.C=*:BTO&22
M\TPU)J^@:S9S+I$&[F8;42J1560E7+<%5P0</THH%3$`YP()O'R'CD0NL<I1
M*;R(!_TF`0\0,(E,'ZB@`_4#<?3\<"S>ME'%1EIW6,NZ0.$9Q8J28"D0%:CR
MSM0B<61NDDDD!Z?,*'CP`@`!6(L^0`1'`K;8%,CMA4RS4N54.@PLT')PKARD
M1-19H$@T502?-RJ\IBZCG!B.$O+](*IEY],"T.B=FS$PU7UOLEN2*W+1FK=C
M;D#I?8,;NV:@#)IM.CIK'54E*7=`0%P42J*JQCL5F3KP.@4ZH9'"`#Z"`#QZ
M^O`\?D/^K`_<!@,#@<AR@K]/W!'U*!@]/4!\3`)1X$/H(<8&G_-5TE$_J=]5
MP+=X:3C%F$=)PR#MN@G_`"Q!2_578#..K3([<"F<1\$YC5",SJ\JIHK>`B)2
M%X#;^;K>Z"@>/'MKK(_7GGVA_>^@<>7/TP.S@,#K.PY0$.>/U)_ZCE'_`%X&
M-_6?_P!EW80?GV)[(*?V>]N.Z'\?_%X_OP,F<!@,!@,!@,!@,!@,!@,!@,!@
M,!@?)O0IA]/W1^OH'T_$?P#`UB^L.\ZX^^?'LKH8U?M["W12]\L`2KR((G4Y
M*)C*:VE7*\=,D=',LO[6RHT@)F2((G*N'/\`AAY!.!V0+X;#Z@'^OGVE8DX^
MG'/7SL%Z\_C^Y_KP*O[0ME'6JFA4D_>,CMOKX[%/P6/Y)L]]:V<JCPW355X(
MFD)N0*(!QR/`<B`4=V@Z5:*[CUZGPV[(RUJN*#8"VNB6W7E^NNJ=@U&9]]NX
M57A+SKZ=@+&U9O56+11PT%<S995DW4.F)T4Q*%A5^H>CNH>MYBQ5"2O<U*S^
MW-"*V'8V]-KW'<-[;5]KN:@`SJ3?8^U;!.6"'H<:_,9XC%INTF2;U=9P)3*'
MY`,]6E]HZS/AE<JF^*T*9-PLULT"JD@H0IB^VX,22,")S''C@>>!^N!AEH+1
M>IKZR[%/IB#8SK2Y]F-YN)PS.9G6T9.`O,-V!5G"$+/-H]9Q]@DFB=9,I3JD
M)^ODWJ`9=:?TQK#0&O:QJC3E.AM>:UI;-TPJM+KJ!FT'`LG;YS)+-8YNJHL9
MNW%X\54\0-QY*#@7,,8O)`\B\^?H'(<CP7D>`YY'@#`.!KJ2-FI".M?C[A)F
M^VR+LLSK/MTO48"O:TJM\I-Q1B:/L5O*LYK9ZVN[78M62#=PNW^U68R];(]0
M]Y)9PHJ@5!4)X-)")M,:B$0$HCK"@B)1-YB`C5(D1`3^"?F(?GXEY_(/I@5O
M/`?^$R!DU#)G(P?F(8OU!0K)P)#A^8IF#D/^MP/X8$?W0;4U!L/3'JU/6&NM
M+#89W1&N9N>G[$M(STS-34A7V3J3E921E7SIT]?R#U8ZJJBAC'$YQ]>!XP+^
M]3P5+K.;:J*BHA#[E[!U^,3'W3`SA:]O*_PL)'IF76<*`VC(E@BW1*!@*4B?
MH'Y!DY@8I5=R4W=#:R!R$*L;K/HU<H\>:OM);6[$M#%%?T_P@72-XI\>@\CS
MZX&5N!B1V89-)?873ROR+-R]C)_L5.,Y)N*:RL.NVCNMF_[&W0FTTW"*2R(R
MT&U51(H4Y#+HE]/3`QV^2C3NMD>K$_.(52#8S$'LOKH>+E(V.;1TC&I2?9?3
MD;,&:.V1$5D_OH=PNU6#D04;+J)B'@H<#!E/M;2.J&NM]A2#6@5%N]8T&U*L
M'*=?CO>8J1\%+.F)VBOM`=NHT<JBH0Q!*8#<"`@(`.!=G59C'UM0#J'.LHI1
MZ@LHLJ<ZJJJJU?8'54555,=555141,8QC"81-ZC@5^(\`(_D`C_;P&!B[U7]
M8K>1_IY=H]^>GY>U=%T`_P#*!+R_OP,H\#"V2US1MD=PMHM[S3ZE;DZ_UNZ^
MK0I;36XJQ?PI2=V;V6)+'8$E4'*;47Z<"V*H)2@)@2#U^H"'EW;K=H=QN/6%
M7=:<U6ZKEPI&V$+5!J:]JW\'L"$&]UG(PJ4Q%!&_PZ4"+D3>^W%PFK["OZT_
M$WK@4)5^M^@-4=^M<2NLM+ZNH$N7JCN54)6FT6LUE]^K;&E&BP"M"QC$YC*M
MGITQ$1_<,(<#S@20X#`8#`8&-F]5%$;?UQ.FH"8J=AH=`XF`!`R2NIMM`=,!
M$0X%3Q``_:/XX&`_S=QH27QU[20,4Y@0DZ\X_2;VP$&O\9X]PP@(%3X`/+\.
M,#!S^F26$G7;MNH#=))`O;E=$Q6XB)$#DTYK9-P'MD(<2@BX'@>>/0?(>`P)
M@MAWA?LS<8S2VL2*RVI(*;CK+OC:C5`[BF24?49E%^TTC2YTJ2D5:K?;K"Q;
MDGA;*J-8B"2<)'4^^=()IAG&U(0C9$I2\%!,OB'J/Z1#]/[P`(!XC].`X^F!
MQH)HE>/E"(@193[;WE>1$5O%,03Y#C@/;+Z8'=P*`V+7Y&>A$A@7BL?98=VG
M-UMV0RQ&X3#(IP;LY3V2F]Z&E2*F:.TS@)107,<`\TR"`>U5+&C:(2-F$4!:
M"[:\O&*BZ2SB-DD#BVD8I<R(F347C7B9TCG*(E,)0$O(&`<"I<!@,!@,"T^U
M(^5(UBKA68U.3M='=*2T>Q]DH.)F$6)[=KK#1\;Q3:.)V&1,*`J&!+[YNV\_
M3U`+A0<U'V**8S44X2=QLHT;/V#A(P&*NR>()N&RPA_L>XDH`\#ZA_;@47L?
M4M%VNWAFMW@FLP6OR:<U!NA,Y92T)+))J(IR,'.Q;EA-PKT$5CD%1JX2,8@^
M)N2B("$.W>O:&^.KW>'XKJ9JK>^QDM5=F.QEGUMN'6]M-5KA7YBKQT%".HME
M&RTW6U[E$NDW\IY%63DQ/P3@WER'`3IX#`8'"X_X"W_J,_\`T#@:EVVRN$?Z
MH72)@<F3%Q6:J\20200*4&A^K6W(]X=VJ*9EG)U5B$33#R)[0>H<\X&V8T+P
M0P_^_EA^GYF'`[>`P.L[_P"`</\`>$A?[.3E]<#&WK"3VX#:)>>>>R?8\_TX
M_P"+MJSJ\?C]//`R;P&`P&`P&`P&`P&`P&`P&`P&`P&!P.1X05,!`.)2^8$$
M1`#&((&*'(?M#`UJ>NFH=:17SY]F-LQ%=C&.PI2-_A\O847,H,C)MK!2;JUF
M6[ANN]6CS%<IZV@^3%3*9,(\@)^`'6!0)O\`L=1MB69UIBRZSB:Q89_6.Y8O
M8KJ`MEE?T^-EX9OK_8=)>LV]A85JV'9R*2EU3<)@=F<ARHB7D/+D`I6XK]HM
M@1,769+46IJDP6NNNYB8GV.]9ZS/(V%JU^KEIEC1\&&EH,LI(.8V&4102,[0
M(*J@"8X``X&8+8.$2!R4PAY`(E$1#R`QO(/7UY`?K^W`Z4U"1%CBWD)/1D=,
MQ$BD*#^+EV+63C7J(B!O9>,'J2S1VCYE`?!0ABB(!Z8%%Q^H=81:9DH_76O6
M)!%3P(QH]:9$*110JIR"FWCB%,)U"%,8>/4P<\?3@*PB8&)@D2MH>.CXIL4Z
MQP:Q;!I'-/)P8#K&!LT222*HJH4#',`>1S!ZB.!9_<VX5:$6$J52@TKMMV].
M';2@:_"80AADDHLS)2P6FP29TG2D'0*@T?HKRS\B"ZP`JFV;I+.UT$CA0;7K
M5)W6.<K;SW%LR]2DXV?IRD!2+-8=,:XC&TJ@=!U$5ZM4*8C;&+1NDJ8A7,M,
M2<D(B)O?)R!"!X;'JGH#K9UAF-5Z2UC6*-2M:ZPV\QU]'(-G,R]I[:Y1<_/V
ME*$L-B>2UG;$GYUVH[=A]Z(KJFY,/`%``OWHKD=(:;$1`PCJK7O)@`I0,/\`
M*,1R(%*`%*`_D'H&!<.7#S8.4OH"R*Z0C_N^;=8.>/QXP,-OCE5][HYU,/X^
M/.@-=DXYY_X,.BESSP'[WCS^S`O1U_+&H4J7;QJ?MI%V=N@ZPB`E$\BXV]=W
M4N/`@'H,HLL(?F'K^.!?+R+P(\AP7GR'D.`X^O(_AQ@8MUC_`.3$VC^WKEIL
M0_;_`.U;[#_3`REP,8M^_P#VS.FW_P`LG.?_`#+793`M?\E'_P`A_>__`*_^
MNG_S2VG\#*O:Y/\`VEVRQY^M`N7X?G79+]O[<!J40_RLUKZA_P"R!3/Q_.MQ
MG'^G`N`82\<"8`\^2!R(!R(@/H'/U'@/I@8P=6S<Q^]B?^FNT&[T^?SYL22G
M(_D/^)Q_=@90X%CHE-,O9._JE33!531^HB**@0H*J$1ON[C(D44`/,Y$C+'$
MH"(@43FXX\AY!<E4F^\=/+K*$211IFYU555#`1-)-/\`RW.H=0YAX*0A"B(B
M/T#`LVVLM<N7<K2]SJ$]#VFKV?I_N!_`6"OR+27@YF(D-K=?9)A*Q4JP579O
MV3UJH0Z:B9S$.0X&`1`0P,U<!@,!@,"U6T=41.TXV(9R-@M58>5VRLK;7I^G
M/H^/G8:<8L'T6B[:+RL7-QYP%C*."&*JV4#A4>.!X'`CE^4C30L_CQ[1R<OL
MS9-P_E+3]JGXZ.M;^M.8AW+LHXZ+!W+LH>KPAGQ6HN#']HJB:9U/4Q1^F!&?
M_3?ZVI.QNMG:56W,UIA1'MM8TWL$-CG4X!9J76NOD(U.7JS&3;0SY,S(H"!'
M2*H"(<B&!M$PL'%5R,CX2!CHZ%A(MJ1E'0\1'M(R+8MDN`1;L6#))!HR;I%]
M`33(4@<_3`X['8(BIP,Q9[`^;Q<#7HN2G)R3=&,5M&P\0Q<24G(.!(4Y_89,
MFIU3^)3&\"#P`CZ8&+.F>YW5W>57;[BU5OG7MOUA;XMJZ@+<%MBHR`>A'2<Q
M#NTVJ4VZCI..>M7[%9)T@[:MU`.0I@\BB`X%X@W[I,5!0+MS6(KE_>1_G^J^
MZ7@"B/*82@G]`.`_0/00'\<#Y_S_`-)B4IB[<U@('-XD-_/M8$IQ`1*($,62
M-YB!@X]/RP+%#V"T=KC9BSO_`#>U\O4=KB9=TN2]5]S$U2]Q$><PO'CC^)`V
MA(F\0C--,#GX3-*-"@'`N,"]G_,7HD%`1'<6K_>,;P!$+W7#K"?]/Z`2(^,<
M3?J#TXY]0P*?N';+K?0ZK/W>U[PU;#5.JPTA8;#-KW.'<-(V$BFRKI\^4!FX
M774*BDD(@1,BBAQ#Q(0QO3`K72FZ-;]A]7TK=&GK3&WC5^Q8)O9*3<(C[LL;
M885RHLBD_9IR#1B^31%9N<O"J*9P,40$H8%U,!@?@_0?40]/J'U#]H?7UP+,
MTQN6@VB4U^W:$2@)=1];J:*1EA0:I.7J2EPKY3+*K"D:+F9,'C=$O"96KL2$
M`H(\"%Y\"`+Y=P\^^7P:DYXX[GVI3G_U'"4P>./VX$_N`P&!PN`Y05#\TS!_
MI`<#4QVX)$/ZH+3:X+MW!UZ%0?)JH<R0LA>Z!VTW$Q!*4WNN#%8`<A?0!*8>
M1#@.0VP&+P7+A^D*?@#%T#8IO(1]X#($6]S@0#Q]3\<!S],#U,!@=1Z'+<P?
M]9/_`-'+@1,[X['/^J/4_>&ZXW9-#U>YK?:?<;).9V#J:^;JC9Y:<VI8F3&D
MPM%US<J'8%K;:9!1%"/=*R2,>V4`3.Q(@8RR07:^-_?O8[L)JRR7'LM/]67-
MM-/H#`4[K?8@L,Q1JLZ;KGCH_=(Q^R=J5F'V#*D0!U_#XR6=MF2)A2,X75(<
MQ0D7P&`P&`P&`P&`P&`P&`P&`P&`Y#\_S'^X/J/]W.!UW)P!NL)>#"5,X@4!
M^H@`^GX^N!KY]>XQ\3YI^Q;AP@4K<C6'>MU"B(@)7L3V&;IJB(AP!U4TP#C\
MBX&PIS_K^G[<!@!$`]1'C^W]OH'^O`8#`8$2>V>V\3UM[<[DG-C=?>X^RC&I
MFLJ9J^9T)U1VENVJDI8QR]KMZC>TT6#?QS.4D[U-"C(-U%BK"$.V\BB5-,0#
MLH?+QJQ=-XL;I]\FS-NP9/'[QY)=`-^1K-NV8-U'3I59T^@FZ")4D$C&$3F`
M.`^N!D]2^SNDNW_4NU;SZ\7F-V/K&T4'8K:,L48B];`$C%UV7:RD2[92#=J]
M9R<8[`4ETCIAXG^@B'`B%Z=`C_[0C28#Z".H]<#Q^/I3H7GT_9S@7,D__,AP
M^O(*!_\`@%<#"[XV^3=%.IAA#Q,&@M>")?Q*96*`QBB`^H"0Q../K@85?)9.
M;/IOQ[VAKJ>[V^B25X[A:XU[;]B4%H_";IVIMI=S8>K;8E?XLT$B]88,*/*O
M47TL!DB-&YSB59+R]PH>1W]ZW;8T?U;L.W-/[VV"QMW7IG"674</6(2\V>V.
M)MO9(.-CZTS3EMI6!*Y/+"A).(X&TE%RYG2;P4P3`X$.4,H^R5BNU*=]U+QK
ME&S%V#6OCF).Z_\`Y;@GDS:`N\3(]FI.I_P.!:L'[N1GR3A6QD6A&ZQS+>)?
M;-SP(8Q:(Z8[UO'2;33-7NO+C7+SI6A;!L,C+4:VS]B=3EC@(B]/)TE\2[`0
M\TF[_BCC[E8Z;A-LL\\U03314%N`7=ZV6W8MXZP?$';]OR%LE-FST]57=XF;
M]&NX:WS=E4Z==BDGTQ/LY!G'NADIM5(7/NF2+]T54%B^13@80OS\ERI4.G&Q
M'!P'P;7;KVY-P'/)4.R&I%A#TY_!/`RRVES_`)8[*XXY_D.W\<CP'/\`+\EQ
MR/X!S@1(]@?\QK5V?^)32T=>;S0M3V_7.][KL(T$P=A3KC?M>::UR.JZ?:)4
MI&[1Q(-B2\Y+QT>+M)556-,O[:I4>"A4VZ]6;'TUW:Z)[%K.V;G.,]F[3N&F
MMFT6(IY%HF<UA_DEM6X-9*XJLW<JLVKU1O\`!PQTGHMVZ35V\("SCR<%*<,5
M^QZ^S)GKOL2@K638%'K.S_FU@=3[%L]:*_C/X;U]MNYZW_'/YCG6(LOX%KV;
M;@@Q=.UG#=LY*[(S56\70D.%YN[/5C9&E=,L-G:?W==F5IUWM+K^EK>L5.LO
M/YH=JS>[M;5F;JT4\1LDF9^PL,!(NT'C0L8O[T>91,2^/)P"5J)X_P"9"^!Z
M<AI'4P\?B`#?=U\#Q]0`>/3`X+NW*YW7J(IO9,)JEN)N"3A/W4%2NV=%`_O)
M`8AE4B^P`&*`AY%,(<A@1\=--4V/1^W-&Z^M.A-/=<9HNE^X<PZUMH>P(6/6
MB:,QO?KO,M;)".T*50S,3SB4IX&8+,EG#%)JDFJ\>G`S@X2^X`1``Y$>`#ZB
M/H&!BGV4[>:ZZQ%J+:TQ5JN=FNMABX>!U[KB+2L^Q9&*=/F;>=M\94$W3>3F
M*[38]=9_(@S*N_.T:+_:-G*B1TP#("C7FI;)J-<O=%L<);:C;(IM-5VQUV1;
MRL-,1CLGF@\CGS<PIN$3<"`_NG(8!*<I3E,4`]]\^18LUGJJR"3=!,ZRJZZR
M2+=)%,ICJJJKJJ)I)))D*)C&,8"E*`B(@`"(!A!I7Y"="[TWM:]!51Y,,+##
MPT99J-8[''*PE1WK57;-5:0MVD)9[X%O54AWR1FPOT0*@^,BNLR%RU047`*8
M^6LQ/_.SN[:AE%$R$Z]7Y4RK<@+*D*E&BH)TB`/"AR>'(!^(X$4G],4W7::'
M[FMUT?:,3MNZ4$2^0I'4=ZMH;Y;VCB'"A"*.1`!#ZX&S=@8U]RP?#U%[2?PM
M59O(_P#+GO'[!VW(11PS>?Y76O[9RW34_2=<B_CX@/H(CZX&MC\:=K[6T7XK
M;K,Z&U9KN9ZW4S2VZ)GJYL9G!-;QN&PJ,=TOSKS,W79^6:A=YN!KTA<)%NS=
M0J"#Q>*C2E7D%':R"09`=(-V:VO'<6G076.S=G=AU9S:]P:VW[#=@)*[W>C6
M.CTO7T-<:#V8A)38=2@T-<6J;N[TL.6-A#&9O&SQ0BR1/!L.!8ZE=HY)[L(]
M9D'_`&*;?(&E"OK)+PJZ=J-IEW>8_LD&OF?5MAIQ.IET^YJ3G6JQ7!I8CA*3
M;M5"OO=*8%5$@NMW>VAJ=IVKVCJ/MB;L[`0TOLO7%;ZY-=%S%^I5/UCK)CIE
M]LU;M)$EUI'BSV/?H[L-%H0[HD^"[&-75C$C"5N*Q%0X=V=NII;KYUJNO:"L
M[6=,F.CIM;9FH-4HV'7%QVMVK:+T=*M5C84GJE)W>Z]$2&L9Y2WLXI@/V+U1
MZ510#`R2*F%7;JO'9>S_`!V=JU^OTU6-A:9A7_8*L0-KWLD<NQY3J@GJ>%?2
M2D?(.7S&QSLC3'LA9XN,DG8.;`\!E'@<')RKN#!(+\)H5;_SKCI\-'.Y5I?^
M7]@"H*/EC.7YJP&R;O\`P$)!TH!57$@6+%$'!E`!0RWD)P`PB&!*A@?@CZ`(
M!Y`/X@/^C^WG`_<"U6UJQ.ST(G)U,2DNM4<M[-42+.S,V+Z8BA7,>%E5B<F_
MA-AC5EXYSZ"!4G@GX$Q""4*DH=UBMA5:*MT$;W(N71,HB!C%!PV<MUE6<E&/
MD?4S24AY)LJT=H'X.@Y143,`"4<""CY@UR(][/@M.`IE44[N6!`!$Y0,)58R
MC)&(3U#R$Q5!'@/RP-@C`8#`XEO5(X?F`%_\H0#_`%<X&I=N)@1E_5":4?@J
M8PO:+04A*L4!2`O^0&XVP&;B8>"'$S0OJ'J(FXP-LMNU*@98P'$_O*%4X$`#
MQ\2^(`'UY`>,#MX#`Z;[_P`S&_88G^LX!_W<#'7KF@4(_:R1R@<BG87?2ABJ
M$*(""M]75`!*8!`0]0XP,CD&C5KY`V;H-P.("<$$4D0,(>@"8$R%\A`/SP.Q
M@,!@,!@,!@,!@,!@,!@,!@,#'W?=]NE)2UFA24:L#JZ;8JFOY>7ML5-3,=7H
MNRQU@,G(),(.1B72[QY-L&+!+S<)(D.^`QQ]``0(0G8CP5]Z^::`YU%10,TU
M1<1323$O"95$S[1$5%4SF*(\F+Y!@1'[$^)#LS?NT]H[0P7R17/34G:W\>NY
MIVH-%Q\$FVC(J%ML4T@4KJ^V(YL;B((]N\H\!%P"@$56*4A@*0N!5(_%WW/\
M'12_,+VW(H\*0JBY(!C[R?@8I@,V,:X&3;FX+P(@4>0YP.@;XI>Y"I>5/F)[
MB*G'ZJGCRE./`^GZ4+RW2#@`X]"!^WG`_2_%/W!;D,8WS`]N!)XG]T[F-.IP
M7@>#%.IL/P;^'H/(!^'K@?,+\3G;%NE(IR7S%=UI5-_^IL*'BV!B0R7`"DX<
M7)ZH/J;DHH&3#Z<\^O(?)?B-[.E1=-"?,-WL%=PH!DGJTP[%=J03@<Y$ED[>
MFF<1+Z`!N2_@("&![K?XG.R*,F=Z?Y=>^*C!1!LDI%A861.%$"E*JX0<'F5$
MVYG(EY,!$@^OIZ\B(5$?XLMX.GJ!U_E9[^%8-C"";%M?&K4RC<Q!,HFY>H+'
M7<+F=&$X+"`&*GPG]`YP+0;H^+#<53TIM><)\JOR%2J=?H6PK0JQE]H*O$9$
MD;5Y:2_A:QU%2>#15)N9`>?,O@H/)1'@0##_`.'33$UL+X.D;?";UWAJ]>S5
MKME8)*`UY*Z\8P:,N6PWQBL1FE.:XL#Y%FL5DF'";@!`O[AB^@X&QSU-BE(3
MJWUMB5Y:3GUXS0NHV)YN;7;NYB4,A0*\F=]).VK=HW<O71D_-0Y$DRG,/(%#
M`OH_]2)!_P"_#?\`JE7`PP^.0_ETCZN\^@FTI4!X_'@J;D`']H"`X%=[!Z9]
M<MJ-;G'7_7QK%#["9V..NE?7MU\:5JR,;<FHE96\G6H^U-8%4)I)=0JXE;$,
M;S$0$I@`<"R4)\6?3.$MTG<"T*W23EU)U69@8*6W%N)]4]?2M09@TC9'6]?4
MO@-*>_='Y<.UT.57#DQC^10,8HA09NF_7JS=F[11YZFS4G4&W7S6\^A776RM
MJ&9M)QKLK9\*E)H&)=TW#=R:+:)HCXG*4Q4^3`)N1P+GM_C%Z9,F4978O6MB
MAM=QM0LM*'4$-MG;<7I^1AK2]BWCX937#2[I5IZY:ECUD&XBB":;>1>$,0WO
MB)0N'KSHAU+U7;ZY?*/IN'C;;3G"KNHS,C.W"SJU9ZM%/X%1_76UJL4TRA9`
MT)*NF?W#9)-8&KA1(#>V<Q1"B?DM+[G379:8\@![9H<!-^0#V%U4`C^7H'K@
M9P/&C60;NXYZ@DZ:/FZ[1XU6(51)PT=)G0<(K)F`2G161.8I@$.!`<#$B9^/
M[IU86D*QFM#4^3;UN2C9FO%=JSQS04Q#HKH1<G#J$FDU8UXQ0<JIIJ(F(<J*
MITP'P.8HAXFL_CGZB:H$CFO:P7F)A`]I^TL][NM\O]L9,+;95K1(03&Q6ZS2
MT@SKK-T9%NS9)&(BV9-&Z!0\$B@`6_IG0GIMLEIL8E_ZX:UMZ*.V=AQY&MGB
M%YUDHT+(LDU"_9RKITW,@Z%HF8Q1*8HB0O//B&!=*O\`QZ]/:Y85[0WTO#2T
ML%RC[["FM4Q9[>RIEDBH.-@8YU0HRS3<K'4E!FA'"X31C4FR9'SIRX*`*N%3
M&#(:A:=U7JU:3<:YU_4Z4XFFL2QEW-;A&,6YDF$`+\T&P>N&R)%G#&'-*NA:
MHF,*:`N51(4HJ'Y"C+HX0)V"T:V4,)5UZMN(S<H<<'*DVHXKB/XAX@(<?VX%
M"6HWCWETD'_ISK#V-+_Y.S>M*G(?WEP,M\#C53!5,R8B(`;CU#\RF`P<A]#%
MY#U`?00]!Y#`B)W#K!'I]VEN_=Z,I4INZ-W&TJ&M)6,7GU)/;6KKK87\;3J+
M5=,-+')C!GU7M6WRS-&>CFA$)>)=G(\0,YCBJ-&P7NU'T:KRG\?ON\W[VPW3
M8L\:[6+5U(M-QJ?72@V-Z+1>10UYKZ%F8=G)/G;J/;J2D_)D7>3[Y$[TR;<'
M!D0#FVS\=^E+55Y5GKEQ8],3CQ%LB8*=/VMSK:SHM'I7[>N;4TRZL0T79-$D
M'294Y./6;MG3MD==$CQ`%U#"&+-EUK,=[-BT/2^S]11&H;#TVM]8E]N[DI<V
M[JEP;V8B$1;*74NI\A$"G:8_5.WJW'I/)F3?J-/X4PYB&Z:\NV<NX\,EOEA2
M71^,?O`#9N[>*M^MNSW)4&95%'(IMH-TZ/[14$%E1(W13$1\4SB!"#Z&X]0T
MD-`=5_D'N%(KM]TGK_LZ?76S7:EXB[%JR0V54JE;HBR&60C[8BC7KC68R8*G
M'0S=-)T=$IQ;@7@H`(!@5#(Z(^21E?[;3A'N\\G*VUB@=PW\:[7/6$:=XP2D
MTR"YJ=TF8M1VYCG23C@[A-4B:I.4^38'5EM)?(3)MHBGSD)W7=$V%(?RG$02
MDAVC8$FW$I&R"SJ*<(7.?)!RCI["-'9#M'*@%63\OTB(<8%,)?&EW>;'C(F&
MZB;T9'KSA1=U!P=!V+$HMV,W)NUXMXH:)O$;"*'<)HKK'!HU;BB<P"J`G$PF
M#H0?Q==WX:0>F8]#-R,4W*3M5RO&:[L$$"XI)`K',CJQEG1<.V:)GK@443^0
M(+*'_,PX':<_%=W8_BS:3)T+W"25=J.7+NQ1E(F$;(G[\.A6Q35G'5F^\(X-
M"I"B=<%S+&34,GS[7B!0I:!^-?N+M9Q99<O0C:UJ:0LU/45M**PL>H,3+52;
M")N$<W/8)"1(N0;)%*I*IIIII)KM>1*<0(?`O'T&^-FL=I?D0V)TP[0:ZO6B
MPUKU_E-OVZGR:-9G[P[ND-8-5QU-=SS^QL[(S<1;JF;&7<M#\"X2:N4VP'(0
MABX&PT3^F0Z5!$IQ*.R]Q-69#F42*S8:J;<(&6!PBQ.F&OSH_8M5/^$F0I`2
M`I0+P`"!@RH^.CIG2?C;WUOOKS1]A[)M6O=O:\UONC6T/L>;9O8^JOJC:[[2
MMIP%)BXIE%P4!$(#9:U(N46R"7N+R8JG`?J`3`69ZZ85^;>LE"I.V</*/6JI
MDP6*1PS8K.$!,D(@"I/=3#DO/Z@],#1DZ7=.G>_.^D)UXV-V1[/O:EL#I16>
MY=LLS#:,E`V5QMG<253M-F@H9F4JL1$:\:25Y>`T8BT.JT1000]\Q">@3N,_
M@"ZW-GH.U.R_=QP4ID#@W'>35-$RB"ZJQ!5`*B852#[HE\1_3]!^N!ZBGP(]
M8#K?<'W]W/,H187!!'>:/!#>V)``/_83`1`!'GZ_4,"*FI?&E17-WO8T'3WR
M"W/2]FOUKK5$?1O:O2M/3L%UH]GNL9M:<GV[GRET8JQRT29P@W?(MWB:B*YC
MD,)PY#RW'QT26M.^'0&S4K6FX-(UO5&XX?=FR)7LYV#A-NC,5&!M]-JYH^@U
MS5M2G@@9PT_-MD%7TTNQC%47*?#A)4H<AN9X#`8'R?\`='^[_I#`U&=_/4V?
M]4#UJ(JX412?TS7L=XJ@59)PN;1.\'C5L@3D1;F*JS$XGX#D?I@;8<2NY/)3
M2"JYU$6TEXH$$`X31&/8&*F`AZ^V99<Y@'\1#^W`J7`8'6>`7[=3R$0*'B81
M`.1X`P"/I_9@6`Z_%.1KL\50*!S[]W5P!3<@!%+6HJD//^^*1"B(?@(C^6!D
M1@,!@,!@,!@,!@,!@,!@,!@,!@6OW%K2,VYKNQ4F0=KQRL@DRD(.;9%(H^K=
MKKT@UGZE9XXAU44SOZ[9(UJ\2*8Y2'.B!3#XB.!9_5_8Q()9MJ;>R,=JW=T<
MW:H.6,L"D)1-G&]HI5+3I2R2YT&MMA'PI&64C?(LW$&4]EXV)X@J<,KP,4Q0
M,!BB4P`)3`("4P&X\1`0]!`W/I^>!\?[?/X?G_=@??(<<\AQ^?X8'RHFFLF=
M-0I3IJ%,0Y1]2F*8.#%'\P$,#](0B9")IE`A"%*0A2AP!2E``*4`_(`#`^L!
M@,"U>](5_9=)[@KD4U6?2E@U=L&#C63<2`X>2$M49A@S:H>8"45G#A<I"<@/
MZC!Z<8$*/PNU>2KGP5Z_B9>NSU:F'.HNPCEW#6"*7B)0KA[,7XJSA./<D(\^
MV=K)>2)SD*94H@;C@0P)E>M"?L]<>OZ7`A[6DM5)\&#@P>%$@2\"'IP/I@7@
M?IJ*-SBD8A3ID4,03@;Q`XIF(0QO#DW@43<B`!R(!Z8$8>EH/Y"=%ZCUUJ"N
M=>^J,O&:TIS*EL)=]V=V3&GED8=%!!A,G8)]<I'^'A(>*BKEK]PO[!Q*0BIP
M`3"%R#W3Y.3NP!+KSTL08"FH(J+]H=QKN2G^_;^SRDCUB23$H18J^?`B/W!2
M\?H$<#NI7#Y*N%_?T+TV.;DH-O8[+[C*`\>P!CK^YUL'Q*J(JF*`>I0`H#R(
MC@1Q7GOCW*U[W:VO2('I3K_9UFHVCM+Q5S5K':)G`5B+4M\WL6YP!6BUXUI`
M2CF1?-G2I52?:E(B1(AA/^O@`J5S\F_R+-.5'7QG:Y;(J.'+9J+GO)KI!58Q
M%A^V4$BE#+_AG;&(8XAR!3#QS@<9?DZ^1?V&SQ?XS]9LVBZ"*ZX.N\U"^\8>
M^7R13=M6^N7`%5.7U`H''@.!'CD.0CH^37Y@.X5)T#6:CN3H]J76-3W7LVD5
M-C=U.TW\Y(P4S3;3';63/(PM8U:H]6CW,9K]9%4Z)U/:%P0_[I1`0O'+_.YW
M0@X!S>'OQX5:-@FM3&VS4U([.WDE&1D&W%),K]VL?K40[%GXKBNHLNBBDBV`
M%%3%+R;`DEZN=L/D;[8:'U;V&I77_I?6:1MJI-[A7F=D[%[J=6%G'.G#IN@E
M),HOKD=D14PM1'R(Y,7@?3G`N'3MK?*1=#7A)'2O1*)/4K<]IB8N=^[Y?)OW
MD<RB7SJ2*+;K^@HFQ.E*@4B:A4G!5$S%.4OI@=>ML_E;J@V9**UI\>0(3]LG
MK27WMS=ECK&<SK@'2WW?GI15--8%`X$J/BD``'B4/7D*B3F_ET,<OO:]^.IN
M03`!A)M?LNZ,!?Q.'CIE`!$/]W\>/K@6\L>XOE5K%\U;K5_K_P"/Q6Q;3;[!
M<1CYOL'LF,+'!0(B.F'*+TRFL"NC*R:$H0J7B7](I'']7H`!<:$J_P`CEBOT
M=<]BH=**\YI5(M<=26E+D-\6E"5MMOD*F1PM:5[#7:>>.K45!0;S@K$5W2[Q
M=#R,FD0X&"JJEK/MZ^[0ZSV]MR2ZY.*54=3;;UY+L=;QNTF5F&0OUEU7/P;V
M/4LSZ0B'3-N-!6(Y\_;,F"H<>0\<!GK@,##;LP:,2VET]5L*B9JN'9$J3])<
MO+9"VN]([B9ZX=*^7"0*%MJC<&RBG)2/_MP+_C&2P,Q$!**2?@8#$`O!3`(#
MR4OH7D0$0Y``]?VX'+SQZCZ!@8GU]%BGW:V@X8^Z#MUUKTXC8?94;`R%=KLC
M<YJZ5XDG_P!H/*BR</#)G4^C;](>@8'C_(@9J3H=W$,]<`U:EZV;C%9P)TTP
M2*%$FQ`PJ*B5,OZN`Y$>/7`A8^-W36BMF]9>GTQV"FIB`CHSX[>KD!06R]^G
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MK2I["&`3>GD"0QK+$,Y)2,)('0;#()LE'(IE7]I/WB@!_$O/`!?/Q_:;_3@6
M$Z[,F;"I6]-BW3;)K[JWR\<II?NF?N-OW`72Q_Q!9PH3W#!_O''\.,"`K1C0
M6']4+W3$`.)9[H77WYE!\2D*9!/K&T`?'CS44`K8`\2\B!?4<#9O3#A-,/R(
M4/H(?0H?@/`A@8T=B]/3U["E;"UC(Q==WEJ61E9?74U-D?*5J?8S3-LSN&JK
MZC')K.U:%LN,8(MG2Z2:CF*?MF4FV(HX9)I*!2D7VBJ%BK\W5]EQKW1&ST:Q
M.$E-;;(42BW(ND&+EHZ4IMM-[-0V'`.5Q*HP>Q3I51PV,45F[9?W6Z(:Z?QE
M2*;GY<="G:C[K5_\,.D9(AE2`*RB*T#IW[51=7@%%!,!3!^KT_+`V\<#X4*!
MTU"#SP<ABCQ]>#%$!X]0]?7\PP(\9R!L_6:]WV4C*W)V+KUN&Y+;+D)6M13^
M5GNO.YY)K%%L-O?5>.8KR$_IZ^R\:><FGK0ZCJ"F'+TZS=1D^45;A&7WLKAN
M[._>D.X=$[,K<Q":_%RT?,ZY(-)P]MNL1V.T;85Z%,QK*;0>5E!S!ZZF'R,D
MNU,LU^U`A?%%RY*8-D!+D0,(E$O)S_I-]0X,)>?3TX-X\A^P<#EP&!^"'(<8
M&HEVOB4V']3WTU7(HJ<TS6=>20B<"@BF>+U#V,AQ;IG*4`$QT"%4\1'RY$1#
M].!MQ(MDD%%13_XBR@*KG]/(PE#@A3<?[)2_3`[F`P.NZ'A!3]OB7^P#'*41
M_N`<#'W09RJ$VDD0#\M=_P"X05\BB'!U)LBY?_%.1V`E'\0P,BL!@,!@,!@,
M!@,!@,!@,!@,`/T'`X%?>,FH5(035,0034$OD!#B'Z3"4>0$`'\,#]03]LG`
M@`'$PF4$O/B900#R.'/X&XP/`L]/K%TC5H:W5^&L\.OR*L38(MA,1YS>`E*?
M[60;.4B*%YY`Y2@<!]0'`TB>I;YY8OZ@"SZ<3V'L)CJVP]B.[\++:THNY=D0
MVOEX;6]-GW]*B%H&!G8-I'!6)&N$$6:1`1(H<Y3>8<<!M;VOK72*-8ZA=*4%
MJ1GHC9>LEFB\OMK;LD@SB'=@;0UI^ZCY>_24+9EI&)?F120?M%4DQ,!BE\R$
M,`9MM@$6Y`,83?4`$?KP!A`H#_UN`]?V\X%G=Y[JC-$U&/M4C6;/<UIJZT;7
MM>JU-0B5[%.6S8=C9UBN1[49^9@(1NDI)/B"LLX=HIHH\G$1X\1"@B=A]DF1
M\S=/>QA#^R=0$SOM`@852IF.5N/AO)0I3*'+X`;D2\B`CP'/`79U-LY#:]1;
M6I*M6*FKFE+%!R=8MA(<L_!S55GY*MS4:_/7YB?@UE&TG%*@4[5XX3.GXF\@
M$1*4+GX#`XE0Y`GKP(*D$OY"(#]!_'Z8$+,/VG6U!JWJIURG*2I-+=E=3]F8
MAE=(V15;MZ3*4!E99F,+.1",&LT+$6QDL+5JY,Z;@61*5+Q,4YE"A*5UX$@Z
M`T:*9RJ)CI[68D4(83$4(-*A!*<IA*03%,7U`1*`B'X!@7@$>./IR(\!S^?`
MB'_1@0U::^2/M5V:F]PQ_7SHC4+)!ZIN]OI:=BOG;R(HBM@_EG96SM6-YL(!
MCI"VN(QO(V+5$H<S<[@ZB3?VA`Q_/D`SOZG[OVGO*HWF4V]IB$TC;:)LVRZR
M>5VO;6;;=B9-W4D(Y*6F&EA0IU'5:(&F'2Z";=5E[@I(E5$_^)X$#*?`CDI*
M-NHO?#N!90TGM&6@M@ZWZI-X;8U=AH)*HSCJI1>VF,W%_P`5L$_#F=RD":1;
M`X3:D7!!-=+S$HF`!#+%7:$Z;CC2VX`XY`1*SH!N0YX_]*WT_H/'I],#@+LJ
MR%'TTUN'@?W@%IKD"F_`!-QL4!_24``/V!@:R/\`5.1&S=M]/>O*T#I#:J$#
M1NQZM@NL^^@8&9KU7C);4]^I$)(S_P#+]BL+E@T=V6TM6Z1C-O;,H?P%1,3`
M;`MGMWY5^OUWZJ;2T3!:DW)!W'8'4V-T;'6"3TE*1;9K?:U6OX`G,34TJV0:
M#"VB2>JE<<NEU2-6Z8F(H"@E*$[WPG.73GXK>EJKQ`&ZY=3J)BD#<68E20M]
MH0;^3(Q2F9*&;I%$R(E**1A$O`<<`%XM9[`V)4;IV`@(70.S[U!?YY6269W"
M*LVJ6L*Y5F*O3G[MC&L+/?*]/I-V3U50AO<:@`*";Q$P8%VR;CW`<3>/5':1
M2@;Q*9:]:+3\P]/U^)=GJF(7U_'@?V8'=3VQMHZ+@ZG6+8:"R8H@@@:\Z;5^
MX]Q3P4$%$=@*$2!`OZA\O40^F!0LNPV=>NP.AK<\U?,5"K:X1V__`!V6FIZH
MOQ7/;*[!P<`C'M*W8)EP=5PX37.J*I4R)I(B;RY,0I@R]P&`P/A4PD3,8`Y$
M`Y`.!,/U_`H"`F'\@Y#G`B0W?L^O]C^V4YT5V%:;?H-M#T.O[/ULJXA2P4UV
M'V!%2))Z%MVG;J_6]A>&Z\V2(8R3F+:>Q+2TH`>^4(QN=-V%U=-=WGAVLQ7=
MSU6Q._\`+N=E*-8.QFK*);KSUXV98Z\5-*6D:C,U2/G)JKOV;TQFLNPD61&,
M?,I.&+1^]!N=0H5'MWO?5ZG0YVW:HUIM#>01;$CU=_7J'>:O0:JR,J"3ZR;$
MV'8JPV:P-6K+83OY48AI.SB$<@HJA&N#`4@AAH?:<QU:W?U_GX.]..U.^^\-
MPC)#=^I=3L$Y>)EZ!(#]E6NP6M7[F14#7NI^N]).WBFX2+K["U0:1W/!9H3J
MJ!G7\D$.E9_CW[K0JR/O$DNKF\VQD3BHB"ARZ[L0E*)BB"B93*IAZ@//'T'\
M<"Q?PP,TG?Q4="_N#>\=OUUI[8%@$#'-[(N43'!40$1%3V0\A_VOK@9AZF1;
MMMR=GD&Y$4^;IK9=82%("JJI].4Q+E<Q0`3&]MN40$?7^[`BS_J,J?+7[XR;
MA3X!!\YG+%NG0</$(QT6^F'AW\GL>*8(E281S=V[4\_N1*)BHJ^V`B82&`.,
M",'M7\FEB[!=,MX=>8KIUVJ@YK;'7$VEXI\MI.Q/#(V`8(8N(?#_``:4>+JQ
MBTF^4^X42:'42;`"Q$O(@E$-C3XWX6>J70OIU7+E%2==LT3UTU7'2T+88][#
MS48_3JT;Y1<G&RB2$@RE&Q1`BR"Q"K)J%$IB@(<8&;A5D3>I54C<&.4?%0@\
M&3.":A?0?WB*&`HA^`CQ@8Z]97BKRJ;$,HU=-"M^P?8AFD#HR)S.R--QW!$)
M!`R)A*5FZ`O*13`!P`!Y^H<!!CJE15'^J`[*M./\&6^/U@Z6Y+^M)(CSKRW(
M'E]43B9MS^T!_LP-ET/3T_+`8'ARU<A)UJJRF8QA*LUS"HJSE&+22:'7X*!5
MS-GR+A'W4P+^D>/T\CQ@:\=29-H_^I4M4<P3;L&$9\?$4U:13)JT9M&S$']3
M;II)(-T4P19D!FF1-,H%23]G@@!^K`V.,!@?"A/<(8GF=/R*8H'3$"G()BB7
MS((@8`.7GD/0?7`UA/EVU)2:1\D_PU7Y@C56"NR^]U8?S4<K6$?XT[O$`6C0
M#>V$L[,6SI!%]6')&#ALN<Z2SM!FJ0G^&L!PV?"F*<!$IBF`!X$2B`@`\`/`
M\<^O`X'U@,!@:CW;MJW9_P!3;TS5:/'**\M7-7NI)LN\.+5RK'ZT[+L6WVS8
MX^*!2,SCS[?C[JO[_EP``&VD@H)G;HO`?I.B7TYY\3-BJ`8?[3B(?E@=_`8'
M6=_^9S_VI_\`JPF!8;0Y034W%P(C[N^]E&-S^'ZXDWIQ@9!8#`8#`8#`8#`8
M#`8#`8#`8#`8#`XU3"1,YP#R,4.2E_WC?[)>>!X\C>G/X8&G)H/K9=]/_P!1
MS(6UTYJKG7]IW3V,OT`*4[,/+H1?>&B]T3!V+Z(48)13%FQFZ'*G_2N<1;G1
M-P!O(N!M5[OD`:1U,X+YF5VWJA@4`-[7MJO+I#A^H1]7!#)`8?$/4#%`?P$,
M#%7MSVN[`:IV[I;0'6K3E`V'>MH1SRTSEKV_>9VD:\IU4;W"N401*I4JQ;;%
M-V%6QW)DK]N5N@B1@BN?W3*`1,P8];.W;OQ<FE]/]L*WI:H;O/VPZKWZM*:5
MMECG]=736+[L%"5LA80+ZRKMV+=Z:X510FDC,19'(NB[0,4BPH(A,PL82M1.
M4.1+X*@'`FY`JA5!X`!`1#@,"+C5N^=[1NO>REDUYI;7E@I^G]\]NXMK(VG;
MT]!3UF5UULZYOIU3^`PVJK$WBDW;])RW;`9XL<WB0XA^KC`S=ZQ[D=]ANO>G
M=XOZBI0G>U:#7[NK359@D^I7/X\S(])%FFB1\223]A-0/\8&R'F`\^!?I@7U
MP.HNX0(G[YEDRHHG$ZJPG*"2*:8*>XHLH(@1--,"#R81``XP-?:6ME-MT)T!
MDZW5=B;3B7^N.ULO7MQZBV-*FU'5'T-4KRFDSVS48*V152MK!VL*@LQ?DE%6
M<DR,U%!(RQEDPFEZRJ^]UNZ^K>V='W=(:H5]E4"E42]RAP!O;4`CAV0#DYX$
M`55#D/0YOJ(7L/\`4G_AA_T&P('/A$^O;S_^LVS/_FS>\>!)MU.#_L?8;]O;
M#>@A^W_UNLP]/[PP,L,#'CM-V*K_`%5TS.[HL]:M-PC(:>H%6;5FFMXI:PS=
MBV;L.J:QJ,:S5G9>"A&*3FTW%F5=R[=I(MV_FH81`O&!1).P'8(?WNBF[B#P
M'/GM3JL(<B'J!12WH?D`'\^,#C-OSLE[2ATNB^T3*D#DJ*FY>MR0J^@^A5`V
M@H0!#CCU$/K@=WK)VF@>S[G>U;_D"WZWNW73;0:7VG3;D>M2?\/N(T6F;$3_
M`(1-U>8G8&QPZM?O#(Q7":@`"WF7Q_0!A#)TL%%E75<E9M_?6%$3J"W;F]$#
M"*92$,D)"<>0AR``8>?4><"RW6:&:P>I6<<S1:-FB=NV@*+=BDFBV137V?<G
M'!2)@!"J<K#Y\>GE^`8'MZB+XO\`<1?7TW%/_7Z\#6J@8!_O`W^C`O+@,!@,
M!@,#\$.0XP,:.SG431?;RJ5RI[MK#R73IEP@;Y2++7IR5IU[I%H@'[=XE(U"
M\5MS'6:NC*MDCL9`K9RF5ZP<*H*`)3!P%\JG3:Q1*Q!4RF0<95ZK6(QI"UZ`
M@6+6*BH:(8)`BRC(YBS22;M635(H%(0I0^G(\B(B(>^9#R(!144$0,)RG'P\
MP,//'KX`'Z>?3T#T],#%[3/3#KAU^VAL[;^I=;QM2O.VPBV]JDVRKER@RAH=
MN4C&JTYD\47;4:F%?"H^-#Q)6D:9^L=?V?/Q\0\_OXF97HQW&33,)#CU@WJ!
M3A]4Q#65E'W.1]`]OCGG\.,#'OX7BF)\5G0]-3[?S)UTI!#&:CR@H8B3@IU"
M")C\B<0`QAY_>,.!E=JD3?YW]I!$BA4QN6LO;5%<BB:PETY42*%30*<5$12.
M'!O(`\AX$/SP.QV'1CUF>G1D6S-RDCV#U,Y0!Z0ATT'J$RNJT=I"IQ[;IHL4
M%$SAP)3E`<"^K8"G\.'"HF,D50">^)P\!'@#%`PG,)>0X\N1_MP,9N\$Y+U?
MJ-V%L4!89&IS<'JRTR$79HETDRE(9R@P,'WD>^6(H#-[[9C%(L4`43$WD0Q3
M@4P!#'0^LW7O0G0(_=[KC2K70]^:O9[$M=4GF^T;](R%FD8#<DK6)6C66)O=
M\EJ9+P^S(^!)#2)9!-,RQ#IJ&61<))JIA-%U,DI^5HEU>V2JN*1++[LW(X=U
M1U)QTPYA%GUW?R"S%U)Q"KB+?N4';I4IU6RBC<QP,*9S%X,(0A:^(HE_5&[O
M6'W"$??'NBFISR"9TTW&@U/(O(>O@LF(<\B`#R'UP-F'`8'YR'YA_I#`UV(M
M4B?]2Y.E`B157WQ\D(<W_I59!M.5U8BA?U?J*FJJ)>>!`.>/K@;%&`P&!KG_
M`#IU>-M'8KX:XZ3!TW1EN\S"JDE(R0"*FF"]E=4-%LK#R+=5&59/VCEF1Z11
ML;GEGX*?X9S#@3S:QM+F?@UV,Z9LG<ZM(J5:Z(-R%13-8H]JW<*R#5$"EX83
MK!PE(-N`X]EP!?J40`+E8#`8&H=WG618?U,O0EVF555=W7]0QJJ90\B(`Y@N
MS"1G7!2@8A?:5*0YA'C]10_'`VZ"`7W!,7@!/QR8.!%0A0_2//KR`<_A@=G`
M8'`Y`#(G`?+Z<AXAR/D4?(OX#Z"8,#'K03K[E]O!`$E$AC.PNQ&AQ5()?>]^
M+JTF59+G]Y$2R`%`WTY#C`R,P&`P&`P&`P&`P&`P&`P&`P&`P&!Q+?\`#-_:
M4?[@,`C_`*L#7#51.G\Y]%=BHB5/^;!1\#&#W!^XZ\]VDTRE+SR*@J")O_`X
M'`FF[+3,76:Q6[)9)1C!5R#W%I64D9=ZLFFV9MB[!KT:9=^JL=))JS!Q)ID\
MP$Q_<.4`*(#@1S]R]C3RV[=(]@NMUUZ\[42H40[I=WUML7<G^47N13G8-&V(
MVME?N/\`*=P8/'H*TTT2+-1N3Q%\1P4YO;.G@6KO;EIV.V+UT[";RI.D83=N
MO^PO7776G:;JBXR&_I^BU^4[$5Z<OUW:[&/2:@@Q;76OUMD9T1G'MS,X=NJ5
MZJ;CQ3"?X?$S82E'DOC[0"`@/(`;V^>0].1XP(TM4]<K/8*1N^%J._[S1:GL
MGL%VHF;%"0E,UE/N$'VPMI6\UD_A,W9ZE)O67MKNE00\@7]DH@`B80YP,V=!
M:?ANO^E]::4KLU8;%!:QJ453XF<MCAB[LDFPB$?MVSJ:<1D?$QZKXZ8!YBBV
M03]/TD`,"FMS;;GJ@\K%!UQ765TV]L)V[3J->D9%2*A(6#@U&G\V;#NKYJ1>
M1:4NHE?-BJE;I&<R+Y\U9(>(K&72#PT>K]3LZ1'FY)^X[=EW"4B#Q"PV.8@J
M:@66*JD^CHG753?PU2;0PMEC($([0?.C(<`LNJ<3&$/33TQJO1/7:S:HTKKN
MI:QUQ`T2_-X*A4.!CZS5XTLK$S\K($CX6&;M&34TA*/5EU/;(43K*F-]1P*B
MZVI^UUVT(EXB3V]+:M3\!]!+X4:"+XB'YEXXP+T#]2_VC_T8$#GPC!P?M\'Y
M;HV:'_\`N=WDP)&.G#B,6'M6G'D<%<M.YF[V\R*QE134DS$JKDAVH**J%*W_
M`(2Y:E$"`F3W`./CY"8Q@S,P,/>]NA[CV4ZW674]"EJ_#6UU<M-WJ"=VI*9/
M7EY'4&Z=>;<2BI=:!924HS93B-(49"LBW6.D=P4X$'Q$,#A/8._G/*>L.H_B
M(CP!]T;C\@+S^GGC0X!Y<?7`^33WR`F_X>M.H28^OHIN3<RG(_AZDT8GXAS]
M?K@4WTPZ^;FT]<>WNR]WS>OGUH[/[]B=P,*]K=Q89."H\)#Z9UCJ9G6%)^RP
M=8D)YX0VNC.A7_AS8H$<E+R<0$0#.T>>!XXYX].?IS^'/[,#"73G8?3U9K5B
MITU>FD=/T_8VSXB=B5(2S"ZBG"M_LDDT0=F_@PE%1Q&O$ER&+R4Z2I3!Z"&!
M=7KU8XFW-ML66`<N7T%,;@G7,3(.&;YD1^V2K%/9*N6B<BR8.#M0?-%DP-X>
M(G3,`"/`X&0V`P&`P&`P&`P&`P&!BIWK()^E';@H<>O6O=HB`_NG*77%C,=,
MWYE4(`E$/QYP(X_A_P"U_76I?'9U(UK8]LUB#MVO]"ZQ)=XN5-(-6M*<7QJ\
MGJFQM-B58DK,"O-Q"I%FB3IVFHHWX/QXCS@2<3?732&Q[+)[+60G@L%S8PAY
MJ;H>V=B5!I9&L,T/'P3QX2@W"!C)0[)B/L).A(90R)"D$YBD*`!Q1?4G2$7/
M5ZS$B+I*2M5FVMD@#6?;VW;?'L)YDFNFREPA;3>9B&<OF9'*GLJ+-U!2,;R+
MP8`$`R"10,D_Y*0P(D8$1*<>1`1*X4$"B<>?(_AP(_CZ\X'CWBD579-0LE!O
M,(QLE.M\+(UZRP$DD"S"7AI5JJS?,728\&%-9%4>!*)3D,`&*(&`!P,"M9_%
MEU7U2OK]"`4WK.U765C>VZJZXV)V*W+LS5Z-I<.6T@PL$A0+U;YZMRDA6YIM
M_$HOWT#IL90YG9"?<""@!>:@!N#5Z^R8M34<S=&T[MK9-W@9B(M](CF*M=M=
MB5DH=FHWG)]M)(R+9L;A4ITBEY$1`?7@`U['&]F6G?ZCK<&Q[]K7;BSB:Z(1
MM;2J5`JK3:,_!(DD-2/7%BF&=/F7IH^O^W'@"CH@*@C]PD*Y4B")P#8S@>R:
M=JA(JQUC4&W[#!RS9N[:3$)':]E8IP@<3`L=*09;+6:#[(E$#@!S&3,`@;U`
M0P,2N^7<CMMH'6#/9'7#IS-;8CZVG/3^V5-BV&)J0U>GQ+)H9FK4X*MV&7GK
MS:)>0=BFDR0*F0J:)Q,<#&3*8,$;S\H7RSZ[H<YL6U_%*XCJY7H-6P3BB%HM
M4L\@XEK#NIF3DI=G&Q2JJ$?"-V_+PZ7NG1`A^2>GH&$/QB]LK)WO^:B&[26V
MF5R@+SW2;9-%K4+4)B7GH"9K5%VBS@T;>24G&,<]!W,R3-VA]M[0`BDQ*?S4
M!4!`-QK`8#`@#^:`&2/9CX87[TR9_L?D%J`MVB@BF9RX=OZ<T*=LL8HH$=M`
M6]TH'$OFF4X%Y-P&!-)9Q;TZV1UT`"-XN9_A]<N:@^)$_%5V#:M3Z_`D3*,7
M(NOM5U1]00=%Y#P)R4+K@("'("`A^8#R'H/`_3\AP/W`8&GQ\BSMC'_U(?Q_
MOWB<FY)[?6>+*V:2/VK9-],V7L$QC9!RE[9O?39K*<'1`0%7W"\CP'&!MVL5
M0,[?`14QP(,>4J0F`WLI':%,'!0`!*)Q]1_,<#VL!@?)P\BB`_0>.?\`2&!B
MSUH,J>P=I2K"(_;]H[BDW\B$`Q6ZFNM4N?`#>(&,3WG!A#U_+\L#*C`8#`8#
M`8#`8#`8#`8#`8#`8#`8'&J'*9@YX]/RY_M#^\,#6?M)EH7YW=5NUY!DE#N;
ML@\D7CU9-@DQ57ZQ=YT2,Q.NH"1Q#[5$`/R'N"?T`!'`F@[)WVFDBJ2@%CK2
MRC?L!UL3>)K3\:A[+>2VO`,RNTA%^G[IV_NB8`_4')1Y*;CC`R-1M-),T%5Q
M;JRJ"0J%<.?YBC`2!1$Z8*^9B/023%,RQ`,`\"43!SZB'(<`WC78CR&P*IXF
M3`P$&U0:B?@J0R9#@15V<HE.7D`$>0'UP.8^P=>I(^V6]4XO(`)?*TPG(@IP
MH!@$[[UY(/(?LP+,:$NE)&M691&W5'V2[@W67R;V*&,D<W^9=F*8PF(],4YS
M'*(B(#ZCZX%]_P"=Z6`<C;ZOQ].?X_%<?Z?N^,"++8G;!EHGMGM2R3O6WL1N
M5Q8Z]0:9JV]Z*I5(OE<+KN+@R6.P12T]);(K00;MYL6>?"[0533!86+8YCF`
MB0%#WGWRH1L0FZ7FND'?&+9,6;N4>2:NL=0NH]I%LFB[YX\=J1F]Y!9(C-HW
M.<X%(8?T\!Y&$"B&2.ONT&HNV?4.=[$:2L#NQZLMM!V4I!6![#2M<<*FKC*Q
MP,U[\9-M&4BQ&/F(Q=`XK)D#E(3A^GUP+G=6G9'O67KFZ*J54'>A]1.BG`Y3
M@J1;7]=4]TI@$0.4WN`/D'(#S@7W'\/V"'_>_P"@<#5[^.?N#J#I[9NUM3WU
M7>QE4L,KO#;2;1M'=2NR]QBW*2':WMA;FSN-L-)U?8XB49/JQL&)=IK)J`D8
MKH"D,<Q3^(2K_&EM6L;?@NVERJ<?>X^$G^Y&S[-#_P`_ZRV'JV4D(&QU;7[J
M'E6D'L>M5>879/$D#A[A4!`BB9B'\3E$N!)=@8?M^SEHD>T6W^ML'IFPSX:J
MU'J/:(7QI9ZE'14Z;:TMLB(1KB<9,R#.0:2$0MKTQS*B!D#D<@(B7Q]0O4YN
M6QD2MQ1T_+.S*K))+$3N%*2%J0X?K<*BM+%*HDB/[P$$3C_L@.!P)W/9RBBX
M#IJ523)X^T9S=Z04RO/ES[96K]W].`_?$GU_MX#'K:_:[8FJ;KUIJDUU[G6S
M+L)O>"TFK//K]2%T*>:6H5ZO*L\M'0KV2?2QFI*2=J9%/VR"HN42G$.<#-T3
M"/Z?ISZ?3U#GT_'D.0_:&!\^P`!P558H`````ISX\!^'D`_Z_P#HP.0A`)SZ
MB81XY,;@3#XAP`B(`'(\8'W@,!@,!@,!@,!@,!@8N]WT$G73+MHW53*L17K5
MO$!1.O\`;E4$-9V8Y2&7\3>T4QBAR;@>`P("/Z9]LWE=5]AVTBT1.W=43HJ9
M=B;R4:&.IU:CDEB>VJ)P42.D0"B`\D.`?3U'`G0L=7B^J[I#8FO60P&EUY5J
MSVWKB*8+J5JL,)5RHT:[-U_7HM(C2K+Q,Y)$<61NU3*T>QAE77ME=-Q%8,Q4
MC"=,AAX$1*'(@'`<AZ#QP(AQZ?AZ?E@?ONIBH*(*$%4"`H*?D'F!!'Q`XDY\
M@*(^G.!]X#`8&L.X(HG_`%2[([?R0!;H9:OOCH`NG[XIQ-&!-=V90@(*'3,5
M,I1`1``(3D`$,"73?\)HO34TA9JA>;-I3=-V:2+J#KVD8=S<[3ME[''1<\R'
M7*(CYB.VD)50]AS)&C4'C5!4Q32;4IO<*&"O9JS?)-NS14KK*]:LJW7>`OL<
M@Q#9%<3<WPTBR+8RE0:;HBJRALR=Z\L9^(2;+OFD1'W-`B2BR"EEB%4P,(>-
M\D_:+Y)*1U*VE>]5=>^HFZM/25(F82WW"D=@+M(S;JH["=):Y^SJ56EM>5V,
M?3Z+:TE?N'!Y?[5FDW4)PJ?DN!!3_3V$^V^0;KD@S%P+3_DU[/IO452BD1FN
MV[)69-LB4I0,F8#I@80#R'Q]?K@;[N`P&!KX?.7)HU[;GQ"V999=,8KY$=7-
MTTD?$"K?Q6PU!HL+@QB'$K=%N!S&$./4`]<"?N6C&,W&2,9(-T7;)^T=L'3=
M8B1TUF[A,R2R1P5(H3@WX\@(`(`/'I@4I1)991O)5J5>?=V"I/&\5)N5"D16
MDT5V*+R)FA2(!4P"58&Y,)``HKI*@`!P(`%?X#`TW?E%'V?ZC'XX3D5.(FE^
MI(JHI-Q$A17VIN=J11VN!N``R1#^V''[P#]<#<19)E#S$I0`!%,?<`.!.9(O
MM@!C?[7@4.,#T<!@?AOH/&!B?UV>),[+VL5=+(MF;;LW;W#ERX4(BBW;HZET
MVZ57764,5-%%(#F,8QA`I2AR(X%SM:]A-([DL%SK&IMGU#9$OKP\:C=0I4JE
M8XRO.Y8SXC&.?3T5]S`_Q4XQJPG:$<G<HE*!E"$`Y!,%X\!@,!@,!@,!@,!@
M,!@,!@,!@,#C5_X9Q$1``*(B)2^0AQ^(%_'`TS^P'>;5.F/G?V/K[?NG$]AZ
MZCQC(]N-81C-H7)U.1^@[A8X5=UIA9N5ZT@ER[?<ME)@5A;HJ,"@8`%;](9_
M6+Y=?BV:J`I9.L6U$!6DF"D.WG.G5>;.3SD2J=ZV/&OIAR#0TB@9$SE`$Q]\
MB3=10@?I\L",OJQIOXT>[7<+Y"=M;O<N--:54F=67'3E7MDG7M$1YXR]0KZ"
MO)W%26.ZCEU4IZEQAU02X\'#HAS@)EB``2"1GQD_`S'-D2LMIUOVBI`FF<^Z
M8-3S;F1<("D)31?MBD=-T;_9^O`@("'.!Z\'\2GP;65-12%N[&P)PH(*.5$-
MSQ[_`.T3:IE!`'9RQYC%321``#R'@"@'X8%/,OC3^`B!4-`M=BPI'+M^JX5(
MVW@_."LBL)A<J'/&IECTG#E83&4``)YJ"(B'D(X%YH3X-/B1W32!N&O8VV7F
MK+%F8]G,5/<\\O'+R$0HX:R#47K03`B]C7R(D4`PE,FH4`,'X"$8%!^$^+V`
MSK=*U5H36%\C*]I;2EYM-^[&]MMRU"RVBQ;=II+,^&(HNK=-VJ,C:I&235XP
M:+"^-YK,52^HD-@5^Y_I]]JL63T675[I-++J-72*;=SW+[9BLI[S=5,G@Y=Z
M`*W1.F<Q1*)BB4>/$0X$1`)7.J?Q,:XZ_=''&@>P:[;>5Q:PFVY*U6:&FMCU
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M]$ZWVK4F2**X[CGI*2.[D+2U.9%&(.<0#GS('("$WI2^HB(?CR'_`*`8'W@,
M!@,!@,!@,!@,!@,");<_<'Y#:WV`V?K?1/Q\Q^Y=34AS`1M?VXMNVO5=*T2,
MC4XRPS*/\(>-5#1ZD#)/C,%4%#E7\RE4`!(<,#&C>_8?Y;]K]?-RT=;XTJ?4
MT;QJB\U*1D9#L/6)%]$L+55I.%D91C#L_9-)NX9E('7(W%9,RZB0$#]X,"E?
MZ>+K9OO1FBMG;`W?2CZ[B-NL>NL5J:#E18C8I?66HM%P57@MASR,=.S#>)>7
MPTN)R,#`FLU^R4]ST42P)Y]I5IK?=;WNEJ!]RG:J=:*^=NEX"HL$U`2,84B8
MF50`BGF[`2CYD_4`!Y%YY`,3NJ&RNZ4YUVT^][!=7('6FX"UJ/B[_4C;SK]@
M-'+1+C^$$FE'\36Y!F9].Q34DD=H1PM]LJN*!EC&*)L"\"5BW2WNTM+?Y4UX
M\>\KT2T;H&VDQ3,"[60DSJN`5&J"4"K)KE#Q]1Y)_9@4+5-K=RGUXV5$6SK)
MK&"I$3),/\K;8V[#-GCVY13B+(J^+-0:%"=J0DC'RP&3Y,H!%4C`)"#XF'`K
M-#8/:$SUNDXZ]:Y;,3MBG7>J=AS**$=>V<QVZ+1+47*A0.!0\A4``*//K@8H
M]HNP/R;:_GM;%ZX=+]/;CJL_%6+_`#!=*;R/_,5+L3,C52OMB1LO%:]CWL!*
M@=4AWB3IPJ50O`H$*'D8(`-BT7YD9+Y)$>Z4?U)8TK::^CVNM+-4:%;*?9V3
MK5$H=FRFY:CV*4M\BI#7EI)0K%JHX^V>$9`Y,(-U3'!1$,_*KN[Y;:*XE)JB
M?%10$+1854#6*TV_:+F?MUE!NQ:,A_C]H?["-)+I?=L#*)-_/[))(Y/;1(/D
M(A;W:>Z/ZB79L]25X+K36](5VJM+(_LL-J:2HCA_?WDQ%A'P323G=EW&WILF
M]4=@+M-!FW;F<J*?XIS$(4F!@=M;J5\Y>WGMLF'FM+[`S=SAHN)M->C-@Z@A
M-5WU**L+.R,W&QZ#77M>K5MD#.&1B'<KE3>D3$B7OBB(IX'E=(NB'R[=(MS5
MG<-`Z@P-EM-"I>Q-8UYA<KW2B4Z1INQ+H_O<FLY)![-92"%A92LBH":HJ`U%
M-(A"A^OD`F.0[*?U`*_^(/1;K2@F=RJ4"+75!%5%N!P`AQ*?=9O=-X"(^GU$
M.,#C;]B?Z@D[<QE>DO68#E][P$+>R!10"J*@F*B`[N$$CBF!1`H&'GGZX'K+
M[T^?SR<%0ZC=8`*F`BB<UC:"*JAT2J))"4-W#XIE5$2**>HE'D>!XP,1>U76
MGYO.YD]UUL6R]/=4*T^ZT[>A]V49.M78K9)]:(W[!1O'3P/;A8C.HEN=EXKE
M1%$ZI3\$,40\@#-W3'>3O;K/NAJCK!\@&M]*U&)[*TNZFT;+Z0/+3+M/8]/>
MIR"T7=)![89..C8:7K*3DS4P)^X9TF`&'CTP,T/\Z-JAV[GJ)9M,-J?2Z+HZ
ME;#<[%B[Q'VQ>X0UOO-JJ;ZJOZFVC8MY`/Z?,UU"5:/06=(J,1>IG\3&3*(9
M]MU2K(IJD/[A3D*8#@`%\@,`&`>`$0#D!P.;`TV?E%^X3_J,?CJ(!!*W=2G3
MM8WI^E4S/<6Z$DU>>>>4A=G+_?@;@D0<1?RQ#'-PD9H4B8F'P+[B(G,(!]/(
MPX%18#`8$9D]$Z+GM;]ZH+LE#R<_IB0[-"SMT1#1-\G)1V=[0NO9X0&D;K)L
M\N[A1*?.U4Y9)F]HA1.KPB50<#I]##:[I>Q=OZAT1;MK6_2+2%@=E-";,UQ9
M*RI4=DW*QV<EPKT=;[1KVAS-C;O89I$O$FSL9!=FBH'BL"1RE`)/\!@,!@,!
M@,!@,!@,!@,!@,!@,#X5$03.("(#XCP(?4/3ZA^W`@1HNOJD3YM-A7%""JZ-
MA-48D7<P>%BE+.[/)4';S)V4LX+499-)5FP9D]OWO#V6H%`O`8$H^^U69=D]
M5$';9-UY]A#I-P530/[#H^BMSK(.@\DOTF!)JJ4!#@P<?7CZA4'9AM!LM4O)
M20",8)-+KJ$QG[XS-JW:D-N&@E,!W;KP2;(+B`$4#R*10!X-SS@73&X4)$`(
MXMM4;G\E"^V>PQ*'[JABB!2&=EYX'T]`^N!R)VJ@N%DVZ5HJKERHLFV003G8
MI=R=PN7R1;()$=&6.NN7U*0H"8_X`.!4:+5B9,56Z*0@J;S]PI`*8YBCX@81
M$I3"8O'H(^N!CEI=-B@R[`>RDB@)MZ[3.X!LD5$RBAVD&HNJ8J92E4<*'<%$
MQQ_481`1$1#T"R&EHJUUO1'5S>^O(F4LIX_KKK:L[-U\DDD-FOFNT*LWF(1Y
M5B+NVK0VP:#,/W#I@V64!*28R#]GR5RLT51#-.C[+HFR8M67HUFC;&U:.$V,
MH@Q,L66@),[=-T,/:(%RDA.56<015**S&2;M7B`B`*)E'TP.W<G+92M6-H"Z
M8N5("=*FW$X%.H)8MP50`(80\BI`J43C]"`("80#`M]UF][_`)<=!`X*4BX:
M8UB58A0*!2JEI4*50I0()B<`8!^@B'Y8%[\!@,!@?GB4/P_[O_3@?G@7\O\`
M6/\`W\#ZP&!T".%#/E$!$/;*3R`./7G@/QP._@,!@,!@,!@,!@,!@<:P*"F<
M$O'W/$?'R^@CP/`"/KQR/X^O&!#EN^T]F.O<EL&;U6^WUV.G]N]EK.+#7^M-
M>ZN:0VIJNCK:MO4F\M;7>LK>W91L4XCV3/[F85*X>+/U%@'A+P$+Q6U7L)8J
M;#P+6<[)LEMK63_*QW,(ZXTH1_J^.LD980<[1LD8G4C+#7JZDV:`JB8I0.L\
M*G[@'(J*874U%U?VQJW46K]6,>W>W)5#6E"JE$;V!_0=$FDYIK5(=G#MWK])
M2@R2`.EVK(I##YJ&`?45#FY.(5NII'<9S"=3MQN3VA,!O9943KTW6#Q\N2@H
MMJ=<O@?R#TXY_3Z#@=!31>W42^XIV^WN8J8@8PDI?7(P"'/J)RIZ;%02``\C
MQ]/K@1V4GL=VZV)N*]ZP4T]WCUK%5[:<+4*U>9Z(T'&QUNU@ZF)&-/N]%H]T
MQ)IQD`]69BD=FX4%V0I"J"9%#_&`,KM75GL5?+=L""M^T.U^LHFHS0)5Z?F6
MO6Q[$[`B4Y)V@F\C2M=&BHS2<HL2JG2(NJ<B+DG^(`CP`9+/M17QZ4Y"]A-Q
MQB:R*`?^LAGJ`BZ2R9C'74!R_P!7.?$'`"4H%`@`7Q'C@!'`\%31%^5__NF[
M)H@`B)02#0(#P//!1$^DU.?']OXX%)AU7NH[>;;:'M7O\XL-;+:\:5!1OITD
M,)'UB96&3L#U='5I74E+N5HQ%)(%!*DU3%7VP`%3!@7+'3]S\2A_S`;I(`?N
M@@751>`X^AN=<$]`_#`XF^E[4E(*R"N_]YNO-@DQ(P7<ZP+&H>VX*N9\BV1U
MT!@DE@+[9U3''E(QB@4.1'`X_P#).U>HG[!;Z6YYXYD]<(^'U^@-]>H@;GG_
M`&N>.,"RVV([>6NK!IVOT&9[#[7;["O*M=N,^0VG$(#5=59PC^6<W*Z2ZM&)
M)^R\D6K:-9(LVKLRBSPZBOLI(BJ`>3H]EV.V9:-VM-I-NQVBH*B[%=U?5\Q*
MWG15D:[AIC!R\1)?XN,@*`X>U)I(BD4",WQA6%+P5#Q\Q*`9'#J&QB8IQWCO
M3]`@/B65UN4IN!YX,'^7H>0#QQ]0P.BKI"R+O2//^8'L"B3WDU18$F]<)LS%
M(<IC('*37!E2HJ`7@WB<#>(^@@/K@>DXTK).$G:0[JW@C]VHBI[C:WP"2C;V
M3@H";10*9R@FIQP<.!\B^F!`3W4H4Q2/G%^'QT?8UYN;!U&[K9KL-A2L9.MH
M\7-<L(J.8<T?"1#AJ_=KH-@$YQ.3E!/@"\&\@G`(5NOW)N[-4A7`.NJ^O$G#
M-3U37;J;7VD@5(X"`E`B_O'(8?7T']F!=;7SZ2BEI'7TZNF>6K:P.(MR"9_<
MEZ2]77+7GYSGX35>L2-Q8/?`."K(E/Z`J3`NO@:<?RH'`G]1/\;W`AYE<=0S
M<?B!7&]MO()#Q^2ATCE#]H8&X:S3+[?F!0`QE#&5,'H85">1.##]1`O'&!W\
M!@,"+2\UMI<=?=S*>[V5`ZH2M/<S7L">U6RK.+M4W;B7ANL+5G2+;4V\Q7@G
MZMLI82P,@U6?-6BS60.1P<$#*`(9"=1-2;2TE6AUU:-[:[W!KVM1";*BQU4U
MN]I,W4/N;'8Y=2+=2"VT=@H2%4C(J2:Q<,T!)L=@QCDTQ46]38&8^`P&`P&`
MP&`P&`P&`P&`P&`P&!Q+^7LJ^'`F\#>(&Y`HFX].1#D0#G`@]HKI_P#^?'7Y
MHYC3"E_+T(JU=1JAE6Q61J+N?VW\X!P#V7`."':IE+R7E0H_7G`D)['J"VVC
MT_/QY`[[,M6YA_\`3?.@.P0DY_\`#\3?G@7%[+P5;L^H)>O6^*:SM=F+7JQC
M)0SZ.;RS&3(MM6E>PR?1KLBK5VQ<.@(58BA3$]L3<@(8$9WR"4"TQUIZ^:GZ
MTH:*Z\NMC2$Y)W#<0]=]7[3N$/#5Z_Z<I;:HU.FVZ'-6?MYUOM-TNL\5255:
M'CT"D(5-50P!9/9E9'IU/:8T;V`VYK[>]^["[NU#,Z&VI,:"UKIC:!;;K_>^
MB0LFODW6GZ\WJ\@T"L6!U)QCDZ,2Y;)HN6ISNP4(*8;"*(E%,!((B7R4XY`0
M$/\`$-^D0$`$!+].!]?3U]<"+#8G8FT==M@T:IUO5,KL^N]C>YVP]67.P1L@
MZ;O]3'L-9JZT1=G<<R@Y%M)5!F_`6SX5UFHH&50$%>3&``S.ZE/#R75SKP]6
M:E9*.=,:W4.S((^+4_\`*444R!?Q`$A#CC\.,#VMB]?=,;+?C-7'7L$_L;E,
MD<K;8\'U:N(LE$@:_;_SE5GD):B$10``0`'?^"<"F)XB`"`09U3K?:TZM\=-
MDBMI]B)]WI/L9W!+.6BQWN1OTA<*3(7N^P:>L=L6F];6KLY(5$*M26'\/;HM
M[*Z*>$!5)F(IG,<)T>N/_P`CWHKDZB@_Y/:UY.L@+94YOY-AO(RC<3'%`YA]
M1+R/B/I@7GP&`P&`P&`P&!P`@D585@`04.'B(\F$!^GX?0,#GP&`P&`P&`P&
M`P&`P&!;FGL6R4E?`(02?>7M\Y7Y$2"HL:O5XISIBGZB!R)E`WD(>@<?@&!7
MI6C<I!3!,!*)/;'R$QCF*/U\E3"*IC#^(B81P.<I0(4I2\\%``#R,8X\!^9C
M")A'^T<#ZP&!X94&O\;5#V@^X4C""=;V.3'2*Y5*4AG(IB4WB8XF`@F^IA-Q
M]1P/9*F0@\E(4H\<<E``]/[@`,#[P&`P&`P&!^"'/XB']@\8'[@,!@,#7:^0
MY1-'YN/AU!T@[6:O&NZ4$5694S"TD6\#,K-5'HF$?"/7]P2FX#S%0">(@`*`
M8):6RIR][K.B(@"2G4O7JHAQZBJCNG8A$^#?4``%Q]/H//[,"\NRF:T0I$[(
MCD72S^E'55EF[)$%EY2E/#(DLT=[(?XCE1DB0DDV(7DPN&0%+^^("%S&#Q%^
MT0=MU2+H.$R+(+I^J;A!4A54'"8_BFNB<IRC^1L#3J^50WC_`%$WQOF%N?C[
MCIJ4SGS#P`B?8+<YN/#GD?%1P0.0#_;#`V_8P5/XI*E,(^V!VXH`43&`4S`H
M*@F*8/;*'N?B4?(?QP*CP&`P(@=[P,-9=2]RJU8$J6X9V#O9H*+:LMDQ[F5U
MQ(RKZ0ZF-H6.V$P9/HYRXHTA*+HI2P$6*;[$ZG`&_=$*_P#CQUA3ZVZO^Q*M
M2NDE83NK%I'@\ZITRPT^Q/0KMCL$8^2NK.=G98B4,60:&-'IHIH<F$YS`/)0
M`)/\!@,!@,!@,!@,!@,!@,!@,!@,#X4Y`AN""<>/0@"`";]G(B`!@0(:KFC&
M^9K9C(9YN*IT#Q9XD'3=-XJS8T':,LU;*,_,'2J#47P+@<2"7_$*//TP)!^P
MMYJDSO/K%2(N882-II7:&F+VN)8OVCB0K*=JZZ=EI&NFG&":@NH].;9Q;@S8
M5"A[Q0$Q>0+S@7X[&/U8W5RSI!NFZ5&_:;:E24!N(`#_`'%0V)UBD<@*:BB!
M'`G*4`$YC%`"?JXP,;NZ/4C:'8I[J:ZZ3W1&Z1VIIZ8>DAYJU4$NSJ3.5.>M
MVN+58XF7JC:TTR1_C`/=6QOV3Q&12]I,7"*A#$<`=,+/[$TCO2O:_0VAV=W'
M4]O;2B]L:/J5*?ZPUT^TI1Z;KZP=D='2<LV&JKWF_P`I-6>?D:RU%\\=RZ[<
MB"14FJ")3N#+!*Y]PD3T,?CDXE#T,(<F.(%#RX$`#C_0&!#YL9VNMM_54.RT
M;L3;C66[X[:5E+K0[%8X>"T2O7Z+!R;&_;+AX4YHFS5MW(,46!228E225.4J
M8#YF#`SVZ:B`]3.MH@!``-)ZV+PF@HV+R6J1A1X;*E*=`>0]2"'!1]`].,#(
MQUQX)\_7[EKX_P!OW"?/_O/.!%;I;056VOIS4>SYBR[.@9S1.U^W]CJ["C[%
ML-3JUB<3V_\`:S%W'[&KT0(,+U7BI12?BR?$,BD)U?0?(>0S[Z]``:#TD!1$
M2_Y2:YX$3H*#Q_*$/_MM1%L?^U/]`_AZ8%X,!@,#C*JF<PE*;DP?4O`@(?N\
M^@@'T\@Y_+`^Q$`^N!^X#`8'6,IRY2(`_I%-0PAQ_M%$O`\\<_3`YDU$U2^:
M1RG((B'D4>0Y*(E,'/Y@(<8'W@,!@,#Y,8I"F.<P%*4!,8QAX`H!ZB(B/H``
M&!\I*IK$!1,WD4?V"`@(?4IBB`&*8H_4!]0'`Y,#\Y#GC\<!Y!SQ^/\`8.`Y
M#]O_`))O^]@?`JD*`\B/I^`%,)OS]"@'D(\8%N*.L<9S8I/-NHF:^+%)[*XJ
MF3*%5K9_%=,Z*)T%S*>0@`"H02>H&Y'@`N7@,!@,#JD52%R9$%!]T$A4]OD_
MB"?NF+Y\<>'(J<A^?]V!VL!@,!@,!@,!@,!@,!@0$?(G"H/?E^^&!T"""+M:
MS]A2_P`1%(AUUDX#7RLX2-$W[X)&2]\Y>?TE,81`?+C`DR1]S_GWL?/_``?^
M46@<#Z?\4=WWWG_K?N@'[,#,)0GN)G)_OD,4?0!]#!P/H;D!#@<"TVNTE*@_
ME]:K@]%C#>W,U!V\537%U5YAPY$(HAQ45<&&IOB"T$3_`+K<[<`$>0P-4;Y7
MFAQ_J&OC3<IJ\&*'47W$>/0S97L;MM(QQY#QY^X1(`?[0<?D(X&TGK?L3KW8
MV[M_]>Z\$V78/6M+4[K8X2#!HVB%&N[*Q+7*D.*^\3D'#R10-%Q#A-R95NV*
MFY2,F05/$Q@#(+`8#`BFV3>E*#2>Y,R&N:OMU)UW?TU2W>MK@UKKF$M<5?8/
MJ369*,$;<]CJHUEA;SYU&#J37(Q:/2I*KC[:9@P,H>MH5-.8MB=<ZFPG6U<T
M9#*O)*)6ZZG5M:)UGAVC-P32-RL\D"<<0XK)FD"(H"#C_!,8WF`!EQ@,!@,!
M@,!@,!@,!@,!@,!@?AC%*')A`.1``Y_$1^@!^8C@?GF7D`Y]1^@<#_WL#X7`
M#(J@;GQ$A@'@1`>!#U]0$!#TP-)3IV\-)_U.&Z[98#B^LSG=O<NFFGEG*BCX
MU4I6HH6)I=><$$XHEBX"#8@DT(0H"3DQA_4<XF"7!]O?0R?R2]@%ZYM:D;(L
M-<W'U+L-QIFL),NR=@TUG0NO7:?7ER4?42BFL-M>JU2>EV+25!LQ5&+5E$$W
M0)',&!(WM?L#KK95/8U&KPFSIJ;E]AZ@!G&R>@=Q,FQ!8[:J<BY>O7%CHL7%
M1J$0TAUW2CEPND1J5$%?(!`O(9MMS%*02";]0*K\AYBIQRLH(!Y^)0]`'Z?[
M/T_#`H7:>MJUMRE/Z1:TY0T0]D:],)KPDLY@IF.F:I8HNU5V7BI9H=-=D_B+
M!"MG*9@$2F,EXG*8AC%$+(/NKIGC-1B7L1VL;E501;">/W(9!VFFDK[OO(OU
M*^+LK@XB/F?S\S%'PY\0``"YVJ]/5K3=6EX"!?6N9_C%@F;?.3MWLTA;[)-V
M*;(W_B,E+S4B)EG/Z&*()AXD30*0"D*4H8'C=52H)=;=&HMS%%)'6%/13$IQ
M5*((0S5(1*J)C>Z')!_5R(&^H"(#S@7HF5ED8UXNV*07#9%=P@"W)2&7;(*N
M$0]?$#D,JF4#>O[O/'K@:Z'PK;/[<=GOC:<[(NFYJG69Q3:O:.#2:QFEH9\*
M9T]IW">?N'ZKJTLT9-*1F+&Z,@5NW9>TU,FF/F<AC&"33K/K;L8KUTT'[?:0
M"IEU+K=8$VNB:$B8C)6G1`M8\_N3#M`P-4A`GO)\>X)0,/U'`PLL?=KLVAOG
M;NF(6O\`<)>OZ8=(LGVZPZB4F.UML9X[GJ!7)!CKP9T0G)L*DYN[AVN_0;J,
M7,?!NUT!7+X@(9=:AO6_=I[8WOJ3_,_>%0>Z&5UTA*72]===6PM%O;_8U=>6
M8\;K::045;68]#(V!C+K-U7#5)TH0I%U#^8$#(1SJWL84PF3[82211`>"?Y)
M:P6\1_(HCX'$_(\`'KS@8MZ9C.UTGVC[85FT]QY:P4ND(Z04HM/:Z1U?&H5U
ME<*K/2DJFLZ*U,\=RBTV@H518QR@9$B)3E*<AA$,V0HNWA<I+COF0^UX*)F1
MM;4<"J?X9@]5_9]TO)Q`?0>/3CZ8&./8VP[RT)J2X[3C-H;KW)(U-B1VRU7I
M[0VN+CLBYR+Y<D?$U^NPC6#%5)9XZ=E5,[7`&K=!`ZBI@(`\AY4-M?>MJWH]
MTJJP[&4N(3HS.]_YT.M1:M'5S)4PIJ*T):7>,Y%4]O49N$CG(5-0B)P62,8J
MJ1BE#)QU!WMG]K(/-]2;*.*50J@NZEKEBB[.<YW"9RK/84B@>RW'PX()>0((
MCZ\C@6^V82]$U_L=>K]GD82SC0[6I5I@*QK)^G6YI.!DOX;*@U4:G0?F92)D
ME@36$Q3^SXB`@)L#S^M[+;UMZ]Z3F[%V#F+5;9'5VM)*VVM.GZY55GK$YJ\9
M(61ZX3C(-&):K2S]T<3)())@@0"@'`\B(7S4J>P``53;@F44D@$Z@'I]'*7V
MR?J,8QCQ7)2@4/4?PP,$-N]C.R5%[`06EJ#IKL?M6J&I#^T6G><'3*-&ZZ@9
M%=I*'@ZZQ>25,4;W&5<.4FQ5B-'#8[,'*9CE5*1;`[<-M7LW9K9U]KBT)V2I
M4/M?4L!=+K<GFNM-O8?45JF(A63+3=B$<5+WVEC:N.&;U)#VDVJY2CXB4QQ3
M#)1T:0AEACI[MJ[82C;Q*Z;R;?1,.]*<`\N58QS5050\P`1`#"4>/R^N!2ED
M>/5XBP/8WNPK&KJQLF:,.V)UV<-8YT5B<&QTDG58,+PK=<`4,55</+U`1`.,
M"Q'5X^Q93KOH!U<>^UL6NLUK&M3=A<VUOUKE;-8I6:B6\L\5<JA20.N,>JY,
MB4Z9?/P3`%!.<ICF#(K^6;D9+W3=W;$=$RS97WD('KHFG[)!X.W(<=>J!_VH
M?]KD1_W>,##7M'LCN5J?<.D]<Z6@>X_8J"ODB9]L[8-'KW66L:WU)4Y"5B8.
M/D)2>L>GWSNV23<';A^>)C%$7@-6HJ&5$IRD$*?_`,R^[BS7K\HM2N[K(=QW
MM]$[$:L&?55TMUVJ:%DCJPC8;JH\U`V<2D<J226DRI(E*Z%@Q,LF90G":@2!
M(ZKO$H+@L?VPW`H+98S!V6/:Z/<F9/42D563=<ZE5%H\(!@*=%7Q,3R_=#D,
M#[7T;LD42>7;#?B``NW,9TW9:'\S`5<@@E[:VF%4?!8>$S<@/)1'Z8&-'Q=2
M=K>:<W2YO6W+1NV=9]Q^TD`.R;;.5B:D)N$J^QGM;K3:/_E`B5?C8)A"1+=-
MJS;$220\3>*:?EX`$F)7;<WJ53D!$``0*?Q$1_`#>/B/^G`&>-BB4#*>/E]!
M,4Y0_O$Q0`/[\#\^]:\"/O%X`?'G\.?V#]!#`_`?-1#GWB`'(%'RY#Q,(\`4
MW(>AA'\,#S$ET?XHHX]PGLF9BB4W/[RH.E%1(4O[PC[9@'Z<>H8'J"];`'E[
MI1#\1#D>.?IR''/K^'[<#Z!VW$OE[H`'(EY,!BAR'U#D0`/PP/C[YGR8/N4N
M2&`AP\PY*82@8"F#Z@(E'D/V8'ZF\;*B()*@H(`)O\,#']"_7]THA@?HO6A1
M\3N4$S<`(D45(FH4!^GDF<Q3E_O#`_/OFH'(05B`*I3F3$W)2G`GB(B0Q@`#
M\@;D..>0^F!RBNB'/*R0<?7_`!"_A_?@?H*IF*4X&_2<.2CP(<A_H],#X,Z;
M$#D[A`H<"/)E4P]`^H^IOPP/LBJ2A"*)J$43.'D10A@,0Q?S`Q>0$,#Y^X2Y
M`/,OJ/'U`?\`H$<#D\B@`F$0`I0$1$?0```Y$1Y_``P(%_D/=>/RY?"<=)8G
MLFO':$#'3$@CP;2TF0_D8_*8(^("!N/U!^&!).FZC![WR2(2;8)%[U(J[A".
M*HF=R[8L=SV<YGR27(J&;MUG8)F,4/$!6#G\,#+0\I')B8JCUJ0Q!X.!UTBB
M0?Q`P&,`@(8%LMGH.F;-CL&)(\<OZ"F]G_LHP$UG,]!':^U8($$%0X<?=1Q!
M<MP*8HD>M$#`!_4@AJ:_*)8(JS_/5\5EMK;Y-_!VN(Z=S,1+(<*MI.(=]F;Z
MLV.0P<@DF#>3\^1`IA,<2_4O`!*AT>[%P=N^7KY9M7M]5;SKTPB3JXI)VFVZ
MO?5^B1K/6.KI*F(*O+DY>'8*H;"<R!I"J`D*HS$6BX=$`A4E?$)S?O&G_P`,
MH?\`P4G_`'\#F*H0Y0.0Y3D'Z&*(&*/`\#P(<_0<#[`>?4,"+3:$95E]9?(>
MTN%5N>PZ\?>,5,R5/UG0*-M>[RRB.FNMJ["*@*)L:!M%)E9<SYDBJ89)DJ@S
M0Y<`9(R8*%"SOQ-4M:"FMLVJ6I5NUY*V^'@S1=(F.H]:TDRJ-7BI:4)'0TWN
MFJ:;U-";?O(%>D%ZT8H!&QG@;[4JQ3'<F":W`8#`8#`8#`8#`8#`8#`8#`\B
M3:/G*T:9FX30(WD&Z[P%$?>]]F0JWO-TP]U+V5#G$G"GZA#C]T<#M.&IEA$2
MKJ)E$OCX)^("/UY$#F*82B//Y#@=$\>=(AU"N'9C$*80*==,Y!'@?0P>P41#
M^_`T>^NM=?VG^HVW+4&]CM5683_8WO&J]EZ5('@Y^/3)I1#A=G9")+K0JYW8
M%\5$P*;]7CP8IA#`G[Z]_'9N#4G>C=_9&Q["HCW7.Q$:F2.3ITMLN*W:["FJ
M2?\`+Q]M7N3=.XG9W\7"1.:7:J(M6YP3:B0ACH',X"9'W67B;R6#R,<3^ASE
M$/U`/B`E$IO;#CC@?00Y`0X$<#B0!@B<IBNS?4X@5:07.41-Y";]"ZY@$`$?
M3T]/PP.PX78JI&2.[2*4>.13>>P8O!@,'^*DJF<O(_M]<#IMUXQ%8"$?<F*!
MO163.N3@P<\B"KI0#?7TY#T'`X9E_$JLG*"[Y`H`D=8QDWB:1B$1**ASBH0X
MB!"$*(G`P>!B`(&_2(X&*71=6DH=/NLP5F:%]#!IBDIQJR\^M)&42"&;F4*9
M0[M0BATUO,H``?X8!X@!0```,DIUW5U8E^@,XT(`^Z[6(C8CH*"HDBH;@12?
MD5!N!^/-$.$S`'!BB&!J,?#O\3'6KNA\>T-LG;EHWY"V2];-[!0LQ'ZQVLK0
M(&.1JNS+=1&JD3'1$*3[=P[C$/>=F4.M]VX5,943E\2@&T%UEZF:OZIZWH&J
MM9/=EN:IK;7$!J^MIWG9UMN2O\M5IX_>QJ[QK(2HPI;`9635(J];LT%5&I4D
M!$$44DB!>JS:ZJ]O;`UFBSXH@?S_`/63<[E7%>>4Q,7[BN3\4X]L_M@!B>7B
M("("'ZC<AA;H?2&L>O/;GL\:KL[1'K=GZ_K;=,@6?O%CML?*V[7RDYK*[&K+
M.PR$B\@@8L']>5>MD%C-Q/()J$*7R,`!F9L5\]@=?W:;@3IMI>,IMIE(EVJ3
M[DK6280$@\CW(MUC`FL5)TD41((@!@]!].<#^?\`?#^]D*U\CFC-FL;?>I"\
M;)G.L-=V"M8)YP[C9B*[9]/MN;EVTTE$"K+HSCQ[LFJ,7L,Y$J)X=-)1`OF5
M4QL#^ALDBBE^HH*<J``CYJK*<C]?0%3F\1Y']F!@+UHUK1IWLQW<[*1AIJ3F
MMB7^BZ3)+K66;7K[BO==*/'5>28P,`+\L,P7B=GS-C:/G:"!57+I`Z9E#E2`
M`#,NR:YJ%N&"-/1[QR:M3;.Q0QFL]8(DS:68(.VK5988B48"_;)MWRI1;.?=
M;'`P>29O$O`86]M/C'ZG]T%(ISNRJWA\^BK2G;VKVL[3O-?32EDZTM43)E@@
MG'-62C7,$L*2C=%BF0RG^-Z*B)Q"(/N+\%71#1/57L=MC6T)MJ)NVI-&;+V'
M3I!UM607CFUEJU2F9F$-(PC2/9M7T<TDFJ8F;@)"+`80/R`8%4_TU;%U!Z![
M#:_:3$J\H=>O'7NX5B%DI1T^6@[%M[J+I+9.SE&3H4F@HP<U=9U=RT:<"#0H
MF*'!1#`G![<2K.J];]V/").UY":UG:Z7!LVQUW4C*VB]1;BG5"$BD%E%"+24
MO:9UHW2)XB)C*!Q^.!R]6^LNKNKVDJ#IG6U;/!UZDU6$KA2N9V<GY%\XC(5I
M%R$E(R\U)2#]Y(OW""AEEA4X5.83@``8`P+U35)K4\]A9*3AV[V0K;A1[`NE
M5G1#QKU5$6ZCA+V5TP,=1+])O,#>0?7G`BONWP;_`!WW_8%_V7/ZGLI;/LNZ
MS&P;2>/V3;D(]>U6`AOXU(Q[!P_<EATI!=958S9N8K<BJICD*41]`QVWW\%?
MQP:^T1MB^0FIKBC/:QU5LZZU1ZIM.Y.#1\U!4B<DV:XH+R"K-Z4J[8/T.4ED
MA`>!*(>F!AM\-?Q.](NTOQM];=\[8UQ8)O8.QH&^C9GD;>[37XHHQ^SKK7T$
MX:OQ\@G&UIK_``N+1(+9EXHE$!$/WAP)22_!9\=)&2C!/5=S(V58R$:9`NWM
MAI-Q9RB9DGB0M4)TC,?<3.)0-[0G(`CXB&!(A0NM6D]:ZVK&HZA0F$7K^FQ*
M,%6Z^K)SDL6.BVZ22*3<LC+R3V47,!$2CY*+&-SZ\\X%R$Z+5FS]M+-(9JE*
M,O?!FZ$[DPMP=E;I.0(F*XI\'2:I@`>/`>`<<8&&75W1VJ^NV[.U&M=<5@:K
M&;'V3%=E?X.K(/7#5U*[/J$97-A3]>%\]=+E9/;K0?-XW3\4VKIX`E`I%2%P
M+A=]IBV5/HOW#L.O)-[!7:N=8-[3=0F(TH*R,38(O65G?Q<A'@JH0`>M'B)5
M$C";]!P`?PXP->S^FLU55+5T-EZ[);JNT?:YS;5_L;[6=:VC!_;(P#N%H!5K
M-%4N3BWDLSBYA^Y*1U(`D5N_<E!;T.H83!LCQ/7]G$L&\6WV7N@6+9,$TDEM
MC.!`I2F\R!]NVC&S=/P'Z`GXE``^F!1R]2U;8['9:N'86X2EHIJS-&U5UIM^
MON9JGN9%FE(QC>:BB-U9.O.)&/6*X;E<$2.LD/F3D/7`]+_)NH`@#/\`SEVX
MDB`!RH&ZG7*AP,4X*JHB)FXK")0'R\.?3`M_::;I.+L=>JML[87^$MUQ?KMZ
M?7)KL%!Q%AM+Q@W-(N6M7BWJ*,A-?9M$A543:E4`A"_J#TXP,<]PZVWA!;FU
M5%:5F=IVK6"[1LYVQ>+3W$5I4;6$&]MBVS:(JE#C5"#9[6>(7?2C]=VBFB=!
M!!L183J"F4,<MBS';RD5;K-8-@V"@4NK.)B,G.[FR)WO?,5N$T)7F<M`J2+*
MBR#JRP+^Y//L'SQ0Q5'(,>$4`!-4RHM\"42/UIJ]_'LG$;O_`&D\CW+5N\9.
MV'8N9<-';5=/E!RU=MYDS9RW5(')3)CX"`@(>G&!UG>G]3$5.]=[ZVNBHMX%
M455[(V%`J@D``)Y`,\1(3E+P'/'/'I],"VE+8=4+RSD'E&[AVRY1]<LTQ79)
MQ!=S+#*-(BUP+K[2=@WBL9=P(G)13H03<-U!$$C?I$H8%0'U-UL475=.]_7U
MTLMP!U'G;Z]*?03&_P`,/\P2E3#DWT`/I@8C=O$NG$[1777%AW2D(#<=QG-6
M/:30HWNB_C;_`#[MO>ZP[AH6.CY&\?<NV=E:QIT"LS`(/BB/M$.J)1P)-5MQ
MZ'2/X+V^KE4\U""!DU_+S35,BH`C]KSY%5((#S_;@>TAN?4JZ9P1NL*=-NHH
MW.`'=<$.GZ*%'R0#R*'Y^I1#\<#SO\S-(.E5"?S!6'"K4&YC!]LHH*97?)FX
MD'[00,"WB/'CS],#AU9V!T[N2R;7I&MK4E8;%HZS0].V;#DAIN*-69RQ5:(N
M<*U$TM&1[:2;2E;G&[A)=H9=`P&,3R`Y#%`+Q!',`$I@9M@$H@)1!!,!`0]0
M$!`OH("&!V_$.!`0Y`>>0'U`>?0>>>>><"!;Y$8J1?\`RX_"D6(0,I_#+AV@
MEI))%-/P)#HZJ29OG"H&+XE31_B(`/'`B*GIZX$F"<0T'O2^E!3:>ZEU+A8U
M(OLH`X30/N*=7.5-0"^\5L<Q0`Q`'P$P`(AR`8&5/\(BN1-_#6`F,83"86;<
M3"8?J83"GY<X'<%%(2@7P*!2@4"E*'B4H%'R*!0#](>(AZ?E@::/R?:S/KWY
MU/C3<M$XL(*4O/6M[3F[;@'\'"%[/SCZ>A7:`&]I",;62P*&8"0A?\)P=/R'
MP*!0V'=*?'Y5M.=R]Z]Q8SLGVFN5UWNW+'7[6&P=AU"QZ;-!LW+Y:DP<'32:
MXCY&NQ6M@572K_VDFFNU0673647*Y<`L$A_VK;_X70_^!)__`$.`4*5)`X)@
M"8%*)B@0I0#D!\N`+P!0$P^G]^!']T1[#;1WY8.[\=L>2A'J.A>^&ZNOU#;P
MT&G#@QUI2:GK6;K#>46!PY4FITJUL7%R\,*?N^0`"90+P`)YBO+0_>^-95[2
M[IP?:T"'\/['D.GI>:75TUH!="2O8MV;U5:OE*V$B8@BH?[Q!,/0/4`\/IAK
M5"O;/V'>/O>G-5=3%"JU5'573F1=/*X#>%GIR6_GBZ&<)P"+B755FQ:,Q1A&
MPH(F4*HZ<>9"I!))@,!@,!@,!@,!@,!@,!@,!@,!@<:H"*9P`.1$H@`?F(_0
M,#3/V/\`&)2^Q7S7;RB;/NK:%.UC>[+9;NUJFKSQE5NT/L:UZDEG5CFFVT7+
M:3DT(EQ(TQXN5BFS*!2O!2]XR8%*`2GJ_P!/YU97*HBOOGNTHDLNFY605["(
MK)*.$VB+,%3BM2E#&Y10+^D?T`/J``/K@?)OZ>[IP#<P.=J]P7"@<B=T;?QP
M7$`'D/T(4]-$?$H<>A.>/S'`Q8AOA9Z-;)W/J^+UAVL[37'6E@UKN"6D6]2[
M'LIQLG;:39-4Q\>`3#.MJGA5F#.XOB/6"R0J*J+)&'VQ3X,&5+'^GIZ:,C*&
M-M/N"^!?@7)'W8-98C@2APF94O\`*0%Y2X#Q\0#Z!@>A_P"X^G2;W3.`N?:@
M%U$2-SJE[`R:)S(IG%0B?^!62E*!3CS^G@1_'G`Z2O\`3S]&5_?%Y8NTK]1?
MR+[RW8N>!0B1R>"B1!)")?H4((E-R`B("(?0<#J1/].;\>==K#"J0!NQ\5!1
MPKBQA8[?L^Q9L!>?^:Q9>Q&D*T!;@/($@(`A]`#`[\=_3L?'G'NFDBB3L*5^
MS:J-6SDV^+$9T@18GMJB1TG'I+"N)!$/<\O/U^O.!*'U*ZGZEZ6:;@]":/CY
MR.UU7I6VSK!&QV%W9YA25NUC>6F><O)9\F1RN9S+2"IBE#Q33()2@`\8&3>`
MP+%[LU+(["9U>PTF<0IVU=;3J]JUW:7+4SR)"0<QJ\3,U:X1Z)TG4O1+G#KF
M92;9(Z:Y`!%RW.FY:H'*%CKWV:@HS5FQX;<]:MFE[BSH=E9N&EDA)27I<I)2
M-<ETHY&E;/@HUS3K;_$!2Y10(NC(@90J2S9-;]&!I1_%[#S-:[GZ,6L<5)0Y
M*#:OB[M&P7<NQ<QYJ5%->B&[X)=2SI.$DUH-!O+RS5H/W)$C`Z7*D/J(!@;Q
ME@VO=MM)K5'KTQGF;=\NM&SN\[!7E8JITEBW,Z:2KFE1EFCV;W8UU37:BDS2
M(W+#HK*$77<*)$%!4+W:GUG6M/4*MZXIK%1C6:M&(Q\<5T[5D))TH)CN9"3E
MY)?_`+1*S4S)N%WKYVJ`*NGKE94P<G'D+CX#`P?^2)!,W0GNL)@$H*=4]Z%.
MH'U`0U].B40$P@3S+]0`?3GZX$*7P);+@]/:BV\6\Q-O:OMC0'3.Z4-K!4VQ
MVQSL"!+THTS5WDE4&U2C)HDDWCK#5WC1XL!RHMW1#%4,3CC`G(AZ=L#>VPZ]
ML#;M3=T?6NN)>-L>J=42DU'.[')79LV>%0VAM%I"'<1T?(0!7O%?A"/7Y&:W
M_K1<&3>IMT$`S#*4I>?$..1Y'U$?P`/Q_LP/K`8%@NUQ"*=6^R9%"F.F?06X
MB*$*/!CD-KNQ@8I1_`QBCP&!&O\`T\R:27P_=/4D2'3(G";+)X**$4.4Q=S;
M#`X"8GI^_P`X$TN`P&!C]NK4<Y=%Z_?=<SS*F[GUV:0<T"U239=]!/&,LFU)
M9M?WJ-;JIN9:@W1)@@5PDD)5V#Q!O(-A^Y;)E,&*';O;%OF>EW9FAVS6&PJQ
MN&S]9]TU^&JE;@);8<%:KA,:PLD>PA:1=:K"NV<N#Z4=)HM!>MXIT<3%]U$A
M^2X&KU\$"4'6]P?&OLR`JJE8V1N:\_(?UZW/+G"?C968H.D.N^DK[1=?OX)_
M)JQ+*,IEJ3,L8J;9%7^()"/U,?D-ZQ1<$4"JG$/JD4QC#P4!.8I!$P^@`4OE
M]1X#\Q`/7`C?ZI==^M=YL^]NV[74='LEQ[1[3GYR0V78ZLUDYZZ:^UXL.N]6
M\JSS=PH6LH0]<7<17M)HIJ-'!%0\RJ%.(9LN=(Z8>)J).M2:R<)K`)52*T2K
MG*H`AP('`8L?(!#\\"QMN^/SI%?;MKC8UPZJ:+G;KJ)W*OM;V)YKRO`^JSF9
M*!7YV8(M$F[DIA#R2(X(L1NI^M$"'_5@5>GU4T66VFF#ZEU:O!A7&\4C7G&O
M:DNT0E4)5V]/-@9>(464>N6CHJ!C&,/Z$@P/,V5T?Z=;>IM@U_LCJ]HBW4^U
M(?;3T)):OJ!$7Q`*4I5?N6D4U?-7B?@7P71537()0$IP$`P*VKW6GKQ586(K
M=<T3J"#@("-:P\)$1FN:@T8Q<8Q3(BU8LT$8DI46Z29`#@/J(<CR/K@=];KQ
MH!P11)QHW3RZ:O\`Q4UM9TM4BG(\C[A5(0Q3\CZ^O/K@6VUKT:Z:Z>C)B%UG
MU9T)3(J>LDS;I9E#ZLIR:3ZPV!S]W+R2OO1*QBG=K@!O;*)4D_H0A0],"YI>
MONA2?N:1U"7GT'QUM3"^@?AZ0H8&ME_4!]>M&:LE.@V[M::=UC0-J63N[I>@
MVC8-1I$-`6:>IK+[F58UV7?0;-DI)1[%Y$(JH`N"AFYD">V8G&!M3^V7_K!Z
MB/Z3G+SR(F'GQ,'/J(X'X=(BG`F+SQSQZF#Z_7Z"'.`,DF;U,0!$```$`X$`
M*/D7@0X$/$?I@66U@U0"Z[Y5%-(5'.QZ\LJ(>)C'$FI-;D2,L'YE(0/$!^@?
M3`O;@,"$CN^^39?+S\/Z9T^1?QW<-E[WF<IDQ-KNL+D(0A3`"@*J(!Y<@/B`
M!]`'`D&*T;F[P.9$#G]__E4C61TOU@4$PW%(+)'^OCY@L!P'\0X_;@98X#`U
M!_F:M23?YQ_B?AD6#8CF*E^NKYR^63(FM*$LW;="+91B*Y0!58D>:*55\1$4
MTS+B/'(@.!MHQR/%@EW()"4%FS`ON_J\5?:._,''(B4#$(X*`\<?ZL"I\#A<
M>B"H_D01'^P/4?\`5@0\?%`Z?GV;\MC!TS31:1_RN;U_ASHJ_F=ZE):?T)(.
M#J(@7A(6ZYO``Y]0]<#(3;=BC:M3^[TQ-0])GXYML/5[)[&;)J*U^HAVL]KW
M2D-]Q:*:WD(MS9(B.+)?<G:)+D4,9(!(!C@4HA;_`./:C475KR8H=4E>M5AD
M$(&RSDK8M3:%M6H-A2+>>V$[L#%G8)"<>2366J<">?69-$`6%1(J*'B4"D/@
M2DX#`8#`8#`8#`8#`8#`8#`8#`8'R<0`IA'Z``C@0049D0OS*VH1(0%RQSB4
M$WBJ;R3'7VQ8T#$,`>VFY*9X;R,80*9,_B'ZRB&!.D1949!PB)2^T1!J8@\^
MODH9<#B(<?D0,#F=G%)`R@>Y_AF3.()%,<XE*H43%*0H@8_D'IP'//Y#@0-?
M&=U\JO7;=LY#T]>I%C;_`+*[I[(F2TV[R-S@9.WVM_U96G9*+75H.NXMDR<.
M8M4X-X]FXBBG\S-5PY42*$M/9GLSK#JEK%?:.TWS]&(4L]4HT!%0Z3!:=MEZ
MO,NV@JC48!.6D8>(&6FY%T4I#.W;5JF0ISJJD*41P,*%/EXZW0[^JA<JMN2E
M5^TV^H41"W3\3K%Y7XVQ7ZP1=/IZ,LA3=J6VT*(3EJF6K,BK*-<D2.N"BO@@
M!E`#DE?EPZWI6G9-=K<%M.]-]8WRV:RG)^I$U,W@WESH4A(0=VBHI*Z[4J%C
M%.M6",<,5'3AB@U=K('.T.L@45<"FW/S5=-2T'6MJ:O;J\M&S-D;&U1':K1&
M@1UVAKKJ&/A)3:+&;FYZ^QFKA:5.*MD2Y379V%VG(DE&@-!6$YP3"I*S\O75
MN5VC$:KMY;IJV8L5.V1<:](VYUJRP1DBVU-49F_WV/.EJC9FR9:+?0U*@GDB
MBH^;-V;U-HJ@@J=VF*)@H",^:7KW8*G$7:L4':DY!V*+&Q5-;^:NM4;_`#/`
MNF;B1BWY&<IO6/EXH9**0]]-H\:M)!NH/MN42'*8F!4#KYD^K4C(T5CKJ/V;
MMA.VZ)J'8Y\[JS&C4XE0UKL`\@E15[#_`)PWK6Z,G/6)Q#/DCQD29^[C_LSG
M=%3(HD8X7JZK?(WI;M3N.XZ*K4/>Z;LFIZRAMOH5VY$IDBE/:YF)\:NI86<W
MKZV7:#:OX>Q^VU=1[IVW=D(Z15(DHF8QR!(;@<)VZ*AO,Y/(0()/43>/B)@-
M^X`^'ER`<#QR'YX&N%\?S?V_GN^9QLN**B:E$ZSO`(`$-[A#0#15L+@I0`!4
M9&,8J8FY,4!]!P-C\$B%.)P`?,0X$?(P\@'`!Y<CP(AQ]1]<#DP/#D[-789T
MS92\[#Q;V12>+Q[.1DV3)T_1CRIG?K,V[I=)5PBR*L05CE`2)>9?(0Y#`Y8J
M?A9PSXD/*1\F,:X*SD/L'K5Y]D\,D1?[-W]LJJ+9T""A#BF?Q/X'*;CQ,`B&
M'GR/<'Z%]UDE">\C_P`IN_%S(#SXJ'1UQ8#D`>!`>1$./K@6G^&U4CKXM>BS
M@&I&8..NE$7.T33!!)$Z[9PHJ!42`5-/S5,(B```8$EY$R)\@0H%`?P#]GT`
M/R*'X`'H&!]X%)V.^4FGN&36V6^L5=Q))+K1J-BGXF#/))M#)%>&CRRCQH+P
M&7OI^][?E[0*$\N/,O(<E<NU/N)7RE1M-=M246^-%RBU;FHR=1C),K=N\&.D
M5HIT[39/_LW:2WLJ"57VE"G\?$P"(6Q[2!Y=9>Q9>1+SHG;H>0?4.=?V$.0_
M:&!&S_3Y-RMOB)ZCD*83>49M$XF'ZB8=U;%#_H+@3.8#`8#Z_P"K_5ZA_KP/
M@Q`'D?U<C^1S%`1X\0^@^@^OUP-)#X=ZI=26;ISM<8*VV/7>F_D(^7)E;K-7
MJC/64:\&U=&:RBZ8TEF]>CY%TR;2UE%XW2=KD3;F4;@03\F#D-IZ7<[A[(K3
MM%)3K+I#2#DI&-AMEM=,HS;.RH@XK(3=8IE,8K2"U!K4FERV<SDJY3DEVZIR
M-&!`,#H`R\K\)&5R$AX&&C&,+$0D6QAXF'C$$FL;$Q<:W3:1\7'-4")(MV$>
MU2(DBF4I2D3*``&![&!P'<)D$0-Y`("(`'@;DW'J/AZ?J``]?3\,#HDDVQI4
M(KA8'9XXTF`&1,5(&H.2M1`QS<"5;W3?N"'/'K@=LSM(G/D58!`3!P**@"8"
M_O'+Y%#E,`]?+Z<!@<QE2D*!C>10$HF]2F].`\A`P\<$'C\!$.1],#X^X((&
M'Q5`"@`B)D52!P(\<@)B%`0#ZC^0>N!S`("`"`@("`"`@/("`^H"`AZ"`A@?
MN!KJ?U%;0KK6GQ_?XX(*)_(;IDR?J7R5YA;9RDF!@'R.(E`0#]F!L5X#`8%E
MM9D0)?M]`D4"G&^U@R_'/ZE/\JZ(0IO41#T23*'IQ],"].`P(->^Q$2?+A\.
M[M0AUS(M.Z8%1((%422_R=C5%7;8PG3*+M-<B)$P,(%\CAZA]<"X7Q\[F@-[
M7VO[)J>QK/M.I3&D;_"05MM#1PG+,8VH]@2QD#495X^J5*DGLO$PKYN+H[IF
MHM]TNL0'3M-)-<X3$8#`TV_FC9+./GB^+QT@F10\<TZK/02145._<@GW0?\`
MFFV:>/LJF33`3_O`/B`^OI@;BS98@F]@IN3IE\E.`_2/*JJ0<&_$?-(0'^S`
M[V!P.1`&ZW/_`*;,'^D./^[@0H_$FLN;L%\T+4ZIS)-/E4OJB20F$4T4WG7C
M0JRGME'T**JH`8W'XA@9&]CF4@\U?WT&(>P$6]C;EJ>R*2EDL[&CQ\:RJM!T
MG9921:W>2923*EV1E%0RRD/+G;K_`,,ERMG)4SG3*40M1\9NQMNW^V[82VW<
M]B6>7KD>BWCHJ\;<93*U6I\I8Y$^N8YYJE73FH[,2;-3XY-)Y<WZ;P+%(MGI
MB&2_4B0)?\!@,!@,!@,!@,!@,!@,!@,!@,#B6`PI*`7]X2#Q@044T71?F9M"
MH"Z%$8D$!*D"PMQ8N]:[`<IE<&``2`$W[<3@0>0`X^7U'`G6`A`6,<"AYF`I
M3&_$2D`PE`?V%$P\?VX'VHF50@D.4#%'CDIOW1X$!#D/Q#D/I],"-^Z5.0Z[
M=FM-.-!=.Y"9U;/4SL5,[!GM*(ZHID1"[1V)<=/S+B3M,'.SM.%[+6]"`>NE
M7Z'OKNED?!3]T!`+,]C;!L?NGK35=FZ_Z1V!-LM,=O*%N6#>V62TBQKVTB]:
MMKS%>N%7:IVC:3.9KC&;=1<FG&RSACYI.V:"ID?95#@*A[?1>^^T6D%]+U+J
M)M"EEL^T-./[1;;':^LQ5:U4-<;4K&S9F?K$8VV[(HS\\\-2$&3-NJHT3`[_
M`.X,8`0%,X=GJ/!=A.N.O[9K6W=6]BW8KS?6]=E0%Q@[=UG:*2L+NG:-CW"5
M>QPSO;*!8B;@9>[O(I0K<SE)9*/2<IBG[YDDPQ,U=U*[+4/MI6.V;OK]9)&3
M==@NY&S+3K<]_P!#(,:Y4.T%"TS38HL':2W]TYG[)6/^7Z)4<MU4F[-<9IT"
M9TP9H^X%Y.XFE>PG<*QZ:8J];KKJVD4"+[`O[5,_SWUTLUKEYK<'7G9/7:/J
M\377%Z<000S9CM5Y-O'CEP0QU(QNV31`'*JJ07\U!8>TFK>MNN=:N.G,S,;$
MUKJ2NT5--ENW1[&E6&=H59:5.&>FG7-I<V*+C;`6,1>J"HQ658@H8@^\H0/<
M##/HGU'['=%[HUDX_2UEVE6[=U:TEH^ZK2.R-#5N=@+?HB3V#*03RKM64X1C
M8ZI8F>TI!J<[UP@_;*1R*HD5!PH9,,J&5/[-O.ZCKM9*=<9F%A*YUK/UTIU/
MC]Q:?D92QH6G9$9LRTVRTNG*Z*,(I!.Z^PCXMDU=.R+>X[554*`HEP,]=#[<
MBM[:AUON&$BY:#A]D4J"N4=#3IF9IJ+;SJ!G!6$H,:NYC3O&GAX'%!11/R`?
M$QB\"(7AP-;[H4JS3^?_`.9-%-/P<'U?UA44,!1X.!X%B0!$WD/K[BOTX_'`
MV0<"AK5LW7E&59-[I=ZI4G$D5=2.0LEAAX-9^FV.DDX49IR;UJ9TF@LX3(<4
M_("'5(!N/(,"'KNBS^/C>_;KK;.=E[YK&R4^G:&[/UNM/%MG.86&AKA;KCUX
M:R39>=I%BCW;2:D:Y'.$D4%G"8*(`L8`$2#P%R^@]YZ"ZIDNS=?ZP;0TA$:M
ME=PUV<_A]9V7&2$<[OSO5%!97J11<S=@?/GSYP\:-OO%"KN"BYY`3^?D4`N'
MW[W_`**L727N'#U[<VJIN:D>K6\H^.B8W8%4=/GKU_KZ>;L4$422W!C.'/!"
M^O(B/IS@<GPZ+*./C`Z1*JH&;G'0=2(*!P`IT"I'?)$;'(`B!#-R$`HE]?$0
MX_#`DLP+>7G;6L=9+1B&P[[4J0I,HO5XD+3/Q<&,DC&G:)R*C`LBZ;G=IQQG
M[<%S)@8J/OI^8AYEY")KMU?/CQW%VAZVAV)M.H-FTR)U'V&9UE%U(.+=&Q%V
ME['HI4@NT:C]\NP7D*[%O?:.[$C<Z:"W')B\@%UNK%PZ$==)C=T/I2T:CU!K
MRV7RL6$(I"4+58N;NB%#AX"S2[!E85&KYTN=C"LFZZX%,FHHW\0,)BF``O=O
MWM#UGLF@][0['>^K7:CW3.SVJA&ET@UCIIN:1.(F.;P>"!``##P(\!S@89_T
M[+MX^^'OJ&Z?I+MW*T?M8ZC9PF9)1L([MV/_`-G%,X`8H(C^G\O3TY#UP)L,
M!@?(G`!X]<#]`>0YP/PP\>/H(\F`/0.>/QY'\@],#7%_IG#"KU#[/^^W3;/4
M_D"[&@[(BX!=,Q1C=?@U`R?B7[8Q6W@'AZCZ<B(\X&QP1),G`%(4/$1$OI^[
MY?7Q$>1#G]F!R8'$L(@0!#R_?)Y>/[PEY_5Q^HIN>/RY']@_3`@P^/BM]FNQ
MW52)W=>M]R<I=MK7_L#(R32T&W7`'K;5ANN_TR%I:E:KFW:]%0@5:(A$60H,
M&$89%,OJ0%_)4X7<Z`63L*YH&X9;<5V'9TMH[8';30T';$XB9C9&QQVI]SS@
MT1=-"=DYN8LC9I5VB,<G)K/'R[U1OXN'"J_F<P6WZ*:V[(]C^C&C]P;"W>G(
M;3WQKJ,V/L!S*J;V@&J-BLZB+QW&E@JAOBN(5Y2#3*:/6;1A8YN`H%X11'W"
M8%NXSL7VC8_!GO3=3G8ENG>R^O:#VRK=7VL2G.6DV9WK3=^RM7TRZ,J^NI-N
M9!W%5"$:NT'RJCH[HB0.SKK',9;`]_L%TQ["U+K==-BTSM@W92E"TK8-A,[7
M**]I'4PSEZ90)>S-K0W<J]RW5-5E#R#)!;S?1SR-.(G]UJJD/A@2W=8;M:=C
M]=-!WZ\?<?SI=M):JN%R^XAU(!0+79J+`3-@(K"+)MUX1<DJ\6\V9TDS(&Y*
M)2\`&!??`UO?ZCX[AOKSXZGR":2@-/D6T^?A8XD3*L-8N@ME##]/\-0G(<_B
M&!LA8%I=C;HI>L9JH5N?):9"Q7D9I2O0E1IMEN4BNRKJ;`\Y+/4:[&2`14/&
M'EFB:KER*20*NDB\\F]`ZT/NF#FK!&5M*I;2BWLL5X+5[/ZUM4)!D,R;*NCI
MO)V18(1;-94B(@D114IU3>A0'ZX'4UH=#_,KL$FFY%18MXIZCAL/`?:F4U52
M?``+]0]X"";]N!>[`8&O9\I^[]/]<_DS^)O;^^;=7*#JFN1_;F-N%VM\N2.K
ME8;V;7]:BHAY(%]M51--_8!:M!5$HI#[H$.)0$!$+A07R[?$/3M^L4ZEW/ZD
MU*FK::F9!^M#6JOUJ#&PS%QJSYHL<S5DQC5I25A61UU3&,+@46Q#'_24!`)/
MNN'<7JSV_B;+/=7-^:OWU"TV39PUKE-86R+M;.NRL@U,]8,)=6-75^R<O6B9
ME$BGX\RD-Q],#)/`TO\`YW)=>)^9_P".M=)<$OM*IUEE"C[`J+@=IW>22]MH
MN0Z:C4RA%C<FY'\OQP-RY`@_?NS\`!?:1)P'Y@JLJ(_^,"G/]N!Z6!PN>`05
MY]0\!_\`=?Z\"%'XE@*'9'YKP`.`_P#/0[&8`_(YNN6A/,W]IA`<#-.X5K^=
M6_=6MM(^0E)/^:]=2T2RC)"`B7I[#7M3:OL]=<-Y"UB%82^RF(5NL<)#AFH1
M(2+?H,;`L]T>O.V]Y[8V/MO;M:ES*U&G-=54G8U?@M?P>EKA&NK(I/6M*B2E
M>V%L6Q;%?QDW%-VSN5!Y_`&BS95NQ`5SO#J!*%@,!@,!@,!@,!@,!@,!@,!@
M,!@<2XF!%7P#D_MF`H<\>H@(`//Y!SS@:N55W#?2?U.EQT4WC8@^N2Z2:W%V
M_2B+(I-M'[?1IGL<+N=1??RLV82$K:WZ:;=1'[A0S8>!Y*.!M%E.!ESD#GE,
M"B;\OU%#CC_3@'!1.B8H'.GY"0OFF?P.4#*%`1*?@?$>!P()NNEO[]]OK?NB
MPQ'=*OZ=CM?6_74E5M9P?6W7]\H9(:R1:-@3J$_:K))1.R+.P$\8NS?/TG<4
MZ62<F5;%;'!,"!G%\9,J\M73+75EG6C1&>GKSV'E9]-JZ<R+,DZ\[)[<7F4V
M#Y\B@^<QA90ROVPK%!7V/'SY-R(AGL+1L/'^`D'CSQP0I0]?KZ%``'ZX'T#=
M`/\`TBGZ>@<D`>/[.0'C``W0`/'V4^../4A1]/VB("(X`K=`G(D13+R``/!"
MAR!>>.?3UXYP/KVDO+R]I/RXX\O`OEQ^7/'/&`]I+R\O:3\OIY>!?+_3QS@=
M1Y[21`,;R*43E$PE\QX*0Q53``%Y'R,4@@4H!R8W``'.!K3ZE@^V"WQB:R[/
M4+O%MG3:I=9:W@:'JJB:TTL\UO4(5+9*>MFB\RAL_6UVO5CM[YM,'?R2ZD@P
M;G=I)-R-VS=+@P3O]4KM==B]?=77/8DG#35UG*T![+,5]FK&PTM*QT@^AUI=
MC&*JK_PL)<D>5RJV(<R+==0Y$A]L"X$'71/Q_P#<@WYB!*'`'U+UF\O3CR,C
M%5\HB/\`8)QX_MP-DT/H&!C1,P\5)=CJJI)QT7(@GI&]*`G(LFKTP>.PM=G,
M=$CI%4I3`//(EX'D0_9P%]2U"IE,!RU>NE.4PF*<L+&E,!A$IA,!@;`(")B%
M$1_$0#\L#Y"FT\%07"J5L%@(5,%@@HL%03*H*I2`I]KY@0JIA,`<\`8>?K@8
ME=U:Y!-NL':A-&OP16?_`"I[X6(V2A8A/F1)KNS^PM[I6979!`@>(>*A2_F'
M/K@65^%4Q5/BHZ+JD.!RK:$K2YQ*G[0?<+NY-9T4""8P@!5SF#^[G\<"4/`Q
M:O#&/==N=$F=M6;E4-(]A4T0<HI+G(0;3H90XIE5(<"%$Q"^0AP(\``X&3*4
M='MU??08LT%O'P%9%LBDJ)/U?H%0A"F$OZA].>/7`*1[!4_N*L6:A^1'S4;(
MG-R)A,(^1B"/(F,(\_F.!CKV^8,T^I7:04&+(IQZZ;MX#[9$I3&#6EF$H'`$
MQ`Q?+Z@(#@1S?T[[M9]\0_5-PN/*AO\`.`#?CZEWAL8IA$>`$PF,`B(CZCS@
M37X'X(\!S@1S]U$]Y6_;?534&E>Q5GZWN]B3FYY"P6FL4NK7EU,1U&UNRF6$
M([@[:@I''9#(.C+>\0Q%2*D*4#>HE$/CITEONC;Q[+:1W?V#M/9`]-C-%7FK
M72R4ZJ416(C]B0&P8^3K",!4&J#`C=O(T,'?O*J+*JJ.C!R`$X`)&Q_#ZCZA
M]./]?/X!@:XW]-,<BW5WMRX%JFU<+?(1V%%VDDM[A2KH1=#:%,9(``K8QT4@
M$``3>91`X\"/&!L=8%ENP/8C3?5K5=FW5OF\1VO=;5%%%27L$@WD'YS+.3^V
MS8141#,Y*;FY5XH`@DU9MUW!P*8P$\2F,`8+%^0KK7VP:UK7O73L;;*7:K#L
MG5,>G+'UY9-:VJR5BR2CUT_:ZS+O+73.-N*4@QAUFC]W#LY(T6FJ)SBB;Q.`
M51,?&_#S,L$Y#]N>]6NU'=@D;=,,-6]A6FOJ_8;)-OAE)F7FZQ6J`UK\@]EG
MQS*.U1;E5>'.8ZYE3F$V!=6O=1'E649Q\/V>[1%8LFYB-F`V_6#5FT9?<>\=
MDC]EIQ)XL1TY6,LLJHL9RJKR<ZACF$1#$K8G3@S/MAH^,ANTW<FM52Z4OL7/
MV:E53?#FLTQ_8:^\UJM&2253A*TPKK-4'%VDG#CQ:F!VY5(HKY')R8,W&'55
M@RKL55VVZ=^MZ]&0IH-*)1O<0#!U&K-@;&;O6?\`*)6KE,&_)/$Q/`0,;D/7
M`L(3XQM:(6)Y/1_8GNY%-'+(L:E24NU>P9?6+*.33221CV.M+$66I32/;IH$
M*FV!D+<A"@0">'Z<"DICNAJ/I7>=BZRWUM?;=]<IS-#_`)&B8^F6[?VV$8"6
MH/\`%I>T3E<TW1YFVQ])-.,E4/XH]CT8\KY0$4C^I@*&7?5WM]H#N-4)R[:!
MNKFV1-8L<A4K0PF:O:Z-::Q8HMPLV=1E@IUXAJ_:(A0RS=0J2BS0B2XI*`F8
MQDE`*$+W]2$05=1=`4B\%,?Y%=,`!S_J3+_["U^`/-'CA4/<,4?J''&!L;'7
M3(;P_6<X<"8J29U!(`_3S\"B!.0^G/`C^&!C+L'[)7M'UW]PZ/OJZQ['H)HJ
M>97"Q`=:364*F7Q_=2%,!-ZAP(AQS^`.W.\4>N&E;?N4:H^O;J@PLU96%(B9
M.,@Y:WNH>"E9,\%&34PJA$Q3H\:S<N?><F!(I&HE#DYB!@6BZ3[11W79]\[:
M9PMKK$=LA+KS=XVL7))DWGH)A9-`TR39M)5K&K/&+244;+$473(X6$HF+R(`
M(!@9^X#`UX_EJ@'=G^1SX?(Z)K4':)>.M_:"U(0L[$L9IC8R5#5#6TGI[R.D
M.6JJ%K9PCEDBJ8BIVCU9!=,GD0>0DQ_DG04QN+7\ZTU=J/\`@TMHC8MC04D*
M)369_L6ECU<J"CGWHXA&?\.:R8IN#+%_[(452F%,1.40N+UOK=764V%M"H5*
M)I]=V!88UC5&\/68NIHSE)HS1>,A+:=A&-FIW"-MDWCY\S5<)D5/&+MA`"D$
MH8&4V!I>_P!0#!R"/RV?'38_!N1A)P'7J"9N/NFX+B_AN[5>D)%J=N*@.$RJ
ML)M(Z1A+X+>VH4!\R>(AN;D53%RJD4!!0I"'4'@``P'.H0GKSR(@)/\`1@=O
M`ZSL>&RP_P#4'_2/`!_KP(5OBA(*79[YKD_0"C\FTBJ!2_3E?K/H=4P_A^HP
M\"/[<#.BOT:L;0V+W:UUL*`3L]"MMDUM!V&O2W)H:=AY/1%)0DHXQ6[A-S[2
MH>(+<"F//'`C@>UUOTE1=6S.RW-8TVKJ@6-H<T.M+FNMGM+>X:[A8R`D86RL
MF$W-R;.O,W4L^=MB-4DR*)E9!R82B4`#+#`8#`8#`8#`8#`8#`8#`8#`8#`X
M')O%NL;U]$S#Z?7Z?A@0755(A?F:LJ!')FY20IY-9J!E$F[IPIK>SI^8ID+[
M;QT*,FC^LX\I@F(!]`Y"=,"@"HF```3<>0_B/!?3G\^,#\7*H9,02\?<`Q#%
M\Q,!>2G*;]0EY'CTP(5=9=$N_P#H+9^Z%M(=P^O<1JC9]RHLA!LK]UJL]VVQ
M`TNNM2Q;Z+>65AM^L5&0LT-$.W)HY^K$+(NW?M'=H^V4Z9@R^^-:*:UKI]2Z
MXU>24DVK6Q^RL"63E2H&E)$(;LWN*/&0DC,F4>T7DWWVWO.#MVZ*)UCF$B9"
MB!0#.T5>!#E-7Q'C@P$$W[W'')"\G*'KZ\@''X\8`RH@8Q?:5'Q\?4I0$#`8
M!'DOZ@YX$.!_'^[UP/SWOI_A+<\AZ>V/IR/'(CSQZ?VX'$+O@4P%L[_6!1$0
M1$P)F,)?T*>(B)1+SR(^I>`^N!]`Z*/E_@N0`HB'(MU0YX'CDH"7D0_;Q@`=
M`//"#G@!XY%`Y>1#Z\`8`'@/S^@_A@=9=8ZHI%(W<`*2Z:IQ,D8I?`GZC>)A
M]#F,4?0`_'T^N!KY:0Z-]J]U]%=6Z_U+WJ+IK1.Q=;U:Q(T*P]<JGMRVTF=<
MVAQ<YI"J[$F+?5G25="Q(MW$<RD8Y^O'\+(G772,F5()P-#:@C="ZEH>HH:9
MEK%%T2O-X1">L"B*L]-.`7</9&6DS-4F[)-:1D7:JH)())I(%,"9`\2EX"![
MHRB4G]03\PIP`H%-IWJV9/\`WO-2*BQ=B?T_%0A/'Z\@'X8&R!@6GG]9.);8
M$'L2/M4E`R<)4K#3?X<W8P\C$R$98)NO3ZKIVE(L%79'[)W7$TTA1723]E93
MS*<P)B0,"]^[W[)V:X;IZY=(Y6/N?9+5>MX&Q6>P;1-5:7I?55BVDPE5]11U
ML=ITNSV*[3$ZSAG<F>-B$")MV2)!=.DCK))&#U4.RVR(^VQVCKU9D:5V.KA^
MO-SN5&*W@;;5[;I[9^TH35M@NU*M#.OUY<8P]G5>Q0D41;/8Y\5,PD42435$
M,CNZA$!ZH]IC*M??$>L&^@$0,)1,F36=F,9$!`!-R?R].,#&?X5A`?BDZ&<%
M,40ZZTHA@.D9$Y3D([(H0Z9@`P'(H`@(CZB/J/UP)0<"Q.S=,K7>]4C9L'>[
M30KA0*[<JQ&OH(M=?1C^#O3ZIR4\WEH>R0$VT6=(N:.R%JX+XF1*=8HE,50>
M`PDV_NG>L1M:P]>>M-RL^^.R51UBPV!:*U<I73FMM/:UC[H-HB-5RVW+0UU?
M(6U4+I8JXZ41B8!JXDSQD<X<""1/;!<+>H]IMLUG8M6TIM;:%IU=V4BK)UYM
MT[I^<1T[>J/M+26S=W5K4-JMFM[C4]<1$\M#(V*6<17LN_X;+Q3@S918ITE2
MKB$@G<+R'J+VF$HB!AZY;O$@\B`E$=96;Q'GUX$!P(V?Z=D$"?$5U>2;F6,1
M%UN1(WO<<@J7=VPQ5*GP8W"0'$?'Z>GX8$VN!AQVWG;@R==;JM4[M9J&ALKL
MS3Z#:Y:HN6#2==59UKG:UF?1;5W*1DRV9IO)"L-#'431(MPD)0.`&'`^MF=*
M];;G:0;;:-LVW:5JL^>256EO\Q7T#8:R[D8[^#RIX2P56/@99FG,Q8BD[3]X
M4URF$!+QP`!Y^L^C>N-,GFU-7WS=E74M+IH[M3D=DK3TK8E8UF9E$#*V&TPT
M]8G2,*W.<C-N+LK9N"ZHE(`G-R%X$-*.$#IJ'V_NY?Q7%4X+7QN<J@*)^R*)
MTR5]$GL@`\@!?$0-Z@//K@0C?TW<6S@NN_<Z"8BN=&&^0G>4>#AV?W7;L&E7
MUXV^Z>+\^3EXY,B)U5!]3G,)A]1P-B[`C%^6.RU*D]98J[WF"=OZI4-GPDI-
MV9%B^>L=;MG],O\`74K[-C&M7KQG%,74V1B*Q4C`1>12`>`,(@&/%@[3]9>S
MM5Z0T?KGLNC;SNFI.RW4>?NK&END;1(:A@6\=-QTA/7-V5,?Y+4>,V[F-2%<
MR3IXNO[!"&*<X@$WJ/'M)^(\AX@`")O(1X#CD3<CR(_C@<()B+L5O3Q]@R8A
M_M>7N$'GCCCC@N!B/L\3?\WG6,"")2EUKVI,<O(@!N4-%B7T#ZB"GK_;ZX&8
M!.!(40]`$I>`_9P'&!]8$0LAV+T'U8[\]J;GOV;8:F@=K:RZFTZH;4L\*HTJ
ME@M5)A=[6*Q:W&VL6SL6T]`UN;9RH-GOVZ*S=T(MS*'17*F%9?&%L_76YJMN
M#8VKFRD[4I;8EQ:1VUD*Q)P,-?44=U;RETHV,?3T?'S4VK5DYT%7!Q*HR(:5
M*+<W^(H0@8-_U'"(FTQT,<)@4SA+Y&-'(MTS?^E%7-6V*4H<<#Z%,F!A'\.,
M#(KN'H&C]E/D`TQ2=K6R^2-"KFKH.1;:KJFU]AZXAE)ZR_\`,&+ZS3K;6]OJ
MC^<=R@4V**V,[%06PPW_`&<2>XMY!Z^KJ%%]=N_6E^L.J:AL9MH.N]==Q;$@
M9BRWZ4O=;H%ON-CJ<2[U;`/+M.3>P8MI+,:HK.-VRJSF/(8RYTSE$X)$#+;O
MS-/:]UVM\FW8W.59%CK`VF(G6LJW@MER42K3+2L\;ZXFW$E$?PB[A]L0[!P1
MRBH10H@41$V!0'0](I);;RJ;ZYO$U:;U3(F.PU%'%Y.1OUVJ:!7]P=K24TN[
MM,D!/<D#J/':GW(&\EE/WL"13`8&OQ\F#RYH_+'\.0T*-K<];8Y;M[(5RO7&
MQRE1K<O*.M,.([VGEBB(6SNXXR#50ZPF)&.U#%3\2`43".!V&3S9K+N14*9W
MP85G2FI+-K?;=AU[4J18OYMTQ:):>VMJ*2LU$ON[W;&NSHL`LB320;PLM#U>
M)?!))-A7?^*C3`GQCO8!L!&R/L(I&%(J?@1,`\`*'Z2D_0!`#T+QP`%`.``.
M,#O8&G#_`%`46^1^4#XY)TZB/\/<L],QS(ADDDED7\;W'H:\@HBY5$IWIUVD
MR@7V$_(R12F5$"AP(AN')HG!^X<<E]M1)ND!>?U`9`71E!$..``PK$X]?7C]
MF!Z&!UG8<MU2_B8OB'Y`8P\%$?[!P(6_BH].T_S8%_+Y*1,`?@`GZOZ$,(_V
MC^.!EHHHNWNOR%JQNRXW2DD1KK1=';LPC!N(G7CO_(B'3:W*2;V91*ON6<$9
M,JJI7ATT13)^HP>@@%:]=9G7SZTO6]7[MS/9J87I#.;6IS^\Z'L[.*A'\BV3
M:W=G'ZLH57GVK9TZ0,T07=.EFABJG+XF4`IRAF)@,!@,!@,!@,!@,!@,!@,!
M@,!@<3@OD@L4`Y$R9P`/KR(E$`_UX$*E*;&7^8O8X+"DHDTUW6Y2/,S`3+HK
M.:C/,GY)#R`X)AXHD$1*!.2J)\F'U``FL_\`2G_H?[N!^G."91.//`<?0!^H
MB`!]/H'(^HCZ`'J/I@18P%^ZW]S.U6BMPZDN<K<4=8P'</2-J6@IV^4H(F\T
M2W:6C;A1;G7"N8+[Z1J4U_B%(X;G]DZY3D4\5``P6G^0746J^O>M-2S%*L%E
MT5!7ON%HS7-XN59VCN6'-6Z7O+<1Y38IZ;'PFQ&-?JMGM]JD!*60^Q6(T4E'
M)VZ`KJ$$`Q^[_;1ZOT+K/);#Z\;4N9=KP>R.NSN#CEMK]HR1%TBMB[RH=&GZ
MI9&<E:8]*2AK+4K._**!'+-V@X*FH54JA``X=WK7L#J*AK':-@[8;=LC.S5'
MM9VLUA]B?:O9D*Q3(77&Z[/JZG0%?CH2]3@1K9>HU5B[=)N'!EG<H[6=""8J
M`0`PPU)N;3$YVRA:C8MEWQ_U?'L_W:IE9GH:[]F)VQ7JI:QT#H*_4FC6N1CK
M[(6&<K<'8-]V900+#I.5$8F*074$&7FJ%X>Z&R^K5%>Z`ANK\K:I:T3JG9=S
M9-22<SVA&&M#"@=0MT;?KDXK5KK9Z@HK,0-]U!#E:*$73]]B[?(&*9-V8Y0O
MMH*V?';=>I>F)O8=IV/*VJVZ.IDELJ[).NY3^2:6ZS4V'D[M*M;G&H/6C!PS
MLDPK]@JF<4D1!(B`B4I0`(]_C:WSI[;6RH1'M8]G5X1MT4ZX;9HU>J,;V1FD
M;M;-G;"W)6+ELVW0E&F[>\G9=O7M90+1!PY1;LV:SQT*)`4>*`0)'M9QO7+:
M_P`CT5I/6S&Q3VDWG26V;=M-'ND?V!JQZE?JCONITRH6*I'V)+UR:KK6W0MF
MER2#9!LLU?*1;9;DITQ$0G2HE(JNMJC7Z)1H&,JU.JL8VAJU6X9'[>*A8EHF
M!&T>Q1#T3;(%#@@?@&!5N!K?=)%BM_Z@_P"7QF<AC+'TGUD?@L4P^'VY86KF
M!#VQX`#D^ZYY_$1'G]H;((?0,`/_`*'.!&@^ZM]DZ)W2WMV/T]L:KN-=]CM8
MZ;K]QU_8'*$/+5'86E&UK@(BR0$FXU_=R2D#9*E84FZ[4QV9FKI-5;_&\DP3
M"R\]U:W77^Q%D[=[JV#7)5].5SJMUFHM$KA6,XRBJU%]N:]M*7M,G-?R%KX[
M=^\E)8C)NS*V=BF@C[IG(G$J9`S3[FKRZVA>S<40JYX93J'OMR":2"?!Y@].
MEFB8%<G.0/>%DJ<`3$0*("(C],"P/PL)F1^*WHRD8``4]!U@A_$Q3%]XKR5!
M8.2B/)@/]1_/`E"P/DY1,0Y0'Q$Q3%`P?4HB`@`A_8.!$-O3K7V\I?<;979C
MJY,5=Y&[ZTKIO6=ZBIF;IM;DJC,Z,F]GOH258O+EKN_MIAC:8W8X$*5-$AVC
MQ@!E042.7@,=93KAVG3WDX[<]I[#74G12]+^M5`JT',52SR3UNR[LT;:\];Y
M*?J-`UM%1K87R[9@W8_9++J"5P<RI""F4X2]]NR^YU-[0D#@/+KQNQ,.?H'.
MM;*7Z>OIS@1K?T[B8I_$9U=YXY,OM\PB'^T<-T[`(H81'ZB=0@CS^/.!-G@8
MC]K*'?+E_D/8==UPUNE=0=B:+M.7K3>P0U<?RM=BJGL&L2Z4<_GG3*',]3)<
M4E?9<+(@LBDH!3>0%`0\/;/;-[HRK.[OM[5Q:!5H^-E9-[+6;<>I8XP(0L>O
M*R#>.CBV,\E89))B@(D:1J+MTJ8Q2D3,)@P*:@N[07/4,WN_76I7NQJ-7J<M
M>Y)6E;8U;+3:$&A7@M@M7,`:?2E8NQJ0(&4"+?I-'P*`*1DRFP,VZW.M[16J
M_9F:3ANTL4/$3K1!VE[+I!K+-&T@W1=)>1O;<IHN`*<O/H8!P(`_Z=H4QTSW
ML!)$$`3^1_L(04P4,J'Z8FDAR"AP`Y@'T'U`./H'H`8&PU@<*R"+A)5%9%)9
M)8@D6253(HDJ0P<&(J0Y3%4(8OH("`@(8%BMR:OF['6HXVKDJ'7;M#WNB7-D
M\LL([-!2:E0E0<!'S/\`+AF,P/O1RRZ#=8AS"T.H!P*8H&*8,`H_MIWAV@2!
MLG5/1NB=]:?;7VX42U;5<[1?46/D/\MY>4J]N>:SA9J3,[NAT+E"NXHCERI&
ML55DC+IJJ)$#W`R%U-V+V?NYJXDZ,;5C!K`'MD+L!&SQUP:2NOM@T"R'K5\U
MI;6#&P.6T9;*LZ\%%P*NN@=N)7"1SH+HJ&#%&!VKVZ[(;8ZW]D=":PT]?.O,
M/&]B:]_F-*W->J*7ZM6H*G'U*]:ZKKF6FYF6J\Q/4!1)LJ^4C#O&;I)S[141
M(80R@A.X,<ZZYVCMA.[`T\ST=2(*\S%PM#)A?C+5)36$Q)US84).197*SPL]
M4;+"/(UTU33.?[Q`2E$Q3%,(40IV&[OL)&3V9-Z"U[#]7F>I&>Q23JUP>GWL
MP?@X/,SR,WJ[[_\`A98^&U^0SW[1*3-)F>I';`D*O!1#*#0#)E;D)_="%PJ&
MQ*ONN/UU?:%+U>/?#!GJ(4=HP@9F/=S#M\X>$L#)4[I-4H)>*2_AX^@B(9*)
MHHHE`J*2:10\N"ID*0H>1A.;@I0``\CF$1_,1$?QP("OZAU%DAUGZG6%=LLH
M^KGR$]<'4:[*U!TVC1>L;_'OWC_R#VV[5./<*""IN"D5`GJ'U`)(NR/0O2O9
MV_47:EMF]PZ_V9KM!1E7M@Z,W%>]/6Q>+$DZ5M"6!_3I5DWL43%'LT@HQ3=I
M*'9G?./:,4%5`,%(:^ZW4KKQN/1\-5I&Y6V2F8?=DG;=C;5N]@V7M>]RJ4'0
MHZ-?7.]6A=U*S)H:&;)LF9/)-%LU3`B:9?U"8,B][I^X?2_`%\B[WH9BB8/H
M`-YT5``>!$/-(#%'\P'CZ8%OM(+$/V:[G(D1]L$IS0RH']TY_<!QIR,,!03,
M'B@5+Q$``HB`_7`R\P&!!AWIACS'S&?#<)"MO*,'MQ+%4<B7DA6&FI!1P5MZ
M&.#E5N<Q2\``"'("(!@9K=GZ(UOVZ-<M#5:,N$C$Z(W[+(5"=C496%ND,%BT
MU&6NB2K)P@X9NHVYP4DHQ.DJ4R8KJ('$O*91`+H=79UHE5W=$CK#(VN$KB<#
M/Z_EI9P=W/'U#=XPDG0FU@?NUSOI22K@M7T,9RMY.54XLIES'7%0Y@RIP-0_
M^H-(T3^0#XTUE4$U7+N7HK)H<B9#.$54>V.CWH.%#'*H*;5`A#AY$`AP,I^]
MP(\!MS%62,X42`0!1,"F,4>`'_$\BE$/SY$HX':P.J]Y^V5X'@>"B`_3C]9?
MQP(8OBR$O_-C\V212\"3Y&XY4W``!1][JOH/U#C_`&A$HB/]N!<CL2%//6?D
MT+>#6!*`(ST6J8]7<5UC-C.IZ]J*E1!H_ML=+U1BF:UIL2KN)1JO'H-Q.=P0
MR)3A@>7T-U_N+0&]]AZHW-+)FG-J4JQ=A4&%;GM-6BO2\_)WF#8WZQ6A]2.N
MNBKM%V=&:L;=O'`Y,^AGS,SH&I4SLC``2YX#`8#`8#`8#`8#`8#`8#`8#`8'
M`Y,8K=8Q?0P$-QZ\>H^GH/U\AY]/VX&OCKW=FMGOSL;4U$%TK(;)95]%).D#
M,F1LIHYGIF)L#E="&$/%RBW8R"+I7Q$>$U04$/TFX#85X#Z\>OYX'`XY]D_!
M0,(^(`40Y`>3E#@0\#A^/XAQ^?I@1*]-*+JJI[61G].R=1G86_[6[G6"[3M;
MA9RN/)?8["PZCK5G4LL=/V*P/W5JB96!<-'3CR:D.F5,HMB>"9Q"3396L:%M
M^FS5`V358BX5*P(HI2D++H"=%8S5PF[9.F[E$R3Z-DXUZB1PT>-547;-RF19
M!1-4A3@%AF?1WJ\P?5Z13T[6)!S5)IC8X`DZ_L\^S83L4/G%2BD?/SDQ&23V
M,<`59N=RW5%%TF1P7A8A#E#NS_3#K=9K5:+K+ZBJ[BR7%U_$;'((/K)&?Q>5
M%,$595ZTB99C&#)O"`!G+DC<CATJ0JBQU%``X!WC]/>MXT"LZQ#3=(-2JG8W
M=Q@XHS>0(ZCK=(G<'EK&G/@]/8W4M-@[53?K+NU%'[<XHN#*)"),#DIO4+KE
M0+BPO]3TW1HBXQ$+(0$-8BLW;Y[$QDOZ2J46C*.7S>-5DD2@@X60!-PX:B9`
MZ@HF%,0HW_D%ZCBQD(X>O^N"LY)=ZNY;)-YA)$?X@L*SI%L4DD48YJ<3"":+
M<2(-R`!$R`0```K2X]0^N%_4I9[AI36LT.NZV-.I2BM;;-1K=3]I%(M7BD8[
M[$C:NH`W(=%B(J-6ZQ?=23*H8QL"JM4]>=,:3=SSW5NKZ10G=G3:IV!Y689N
MS?2Z;`3D8-GSX4Q=*L6:1A%-$#%2*JHH?Q$YA,(7K``````X`/0`#T``#Z``
M8#`UO.FWV7_N0Y\MHHHN$7W_`"\=:PD3*"N9JL'\)IGV*K43_P"$4?MO^(!?
M7S_9P.!.QV0ML]K_`*_;POM6>)Q]FI.GMGVVNOUVA)!NRG:U1IV<B7:\>JHB
MD_2;/X],XI'.4JGCXB/`C@6ZJ&NMFW'6]%E?^9G<43+2M1KLO(R32$T@LLY>
M3$*PD7`F;O=0.FQ4TU7)O`I"D$H#P)C>@X%2LM(7]!N5)YVDWI(+%Y_[2>/T
MFU,//XBFTU`DF/'[0'`H>\=5K;?89I"3':WL*DT966GVI!1DEHY!T$M2++&V
MJ'6]\-)B'VRDI%)"X;B42+)`*8"3GR`+>=O=4WL.L/9(#=@-N.@+U\W.X3`T
M;J1-)4R>O+")V!TVNL6PF2<)\^0^0*%+^Z8H^N!0'PIE\/BIZ-$$$RB714"'
M"7()^/\`$I?Q,'/J)S!ZF$?4QAY$1P)&KW,.:]1[E/LO'[R#JEAF&GF`&)]S
M&1#QZAY%,`E$ONH!R`^G&!ASH_4NRMB:>U??;7VI[#EGKQKBA6V6)"R.HV,:
MA)V6H0TU)IL&AM-'.V:$?OE/9(914Q4^`$PCS@7G@-"6"#?JOG'8[L'92*-A
M;E8V2:ULNQ;G'SX=-THK5T2HF\*!_0XG,`<!^D?Q"BMG=1&^V6T`RLW8#L8P
M8U^QU6VMF%=N-)CV;FPTBTQESJTE()+:U="]4B[##ME@(803."0$.4Q1$!"W
MO:73%CBNKW95ZY[!;SF&C/KUN,YHZ1D=;>P\*WUS93J)O%6.LF+LQ7)0\3BF
MJD;C]T0'UP,./Z<951;XANM!E3JG.6:W@E_BJBJ!"I;TV(F1)$1*02MTB%`I
M`'DWB'J(CR(A.1@<8I)"83"DF)C>/D82%$P^(&`O(B'(^(&'C\N1P(+>RO9V
ML]4_E'EKGNJF;`M>O)WI5KV/TQ*&=:V84>KWQCN'93C<[.H2>RKM1XIK;Y:L
M'J;B509*N)`S%J@H<J:'B*@6NK799GV:[U[=NFEZ7L.K:JC_`(S]U,-SRZ4I
MKR5H%CV,2ZUYQI0MG?:PN5TA3WJ&I[JT'CR/G*<@2.?*`"8HE*9,)Z]9<CK7
M7Q@`1]RFU53]H%4AF*OK^T`'UP(#?Z<M%5/4OR`@=R"Y0^2;?X%`ISF*D8D+
M2$UTN#^A3)K`)3<>GD4<#8NP&!QJE.8"^'@/!RF$J@?I-X^I0YX-X"!P`0-P
M/'&!#7U5ZO=Z.JFIW6BJ_L+5,I3J-M/;TSKM\E18M=S,Z_V3M2Z[-CFK_P#B
M=O:+,Y^-)<!:.1.F@F*R1O;]Q$"G$,D.CG5C9>BM?;;)N6[Q-GV5NW?V_P#>
M-G4J\3_!8&`3W38&\A'0+)B$C)I*24'%1C8%W)%C)JN15`G"?@.!:3J7UK[<
M]1^L.M>N$?=ZE=B:8KZ]+K%F;1%>B$9ZO1LY)K5YV=M+_>NF$D6%<(_=`X46
M(+OS\/$G`"'CT7X]=DMOB]WUTHN^RZ\XVEV#@.V$E.[!800-ZK7;WV;N^P-B
M`HC!-W1P6@ZS.70B2A43I$<E34,1-(HD3P*_N>J^[]JZRR>J4KW1XW94]J=;
M6[ZR-&-05K;::F:>-7E[01@[@%W802;Q8ZY&9#?='0\2@;S`1P,V.O.K5](:
M+TWIYQ,$L*VK=4:WURXGBMOLPFW-%ID)5%Y@K,``K,DF:(]X$@Y]ORX^O.!>
M3`@$_J,D4E.F>@U56AW@MN^W5U5(GNJ)-TE!DK4G[[XR)TEQ9$(<Q5"D,`F`
MW'J&!/W@8X;;97MKMO1MQJU*=7*NUYIM2+N98V>KD1*0Z-EA:^6#?M6=CDXE
M.614D8@R2Q4%?=1*?W/$Q0$,#CN3B\7B0U0D36TS!LX;:$'9[%(3-CI2J4+&
M0L/.*G-]O$3\HYDG+IXN1LFFW*8P*&\AX(`FP*4T<`!V8[BCP'*C_K\J(_B(
M#J%JF'D/U$P"D/\`=@9?8#`U>/FSID9M'Y._A;U5)6F_5!AL/9&XJE8YS6&P
M;'K6\-*Q+UMDH];PMPJ4C'V&NGF%HPK51=L<BCA`ZC<%"%4/R&7T_P#$'U3;
M]D=2-/YI[>.D#ZGW"J"SWO7VX<22?V%FTV0R*$JIMA24:L'A7ZIW+9)P5!RL
M5(YR@9%,2!FSU0ZH:IZ76G8%!UK_`#NXA]FODKU"/]A;*O\`M.78MF)C-9&A
M0LSL&P6&0AZ_6I27<239J@<I5!F5SJ"8Y#G$,\,#3Y_J')`6OR#_`!H)((.%
MW1WU.6$&XD(<6R7:K2QE$P,<Q!4$X%']`"/TY$.,#;L:,RA(.9#R.)EBJM3$
M,81+RW>KF(<I1Y*`@F;CGZX'M8'5>@(MSB`\`42','^\4IRB8O\`>`8$,OQ<
ME\>WGS:@``'_`/T-KAO0.`_7U/T$<?[^1]?VX%]=C*VXC[Y)DJ'5H2Z6I6"U
M&1A6+'5/Y]A99F^T^P932;NA@(#>CM((KMPE"_2663(U]?=XP+6_'G6]24O;
MET@NOMW?;FH\AK?^);)V/9=#PNL;!4=B,[+$(5[7\9;X77&M4I&"DH5_)NE*
MF=LZ/55&")Q.B$@"9PF!P&`P&`P&`P&`P&`P&`P&`P&`P.J^_P#,;GCT$$3B
M`_D(!R`@/X"`AS@:5.B(Z-:_U0-RD`;?>O''8CL6FI*#Y*':"KTP2.A'G5()
MG!445#'*0AP%`@@/`EP-ONM[NJUJV-/:VC(>]IR]=(47TM)46TQ5445_[6"B
M#*SR46UA7YBBT'P.@LJFOY?X1C<&X"\@@`AP(`(?D/J&!AQM>L=A#]H]!7'5
MU=U9)Z=@*;N&#VRO:[7*URW,;%<GNN'%8?U>,C:G.-YIL5I7WY71#N6ISK+I
MB<WB4.0[5)VGV'V;6(VY4[6NI$:Y,/[$WCQM6U;FQF31L-8Y>!;N'\=&:M?-
M6T@\2C`541*L8J)U/'R-X\X%5#+]M"\\4+KL!0]"A_FOLDY_$/0O)2:>'U\?
MKQS@=UC*]I#+%&1J6@&[82'\@9['V(Y<$/Q_AE`CK63%,Q>?J(^(A^`#@6P=
M[5[/EW@&H8[7VA1!UJ];91+"\V7L(H>RTM#.L'B5(QOK97_&4=/3K%5*KX@F
M``(>6!7Z[WMV=9,A*QUO!L"8BH([!VD5R"_IX@0$=<D#V1#GGDW/[,#MD6[6
M^)15ANOA`\0_22V;.4$IN.>/>-4TS*`'YB4HC^08%L=U[([8:DU-L?:!:MUY
MF"T"FV&V%BU+CM%K]^,+&KODVAER5)82`X]KQ$WCZ<\X%Q%ENW!A1.RB>NAT
M#-TS&,ZM6TRJ^Z8I3'\/:J@%%+GGQ$0`PAQR&!]ID[:&Y%9GUX3-P'B"<WM-
M<H>0@"I1\XU`!X)SXFX^OX!@=CV^UP+-RIAU]0:^X)79S.MF.W`-_'@GVI%$
MD4@6`WU$P\<8$%_0J0NZWSZ?+!%[!)5BV)KHCKVH9:F&FRP;E@LQIW\-/[,^
MHJ]%^C'F12<'`2)F6(?Q+X\&$-A?;FO6NVM7;'U<_D',0PV1K^Z4!]+L0*:0
MBFETKDC6W,BP(J`HG=LF\F=5,#_I$Y"@/IS@6AJFL.P]3J%7JC/<VME2UF#B
MJ^D[6TW.G^Z90L:RBV*AD?\`-LOMN3(M/)4WD8#F-Z`7C`]8*=V>%10Q]W:M
M\!\?;*31TV42?7R\O_:PB!OJ''H'TP.J%%[3`!O_`&X+69A%10X`/7^0#])A
M`2)^0[E.)>/ISP(?LP,$^T6P=K&ZJ]EIA]V&H#N*-J?L%KQK)M='O(D9&^Q<
M/>ZVM5XHIMIOEDWC9]67I`<G2,58"`;Q``$,"X7PN+D<?%KTE43]SQ#2<0D`
MJ@D50XMYF<;F5.5$`2*94R0F$"\%#G@,"2N=BDIR$F818W@C,14A%*G\"*>"
M4@T6:*&]M0IDS^)5A'@P"`_00XP,6:1I#L!0*-3Z'"]CJV,31ZM!U&)<O-$1
MKF0<1E;BVT/&N9!5/8#5NH_.S9D,L*:229E!,)2E`0``J`NNNS2H>O9FLE#U
M+Y)]?X<JA?0/4@J;!7(!@Y]!$I@Y^H#@?)M8=F!`?'M+&E'CT$="U0P`/X<A
M_-!>0_T8%M=QZ<W_`#FF-QU^T=EHR6@[!JK84'*MT-(5Z*<C'2U1F&#[[9XG
M;5DD'`MG!O`YTE"D-ZB4P!Q@8&?TUYP5^'CK`IY%,8TIND3G!5)4RAPW5?2F
M55.BFBF+A7CR4$"AY*"(\!SP`3L'`!+P("("(`(`(@/`F#U`0]>0^N!BE4=X
M;=O4.]L-<T$DY@D[/<J]&JOMN5MB_D24VX3=.<2*S(\(O]@E(.811PFB98RB
M:1R@?@_(8%QT+%LU4J3U73L:D^*@HX*F&Q(%<$G8&,V*V*^""]X%56JAA]PH
M>(%$2"/K@4OLXNU[AK38M:@==5MI.VND6RO13Y_L)LG%IRDU7Y"'CG,DY:U=
M\Z!DBLY)[IRHJF(F`\%'CC`INB3_`&0@*)3X27T34E)V#J4%%OBLM]H*Q:\K
M&1;9DHDW='UZW7%!=5'R*<6Y>/+]W`AO_IL)-:4T9WKD'3%.,=2/R-[Y>NH]
M!R9Z@R=OX&DR+ELF^.V9FD"(*KB3[CVB`N)?<``*8,#9$P&`P/GP)]?$O/(C
MSXA]1^H_3ZC@8^/^QNOX:RA67QUB2CFSJU)FQ;`@K*O)<MYK5`]U*)]XKX\2
MG.6MH*[T">P@D?DQN1*`AD$!""`#X%]0$?W0_P!O]1OP_$?K^>!^@0A>?$I0
MY^O!0#GTX]>`]?0.,#\]I/\`]-D_\@OX_7\/QP/O`8&O]_4A2/\`">BNII$`
M0.=MW=ZP^VDX,J4JHJSL^@<I?:]3&324,H(#Z>)!_'C`V`<#Y,0AOWBE-Z<?
MJ*`^@_4/4/H.!^>!"AZ$*''J'!0#CUYY#T^O/K@8I:;\"]DNW/B4"B+[1A1$
M``.?'6IRE`>/J!2AP'Y!@988#`U;OEF]H/G)^#P5%BIJ#=++[21@$I')2OY`
MBGNJ&#P,9NHLF*10_5[APY_#`G[N;ARGVOT,@F8H-G.G^POW!1`?(QD)_11T
M?'\/0QQYYP+J[%B#NX=&=:>V27ISU&T12@F%(RQXXIQ?Q2BQ"'4*UFXPRK50
MH<^7F4>!$H8%6PDJRG(B.F(U8B["2:(/&:I#"8#-UTRJ)<\_J*H4IN#`/J4P
M"`^N!IK?U/RSVO=CNHNP8%=9K;J%I;9MXJCQ)-NZ^SL%"V=KFV0BHL7R:[!T
M095DD)RJIG`Y2>/`@(A@6-;_`#>]Y([JWUV[1V7N[H=I+;RW]&ZD9=<(SJBT
M"_$"K;@9TC:Z;RT.)UU$?PZM5TYWCB72:MD!.\0*@0R@B4`W%:OV^ZWVJ[16
MKZUM",F;W+)NCQ-;;1=G%^]08IK*KJ$7=0J+0?:0;G,83*@'Z1XYP,DG(>XV
M4`O^TGR'/IP'H/KSZAP'UP(8_C$24:]S?FS05$ON+]]J#($3(83%^SDNI&CG
M+-SR(%`0<)EX]`^I>/7CG`R'N-Y7UK9OD.OK2;?5=:HQ>DY@]EC(J+FWT"W0
MU>V!W-(1$TBYBI#^%LE#K&3<)G(*9#?I$0`,"ENF>W:3OG;LC<T^W;W=UNI-
M2VM1(/6\A3M?TA1M5'.SJPQD-J-6509-GLI%6L^NXQ:-.X,!D8Y^03ID.L`B
M$HV`P&`P&`P&`P&`P&`P&`P&`P&!UW:?NM7"?/'FBH7G\@$H\_3@<#1Y7VGK
M_0/]1O;]O[>DXND:XJF[MRM[/>WK226:1(73K&2NU=%ZE#L7SU8TK.O&R!1*
MD<"G6(902AP80G;JWRE=-(7>%WEYOO;JB;I#UJ#ME1H+0>T6=A8*QK91+_UO
M;#!M-ED31:#U+VDBLT/=,KP4H&`W(9%0WS`_&[8(J8FHCM-3W,=`+O&LTX4K
MNP601KJ/>-8]XU=IOZ>U42<(/GR*(D$`$5%"@'(B&!X3OYF?C8:+F0<=D8@I
MBI'.LN%)V.HS1.@!U#LW#\E/%FD\(4@C[1C@;D0``Y'C`QGU!\P?3O66MF=3
MD;_!SY*[)W!8\['62+%A(1\C:9.QM'J*+LQ'J0$C9M/S1.3W4SIF)X\AQ@5?
M"?.KTIL34DI`OYB18+-P=-9-"+F$V#YL=N=8BS)XK7DP<I'(3CD/T\_B(!S@
M=.R_/+THJKN,9S4M*-%IJ7C8.,$Z4BBBXDY(YTF[4SIQ!(M$%14*``!U`Y\O
M3`M\/R\=70[&MMC#(M21)-,S.NUFJ]EARRC6PMM@-IU4CML1(XIQZC5#A-<I
MCE.I^CQ`Q1P+ZM?FOZBN#IH#/,$7/M**KI'L"!B-RD542)RHG&&\_>]L1+P7
MCC`M_8_GSZ85E_68=\]D'$O;U'98)O&#*S#9VFS,M[Y_O(>M2`E,F1(!,7VQ
M$HG`!X'`MEO3YH.K&V-';7U[%*NXR5NVOK+66"DNE:B-VCZ;C5&":C\K6B.U
M$46HNRF,(EX.8IDRCYA@7%@/GDZG3J\Q%PS.5?O*C*HUNU))OWS8(&6"+:21
MR.C2E8C3*MD&[DON'(7W.1Y*D8.1`/>5^<;K*FL5(&`GY.0IO*QJ&/\`XOO"
MG[*3>KN#N#>*7ZO#D"B/'(C@>>]^=#K<V>HM6U8F'R#@P)H/DIEVW:BN(<F1
M.=W64"I"4/Q$<"&_IC\E77%C\NOR$=TKFYM]=U)NO7FM=.T1Y$U2R6YU+VW4
M[JMPE@9%C8R(;2S(K96&6$%'#1$BP&_08_B(B$W=K^>CXYJ0T:/K-?-H1C-_
M*0D*R=KZ/V8#9Q*6&1_A,0U%S_`/MVHNY$!2]Q<R213AZF`/7`J-G\X/Q[O9
MB&KZ6R+469G7J$<QCST*=%8'SD3%;M7)DB*HM5%!(;]\P%+Q^H0].0]%7YK_
M`(^22;^&1VE//):/2*JHP:T>P&4<F/Y>+:.55;I-9%Z/@/""*AU1`!X+Z8'G
MWKYO?C^UVA&KV.^W8P2\_!5ABA":WLMB>+3ED*[/$L2,(1!\\6,NFQ6,)DR'
M(0J8\B&!']V=^1;XV+9UEW3I*OFW%-V&9AMTW?7'W>G;^8Q-PW6+OEB:.$)Q
M:+$C)N::MRQB)"`"@S4-P''("%5?#]\EG5C7_P`>6A-36ZQS<!>M%0TEJ/8<
M')1C5F>,NM=G95Q*1\<[?RC1.>8HH2*(D>M0.U5,<2D.8Y#E($E[;Y5.F[AR
MFT-?735PN(`@FZ;19!6$QO`O@*<RJ4.5!\?40]<"GT/ETZ:NFGW;:S65P07\
MA%IIIQ4,*BS^->J1[ELF8UC*W$PNT_`HB<"\B'(AZ\!8.N?/[T"M*:JD,7?[
MD$)B?A%/9T?9')/NJS(N8F8<)N&+ATU7CVT@S52]]-0Z9C)FX'@.<#U3_//T
M+`CHZ1M\N/LC)E<@AI"TC[0J"(?K4.9-$@%XY-Y&#@,"V.V/GCZ)S6J-@1C1
M+?Y7%CIEMKD>8VD+(?PE):OR#)BFX01<J.D2*N%R@!Q)X\^G(#Q@1Z_#9\FW
M6WH7\;VC>NV]83=;6_4)783B8"J:FF+!!N/YGV39;#')Q4N@Z1))JF8S*1CG
M`A"^?D'(B7D0DD??U"W1.*9!(2=3[0Q[,RZ#9!9_I06IG2[Q86[))HW7M";I
MRJ\<?H2*4@F.80``P+1Z$^>7I94->(5>>IW:9O,I7+:$H9I_D/*+#_#K)LRW
MVB#7271FE6KC[N%EVZGMHJ**I"?Q.4H@.!>=#^H`Z0*D^X5I':ID!S'3;G?Z
M*=M#.A(<2B5$%;`50H<A_M@0!_#GTP.-Y\__`$=CV:LA(4CLVS:HBF)UW>ER
M-VQ$#*E(HY4=N+*DS10;D'S,)E`]`X#DW`"'DL?Z@_IE*IKNHG4?;V7CD!`R
M4M#Z.93#"053$#'2BE8^YKC(K%*02B9,!(02CR8/$>`B3^'KY$-0]"M;=FJ7
MMO578Z5F-S]OMC[PJ+37^J7%B(UI=WAZZWB4)87DM#'8SK56%7*]:I$6*U,7
MQ%0WU$)<?_<@OJ262;1/^1/=LT@\>.F;9`G7I98H_:&$%EE54[09-!,/$1]1
MYXP.XC_4`]2UK&SJ!-*=P!M<C_B1U9+I=@:PR#,!=>[)L8,MS&4=1C=-BL=1
M<B(ID(D81$`#`[SGYW=&-5W3<W4COVJJV.5(I6_7MJM]VL*Z2`I-`)=?(Y@]
MP3`)@(42D'U^@"'JI?.%IYZBFO$=0N_4HBH5T;WTNO16Z!!9G*FJFHHZMJ1B
MJF,?]`>/!P`1`>`P,6]I_+[U4US6[/O78G1[O!$5.H.WE[FI28TM`Q+5K.%N
M-;M[6R+6*0OC-&,1;RM=:JJE5.1KY()F.(`41P/):?U..CG,8W?Q?QW_`"@R
M3)PQ;O(YPRZTHNVT@T<)$5:N&CUO;5FSENY14*=-4AC)G*("41`0'`[R?]2_
MJM=`QT/C5^5`RX(D4304ZOF*"AC``^V"R=F6`@AS]3``#@<S?^I)J2WJI\7?
MREMRB4#%.?K>98#\_@`-)MP8OIZ\F``P*@:?U%%==MO>3^+7Y6W!U5D`:$C^
MKKEZFY:JG%,[GWC3S8$3H&#]21B^7'K],#L,_P"HIID@F99E\8GRN.T"JN$?
MN&O591P@*C9VY:*$!5&T'()RG;"(ASR'.!$1\PWRY%[Z=:JGH?6OQ[?(O4KA
M5^P^H-ONE+]USFHN-6BM;R$I)O8=0L4XEY,CR917%-$`2*41*/)N.>0E)2_J
M6]:N2B+'XS_E,DA2*D=V$=UF!T#!)10B9W#L?YE)[;=(Q_4P`(CQZ!@<J7]2
MC072)%&'QE_**^4,;]:"/6XY%$D@Y`RQO?G4@,4!X#]//J.!^E_J,W;A9JT9
M?$3\JJKUX]:M$$%NOR2!3)O5?;;N/NBRJ[5(3?4Q%#$$H_7\\"S=-^<[9](V
MMO79<O\`#[\G[BL[0>:M<5]K'Z)-_%(EI4J@>N32\V*[PB#M1Q+#RV*R%<!2
M`1,)1`/(+E2O]2),03-62G/A^^42%B2(-'@R<KIIE&M$H^0.1*/>/%WSYN@Q
M-(+*%3104.#@ZI@(*8&$`$/DW]2%+>1R)_$)\HBATCBFJ3_));E)4/JD<"D/
MYC_X'GS^'(^F!'#L7O',_)%\Q'Q,R;CJ'V-ZGS>I]LE>M(?L76OY2F;K6_8M
M=JFY:LLW#=L8\9#MJF8KDX_J,J)4P#D0P-J"3==E)GNKI^9>:`@HS1U:UYOF
MHR^U4=QUZ2EV\I9Y?5,O5%1H'\O-IE1M+MZ0Y3%-!=11`ZQ3JG(FF8%`SN.7
MS(8G/CY%$`-P`^(B'H(`/H(A@4#".$H2Q/*:5%!B@JV)8X4&R14D7*3ERH6>
M;IICSR+:2,"JG'J0KLGT`2A@:CO]2M5;1M3M3U*U!08Z1L-TM77K=RL=7:_7
M++;;$X%&TUAT1TW@ZK$2TJK'(Q\6_.L<I/`@I%$_H&!BJ\K>XG'QBZ&Z11'Q
MS]G76S-2;#T7;5]AM]-*,Z@[D-7=BWN[+9;8M-U#&LL78K_6GRT(L[%)-P83
M@58QD.2X$^3KY>.R(JF3C/B+[GR")!;+.#@HT8+`V<'4%4[=%2MF,X=$.GX%
M2*<H'4,!?,I1$P!.!'O%)B"CWYFJ\:M(,6;L[%UP#IBLX23549.0*/HY:G,*
M:@?@<HX$0GQOQKICWA^:LSI853NN[.HGR?(G,9-HXZ<Z3.U;>1Q$?!)-0/$`
M_2`?0`P,V];R+&'[&]Q)68=,X:)CRZ)>.Y>2=-F,<BV1UO("X=NG;DZ*#9%N
M4O!SJ&`H`'J/&!<36FP&$KL;<U%DMS:PO-EB;G_%Z]KNJ6&NN;MK37Z52H\2
MK#7:OQZI9MN_"\EDG8N'29N$I-NE[@<%3*%]L!@,!@,!@,!@,!@,!@,!@,!@
M,#Y.4#E$H_C_`'_CS@1.;T^%_I?V&W-=MZWY#;S:[["DB2UI2JNU)BN5]]))
MQ<9#%>EB6C4Q2*_P^';E$OGX"*8#Q].`MTU^!GH6U+)-6?\`GZW.[222<+I;
MQM":A@$3*^1/%/VR*&\N#&\!$>`_$`'`];7'P@=7M004A6M7[C[@4F#F+1/W
M2;81&^!4"<M-G<,G,S-2KJ3J4@^<N'2D<AP3W013]HHE(4W(X%SV_P`4>I$0
M5\^Q'<UR=8_N**.=]F.<ROT]X03JB2?O`7Z'\?+]O/K@=3_SI;3?L*-_^8;N
MD*2@*@<G_,(\`H^\83*#P%:\>>1Y^GX!@6:@/Z?SX\:Y76=:CX;>`LV#AXX;
M.7.^+XO(I`_7%PNT!\9V50['WC&,5,P"!1,/'UP#S^G_`/CX=OJS*_8;[;2=
M/L32VUUXR[![#9N(ZS1QO=BIQ)PB]!4DA$N@*NW$/TE53*(@(<@(7N3^)?0Z
M`.?M]V=T$3N5O?\`N@[5;)5>HG#VO$B#MRZ6<E3+[7/ZCF$QC")N1X$`])+X
MJ=%$4745W-W2<*+G\S*G[?;I04+ZB/MD^QL+,"I<B(^/J'.!0=[^$_I/M,]4
M-M%QV2V5_)$TYL%4"Z]J][S)*_+/&1H]V\C4%;F"*:KEH<Y#^GZBG-^8A@?!
MO@Z^.X60QY-8WENU%N1J`-MT;625!!,>2)@K_-8G`"F_4`@("!O7`_*%\)/1
MW5S6>8:Z+V1HK"T6)S;[$SJ7;GL=!-INUNF*$8:Q2B$=L5LD]F$HYF@DFN</
M-,B)`#]W`N:;XK^N2C`8M?8/<-PR.@#=9-3NWVC(=5`'2SPR1U$-GI*>*KA<
MWEXF*(E'CZ>F!U5/B?ZPKF!5Q<NW[EP1)VW;N5^\W;8ZS)N^12;.D61O\W0*
M@59!+CD"^1.1\1#Z@%M8'X+?C>@7DY)IZDO,I*628<6&;EK)OK=UGE9&>?&]
MR1F'$E.7MZ]-(2*P>XX5\_)53]1O7G`]"7^#WXW9M:%=/M+VD'M;F&-BKS]G
MN[=L=(PE@BUON8N:BY!C?T7C"2C7/*B"J1RF3.(F#UP+I+_%KU@<`(&L7:TH
M&,8Z@?\`._V_."AS\"8QP/NLP"(B'KZ>N!Q+?%9U2=`W*]?]F7Y6:H+LRO>Y
MO:]8K-<`X]]J`[@X06\1X\R\&X_'`\>S?$#T4NK:.C[M0-F7:'BI1A.L8&Y]
MENR]H@DIN*5%:*E1B9C;KI@9[%J',9N<4Q%(YO(/RP.)[\.GQSO5?-QUNA50
M.BN@(#>=JI<`Z,3[E4H(WHH%<J$(!05X]PH?0>,#DJ/Q`=#J#'/8BCZPO%+B
MY&:D;$^C:AV+[,5E@[GI<Z:DI-/&4)N)BS=3+]5(HK.C)@HKXEY^F![IOBDZ
M7*']Q>I[@<J&,!E3N>V';5;WAY#D%"'WEX"4P!P)>.!#`[R?Q9]*T""FCKN^
MD(8QCB`]D>T1Q`YO0QB^6ZA\1'Z^GX^N!2\/\.GQO02BCAAU?K'W:IW1U7;J
MX[3D';@[U=1T[5=O9.^/GKM=XY6.=4ZBAQ4,<1'D1'D*E:_%!\>C,ZRC?JUK
MI,ZY/;4."EJ,<Y?^LH>RF4,IR/[_`#Y?V8'VX^*7X_'0I"KUFI8@DJ18I4I>
M\-BG4((&#[CV;4`.DP$H#X'`2^F!3B7P]_'(@T,Q0ZQUA!H*_O@BA:=C(B4_
ML1C?_C$N/NF2]J'0_P`,1\`,!AXY,;D-83Y"[_T;^,SYPNDD&2NR^H.OVJ-2
M1^\=U%J5<N.S"K6IS);=:4.4<L5Y6P3*8MGS)B199%,I&R*I3CY`7`DOW-_5
M%_']3*I4)/KYK;>W9.ZW>PN(F/I$9J:XZP<.&L>WE'4L\93ENIKAI8Y=J,>0
MB<9%H/'1_N2&/[*1%#D"T/\`[D^R*[)P[3^*+MD!$*LQMBH.XJ[`<(U\X]E$
M#"ST.\(`>`@8''JT'D`]WGUP+(]J_GTNG9;JSOC0Z/Q==MZJOM[5;[6SJ54J
M>SYG^4W.U81XQA)`T<CHV,1DCH)*?<I$(N@9T8H`U%8X"`!2W2?YR=N=0>HN
MB^K\K\6O<78$CI&O16FTK:M4ML19+98&"T@Z_P#7&?1DJ]BP1CU2E.F=9=R`
ME'E("X&5[+^I2V[(-F;EG\07<IU]Z:12:D:U[:_N+&AR&4E!(HXT&U1%)F4"
MB8!5]T`,`F3+@=0?ZD_?[I&*5B?AU[AN2R\-)3K0BT%MC]#"/'V5EQ48Z#>J
MKH??$50.HF4W@H3Z&*(F*&#.QOE([,6KY"]-=_7GQ=]OX)'K_HR1H[W4Z>L]
MNOG5DB]E,[NS"VC;":71_A:;-2SH%1:K-#"M]LIYF3$2\!G<;^HR[2D4?MU/
MA9[GD=LYV.@P9C%;B,Y%:7(LHS=*F;Z!49I(@1+]1`4\O4/'G`X__<B3N<+P
MK)/X1.XBP!+N88SHC'<I2G78)"M(+HIEZ^JJ*-V:93^7D8IA,7]("7R,4(M.
M^O\`4";V^0OI=<^LE)Z';+TU5NV]AJND(S?*]TM,[6V49+;HKE'G&R"KC6-?
M@I).R2K!Y77!`DTR(.#KHJ>2B9D<#93JVMOF2D(9@IJKM3THJ6J0CB1VMH*V
M:!OEGM$#2HAU*QE-:SDQ$W&&BYF:<5)K&JO%D4&I3.E5BIID(D4%`]YUI_YR
M#.W(H]ZNBK9J94ID"'ZFWA15%NF^;*"7S'9I0Y78(+$4()C&*;]TX#P<@63M
MVM_ZD:$L#9"C]F?CMV)7'$21)T]E-37FB/H64!1,RJQ8PX68\CR0#%34,Z%(
M4S?J1!0`.(6XGH[^HOK[F[INNT_00SRDZS:WA_$_Y56E85FA@N*JBZ+A&MHB
M$FJM$G1\2F,B)&B0E2*8RHF#F7B?ZBEHE.MW?:OH5S'Z]+LM)XCJ2T^\2+6=
M39OL$&Y8(P`H1JCP0Z_N%Y;IB)#<J@<.^E6_Z@U511DIW#Z7JN7NOVM]2-&Z
M;F&ZD4S53;,%.1=TY^DX]I5(ZPMQ*9RJL8P$3*4,#*[J=$?*S_-]K@NVG8S1
MUHBIS6\%:-9FU/1F-=DXZ1_CPH2+JPKOJ6HV=1TA'.4DR$*F#@BA#&]HH8&=
M;^J=FU/<1C=A5@4%!$2NG*_@]3!8[XZ@E2;:[%),4`%J5(#>@E(MY<B8H@'N
M258W\*OE&7V`;)^^W,FF\$SGA))Q'"L57VJF/N&<-2.BC^HI2G5((<>&!YLM
M3>Q;A,BK':%<8JIMBE43*B(MS*I-5P`X!_+2JWBH[,0QOWC"0HE]?3`C>[@[
M:W/76.V]43DG=KS%/]=6"FPS34$%'6=](;)V+490VMX^SLI>*A9.NO*W8GT4
M^;R45*'(8B2AW:"1"EY"6736Q6>QM,:XV@HZ00:7+6E)O;A5=XA[#%"QT^)L
M*XKORF^W!-N5X85%?+Q#@1YXP-%KOQ\B5VTC\Y%7[6/=<W?8+#4FB-8DU-5)
MVMV6:IE$I&[%M@4:K#,JU-,\S7;1M=A9C3;-44W!S24DBQ]M8&Y4Q"7G27]4
M?T^M3;V=T:\O6N)!%\5BHO4#_P`\-Q,DD4'+A6M34;2+W&ILW8>VJF:.<&2Y
M`1,(#P`2Y::^6/X]=[D0"B=I-7M9!8C(1@+S,GUS8DU'QRIHHA%7=M!F=G\S
M@7EN=8@F`0`1X'`RZM\FE,U5"^TQ=K8EJU[MBB302K692L$>U3-_%H=B]CU5
MVS@)F+*<A"IJ&Y<`D/J)0#`U$_D.NFR>QOSMZ4HG5O=4MJ7;E;Z\52MZ[V57
M6L=83P-?N-)V!M;8<H,`\3=*)L7%(L+,'R@D1<HH>!RI+!Z`%S[7!?,%K'O?
MULZ:*_)NC9[AVHUUO"]-;&G0FK^NZOJNE&#124F']:DJJS+(2=H?R*;)EXJI
M$;.B&./D3].!((^Z3?,BYBF[)K\LE3"2.<J:,@WT=&E4]AOP@Z,5-N"Q'2R9
M2FY.H00]X0YX'C`G9A&[UM"QC*0=GD9!K'LFK^043]H[UZW;I(NWQDQ(GX"[
M<$,J(``<>7H&!%/T+X)W\^9HH"`E-V8ZTF`"B'B!S=,]0B<>"B)?,?;X-^/I
MZ_3`N_<J"UVG9_D.UV^9V>2;VZEZAABL:8-?_FM9PXUC)G9A7BVU_%U924*\
M(F9(D@Y09J"7Q6.4@B(!87HO9;#L'L]L>8ME32&6I%3NL5)7K4>LZ]6-%R.P
M[K:Z4\VFI;=BQ&ZMN)7G=$^[I\692&C7*D964&#DBQS.W'Z0F-P&`P&`P&`P
M&`P&`P&`P&`'T`1_+`^`/R(!Q]1_/_W6!UU5A$RR!>2&*B"@*`8`]3&$H%#R
M`0*(B'U]?K@="++)*F?K2A6I"G?F&.1:JBL!&*/HW555X(!EW`#YF*`<%YXY
M'ZX'M8'SX_J\O^Y^SCZX'U@,!@,!@,!@,!@,!@,!@,!@,!@?@AR(#^0X'[@,
M!@,!@,#A<^0H*@3@3&(8H`//J)@XX#CU\AY]/VX&K;TFK$-V3_J,?EZW+*P,
M=9J3H/2.BNK$>>=03L,4G89..K#^VQC9J_(ZCFZ1G5+DD5VX$$`.<_H`B<!#
M,G07P#]3.LG:C5W:#3VS.QD6?5EPM5WAM-6G90W?4@3MKI5GI#E_'PL[&*24
M%(-F%H4,1PV<@H8B8(FY2,8!"<LJ8E#@#G$`'G]1A./K^8F'D<#Z\3?[P_Z/
M_=X'YXC_`+P_^A_?@`)P;RY,(_M,;Q_N+SXA@?H@(_[0A_Z']N``!#ZF$?\`
MT/[<#]`!Y^O(>OI_:.!T)5D$C'NV)E5$"O&SEH91(0\R$=-U6YSE`?03$*J)
MB\^@&`!_#`_G^;JZ+Q'2;Y)>J_1FG[[W!LS2R6QM'[S4JVPILO\``XQM%7K<
M>\Y2H)U.)4:5]W$0A-:.Y!FZ.V%9%[+N%3^9_`P!OVTR+1A*A5H=!`C9*+KL
M)'D03`@%2!G&-6P$#VRD(/B"7'(``#Q@5+P`_@'^C^W_`+^!^X&)NWEA23WV
M=G%IN)9+KJ[]DX`T$[_S-LTK*.<^XNT<"B#DQC#RH1'Q.(`<#@(8')+LDAKL
MX^5723D%NKR3,S)-)H!D2F821O<*HY343%(5S"4"J*F;AQR8O'D<0\`&SM":
M11\R\M>H+M`PF38B8[U!VQX,/L)J$\/^H0QFH\_I*/KP'IZ[;F/L+6;MT5`J
MRW5BN(KF33CBN.33\&Y71342'[DC4AN.4R@#01X^AO$!#+D``/H`!_8`!@!`
M!^H`/'TY#GC`^5?^&IZ@'Z#^I@\BA^D?42^G(!^6!'I7]3:KVMVAV#=[+3HJ
MVN->.X.0KDE-0\<[&OWH7B-76DJW+%=+2L?)M6&NB)K\>VE]LL!1`W)@$+8:
MGFWTQJ+7?3V&DG7\:1OFXM8;&<F]HSVLZ*TGLN:KDPJNLQ]@K=78,`ZA*]&*
M"00,:4752`0:J^`0`[->$W-\V%YA(6/!=A(?*1\=O7W^&-U5DF!*/T:ZQ[<[
M36X$VC<H(.F+*YN8A=8A@$K9=!'GCD#"&WQL/2VF;S'20[$U9JRXQA6;QP\2
MNE%JLTU\3)G.]7=.YE@NFBBJB3_%,;Q#Q`1,;CG@(1]-?'ST:WEV^W];++U8
MT4KJ?8.I].V?KHR@*R>KMI:O5.P;0H^R=C,VU9=PJ?VMYE9"*%#Q(1(T02/6
M*!O?`Q@MUWY^&;KYH[2.W>U?6_LEW(Z;O^M.D]P[9K=/Z_;UGH:B/K)4Z5,6
M.((]@YM&<=&:N'L8FU4;).")+(J"7Q`P^6!&_;?Z5?<&U8VG;EC?D9NK[:-Z
MJ^OK5?T-\:W6M<X%H&#K3V=8M-HU^XQEO8,&YF8,2IHD2668I@T55.W*"8!D
M9UA_IG&</VV=[7[BVBB[9U)'ZJGJW7J]JC:G9ZGV60V-+VAG((6V;7G;Z^GX
M-F%;*[;N64=/EBEU2M^&0"D8Q@E3)_3]_%HBV:-&^CK\@DQKTK6FID>S'9I-
M=)A,OSR+U8C@FW`.5^+A0W@OP*I"\`!N`XP/&^8#8=0ZU]7].,C=<J[V.K52
MV!!0M;UO88S8-ZE2IU:@SH0`0E5H4P%_N<HW8L1*^4(WF$F\<FX=OFQB%]T@
M6Z^&78%0O78SY/7%(C6D;65KQT=LL`WAH9"O5Y.`M71G5BL,E"5]&:L"M=9H
MMHPQ0CUW:ZS0O@110Y_(<#/:X1AY*V?(A'IQD9.J2>IM;I)PDU-&K4-*J+:F
MO+9.-F+`2QU`8:,>G3`CAS_%8P$D3&$7*``*A0Q)^,.2UJSV5,T"E.EJVZH&
MMY2$_P`K*E0MQHZDK3!W8JY,N'57V6Q[7=E.L$YR_=_I;12B$T)UEC<I)E<I
MG";_``&`P&`P&`P&`P&`P&`P&`P&`P&`P.N)^%_#C_9(;GG_`'Q.3CZ?AX?Z
M\#L8#`8#`8#`8#`8#`8#`8#`8#`8'X(<B`_D.!^X#`8#`8#`^#\@41`2AQP/
M)OW2@`@(F'U#]T/7`UA?Z;-%QL17Y7.V;]4'#[L;\F.XT6C[V_$'5;UV5888
MQ.#``@"MU<!^Z'`CR//T`-GW`8#`8#`8#`8#`T^YUS+[L_J*-DKQS5(Z6KH>
M7JC*0?NH\K6"3A=6ZCUBH]8(E<.G4DK+2V])!H4HIM?M'`*<BH(8&X"GQ[:?
MCP!?`O''TX\0XX^GIQ@?>`P,3]FE?+2^\D4RIBBMUT,=MP?P5-(`ZV<FB(G*
MH4Z:0<!Z^@`/KZX''+/7;9&1;_;*+M$^JSQ41/()B@9\T`R8M"MQ;&!1R]17
M_P"-[H@($\1)^(AT`!PX48+N47*;97J/)+K(`U#T<K'CC+MQ6!P01<(I*B4$
M@`H>O/D'TP/5UDT(%IU87WQ4)_RSP)/MUD52G.D1Y4$BJ+$*)FC90HJ<F)[@
MG/\`[(&`HB`978#`^3F`A#'-^Z0IC&X_(H"(_P"H,##+K2*L14=P[$O"\)!)
M2EGE)N5?IF&/B8N`CH!*;?OG+]9NQ;*-F[F5>KJO4RBB</(WD82F'`Q]^/\`
M@'RVS^XFSK?$,6=B[#;&HVZJ:T.5RA)UG05SI*<;K2D2;);A%E)E6J,I87Y$
M2D`9&Q*E4Y42'`B)^*WJYM3L-M9O\F]=LU0-&)=^/DXO)*#:QL$8:[0^PF=3
MZ[ZPMS>8BF$NBT>TJNZSD$_8,T.#AO)#X+%,7@P;&[_55LVDP".W#8X/^7CB
M5*9U_KA.:CZ]8">+5R$7;++).T['/1"3M/\`6V:%B6S]+@CI)5(3)"''N35-
MB=M*C>=2JQ,;LS48/751B9`PQ59NE<>Q`Q=@U39'3("%BJ]9V[5HHU=E24"'
ME&+1T1(Z:)D3A&Y\C6_JON3I;;]-)1MLIFS=Q;GZT]:K-JJS,WE:OC!;;G8#
M5->M2$?[Q6T;;*\6H23\P2\*M(Q3Q`_(*@*AB%":QFD"*0IE%,4RJ'!$$^/$
MB`#PBD''H`))@!0_8`8';X#GGCU'ZC^(\?3_`$<X#`B!^8*J5^W:2HD?8=F-
M]9,DMJ`LH_A=QONO.VY4JVMKS&!&Z:WG%4R^R.N[2#F31<2(DCREE8!!\Q56
M*DX,FH&$GP(L?X=OWY+&X-V3,%V'QP/P91E:?TV+9E-TJK\8#:+JTHTCWT-'
M"$5[J)#MFGFFJ!RMT"F!,H2TWU2&JMG[RV*W/Z5"51UI_5\C*S-UIY[O5$(I
M.I;$A)4UUIH2L4%U@FJ3?E6/^Y:@Z15%$3``B(A3?3GK-I[3%QL=NU7V/F+\
MTL5?5C/\G*-=:M&]<*D*4BT7?3>O=(T]=_#4Y\5PD5'W$W*Q4$UE$PX]P``)
M%,!@,!@,!@,!@,!@,!@,!@,!@,!@,#C_`/2G_H?[N!R8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`LGV5V.UT]UTWUMEXM]NVUGIK9M]55]U)$Q0J5+FIT
MH)J+"5(JQSL0*3R'@3B`8$-_],EJ]:@?#OULLLF*REBW9.;<WG87+HAR.7<C
M?=EV!)%TJ!@(`_<0L$R,0P!XG3\3!]<"?S`8#`8#`8#`8'&J'D4"\<\G)]0Y
M]`,`F_\`>0'`T&?CM[?U-+YA-X;`FZZSG7>[-H;P=T]%.U0]/=,FT?MG:UQL
M$V$E=TXN(L!))KJR#15;I/VR+50S<>3F633`-RFI]Q*O;$UQAM;WZ83;J*I)
MKTJ4U7LAHL5%)NH4I#:]V19':3E3WA*5$Z!5!,00XXX$0X*MW<UE8K'L6M2E
M*WE0W>M+:E4IIW>-(;/BXMTH[@8BP1DXRE&%6E8].!F&DN'VJCA5!<X(G.9$
MJ8IG.'JS/>+JY6ZS8+C9-R4VMUVL,'\C,/K.YD*F9NE',1DUVY&UJCH5PN_6
M8"4R")"B=PH<J9.3&+R&"5W[^Z%MSG9$O!H[&E82Y];`B:RX:T7WVLO,RKJ_
M.48XKLG\12(Z`DDDFLF8%DT1-P*?N>0`'4/\@^CU%SH(QVQVQB]7#5MNF?6<
MB0QK:=(@DA47:Z"97"J!R"D5N=,0,L!N$Q^F!["G>_423.-.^A=FQ:ZW71]1
M&J<A2$4OO+LH$6)89LF:6,NL]`2',+?VP-[9#"<H`!0P+D=8NV^L-M[>I6L*
M\I;XJXUOK4T3DH&SPL'$D<&A9BM,'\AQ%3,R[;&04;#[)5"MVQR',*?N&#@`
ME+^N`P+8;HM"]-U/LJRMDSJ.H2A6V38E3*J=4\DU@WJL<B1-$Z*IA6>%(7]*
MA!#G]X/J`1E5JU3.XZUUPZRPRS.1:[>4M.Z]\OXZ0;2!(KJ_3+HYCH6$=+L5
M'2#AQO:R-8R!$`6$ZL>6<.0YQ0.H4+^=E]BL.NM]O.TI)^SCX=STKWG9#K*I
M))%;RG6Y9*^QR_!`(0B2$/L!\`%`/U`D4H?3`M'\&%0)2_B<Z2LSD$LE8]1-
M]E3ZA_(5G-@VS.S6SY5XL)A'D[I>V^8?D0P!^&!+)@,#PY:M0$\K&+S4)#RR
ML*_0E(=24C&4@K%23;G[>1BU7:*JD=(-^>4UT!34(/T'`]HI0(4"E]"AZ%`/
MH`?@']V!]8#`C2^3Z,ZNM]!J7CM99;)1Z71Y=^^KMPKUGVY2VD=;[#3++56;
M&XVC3D9-6.$I,['R"[%ZY70^T2,NGP8'`H@<,._B8D8Z8[S?+-,1$O8I^)EB
M_&](1<W;WEHD;1*Q[WIE$O&TA/2-X81-SD9%R1?D[B6:-9!;T.NBF<PD`)`-
MTUJP77_G=J-5JK*[V*P:&UM%0U/D7R$<TM#YY&;7(E!G>NU6S1LI(_\`"3,L
MJBE[AB@=1,O)RA:SK?9K6CV=6925.Z^ZOA+_`%#9$E"Z*@Z]K&![!Z<J]-F*
M"UILIL23I=KF7LQ)[71F'[Z2B4V@L8,6;9('AUDU2K!*)@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@?/C^KRY_N_NXP/K`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8$+O\`4*;8/IKX>.]5F1>"T>674!-61YN>>7>U[57]?*)II<#Y*KQUB<`!
MO]GQ`?IS@9J_'1JQKI'H/TTU.T3.D6C=9M+0KHBI1(K_`!0NOX%S,'4*)C"5
M165<K&,'/H(X&9N`P&`P&`P&`P+1;_V`VU/HW<&T7@_]GUSK"_7DY06!LHH-
M4J<O.$217-R1)90[$`*8P&`!'Z#@:)OPI(F)WDA9\=N:ITW8M?=7;K-OYG=4
M'%S["?EMHVK5U;=TEE_[&-',25:'@YE59T@[`_@[-PB<%%/`-O.0HELNJ,W(
MI:?Z2[R9.RE0:2M#E3U"VJI&1*!GO\2?4_8D>UD6SM-/[4?OP33-XF.?]/!@
MPDZ$]<6&N>M=.GI'5'<I5[<)BXW:,DJ=V[LFR'-?B[%.S`P;"%4/MRJD4A4*
MNU9!]JM&JIH/#JG;HI%4,4`NGV1O$37M+VNL,MO]KJW*S*<3%HU3?&GU[I"3
M365L$6SEH$T]<]4N8\X.HIPND+G^8`721`QVXG.!1$)$^L="CJYU]TQ#/:O#
M13MIK*F&>L$XIF4C)Z\@V<F]:$*JS25_P'S]8#^92F]SRY#GD1"^Q:W!)B(I
M0T.0QA`3F"*8`)A#Z"(D0)R("/XX'9+$QQ/4C)F41]1$&C;U']G^%Z8$.4S0
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M*U:8N_1T5N^JS.N[+-?R]:X.!?*,8L)%`'?VX+`1)03"`F`H`&SYH/7S+4VD
M=1:NCFS1HRUUK*A4AL@Q1%NU(G5JG$0?^`@(B=)/R8B`%-^H`#UP+N8#`8#`
M8#`AA^<2H:XV)U$B]>;'W.MHM&Z;DHT+4+PAU]'LN9"]N8^>""9J:^1;KR,.
M0Z)%U26!F9!W#J)@HBJF8PF`,:?A"B9"N]F?DE@)FB3>K9.%JWQJPSG7EIF+
M5.V6IJ1G3U!DG$3LM?'LC=7DN#9`BRX2KA>02.M[:YS'((X$J.V)Z%K[KNU-
MV-O-.Z[#=?J&^G4*U99"G6%6%+7]P&DQA+=$*H2M6DR,A4,A(-CD7:G*"A#`
M8H"`8-_'FKHK7O8.T:ZZN;2K-RUQ:2;2/;Z_,U_6,ML9BOII3750K5[C=FZU
M;UE],T._DGSK(J3[*1=O%FQUP=&657.(3CX#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`UF/ZHB2=VOJ-U<ZOQ`"Y
MG>V??CK;JYM$(B=1W*1+&:?SK\4TN/:*BVDT&(G\A`.!Y$>`P-E6'9-8V,8Q
M;%,J3*+:H1C1(@"4J;:/2(T03*`^OBFDB`!^`\>GI@>E@,!@,!@,!@,"+KYH
M[JZHWQB=MGL>X<M9*RT*,US'K-"%47(OLZXUN@JJ`0PAYI(LK"JHH`<C[1#<
M>N!KT_`Y7'C+<W>.\U3:&C8(4*[H&D'B=S4\\I"S[676VAM%ZHTF4KM47S16
M%:VQFU7*";X"BLB)R%#QY"?[<6N%935VP[C9>M?4B]#"TFTRC*XZUNZ=<7<F
M3BG)XP[EV]H#%:+(3R!Q[A)P1`Y"E*8W/E@<FEM&--+:;T[4E]?=MZ!-T2E5
MFIOD]8[7DKM%*/XZL,F\M8U:\:^S\.9H_EU'!BH%C%"D4``*B4A"``6B[6R+
M60UW2J"KV%V_]O?-HP=+)K/;.MX*`GI]_8F$E'-$FT^ZUA2)LYHI]*M7AO95
M6,H<G@!_$WD(36,FZ+-HV9MR>#=HW0;-R\F'A%!(J21>3B)A\2$#ZB(_G@=K
M`8$:FKY2;L]ZWA+06P-/-#&LK2LNJA=JP_DFIE0<2=S/)M[&:4JSF49S%?OS
M8YD/L'"+=RF*::YTE!X"^\A!S;MBUD'.I-17*<;FC2$-3[6->0*W3537>G;.
MW-;,Y*8A7)CM6YUC^\!A,42^0X'U&I'@V,L9S2-Y4;V%2I%)!VD;RT<++HBD
M9W$L4;#:E`C6QT@]E15FU$WES[1>!X#'O?U@>32>LH6+OUQ>)WG82C+^!7.J
M/:O*-CNR+:_9(,3C3XAXV9%F;LU_6^4$'!"![*BGG@23J,$7""C9R4CANIR4
MZ+A)-<BB?T\%2."JIJE$GZ1Y+R(8%G+3UFZ\W=\RD[AHS3UGD8UTU?QTC.:U
MJ4C),'S%P5XR>,WZ\89RV<M79"J)G(8#D.4#`(#@7M21(B42D#@!'G\1$?VB
M(B/(B/U'\<#EP&`P&`P&!#Y\R5IH]9Z[PA[!JW0>U;?)79ZQUW`]B[/<JCKQ
M*?:ZXNLQ*/W,I3D6[AZ^"HLI!L6/=R,2P>I.#D5=ICP`A#GT`V1V.LO??;-K
MZVV!M%42V["^/Z/[#QMLU^G/1,QKI;J`6(FHH[LVQI>;J]HKUIB)4U??L)6;
M;NA374=*.&_MC@;.M/D8]IV*["N'[MHS0::RT+*/S.U2-VS&.(;<0K/';M82
MLTVB9$U!.<3^)`(83<%]<"OJTVL,VXV8_GI.HV36UJ=PZVJ?Y8$#*_R&^H5<
M:3K>:E6)"IR"\G</XJY;+MEE2_8.$`*8#%$`"DZPX<6C9T.G,)/WJNLJ_*M$
M'S*.8M(MK9I,C*)E%)U_%7F<0_B+^*3,+2*,T,+4@J*KJ@J*!2AD1@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@1G=
MU_CE@^Z79/H7OBS;8L=1BNC>X9/=##6T;7(^6@]FV-R%<-$A-RSIXV=0@PBU
M<`B9D2+"9)VL'B`B!@"2Y,@ID`GD)O'T`1``X#\`X#\`#`^\!@,!@,!@,!@8
MJ]R>HNON[FE7.B]FV.^5:K.K;3;H:5US,1L)8R2]%FV]A@TP=RT-/QZL>,HT
M3.NBHV.58I/$?3G`M?T?^._3?1?3MJTG2IBR[-J]PVA:=IS+W;+2J3<LO*VB
M(K4$I%'"&KL#$GB8Z-JK4B!!:\AP(_EP%>[@Z,=:-TTVR4:T:UAHB&MQ62-A
M5HB)J'*2#=B_;/@;JR%1/#JG3>)MA:N14!0RC-91(!(!^0"M$.M]?C5E'-<V
M/N^L++))$4(PVM9YAF4Y')'2AT(^YN+4T:E74+XF(F4I`3'P*!0XP/,G>M#"
MW3=(G+WL:[W9;7%L2M5,1EFE-9EBEDUH-P+-56`J\0J]3]Z#+X+''[A,JI@`
M_P".!DT0#%(0IC>9BE*!C\<>1@``$W'(\>0^O'(X'U@?)R^9#%`QB"8IB^9.
M`.7D!#R*(@8`,7GD.0'UP+5Z]U!5->0[V'8)&F/XE*K3,C(SC"%/(OY!PQCH
MY9R[-&1D:R.HHUBD"CXHD#]'H`!P`!Q):*U2W/(JLJ3!Q3F6,"DB]@VHP#]V
MX"/;Q972SV$48.3.2Q[1)$#>7Z4TB@7C@1$.5+4L>R3>)Q-OV%&%>NB.U"C:
MW<TDB8IG7FDS0LZ<XBT;JINO`2$*!0(FGQP)`'`Z,[IUA:7.NW]FLL]+R>N9
M=.<CGIVM>2"6E$Y!M(%<3"`0RA"`4S--,/LA:&`GER81,`E"\F`P&`P&`P&`
MP/DQRD*)SF*0I?43&$"E#\/41$`#`@&^<Q(N^.GLC&:!NL=L39.M=JPUD_RZ
MUC:M9SMHE'K"KWJKIHOV\QM*D/X,]+GYM*5-]A_$),SI@F@$<]3.LB4(P?C4
M7MD5W@V7'ZGD.OT/`56=^,-MLW6K!]"PU10KQ>F,_2IEKJN/W9,)[AA;WKR<
ME%$F8)IN9LZJCMH[,'W!0(&Q9LDU4?WSOG7=BV5>K:R>=.=8)W"T-D!=N:]5
MYMIV;A+).-&OVSP7SR+A6AUTD@16,LJ'@!#\@40IS3KOJ1J?L1:]?:N>[0U?
M8JU0I)I;:FC#WFK]9;4O6:A1+?+R,+!R$<35S;9-.J5KCGT@C6_X:]*W?JB\
M36$HBF&:-'UT2LR+20:2K=:%;LC(U^.BW=[9M&T:\8LBF+(,)F^V6%G'`K-O
M<0<F:MU&Z1O`@"/FH<+OX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8'$NBFX2.BL4ITS\>13%*8I@`P&`!*<#%,'(?00P(I^RFA.YS[?U
M-1ZH5CH'5-!V"KSJ^UK1NKKG-WK9\!L1FHH_@7T3'52Y4&*NE=M8.!;K#]PB
M]BG"(JG!PFL'@&M%N&FVVE?*=;ZC;);6D'L.>[J_%S3KW+:T8%U/K^PRBVCJ
MQ,V![0=3R#.:=V8#2S=NL2(5E4Y-@W<KR"#QT#9R5,-L^Q1D9,;I[@,)]I57
M4/.=3]2Q\RQOTDM%496,"2[,IN$[A--`6=1=7<-7A_X@Z3`RC=GY*$*!B\8$
M>?02QV_=.T+A8GUG_P"8&@5?3%RUIK+8\UVC:V1U+PLBM"HV"'T_KP--ZILT
M]&3;V`CVLAL.SD(X>%;-RM'#I$%%#!*MK!1S!ST)#5K0T;1Z&,A:J]#RS--G
M'RT/#P\'"N5;%-,&[0I&K"Z6=FHR9H>X*ZZ#%!Z<PE6!)$+Q4G9M-V`O/LJY
M+%4EJO-3$%8*_((+1%FAW</,R$(+F1KDD5O-,HJ67C5%XUVJ@1O),C)N6QE$
M%4U#!7^`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!TW[]
MC%LG4C)/6D>P8MUG;U\^<)-&;-HV2,NY=.G*YTT4&[=!,QSG,8"E*41$>`P(
MQDZ#TKW'O.N[@O'3AXRN.S=@4>]:X[&;-U[5PBKOLC5=8>1.IK77I!.VR]MI
M=F_DH%BU]Q*Q,(M(LB%2'S4]A(0N;L&S0M+VMW,L]D,_&O5?IUK*Q38Q@L/X
MN>,C'/9)R_)'C*M'T4,@HU;F!$72"S?W1`52')Y%$,-.G%=1TMO*)E]IS>G$
M[+LC6&P)N$D-6[$U-<D*^>!:P=HM-1VFK5M'Z\L3N0CH8IG:<Y&R1X9XHP<E
M4:)&%H94)"]03#F]WQ[*+5Z)J[ZAC(Q5@;UZEV2O'<R5EBXV=B8RR2\JFW@9
M)5&K3#&0*C&K3)"J.R*"Y;@84E0\O16JFE7[!]AK\[UVYJDQ;)`A6$LWL%<=
MUN4AG$W)O'4]&UIA>+'/P,_>G3=!S+JNF$8B]6C4CD2(H54#!F9@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@6SVQJ2B[HJ+NF;!B#3,(
MX^[5133<+-G#"0=PLK`IR[%1(W@64C6<TNHT44(H5NY!-<I?<23,4,/=)]-K
M)J^/U_KP\CJN'U5KVX5^]OS4"H66)N^W;/1F";&B2EZ7FK%*0E;58N6;.1E`
MC2N`DG[(@(_9-3J-S!7DJ=NU[%]H5UX%G:T`ZIZA5=5:28O96/L:3>?[$^5?
M>Q<7"623D6<VEY-U6[>.D'"Y%!(FV7,()'#"/2323LF[J5*ZYZ=:NZV-X"E[
M;"QGH^F-OT8=D_QBCJL:W1YJSWSI]I2H-(Q*R`W>^R]EC`L=N7Q;J"40`)1M
M>:Y94QVG(Q]/HE:<S"2S^SK5AH\8N'\VHRC6"3LX()IQSLY8^/2;J'.')4T$
MR)#[9"E`*5U%LFK7O:V[XIC1[-!7>A2<94+I:9&-395^>C(Z9N"M&8P3E6<>
M.WYD8=XL^6,1FV1`[_GR,)B@`9)8#`8#`8'&F<3\\EX$./[^>?S_`+,#DP&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P,%KE)143O?MG(SJ5=7@H
M[I_JR2G$;>H]1J2T2SF>RBTHE:5XZ/EI!*MGCTC@^,W:.ERMA.*:*I_$A@P"
MZJS544WHE<8"GZQT*&M]?[00G]?:6U_V>JS?<-A9T>OSCVCVM;;6M].4J0G*
M!'RZ<TG$`T>SS8%T#IJHM_NA,$LVH['#6%91[&[==V@LDL[>IT59E6V3:J`@
MPBTGU=9)EA$+:5"!=+%44!Z]<KD7<&*8X)^VD0.OKVB4&M[HVI8H_8-CN&P[
M$FV_F&#GW5<>IT>(.HVF6$)$&AZM#RC**,WF6OVZ,B]?*BW(F"9N"''`R(P&
M`P&`P.!$WEY?3TX^G[><#GP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P,0$X.,MW:SL'2K.R1F*E9^KVDHF8A'?JSDXV=N/8V&G&3@$C$7]A]&J
M"D</(.2F'@>?7`IK3W7CK14MO['C*1I*(@)_5Q(T6]A>6"R61*35V[4`)9W0
M1-AD9)DSD)"%BDF#UR8%EW;0I2&."8>&!>B"V/(V;9:-)BI*A-6552>2%FBJ
MU9EKC+*PKI@NPK2<LDSJC*-I)UYA-51))9Z"S@C(Y4BJ%!7VPPFZWZJEJ#\E
MG=:\2%F<7)MN>AZTFHZ27C':<C`,:/\`;5]"N2TDC$,:RZAV2\HNR@E&*IG"
MW\+D6[XIG+`RZH2JX#`8#`8'6;@`>?'_`%?_`+K`[.`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&!C(FX@ZWV<VA:)->.AF:?7/7,A9)Y^LDS;-X
MBLWG<#HCJ3>KG(@V81#9\Y4,H<2E3(8PF'@,#N4NNNF-\WGNZON*]<ZWM.I:
MQ?45:MV%64+84Z36;(@*`';-'$.DUDG4H06CMHJ[%RFM^L`]H@&"FM:6L\M>
MV<M#:>V72F]A=?R3+.IR%L4+!)5VHT%I>8:96C+)!Q*L(R:V^]R4`T3;I-R.
MG;9PH`J)E3*0+OU32.J*1=+%L6JT>&A;Q;5)E2Q69L5R>4DBV&0CYB8:G67<
M+%0CWLS&IO!;)`FW(\.LN0A57#@ZH75P&`P&`P.NA_M_^+_W<#L8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'P(G\P``_3QZC_IP/
MO`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`Q:M*QF>Z]L
M/&TBI$.V_6.`7)*I02MJ4B_8M&U%49)*KH`9:R*,E@%0&!.3O1*"(!R<,"-K
MXZ9S4=ZV=<H?14!N56*I\&XF-A;*O>[H_7[&2M6U(UPHD]K?2W5C\VK:,!W,
M0J<$7$16GT,H?S4;*.E3G.$HFNJ9%Q%P+)M;G3K-[L$W5B(Y"!-_%8J-0AH*
M&>O*C+*V^4!K79=TW2=/A2;+^^]=CYN.3%#`R&P&`P&`P&!UT/\`;_\`%_[N
M!V,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#%&[*6]/<>X#ZZ2
M8N-A%ZJ11Z,WDQ3+&KW)&U;0&JHR!EEFR)6*DX9$JPF43)[8CR8H>H!$7UUD
M-HO^ZT(3L'*(6O8$-K3<\9/-9S975F\[&I>L6U$B`:.4XWK_`%V.LL=LQU;S
MR;5Q(/E(^/=0CU%L1L=PU]X0D_IUFJ4KM#4<'!;%BG#2BN5JC7*/%U&,86.,
MCY30S6W)15JEB7%^Y3@W$*LT=A[,8W(:2CDD#<^R)Q#)ZO[=U?:KE8-=UN_U
M.>O=32<*V:IQ4VQ?3L$5F[;L'O\`%(]NL==F=D]=HI+%.`&1.LF!P+YEY"XN
M`P&`P&!UT/\`;_\`%_[N!V,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?@"`_
M3`_<!@,!@,!@8OSK-"3W[LJ.5B#6%)_UDKK%>`(\+''G$GEWV8V4AR/U%FQ&
M)I0!,@"PJ)@D)_(3%`.<"*[X]V3+5?:F;U'2:!8.KB,Q0PE+_P!8MO[;JEUO
M9ZO4$)5G0+5K\D7J1U(ST9"/K#[;QTEL"4;D1?`"P*+)E*0)6M=IR[6^MF"Z
MUS=0[*-L3!*6V//2[*S3CUNXBQ159UUBU-7YZ/10]\3O'HL7"("E]L@<#KG*
M%E>N]_&;[0;^J4K-MG;J(DKPM3X]T]9$<GKT;=X^-M+RKM"U2&=RL)&6-RWC
MY9T50B3.71^T.K*J@+IN$@.`P&`P&!PI>/ZO']G/U_;^>!S8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`_```^F!^X#`8#`8#`Q`MZCE7L+M:*2D4*^BZZB1B
MQ;*X,[42A'07C9:!))=O%R,7,';1Q7(N3BV<MEA!/Q363.)3`&"'QKZ</46K
M2WU766]*!&6!A88%G?9/8C:1TULZ(1C%)&M[094+;B5>[)N&<\Z>"M'&L+!S
M))!Q[CYVT$KDX9_UENW)LO5S.O2\?]Q#UJ=_G>PFNJCIWLH1K<<V^U0K9I.0
M?S;AI8%TI%:0E$T'#`C;VD#*$=+<!8;KS!6I+NSV+L;F9FEJ@_;6F/BZ@P@J
MM7:Q4)2.M%8*[E+$SK%XEW+VV[",NJ_92$K#Q\A+QC<7!C'*0H8$E&`P&`P&
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MJDF4$O(5`\'6W74*CV+V?OJ480"DQ<8R4KT/,MIN6E+(6N2<M7Y=6)E@>P<>
MDG&D=UY%1JT^Z>(QI@.5J)2.%0P,J$G2"YUDTE`.=NJ9%8`Y_P`-4I$E!(;\
M`-X+%']H#@<^`P&`P.DS,)C.@$>?!THF7]A2@42E_N\L#NX#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'YP'//XX'[@,!@4I7XJ0CY6WNG8(@VE
MYY)_'^!Q.H9L6$B61C*AY""1ON6AP\>`]`Y_'`JO`8#`8'08_O/O_BU7_P!%
M)@=_`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M'08_O/O_`(M5_P#128'?P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&!T&/[S[_`.+5?_128'?P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!U&OU<?\`"_\`-!_^']?H'_%_]_?G
M^SC`[>`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
$`P/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
